

SECURITIES AND EXCHANGE COMMISSION

FORM 10-K

Annual report pursuant to section 13 and 15(d)

Filing Date: **2012-02-24** | Period of Report: **2011-12-31**
SEC Accession No. [0001193125-12-077942](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

DAVITA INC

CIK:[927066](#) | IRS No.: **510354549** | State of Incorp.:**DE** | Fiscal Year End: **1231**
Type: **10-K** | Act: **34** | File No.: **001-14106** | Film No.: **12637617**
SIC: **8090** Misc health & allied services, nec

Mailing Address
*1551 WEWATTA STREET
6TH FLOOR
DENVER CO 80202*

Business Address
*1551 WEWATTA STREET
6TH FLOOR
DENVER CO 80202
3034052100*

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 10-K

For the Fiscal Year Ended December 31, 2011

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 1-14106

DAVITA INC.

1551 Wewatta Street

Denver, Colorado 80202

Telephone number (303) 405-2100

Delaware
(State of incorporation)

51-0354549
(I.R.S. Employer
Identification No.)

Securities registered pursuant to Section 12(b) of the Act:

Class of Security:
Common Stock, \$0.001 par value

Registered
on:
New York Stock Exchange

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	<input checked="" type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/> (Do not check if a smaller reporting company)	Smaller reporting company	<input type="checkbox"/>

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of June 30, 2011, the number of shares of the Registrant's common stock outstanding was approximately 93.5 million shares and the aggregate market value of the common stock outstanding held by non-affiliates based upon the closing price of these shares on the New York Stock Exchange was approximately \$8.1 billion.

As of January 31, 2012, the number of shares of the Registrant's common stock outstanding was approximately 93.7 million shares and the aggregate market value of the common stock outstanding held by non-affiliates based upon the closing price of these shares on the New York Stock Exchange was approximately \$7.7 billion.

Documents incorporated by reference

Portions of the Registrant's proxy statement for its 2012 annual meeting of stockholders are incorporated by reference in Part III of this Form 10-K.

PART I

Item 1. Business

We were incorporated as a Delaware corporation in 1994. Our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to section 13(a) or 15(d) of the Exchange Act are made available free of charge through our website, located at <http://www.davita.com>, as soon as reasonably practicable after the reports are filed with or furnished to the Securities and Exchange Commission, or SEC. The SEC also maintains a website at <http://www.sec.gov> where these reports and other information about us can be obtained. The contents of our website are not incorporated by reference into this report.

Overview

DaVita is a leading provider of kidney dialysis services primarily in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease, or ESRD. As of December 31, 2011, we provided dialysis and administrative services through a network of 1,809 outpatient dialysis centers located in the United States throughout 43 states and the District of Columbia, serving a total of approximately 142,000 patients. We also provide acute inpatient dialysis services in approximately 900 hospitals and related laboratory services throughout the United States. Our U.S. dialysis and related lab services business accounts for approximately 93% of our consolidated net operating revenues. Our other ancillary services and strategic initiatives accounted for approximately 7% of our consolidated net operating revenues for the year ended December 31, 2011, and relate primarily to our core business of providing kidney dialysis services.

In addition, as of December 31, 2011, we provided dialysis and administrative services to a total of 11 outpatient dialysis centers located in three countries outside of the United States. Our international dialysis operations are currently in a start-up phase in which we primarily commenced operations during the fourth quarter of 2011. The total net operating revenues generated from our international operations were not material during 2011 and are included as a component of our ancillary services and strategic initiatives. Therefore, all references in this document to dialysis and related lab services continue to refer only to our U.S. dialysis and related lab services business for the year ended December 31, 2011.

The dialysis industry

The loss of kidney function is normally irreversible. Kidney failure is typically caused by Type I and Type II diabetes, high blood pressure, polycystic kidney disease, long-term autoimmune attack on the kidney and prolonged urinary tract obstruction. ESRD is the stage of advanced kidney impairment that requires continued dialysis treatments or a kidney transplant to sustain life. Dialysis is the removal of toxins, fluids and salt from the blood of ESRD patients by artificial means. Patients suffering from ESRD generally require dialysis at least three times a week for the rest of their lives.

According to United States Renal Data System, there were approximately 399,000 ESRD dialysis patients in the United States in 2009 and the underlying ESRD dialysis patient population has grown at an approximate compound rate of 4.0% from 2000 to 2009, the latest period for which such data is available. The growth rate is attributable to the aging of the population, increased incidence rates for diseases that cause kidney failure such as diabetes and hypertension, lower mortality rates for dialysis patients and growth rates of minority populations with higher than average incidence rates of ESRD.

Since 1972, the federal government has provided health care coverage for ESRD patients under the Medicare ESRD program regardless of age or financial circumstances. ESRD is the first and only disease state eligible for Medicare coverage both for dialysis and dialysis-related services and for all benefits available under the Medicare program. Beginning in January 2011, Congress established a new single bundled Medicare

payment rate system in which all ESRD payments are now made under a single bundled payment rate that provides for an annual inflation adjustment beginning in 2012, based upon a market basket index, less a productivity improvement factor. The bundled payment rate provides a fixed payment rate to encompass all goods and services provided during the dialysis treatment, including pharmaceuticals that were historically separately reimbursed to the dialysis providers, such as Epogen[®], or EPO, vitamin D analogs and iron supplements, irrespective of the level of pharmaceuticals administered or additional services performed. Most lab services that used to be paid directly to laboratories are also included in the new bundled payment. The new bundled payment rate is also adjusted for certain patient characteristics, a geographic usage index and certain other factors.

Also, beginning January 1, 2014, certain oral-only ESRD drugs (currently paid separately to pharmacies under Medicare Part D) will be included in the ESRD bundled payment to dialysis facilities. It is currently unclear how CMS will “price” the oral-only drugs for inclusion in the ESRD bundle in 2014.

Although Medicare reimbursement limits the allowable charge per treatment, it provides industry participants with a relatively predictable and recurring revenue stream for dialysis services provided to patients without commercial insurance. For the year ended December 31, 2011, approximately 89% of our total patients were under government-based programs, with approximately 80% of our patients under Medicare and Medicare-assigned plans.

Treatment options for ESRD

Treatment options for ESRD are dialysis and kidney transplantation.

Dialysis Options

Hemodialysis

Hemodialysis, the most common form of ESRD treatment, is usually performed at a freestanding outpatient dialysis center, at a hospital-based outpatient center, or at the patient’s home. The hemodialysis machine uses an artificial kidney, called a dialyzer, to remove toxins, fluids and salt from the patient’s blood. The dialysis process occurs across a semi-permeable membrane that divides the dialyzer into two distinct chambers. While blood is circulated through one chamber, a pre-mixed fluid is circulated through the other chamber. The toxins, salt and excess fluids from the blood cross the membrane into the fluid, allowing cleansed blood to return into the patient’s body. Each hemodialysis treatment that occurs in the outpatient dialysis centers typically lasts approximately three and one-half hours and is usually performed three times per week.

Hospital inpatient hemodialysis services are required for patients with acute kidney failure resulting from trauma, patients in early stages of ESRD, and ESRD patients who require hospitalization for other reasons. Hospital inpatient hemodialysis is generally performed at the patient’s bedside or in a dedicated treatment room in the hospital, as needed.

Some ESRD patients who are healthier and more independent may perform home-based hemodialysis in their home or residence through the use of a hemodialysis machine designed specifically for home therapy that is portable, smaller and easier to use. Patients receive training, support and monitoring from registered nurses, usually in our outpatient dialysis centers, in connection with their dialysis treatment. Home-based hemodialysis is typically performed with greater frequency than dialysis treatments performed in outpatient dialysis centers and on varying schedules.

Peritoneal dialysis

Peritoneal dialysis uses the patient’s peritoneal or abdominal cavity to eliminate fluid and toxins and is typically performed at home. The most common methods of peritoneal dialysis are continuous ambulatory peritoneal dialysis, or CAPD, and continuous cycling peritoneal dialysis, or CCPD. Because it does not involve

going to an outpatient dialysis center three times a week for treatment, peritoneal dialysis is an alternative to hemodialysis for patients who are healthier, more independent and desire more flexibility in their lifestyle. However, peritoneal dialysis is not a suitable method of treatment for many patients, including patients who are unable to perform the necessary procedures and those at greater risk of peritoneal infection.

CAPD introduces dialysis solution into the patient's peritoneal cavity through a surgically placed catheter. Toxins in the blood continuously cross the peritoneal membrane into the dialysis solution. After several hours, the patient drains the used dialysis solution and replaces it with fresh solution. This procedure is usually repeated four times per day.

CCPD is performed in a manner similar to CAPD, but uses a mechanical device to cycle dialysis solution through the patient's peritoneal cavity while the patient is sleeping or at rest.

Kidney transplantation

Although kidney transplantation, when successful, is generally the most desirable form of therapeutic intervention, the shortage of suitable donors, side effects of immunosuppressive pharmaceuticals given to transplant recipients and dangers associated with transplant surgery for some patient populations limit the use of this treatment option.

Services we provide

Dialysis and Related Lab Services

Outpatient dialysis services

As of December 31, 2011, we operated or provided administrative services through a network of 1,809 outpatient dialysis centers located in the United States and 11 outpatient dialysis centers located outside the United States that are designed specifically for outpatient hemodialysis. In 2011, our overall network of outpatient dialysis centers increased by 208 primarily as a result of acquisitions and the opening of new centers, net of center closures and divestitures, representing a total increase of approximately 13%. A large portion of this increase was driven from the acquisition of DSI, a medium sized dialysis provider that we acquired in September 2011, that contributed a net 83 outpatient dialysis centers.

As a condition of our enrollment in Medicare, we contract with a nephrologist or a group of affiliated nephrologists to provide medical director services at each of our centers. In addition, other nephrologists may apply for practice privileges to treat their patients at our centers. Each center has an administrator, typically a registered nurse, who supervises the day-to-day operations of the center and its staff. The staff of each center typically consists of registered nurses, licensed practical or vocational nurses, patient care technicians, a social worker, a registered dietician, biomedical technician support and other administrative and support personnel.

Many of our outpatient dialysis centers offer certain support services for dialysis patients who prefer and are able to perform either home-based hemodialysis or peritoneal dialysis in their homes. Home-based hemodialysis support services consist of providing equipment and supplies, training, patient monitoring, on-call support services and follow-up assistance. Registered nurses train patients and their families or other caregivers to perform either home-based hemodialysis or peritoneal dialysis.

Under Medicare regulations, we cannot promote, develop or maintain any kind of contractual relationship with our patients which would directly or indirectly obligate a patient to use or continue to use our dialysis services, or which would give us any preferential rights other than those related to collecting payments for our services. Our total patient turnover which is based upon all causes averaged approximately 30% per year for the last two years. However, in 2011 the overall number of patients to whom we furnished services in the U.S. increased by approximately 13%, primarily from new centers and acquisitions, as well as continued growth within the industry and lower mortality rates.

Hospital inpatient hemodialysis services

As of December 31, 2011, we provided hospital inpatient hemodialysis services, excluding physician services, to patients in approximately 900 hospitals throughout the United States. We render these services for a contracted per-treatment fee that is individually negotiated with each hospital. When a hospital requests our services, we typically administer the dialysis treatment at the patient's bedside or in a dedicated treatment room in the hospital, as needed. Hospital inpatient hemodialysis services are required for patients as discussed above. In 2011, hospital inpatient hemodialysis services accounted for approximately 4.5% of our total U.S. dialysis treatments.

ESRD laboratory services

We own two separately incorporated, licensed, clinical laboratories which specialize in ESRD patient testing. These specialized laboratories provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients. Our laboratories provide these tests predominantly for our network of ESRD patients throughout the United States. These tests are performed to monitor a patient's ESRD condition, including the adequacy of dialysis, as well as other medical conditions. Our laboratories utilize information systems which provide information to certain members of the dialysis centers' staff and medical directors regarding critical outcome indicators.

Management services

We currently operate or provide management and administrative services to 33 outpatient dialysis centers located in the United States and 3 outpatient dialysis centers located outside of the United States in which we either own a minority equity investment or are wholly-owned by third parties. These services are provided pursuant to management and administrative services agreements. Management fees are established by contract and are recognized as earned typically based on a percentage of revenues or cash collections generated by the centers.

Ancillary services and strategic initiatives

Ancillary services and strategic initiatives, which include our international dialysis operations, as described above, accounted for approximately 7% of our total consolidated net operating revenues for the year ended December 31, 2011, consist primarily of the following:

Pharmacy services. DaVita Rx is a pharmacy that provides oral medications to DaVita's patients with ESRD. The main objectives of the pharmacy are to improve clinical outcomes by facilitating increased patient compliance and to provide our patients a convenient way to fill their prescription needs by delivering the prescriptions to the center where they are treated. Revenues are recognized as prescriptions are filled and shipped to patients.

Infusion therapy services. HomeChoice Partners provides comprehensive personalized infusion therapy services to patients typically in their own homes as a cost-effective alternative to inpatient hospitalization. Intravenous and nutritional support therapies are typically managed by registered and/or board-certified professionals including pharmacists, nurses and dietitians in collaboration with the patient's physician in support of the patient's ongoing health care needs. Revenues are recognized in the period when infusion therapy services are provided.

Disease management services. VillageHealth provides advanced care management services to health plans and government agencies for employees/members diagnosed with Chronic Kidney Disease (CKD) or ESRD. Through a combination of clinical coordination, medical claims analysis and information technology, we endeavor to assist our customers and patients in obtaining superior renal health care and improved clinical outcomes, as well as helping to reduce overall medical costs. Revenues are typically based upon an established contract fee and are recognized as earned over the contract period and can include additional fees for cost savings recognized by certain customers.

Vascular access services. Lifeline provides management and administrative services to physician-owned vascular access clinics that provide surgical and interventional radiology services for dialysis patients. Lifeline also is the majority-owner of one vascular access clinic. Management fees generated from providing management and administrative services are recognized as earned typically based on a percentage of revenues or cash collections generated by the clinics. Revenues associated with the vascular access clinic that is majority-owned are recognized in the period when physician services are provided.

ESRD clinical research programs. DaVita Clinical Research conducts research trials principally with dialysis patients and provides administrative support for research conducted by DaVita-affiliated nephrology practices. Revenues are based upon an established fee per study, as determined by contract with drug companies and other sponsors and are recognized as earned according to the contract terms.

Physician services. DaVita Nephrology Partners offers practice management and administrative services to physicians who specialize in nephrology under management and administrative services agreements. Practice management and administrative services typically include operations management, IT support, billing and collections, credentialing and coding, and other support functions. Management fees generated from providing practice management and administrative services to physician practices are recognized as earned typically based upon cash collections generated by the practices.

Quality care

We employ 200 clinical service teammates. The primary focus of this group is assuring and facilitating processes that aim to achieve superior clinical outcomes at our centers.

Our physician leadership in the Office of the Chief Medical Officer (OCMO) includes nine senior nephrologists, led by our Chief Medical Officer, with a variety of academic, clinical practice, and clinical research backgrounds. Our Physician Council is an advisory body to senior management, currently composed of ten physicians with extensive experience in clinical practice in addition to the members of OCMO and currently six Group Medical Directors.

Sources of revenue—concentrations and risks

Our dialysis and related lab services business net operating revenues represent approximately 93% of our consolidated net operating revenues for the year ended December 31, 2011, with the balance of our revenues from ancillary services and strategic initiatives which also includes our international dialysis operations. Our dialysis and related lab services revenues are derived primarily from our core business of providing kidney dialysis services, the administration of pharmaceuticals, related laboratory services and to a lesser extent management fees generated from providing management and administrative services to certain outpatient dialysis centers.

The sources of our dialysis and related lab services revenues are principally from government-based programs, including Medicare and Medicare-assigned plans, Medicaid and Medicaid-assigned plans and commercial insurance plans.

The following table summarizes our dialysis and related lab services revenues by source for the year ended December 31, 2011:

	Revenue	
	<u>percentages</u>	
Medicare and Medicare-assigned plans	58	%
Medicaid and Medicaid-assigned plans	5	%
Other government-based programs	3	%
Total government-based programs	66	%
Commercial (including hospital inpatient dialysis services)	34	%
Total dialysis and related lab services revenues	<u>100</u>	<u>%</u>

The following table summarizes our dialysis and related lab services revenues by modality for the year ended December 31, 2011:

	Revenue	
	<u>percentages</u>	
Outpatient hemodialysis centers	81	%
Peritoneal dialysis and home-based hemodialysis	14	%
Hospital inpatient hemodialysis	5	%
Total dialysis and related lab services revenues	<u>100</u>	<u>%</u>

Medicare revenue

Under the Medicare ESRD program, payment rates for dialysis are established by the U.S. Congress. On January 1, 2011 we implemented Medicare's new payment system in which all ESRD payments are made under a single bundled payment rate that, beginning in 2012, will provide for an annual inflation adjustment based upon a market basket index, less a productivity adjustment that was determined to be 2.1% by the Centers for Medicare and Medicaid Services, or CMS, for 2012. Also beginning in 2012, the rule provides for up to a 2% annual payment withhold that can be earned back by the facilities that meet certain defined clinical performance standards. The new payment system reimburses providers based upon a single bundled or average payment for each Medicare treatment provided. This new bundled payment amount is designed to cover all dialysis services which were historically included in the composite rate and all separately billable ESRD services such as pharmaceuticals and laboratory costs. In the past the amount of services that were separately billable accounted for approximately 30% of our total dialysis and related lab services revenues. The new bundled payment rate is adjusted for certain patient characteristics, a geographic wage index and certain other factors. The initial 2011 bundled payment rate included reductions of 2.0% from the prior reimbursement and further reduced overall rates by 5.94% tied to an expanded list of case mix adjusters which can be earned back based upon the presence of certain patient characteristics and co-modalities at the time of treatment. There are also other provisions which may impact payment including an outlier pool and a low volume facility adjustment. With regard to the expanded list of case-mix adjusters, these are difficult and in some cases, have not been possible for our dialysis centers to document and track, which has resulted in lower reimbursement amounts than we would otherwise have received.

ESRD patients receiving dialysis services become eligible for primary Medicare coverage at various times, depending on their age or disability status, as well as whether they are covered by an employer group health plan. Generally, for a patient not covered by an employer group health plan, Medicare becomes the primary payor either immediately or after a three-month waiting period. For a patient covered by an employer group health plan, Medicare generally becomes the primary payor after 33 months, which includes a three month waiting period, or earlier if the patient's employer group health plan coverage terminates. When Medicare becomes the primary payor, the payment rate we receive for that patient shifts from the commercial insurance plan rate to the Medicare payment rate.

Medicare pays 80% of the amount set by the Medicare system for each covered treatment. The patient is responsible for the remaining 20%. In most cases, a secondary payor, such as Medicare supplemental insurance, a state Medicaid program or a commercial health plan, covers all or part of these balances. Some patients, who do not qualify for Medicaid but otherwise cannot afford secondary insurance, can apply for premium payment assistance from charitable organizations through a program offered by the American Kidney Fund. We and other dialysis providers support the American Kidney Fund and similar programs through voluntary contributions. If a patient does not have secondary insurance coverage, we are generally unsuccessful in our efforts to collect from the patient the 20% portion of the ESRD composite rate that Medicare does not pay. However, we are able to recover some portion of this unpaid patient balance from Medicare through an established cost reporting process by identifying these Medicare bad debts on each center's Medicare cost report.

In 2011 we experienced a decrease in our operating costs primarily from a decline in the utilization of physician-prescribed pharmaceuticals due to continued evolution of clinical practices which helped minimize the overall negative financial impact that we incurred from reductions in our reimbursement amounts for services we provide to Medicare patients. However, certain operating expenditures, such as labor and supply costs, are subject to inflation, and without a compensating inflation-based increase in the new bundled payment rate system, could significantly impact our operating results. Our operating results can also be impacted by the cost of physician-prescribed pharmaceuticals.

In 2011, we operated a Medicare Advantage ESRD Special Needs Plan in partnership with a payor that works with CMS to provide ESRD patients full service health care. We are at risk for all medical costs of the program in excess of the capitation payments. We also participated in a CKD/ESRD demonstration program until April 2011, when we terminated the program. We were paid a management fee for program enrollees relating to CKD and ESRD disease states, which are subject to retraction if certain medical cost savings targets were not met. The demonstration program is still in the process of evaluating costs to determine whether these targets were actually met.

Medicaid revenue

Medicaid programs are state-administered programs partially funded by the federal government. These programs are intended to provide health coverage for patients whose income and assets fall below state-defined levels and who are otherwise uninsured. These programs also serve as supplemental insurance programs for co-insurance payments due from Medicaid-eligible patients with primary coverage under Medicare. Some Medicaid programs also pay for additional services, including some oral medications that are not covered by Medicare. We are enrolled in the Medicaid programs in the states in which we conduct our business.

Commercial revenues

Before a patient becomes eligible to have Medicare as their primary payor for dialysis services, a patient's commercial insurance plan, if any, is responsible for payment of such dialysis services. Although commercial payment rates vary, average commercial payment rates are generally significantly higher than Medicare rates. The payments we receive from commercial payors generate nearly all of our profits. Payment methods from commercial payors include a single lump-sum per treatment, referred to as bundled rates, and in some cases separate payments for treatments and pharmaceuticals, if used as part of the treatment, referred to as fee for service rates. Commercial payment rates are the result of negotiations between us and insurers or third-party administrators. Our out-of-network payment rates are on average higher than in-network payment rates. In 2011, we continued to enter into some commercial contracts, covering certain patients that will primarily pay us a single bundled payment rate for all dialysis services provided to these patients. However, some of the contracts will pay us for certain other services and pharmaceuticals in addition to the bundled payment. These contracts typically contain annual price escalator provisions. We are continuously in the process of negotiating agreements with our commercial payors and if our negotiations result in overall commercial rate reductions in excess of our commercial rate increases, our revenues and operating results could be negatively impacted. In addition, if there

are sustained or increased job losses in the United States as a result of current economic conditions, or depending upon changes to the healthcare regulatory system, we could experience a decrease in the number of patients covered under commercial plans.

Approximately 34% of our dialysis and related lab services revenues and approximately 11% of our patients were associated with commercial payors for the years ended December 31, 2011. Our commercial patients as a percentage of our total patients declined in 2011 and 2010, but the actual number of commercial patients has increased during these same periods. In the fourth quarter of 2011, our actual percentage of commercial patients was approximately 10%. Less than 1% of our dialysis and related lab services revenues are due directly from patients. No single commercial payor accounted for more than 6% of total dialysis and related lab services revenues for the year ended December 31, 2011.

Revenue from EPO and other pharmaceuticals

Approximately 4% of our total dialysis and related lab services revenues for the year ended December 31, 2011 are associated with the administration of physician-prescribed pharmaceuticals that are separately billable, which help improve clinical outcomes when included with the dialysis treatment. These pharmaceuticals include EPO, vitamin D analogs and iron supplements.

EPO is an erythropoiesis stimulating agent, or ESA, genetically-engineered form of a naturally occurring protein that stimulates the production of red blood cells. EPO is used in connection with all forms of dialysis to treat anemia, a medical complication most ESRD patients experience. The administration of EPO, when separately billable, accounted for approximately 3% of our dialysis and related lab services revenues for the year ended December 31, 2011.

These percentages represent a significant decrease from prior years in the amount of revenue that we generated from separately billable pharmaceuticals as a result of implementing Medicare's new single bundled payment rate system, whereby pharmaceuticals, including EPO, are now included in a single bundled payment. In addition, we also entered into some commercial contracts covering certain patients that also pay us under a single bundled rate for all dialysis services provided to these patients.

EPO is produced by a single manufacturer, Amgen. Any interruption of supply or product cost increases could adversely affect our operations. As an example, in 2011 we experienced an increase in the cost of EPO of approximately 5%. In November 2011, we entered into a seven year Sourcing and Supply Agreement with Amgen USA Inc. that expires on December 31, 2018. Under the terms of the agreement we will purchase EPO in amounts necessary to meet no less than 90% of our requirements for erythropoiesis stimulations agents. The agreement replaces in its entirety the prior one-year supply agreement between us and Amgen that expired on December 31, 2011. As long as certain conditions are met by us, the agreement limits Amgen's ability to unilaterally decide to increase the price it charges us for EPO. The agreement, among other things, provides for discounted pricing and rebates for EPO. Some of the rebates are subject to various conditions including future pricing levels of EPO by Amgen and data submission by us. In the initial years of the agreement the total rebate opportunity is less than what was provided for in the agreement that expired as the end of 2011, however, the opportunity for us to earn discounts and rebates increases over the term of the agreement.

Since late 2006, there has been significant media discussion and government scrutiny regarding anemia management practices in the United States, which has created confusion and concern in the nephrology community. In late 2006, the U.S. House of Representatives Ways and Means Committee held a hearing on the issue of the utilization of ESAs, which include EPO, and in 2007, the FDA required changes to the labeling of EPO and Aranesp® to include a black box warning, the FDA's strongest form of warning label. An FDA advisory panel on ESA use met in October 2010, which meeting was similar to the prior meeting held in 2007 in that there was significant discussion and concern about the safety of ESAs. The panel concluded it would not recommend a change in ESA labeling. However, the FDA is not bound by the panel's recommendation. In June

2011, the FDA required that the black box warning be slightly revised and also include more conservative dosing recommendations for patients with chronic kidney disease. In addition, in June 2011, CMS opened a National Coverage Analysis, or NCA, for ESAs. Further, in January 2011, CMS convened a meeting of the Medicare Evidence Development and Coverage Advisory Committee, or MEDCAC, to evaluate evidence for the pending NCA. In June 2011, CMS determined not to issue a national coverage determination for ESAs due to a lack of available evidence to establish coverage criteria or limitations.

The forgoing congressional and agency activities and related actions could result in further restrictions on the utilization and reimbursement for ESAs. Commercial payors have also increasingly examined their administration policies for EPO and, in some cases, have modified those policies. Further changes in labeling of EPO and other pharmaceuticals in a manner that alters physician practice patterns or accepted clinical practices, changes in private and governmental payment criteria, including the introduction of EPO administration policies or the conversion to alternate types of administration of EPO or other pharmaceuticals that result in further decreases in utilization or reimbursement for EPO and other pharmaceuticals, could have a material adverse effect on our revenues, earnings and cash flows.

Physician relationships

An ESRD patient generally seeks treatment at an outpatient dialysis center near his or her home where his or her treating nephrologist has practice privileges. Our relationships with local nephrologists and our ability to meet their needs and the needs of their patients are key factors in the success of our dialysis operations. Approximately 4,300 nephrologists currently refer patients to our outpatient dialysis centers. As is typical in the dialysis industry, one or a few physicians, including the outpatient dialysis center's medical director, usually account for all or a significant portion of an outpatient dialysis center's patient base. If a significant number of physicians, including an outpatient dialysis center's medical directors, were to cease referring patients to our outpatient dialysis centers, our business could be adversely affected.

Participation in the Medicare ESRD program requires that dialysis services at an outpatient dialysis center be under the general supervision of a medical director who is a licensed physician. We have engaged physicians or groups of physicians to serve as medical directors for each of our outpatient dialysis centers. At some outpatient dialysis centers, we also separately contract with one or more other physicians to serve as assistant or associate medical directors or to direct specific programs, such as home dialysis training programs. We have contracts with approximately 1,700 individual physicians and physician groups to provide medical director services.

Medical directors enter into written contracts with us that specify their duties and fix their compensation generally for periods of ten years. The compensation of our medical directors is the result of arm's length negotiations and generally depends upon an analysis of various factors such as the physician's duties, responsibilities, professional qualifications and experience, among others.

Our medical director contracts generally include covenants not to compete. Also, when we acquire an outpatient dialysis center from one or more physicians or where one or more physicians own minority interests in our outpatient dialysis centers, these physicians have agreed to refrain from owning interests in other competing outpatient dialysis centers within a defined geographic area for various time periods. These non-compete agreements restrict the physicians from owning or providing medical director services to other outpatient dialysis centers, but do not prohibit the physicians from referring patients to any outpatient dialysis center, including competing centers. Many of these non-compete agreements continue for a period of time beyond expiration of the corresponding medical director agreements, although some expire at the same time as the medical director agreement. Occasionally, we experience competition from a new outpatient dialysis center established by a former medical director following the termination of his or her relationship with us.

Government regulation

Our dialysis operations are subject to extensive federal, state and local governmental regulations. These regulations require us to meet various standards relating to, among other things, government payment programs, dialysis facilities and equipment, management of centers, personnel qualifications, maintenance of proper records and quality assurance programs and patient care.

Because we are subject to a number of governmental regulations, our business could be adversely impacted by:

Loss or suspension of federal certifications;

Loss or suspension of licenses under the laws of any state or governmental authority from which we generate substantial revenues;

Exclusion from government healthcare programs including Medicare and Medicaid;

Significant reductions or lack of inflation-adjusted increases in payment rates or reduction of coverage for dialysis and ancillary services and related pharmaceuticals;

Fines, damages and monetary penalties for anti-kickback law violations, Stark Law violations, submission of false claims, civil or criminal liability based on violations of law or other failures to meet regulatory requirements;

Claims for monetary damages from patients who believe their protected health information has been used or disclosed in violation of federal and state patient privacy laws;

Mandated changes to our practices or procedures that significantly increase operating expenses; or

Refunds of payments received from government payors and government health care program beneficiaries because of any failures to meet applicable requirements.

We expect that our industry will continue to be subject to substantial regulation, the scope and effect of which are difficult to predict. Our activities could be reviewed or challenged by regulatory authorities at any time in the future. This regulation and scrutiny could have a material adverse impact on us.

Licensure and Certification

Our dialysis centers are certified by CMS, as is required for the receipt of Medicare payments. In some states, our dialysis centers also are required to secure additional state licenses and permits. Governmental authorities, primarily state departments of health, periodically inspect our centers to determine if we satisfy applicable federal and state standards and requirements, including the conditions of participation in the Medicare ESRD program.

To date, we have not experienced significant difficulty in maintaining our licenses or our Medicare and Medicaid authorizations. However, we have experienced delays in obtaining certifications from CMS.

CMS continues to study the regulations applicable to Medicare certification to provide dialysis services. On April 15, 2008, CMS issued new regulations for Medicare-certified ESRD facilities to provide dialysis services, referred to as Conditions for Coverage. The Conditions for Coverage were effective October 14, 2008, with some provisions having a phased in implementation date of February 1, 2009. The regulations are patient, quality and outcome focused. Among other things, they establish performance expectations for facilities and staff, eliminate certain procedural requirements, and promote continuous quality improvement and patient safety measures. We have established an interdisciplinary work group that includes a comprehensive auditing process to monitor our continued compliance with the Conditions of Coverage.

Federal anti-kickback statute

The “anti-kickback” statute contained in the Social Security Act imposes criminal and civil sanctions on persons who receive, make, offer or solicit payments in return for:

The referral of a Medicare or Medicaid patient for treatment;

The ordering or purchasing of items or services that are paid for in whole or in part by Medicare, Medicaid or similar federal and state programs; or

Arranging for or recommending the ordering or purchasing of such items.

Federal criminal penalties for the violation of the anti-kickback statute include imprisonment, fines and exclusion of the provider from future participation in the Medicare and Medicaid programs. Violations of the anti-kickback statute are punishable by imprisonment for up to five years and fines of up to \$250,000 or both. Larger fines can be imposed upon corporations under the provisions of the U.S. Sentencing Guidelines and the Alternate Fines Statute. Individuals and entities convicted of violating the anti-kickback statute are subject to mandatory exclusion from participation in Medicare, Medicaid and other federal healthcare programs for a minimum of five years. Civil penalties for violation of this law include up to \$50,000 in monetary penalties per violation, repayments of up to three times the total payments between the parties and suspension from future participation in Medicare and Medicaid. Court decisions have also held that the statute is violated whenever one of the purposes of remuneration is to induce referrals.

The Department of Health and Human Services regulations create exceptions or “safe harbors” for some business transactions and arrangements. Transactions and arrangements structured within these safe harbors are deemed to not violate the anti-kickback statute. A business transaction or arrangement must satisfy every element of a safe harbor to be protected by that safe harbor. Transactions and arrangements that do not satisfy all elements of a relevant safe harbor do not necessarily violate the statute, but can be subject to greater scrutiny by enforcement agencies.

Our medical directors refer patients to our centers, and these arrangements, by which we pay them for their medical director services, must be in compliance with the federal anti-kickback statute. Among the available safe harbors is one for personal services furnished for fair market value. However, most of our agreements with our medical directors do not satisfy all seven of the requirements of the personal services safe harbor. We believe that because of the nature of our medical directors’ duties, it is impossible to satisfy the anti-kickback safe-harbor requirement that services provided under an agreement on a part-time basis must specify the schedule of intervals of service, and their precise length and the exact charge for such intervals. Accordingly, while we believe that our agreements with our medical directors satisfy as many of the elements of this safe harbor as we believe is reasonably possible, our arrangements do not qualify for safe harbor protection, as precise scheduling is not possible. We also note that there is little guidance available as to what constitutes fair market value for medical director services. We believe that our agreements do not violate the federal anti-kickback statute; however, since the arrangements do not satisfy all of the requirements for safe harbor protection, these arrangements could be challenged.

We own a controlling interest in numerous dialysis related joint ventures. These joint ventures represented approximately 18% of our dialysis and related lab services revenues. In addition, we also own minority equity investments in several other dialysis related joint ventures. Our relationships with physicians and other referral sources relating to these joint ventures are required to comply with the anti-kickback statute. Although there is a safe harbor for certain investment interests in “small entities,” it is not clear if any of our joint ventures satisfies all of the requirements for protection by this safe harbor. Under current law, physician joint ventures are not prohibited but instead require a case-by-case evaluation under the anti-kickback statute. We have structured our joint ventures to satisfy as many safe harbor requirements as we believe are reasonably possible. We believe that these investments are offered on a fair market value basis and provide returns to the physician investors only in proportion to their actual investment in the venture. We believe that our agreements do not violate the federal anti-kickback statute; however, since the arrangements do not satisfy all of the requirements for safe harbor protection, these arrangements could be challenged.

We lease space for approximately 560 of our centers from entities in which physicians hold ownership interests and we sublease space to referring physicians at approximately 220 of our dialysis centers. These arrangements must be in compliance with the anti-kickback statute. We believe that we meet the elements of the safe harbor for space rentals in all material respects.

Some medical directors and other referring physicians may own our common stock. We believe that these interests materially satisfy the requirements of the safe harbor for investments in large publicly traded companies for the anti-kickback statute.

Because we are purchasing and selling items and services in the operation of our centers that may be paid for, in whole or in part, by Medicare or a state healthcare program and because we acquire certain items and services at a discount, we must structure these arrangements in compliance with the federal anti-kickback statute. Subject to certain requirements and limitations, discounts representing reductions in the amounts we are charged for items or services based on arm's-length transactions can qualify for safe harbor protection if we fully and accurately report the discounts in the applicable Medicare cost reports. While some of the safe harbor criteria are subject to interpretation, we believe that our vendor contracts with discount provisions are in compliance with the anti-kickback statute.

Stark Law

Another federal law, known as the "Stark Law", prohibits a physician who has a financial relationship, or who has an immediate family member who has a financial relationship, with entities providing designated health services, or DHS, from referring Medicare patients to such entities for the furnishing of such services, unless an exception applies. Stark Law DHS include home health services, outpatient prescription drugs, inpatient and outpatient hospital services and clinical laboratory services. The Stark Law also prohibits the DHS entity receiving a prohibited referral from filing a claim or billing for the services arising out of the prohibited referral. The prohibition applies regardless of the reasons for the financial relationship and the referral; unlike the federal anti-kickback statute, intent to induce referrals is not required. Sanctions for violation of the Stark Law include denial of payment for claims for services provided in violation of the prohibition, refunds of amounts collected in violation, a civil penalty of up to \$15,000 for each service arising out of the prohibited referral, exclusion from the federal healthcare programs, including Medicare and Medicaid and a civil penalty of up to \$100,000 against parties that enter into a scheme to circumvent the Stark Law prohibition. Stark Law violations also can form the basis for False Claims Act liability. The types of financial arrangements between a physician and a DHS entity that trigger the self-referral prohibitions of the Stark Law are broad and include direct and indirect ownership and investment interests and compensation arrangements.

CMS has adopted implementing regulations under the Stark Law, collectively, Stark Regulations. CMS has not yet adopted implementing regulations regarding application of the Stark Law to Medicaid, but has indicated that it anticipates issuing additional regulations regarding the application of the Stark Law to Medicaid referrals.

The definition of DHS under the Stark Law excludes services paid under a composite rate, even if some of the components bundled in the composite rate are DHS. Although the new ESRD bundled payment system is no longer titled a "composite rate", we believe that the former composite rate payment system and the current bundled system are both composite systems excluded from the Stark Law. Since most services furnished to Medicare beneficiaries provided in our dialysis centers are reimbursed through a composite or bundled rate, the services performed in our facilities generally are not DHS, and the Stark Law referral prohibition does not apply to those services. The definition of DHS also excludes inpatient dialysis performed in hospitals that are not certified to provide ESRD services. Consequently, our arrangements with such hospitals for the provision of dialysis services to hospital inpatients do not trigger the Stark Law referral prohibition.

In addition, although prescription drugs are DHS, there is an exception in the Stark Regulations for EPO and other specifically enumerated dialysis drugs when furnished in or by an ESRD facility, in compliance with the

anti-kickback statute and applicable billing requirements. The exception is available only for drugs included on a list of CPT/HCPCS codes published by CMS, and in the case of home dialysis, the exception applies only to EPO, Aranesp® and equivalent drugs dispensed by the facility for use at home. While we believe that most drugs furnished by our dialysis centers are covered by the exception, dialysis centers may administer drugs that are not on the list of CPT/HCPCS codes and therefore do not meet this exception. In order for a physician who has a financial relationship with a dialysis center to order one of these drugs from the center and for the center to obtain Medicare reimbursement, another exception must apply.

We have entered into several types of financial relationships with referring physicians, including compensation arrangements. We believe that the compensation arrangements under our medical director agreements satisfy the personal services compensation arrangement exception to the Stark Law. While we believe that compensation under our medical director agreements, which is the result of arm's length negotiations, results in fair market value payments for medical director services, an enforcement agency could nevertheless challenge the level of compensation that we pay our medical directors. If the arrangement does not meet a Stark Law exception, we could in the future be required to change our practices, face civil penalties, pay substantial fines, return certain payments received from Medicare and beneficiaries or otherwise experience a material adverse effect as a result of a challenge to payments made pursuant to referrals from these physicians under the Stark Law.

Some of our dialysis centers are leased from entities in which referring physicians hold interests and we sublease space to referring physicians at some of our dialysis centers. The Stark Law provides an exception for lease arrangements if specific requirements are met. We believe that our leases and subleases with referring physicians satisfy the requirements for this exception.

Some medical directors and other referring physicians may own our common stock. We believe that these interests satisfy the Stark Law exception for investments in large publicly traded companies.

Some of our referring physicians also own equity interests in entities that operate our dialysis centers. None of the Stark Law exceptions applicable to physician ownership interests in entities to which they make DHS referrals applies to the kinds of ownership arrangements that referring physicians hold in several of our subsidiaries that operate dialysis centers. Accordingly, these dialysis centers cannot bill Medicare for DHS referrals from physician owners. If the dialysis centers bill for DHS referred by physician owners, the dialysis center would be subject to the Stark Law penalties described above.

While we believe that most of our operations do not implicate the Stark Law, particularly under the new ESRD bundled payment system, and that to the extent that our dialysis centers furnish DHS, they either meet an exception or do not bill for services that do not meet a Stark Law exception, if CMS determined that we have submitted claims in violation to the Stark Law, we would be subject to the penalties described above. In addition, it might be necessary to restructure existing compensation agreements with our medical directors and to repurchase or to request the sale of ownership interests in subsidiaries and partnerships held by referring physicians or, alternatively, to refuse to accept referrals for DHS from these physicians. Any such penalties and restructuring could have a material adverse effect on our operations.

If any of our business transactions or arrangements, including those described above, were found to violate the federal anti-kickback statute of Stark Law, we could face criminal, civil or administrative sanctions, including possible exclusion from participation in Medicare, Medicaid and other state and federal healthcare programs. Any findings that we have violated these laws could have a material adverse impact on our operations.

Fraud and abuse under state law

Many states in which we operate dialysis centers have statutes prohibiting physicians from holding financial interests in various types of medical facilities to which they refer patients. Some of these statutes could be interpreted as prohibiting physicians who hold shares of our publicly traded stock from referring patients to our

dialysis centers if the centers use our laboratory subsidiary to perform laboratory services for their patients. Some states also have laws similar to the federal anti-kickback statute that may affect our ability to receive referrals from physicians with whom we have financial relationships, such as our medical directors. Some state anti-kickback statutes also include civil and criminal penalties. Some of these statutes include exemptions applicable to our medical directors and other physician relationships or for financial interests limited to shares of publicly traded stock. Some, however, include no explicit exemption for medical director services or other services for which we contract with and compensate referring physicians or for joint ownership interests of the type held by some of our referring physicians or for financial interests limited to shares of publicly traded stock. If these statutes are interpreted to apply to referring physicians with whom we contract for medical director and similar services, to referring physicians with whom we hold joint ownership interests or to physicians who hold interests in DaVita limited solely to publicly traded stock, we may be required to terminate or restructure some or all of our relationships with or refuse referrals from these referring physicians and could be subject to civil and administrative sanctions, refund requirements and exclusions from government healthcare programs, including Medicare and Medicaid. Such events could negatively affect the decision of referring physicians to refer patients to our centers.

The False Claims Act

The federal False Claims Act, or FCA, is a means of policing false bills or false requests for payment in the healthcare delivery system. In part, the FCA authorizes the imposition of up to three times the government's damages and civil penalties on any person who:

Knowingly presents or causes to be presented to the federal government, a false or fraudulent claim for payment or approval;

Knowingly makes, uses or causes to be made or used, a false record or statement to get a false or fraudulent claim paid or approved by the federal government;

Conspires to defraud the federal government by getting a false or fraudulent claim allowed or paid; or

Knowingly makes, uses or causes to be made or used, a false record or statement to conceal, avoid or decrease an obligation to pay or transmit money or property to the federal government.

In addition, recent amendments to the FCA impose severe penalties for the knowing and improper retention of overpayments collected from government payors. These amendments could subject our procedures for identifying and processing overpayments to greater scrutiny. We have made significant investments in additional resources to accelerate the time it takes to identify and process overpayments and we may be required to make additional investments in the future. An acceleration in our ability to identify and process overpayments could result in us refunding overpayments to government or other payors sooner than we have in the past. A significant acceleration of these refunds could have a material adverse affect on our operating cash flows.

The penalties for a violation of the FCA range from \$5,500 to \$11,000 for each false claim plus three times the amount of damages caused by each such claim. The federal government has used the FCA to prosecute a wide variety of alleged false claims and fraud allegedly perpetrated against Medicare and state healthcare programs, including coding errors, billing for services not rendered, the submission of false cost reports, billing for services at a higher payment rate than appropriate, billing under a comprehensive code as well as under one or more component codes included in the comprehensive code and billing for care that is not considered medically necessary. Although still subject to dispute, several courts have also determined that a violation of the federal anti-kickback statute can form the basis for liability under the FCA, and filing claims or failing to refund amounts collected in violation of the Stark Law can form the basis for liability under the FCA. In addition to the provisions of the FCA, which provide for civil enforcement, the federal government can use several criminal statutes to prosecute persons who are alleged to have submitted false or fraudulent claims for payment to the federal government.

The Health Insurance Portability and Accountability Act of 1996

The Health Insurance Portability and Accountability Act of 1996 and its implementing privacy and security regulations, as amended by the federal Health Information Technology for Economic and Clinical Health Act (HITECH Act) (collectively referred to as HIPAA), requires us to provide certain protections to patients and their health information (Protected Health Information, or PHI). HIPAA requires us to afford patients certain rights regarding their PHI, and to limit uses and disclosure of their PHI existing in any media form (electronic and hardcopy). HIPAA also requires us to implement administrative, physical, and technical safeguards with respect to electronic PHI. We believe our HIPAA Privacy and Security Program sufficiently address HIPAA requirements.

Other regulations

Our operations are subject to various state hazardous waste and non-hazardous medical waste disposal laws. These laws do not classify as hazardous most of the waste produced from dialysis services. Occupational Safety and Health Administration regulations require employers to provide workers who are occupationally subject to blood or other potentially infectious materials with prescribed protections. These regulatory requirements apply to all healthcare facilities, including dialysis centers, and require employers to make a determination as to which employees may be exposed to blood or other potentially infectious materials and to have in effect a written exposure control plan. In addition, employers are required to provide or employ hepatitis B vaccinations, personal protective equipment and other safety devices, infection control training, post-exposure evaluation and follow-up, waste disposal techniques and procedures and work practice controls. Employers are also required to comply with various record-keeping requirements. We believe that we are in material compliance with these laws and regulations.

A few states have certificate of need programs regulating the establishment or expansion of healthcare facilities, including dialysis centers. We believe that we are in material compliance with all applicable state certificate of need laws.

Corporate compliance program

Our dialysis operations are subject to extensive federal, state and local government regulations. Management has designed and implemented a company-wide corporate compliance program as part of our commitment to comply fully with all applicable laws and regulations and to maintain the high standards of conduct we expect from all of our teammates. We continuously review this program and enhance it as necessary. The primary purposes of the program include:

- Increasing, through training and education, the awareness of our teammates and affiliated professionals of the necessity of complying with all applicable laws and regulations;

- Auditing and monitoring the activities of our dialysis centers, laboratories and billing offices on a regular basis to identify potential instances of noncompliance in a timely manner;

- Establishing guidelines around physicians roles and responsibilities that require our physicians attest to their adherence to these guidelines on a periodic basis; and

- Ensuring that we take steps to resolve instances of noncompliance or to address areas of potential noncompliance as promptly as we become aware of them.

When evaluating the effectiveness of our corporate compliance program, we take into consideration a number of factors, including favorable results under various government inquiries and adherence to industry standards.

We have a code of conduct that each of our teammates and affiliated professionals must follow and we have a confidential toll-free hotline (888-458-5848) for teammates and patients to report potential instances of noncompliance. Our Chief Compliance Officer administers the compliance program. The Chief Compliance Officer reports directly to our Chief Executive Officer, our Chief Operating Officer and to the Compliance Committee of our Board of Directors.

Insurance

We maintain insurance for property and general liability, professional liability, directors' and officers' liability, workers compensation and other coverage in amounts and on terms deemed adequate by management based on our actual claims experience and expectations for future claims. Future claims could, however, exceed our applicable insurance coverage. Physicians practicing at our dialysis centers are required to maintain their own malpractice insurance and our medical directors are required to maintain coverage for their individual private medical practices. Our liability policies cover our medical directors for the performance of their duties as medical directors at our outpatient dialysis centers.

Capacity and location of our centers

We are able to increase our capacity by extending hours at our existing centers, expanding our existing centers, relocating our centers, developing new centers and by acquiring centers. The development of a typical outpatient dialysis center by us generally requires approximately \$2.5 million for leasehold improvements, equipment and first-year working capital. Based on our experience, a new center typically opens within a year after the property lease is signed, normally achieves operating profitability in the second year after certification and normally reaches maturity within three to five years. Acquiring an existing outpatient dialysis center requires a substantially greater initial investment, but profitability and cash flow are generally initially more predictable. To a limited extent, we enter into agreements to provide management and administrative services to outpatient dialysis centers in which we either own a minority equity investment, or are wholly-owned by third parties in return for management fees, which are typically based on a percentage of revenues or cash collections of the managed operations.

The table below shows the growth of our company by number of dialysis centers.

	<u>2011</u>	<u>2010</u>	<u>2009</u>	<u>2008</u>	<u>2007</u>
Number of centers at beginning of year	1,612	1,530	1,449	1,359	1,300
Acquired centers	178 ⁽¹⁾	41	19	20	16
Developed centers	65	65	78	86	64
Net change in centers with management and administrative services agreements*	4	–	8 ⁽²⁾	1	(15) ⁽³⁾
Sold and closed centers**	(32) ⁽¹⁾	(10)	(8)	(9)	(4)
Closed centers***	(7)	(14)	(16)	(8)	(2)
Number of centers at end of year	<u>1,820</u>	<u>1,612</u>	<u>1,530</u>	<u>1,449</u>	<u>1,359</u>

(1) In 2011, we acquired 113 dialysis centers and divested a total of 30 centers in connection with the acquisition of DSI.

(2) During 2009, we made minority equity investments in 6 centers and we entered into 2 additional management and administrative service agreements.

(3) In November 2007, one of our management and administration service agreements was terminated, in which we provided management and administrative services to 20 dialysis centers.

* Represents dialysis centers in which we either own a minority equity investment, or are wholly-owned by third parties.

** Represents dialysis centers that were sold and/or closed in which patients were not retained.

*** Represents dialysis centers that were closed and the majority of patients were retained and transferred to one of our other existing outpatient dialysis centers.

As of December 31, 2011, we operated or provided administrative services to a total of 1,820 outpatient dialysis centers, of which 1,809 are located in the United States and 11 are located in three countries outside of the United States. A total of 1,784 are consolidated in our financial statements. Of the remaining 36 unconsolidated outpatient dialysis centers, we own a minority equity investment in 19 centers and provide management and administrative services to 17 centers, of which three centers are located outside of the United States, that are wholly-owned by third parties. The locations of the 1,784 outpatient dialysis centers consolidated in our financial statements at December 31, 2011 were as follows:

<u>State</u>	<u>Centers</u>	<u>State</u>	<u>Centers</u>	<u>State</u>	<u>Centers</u>
California	216	New York	40	Kansas	19
Texas	151	Minnesota	39	Nevada	18
Florida	139	Kentucky	32	Nebraska	14
Georgia	105	Oklahoma	31	Massachusetts	13
Ohio	84	Colorado	30	Mississippi	11
Pennsylvania	75	New Jersey	30	District of Columbia	9
Illinois	70	Wisconsin	28	Idaho	9
North Carolina	62	Louisiana	27	Utah	4
Michigan	56	South Carolina	26	New Mexico	4
Virginia	55	Arizona	25	West Virginia	4
Maryland	51	Washington	25	South Dakota	3
Indiana	48	Connecticut	21	New Hampshire	2
Tennessee	47	Iowa	20	North Dakota	2
Missouri	46	Oregon	20	Rhode Island	1
Alabama	44	Arkansas	20		

<u>International</u>	<u>Centers</u>
India	6
Germany	2

Competition

The U.S. dialysis industry has consolidated significantly over time but still remains highly competitive, particularly in terms of acquiring existing outpatient dialysis centers. We continue to face increased competition in the U.S. dialysis industry from large and medium-sized providers who compete directly with us for the acquisition of dialysis businesses, relationships with physicians to act as medical directors and for individual patients. In addition, as we continue our international dialysis expansion into various international markets, we will face competition from large and medium-sized providers for these acquisition targets as well. Acquisitions, developing new outpatient dialysis centers, patient retention and physician relationships are an important part of our growth strategy and our business could be adversely affected if we are not able to continue to make acquisitions on reasonable terms, experience significant patient attrition to our competitors and are not able to maintain or establish new relationships with physicians. Competition for qualified physicians to act as medical directors and for inpatient dialysis services agreements with hospitals is also intense. Occasionally, we have also experienced competition from former medical directors or referring physicians who have opened their own dialysis centers. In addition, we experience competitive pressures in connection with negotiating contracts with commercial healthcare payors.

The two largest dialysis companies, Fresenius Medical Care, or Fresenius, and our company, account for approximately two-thirds of outpatient dialysis patients in the United States with our company serving approximately 32% of the total outpatient dialysis patients. Approximately 47% of the centers not owned by us or Fresenius are owned or controlled by hospitals or non-profit organizations. Hospital-based and non-profit dialysis units typically are more difficult to acquire than physician-owned centers. Because of the ease of entry into the dialysis business and the ability of physicians to be medical directors for their own centers, competition for growth in existing and expanding markets is not limited to large competitors with substantial financial resources.

Fresenius also manufactures a full line of dialysis supplies and equipment in addition to owning and operating outpatient dialysis centers. This may give them cost advantages over us because of their ability to manufacture their own products. However, Fresenius has been one of our largest suppliers of dialysis products. In January 2010, we entered into an agreement with Fresenius which committed us to purchase a certain amount of dialysis equipment, parts and supplies from them through 2013. In addition, in August 2006 in connection with the DVA Renal Healthcare acquisition, we also entered into a product supply agreement with Gambro Renal Products that requires us to purchase a certain amount of our hemodialysis non-equipment product supplies, such as dialyzers, at fixed prices through 2015. Our purchases of products in these categories generally offered by both Fresenius and Gambro Renal Products represent approximately 4% of our total operating expenses. During 2011, we purchased hemodialysis products and supplies from Gambro Renal Products representing approximately 2% of our total operating expenses.

Teammates

As of December 31, 2011, we had approximately 41,000 teammates:

Licensed professional staff (nurses, dieticians and social workers)	18,000
Other patient care and center support staff and laboratory personnel	17,500
Corporate, billing and regional administrative staff	5,500

Our dialysis business requires nurses with specialized training for treating patients with complex care needs. Recruitment and retention of nurses are continuing concerns for healthcare providers due to short supply. We have an active program of investing in our professional healthcare teammates to help ensure we meet our recruitment and retention targets, including expanded training opportunities, tuition reimbursements and other incentives.

Item 1A. Risk Factors.

This Annual Report on Form 10-K contains statements that are forward-looking statements within the meaning of the federal securities laws. These statements involve known and unknown risks and uncertainties including the risks discussed below. The risks discussed below are not the only ones facing our business. Please read the cautionary notice regarding forward-looking statements in Item 7 of this Part 1 under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations".

If the average rates that commercial payors pay us decline significantly, it would have a material adverse effect on our revenues, earnings and cash flows.

Approximately 34% of our dialysis and related lab services revenues for the year ended December 31, 2011 were generated from patients who have commercial payors as the primary payor. The majority of these patients have insurance policies that pay us on terms and at rates that are generally significantly higher than Medicare rates. The payments we receive from commercial payors generate nearly all of our profit and all of our nonacute dialysis profits come from commercial payors. We continue to experience downward pressure on some of our commercial payment rates and it is possible that commercial payment rates could be materially lower in the future. The downward pressure on commercial payment rates is a result of general conditions in the market, recent and future consolidations among commercial payors, increased focus on dialysis services and other factors.

We are continuously in the process of negotiating our existing or potentially new agreements with commercial payors who tend to be aggressive in their negotiations with us. Sometimes many significant agreements are up for renewal or being renegotiated at the same time. In the event that our continual negotiations result in overall commercial rate reductions in excess of overall commercial rate increases, the cumulative effect could have a material adverse effect on our financial results. Consolidations have significantly increased the negotiating leverage of commercial payors. Our negotiations with payors are also influenced by competitive pressures. We expect that some of our contracted rates with commercial payors may decrease or that we may experience decreases in patient volume as our negotiations with commercial payors continue. In addition to increasing downward pressure on contracted commercial payor rates, payors have been attempting to impose restrictions and limitations on non-contracted or out-of-network providers. In some circumstances for some commercial payors, our centers are designated as out-of-network providers. Rates for out-of-network providers are on average higher than rates for in-network providers. We believe commercial payors have or will begin to restructure their benefits to create disincentives for patients to select or remain with out-of-network providers and to decrease payment rates for out-of-network providers. Decreases in out-of-network rates and restrictions on out-of-network access combined with decreases in contracted rates could result in a significant decrease in our overall revenue derived from commercial payors. If the average rates that commercial payors pay us decline significantly, it would have a material adverse effect on our revenues, earnings and cash flows.

If the number of patients with higher-paying commercial insurance declines, then our revenues, earnings and cash flows would be substantially reduced.

Our revenue levels are sensitive to the percentage of our patients with higher-paying commercial insurance coverage. A patient's insurance coverage may change for a number of reasons, including changes in the patient's or a family member's employment status. Currently, for a patient covered by an employer group health plan, Medicare generally becomes the primary payor after 33 months, or earlier, if the patient's employer group health plan coverage terminates. When Medicare becomes the primary payor, the payment rate we receive for that patient shifts from the employer group health plan rate to the lower Medicare payment rate. We have seen an increase in the number of patients who have government-based programs as their primary payors which we believe is largely a result of improved mortality and recent economic conditions which have a negative impact on the percentage of patients covered under commercial insurance plans. To the extent there are sustained or increased job losses in the United States, independent of whether general economic conditions might be improving, we could experience a continued decrease in the number of patients covered under commercial plans.

We could also experience a further decrease if changes to the healthcare regulatory system result in fewer patients covered under commercial plans or an increase of patients covered under more restrictive commercial plans with lower reimbursement rates. In addition, our continuous process of negotiations with commercial payors under existing or potentially new agreements could result in a decrease in the number of patients under commercial plans to the extent that we cannot reach agreement with commercial payors on rates and other terms, resulting in termination or non-renewals of existing agreements or our inability to enter into new ones. If there is a significant reduction in the number of patients under higher-paying commercial plans relative to government-based programs that pay at lower rates, it would have a material adverse effect on our revenues, earnings and cash flows.

Changes in the structure of, and payment rates under the Medicare ESRD program, including the Budget Control Act of 2011 and other healthcare reform initiatives, could substantially reduce our revenues, earnings and cash flows.

Approximately 49% of our dialysis and related lab services revenues for the year ended December 31, 2011 was generated from patients who have Medicare as their primary payor. Prior to January 1, 2011, the Medicare ESRD program paid us for dialysis treatment services at a fixed composite rate. The Medicare composite rate was the payment rate for a dialysis treatment including the supplies used in those treatments, specified laboratory tests and certain pharmaceuticals. Certain other pharmaceuticals, including EPO, vitamin D analogs and iron supplements, as well as certain specialized laboratory tests, were separately billed.

In July 2008, MIPPA was passed by Congress. This legislation introduced a new payment system for dialysis services beginning in January 2011 whereby payment for dialysis treatment and related services is now made under a bundled payment rate which provides a fixed rate to encompass all goods and services provided during the dialysis treatment, including pharmaceuticals that were historically separately reimbursed to the dialysis providers, such as EPO, vitamin D analogs and iron supplements, as well as laboratory testing. On August 12, 2010, the Centers for Medicare & Medicaid Services, or CMS, published the final rule implementing the bundled payment in the Federal Register. The initial 2011 bundled rate included reductions of 2% from the prior reimbursement and further reduced overall rates by 5.94% tied to an expanded list of case-mix adjusters which can be earned back based upon the presence of these certain patient characteristics and co-morbidities at the time of treatment. There are also other provisions which may impact payment including an outlier pool and a low volume facility adjustment.

Another important provision in the new law is an annual adjustment, or market basket update, each year to the base ESRD Prospective Payment Rate (PPS). Absent action by Congress the PPS annual rate will be automatically updated by a formulaic inflation adjustment. On October 14, 2011, the Medicare Payment Advisory Commission, or MedPAC, sent a letter to chairmen and ranking members of the Senate Finance Committee and the House Committees on Ways and Means and Energy and Commerce that included a number of recommendations, including a reduction in the 2012 dialysis PPS update to 1.0% (rather than the 2.1% update that eventually was adopted). Although this 1.0% update was not adopted, the MedPAC focus on such a reduction indicates further scrutiny of the annual update is possible.

On November 1, 2011, CMS issued the final ESRD Prospective Payment System (PPS) rule for 2012. The base will increase by 2.1%, representing a market base of increase of 3.0% less a productivity adjustment of 0.9%. The increase in the final base rate for 2012 (2.1%) is slightly greater than the increase of 1.8% stated in the proposed 2012 ESRD PPS rule published in July 2011, and was made irrespective of the MedPAC recommendation for a reduction of the dialysis update. In 2012 and beyond the ESRD PPS system also includes a quality incentive program (QIP) that reduces payments by up to 2% and provides facilities the opportunity to earn all or some of the amount withheld based on meeting certain defined clinical goals. In December 2011, CMS published the list of facilities subject to a QIP reduction for 2012. The vast majority of our facilities will not be subject to a QIP reduction in 2012 and the overall reduction to our rates is 0.2%.

We believe the new payment system presents operating clinical and financial risks. For example, with regard to the expanded list of case-mix adjusters, there is a risk that our dialysis centers or billing and other systems may not accurately document and track the appropriate patient-specific characteristics, resulting in a reduction or overpayment in the amounts of the payments that we would otherwise be entitled to receive.

Beginning January 1, 2014, certain oral-only ESRD drugs (currently paid separately to pharmacies under Medicare Part D) will be included in the ESRD bundled payment to dialysis facilities. CMS delayed the inclusion of these oral only ESRD drugs until 2014 in order to assess whether the pricing mechanism used for oral drugs with injectable equivalents (included in the bundle beginning January 1, 2011) could be applied to oral only drugs. It is currently unclear how CMS will “price” the oral-only drugs for inclusion in the ESRD bundle in 2014. Inadequate pricing could have a significant negative financial impact on our dialysis facilities given the volume and value of these drugs.

We expect to continue experiencing increases in operating costs that are subject to inflation, such as labor and supply costs, regardless of whether there is a compensating inflation-based increase in Medicare payment rates or in payments under the new bundled payment rate system.

On August 2, 2011, the President signed into law the “Budget Control Act of 2011” (Public Law 112-25), which raised the debt ceiling and put into effect a series of actions to reduce the federal budget deficit over ten years. The first phase required reductions of \$917 billion in domestic and defense discretionary spending only. Under the second phase, the law created a 12-member Joint Select Committee on Deficit Reduction, or the Committee, which was given a goal of \$1.5 trillion in deficit reduction, but a mandatory \$1.2 trillion in deficit reduction over ten years. The deficit reduction could have been through spending cuts, increased revenues, or a combination of both. The Committee was required to report its recommendations to the Congress no later than November 23, 2011. The Congress was required to act on the recommendations, without amendment, by December 23, 2011. The Committee failed to report a deficit reduction bill by November 23, and the Congress subsequently failed to enact deficit reduction legislation. As a result, in January 2012, a \$1.2 trillion sequestration order requiring across-the-board spending cuts will be developed. The order would take effect in January 2013 for the entire fiscal year 2013 budget. The cuts in the sequestration order will be distributed equally between defense and nondefense spending. Among the health-related programs exempted from sequestration are Social Security, Medicaid, Veterans Health Administration, or VA, benefits and pensions, federal retirement funds, civilian and military pay, child nutrition, SSI, and WIC. Medicare providers would be cut by 2% of total program costs.

We also cannot predict whether we will be able to comply with the CMS rules related to the bundled payment system as processes and systems are modified substantially to capture all required data. To the extent we are not able to adequately bill and collect for certain payment adjusters and are not able to offset the mandated reductions in reimbursement or if we face regulatory enforcement actions and penalties as a result of alleged improper billing of governmental programs, it could have a material adverse effect on our revenues, earnings and cash flows. (For additional details regarding the risks we face for failing to adhere to our Medicare and Medicaid regulatory compliance obligations, see the risk factor below under the heading “If we fail to adhere to all of the complex government regulations that apply to our business, we could suffer severe consequences that would substantially reduce our revenues, earnings and cash flows”).

Health care reform could substantially reduce our revenues, earnings and cash flows.

In March 2010, broad health care reform legislation was enacted in the United States. Although many of the provisions of the new legislation do not take effect immediately, and may be modified before they are implemented, the reforms could have an impact on our business in a number of ways. We cannot predict how employers, private payors or persons buying insurance might react to these changes or what form many of these regulations will take before implementation. In July 2011, the Department of Health and Human Services, or HHS, issued two proposed rules related to the establishment of health care insurance exchanges due to be operating by 2014 that will provide a

marketplace for eligible individuals to purchase health care insurance. The proposed rules provide clarifications on the requirements related to implementation of such exchanges, outline areas of state flexibility in their implementation of such exchanges and provide standards for certain risk adjustment mechanisms. We believe the establishment of health care insurance exchanges could result in a reduction in patients covered by commercial insurance or an increase of patients covered under more restrictive commercial plans with lower reimbursement rates. To the extent that the implementation of such exchanges results in a reduction in patients covered by commercial insurance or a reduction in reimbursement rates for our services from commercial and/or government payors, our revenues, earnings and cash flows could be adversely affected.

In October 2011, CMS issued a final rule concerning the Medicare Shared Savings Program established by the health care reform legislation, which under the statute was required to be implemented no later than January 1, 2012. The Medicare Shared Savings Program will provide financial incentives to health care providers and suppliers that work together to furnish coordinated, high-quality care to Medicare beneficiaries through accountable care organizations, or ACOs.

To qualify for financial incentives, ACOs must successfully satisfy quality performance standards and also reduce health care costs. ACOs will receive higher percentages of shared savings if they demonstrate they are providing high quality care and achieving a minimum savings based upon the average per capita Medicare expenditures for beneficiaries who have been assigned to the ACOs. Separate expenditure calculations will be made for certain Medicare beneficiary populations, including beneficiaries with ESRD. During an ACO's initial three-year agreement period, the ACO may elect to operate under a one-sided model, where the ACO shares in savings but is not responsible for losses (i.e., costs that exceed a target established by CMS) or a two-sided model, whereby the ACO is eligible for higher sharing rates but in addition to sharing in savings, is at risk for sharing in any losses. During subsequent agreement periods, the ACO must operate under the two-sided model.

CMS will start accepting applications from prospective ACOs in early 2012: ACOs may apply to participate in the program with a start date of April 1, 2012 or July 1, 2012. We are currently uncertain of the extent to which ACOs will impact the health care market. As a provider of dialysis services, we may choose to participate in one or several ACOs. Even if we do not participate in this program, we will need to be aware of how we are performing under the program's criteria. An ACO's quality measures and expenditures include the care furnished by non-participating providers. Therefore, if our patients are assigned to ACOs, the quality and cost of care that we furnish will be included in the ACOs' calculations regardless of our participation in the program. We may also be competing against ACOs. If we are unable to perform at the levels established under the program we may be at risk for losing our Medicare patient base, which would have a materially adverse effect on our revenues, earnings and cash flow. Furthermore, even if providers and suppliers elect not to participate in ACOs, there are many similar initiatives with government and private payors that are being implemented and which may arise in the future, including the development of models similar to ACOs, Independent Practice Associations and Integrated Delivery Systems or evolutions of those concepts.

For example, the CMS Center for Medicare & Medicaid Innovation, or Innovation Center, has developed several other demonstration projects aimed at reforming care delivery that include shared savings, such as the Pioneer Accountable Care Organizations Model, the Bundled Payments for Care Improvement Initiative and the Comprehensive Primary Care Initiative. In addition, the Innovation Center may establish other demonstration projects that involve shared savings in the future and it is possible that partial capitation arrangements and specific diseases or care settings may be targeted. The further development of these types of models could create situations where ACOs or similar entities are accountable for coordinating more care for patients. This shift in accountability may require us to negotiate contracts for services with intermediaries instead of directly with the payors. It is possible that payment rates negotiated with intermediaries could be materially lower in the future, which would have a material adverse effect on our revenues, earnings and cash flows.

In addition, the health care reform legislation introduced severe penalties for the knowing and improper retention of overpayments collected from government payors. As a result, we have made significant investments

in additional resources to accelerate the time it takes to identify and process overpayments and we may be required to make additional investments in the future. Acceleration in our ability to identify and process overpayments could result in us refunding overpayments to government or other payors sooner than we have in the past, which could have a material adverse effect on our operating cash flows. The failure to return identified overpayments within the specified time frame is now a violation of the federal False Claims Act, or FCA.

The health care reform legislation also reduced the timeline to file Medicare claims, which now must be filed with the government within one calendar year after the date of service. To comply with this reduced timeline, we must deploy significant resources and may change our claims processing methods to ensure that our Medicare claims are filed in a timely fashion. Failure to file a claim within the one year window could result in payment denials, adversely affecting our revenues, earnings and cash flows.

Effective March 2011, CMS instituted new screening procedures and a new \$500 enrollment fee for providers enrolling and re-enrolling in government health care programs. A provider is subject to screening upon initial enrollment and each time the provider re-validates its enrollment application. Screening includes verification of enrollment information and review of various federal databases to ensure the provider has valid tax identification, NPI numbers and is not excluded. We expect this screening process to delay the Medicare contractor approval process, potentially causing a delay in reimbursement. The enrollment fee is also applicable upon initial enrollment, re-validation, and each time an existing provider adds a new facility location. This fee is an additional expense that must be paid for each center every three years and could be more significant if other government and commercial payors follow this trend. Ultimately, we anticipate the new screening and enrollment requirements will require additional personnel and financial resources and will potentially delay the enrollment and revalidation of our centers which in turn will delay payment.

Other reform measures allow CMS to place a moratorium on new enrollment of providers and to suspend payment to providers upon a credible allegation of fraud from any source. These types of reform measures, or others, depending upon the scope and breadth of the implementing regulations, could adversely impact our revenues, earnings and cash flows.

Changes in state Medicaid or other non-Medicare government-based programs or payment rates could reduce our revenues, earnings and cash flows.

Approximately 16% of our dialysis and related lab services revenues for the year ended December 31, 2011 was generated from patients who have state Medicaid or other non-Medicare government-based programs, such as Medicare-assigned plans or the VA, as their primary coverage. As state governments and governmental organizations face increasing budgetary pressure, we may in turn face reductions in payment rates, delays in the timing of payments, limitations on eligibility or other changes to the applicable programs. For example, some programs, such as certain state Medicaid programs and the VA, have recently considered, proposed or implemented rate reductions.

On December 17, 2010, the Department of Veterans Affairs published a final rule in which it materially changed the payment methodology and ultimately the amount paid for dialysis services furnished to veterans in non-VA centers such as ours. In the final rule, the VA adopted the bundled payment system implemented by Medicare and estimated a reduction of 39% in payments for dialysis services to veterans at non-VA centers. Approximately 2% of our dialysis and related lab services revenues for the year ended December 31, 2011 was generated by the VA. The new VA payment methodology will have a significant negative impact on our revenues, earnings and cash flows as a result of the reduction in rates or as a result of the decrease in the number of VA patients we serve. We recently executed contractual agreements with the VA and there is some uncertainty as to when this rule will take effect for the patients covered by these contracts. While at this time the contracts remain in force, these agreements provide for the right for either party to terminate the agreement without cause on short notice. Further, patients who are not covered by the contractual arrangements will likely be reimbursed at Medicare rates beginning with the date of implementation of the rule. If the VA proceeds with payment rate reductions or fails to renew our existing contracts, we might have to cease accepting patients under this program and could even be forced to close centers.

State Medicaid programs are increasingly adopting Medicare-like bundled payment systems, but sometimes these new payment systems are poorly defined and could include all drugs (even those oral-only drugs that Medicare will not include in the bundled payment until 2014) and are implemented without any claims processing infrastructure, or patient or facility adjusters. If these new payment systems are implemented without any adjusters and claims processing changes, Medicaid payments will be substantially reduced and the costs to submit such claims may increase. In addition, some state Medicaid program eligibility requirements mandate that citizen enrollees in such programs provide documented proof of citizenship. If our patients cannot meet these proof of citizenship documentation requirements, they may be denied coverage under these programs. These Medicaid payment and enrollment changes, along with similar changes to other non-Medicare government programs could reduce the rates paid by these programs for dialysis and related services, delay the timing of payment for services provided, and further limit eligibility for coverage which could adversely affect our revenues, earnings and cash flows.

Changes in clinical practices, payment rates or regulations impacting EPO and other pharmaceuticals could reduce our revenues, earnings and cash flows.

Historically, Medicare and most Medicaid programs paid for EPO outside of the composite rate. This separate payment has long been the subject of discussions regarding appropriate dosing and payment in an effort to reduce escalating expenditures for EPO. Since January 1, 2011, Medicare has bundled EPO into the prospective payment system such that dosing variations will not change the amount paid to a dialysis facility. Although some Medicaid programs and other payors suggest movement towards a bundled payment system inclusive of EPO, some non-Medicare payors continue to pay for EPO separately from the treatment rate. The administration of EPO and other pharmaceuticals that are separately billable accounted for approximately 4% of our dialysis and related lab services revenues for the year ended December 31, 2011, with EPO alone accounting for approximately 3% of our dialysis and related lab services revenues for the same period. Changes in clinical practices that result in further decreased utilization of prescribed pharmaceuticals or changes in payment rates for those pharmaceuticals could reduce our revenues, earnings and cash flows.

Since late 2006, there has been significant media discussion and government scrutiny regarding anemia management practices in the United States which has created confusion and concern in the nephrology community. In late 2006, the U.S. House of Representatives Ways and Means Committee held a hearing on the issue of the utilization of ESAs, which include EPO, and in 2007, the FDA required changes to the labeling of EPO and Aranesp® to include a black box warning, the FDA's strongest form of warning label. An FDA advisory panel on ESA use met in October 2010, which meeting was similar to the prior meeting held in 2007 in that there was significant discussion and concern about the safety of ESAs. The panel concluded it would not recommend a change in ESA labeling. However, the FDA is not bound by the panel's recommendation. In June 2011, the FDA required that the black box warning be slightly revised and also include more conservative dosing recommendations for patients with chronic kidney disease. In addition, in June 2011, CMS opened a National Coverage Analysis, or NCA, for ESAs. Further in January 2011, CMS convened a meeting of the Medicare Evidence Development and Coverage Advisory Committee, or MEDCAC, to evaluate evidence for the pending NCA. In June 2011, CMS determined not to issue a national coverage determination for ESAs due to a lack of available evidence to establish coverage criteria or limitations.

The forgoing congressional and agency activities and related actions could result in further restrictions on the utilization and reimbursement for ESAs. Commercial payors have also increasingly examined their administration policies for EPO and, in some cases, have modified those policies. Further changes in labeling of EPO and other pharmaceuticals in a manner that alters physician practice patterns or accepted clinical practices, changes in private and governmental payment criteria, including the introduction of EPO administration policies or the conversion to alternate types of administration of EPO or other pharmaceuticals that result in further decreases in utilization or reimbursement for EPO and other pharmaceuticals, could have a material adverse effect on our revenues, earnings and cash flows.

Changes in EPO pricing could materially reduce our earnings and cash flows and affect our ability to care for our patients.

In November 2011, we entered into a seven year Sourcing and Supply Agreement with Amgen USA Inc. Under the agreement we committed to purchase EPO in amounts necessary to meet no less than 90% of our requirements for erythropoiesis stimulating agents. The agreement replaces in its entirety the prior one-year supply agreement between us and Amgen that expired on December 31, 2011. As long as certain conditions are met by us, the agreement limits Amgen's ability to unilaterally decide to increase the price for EPO. Future increases in the cost of EPO without corresponding increases in payment rates for EPO from commercial payors and without corresponding increases in the Medicare bundled rate could have a material adverse effect on our earnings and cash flows and ultimately reduce our income. Our agreement with Amgen for EPO provides for discounted pricing and rebates for EPO. Some of the rebates are subject to various conditions including but not limited to future pricing levels of EPO by Amgen and data submission by us. In addition, the rebates are subject to certain limitations. We cannot predict whether, over the seven year term of the agreement, we will continue to receive the rebates for EPO that we have received in the past, or whether we will continue to achieve the same levels of rebates within that structure as we have historically achieved. In the initial years of the agreement, however, the total rebate opportunity is less than what was provided in the agreement that expired at the end of 2011, however, the opportunity for us to earn discounts and rebates increases over the term of the agreement. Factors that could impact our ability to qualify for rebates provided for in our agreement with Amgen in the future include, but are not limited to, our ability to track certain data elements. We cannot predict whether we will be able to meet the applicable qualification requirements for receiving rebates. Failure to meet certain targets and earn the specified rebates could have a material adverse effect on our earnings and cash flows.

We are the subject of a number of inquiries by the federal government and two private civil suits, any of which could result in substantial penalties or awards against us, imposition of certain obligations on our practices and procedures, exclusion from future participation in the Medicare and Medicaid programs and, in certain cases, criminal penalties.

We are the subject of a number of inquiries by the federal government. We have received subpoenas or other requests for documents from the federal government in connection with the 2005 U.S. Attorney investigation, the Woodard private civil suit, the Vainer private civil suit, the 2010 U.S. Attorney physician relationship investigation, the 2011 U.S. Attorney physician relationship investigation and the 2011 U.S. Attorney Medicaid investigation. Certain current and former members of the Board and executives have been subpoenaed to testify before the grand jury in Colorado, and other Company representatives may also receive subpoenas for testimony related to the 2011 U.S. Attorney physician relationship investigation (see Part I, Item 3, of this report under the caption "Legal Proceedings" for additional details regarding these matters). After investigation, the government did not intervene and is not actively pursuing either the Woodard or the Vainer private civil suits mentioned above. In each of these private civil suits, a relator has filed a complaint against us in federal court under the *qui tam* provisions of the FCA and is pursuing the claims independently. The parties are engaged in active litigation. We are cooperating with the OIG and those offices of the U.S. Attorney still actively pursuing the matters mentioned above and are producing the requested records. Although we cannot predict whether or when proceedings might be initiated by the federal government, the scope of such proceedings or when these matters may be resolved, it is not unusual for investigations such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators. Responding to the subpoenas or investigations and defending ourselves in the private civil suits will continue to require management's attention and significant legal expense. Any negative findings could result in substantial financial penalties or awards against us, imposition of certain obligations on our practices and procedures, exclusion from future participation in the Medicare and Medicaid programs and, in certain cases, criminal penalties. To our knowledge, no proceedings have been initiated by the federal government against us at this time.

Continued inquiries from various governmental bodies with respect to our utilization of EPO and other pharmaceuticals will require management's attention, cause us to incur significant legal expense and could result in substantial financial penalties against us, repayment obligations or exclusion from future participation in the Medicare and Medicaid programs, and could have a material adverse effect on our revenues, earnings and cash flows.

In response to clinical studies which identified risks in certain patient populations related to the utilization of EPO and other ESAs, i.e., Aranesp®, and in response to changes in the labeling of EPO and Aranesp®, there has been substantial media attention and government scrutiny resulting in hearings and legislation regarding pharmaceutical utilization and reimbursement. Although we believe our anemia management practices and other pharmaceutical administration practices have been compliant with existing laws and regulations, as a result of the current high level of scrutiny and controversy, we may be subject to increased inquiries from a variety of governmental bodies and claims by third parties. Additional inquiries from or audits by various agencies and claims by third parties with respect to these issues would continue to require management's attention and significant legal expense and any negative findings could result in substantial financial penalties or repayments, imposition of certain obligations on our practices and procedures and the attendant financial burden on us to comply, or exclusion from future participation in the Medicare and Medicaid programs, and could have a material adverse effect on our revenues, earnings and cash flows.

If we fail to adhere to all of the complex government regulations that apply to our business, we could suffer severe consequences that would substantially reduce our revenues, earnings and cash flows.

Our dialysis operations are subject to extensive federal, state and local government regulations, including Medicare and Medicaid payment rules and regulations, federal and state anti-kickback laws, the Stark Law physician self-referral prohibition and analogous state referral statutes, the FCA and federal and state laws regarding the collection, use and disclosure of patient health information and the storage, handling and administration of pharmaceuticals. The Medicare and Medicaid reimbursement rules related to claims submission, enrollment and licensing requirements, cost reporting, and payment processes impose complex and extensive requirements upon dialysis providers. A violation or departure from any of these requirements may result in government audits, lower reimbursements, significant fines and penalties, the potential loss of certification and recoupments or voluntary repayments. CMS has indicated that after implementation of the Medicare bundled payment system, it will monitor use of EPO and whether blood transfusions replace EPO for anemia management.

The regulatory scrutiny of healthcare providers, including dialysis providers continues to increase. Medicare has increased the frequency and intensity of its certification inspections of dialysis centers. For example, we are required to provide substantial documentation related to the administration of pharmaceuticals, including EPO, and, to the extent that any such documentation is found insufficient, we may be required to refund to government or commercial payors any amounts received for such administration, and be subject to substantial penalties under applicable laws or regulations. In addition, Medicare contractors have increased their prepayment and post-payment reviews.

We endeavor to comply with all of the requirements for receiving Medicare and Medicaid payments, to structure all of our relationships with referring physicians to comply with state and federal anti-kickback laws and physician self-referral law (Stark Law), and for storing, handling and administering pharmaceuticals. However, the laws and regulations in these areas are complex, require considerable resources to monitor and implement and are subject to varying interpretations. For example, if an enforcement agency were to challenge the level of compensation that we pay our medical directors or the number of medical directors whom we engage, we could be required to change our practices, face criminal or civil penalties, pay substantial fines or otherwise experience a material adverse effect as a result of a challenge to these arrangements. In addition, amendments to the FCA impose severe penalties for the knowing and improper retention of overpayments collected from government payors. These amendments could subject our procedures for identifying and processing overpayments to greater scrutiny. We have made significant investments in additional resources to decrease the time it takes to identify and process overpayments and we may be required to make additional investments in the

future. An acceleration in our ability to identify and process overpayments could result in us refunding overpayments to government or other payors sooner than we have in the past. A significant acceleration of these refunds could have a material adverse effect on our operating cash flows. Additionally, amendments to the federal anti-kickback statute in the health reform law make anti-kickback violations subject to FCA prosecution, including *qui tam* or whistleblower suits.

If any of our operations are found to violate these or other government regulations, we could suffer severe consequences that would have a material adverse effect on our revenues, earnings and cash flows including:

Suspension or termination of our participation in government payment programs;

Refunds of amounts received in violation of law or applicable payment program requirements;

Loss of required government certifications or exclusion from government payment programs;

Loss of licenses required to operate health care facilities or administer pharmaceuticals in some of the states in which we operate;

Reductions in payment rates or coverage for dialysis and ancillary services and related pharmaceuticals;

Fines, damages or monetary penalties for anti-kickback law violations, Stark Law violations, FCA violations, civil or criminal liability based on violations of law, or other failures to meet regulatory requirements;

Claims for monetary damages from patients who believe their protected health information has been used or disclosed in violation of federal or state patient privacy laws;

Mandated changes to our practices or procedures that significantly increase operating expenses;

Termination of relationships with medical directors; and

Harm to our reputation, which could impact our business relationships, ability to obtain financing and access to new opportunities.

Delays in state Medicare and Medicaid certification of our dialysis centers could adversely affect our revenues, earnings and cash flows.

Before we can begin billing for patients treated in our outpatient dialysis centers who are enrolled in government-based programs, we are required to obtain state and federal certification for participation in the Medicare and Medicaid programs. As state agencies responsible for surveying dialysis centers on behalf of the state and Medicare program face increasing budgetary pressure, certain states are having difficulty keeping up with certifying dialysis centers in the normal course resulting in significant delays in certification. If state governments continue to have difficulty keeping up with certifying new centers in the normal course and we continue to experience significant delays in our ability to treat and bill for services provided to patients covered under government programs, it could cause us to incur write-offs of investments or accelerate the recognition of lease obligations in the event we have to close centers or our centers' operating performance deteriorates, and it could have an adverse effect on our revenues, earnings and cash flows.

If our joint ventures were found to violate the law, we could suffer severe consequences that would have a material adverse effect on our revenues, earnings and cash flows.

As of December 31, 2011, we owned a controlling interest in numerous dialysis-related joint ventures, which represented approximately 18% of our dialysis and related lab services revenues for the year ended December 31, 2011. In addition, we also owned minority equity investments in several other dialysis related joint ventures. We anticipate that we will continue to increase the number of our joint ventures. Many of our joint ventures with physicians or physician groups also have the physician owners providing medical director services

to those centers or other centers we own and operate. Because our relationships with physicians are governed by the federal anti-kickback statute, we have sought to structure our joint venture arrangements to satisfy as many safe harbor requirements as we believe are reasonably possible. However, our joint venture arrangements do not satisfy all elements of any safe harbor under the federal anti-kickback statute (and possibly the Stark Law). The subpoena and related requests for documents we received from the U.S. Attorney's Office for the Eastern District of Missouri in the 2005 U.S. Attorney investigation, the OIG's Office in Dallas in the 2010 U.S. Attorney physician relationship investigation and the U.S. Attorney's Office for the District of Colorado in the 2011 U.S. Attorney physician relationship investigation, included requests for documents related to our joint ventures. We were advised by the U.S. Department of Justice that it is conducting civil and grand jury investigations into our financial relationships with physicians.

If our joint ventures are found to be in violation of the anti-kickback statute or the Stark Law provisions, we could be required to restructure the joint ventures or refuse to accept referrals for designated health services from the physicians with whom the joint venture centers have a financial relationship.

We also could be required to repay amounts received by the joint ventures from Medicare and certain other payors to the extent that these arrangements are found to give rise to prohibited referrals, and we could be subject to monetary penalties and exclusion from government healthcare programs. If our joint venture centers are subject to any of these penalties, we could suffer severe consequences that would have a material adverse effect on our revenues, earnings and cash flows.

There are significant estimating risks associated with the amount of dialysis revenue and related refund liabilities that we recognize and if we are unable to accurately estimate our revenue and related refund liabilities, it could impact the timing and the amount of our revenue recognition or have a significant impact on our operating results.

There are significant estimating risks associated with the amount of dialysis and related lab services revenues and related refund liabilities that we recognize in a reporting period. The billing and collection process is complex due to ongoing insurance coverage changes, geographic coverage differences, differing interpretations of contract coverage, and other payor issues. Determining applicable primary and secondary coverage for approximately 142,000 U.S. patients at any point in time, together with the changes in patient coverage that occur each month, requires complex, resource-intensive processes. Errors in determining the correct coordination of benefits may result in refunds to payors. Revenues associated with Medicare and Medicaid programs are also subject to estimating risk related to the amounts not paid by the primary government payor that will ultimately be collectible from other government programs paying secondary coverage, the patient's commercial health plan secondary coverage or the patient. Collections, refunds and payor retractions typically continue to occur for up to three years and longer after services are provided. We generally expect our range of dialysis and related lab services revenues estimating risk to be within 1% of revenues for the segment, which can represent as much as 6% of consolidated operating income. If our estimates of dialysis and related lab services revenues and related refund liabilities are materially inaccurate, it could impact the timing and the amount of our revenue recognition and have a significant impact on our operating results.

The ancillary services we provide or the strategic initiatives, including our international dialysis operations, that we invest in now or in the future may generate losses and may ultimately be unsuccessful. In the event that one or more of these activities is unsuccessful, we may have to write off our investment and incur other exit costs.

Our ancillary services and strategic initiatives currently include pharmacy services, infusion therapy services, disease management services, vascular access services, ESRD clinical research programs, physician services and our international dialysis operations. We expect to add additional service offerings and pursue additional strategic initiatives in the future as circumstances warrant, which could include healthcare services not related to dialysis. Many of these initiatives require or would require investments of both management and

financial resources and can generate significant losses for a substantial period of time and may not become profitable. There can be no assurance that any such strategic initiative will ultimately be successful. Any significant change in market conditions, or business performance, or in the political, legislative or regulatory environment, may impact the economic viability of any of these strategic initiatives. For example, during 2011 and 2010, several of our strategic initiatives generated net operating losses and some are expected to generate net operating losses in 2012. If any of our ancillary services or strategic initiatives, including our international dialysis operations, do not perform as planned, we may incur a material write-off or an impairment of our investment, including goodwill, in one or more of these activities or we could incur significant termination costs if we were to exit a certain line of business. As an example, during the second quarter of 2011 we recorded a goodwill impairment charge of \$24 million related to a decrease in the implied fair value of goodwill below its carrying amount associated with our infusion therapy business.

If a significant number of physicians were to cease referring patients to our dialysis centers, whether due to regulatory or other reasons, it would have a material adverse effect on our revenues, earnings and cash flows.

We believe that physicians prefer to have their patients treated at dialysis centers where they or other members of their practice supervise the overall care provided as medical director of the center. As a result, the primary referral source for most of our centers is often the physician or physician group providing medical director services to the center. Neither our current nor former medical directors have an obligation to refer their patients to our centers. If a medical director agreement terminates, whether before or at the end of its term, and a new medical director is appointed, it may negatively impact the former medical director's decision to treat his or her patients at our center. If we are unable to enforce noncompetition provisions contained in the terminated medical director agreements, former medical directors may choose to provide medical director services for competing providers or establish their own dialysis centers in competition with ours. Also, if the quality of service levels at our centers deteriorates, it may negatively impact patient referrals and treatment volumes.

Our medical director contracts are for fixed periods, generally three to ten years, and at any given time a large number of them could be up for renewal at the same time. Medical directors have no obligation to extend their agreements with us, and there are a number of factors, including opportunities presented by our competitors or different affiliation models in the changing healthcare environment, that could negatively impact their decisions to extend their agreements with us. In addition, we may take actions to restructure existing relationships or take positions in negotiating extensions of relationships to assure compliance with the anti-kickback statute, Stark Law and other similar laws. These actions also could negatively impact the decision of physicians to extend their medical director agreements with us or to refer their patients to us. If the terms of any existing agreement are found to violate applicable laws, we may not be successful in restructuring the relationship which could lead to the early termination of the agreement, or cause the physician to stop referring patients to our dialysis centers. If a significant number of physicians were to cease referring patients to our dialysis centers, whether due to regulatory or other reasons, then our revenues, earnings and cash flows would be substantially reduced.

Current economic conditions as well as further disruptions in the financial markets could have a material adverse effect on our revenues, earnings and cash flows and otherwise adversely affect our financial condition.

Current economic conditions could adversely affect our business and our profitability. Among other things, the potential decline in federal and state revenues that may result from such conditions may create additional pressures to contain or reduce reimbursements for our services from Medicare, Medicaid and other government sponsored programs. Increasing job losses or slow improvement in the unemployment rate in the United States as a result of current or recent economic conditions has and may continue to result in a smaller percentage of our patients being covered by an employer group health plan and a larger percentage being covered by lower paying Medicare and Medicaid programs. Employers may also begin to select more restrictive commercial plans with

lower reimbursement rates. To the extent that payors are negatively impacted by a decline in the economy, we may experience further pressure on commercial rates, a further slowdown in collections and a reduction in the amounts we expect to collect. In addition, uncertainty in the financial markets could adversely affect the variable interest rates payable under our credit facilities or could make it more difficult to obtain or renew such facilities or to obtain other forms of financing in the future. Any or all of these factors, as well as other consequences of the current economic conditions which cannot currently be anticipated, could have a material adverse effect on our revenues, earnings and cash flows and otherwise adversely affect our financial condition.

We may engage in acquisitions, mergers or dispositions, which may affect our results of operations, debt-to-capital ratio, capital expenditures or other aspects of our business.

We may engage in acquisitions, mergers or dispositions, which may affect our results of operations, debt-to-capital ratio, capital expenditures, or other aspects of our business. There can be no assurance that we will be able to identify suitable acquisition targets or merger partners or that, if identified, we will be able to acquire these targets on acceptable terms or agree to terms with merger partners. There can also be no assurance that we will be successful in completing any acquisitions, mergers or dispositions that we might be considering or announce, or integrating any acquired business into our overall operations or operate them successfully as stand-alone businesses, or that any such acquired business will operate profitably or will not otherwise adversely impact our results of operations. Further, we cannot be certain that key talented individuals at the business being acquired will continue to work for us after the acquisition or that they will be able to continue to successfully manage or have adequate resources to successfully operate any acquired business.

If we are not able to continue to make acquisitions, or maintain an acceptable level of non-acquired growth, or if we face significant patient attrition to our competitors or a reduction in the number of our medical directors, it could adversely affect our business.

The dialysis industry is highly competitive, particularly in terms of acquiring existing dialysis centers. We continue to face increased competition in the U.S. dialysis industry from large and medium-sized providers which compete directly with us for acquisition targets as well as for individual patients and medical directors. In addition, as we continue our international dialysis expansion into various international markets, we will face competition from large and medium-sized providers for these acquisition targets as well. Acquisitions, patient retention and medical director retention are an important part of our growth strategy. Because of the ease of entry into the dialysis business and the ability of physicians to be medical directors for their own centers, competition for growth in existing and expanding markets is not limited to large competitors with substantial financial resources. Occasionally, we have experienced competition from former medical directors or referring physicians who have opened their own dialysis centers. In addition, Fresenius, our largest competitor, manufactures a full line of dialysis supplies and equipment in addition to owning and operating dialysis centers. This may give it cost advantages over us because of its ability to manufacture its own products. If we are not able to continue to make acquisitions, continue to maintain acceptable levels of non-acquired growth, or if we face significant patient attrition to our competitors or a reduction in the number of our medical directors, it could adversely affect our business.

If businesses we acquire have liabilities that we are not aware of, we could suffer severe consequences that would substantially reduce our earnings and cash flows.

Our business strategy includes the acquisition of dialysis centers and businesses that own and operate dialysis centers, as well as other ancillary and non-dialysis services and strategic initiatives. Businesses we acquire may have unknown or contingent liabilities or liabilities that are in excess of the amounts that we originally estimated. Although we generally seek indemnification from the sellers of businesses we acquire for matters that are not properly disclosed to us, we are not always successful. In addition, even in cases where we are able to obtain indemnification, we may discover liabilities greater than the contractual limits or the financial resources of the indemnifying party. In the event that we are responsible for liabilities substantially in excess of any amounts recovered through rights to indemnification, we could suffer severe consequences that would substantially reduce our earnings and cash flows.

Expansion of our operations to and offering our services in markets outside of the United States subjects us to political, legal, operational and other risks that could adversely affect our business, results of operations and cash flows.

We are undertaking an expansion of our operations and are in the early stages of offering our services outside of the United States, which increases our exposure to the inherent risks of doing business in international markets. Depending on the market, these risks include, without limitation, those relating to:

- changes in the local economic environment;
- political instability, armed conflicts or terrorism;
- social changes;
- intellectual property legal protections and remedies;
- trade regulations;
- procedures and actions affecting approval, production, pricing, reimbursement and marketing of products and services;
- foreign currency;
- repatriating or moving to other countries cash generated or held abroad, including considerations relating to tax-efficiencies and changes in tax laws;
- export controls;
- lack of reliable legal systems which may affect our ability to enforce contractual rights;
- changes in local laws or regulations;
- potentially longer payment and collection cycles; and
- financial and operational, and information technology systems integration.

Conducting international operations requires us to devote significant management resources to implement our controls and systems in new markets, to comply with local laws and regulations and to overcome the numerous new challenges inherent in managing international operations, including those based on differing languages, cultures and regulatory environments, and those related to the timely hiring, integration and retention of a sufficient number of skilled personnel to carry out operations.

We anticipate expanding our international operations through acquisitions of varying sizes or through organic growth, which could increase these risks. Additionally, though we might invest material amounts of capital and incur significant costs in connection with the growth and development of our international operations, there is no assurance that we will be able to operate them profitably anytime soon, if at all. As a result, we would expect these costs to be dilutive to our earnings over the next several years as we start-up or acquire new operations.

These risks could have a material adverse effect on our financial condition, results of operations and cash flows.

The level of our current and future debt could have an adverse impact on our business and our ability to generate cash to service our indebtedness depends on many factors beyond our control.

We have substantial debt outstanding and we may incur additional indebtedness in the future. The high level of our indebtedness, among other things, could:

- make it difficult for us to make payments on our debt securities;
- increase our vulnerability to general adverse economic and industry conditions;

require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow to fund working capital, capital expenditures, acquisitions and investments and other general corporate purposes;

limit our flexibility in planning for, or reacting to, changes in our business and the markets in which we operate;

place us at a competitive disadvantage compared to our competitors that have less debt; and

limit our ability to borrow additional funds.

Our ability to make payments on our indebtedness and to fund planned capital expenditures and expansion efforts, including any strategic acquisitions we may make in the future, will depend on our ability to generate cash. This, to a certain extent, is subject to general economic, financial, competitive, regulatory and other factors that are beyond our control.

We cannot provide assurance that our business will generate sufficient cash flow from operations in the future or that future borrowings will be available to us in an amount sufficient to enable us to service our indebtedness or to fund other liquidity needs. The borrowings under our Senior Credit Agreement are guaranteed by substantially all of our direct and indirect wholly-owned domestic subsidiaries and are secured by substantially all of DaVita's and its guarantors' assets.

Increases in interest rates may increase our interest expense and adversely affect our earnings and cash flow and our ability to service our indebtedness.

A portion of our outstanding debt bears interest at variable rates. We are subject to LIBOR-based interest rate volatility from a floor of 1.50% to a cap of 4.00% on \$1.25 billion notional amounts of our Term Loan B outstanding debt as a result of several interest rate cap agreements that were entered into in January 2011. The remaining \$483 million of outstanding debt on the Term Loan B is subject to LIBOR-based interest rate volatility above a floor of 1.50%. At December 31, 2011, we were also subject to LIBOR-based interest rate volatility above a floor of 1.00% on \$199.5 million of outstanding debt associated with our Term Loan A-2.

We also have approximately \$350 million of additional borrowings available under our new Senior Secured Credit Facilities that are subject to LIBOR-based interest rate volatility. We may also incur additional variable rate debt in the future. Increases in interest rates would increase our interest expense of the variable portion of our indebtedness, which could negatively impact our earnings and cash flow and our ability to service our indebtedness which would be particularly significant in the event of rapid and substantial increases in interest rates.

At December 31, 2011, if interest rates were to hypothetically increase by 100 basis points it would have increased our interest expense by approximately \$0.6 million, which increase solely relates to our Term Loan A-2 that is subject to LIBOR-based interest rate volatility above a floor of 1.00%.

However, interest expense would not be impacted by any LIBOR-based interest rate volatility associated with our other Term Loans since all of our Term Loan A is economically fixed and our Term Loan B is subject to LIBOR-based interest rate volatility above a floor of 1.50%, as described above. The current LIBOR rate in effect, plus a hypothetical increase of 100 basis points, is currently less than our Term Loan B floor of 1.50%. Therefore, LIBOR-based interest rates would have to increase above a floor of 1.50% for the Term Loan B to have a negative impact on our financial results. See "Item 3—Quantitative and Qualitative Disclosures about Market Risk" for more information.

If there are shortages of skilled clinical personnel or if we experience a higher than normal turnover rate, we may experience disruptions in our business operations and increases in operating expenses.

We are experiencing increased labor costs and difficulties in hiring nurses due to a nationwide shortage of skilled clinical personnel. We compete for nurses with hospitals and other health care providers. This nursing

shortage may limit our ability to expand our operations. In addition, changes in certification requirements or increases in the required staffing levels for skilled clinical personnel can impact our ability to maintain sufficient staff levels to the extent our teammates are not able to meet new requirements or competition for qualified individuals increases. If we are unable to hire skilled clinical personnel when needed, or if we experience a higher than normal turnover rate for our skilled clinical personnel, our operations and treatment growth will be negatively impacted, which would result in reduced revenues, earnings and cash flows.

Our business is labor intensive and could be adversely affected if we were unable to maintain satisfactory relations with our employees or if union organizing activities were to result in significant increases in our operating costs or decreases in productivity.

Our business is labor intensive, and our results are subject to variations in labor-related costs, productivity and the number of pending or potential claims against us related to labor and employment practices. If political efforts at the national and local level result in actions or proposals that increase the likelihood of union organizing activities at our facilities or if union organizing activities increase for other reasons, or if labor and employment claims, including the filing of class action suits, trend upwards, our operating costs could increase and our employee relations, productivity, earnings and cash flows could be adversely affected.

Upgrades to our billing and collections systems and complications associated with upgrades and other improvements to our billing and collections systems could have a material adverse effect on our revenues, cash flows and operating results.

We are continuously performing upgrades to our billing systems and expect to continue to do so in the near term. In addition, we continuously work to improve our billing and collections performance through process upgrades, organizational changes and other improvements. We may experience difficulties in our ability to successfully bill and collect for services rendered as a result of these changes, including a slow-down of collections, a reduction in the amounts we expect to collect, increased risk of retractions from and refunds to commercial and government payors, an increase in our provision for uncollectible accounts receivable and noncompliance with reimbursement regulations. The failure to successfully implement the upgrades to the billing and collection systems and other improvements could have a material adverse effect on our revenues, cash flows and operating results.

Our ability to effectively provide the services we offer could be negatively impacted if certain of our suppliers are unable to meet our needs or if we are unable to effectively access new technology, which could substantially reduce our revenues, earnings and cash flows.

We have significant suppliers that are either the sole or primary source of products critical to the services we provide, including Amgen, Baxter Healthcare Corporation, NxStage Medical, Inc. and others or to which we have committed obligations to make purchases including Gambro Renal Products and Fresenius. If any of these suppliers are unable to meet our needs for the products they supply, including in the event of a product recall, or shortage, and we are not able to find adequate alternative sources, or if some of the drugs that we purchase are not reimbursed through the bundled payment rate by Medicare, our revenues, earnings and cash flows could be substantially reduced. In addition, the technology related to the products critical to the services we provide is subject to new developments and may result in superior products. If we are not able to access superior products on a cost-effective basis or if suppliers are not able to fulfill our requirements for such products, we could face patient attrition which could substantially reduce our revenues, earnings and cash flows.

We may be subject to liability claims for damages and other expenses not covered by insurance that could reduce our earnings and cash flows.

The administration of dialysis and related services to patients may subject us to litigation and liability for damages. Our business, profitability and growth prospects could suffer if we face negative publicity or we pay

damages or defense costs in connection with a claim that is outside the scope of any applicable insurance coverage, including claims related to adverse patient events, contractual disputes and professional and general liability claims. In addition, we have received several notices of claims from commercial payors and other third parties related to our historical billing practices and the historical billing practices of the centers acquired from Gambro Healthcare and other matters related to their settlement agreement with the Department of Justice. Although the ultimate outcome of these claims cannot be predicted, an adverse result with respect to one or more of these claims could have a material adverse effect on our financial condition, results of operations, and cash flows. We currently maintain programs of general and professional liability insurance. However, a successful claim, including a professional liability, malpractice or negligence claim which is in excess of our insurance coverage could have a material adverse effect on our earnings and cash flows.

In addition, if our costs of insurance and claims increase, then our earnings could decline. Market rates for insurance premiums and deductibles have been steadily increasing. Our earnings and cash flows could be materially and adversely affected by any of the following:

the collapse or insolvency of our insurance carriers;

further increases in premiums and deductibles;

increases in the number of liability claims against us or the cost of settling or trying cases related to those claims; and

an inability to obtain one or more types of insurance on acceptable terms, if at all.

Provisions in our charter documents, compensation programs and Delaware law may deter a change of control that our stockholders would otherwise determine to be in their best interests.

Our charter documents include provisions that may deter hostile takeovers, delay or prevent changes of control or changes in our management, or limit the ability of our stockholders to approve transactions that they may otherwise determine to be in their best interests. These include provisions prohibiting our stockholders from acting by written consent; requiring 90 days advance notice of stockholder proposals or nominations to our Board of Directors; and granting our Board of Directors the authority to issue preferred stock and to determine the rights and preferences of the preferred stock without the need for further stockholder approval.

Most of our outstanding employee stock options include a provision accelerating the vesting of the options in the event of a change of control. We also maintain a change of control protection program for our employees who do not have a significant number of stock awards, which has been in place since 2001, and which provides for cash bonuses to the employees in the event of a change of control. Based on the market price of our common stock and shares outstanding on December 31, 2011, these cash bonuses would total approximately \$277 million if a change of control transaction occurred at that price and our Board of Directors did not modify this program. These change of control provisions may affect the price an acquirer would be willing to pay for our Company.

We are also subject to Section 203 of the Delaware General Corporation Law that, subject to exceptions, would prohibit us from engaging in any business combinations with any interested stockholder, as defined in that section, for a period of three years following the date on which that stockholder became an interested stockholder.

These provisions may discourage, delay or prevent an acquisition of our Company at a price that our stockholders may find attractive. These provisions could also make it more difficult for our stockholders to elect directors and take other corporate actions and could limit the price that investors might be willing to pay for shares of our common stock.

Item 1B. Unresolved Staff Comments.

None.

Item 2. Properties.

We own the land and buildings for 25 of our outpatient dialysis centers. We also own the buildings for seven other outpatient dialysis centers and the building at one of our Florida labs and we own two separate land parcels and sublease a total of five properties to third-party tenants. In addition, we also own the land associated with the development of our new corporate headquarters. Our remaining outpatient dialysis centers are located on premises that we lease.

Our leases generally cover periods from five to ten years but in some cases can extend for 15 years and typically contain renewal options of five to ten years at the fair rental value at the time of renewal. Our leases are generally subject to periodic consumer price index increases, or contain fixed escalation clauses. Our outpatient dialysis centers range in size from approximately 500 to 30,000 square feet, with an average size of approximately 6,800 square feet.

The following is a summary of our business, administrative offices, laboratories and pharmacies:

<u>Office</u>	<u>Location</u>	<u>Square Feet</u>	<u>Expiration</u>
Corporate Headquarters	Denver, CO	89,000	2012
Administrative Office	Vernon Hills, IL	29,000	2013
Administrative Office	Burlingame, CA	3,725	2012
Administrative Office	Norfolk, VA	20,000	2015
Administrative Office	Tempe, AZ	11,000	2016
Administrative Office	Washington, DC	5,000	2013
Business Office	El Segundo, CA	61,000	2013
Business Office	Tacoma, WA	201,000	2013 through 2021
Business Office	Berwyn, PA	182,000	2012 through 2022
Business Office	Lakewood, CO	82,000	2012
Business Office	Brentwood, TN	95,000	2021
Business Office	Irvine, CA	65,000	2015
Business Office	Nashville, TN	35,000	2017
Business Office	Franklin, TN	9,500	2013
DaVita Rx	Orlando, FL	17,000	2013
DaVita Rx	Coppell, TX	95,600	2013
DaVita Rx	San Bruno, CA	7,000	2015
Lab Warehouse	DeLand, FL	11,000	2015
Laboratory	DeLand, FL	40,000	Owned
Laboratory	DeLand, FL	20,000	2015
Laboratory	Ft. Lauderdale, FL	43,000	2015
Laboratory Administrative Office	DeLand, FL	23,000	2012

Some of our outpatient dialysis centers are operating at or near capacity. However, we believe that we have adequate capacity within most of our existing dialysis centers to accommodate additional patient volume through increased hours and/or days of operation, or, if additional space is available within an existing facility, by adding dialysis stations. We can usually relocate existing centers to larger facilities or open new centers if existing centers reach capacity. With respect to relocating centers or building new centers, we believe that we can generally lease space at economically reasonable rates in the areas planned for each of these centers, although there can be no assurances in this regard. Expansion of existing centers or relocation of our dialysis centers is subject to review for compliance with conditions relating to participation in the Medicare ESRD program. In states that require a certificate of need or center license, additional approvals would generally be necessary for expansion or relocation.

Item 3. Legal Proceedings.***Inquiries by the Federal Government and Certain Related Civil Proceedings***

2005 U.S. Attorney Investigation: In March 2005, we received a subpoena from the U.S. Attorney's Office for the Eastern District of Missouri in St. Louis. The subpoena required production of a wide range of documents relating to our operations, including documents related to, among other things, pharmaceutical and other services provided to patients, relationships with pharmaceutical companies, and financial relationships with physicians and joint ventures. The subpoena covers the period from December 1, 1996 through March 2005. In October 2005, we received a follow-up request for additional documents related to specific medical director and joint venture arrangements. In February 2006, we received an additional subpoena for documents, including certain patient records relating to the administration and billing of EPO. In May 2007, we received a request for documents related to durable medical equipment and supply companies owned and operated by us. We cooperated with the inquiry and have produced the requested records. The subpoenas were issued in connection with a joint civil and criminal investigation. It is possible that criminal proceedings may be initiated against us in connection with this investigation. We have not received a communication from the St. Louis U.S. Attorney's Office on this matter in over two years.

Woodard Private Civil Suit: In February 2007, we received a request for information from the Office of Inspector General, U.S. Department of Health and Human Services, or OIG, for records relating to EPO claims submitted to Medicare. In August 2007, we received a subpoena from the OIG seeking similar documents. The requested documents relate to services provided from 2001 to 2004 by a number of our centers. The request and subpoena were sent from the OIG's offices in Houston and Dallas, Texas. We cooperated with the inquiry and have produced all previously requested records to date. We were contacted by the U.S. Attorney's Office for the Eastern District of Texas, which stated that this was a civil investigation related to EPO claims. On July 6, 2009, the United States District Court for the Eastern District of Texas lifted the seal on the civil *qui tam* complaint related to these previous requests for information. We were subsequently served with a complaint by the relator, Ivey Woodard, purportedly on behalf of the federal government, under the *qui tam* provisions of the federal False Claims Act. The government did not intervene and is not actively pursuing this matter. The relator is pursuing the claims independently and the parties are engaged in active litigation. The complaint contains allegations relating to our EPO practices for the period from 1992 through 2010 and seeks monetary damages and civil penalties as well as costs and expenses. The court has ruled that claims earlier than 1996 are beyond the statute of limitations. We believe that there is some overlap between the subject of this complaint and the review of EPO utilization in the 2005 U.S. Attorney investigation described above. We are vigorously defending this matter and intend to continue to do so. We can make no assurances as to the time or resources that will be needed to devote to this litigation or its final outcome.

Vainer Private Civil Suit: In December 2008, we received a subpoena for documents from the OIG relating to the pharmaceutical products Zemplar, Hectorol, Venofer, Ferrlecit and EPO, as well as other related matters. The subpoena covers the period from January 2003 to December 2008. We were in contact with the U.S. Attorney's Office for the Northern District of Georgia and the U.S. Department of Justice in Washington, DC, since November 2008 relating to this matter, and were advised that this was a civil inquiry. On June 17, 2009, we learned that the allegations underlying this inquiry were made as part of a civil complaint filed by individuals and brought pursuant to the *qui tam* provisions of the federal False Claims Act. On April 1, 2011, the United States District Court for the Northern District of Georgia ordered the case to be unsealed. At that time, the Department of Justice and U.S. Attorney's Office filed a notice of declination stating that the United States would not be intervening and not pursuing the relators' allegation in litigation. On July 25, 2011, the relators, Daniel Barbir and Dr. Alon Vainer, filed their amended complaint in the United States District Court for the Northern District of Georgia, purportedly on behalf of the federal government. The allegations in the complaint relate to our drug administration practices for Vitamin D and iron agents for a period from 2003 through 2010. The complaint seeks monetary damages and civil penalties as well as costs and expenses. We are vigorously defending this matter and intend to continue to do so. We can make no assurances as to the time or resources that will be needed to devote to this litigation or its final outcome.

2010 U.S. Attorney Physician Relationship Investigation: In May 2010, we received a subpoena from the OIG's office in Dallas, Texas. The subpoena covers the period from January 1, 2005 to May 2010, and seeks production of a wide range of documents relating to our operations, including documents related to, among other things, financial relationships with physicians and joint ventures. The general subject matter of the inquiry appears to overlap with the 2005 U.S. Attorney Investigation described above. We met with representatives of the government to discuss the scope of the subpoena and the production of responsive documents. We have been advised that this is a civil investigation. We are cooperating with the inquiry and are producing the requested records. We can make no assurances as to the time or resources that will be needed to devote to this litigation or its final outcome.

2011 U.S. Attorney Physician Relationship Investigation: In August 2011, we announced we had learned that the U.S. Attorney's Office for the District of Colorado would be looking into certain activities of ours in connection with information being provided to a grand jury. We announced further that we understood that this investigation was at a very preliminary stage, and while its precise scope was unclear, it appeared to overlap, at least in part, with the 2005 U.S. Attorney Investigation and 2010 U.S. Attorney Physician Relationship Investigation described above. Subsequent to our announcement of this 2011 U.S. Attorney Physician Relationship Investigation, we received a subpoena for documents which substantially overlaps with the subpoena in the 2010 U.S. Attorney Physician Relationship Investigation described above and covers the period from January 2006 to September 2011. We are cooperating with the government and are producing the requested records. Certain current and former members of the Board and executives received subpoenas in November 2011 and thereafter to testify before the grand jury, and other Company representatives may also receive subpoenas for testimony related to this matter. We can make no assurances as to the time or resources that will be needed to devote to this litigation or its final outcome.

2011 U.S. Attorney Medicaid Investigation: In October 2011, we announced that we would be receiving a request for documents, which could include an administrative subpoena from the Office of Inspector General for the U.S. Department of Health and Human Services. Subsequent to our announcement of this 2011 U.S. Attorney Medicaid Investigation, we received a request for documents in connection with the inquiry by the United States Attorney's Office for the Eastern District of New York. The request relates to payments for infusion drugs covered by Medicaid composite payments for dialysis. We believe this inquiry is civil in nature. We do not know the time period or scope. We understand that certain other providers that operate dialysis clinics in New York may be receiving or have received a similar request for documents. We intend to cooperate with the government to provide responsive documents.

Except for the private civil complaints filed by the relators as described above, to our knowledge, no proceedings have been initiated against us at this time in connection with any of the inquiries by the federal government. Although we cannot predict whether or when proceedings might be initiated or when these matters may be resolved, it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators. Responding to the subpoenas or inquiries and defending us in the relator proceedings will continue to require management's attention and significant legal expense. Any negative findings in the inquiries or relator proceedings could result in substantial financial penalties or awards against us, exclusion from future participation in the Medicare and Medicaid programs and, to the extent criminal proceedings may be initiated against us, possible criminal penalties. At this time, we cannot predict the ultimate outcome of these inquiries, or the potential outcome of the relators' claims, or the potential range of damages, if any.

Other

We have received several notices of claims from commercial payors and other third parties related to historical billing practices and claims against DVA Renal Healthcare (formerly known as Gambro Healthcare), a subsidiary of ours, related to historical Gambro Healthcare billing practices and other matters covered by its 2004 settlement agreement with the Department of Justice and certain agencies of the U.S. government. We have

received no further indication that any of these claims are active, and some of them may be barred by applicable statutes of limitations. To the extent any of these claims might proceed, we intend to defend against them vigorously; however, we may not be successful and these claims may lead to litigation and any such litigation may be resolved unfavorably. At this time, we cannot predict the ultimate outcome of this matter or the potential range of damages, if any.

A wage and hour claim, which has been styled as a class action, is pending against us in the Superior Court of California. We were served with the complaint in this lawsuit in April 2008, and it has been amended since that time. The lawsuit, as amended, alleges that we failed to provide meal periods, failed to pay compensation in lieu of providing rest or meal periods, failed to pay overtime, and failed to comply with certain other California Labor Code requirements. In September 2011, the court denied the plaintiffs' motion for class certification. Plaintiffs have appealed that decision. We intend to continue to vigorously defend against these claims. Any potential settlement of these claims is not anticipated to be material to our consolidated financial statements.

In October 2007, we were contacted by the Attorney General's Office for the State of Nevada. The Attorney General's Office informed us that it was conducting a civil and criminal investigation of our operations in Nevada and that the investigation related to the billing of pharmaceuticals, including EPO. In February 2008, the Attorney General's Office informed us that the civil and criminal investigation had been discontinued. The Attorney General's Office further advised us that Nevada Medicaid intended to conduct audits of end stage renal disease (ESRD) dialysis providers in Nevada and such audits would relate to the issues that were the subjects of the investigation. To our knowledge, no court proceedings have been initiated against us at this time. Any negative audit findings could result in a substantial repayment by us. At this time, we cannot predict the ultimate outcome of this matter or the potential range of damages, if any.

In June 2004, DVA Renal Healthcare was served with a complaint filed in the Superior Court of California by one of its former employees who worked for its California acute services program. The complaint, which is styled as a class action, alleges, among other things, that DVA Renal Healthcare failed to provide overtime wages, defined rest periods and meal periods, or compensation in lieu of such provisions and failed to comply with certain other California Labor Code requirements. The parties have reached an agreement, subject to approval by the court, which fully resolves this matter for an amount that did not materially impact our financial results.

In addition to the foregoing, we are subject to claims and suits, including from time to time, contractual disputes and professional and general liability claims, as well as audits and investigations by various government entities, in the ordinary course of business. We believe that the ultimate resolution of any such pending proceedings, whether the underlying claims are covered by insurance or not, will not have a material adverse effect on our financial condition, results of operations or cash flows.

Item 4. Mine Safety Disclosures.

Not applicable.

PART II

Item 5. Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Our common stock is traded on the New York Stock Exchange under the symbol "DVA". The following table sets forth, for the periods indicated, the high and low closing prices for our common stock as reported by the New York Stock Exchange.

	High	Low
Year ended December 31, 2011:		
1st quarter	\$85.51	\$69.07
2nd quarter	89.17	82.70
3rd quarter	89.36	62.67
4th quarter	76.81	60.64
Year ended December 31, 2010:		
1st quarter	\$64.19	\$58.98
2nd quarter	66.63	60.43
3rd quarter	69.03	56.83
4th quarter	74.11	68.24

The closing price of our common stock on January 31, 2012 was \$81.81 per share. According to The Bank of New York, our registrar and transfer agent, as of January 31, 2012, there were 9,240 holders of record of our common stock. We have not declared or paid cash dividends to holders of our common stock since 1994. We have no current plans to pay cash dividends and we are restricted from paying dividends under the terms of our Senior Secured Credit Facilities and the indentures governing our senior and senior subordinated notes. Also, see the heading "Liquidity and capital resources" under "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations" and the notes to our consolidated financial statements.

Stock Repurchases

The following table summarizes our repurchases of our common stock during 2011:

Period	Total Number of Shares Purchased	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(1)	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (in millions)
March 1–31, 2011	162,300	\$ 84.02	162,300	\$ 667.9
April 1–30, 2011	969,100	87.08	969,100	583.5
May 1–31, 2011	354,515	85.26	354,515	553.3
June 1–30, 2011	2,224,171	84.45	2,224,171	365.4
July 1–31, 2011	84,600	85.83	84,600	358.2
Total	<u>3,794,686</u>	<u>\$ 85.21</u>	<u>3,794,686</u>	

- (1) On November 3, 2010, we announced that the Board of Directors authorized an additional \$800 million for repurchases of our common stock.

This stock repurchase program has no expiration date. We are authorized to make purchases from time to time in the open market or in privately negotiated transactions, depending upon market conditions and other considerations. However, we are subject to share repurchase limitations under the terms of the Senior Secured Credit Facilities and the indentures governing our senior notes.

Item 6. Selected Financial Data.

The following financial and operating data should be read in conjunction with “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements filed as part of this report. The following table presents selected consolidated financial and operating data for the periods indicated. Effective January 1, 2009, we were required to present consolidated net income attributable to us and to noncontrolling interests on the face of the consolidated statement of income, which changed the presentation of minority interests (noncontrolling interests) in our consolidated statements of income. These consolidated financial results have been recast for all prior periods presented to reflect the retrospective application of adopting these new presentation and disclosure requirements for noncontrolling interests.

	Year ended December 31,				
	2011	2010	2009	2008	2007
(in thousands, except share data)					
Income statement data:					
Net operating revenues	\$6,982,214	\$6,438,050	\$6,100,648	\$5,653,003	\$5,257,425
Operating expenses and charges(1)	5,851,432	5,441,490	5,161,020	4,783,977	4,348,770
Operating income	1,130,782	996,560	939,628	869,026	908,655
Debt expense(2)	(241,090)	(181,607)	(185,755)	(224,716)	(257,147)
Debt refinancing and redemption charges	–	(74,382)	–	–	–
Other income, net(3)	2,982	3,419	3,706	12,410	22,459
Income from continuing operations before income taxes	892,674	743,990	757,579	656,720	673,967
Income tax expense	315,744	260,052	278,213	235,443	245,478
Income from continuing operations	576,930	483,938	479,366	421,277	428,489
Income from operations of discontinued operations, net of tax(4)	1,221	281	393	43	154
Loss on disposal of discontinued operations, net of tax(4)	(4,756)	–	–	–	–
Net income	\$573,395	\$484,219	\$479,759	\$421,320	\$428,643
Less: Net income attributable to noncontrolling interests	\$(95,394)	\$(78,536)	\$(57,075)	\$(47,160)	\$(46,865)
Net income attributable to DaVita Inc.	\$478,001	\$405,683	\$422,684	\$374,160	\$381,778
Basic income from continuing operations per share attributable to DaVita Inc.(4)	\$5.09	\$3.99	\$4.07	\$3.56	\$3.60
Diluted income from continuing operations per share attributable to DaVita Inc.(4)	\$4.99	\$3.93	\$4.05	\$3.53	\$3.55
Weighted average shares outstanding:(6)					
Basic	94,658,000	101,504,000	103,604,000	105,149,000	105,893,000
Diluted	96,532,000	103,059,000	104,168,000	105,940,000	107,418,000
Ratio of earnings to fixed charges(5)	3.31:1	3.44:1	3.58:1	3.01:1	2.92:1
Balance sheet data:					
Working capital	\$1,128,492	\$1,698,509	\$1,255,580	\$965,233	\$889,917

Total assets	8,892,172	8,114,424	7,558,236	7,286,083	6,943,960
Long-term debt	4,417,624	4,233,850	3,532,217	3,622,421	3,683,887
Total DaVita Inc. shareholders' equity(6)	2,141,075	1,978,422	2,135,066	1,767,747	1,504,285

- (1) Operating expenses and charges in 2011 include \$24,000 of a non-cash goodwill impairment charge related to our infusion therapy business and \$55,275 in 2007 of valuation gains on the alliance and product supply agreement with Gambro Renal Products, Inc. Operating expenses and charges in 2007 also includes \$6,779 of gains from insurance settlements related to Hurricane Katrina and a fire that destroyed one center.

-
- (2) Debt expense in 2007 includes the write-off of approximately \$4.4 million of deferred financing costs associated with our principal prepayments on our term loans.
 - (3) Other income, net, includes \$5,868 in 2007 of gains from the sale of investment securities.
 - (4) During 2011, we divested a total of 28 outpatient dialysis centers in conjunction with a consent order issued by the Federal Trade Commission on September 30, 2011 in order for us to complete the acquisition of DSI. In addition, we also completed the sale of two additional centers that were previously pending state regulatory approval in conjunction with the acquisition of DSI on October 31, 2011. The operating results of the historical DaVita divested centers are reflected as discontinued operations in our consolidated financial statements for all periods presented. In addition, the operating results for the DSI divested centers are reflected as discontinued operation in our consolidated financial statements beginning September 1, 2011.
 - (5) The ratio of earnings to fixed charges was computed by dividing earnings by fixed charges. Earnings for this purpose is defined as pretax income from continuing operations adjusted by adding back fixed charges expensed during the period. Fixed charges include debt expense (interest expense and the write-off and amortization of deferred financing costs), the estimated interest component of rental expense on operating leases, and capitalized interest.
 - (6) Share repurchases consisted of 3,794,686 shares of common stock for \$323,348 in 2011, 8,918,760 shares of common stock for \$618,496 in 2010, 2,902,619 shares of common stock for \$153,495 in 2009, and 4,788,881 shares of common stock for \$232,715 in 2008. Shares issued in connection with stock awards amounted to 1,260,259 in 2011, 1,771,384 in 2010, 2,104,304 in 2009, 1,314,074 in 2008, and 2,480,899 in 2007.

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.*Forward-looking statements*

This Management's Discussion and Analysis of Financial Condition and Results of Operations contain statements that are forward-looking statements within the meaning of the federal securities laws. All statements that do not concern historical facts are forward-looking statements and include, among other things, statements about our expectations, beliefs, intentions and/or strategies for the future. These forward-looking statements include statements regarding our future operations, financial condition and prospects, expectations for treatment growth rates, revenue per treatment, expense growth, levels of the provision for uncollectible accounts receivable, operating income, cash flow, operating cash flow, estimated tax rates, capital expenditures, the development of new centers and center acquisitions, government and commercial payment rates, revenue estimating risk and the impact of our related level of indebtedness on our financial performance, including earnings per share. These statements involve substantial known and unknown risks and uncertainties that could cause our actual results to differ materially from those described in the forward-looking statements, including, but not limited to, risks resulting from uncertainties associated with government regulations, general economic and other market conditions, competition, accounting estimates, the variability of our cash flows, the concentration of profits generated from commercial payor plans, continued downward pressure on average realized payment rates from commercial payors, which may result in the loss of revenue or patients, a reduction in the number of patients under higher-paying commercial plans, a reduction in government payment rates under the Medicare ESRD program or other government-based programs, the impact of health care legislation that was enacted in the United States in March 2010, changes in pharmaceutical or anemia management practice patterns, payment policies or pharmaceutical pricing, our ability to maintain contracts with physician medical directors, legal compliance risks, including our continued compliance with complex government regulations, current or potential investigations by various government entities and related government or private-party proceedings, continued increased competition from large and medium-sized dialysis providers that compete directly with us, our ability to complete any acquisitions, mergers or dispositions that we might be considering or announce, or integrate and successfully operate any business we may acquire, expansion of our operations and services to markets outside the United States, or to businesses outside of dialysis and the risk factors set forth in this Annual Report on Form 10-K. We base our forward-looking statements on information currently available to us, and we undertake no obligation to update or revise these statements, whether as a result of changes in underlying factors, new information, future events or otherwise.

The following should be read in conjunction with our consolidated financial statements and "Item 1. Business".

Overview

We are a leading provider of kidney dialysis services, primarily in the United States, through a network of approximately 1,809 outpatient dialysis centers and approximately 900 hospitals, located in the United States throughout 43 states and District of Columbia, serving a total of approximately 142,000 patients. We estimate that we have approximately a 32% market share in the United States based upon the number of patients that we serve. In 2011, our overall network of dialysis centers increased by 208 centers primarily as a result of acquisitions and from opening new centers. In September 2011 we acquired DSI, a medium sized dialysis provider, for approximately \$723 million in net cash plus the assumption of certain liabilities. DSI contributed a net 83 dialysis centers, after which we agreed to divest a total of 30 dialysis centers in order to complete the acquisition of DSI. In addition, the overall number of patients that we serve in the U.S. increased by approximately 13.0% as compared to 2010.

In addition, as of December 31, 2011, we provided dialysis and administrative services to a total of 11 outpatient dialysis centers located in three countries outside of the United States. Our international dialysis operations are currently in a start-up phase in which we primarily commenced operations during the fourth quarter of 2011. The total net operating revenues generated from our international operations were not material

during 2011 and are included as a component of our ancillary services and strategic initiatives. Therefore, all references in this document to dialysis and related lab services continue to refer only to our U.S. dialysis and related lab services business for the year ended December 31, 2011.

Our national scale and size, among other things, allows us to provide industry-leading quality care with superior clinical outcomes that attracts patients and referring physicians, as well as qualified medical directors, provides our patient base with convenient locations and access to a full range of services and provides us the ability to effectively control certain costs while maintaining strong compliance programs.

Our stated mission is to be the provider, partner and employer of choice. We believe our attention to these three stakeholders—our patients, our business partners, and our teammates—represents the major driver of our long-term performance, although we are subject to the impact of external factors such as government policy and physician practice patterns. Accordingly, two principal non-financial metrics we track are quality clinical outcomes and teammate turnover. We have developed our own composite index for measuring improvements in our clinical outcomes, which we refer to as the DaVita Quality Index, or DQI. Our clinical outcomes as measured by DQI have improved over each of the past three years which we believe directly decreases patient mortalities. Although it is difficult to reliably measure clinical performance across our industry, we believe our clinical outcomes compare favorably with other dialysis providers in the United States and generally exceed the dialysis outcome quality indicators of the National Kidney Foundation. In addition, over the past several years our teammate turnover has remained relatively constant, which we believe was a major contributor to our continued clinical performance improvements and also a major driver of our ability to maintain or improve clinical hours per treatment. We will continue to focus on these stakeholders and our clinical outcomes as we believe these are fundamental long-term value drivers.

Our overall financial performance was strong for 2011 and was characterized by strong treatment volume growth, primarily from acquisitions and non-acquired growth rates and by decreased operating costs from a decline in the utilization of physician-prescribed pharmaceuticals due to continued evolution of clinical practices and physicians responding to the new FDA label for EPO.

Our major financial operating performance indicators in 2011 as compared to 2010 were as follows:

consolidated revenue growth of approximately 8.5%;

an increase of approximately 9.1% in the overall number of treatments that we provided;

normalized non-acquired treatment growth of 4.6%;

consolidated operating income growth of approximately 13.4%, which includes the impact of a noncash goodwill impairment charge of 2.4%;

effective operating cost control initiatives; and

strong operating cash flows of \$1,180 million.

However, we believe that 2012 will continue to be challenging as we implement some additional Medicare billing requirements and as we implement system and process upgrades to enhance our ability to capture certain patient characteristics that can impact our overall reimbursements from Medicare. In addition, there remains significant scrutiny and uncertainty around the utilization of physician-prescribed pharmaceuticals, which along with pharmaceutical cost increases and changes in certain government policies, can have a significant impact on our operating results. We are also committed to our international expansion plans that will continue to require a significant investment in 2012. In addition, if the percentage of our patients with commercial payors continues to deteriorate this would also impact our operating results.

Approximately 93% of our 2011 consolidated net operating revenues were derived directly from our dialysis and related lab services business. Approximately 81% of our 2011 dialysis and related lab services revenues were derived from outpatient hemodialysis services in the 1,776 U.S. centers that we consolidate. Other dialysis

services, which are operationally integrated with our dialysis operations, are peritoneal dialysis, home-based hemodialysis, hospital inpatient hemodialysis services and management and administrative services. These services collectively accounted for the balance of our 2011 dialysis and related lab services revenues.

Our other business operations include ancillary services and strategic initiatives which are primarily aligned with our core business of providing dialysis services to our network of patients. These consist primarily of pharmacy services, infusion therapy services, disease management services, vascular access services, ESRD clinical research programs, physician services and our international dialysis operations. These services generated approximately \$514 million of net operating revenues in 2011, representing approximately 7% of our consolidated net operating revenues. We currently expect to continue to invest in our ancillary services and strategic initiatives including our continued expansion into certain international markets as we work to develop successful new business operations in the United States as well as outside the United States. However, any significant change in market conditions, business performance or in the regulatory environment may impact the economic viability of any of these strategic initiatives. Any unfavorable changes in these strategic initiatives could result in a write-off or an impairment of some or all of our investments, including goodwill, which occurred in 2011 when we recorded a non-cash goodwill impairment charge relating to our infusion therapy business, and could also result in significant termination costs if we were to exit a certain line of business.

The principal drivers of our dialysis and related lab services revenues are:

- the number of treatments, which is primarily a function of the number of chronic patients requiring approximately three treatments per week, as well as, to a lesser extent, the number of treatments for peritoneal dialysis services and home-based dialysis and hospital inpatient dialysis services; and
- average dialysis revenue per treatment.

The total patient base is a relatively stable factor, which we believe is influenced by a demographically growing need for dialysis services, our relationships with referring physicians, together with the quality of our clinical care which can lead to reduced patient mortalities, and our ability to open and acquire new dialysis centers. In 2011, we were able to increase our overall network of patients that we serviced in the U.S. by approximately 13% as compared to 2010.

Our average dialysis and related lab services revenue per treatment in 2011 was primarily driven by our mix of commercial and government (principally Medicare and Medicaid) patients, commercial and government payment rates, our billing and collecting operations performance, and the mix and intensity of physician-prescribed pharmaceuticals that are separately billable. Beginning in 2011, with the implementation of Medicare's new single bundled payment rate system, the intensities of physician-prescribed pharmaceuticals had a lesser impact on our average dialysis and related lab services revenue per treatment since payment for these pharmaceuticals is included in a single bundled payment. In addition, some of our commercial contracts covering certain patients also pay us under a single bundled payment rate for all dialysis services provided.

On average, payment rates from commercial payors are significantly higher than Medicare, Medicaid and other government program payment rates, and therefore the percentage of commercial patients to total patients represents a major driver of our total average dialysis revenue per treatment. The percentage of commercial patients covered under contracted plans as compared to commercial patients with out-of-network providers can also significantly affect our average dialysis revenue per treatment. In 2011, the growth of our government-based patients continued to outpace the growth of our commercial patients, which has been a trend that we have experienced for the past several years. We believe the growth in our government-based patients is driven primarily by improved mortality and the current economic environment, which impacts the number of individuals that are covered under commercial insurance plans. This trend has negatively impacted our average dialysis revenue per treatment as a result of receiving a larger proportion of our revenue from government-based payors, such as Medicare, that reimburse us at lower payment rates.

The following table summarizes our dialysis and related lab services revenues for the year ended December 31, 2011:

	<u>Revenues</u>	
Medicare and Medicare-assigned plans	58	%
Medicaid and Medicaid-assigned plans	5	%
Other government-based programs	3	%
Total government-based programs	66	%
Commercial (including hospital dialysis services)	34	%
Total dialysis and related lab services revenues	100	%

Government payment rates in the United States are principally determined by federal Medicare and state Medicaid policy. These payment rates have historically had limited potential for rate increases and are sometimes at risk of reduction as federal and state governments face increasing budget pressures. On January 1, 2011 we implemented Medicare's new payment system in which all ESRD payments are made under a single bundled payment rate that, beginning in 2012, will provide for an annual inflation adjustment based upon a market basket index, less a productivity adjustment. Also beginning in 2012, the rule provides for up to a 2% annual payment withhold that can be earned back by the facilities that meet certain defined clinical performance standards. The new payment system reimburses providers based upon a single bundled or average payment for each Medicare treatment provided. This new bundled payment amount is designed to cover all dialysis services which were historically included in the composite rate and all separately billable ESRD services such as pharmaceuticals and laboratory costs. In the past the amount of services that were separately billable accounted for approximately 30% of our total dialysis and related lab services revenues. The new bundled payment rate is adjusted for certain patient characteristics, a geographic wage index and certain other factors. The initial 2011 bundled payment rate included reductions of 2.0% from the prior reimbursement and further reduced overall rates by 5.94% tied to an expanded list of case mix adjusters which can be earned back based upon the presence of certain patient characteristics and co-modalities at the time of treatment. There are also other provisions which may impact payment including an outlier pool and a low volume facility adjustment with regard to the expanded list of case-mix adjusters. These are difficult and, in some cases, have not been possible for our dialysis centers to document and track, which has resulted in lower reimbursement amounts than we would otherwise have received.

On April 1, 2011, CMS released an interim final rule correcting the 3.1% transition adjustment factor to properly update the number of ESRD facilities that elected to opt fully into the new Prospective Payment System (PPS). This new rule is prospective and as a result, effective April 1, 2011 we began recognizing revenues in accordance with the new rule, which resulted in an increase in Medicare revenue per treatment of approximately 3.1% in comparison to our levels recorded in the first quarter of 2011. This reduced our transition adjustment to zero for the balance of 2011 and to an aggregate of approximately 0.75% for 2011.

On November 1, 2011, CMS issued the final ESRD Prospective Payment System (PPS) rule for 2012. The base rate will increase by 2.1%, representing a market basket increase of 3.0% less a productivity adjustment of 0.9%. The increase in the final base rate for 2012 (2.1%) is slightly greater than the increase of 1.8% stated in the proposed 2012 ESRD PPS rule published in July 2011, and higher than the 1.0% increase recommended by MedPAC. In 2012 and beyond, the ESRD PPS system includes additional quality measures that could result in decreased payments if a dialysis facility fails to meet the standards.

Also, beginning January 1, 2014, certain oral-only ESRD drugs (currently paid separately to pharmacies under Medicare Part D) will be included in the ESRD bundled payment to dialysis facilities. It is currently unclear how CMS will "price" the oral-only drugs for inclusion in the ESRD bundle in 2014.

We believe the new payment system presents additional operating clinical and financial risks that our dialysis centers or billing and other systems may not accurately document and track the appropriate patient-specific characteristics, resulting in a reduction or overpayment in the amounts of the payments that we would otherwise be entitled to receive.

Dialysis payment rates from commercial payors can vary and a major portion of our commercial rates are set at contracted amounts with payors and are subject to intense negotiation pressure. Our commercial payment rates also include payments for out-of-network patients that on average are higher than our in-network contract rates. In 2011, we were successful in increasing some of our commercial payment rates which contributed to an increase in our average dialysis revenue per treatment, which helped offset some of the overall decline in our average dialysis revenue per treatment. In 2011, we also entered into some commercial contracts covering certain patients that will primarily pay us a single bundled payment rate for all dialysis services provided to these patients. We are continuously in the process of negotiating agreements with our commercial payors, and payors are aggressive in their negotiations. If our negotiations result in overall commercial rate reductions in excess of overall commercial rate increases, this would have a material adverse effect on our operating results. In addition, if there are sustained or increased job losses in the United States as a result of current economic conditions, or depending upon changes to the healthcare regulatory system, we could experience a decrease in the number of patients under commercial plans.

Approximately 4% of our dialysis and related lab services revenues for the year ended December 31, 2011, were from physician-prescribed pharmaceuticals that are separately billable, with EPO accounting for approximately 3% of our dialysis and related lab services revenues. The impact of physician-prescribed pharmaceuticals on our overall revenues that are separately billable in 2011 has significantly decreased from prior years primarily as a result of implementing Medicare's new single bundled payment system as well as some additional commercial contracts that pay us a single bundled payment rate. Therefore, in 2010 and prior, changes in physician practice patterns, pharmaceutical protocols, pharmaceutical intensities and changes in commercial and governmental payment rates for EPO had a greater significant influence on our revenues.

Our operating performance with respect to dialysis services billing and collection can also be a significant factor in the average dialysis and related lab services revenue per treatment we actually realize. Over the past several years we have invested heavily in upgrades to our systems and processes that we believe have helped improve our operating performance and reduced our regulatory compliance risks and we expect to continue to improve these systems and processes. In 2011, we continued to upgrade our information technology systems and implemented process changes and will continue to do so in 2012 to improve our ability to capture the necessary patient characteristics and certain other factors under Medicare's new bundled payment system. We believe this will help us capture additional reimbursement amounts from Medicare and enhance our overall billing and collection performance. However, as we continue to make upgrades to our systems and processes, or as payors change their systems and requirements, our collection performance as well as our dialysis and related lab services revenue per treatment could be negatively impacted.

Our revenue recognition involves significant estimation risks. Our estimates are developed based on the best information available to us and our best judgment as to the reasonably assured collectability of our billings as of the reporting date based upon our actual historical collection experience. Changes in estimates are reflected in the then-current period financial statements based upon on-going actual experience trends, or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies.

Our annual average dialysis and related lab services revenue per treatment was approximately \$330, \$337 and \$340 for 2011, 2010 and 2009, respectively. In 2011, the average dialysis and related lab services revenue per treatment decreased by approximately \$7 per treatment primarily due to a decline in our Medicare reimbursements as a result of operating in the new single bundled payment system, a decline in the commercial payor mix, and a decline in the intensities of physician-prescribed pharmaceuticals, partially offset by an increase in some of our commercial payment rates. In 2010, the average dialysis and related lab services revenue per treatment decreased by approximately \$3 per treatment primarily due to a decline in the intensities of physician-prescribed pharmaceuticals, and a decline in the commercial payor mix, partially offset by an increase of 1.0% in the Medicare composite rate and an increase in some of our commercial payment rates. Commercial payment rates, changes in the mix and intensities of physician-prescribed pharmaceuticals that are billed separately, government payment policies regarding reimbursement amounts for dialysis treatments and pharmaceuticals

under the new Medicare bundled payment rate system including our ability to capture all patient characteristics, and changes in the mix of government and commercial patients may materially impact our average dialysis and related lab services revenue per treatment in the future.

The principal drivers of our dialysis and related lab services patient care costs are clinical hours per treatment, labor rates, vendor pricing of pharmaceuticals, utilization levels of pharmaceuticals, business infrastructure, including the operating costs of our dialysis centers, and compliance costs. However, other cost categories can also represent significant cost variability, such as employee benefit costs and insurance costs. Our average clinical hours per treatment in 2011 were relatively flat or increased slightly compared to 2010, which continues to be impacted by our ability to maintain or reduce clinical teammate turnover and improve training and processes. We are always striving for improved productivity levels, however, changes in federal and state policies or regulatory billing requirements can adversely impact our ability to achieve optimal productivity levels. In addition, improvements in the U.S. economy could stimulate additional competition for skilled clinical personnel and result in higher teammate turnover which would adversely affect productivity levels. In 2011 and 2010, we experienced an increase in our clinical labor rates of approximately 2.0% in both years, as clinical labor rates have increased consistent with general industry trends, mainly due to the demand for skilled clinical personnel, along with general inflation increases. However, in 2011, we continued to implement certain cost control initiatives to minimize increases in our clinical labor rates. In addition, in 2011, we experienced an approximately 5.0% increase in our EPO costs. Our new agreement with Amgen requires us to purchase EPO in amounts necessary to meet no less than 90% of our requirements for erythropoiesis stimulation agents and provides for discounted pricing and rebates, which are subject to various conditions including future pricing levels of EPO and data submission, which could negatively impact our earnings if we are unable to continue to qualify for discount pricing and rebates. In the initial years of the agreement the total rebate opportunity is less than what was provided for in the agreement that expired at the end of 2011, however, the opportunity for us to earn discounts and rebates increases over the term of the agreement. In 2011, we also experienced increases in our infrastructure and operating costs of our dialysis centers, primarily due to the number of new centers opened, and general increases in rent, utilities and repairs and maintenance.

General and administrative expenses represented 9.9% of our net operating revenues in 2011 as compared to 9.0% in 2010. This represents a fairly significant increase in the dollar amount of our general and administrative expenses primarily related to strengthening our dialysis business, improving our regulatory compliance and other operational processes, responding to certain legal and compliance matters, professional fees associated with information technology matters and international growth initiatives, transaction and integration costs associated with the acquisition of DSI and supporting the growth in some of our ancillary services and strategic initiatives. We expect that these levels of expenditures on general and administrative expenses in 2012 will continue and could possibly increase as we seek out new business opportunities within the dialysis industry or to other healthcare services outside of dialysis, making additional investments in our existing long-term initiatives, such as our ancillary services and strategic initiatives, and the expansion of our international operations, as well as investments in improving our information technology infrastructure and the level of support required for our regulatory compliance and legal matters.

Outlook for 2012. Our operating income for 2012 is expected to be in the range of \$1,200 million to \$1,300 million. We also expect our operating cash flows for 2012 to be in the range of \$950 million to \$1,050 million. These projections and the underlying assumptions involve significant risks and uncertainties, and actual results may vary significantly from these current projections. These risks and uncertainties, among others, include those relating to the concentration of profits generated from commercial payor plans, continued downward pressure on average realized payment rates from commercial payors, which may result in the loss of revenue or patients, a reduction in the number of patients under higher-paying commercial plans, a reduction in government payment rates under the Medicare ESRD program or other government-based programs, the impact of healthcare legislation that was enacted in the United States in March 2010, changes in pharmaceutical or anemia management practice patterns, payment policies or pharmaceutical pricing, our ability to maintain contracts with physician medical directors, legal compliance risks, including our continued compliance with complex

government regulations, current or potential investigations by various government entities and related government or private-party proceedings, continued increased competition from large and medium-sized dialysis providers that compete directly with us, our ability to complete any acquisitions, mergers or dispositions that we might be considering or announce, or integrate and successfully operate any business we may acquire, and expansion of our operations and services to markets outside of the United States, or to businesses outside of dialysis. You should read “Risk Factors” in Item 1A of this Annual Report on Form 10-K and the cautionary language contained in the forward-looking statements and associated risks as discussed on page 43 for more information about these and other potential risks. We undertake no obligation to update or revise these statements, whether as a result of changes in underlying factors, new information, future events or otherwise.

Results of operations

We operate principally as a dialysis and related lab services business in the United States but also operate other ancillary services and strategic initiatives. These ancillary services and strategic initiatives consist primarily of pharmacy services, infusion therapy services, disease management services, vascular access services, ESRD clinical research programs, physician services and our international dialysis operations. The U.S. dialysis and related lab services business qualifies as a separately reportable segment and all of the other ancillary services and strategic initiatives have been combined and disclosed in the other segments category.

Following is a summary of consolidated operating results for reference in the discussion that follows. The operating results of DSI are included in our operating results effective September 1, 2011.

	Year ended December 31,					
	2011		2010		2009	
	(dollar amounts rounded to nearest million)					
Net operating revenues:						
Current period services	\$6,982	100%	\$6,438	100%	\$6,101	100%
Operating expenses and charges:						
Patient care costs	4,681	67 %	4,467	69 %	4,242	70 %
General and administrative	691	10 %	579	9 %	532	9 %
Depreciation and amortization	267	4 %	234	4 %	228	4 %
Provision for uncollectible accounts	198	3 %	171	3 %	161	3 %
Goodwill impairment charge	24	–	–	–	–	–
Equity investment income	(9)	–	(9)	–	(2)	–
Total operating expenses and charges	5,851	84 %	5,441	84 %	5,161	85 %
Operating income	\$1,131	16 %	\$997	16 %	\$940	15 %

The following table summarizes consolidated net operating revenues:

	Year ended		
	2011	2010	2009
	(dollar amounts rounded to nearest million)		
Dialysis and related lab services	\$ 6,485	\$ 6,063	\$ 5,784
Other-ancillary services and strategic initiatives	514	384	334
Total segment revenues	6,999	6,447	6,118
Elimination of intersegment revenues	(17)	(9)	(17)
Consolidated net operating revenues	\$ 6,982	\$ 6,438	\$ 6,101

The following table summarizes consolidated operating income:

	Year ended		
	2011 ⁽¹⁾	2010	2009
	(dollar amounts rounded to nearest million)		
Dialysis and related lab services	\$ 1,225	\$ 1,039	\$ 994
Other-ancillary services and strategic initiatives loss	(54)	(6)	(12)
Total segment operating income	1,171	1,034	982
Reconciling items:			
Stock-based compensation	(49)	(46)	(44)
Equity investment income	9	9	2
Consolidated operating income	1,131	997	940
Reconciliation of non-GAAP measure:			
Add: Goodwill impairment charge	24	-	-
Non-GAAP consolidated operating income	<u>\$ 1,155</u>	<u>\$ 997</u>	<u>\$ 940</u>

- (1) For the year ended December 31, 2011 we have excluded a non-cash goodwill impairment charge from operating expenses and operating income because management believes that this presentation enhances a user's understanding of our normal consolidated operating income by excluding a non-cash goodwill impairment charge that resulted from a decrease in the implied fair value of goodwill below its carrying amount associated with HomeChoice Partners (HCP), which provides infusion therapy services, during the second quarter of 2011 and is therefore more meaningful and comparable to our prior period results and more indicative of our normal consolidated operating income.

Consolidated net operating revenues

Consolidated net operating revenues for 2011 increased by approximately \$544 million or approximately 8.5% from 2010. This increase was primarily due to an increase in dialysis and related lab services net revenues of approximately \$422 million, principally due to strong volume growth from additional treatments from non-acquired growth and acquisitions including the acquisition of DSI, partially offset by a decline of \$7 in the average dialysis revenue per treatment, primarily from a decrease in our Medicare revenues as a result of operating in the new single bundled payment system, as described above. Consolidated net operating revenues also increased as a result of an increase of approximately \$130 million in the ancillary services and strategic initiatives net revenues driven primarily from growth in our pharmacy services and from our disease management services.

Consolidated net operating revenues for 2010 increased by approximately \$337 million or approximately 5.5% from 2009. This increase was primarily due to an increase in our dialysis and related lab services net revenues of approximately \$279 million, principally due to an increase in the number of treatments from non-acquired growth and acquisitions, partially offset by a decline of \$3 in the average dialysis revenue per treatment, as described above, and an increase of approximately \$50 million in the ancillary services and strategic initiatives net revenues driven primarily from growth in our pharmacy services and from our infusion therapy services.

Consolidated operating income

Consolidated operating income of \$1,131 million for 2011 increased by approximately \$134 million, or 13.4%, from 2010 which includes the \$24 million HCP goodwill impairment charge. Excluding this item, consolidated operating income would have increased by \$158 million, or 15.8%, primarily due to an increase in the dialysis and related lab services net operating revenues as a result of strong volume growth in revenue from additional treatments as a result of non-acquired growth and acquisitions, partially offset by a decline in our

average dialysis revenue per treatment of approximately \$7, as described below. Consolidated operating income also increased as a result of overall lower pharmaceutical costs mainly from a decline in the intensities of physician-prescribed pharmaceuticals, additional operating income from the acquisition of DSI and from cost control initiatives. However, consolidated operating income was negatively impacted by higher labor and benefit costs, an increase in our professional fees for compliance and legal initiatives, and for information technology matters, transaction and integration costs associated with the acquisition of DSI, an increase in EPO pharmaceutical costs and an increase in expenses associated with our international expansion.

Consolidated operating income of \$997 million for 2010 increased by approximately \$57 million, or 6.1%, from 2009. This increase was primarily attributable to an increase in revenue as a result of additional treatments from non-acquired growth and acquisitions in dialysis and related lab services, partially offset by a decline in our average dialysis revenue per treatment of approximately \$3, as described below. Operating income also increased as a result of continued cost control initiatives, improved productivity, overall lower pharmaceutical costs and lower operating losses in our ancillary services and strategic initiatives, partially offset by the negative impact on our operating margin from a decline in the intensities of physician-prescribed pharmaceuticals, higher labor costs and increases in other operating costs of our dialysis centers.

Operating segments

Dialysis and Related Lab Services

	Year ended		
	2011	2010	2009
	(dollar amounts rounded to nearest million, except per treatment data)		
Revenues	\$6,485	\$6,063	\$5,784
Segment operating income	\$1,225	\$1,039	\$994
Dialysis treatments	19,599,472	17,963,862	16,984,959
Average dialysis treatments per treatment day	62,618	57,392	54,352
Average dialysis and related lab services revenue per treatment	\$330	\$337	\$340

Net operating revenues

Dialysis and related lab services net operating revenues for 2011 increased by approximately \$422 million or approximately 7.0% from 2010. The increase in net operating revenues was primarily due to strong volume growth from additional treatments of approximately 9.1% due to an increase in non-acquired treatment growth at existing and new centers and growth through acquisitions, which includes additional treatments associated with the acquisition of DSI. However, this increase was partially offset by a decrease in the average dialysis revenue per treatment of approximately \$7, or 2.1%. The decrease in the average dialysis revenue per treatment in 2011, as compared to 2010, was primarily due to a decline in our Medicare reimbursements as a result of operating in the new single bundled payment system, continued decline in the commercial payor mix and a decline in the intensities of physician-prescribed pharmaceuticals, partially offset by an increase in some of our commercial payment rates.

Dialysis and related lab services net operating revenues for 2010 increased by approximately \$279 million or approximately 4.8% from 2009. The increase in net operating revenues was primarily due to an increase in the number of treatments of approximately 5.8% due to an increase in non-acquired treatment growth at existing and new centers and growth through acquisitions. However, this increase was partially offset by a decrease in the average dialysis revenue per treatment of approximately \$3, or 0.9%. The decrease in the average dialysis revenue per treatment in 2010, as compared to 2009, was primarily due to a decline in the intensities of physician-prescribed pharmaceuticals and a decline in the commercial payor mix, partially offset by a 1% increase in the Medicare composite rate and an increase in some of our commercial payment rates.

The following table summarizes our dialysis and related lab services revenues by modality for the year ended December 31, 2011:

	Revenue	
	<u>percentages</u>	
Outpatient hemodialysis centers	81	%
Peritoneal dialysis and home-based hemodialysis	14	%
Hospital inpatient hemodialysis	5	%
Total dialysis and related lab services revenues	<u>100</u>	<u>%</u>

Approximately 66% of our total dialysis and related lab services revenues for the year ended December 31, 2011 were from government-based programs, principally Medicare, Medicaid, and Medicare-assigned plans, representing approximately 89% of our total patients. Over the last several years, we have been experiencing growth in our government-based patients that has been outpacing the growth in our commercial patients which has negatively impacted our average dialysis and related lab services revenue per treatment. Our overall percentage of patients and revenues associated with commercial payors continued to decline in 2011. Less than 1% of our dialysis and related lab services revenues are due directly from patients. No single commercial payor accounted for more than 6% of total dialysis and related lab services revenues for the year ended December 31, 2011.

On average we are paid significantly more for services provided to patients covered by commercial healthcare plans in the United States than we are for patients covered by Medicare, Medicaid or other government plans such as Medicare-assigned plans. Patients covered by commercial health plans transition to Medicare coverage after a maximum of 33 months. As a patient transitions from commercial coverage to Medicare or Medicaid coverage, the payment rates normally decline substantially. Medicare payment rates are insufficient to cover our costs associated with providing dialysis treatments, and therefore we lose money on each Medicare treatment.

Nearly all of our net earnings from our dialysis and related lab services are derived from commercial payors, some of which pay at established contract rates and others which pay negotiated payment rates based on our usual and customary fee schedule for our out-of-network patients. If we experience a net overall reduction in our contracted and non-contracted commercial rates as a result of these negotiations or restrictions, it could have a material adverse effect on our operating results.

Our average dialysis and related lab services revenue per treatment can be significantly impacted by several major factors, including our commercial payment rates, government payment policies regarding reimbursement amounts for dialysis treatments and pharmaceuticals under the new Medicare bundled payment rate system, including our ability to capture all patient characteristics, changes in the mix of government and commercial patients, and changes in the mix and intensities of physician-prescribed pharmaceuticals that are billed separately.

Operating expenses and charges

Patient care costs. Dialysis and related lab services patient care costs are those costs directly associated with operating and supporting our dialysis centers and consist principally of labor, pharmaceuticals, medical supplies and operating costs of the dialysis centers. The dialysis and related lab services patient care costs on a per treatment basis were \$217 and \$232 for 2011 and 2010, respectively. The \$15 decrease in the per treatment costs in 2011 as compared to 2010 was primarily attributable to a decline in the intensities of physician-prescribed pharmaceuticals, continued cost control initiatives, partially offset by higher labor and benefit costs, and higher EPO costs.

Dialysis and related lab services patient care costs on a per treatment basis were \$232 and \$235 for 2010 and 2009, respectively. The \$3 decrease in the per treatment costs in 2010 as compared to 2009 was primarily attributable to a decline in the intensities of physician-prescribed pharmaceuticals, a decrease in our overall pharmaceutical costs and continued improvements in productivity, partially offset by higher labor rates.

General and administrative expenses. Dialysis and related lab services general and administrative expenses for the years ended 2011, 2010 and 2009 were approximately \$551 million, \$471 million and \$428 million, respectively. The increase of approximately \$80 million in 2011 as compared to 2010 was primarily due to increases in labor and benefit costs, an increase in our professional expenses for legal and compliance initiatives and for information technology matters as well as transaction and integration costs associated with the acquisition of DSI. The increase in general and administrative expenses of approximately \$43 million in 2010 as compared to 2009 was primarily due to increases in labor and benefit costs, partially offset by the timing of certain other expenditures.

Depreciation and amortization. Dialysis and related lab services depreciation and amortization expenses for 2011, 2010 and 2009 were approximately \$260 million, \$227 million and \$221 million, respectively. The increase of approximately \$33 million in depreciation and amortization for dialysis and related lab services in 2011 and \$6 million in 2010 were primarily due to growth through new center developments and acquisitions.

Provision for uncollectible accounts receivable. The provision for uncollectible accounts receivable for dialysis and related lab services was 2.9% for 2011, 2.7% for 2010, and 2.7% for 2009. The increase in the provision for uncollectible accounts during 2011 was primarily the result of a slowdown in our historical collection experience from some of our non-government payors. The current provision level of 3.0% at the end of 2011 may increase if we encounter problems with our billing and collection process as a result of sustained weakness in the U.S. economy.

Segment operating income

Dialysis and related lab services operating income for 2011 increased by approximately \$186 million as compared to 2010. The increase in the operating income for 2011 as compared to 2010 was primarily due to strong treatment growth as a result of additional dialysis treatments from non-acquired growth and acquisitions, partially offset by a decrease in the average dialysis revenue per treatment of approximately \$7 as described above. The dialysis and related lab services operating income also increased as a result of a decline in the intensities of physician-prescribed pharmaceuticals, and additional operating income from the acquisition of DSI. However, the dialysis and related lab services operating income was negatively impacted by higher labor and benefit costs, an increase in the cost of EPO, an increase in our professional fees in conjunction with compliance and legal initiatives and for information technology matters as well as transaction and integration costs associated with the acquisition of DSI.

Dialysis and related lab services operating income for 2010 increased by approximately \$45 million as compared to 2009. The increase in the operating income for 2010 as compared to 2009 was primarily due to growth in the number of dialysis treatments from non-acquired growth and acquisitions, partially offset by a decrease in the average dialysis revenue per treatment of approximately \$3 as described above. The dialysis and related lab services operating income also increased as a result of certain cost control initiatives, improved productivity, and overall lower pharmaceutical costs. However, the dialysis and related lab services operating income was negatively impacted by an operating margin decrease due to a decline in the intensities of physician-prescribed pharmaceuticals, higher labor costs and an increase in other operating costs of our dialysis centers.

Other—Ancillary services and strategic initiatives

	Year ended		
	2011	2010	2009
	(dollar amounts rounded to nearest million)		
Revenues	\$ 514	\$ 384	\$ 334
Segment operating loss	\$ (54)	\$ (6)	\$ (12)

Net operating revenues

The ancillary services and strategic initiatives net operating revenues for 2011 increased by approximately \$130 million or 33.9% as compared to 2010, primarily from growth in pharmacy services, and from our disease management services.

The ancillary services and strategic initiatives net operating revenues for 2010 increased by approximately \$50 million or 15.0% as compared to 2009, primarily from growth in pharmacy services, and from our infusion therapy services, partially offset by a decline in our net operating revenues in our disease management services as a result of discontinuing the full service health care plans at the end of 2009.

Operating expenses

Ancillary services and strategic initiatives operating expenses for 2011 increased by approximately \$179 million from 2010, which includes the \$24 million HCP goodwill impairment charged as described below. Excluding this item, ancillary services and strategic initiatives adjusted operating expenses would have increased by \$155 million. This increase in operating expenses was primarily due to an increase in volume in our pharmacy business, an increase in expenses associated with our international dialysis expansion and an increase in labor and benefit costs.

Ancillary services and strategic initiatives operating expenses for 2010 increased by approximately \$43 million from 2009, primarily due to an increase in volume in our pharmacy business and an increase in labor costs, partially offset by lower operating costs of our disease management services as a result of discontinuing the full service health care plans at the end of 2009.

Goodwill

In the second quarter of 2011, we determined that circumstances indicated it was more likely than not that the fair value of one of our ancillary businesses, HCP, which provides infusion therapy services, was less than its carrying amount. The primary factor informing our conclusion was the recent decline in the operating performance of HCP caused mainly by rapid expansion. This led management to revise its view of HCP's organizational growth capability and scale back significantly its current plans for HCP's future growth initiatives and to update HCP's forecasts and current operating budgets accordingly. These revisions reflected the current and expected future cash flows that we believed market participants would use in determining the fair value of the HCP business. As a result, in the second quarter of 2011, we estimated that the carrying amount of goodwill related to HCP exceeded its implied fair value by \$24 million, resulting in a pre-tax goodwill impairment charge of that amount. As of December 31, 2011, after giving effect to this impairment charge, we have approximately \$32 million of HCP goodwill remaining. During the fourth quarter of 2011, we finalized our calculation of this impairment charge, which did not change the goodwill impairment charge previously recorded.

Segment operating loss

Ancillary services and strategic initiatives operating losses for 2011 increased by approximately \$48 million from 2010, which includes the \$24 million HCP goodwill impairment charge, as described above. Excluding this item, ancillary services and strategic initiatives adjusted operating losses would have increased by \$24 million. This increase in operating losses was primarily due to an increase in expenses associated with our international dialysis expansion and a deterioration in the operating performance of our infusion therapy services, partially offset by an increase in the operating performance of our pharmacy business, and in our vascular access services.

Ancillary services and strategic initiatives operating losses for 2010 decreased by approximately \$6 million from 2009. The decrease in operating losses was primarily due to volume growth in revenues associated with our pharmacy business, and a decrease in operating losses in our disease management business as a result of discontinuing the full service health care plans at the end of 2009.

Corporate level charges

Stock-based compensation. Stock-based compensation of approximately \$49 million for 2011 increased by approximately \$3 million from 2010. Stock-based compensation of approximately \$46 million for 2010 increased by approximately \$2 million from 2009. The increase in 2011 resulted from an increase in the overall grant date fair value for the grant years that contributed expense to 2011, driven by both an increase in the grant date fair value of 2011 grants over that for recent years and an increase in the number of awards granted in 2011 over 2010. The increase in 2010 resulted principally from an increase in the overall grant date fair value for the grant years that contributed expense to 2010, driven in part by a substantial increase in the grant date fair value of 2010 grants over that for recent years offset by a significant reduction in the number of awards granted in 2010.

Debt expense. Debt expense for 2011, 2010, and 2009 consisted of interest expense of approximately \$231 million, \$172 million, and \$176 million, respectively, including the amortization and accretion of debt discounts and premiums and the amortization of deferred financing costs of approximately \$10 million in 2011, \$9 million in 2010 and \$10 million in 2009. The increase in interest expense in 2011 as compared to 2010 was primarily related to additional borrowings under our Senior Secured Credit Facilities that were issued in the fourth quarter of 2010 and additional borrowings associated with the new Term Loan A-2 that contain significantly higher interest rates than our previous facility. In addition, debt expense in 2011 was also impacted by the amount of interest rate swaps that resulted in a higher overall weighted average effective interest rate on the Term Loan A and from the amortization of an interest rate cap premium associated with our Term Loan B. However, debt expense in 2011 benefited from lower rates and lower outstanding balances associated with our new senior notes that were issued in the fourth quarter of 2010. Our overall weighted average effective interest rate in 2011 was 5.28% as compared to 4.68% in 2010.

The decrease in interest expense in 2010 as compared to 2009 was primarily related to lower average outstanding principal balances on our previously outstanding Term Loan A, lower average outstanding principal balances on our previously outstanding senior notes, lower interest rates associated with the issuance of our New Senior Notes and a decrease in our weighted average effective interest rate on the Term Loan B as a result of lower notional amounts of fixed rate swap agreements that contained higher rates. Our overall weighted average effective interest rate in 2010 was 4.68% as compared to 4.86% in 2009. However, interest expense in the fourth quarter of 2010 was negatively affected by the refinancing of our Senior Secured Credit Facilities that occurred on October 20, 2010, as the interest rates under our new Senior Secured Credit Facilities are substantially higher than the interest rates under the previous facility. Our overall weighted average effective interest rate in the fourth quarter of 2010 was 4.86%.

Equity investment income. Equity investment income was approximately \$9.0 million in 2011 as compared to \$9.0 million in 2010 and \$2.4 million in 2009. Equity investment income in 2011 as compared to 2010 was flat but was impacted by an increase in the profitability of certain of our nonconsolidated joint ventures, offset by a decrease in the operating performance of certain other joint ventures. The increase in equity investment income in 2010 as compared to 2009 was primarily due to an increase in the profitability of our nonconsolidated joint ventures.

Other income. Other income was approximately \$3 million, \$3 million, and \$4 million in 2011, 2010, and 2009, respectively, and consisted principally of interest income. Other income in 2011 was slightly down from 2010, primarily as a result of lower average interest rates and lower average cash balances. The decrease in 2010 as compared to 2009 was primarily the result of lower average interest rates, partially offset by higher average cash balances.

Provision for income taxes. The provision for income taxes for 2011 represented an effective annualized tax rate of 35.4%, compared with 35.0% and 36.7% in 2010 and 2009, respectively. The effective tax rate in 2011 was higher primarily due to non-deductible transaction costs associated with the DSI acquisition.

Impairments and valuation adjustments. We perform impairment or valuation reviews for our property and equipment, amortizable intangible assets with finite useful lives, equity investments in non-consolidated businesses, and our investments in ancillary services and strategic initiatives at least annually and whenever a change in condition indicates that an impairment review is warranted. Such changes include shifts in our business strategy or plans, the quality or structure of our relationships with our partners, or when a center experiences deteriorating operating performance. Goodwill is also assessed at least annually for possible valuation impairment using fair value methodologies. These types of adjustments are charged directly to the corresponding operating segment that incurred the charge. Except for the HCP goodwill charge in 2011, there were no other significant impairments or valuation adjustments recognized during the periods presented.

Noncontrolling interests

Net income attributable to noncontrolling interests for 2011, 2010 and 2009 was approximately \$95 million, \$79 million and \$57 million, respectively. The increases in noncontrolling interests in 2011 and 2010 were primarily due to increases in the number of new joint ventures and increases in the profitability of our dialysis-related joint ventures. The percentage of dialysis and related lab services net operating revenues generated from dialysis-related joint ventures was approximately 18% in both 2011 and 2010.

Accounts receivable

Our accounts receivable balances at December 31, 2011 and 2010 represented approximately 61 days of revenue for both periods, net of bad debt allowance. Our days outstanding in 2011, represent solid improved cash collections that enabled us to keep pace with our growth in revenue. However, our cash collections in early 2012 could be negatively impacted as Medicare upgrades its systems to meet their new billing requirements.

As of December 31, 2011 and 2010, approximately \$188 million and \$153 million in unreserved accounts receivable, respectively, representing approximately 16% and 15% of our total accounts receivable balance, respectively, were more than six months old. During 2011, we experienced improved cash collections from certain government payors and certain commercial payors. There were no significant unreserved balances over one year old. Less than 1% of our revenues are classified as "patient pay". Substantially all revenue realized is from government and commercial payors, as discussed above.

Amounts pending approval from third-party payors as of December 31, 2011 and 2010, other than the standard monthly billing, consisted of approximately \$57 million in 2011 and \$46 million in 2010, associated with Medicare bad debt claims, classified as "other receivables". Currently, a significant portion of our Medicare bad debt claims are typically paid to us before the Medicare fiscal intermediary audits the claims. However, the payment received from Medicare is subject to adjustment based upon the actual results of the audits. Such audits typically occur one to four years after the claims are filed. As a kidney dialysis provider, our revenue is not subject to cost report settlements, except for potentially limiting the collectability of these Medicare bad debt claims.

Liquidity and capital resources

Available liquidity. As of December 31, 2011, our cash balance was \$394 million and we had undrawn credit under our Senior Secured Credit Facilities totaling \$350 million, of which approximately \$52 million was committed for outstanding letters of credit. We believe that we will have sufficient liquidity, operating cash flows and access to borrowings to fund our scheduled debt service and other obligations for the foreseeable future. Our primary sources of liquidity are cash from operations and cash from borrowings.

Cash flow from operations during 2011 amounted to \$1,180 million, compared with \$840 million for 2010. The increase in our operating cash flows in 2011 as compared to 2010 was primarily due to improved cash earnings, a reduction in income tax payments and the timing of other working capital items, partially offset by an

increase in our accounts receivable balances from growth in revenue. Cash flow from operations in 2011 included cash interest payments of approximately \$236 million and cash tax payments of \$146 million. Cash flow from operations in 2010 included cash interest payments of approximately \$191 million and cash tax payments of \$207 million.

Non-operating cash outflows in 2011 included \$436 million for capital asset expenditures, including \$176 million for new center developments and relocations, and \$260 million for maintenance and information technology. We also spent an additional \$1,077 million for acquisitions. During 2011, we also received \$49 million from the maturity and sale of investments. However, the majority of these proceeds was either used to repurchase other investments or was used to fund distributions from our deferred compensation plans. In addition, during 2011, we received \$32 million associated with stock option exercises and other share issuances and the related excess tax benefits. We also made distributions to noncontrolling interests of \$101 million, and received contributions from noncontrolling interests of \$21 million associated with new joint ventures and from additional equity contributions. We also repurchased 3.8 million shares of our common stock for approximately \$323 million.

Non-operating cash outflows in 2010 included \$279 million for capital asset expenditures, including \$120 million for new center developments and relocations, and \$159 million for maintenance and information technology. We also spent an additional \$189 million for acquisitions. During 2010, we also received \$61 million from the maturity and sale of investments. However, these proceeds were either used to repurchase other investments or were used to fund distributions from our deferred compensation plans. In addition, during 2010, we received \$60 million associated with stock option exercises and other share issuances and the related excess tax benefits. We also made distributions to noncontrolling interests of \$84 million, and received contributions from noncontrolling interests of \$10 million associated with new joint ventures and from additional equity contributions. We also repurchased 8.9 million shares of our common stock for approximately \$619 million.

During 2011, we acquired a total of 178 dialysis centers, eight of which were located outside of the United States, opened 65 new dialysis centers, sold two centers, merged seven centers, and divested a total of 30 dialysis centers in connection with the acquisition of DSI. We also added three dialysis centers under management and administrative service agreements that are located outside of the United States and added one center in which we own a minority equity interest. During 2010, we acquired a total of 41 dialysis centers, opened 65 new dialysis centers, sold six centers, closed 18 centers, and made minority equity investments in three centers that were previously under management and administrative service agreements.

Acquisition

On September 2, 2011, we completed our acquisition of all of the outstanding common stock of CDSI I Holding Company, Inc., the parent company of dialysis provider DSI Renal Inc. (DSI), pursuant to an agreement and plan of merger for approximately \$723 million in net cash, plus the assumption of certain liabilities totaling approximately \$6.5 million, subject to certain post-closing adjustments. DSI had 113 outpatient dialysis centers that provided services to approximately 8,000 patients in 23 states. We also incurred approximately \$22 million in transaction and integration costs during the year ended December 31, 2011 associated with this acquisition that are included in general and administrative expenses.

Pursuant to a consent order issued by the Federal Trade Commission on September 2, 2011, we agreed to divest a total of 30 outpatient dialysis centers and several home-based dialysis programs in order to complete the acquisition of DSI. In conjunction with the consent order, on September 30, 2011, we completed the sale of 28 outpatient dialysis centers to Dialysis Newco, Inc., or Dialysis Newco, a portfolio company of Frazier Healthcare VI, L.P. and New Enterprise Associates 13, Limited Partnership pursuant to an asset purchase agreement dated August 26, 2011. Effective October 31, 2011, we also completed the sale of two additional outpatient dialysis centers to Dialysis Newco that were previously pending state regulatory approval. We anticipate receiving total net cash consideration of approximately \$82.0 million for all of the outpatient dialysis centers that were divested.

2011 capital structure changes and other items

On August 26, 2011, we entered into an Increase Joinder Agreement under our existing Senior Secured Credit Agreement. Pursuant to the Increase Joinder Agreement, we increased the revolving credit facility by \$100 million, to a total of \$350 million, and entered into an additional \$200 million Term Loan A-2. The new Term Loan A-2 required a principal payment of \$0.5 million on December 31, 2011 and thereafter requires annual principal payments of \$2.0 million with the balance of \$191.5 million due in 2016, and bears interest at LIBOR (floor of 1.00%) plus an interest rate margin of 3.50% subject to a rating based step-down to 3.25%.

During the year ended December 31, 2011 we made mandatory principal payments under our Senior Secured Credit Facilities totaling \$50 million on the Term Loan A, \$0.5 million on Term Loan A-2 and \$17.5 million on the Term Loan B.

Interest rate swaps and caps

In January 2011, we entered into nine interest rate swap agreements with amortizing notional amounts totaling \$1.0 billion that went effective on January 31, 2011, as a means of hedging our exposure to and volatility from variable-based interest rate changes as part of our overall risk management strategy. As of December 31, 2011, we maintained a total of nine interest rate swap agreements with amortizing notional amounts totaling \$950 million. These agreements had the economic effect of modifying the LIBOR variable component of our interest rate on an equivalent amount of our Term Loan A to fixed rates ranging from 1.59% to 1.64%, resulting in an overall weighted average effective interest rate of 4.11%, including the Term Loan A margin of 2.50%. The swap agreements expire by September 30, 2014 and require monthly interest payments. During the year ended December 31, 2011, we accrued net charges of \$12.6 million from these swaps which are included in debt expense. As of December 31, 2011, the total fair value of these swap agreements was a liability of \$23.1 million. We estimate that approximately \$10.9 million of existing unrealized pre-tax losses in other comprehensive income at December 31, 2011 will be reclassified into income over the next year.

In addition, in January 2011, we also entered into five interest rate cap agreements with notional amounts totaling \$1.25 billion that went effective on January 31, 2011. These agreements have the economic effect of capping the LIBOR variable component of our interest rate at a maximum of 4.00% on an equivalent amount of our Term Loan B debt. The cap agreements expire on September 30, 2014. As of December 31, 2011, the total fair value of these cap agreements was an asset of \$1.4 million. During the year ended December 31, 2011, we recorded \$5.2 million, net of tax, as a decrease to other comprehensive income due to unrealized valuation changes in the cap agreements, net of the amortization of the interest rate cap premiums that were reclassified into net income.

As a result of the swap and cap agreements, our overall weighted average effective interest rate on the Senior Secured Credit Facilities was 4.61%, based upon the current margins in effect of 2.50% for the Term Loan A, 3.50% for the Term Loan A-2 and 3.00% for the Term Loan B, as of December 31, 2011.

As of December 31, 2011, interest rates on our Term Loan A-2 and Term Loan B are set at their LIBOR floors plus their interest rate margins. Interest rates on our senior notes and Term Loan A are fixed and economically fixed, respectively, with rates on the \$1.25 billion of our Term Loan B subject to interest rate caps.

Our overall weighted average effective interest rate in 2011 was 5.28% and as of December 31, 2011 was 5.27%.

Stock repurchases

During 2011, we repurchased a total of 3,794,686 shares of our common stock for \$323.3 million, or an average price of \$85.21 per share, pursuant to a previously announced authorization by the Board of Directors on

November 3, 2010, that authorized an additional \$800 million of share repurchases of our common stock. As a result of these transactions, the total outstanding authorization for share repurchases as of December 31, 2011 was \$358.2 million. We have not repurchased any additional shares of our common stock from January 1, 2012 through February 24, 2012. This stock repurchase program has no expiration date.

Stock-based compensation

Stock-based compensation recognized in a period represents the straight-line amortization during that period of the estimated grant-date fair value of stock-based awards over their vesting terms, adjusted for expected forfeitures. Shares issued upon exercise of stock awards are generally issued from shares in treasury. We have utilized the Black-Scholes-Merton valuation model for estimating the grant date fair value of stock options and stock-settled stock appreciation rights granted in all prior periods. During 2011, we granted 2,707,500 stock-settled stock appreciation rights with a grant-date fair value of \$59.4 million and a weighted-average expected life of approximately 4.2 years, and also granted 150,246 stock units with a grant-date fair value of \$12.8 million and a weighted-average expected life of approximately 3.1 years.

For the years ended December 31, 2011 and 2010, we recognized \$48.7 million and \$45.6 million, respectively, in stock-based compensation expense for stock-settled stock appreciation rights, stock options, stock units and discounted employee stock plan purchases, which is primarily included in general and administrative expenses. The estimated tax benefits recorded for this stock-based compensation in 2011 and 2010 were \$18.4 million and \$17.3 million, respectively. As of December 31, 2011, there was \$91.3 million of total estimated unrecognized compensation cost related to nonvested stock-settled compensation arrangements under our equity compensation and stock purchase plans. We expect to recognize this cost over a weighted average remaining period of 1.4 years.

During the years ended December 31, 2011 and 2010, we received \$5.4 million and \$48.7 million, respectively, in cash proceeds from stock option exercises and \$38.2 million and \$26.7 million, respectively, in total actual tax benefits upon the exercise of stock awards.

Other items

On July 22, 2010, we entered into a First National Service Provider Agreement, or the Agreement, with NxStage Medical Inc., or NxStage. Under the terms of the Agreement we have the ability to continue to purchase NxStage System One hemodialysis machines and related supplies at discount prices. In addition, we may, in lieu of cash rebate, vest in warrants to purchase NxStage common stock based upon achieving certain System One home patient growth targets by June 30, 2011, 2012 and 2013. The warrants are exercisable for up to a cumulative total of 5.5 million shares of common stock over the three years at an initial exercise price of \$14.22 per share. From the period July 1, 2010 through June 30, 2011, we earned warrants to purchase 250,000 shares of NxStage common stock. In October 2011 we exercised our right to purchase 250,000 shares of NxStage common stock at \$14.22 per share, for a total of approximately \$3.6 million and in February 2012, we sold all 250,000 shares for approximately \$5.2 million.

In July 2010, we announced that we will construct a new corporate headquarters in Denver, Colorado. In July 2010, we acquired the land and existing improvements for approximately \$12 million. Effective December 18, 2010, we entered into a construction agreement for the construction of the new building. We currently estimate the total construction costs and other project costs of the building will be approximately \$95 million. Construction began in early 2011, and is still estimated to be complete in the second half of 2012. Through December 31, 2011, we have paid construction costs and architecture and other design fees totaling approximately \$49 million.

2010 capital structure changes

On October 20, 2010, we entered into a \$3,000 million Senior Secured Credit Agreement (the Credit Agreement), consisting of a five year \$250 million revolving line of credit, a five year \$1,000 million Term Loan

A and a six year \$1,750 million Term Loan B. We also have the right to request an increase to the borrowing capacity to a total aggregate principal amount of not more than \$4,000 million subject to bank participation. The revolving line of credit and the Term Loan A initially bore interest at LIBOR plus an interest rate margin of 2.75% until June 30, 2011, when the interest rate margin was reduced to 2.50%. The interest rate margin is still subject to adjustment depending upon our leverage ratio and can range from 2.25% to 2.75%. The Term Loan A requires annual principal payments of \$50 million in 2011, \$50 million in 2012, \$100 million in 2013, and \$150 million in 2014, with the balance of \$650 million due in 2015. The Term Loan B bears interest at LIBOR (floor of 1.50%) plus 3.00% subject to a ratings based step-down to 2.75%. The Term Loan B requires annual principal payments of \$17.5 million in each year from 2011 through 2015 with the balance of \$1,663 million due in 2016. The borrowings under the Credit Agreement are guaranteed by substantially all of our direct and indirect wholly-owned domestic subsidiaries and are secured by substantially all of DaVita's and its guarantors' assets. The Credit Agreement contains customary affirmative and negative covenants such as various restrictions on investments, acquisitions, the payment of dividends, redemptions and acquisitions of capital stock, capital expenditures and other indebtedness, as well as limitations on the amount of tangible net assets in non-guarantor subsidiaries. However, many of these restrictions will not apply as long as our leverage ratio is below 3.50:1.00. In addition, the Credit Agreement requires compliance with financial covenants including an interest coverage ratio and a leverage ratio that determines the interest rate margins as described above.

On October 20, 2010, we also issued \$775 million aggregate principal amount of 6 ³/₈% senior notes due 2018 and \$775 million aggregate principal amount of 6 ⁵/₈% senior notes due 2020 (the New Senior Notes). The New Senior Notes will pay interest on May 1 and November 1, of each year beginning May 1, 2011. The New Senior Notes are unsecured senior obligations and rank equally to other unsecured senior indebtedness. The New Senior Notes are guaranteed by substantially all of our direct and indirect wholly-owned domestic subsidiaries. We may redeem some or all of the 6 ³/₈% senior notes at any time on or after November 1, 2013 at certain redemption prices and may redeem some or all of the 6 ⁵/₈% senior notes at any time on or after November 1, 2014 at certain redemption prices.

We received total proceeds of \$4,300 million from these transactions, \$2,750 million from the borrowings on Term Loan A and Term Loan B and an additional \$1,550 million from the issuance of the New Senior Notes. We used a portion of the proceeds to pay-off the outstanding principal balances of our existing senior secured credit facilities plus accrued interest totaling \$1,795 million and to purchase pursuant to a cash tender offer \$558 million of the outstanding principal balances of our \$700 million 6 ⁵/₈% senior notes due 2013 and \$731 million of the outstanding balances of our \$850 million 7 ¹/₄% senior subordinated notes due 2015 (the Existing Notes), plus accrued interest totaling \$1,297 million. The total amount paid for the Existing Notes was \$1,019.06 per \$1,000 principal amount of the 6 ⁵/₈% senior notes and \$1,038.75 per \$1,000 principal amount of the 7 ¹/₄% senior subordinated notes. This resulted in us paying a cash tender premium of \$39 million in order to extinguish this portion of the Existing Notes. On November 19, 2010, we redeemed the remaining outstanding balance of the existing 6 ⁵/₈% senior notes of \$142 million at 101.656% per \$1,000 and the remaining outstanding balance of the existing 7 ¹/₄% senior subordinated notes of \$119 million at 103.625% per \$1,000 plus accrued interest totaling \$265 million. In addition, we paid a call premium totaling \$7 million. We also paid an additional \$74 million in fees, discounts and other expenses. As a result of the above transactions, we received approximately \$823 million in excess cash which we have been using for general purposes and other opportunities, including share repurchases, acquisitions and other growth investments.

In connection with these transactions, we expensed debt refinancing and redemption charges totaling \$70.3 million in the fourth quarter of 2010, which includes the write off of certain existing deferred financing costs and other new financing costs, the cash tender and call premiums, as described above and other expenses.

On June 7, 2010, we redeemed \$200 million aggregate principal amount of our outstanding 6 ⁵/₈% senior notes due 2013, at a price of 101.656% plus accrued interest. As a result of this transaction, we expensed debt redemption charges of \$4.1 million, which includes the call premium and the net write-off of other finance costs.

Senior Secured Credit Facilities and senior and senior subordinated notes

During 2010, we made mandatory principal payments totaling \$65.6 million on our prior outstanding Term Loan A. We did not make any principal payments on Term Loan B during 2010, nor were we required to.

All of the outstanding balances under the prior Term Loan A, Term Loan B and the senior and senior subordinated notes were extinguished as part of our debt refinancing transactions that occurred on October 20, 2010, as described above.

Stock repurchases

During 2010, we repurchased a total of 8,918,760 shares of our common stock for \$618.5 million, or an average price of \$69.35 per share, pursuant to previously announced authorizations by the Board of Directors.

Interest rate swaps

Our previous interest rate swap agreements expired on September 30, 2010. The agreements that were effective during 2010 had the economic effect of modifying the LIBOR variable component of our interest rate on an equivalent amount of our debt to fixed rates ranging from 4.05% to 4.70%, resulting in an overall weighted average effective interest rate of 5.84% on the hedged portion of our Senior Secured Credit Facilities, including the Term Loan B margin of 1.50%. During 2010 and 2009, we accrued net cash obligations of approximately \$9.1 million and \$17.3 million, respectively, from these swaps, which are included in debt expense.

Our overall weighted average effective interest rate on our Senior Secured Credit Facilities was 4.05%, based upon the current margins in effect of 2.75% for the Term Loan A and 3.00% for the Term Loan B, as of December 31, 2010.

As of December 31, 2010, interest rates on our Term Loan B are set at its LIBOR floors plus its interest rate margin and interest rates on our senior notes are fixed.

Our overall weighted average effective interest rate in 2010 was 4.68% and as of December 31, 2010 was 4.94%.

Off-balance sheet arrangements and aggregate contractual obligations

In addition to the debt obligations reflected on our balance sheet, we have commitments associated with operating leases and letters of credit as well as potential obligations associated with our equity investments in nonconsolidated businesses and to dialysis centers that are wholly-owned by third parties. Substantially all of our facilities are leased. We have potential acquisition obligations for several joint ventures and for some of our non-wholly-owned subsidiaries in the form of put provisions. If these put provisions were exercised, we would be required to purchase the third-party owners' noncontrolling interests at either the appraised fair market value or a predetermined multiple of earnings or cash flow attributable to the noncontrolling interests put to us, which is intended to approximate fair value. For additional information see Note 22 to the consolidated financial statements.

We also have potential cash commitments to provide operating capital advances as needed to several other dialysis centers that are wholly-owned by third parties or centers in which we own an equity investment, as well as to physician-owned vascular access clinics that we operate under management and administrative services agreements.

The following is a summary of these contractual obligations and commitments as of December 31, 2011 (in millions):

	Less Than 1 year	2-3 years	4-5 years	After 5 years	Total
Scheduled payments under contractual obligations:					
Long-term debt	\$ 85	\$297	\$2,531	\$1,557	\$4,470
Interest payments on the senior notes	100	202	202	279	783
Interest payments on the Term Loan B ⁽¹⁾	79	155	137	–	371
Interest payments on the Term Loan A-2 ⁽²⁾	9	18	16	–	43
Capital lease obligations	2	5	4	32	43
Operating leases	258	444	370	636	1,708
Construction of the new corporate headquarters	46	–	–	–	46
	<u>\$ 579</u>	<u>\$1,121</u>	<u>\$3,260</u>	<u>\$2,504</u>	<u>\$7,464</u>
Potential cash requirements under existing commitments:					
Letters of credit	\$ 52	\$–	\$–	\$–	\$52
Noncontrolling interests subject to put provisions	260	98	76	44	478
Pay-fixed swaps potential obligations	11	12	–	–	23
Operating capital advances	4	–	–	–	4
	<u>\$ 327</u>	<u>\$110</u>	<u>\$76</u>	<u>\$44</u>	<u>\$557</u>

(1) Assuming no changes to LIBOR-based interest rates as the Term Loan B currently bears interest at LIBOR (floor of 1.50%) plus an interest rate margin of 3.00%.

(2) Assuming no changes to LIBOR-based interest rates as the Term Loan A-2 currently bears interest at LIBOR (floor of 1.00%) plus an interest rate margin of 3.50%

The pay-fixed swap obligations represent the estimated fair market values of our interest rate swap agreements as reported by various broker dealers that are based upon relevant observable market inputs as well as other current market conditions that existed as of December 31, 2011, and represent the estimated potential obligation that we would be required to pay based upon the estimated future settlement of each specific tranche over the term of the swap agreements, assuming no future changes in the forward yield curve. The actual amount of our obligation associated with these swaps in the future will depend upon changes in the LIBOR-based interest rates that can fluctuate significantly depending upon market conditions, and other relevant factors that can affect the fair market value of these swap agreements.

In addition to the above commitments, we are obligated to purchase a certain amount of our hemodialysis products and supplies at fixed prices through 2015 from Gambro Renal Products, Inc. in connection with the Product Supply Agreement. Our total expenditures for the years ended December 31, 2011 and 2010 on such products were approximately 2% of our total operating costs in each year. In January 2010, we entered into an agreement with Fresenius which committed us to purchase a certain amount of dialysis equipment, parts and supplies from them through 2013. Our total expenditures for the year ended December 31, 2011 on such products were approximately 2% of our total operating costs.

The actual amount of purchases in future years from Gambro Renal Products and Fresenius will depend upon a number of factors, including the operating requirements of our centers, the number of centers we acquire, growth of our existing centers, and in the case of the Product Supply Agreement, Gambro Renal Products' ability to meet our needs.

In November 2011, we entered into a seven year Sourcing and Supply Agreement with Amgen USA Inc. that expires on December 31, 2018. Under the terms of the agreement we will purchase EPO in amounts

necessary to meet no less than 90% of our requirements for erythropoiesis stimulating agents. The actual amount of EPO that we will purchase from Amgen will depend upon the amount of EPO administered during dialysis as prescribed by physicians and the overall number of patients that we serve.

Settlements of approximately \$12 million of existing income tax liabilities for unrecognized tax benefits are excluded from the above table as reasonably reliable estimates of their timing cannot be made.

Contingencies

The information in Note 16 to the consolidated financial statements of this report is incorporated by reference in response to this item.

Critical accounting estimates and judgments

Our consolidated financial statements and accompanying notes are prepared in accordance with United States generally accepted accounting principles. These accounting principles require us to make estimates, judgments and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and temporary equity. All significant estimates, judgments and assumptions are developed based on the best information available to us at the time made and are regularly reviewed and updated when necessary. Actual results will generally differ from these estimates. Changes in estimates are reflected in our financial statements in the period of change based upon on-going actual experience trends, or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies. Interim changes in estimates are applied prospectively within annual periods. Certain accounting estimates, including those concerning revenue recognition and accounts receivable, impairments of long-lived assets, accounting for income taxes, quarterly and annual variable compensation accruals, purchase accounting valuation estimates, fair value estimates and stock-based compensation are considered to be critical to evaluating and understanding our financial results because they involve inherently uncertain matters and their application requires the most difficult and complex judgments and estimates.

Revenue recognition and accounts receivable. There are significant estimating risks associated with the amount of revenue that we recognize in a given reporting period. Payment rates are often subject to significant uncertainties related to wide variations in the coverage terms of the commercial healthcare plans under which we receive payments. In addition, ongoing insurance coverage changes, geographic coverage differences, differing interpretations of contract coverage, and other payor issues complicate the billing and collection process. Net revenue recognition and allowances for uncollectible billings require the use of estimates of the amounts that will ultimately be realized considering, among other items, retroactive adjustments that may be associated with regulatory reviews, audits, billing reviews and other matters.

Revenues associated with Medicare and Medicaid programs are recognized based on (a) the payment rates that are established by statute or regulation for the portion of the payment rates paid by the government payor (e.g., 80% for Medicare patients) and (b) for the portion not paid by the primary government payor, the estimated amounts that will ultimately be collectible from other government programs paying secondary coverage (e.g., Medicaid secondary coverage), the patient's commercial health plan secondary coverage, or the patient. Effective January 1, 2011, our reimbursements from Medicare became subject to certain variations under Medicare's new single bundled payment rate system whereby our reimbursements can be adjusted for certain patient characteristics and certain other factors. Our revenue recognition depends upon our ability to effectively capture, document and bill for Medicare's base payment rate and these other factors. In addition, as a result of the potential range of variations that can occur in our reimbursements from Medicare under the new single bundled payment rate system, our revenue recognition is now subject to a greater degree of estimating risk.

Commercial healthcare plans, including contracted managed-care payors, are billed at our usual and customary rates; however, revenue is recognized based on estimated net realizable revenue for the services provided. Net realizable revenue is estimated based on contractual terms for the patients under healthcare plans

with which we have formal agreements, non-contracted healthcare plan coverage terms if known, estimated secondary collections, historical collection experience, historical trends of refunds and payor payment adjustments (retractions), inefficiencies in our billing and collection processes that can result in denied claims for payments, slow down in collections, a reduction in the amounts that we expect to collect and regulatory compliance issues. Determining applicable primary and secondary coverage for our more than 142,000 patients at any point in time, together with the changes in patient coverages that occur each month, requires complex, resource-intensive processes. Collections, refunds and payor retractions typically continue to occur for up to three years or longer after services are provided.

We generally expect our range of dialysis and related lab services revenues estimating risk to be within 1% of its revenue, which can represent as much as 6% of consolidated operating income. Changes in estimates are reflected in the then-current financial statements based on on-going actual experience trends, or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies. Changes in revenue estimates for prior periods are separately disclosed and reported if material to the current reporting period and longer term trend analyses, and have not been significant.

Lab service revenues for current period dates of services are recognized at the estimated net realizable amounts to be received.

Impairments of long-lived assets. We account for impairments of long-lived assets, which include property and equipment, equity investments in non-consolidated businesses, amortizable intangible assets with finite useful lives and goodwill, in accordance with the provisions of applicable accounting guidance. Impairment reviews are performed at least annually and whenever a change in condition occurs which indicates that the carrying amounts of assets may not be recoverable.

Such changes include changes in our business strategies and plans, changes in the quality or structure of our relationships with our partners and deteriorating operating performance of individual dialysis centers or other operations. We use a variety of factors to assess the realizable value of assets depending on their nature and use. Such assessments are primarily based upon the sum of expected future undiscounted net cash flows over the expected period the asset will be utilized, as well as market values and conditions. The computation of expected future undiscounted net cash flows can be complex and involves a number of subjective assumptions. Any changes in these factors or assumptions could impact the assessed value of an asset and result in an impairment charge equal to the amount by which its carrying value exceeds its actual or estimated fair value.

Accounting for income taxes. We estimate our income tax provision to recognize our tax expense for the current year, and our deferred tax liabilities and assets for future tax consequences of events that have been recognized in our financial statements, measured using enacted tax rates and laws expected to apply in the periods when the deferred tax liabilities or assets are expected to be realized. We are required to assess our tax positions on a more-likely-than-not criteria and to also determine the actual amount of benefit to recognize in the financial statements. Deferred tax assets are assessed based upon the likelihood of recoverability from future taxable income and, to the extent that recovery is not likely, a valuation allowance is established. The allowance is regularly reviewed and updated for changes in circumstances that would cause a change in judgment about the realizability of the related deferred tax assets. These calculations and assessments involve complex estimates and judgments because the ultimate tax outcome can be uncertain and future events unpredictable.

Variable compensation accruals. We estimate variable compensation accruals quarterly based upon the annual amounts expected to be earned and paid out resulting from the achievement of certain teammate-specific and/or corporate financial and operating goals. Our estimates, which include compensation incentives for bonuses, and other awards, are updated periodically based on changes in our economic condition or cash flows that could ultimately impact the actual final award. Actual results reflected in each fiscal quarter may vary due to the subjectivity involved in anticipating fulfillment of specific and/or corporate goals, as well as the final determination and approval of amounts by our Board of Directors.

Purchase accounting valuation estimates. We make various assumptions and estimates regarding the valuation of tangible and intangible assets, liabilities, noncontrolling interests and contractual as well as non-contractual contingencies associated with our acquisitions. These assumptions can have a material effect on our balance sheet valuations and the related amount of depreciation and amortization expense that will be recognized in the future.

Fair value estimates. We have recorded certain assets, liabilities and noncontrolling interests (temporary equity) subject to put provisions at fair value. The FASB defines fair value which is measured based upon certain valuation techniques that include inputs and assumptions that market participants would use in pricing assets, liabilities and noncontrolling interests subject to put provisions. We have measured the fair values of our applicable assets, liabilities and noncontrolling interests subject to put provisions based upon certain market inputs and assumptions that are either observable or unobservable in determining fair values and have also classified these assets, liabilities and noncontrolling interests subject to put provisions into the appropriate fair value hierarchy levels. The fair value of our investments available for sale are based upon quoted market prices from active markets and the fair value of our swap and cap agreements were based upon valuation models utilizing the income approach and commonly accepted valuation techniques that use inputs from closing prices for similar assets and liabilities in active markets as well as other relevant observable market inputs at quoted intervals such as current interest rates, forward yield curves, implied volatility and credit default swap pricing. For our noncontrolling interests subject to put provisions we have estimated the fair values of these based upon either the higher of a liquidation value of net assets or an average multiple of earnings based on historical earnings, patient mix and other performance indicators, as well as other factors. During the second quarter of 2010, we refined the methodology used to estimate the fair value of noncontrolling interests subject to put provisions by eliminating an annual inflation factor that was previously applied to the put provisions until they became exercisable. We believe that eliminating an annual inflation factor will result in a better representation of the estimated actual fair value of the noncontrolling interests subject to put provisions. The estimate of the fair values of the noncontrolling interests subject to put provisions involves significant judgments and assumptions and may not be indicative of the actual values at which the noncontrolling interests may ultimately be settled, which could vary significantly from our current estimates. The estimated fair values of the noncontrolling interests subject to put provisions can also fluctuate and the implicit multiple of earnings at which these noncontrolling interests obligations may be settled will vary depending upon market conditions including potential purchasers' access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners' noncontrolling interests.

Stock-based compensation. Stock-based compensation recognized in a period represents the straight-line amortization during that period of the estimated grant-date fair value of stock-based awards over their vesting terms, adjusted for expected forfeitures. We estimate the grant-date fair value of stock awards using complex option pricing models that rely heavily on estimates from us about uncertain future events, including the expected term of the awards, the expected future volatility of our stock price, and expected future risk-free interest rates.

Significant new accounting standards

On January 1, 2012, we adopted FASB' s Accounting Standard Update (ASU) No. 2011-08, *Intangibles - Goodwill and Other*. This standard amends the current two-step goodwill impairment test required under the existing accounting guidance. This amendment allows entities the option to first assess certain qualitative factors to ascertain whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount to determine if the two-step impairment test is necessary. If an entity concludes that certain events or circumstances prove that it is more likely than not that the fair value of a reporting unit is less than its carrying amount then an entity is required to proceed to step one of the two-step goodwill impairment test. This standard is effective during interim and annual periods beginning after December 15, 2011. The adoption of this standard did not have a material impact on our consolidated financial statements.

On January 1, 2012, we adopted FASB' s ASU No. 2011-07, *Health Care Entities-Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debts, and the Allowance for Doubtful Accounts*. This standard amends the current presentation and disclosure requirements for Health Care Entities that recognize significant amounts of patient service revenue at the time the services are rendered without assessing the patient' s ability to pay. This standard requires health care entities to reclassify the provision for bad debts from an operating expense to a deduction from patient service revenues. In addition, this standard requires more disclosure on the policies for recognizing revenue, assessing bad debts, as well as quantitative and qualitative information regarding changes in the allowance for doubtful accounts. This standard is applied retrospectively to all prior periods presented and is effective during interim and annual periods beginning after December 15, 2011. The adoption of this standard will require us to change the presentation in our financial statements.

On January 1, 2012, we adopted FASB' s ASU No. 2011-05, *Comprehensive Income-Presentation of Comprehensive Income*. This standard amends the current presentation requirements for comprehensive income by eliminating the presentation of the components of other comprehensive income within the statement of equity. This standard allows two options on how to present the various components of comprehensive income. These options are either to report the components of comprehensive income separately on the income statement or to present total other comprehensive income and the components of other comprehensive income in a separate statement. This standard does not change the items that must be reported in other comprehensive income or when an item must be reclassified into net income. This standard is applied retrospectively and is effective for fiscal years and interim periods within those years beginning after December 15, 2011. Early adoption is permitted. The adoption of this standard will require us to change the presentation in our financial statements.

On January 1, 2012, we adopted FASB' s ASU No. 2011-04, *Fair Value Measurement*. This standard amends the current fair value measurement and disclosure requirements to improve comparability between U.S. GAAP and International Financial Reporting Standards (IFRS). The intent of this standard is to update the disclosures that describe several of the requirements in U.S. GAAP for measuring fair value and to enhance disclosures about fair value measurements which will improve consistency between U.S. GAAP and IFRS. This standard does not change the application of the requirements on fair value measurements and disclosures. This standard is applied prospectively and is effective during interim and annual periods beginning after December 15, 2011. The adoption of this standard did not have a material impact on our consolidated financial statements.

Item 7A. Quantitative and Qualitative Disclosures about Market Risk.

Interest rate sensitivity

The tables below provide information about our financial instruments that are sensitive to changes in interest rates. For our debt obligations the table presents principal repayments and current weighted average interest rates on our debt obligations as of December 31, 2011. The variable rates presented reflect the weighted average LIBOR rates in effect for all debt tranches plus interest rate margins in effect at December 31, 2011. The Term Loan A margin currently in effect is 2.50% and along with the revolving line of credit is subject to adjustment depending upon changes in certain of our financial ratios including a leverage ratio. The Term Loan A-2 currently bears interest at LIBOR (floor of 1.00%) plus an interest rate margin of 3.50% subject to a ratings based step-down to 3.25%. The Term Loan B currently bears interest at LIBOR (floor of 1.50%) plus an interest rate margin of 3.00% subject to a ratings based step-down to 2.75%.

	Expected maturity date						Total	Fair Value	Average interest rate
	2012	2013	2014	2015	2016	Thereafter			
	(dollars in millions)								
Long-term debt:									
Fixed rate	\$35	\$24	\$24	\$24	\$1,858	\$1,585	\$3,550	\$3,543	5.59 %
Variable rate	\$52	\$101	\$153	\$652	\$1	\$4	\$963	\$951	2.81 %

	Notional amount	Contract maturity date					Pay fixed	Receive variable	Fair value
		2012	2013	2014	2015	2016			
(dollars in millions)									
Swaps:									
Pay-fixed rate	\$950	\$50	\$100	\$800	\$-	\$-	1.59% to 1.64%	LIBOR	\$(23.1)
Cap agreements	\$1,250	\$-	\$-	\$1,250	\$-	\$-		LIBOR above 4.00%	\$1.4

Our Senior Secured Credit Facilities, which include the Term Loan A, the Term Loan A-2 and the Term Loan B, consist of various individual tranches of debt that can range in maturity from one month to twelve months (currently, all tranches are one month in duration). For the Term Loan A, each tranche bears interest at a LIBOR rate that is determined by the duration of such tranche plus an interest rate margin. The LIBOR variable component of the interest rate for each tranche is reset as such tranche matures and a new tranche is established. LIBOR can fluctuate significantly depending upon conditions in the credit and capital markets.

The Term Loan A-2 and Term Loan B are subject to LIBOR floors of 1.00% and 1.50%, respectively. Because LIBOR, as of December 31, 2011, was lower than either of these floors, the interest rates on the Term Loan A-2 and the Term Loan B are treated as “fixed” for purposes of the table above. We have included both of these Term Loans in the fixed rate totals in the table above until such time as the LIBOR-based component of our interest rate exceeds 1.00% on the Term Loan A-2 and 1.50% on the Term Loan B. At such time, we will then be subject to LIBOR-based interest rate volatility on the LIBOR variable component of our interest rate on all of the Term Loan A-2, as well as for the Term Loan B, but limited to a maximum rate of 4.00% on \$1.25 billion of outstanding principal debt on the Term Loan B. The remaining \$483 million outstanding principal balance of the Term Loan B is subject to LIBOR-based interest rate volatility above a floor of 1.50%.

In January 2011, we entered into nine interest rate swap agreements with amortizing notional amounts totaling \$1.0 billion that went effective on January 31, 2011, as a means of hedging our exposure to and volatility from variable-based interest rate changes as part of our overall risk management strategy. As of December 31, 2011, we maintained a total of nine interest rate swap agreements with amortizing notional amounts totaling \$950 million. These agreements had the economic effect of modifying the LIBOR variable component of our interest rate on an equivalent amount of our Term Loan A to fixed rates ranging from 1.59% to 1.64%, resulting in an overall weighted average effective interest rate of 4.11%, including the Term Loan A margin of 2.50%. The swap agreements expire by September 30, 2014 and require monthly interest payments. During the year ended December 31, 2011, we accrued net charges of \$12.6 million from these swaps which are included in debt expense. As of December 31, 2011, the total fair value of these swap agreements was a liability of \$23.1 million. We estimate that approximately \$10.9 million of existing unrealized pre-tax losses in other comprehensive income at December 31, 2011 will be reclassified into income over the next year.

In addition, in January 2011, we also entered into five interest rate cap agreements with notional amounts totaling \$1.25 billion that went effective on January 31, 2011. These agreements have the economic effect of capping the LIBOR variable component of our interest rate at a maximum of 4.00% on an equivalent amount of our Term Loan B debt. The cap agreements expire on September 30, 2014. As of December 31, 2011, the total fair value of these cap agreements was an asset of \$1.4 million. During the year ended December 31, 2011, we recorded \$5.2 million, net of tax, as a decrease to other comprehensive income due to unrealized valuation changes in the cap agreements, net of the amortization of the interest rate cap premiums that were reclassified into net income.

As a result of the swap and cap agreements, our overall weighted average effective interest rate on the Senior Secured Credit Facilities was 4.61%, based upon the current margins in effect of 2.50% for the Term Loan A, 3.50% for the Term Loan A-2 and 3.00% for the Term Loan B, as of December 31, 2011.

As of December 31, 2011, interest rates on our Term Loan A-2 and Term Loan B are set at their LIBOR floors plus their interest rate margins. Interest rates on our senior notes and Term Loan A are fixed and economically fixed, respectively, with rates on the \$1.25 billion of our Term Loan B subject to interest rate caps.

Our overall weighted average effective interest rate in 2011 was 5.28% and as of December 31, 2011 was 5.27%.

One means of assessing exposure to debt-related interest rate changes is a duration-based analysis that measures the potential loss in net income resulting from a hypothetical increase in interest rates of 100 basis points across all variable rate maturities (referred to as a “parallel shift in the yield curve”). Under this model, with all else constant, it is estimated that such an increase would have reduced net income by approximately \$0.6 million, \$11.1 million, and \$8.5 million, net of tax, for the years ended December 31, 2011, 2010, and 2009, respectively.

Exchange rate sensitivity

We are currently not exposed to any significant foreign currency exchange rate risk.

Item 8. Financial Statements and Supplementary Data.

See the Index to Financial Statements and Index to Financial Statement Schedules included at “Item 15. Exhibits, Financial Statement Schedules.”

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

None.

Item 9A. Controls and Procedures.

Management has established and maintains disclosure controls and procedures designed to ensure that information required to be disclosed in the reports that it files or submits pursuant to the Securities Exchange Act of 1934, as amended, or Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management including our Chief Executive Officer and Chief Financial Officer as appropriate to allow for timely decisions regarding required disclosures.

At the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures in accordance with the Exchange Act requirements. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective for timely identification and review of material information required to be included in our Exchange Act reports, including this report on Form 10-K. Management recognizes that these controls and procedures can provide only reasonable assurance of desired outcomes, and that estimates and judgments are still inherent in the process of maintaining effective controls and procedures.

There has not been any change in our internal control over financial reporting that was identified during the evaluation that occurred during the fourth fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Item 9B. Other Information.

None.

PART III

Item 10. Directors, Executive Officers and Corporate Governance.

In 2002, we adopted a Corporate Governance Code of Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, and to all of our financial accounting and legal professionals who are directly or indirectly involved in the preparation, reporting and fair presentation of our financial statements and Exchange Act Reports. The Code of Ethics is posted on our website, located at <http://www.davita.com>. We also maintain a Corporate Code of Conduct that applies to all of our employees, which is posted on our website.

Under our Corporate Governance Guidelines all Board Committees including the Audit Committee, Nominating and Governance Committee and the Compensation Committee, which are comprised solely of independent directors as defined within the listing standards of the New York Stock Exchange, have written charters that outline the committee's purpose, goals, membership requirements and responsibilities. These charters are regularly reviewed and updated as necessary by our Board of Directors. All Board Committee charters as well as the Corporate Governance Guidelines are posted on our website located at <http://www.davita.com>.

The other information required to be disclosed by this item will appear in, and is incorporated by reference from, the sections entitled "Proposal No. 1. Election of Directors", "Corporate Governance", and "Security Ownership of Certain Beneficial Owners and Management" included in our definitive proxy statement relating to our 2012 annual stockholder meeting.

Item 11. Executive Compensation.

The information required by this item will appear in, and is incorporated by reference from, the sections entitled "Executive Compensation" and "Compensation Committee Interlocks and Insider Participations" included in our definitive proxy statement relating to our 2012 annual stockholder meeting. The information required by Item 407(e)(5) of Regulation S-K will appear in and is incorporated by reference from the section entitled "Compensation Committee Report" included in our definitive proxy statement relating to our 2012 annual stockholder meeting; however, this information shall not be deemed to be "filed".

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The following table provides information about our common stock that may be issued upon the exercise of stock options, stock-settled stock appreciation rights, restricted stock units and other rights under all of our existing equity compensation plans as of December 31, 2011, including our omnibus 2011 Incentive Award Plan (formerly known as our 2002 Equity Compensation Plan) and our Employee Stock Purchase Plan. The material terms of these plans are described in Note 17 to the Consolidated Financial Statements.

<u>Plan category</u>	<u>Number of shares to be issued upon exercise of outstanding options, warrants and rights</u> <i>(a)</i>	<u>Weighted average exercise price of outstanding options, warrants and rights</u> <i>(b)</i>	<u>Number of shares remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</u> <i>(c)</i>	<u>Total of shares reflected in columns (a) and (c)</u> <i>(d)</i>
Equity compensation plans approved by shareholders	10,728,672	\$ 56.90	9,192,928	19,921,600
Equity compensation plans not requiring shareholder approval	—		—	—
Total	10,728,672	\$ 56.90	9,192,928	19,921,900

Other information required to be disclosed by Item 12 will appear in, and is incorporated by reference from, the section entitled “Security Ownership of Certain Beneficial Owners and Management” included in our definitive proxy statement relating to our 2012 annual stockholder meeting.

Item 13. Certain Relationships and Related Transactions and Director Independence.

The information required by this item will appear in, and is incorporated by reference from, the section entitled “Certain Relationships and Related Transactions” and the section entitled “Corporate Governance” included in our definitive proxy statement relating to our 2012 annual stockholder meeting.

Item 14. Principal Accounting Fees and Services.

The information required by this item will appear in, and is incorporated by reference from, the section entitled “Ratification of Appointment of Independent Registered Public Accounting Firm” included in our definitive proxy statement relating to our 2012 annual stockholder meeting.

PART IV

Item 15. Exhibits, Financial Statement Schedules.

(a) Documents filed as part of this Report:

(1) Index to Financial Statements:

	<u>Page</u>
Management' s Report on Internal Control Over Financial Reporting	F-1
Report of Independent Registered Public Accounting Firm	F-2
Report of Independent Registered Public Accounting Firm	F-3
Consolidated Statements of Income for the years ended December 31, 2011, 2010, and 2009	F-4
Consolidated Balance Sheets as of December 31, 2011, and 2010	F-5
Consolidated Statements of Cash Flow for the years ended December 31, 2011, 2010, and 2009	F-6
Consolidated Statements of Equity and Comprehensive Income for the years ended December 31, 2011, 2010, and 2009	F-7
Notes to Consolidated Financial Statements	F-9

(2) Index to Financial Statement Schedules:

Report of Independent Registered Public Accounting Firm	S-1
Schedule II-Valuation and Qualifying Accounts	S-2

(1) Exhibits:

2.1	Stock Purchase Agreement dated as of December 6, 2004, among Gambro AB, Gambro, Inc. and DaVita Inc.(9)
2.2	Amended and Restated Asset Purchase Agreement effective as of July 28, 2005, by and among DaVita Inc., Gambro Healthcare, Inc. and Renal Advantage Inc., a Delaware corporation, formerly known as RenalAmerica, Inc.(12)
2.3	Agreement and Plan of Merger by and among DaVita Inc., DVA Acquisition Company, CDSI I Holding Company, Inc. and CDSI Representative LLC, dated as of February 4, 2011.(47)
3.1	Amended and Restated Certificate of Incorporation of Total Renal Care Holdings, Inc., or TRCH, dated December 4, 1995.(1)
3.2	Certificate of Amendment of Certificate of Incorporation of TRCH, dated February 26, 1998.(2)
3.3	Certificate of Amendment of Certificate of Incorporation of DaVita Inc. (formerly Total Renal Care Holdings, Inc.), dated October 5, 2000.(4)
3.4	Certificate of Amendment of Amended and Restated Certificate of Incorporation of DaVita Inc., as amended dated May 30, 2007.(23)
3.5	Amended and Restated Bylaws for DaVita Inc. dated as of March 10, 2011.(25)
4.1	Indenture for the 6 5/8% Senior Notes due 2013 dated as of March 22, 2005.(3)
4.2	Indenture for the 7 1/4% Senior Subordinated Notes due 2015 dated as of March 22, 2005.(3)

-
- 4.3 First Supplemental Indenture, dated October 5, 2005, by and among DaVita Inc., the Guarantors, the persons named as Additional Guarantors and The Bank of New York Trust Company, N.A., as Trustee.(11)
- 4.4 First Supplemental Indenture, dated October 5, 2005, by and among DaVita Inc., the Guarantors, the persons named as Additional Guarantors and The Bank of New York Trust Company, N.A., as Trustee.(13)
- 4.5 Rights Agreement, dated as of November 14, 2002, between DaVita Inc. and the Bank of New York, as Rights Agent.(21)
- 4.6 Second Supplemental Indenture (Senior), dated February 9, 2007, by and among DaVita Inc., the Guarantors, the persons named as Additional Guarantors and The Bank of New York Trust Company, N.A., as Trustee.(22)
- 4.7 Second Supplemental Indenture (Senior Subordinated), dated February 9, 2007, by and among DaVita Inc., the Guarantors, the persons named as Additional Guarantors and The Bank of New York Trust Company, N.A., as Trustee.(22)
- 4.8 Registration Rights Agreement for the 6 5/8% Senior Notes due 2013 dated as of February 23, 2007.(26)
- 4.9 Third Supplemental Indenture, dated October 14, 2010, by and among DaVita Inc., the guarantors named therein and The Bank of New York Mellon Trust Company, N.A., as Trustee.(38)
- 4.10 Third Supplemental Indenture, dated October 14, 2010, by and among DaVita Inc., the guarantors named therein and The Bank of New York Mellon Trust Company, N.A., as Trustee.(38)
- 4.11 Indenture, dated October 20, 2010, by and among DaVita Inc., the guarantors named therein and The Bank of New York Mellon Trust Company, N.A., as Trustee.(39)
- 4.12 Indenture, dated October 20, 2010, by and among DaVita Inc., the guarantors named therein and The Bank of New York Mellon Trust Company, N.A., as Trustee.(39)
- 4.13 First Amendment to Rights Agreement, dated as of March 10, 2011, between DaVita Inc. and The Bank of New York Mellon Trust Company, N.A., as Rights Agent.(42)
- 10.1 Employment Agreement, dated as of October 19, 2009, by and between DaVita Inc. and Kim M. Rivera.(40)*
- 10.2 Employment Agreement, dated as of June 15, 2000, by and between DaVita Inc. and Joseph C. Mello.(6)*
- 10.3 Second Amendment to Mr. Mello' s Employment Agreement, effective December 12, 2008.(33)*
- 10.4 Employment Agreement, effective as of August 16, 2004, by and between DaVita Inc. and Tom Usilton.(7)*
- 10.5 Amendment to Mr. Usilton' s Employment Agreement, dated February 12, 2007.(24)*
- 10.6 Second Amendment to Mr. Usilton' s Employment Agreement, effective December 12, 2008.(32)*
- 10.7 Employment Agreement, effective as of November 18, 2004, by and between DaVita Inc. and Joseph Schohl.(14)*
- 10.8 Amendment to Mr. Schohl' s Employment Agreement, effective December 30, 2008.(32)*
- 10.9 Employment Agreement, dated as of October 31, 2005, effective October 24, 2005, by and between DaVita Inc. and Dennis Kogod.(13)*
- 10.10 Amendment to Mr. Kogod' s Employment Agreement, effective December 12, 2008.(32)*

-
- 10.11 Employment Agreement, effective September 22, 2005, by and between DaVita Inc. and James Hilger.(15)*
- 10.12 Amendment to Mr. Hilger' s Employment Agreement, effective December 12, 2008.(32)*
- 10.13 Employment Agreement effective February 13, 2008, by and between DaVita Inc. and Richard K. Whitney.(28)*
- 10.14 Amendment to Equity Award Agreement, entered into on December 11, 2009, between DaVita Inc. and Richard K. Whitney.(40)*
- 10.15 Amendment to Stock Appreciation Rights Agreements, effective November 2008, by and between DaVita Inc. and Richard K. Whitney.(36)*
- 10.16 Employment Agreement, effective July 25, 2008, between DaVita Inc. and Kent J. Thiry.(29)*
- 10.17 Employment Agreement, effective August 1, 2008, between DaVita Inc. and Allen Nissenson.(30)*
- 10.18 Employment Agreement, effective March 3, 2008, between DaVita Inc. and David Shapiro.(32)*
- 10.19 Amendment to Mr. Shapiro' s Employment Agreement, effective December 4, 2008.(32)*
- 10.20 Employment Agreement, effective March 17, 2010, by and between DaVita Inc. and Javier Rodriguez.(35)*
- 10.21 Employment Agreement, effective February 26, 2010, by and between DaVita Inc. and Luis Borgen.(36)*
- 10.22 Amendment to Mr. Borgen' s Employment Agreement, effective March 18, 2010.(36)*
- 10.23 Memorandum Relating to Bonus Structure for Kent J. Thiry.(36)*
- 10.24 Memorandum Relating to Bonus Structure for Dennis L. Kogod.(36)*
- 10.25 Memorandum Relating to Bonus Structure for Thomas O. Usilton, Jr.(36)*
- 10.26 Form of Indemnity Agreement.(20)*
- 10.27 Form of Indemnity Agreement.(14)*
- 10.28 Executive Incentive Plan (as Amended and Restated effective January 1, 2009).(34)*
- 10.29 Executive Retirement Plan.(32)*
- 10.30 Post-Retirement Deferred Compensation Arrangement.(14)*
- 10.31 Amendment No. 1 to Post Retirement Deferred Compensation Arrangement.(32)*
- 10.32 DaVita Voluntary Deferral Plan.(11)*
- 10.33 Deferred Bonus Plan (Prosperity Plan).(31)*
- 10.34 Amendment No. 1 to Deferred Bonus Plan (Prosperity Plan).(32)*
- 10.35 Amended and Restated Employee Stock Purchase Plan.(27)*
- 10.36 Severance Plan.(36)*
- 10.37 Change in Control Bonus Program.(32)*
- 10.38 First Amended and Restated Total Renal Care Holdings, Inc. 1999 Non-Executive Officer and Non-Director Equity Compensation Plan.(5)
- 10.39 Non-Management Director Compensation Philosophy and Plan.(28)*
- 10.40 Amended and Restated 2002 Equity Compensation Plan.(10)*

-
- 10.41 Amended and Restated 2002 Equity Compensation Plan.(19)*
- 10.42 Amended and Restated 2002 Equity Compensation Plan.(27)*
- 10.43 Amended and Restated 2002 Equity Compensation Plan.(32)*
- 10.44 DaVita Inc. 2002 Equity Compensation Plan.(37)*
- 10.45 Form of Non-Qualified Stock Option Agreement–Employee (DaVita Inc. 1999 Non-Executive Officer and Non-Director Equity Compensation Plan).(18)*
- 10.46 Form of Non-Qualified Stock Option Agreement–Employee (DaVita Inc. 2002 Equity Compensation Plan).(7)*
- 10.47 Form of Non-Qualified Stock Option Agreement–Employee (DaVita Inc. 2002 Equity Compensation Plan).(16)*
- 10.48 Form of Non-Qualified Stock Option Agreement–Employee (DaVita Inc. 2002 Equity Compensation Plan).(18)*
- 10.49 Form of Restricted Stock Units Agreement–Employee (DaVita Inc. 2002 Equity Compensation Plan).(7)*
- 10.50 Form of Restricted Stock Units Agreement–Employee (DaVita Inc. 2002 Equity Compensation Plan).(16)*
- 10.51 Form of Restricted Stock Units Agreement–Employee (DaVita Inc. 2002 Equity Compensation Plan).(18)*
- 10.52 Form of Restricted Stock Units Agreement–Employee (DaVita Inc. 2002 Equity Compensation Plan).(32)*
- 10.53 Form of Stock Appreciation Rights Agreement–Employee (DaVita Inc. 2002 Equity Compensation Plan).(16)*
- 10.54 Form of Stock Appreciation Rights Agreement–Employee (DaVita Inc. 2002 Equity Compensation Plan).(18)*
- 10.55 Form of Stock Appreciation Rights Agreement–Board (DaVita Inc. 2002 Equity Compensation Plan).(30)*
- 10.56 Form of Stock Appreciation Rights Agreement–Board members (DaVita Inc. 2011 Incentive Award Plan).(44)*
- 10.57 Form of Restricted Stock Units Agreement–Board (DaVita Inc. 2002 Equity Compensation Plan).(30)*
- 10.58 Form of Restricted Stock Units Agreement–Board members (DaVita Inc. 2011 Incentive Award Plan).(44)*
- 10.59 Form of Non-Qualified Stock Option Agreement–Board (DaVita Inc. 2002 Equity Compensation Plan).(30)*
- 10.60 Form of Stock Appreciation Rights Agreement–Executives (DaVita Inc. 2011 Incentive Award Plan).(44)*
- 10.61 Form of Restricted Stock Units Agreement–Executives (DaVita Inc. 2011 Incentive Award Plan).(44)*

-
- 10.62 Credit Agreement, dated as of October 5, 2005, among DaVita Inc., the Guarantors party thereto, the Lenders party thereto, Bank of America, N.A., Wachovia Bank, National Association, Bear Stearns Corporate Lending Inc., The Bank of New York, The Bank of Nova Scotia, The Royal Bank of Scotland plc, WestLB AG, New York Branch as Co-Documentation Agents, Credit Suisse, Cayman Islands Branch, as Syndication Agent, JPMorgan Chase Bank, N.A., as Administrative Agent and Collateral Agent, JPMorgan Securities Inc., as Sole Lead Arranger and Bookrunner and Credit Suisse, Cayman Islands Branch, as Co-Arranger.(11)
- 10.63 Credit Agreement, dated as of October 5, 2005, as Amended and Restated as of February 23, 2007, by and among DaVita Inc., the Guarantors party thereto, the Lenders party thereto and JPMorgan Chase Bank, N.A.(26)
- 10.64 Amendment Agreement, dated February 23, 2007, by and among DaVita Inc., the Guarantors party thereto, the Lenders party thereto and JPMorgan Chase Bank, N.A.(26)
- 10.65 Security Agreement, dated as of October 5, 2005, by DaVita Inc., the Guarantors party thereto and JPMorgan Chase Bank, N.A., as Collateral Agent.(11)
- 10.66 Credit Agreement, dated as of October 20, 2010, by and among DaVita Inc., the guarantors party thereto, the lenders party thereto, Credit Suisse AG, Barclays Bank PLC, Goldman Sachs Bank USA, Wells Fargo Bank, National Association, Credit Agricole Corporate and Investment Bank, RBC Capital Markets, Scotia Capital (USA) Inc., SunTrust Robinson Humphrey, Inc. and Union Bank, N.A., as Co-Documentation Agents, Bank of America, N.A., as Syndication Agent, JPMorgan Chase Bank, N.A., as Administrative Agent and Collateral Agent, and J.P. Morgan Securities LLC, Banc of America Securities LLC, Credit Suisse Securities (USA) LLC, Barclays Capital, Goldman Sachs Bank USA and Wells Fargo Securities, LLC, as Joint Lead Arrangers and Joint Bookrunners.(46)**
- 10.67 Perfection Certificate executed as of October 20, 2010 and delivered in connection with the closing of the Credit Agreement filed as Exhibit 10.66.(46)**
- 10.68 Corporate Integrity Agreement between the Office of Inspector General of the Department of Health and Human Services and Gambro Healthcare, Inc. effective as of December 1, 2004.(11)
- 10.69 Amended and Restated Alliance and Product Supply Agreement, dated as of August 25, 2006, among Gambro Renal Products, Inc., DaVita Inc. and Gambro AB.(17)**
- 10.70 Letter dated March 19, 2007 from Willard W. Brittain, Jr. to Peter T. Grauer, Lead Independent Director of the Company.(22)
- 10.71 Dialysis Organization Agreement between DaVita Inc. and Amgen USA Inc. dated December 20, 2007.(31)**
- 10.72 Dialysis Organization Agreement between DaVita Inc. and Amgen USA Inc. dated December 17, 2010.(41)**
- 10.73 DaVita Inc. 2011 Incentive Award Plan.(43)*
- 10.74 Amendment No. 2 to Dialysis Organization Agreement between DaVita Inc. and Amgen USA Inc. effective as of July 1, 2011.(45)**
- 10.75 Sourcing and Supply Agreement between DaVita Inc. and Amgen USA Inc. effective as of January 1, 2012.✓**
- 12.1 Computation of Ratio of Earnings to Fixed Charges.✓
- 14.1 DaVita Inc. Corporate Governance Code of Ethics.(8)
- 21.1 List of our subsidiaries.✓

23.1	Consent of KPMG LLP, independent registered public accounting firm. ✓
24.1	Powers of Attorney with respect to DaVita. (Included on Page II-1).
31.1	Certification of the Chief Executive Officer, dated February 24, 2012, pursuant to Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. ✓
31.2	Certification of the Chief Financial Officer, dated February 24, 2012, pursuant to Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. ✓
32.1	Certification of the Chief Executive Officer, dated February 24, 2012, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. ✓
32.2	Certification of the Chief Financial Officer, dated February 24, 2012, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. ✓
101.INS	XBRL Instance Document.
101.SCH	XBRL Taxonomy Extension Schema Document.
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.

✓ Included in this filing.

* Management contract or executive compensation plan or arrangement.

** Portions of this exhibit are subject to a request for confidential treatment and have been redacted and filed separately with the SEC.

- (1) Filed on March 18, 1996 as an exhibit to the Company' s Transitional Report on Form 10-K for the transition period from June 1, 1995 to December 31, 1995.
- (2) Filed on March 31, 1998 as an exhibit to the Company' s Annual Report on Form 10-K for the year ended December 31, 1997.
- (3) Filed on March 25, 2005 as an exhibit to the Company' s Current Report on Form 8-K.
- (4) Filed on March 20, 2001 as an exhibit to the Company' s Annual Report on Form 10-K for the year ended December 31, 2000.
- (5) Filed on February 28, 2003 as an exhibit to the Company' s Annual Report on Form 10-K for the year ended December 31, 2002.
- (6) Filed on August 15, 2001 as an exhibit to the Company' s Quarterly Report on Form 10-Q for the quarter ended June 30, 2001.
- (7) Filed on November 8, 2004 as an exhibit to the Company' s Quarterly Report on Form 10-Q for the quarter ended September 30, 2004.
- (8) Filed on February 27, 2004 as an exhibit to the Company' s Annual Report on Form 10-K for the year ended December 31, 2003.
- (9) Filed on December 8, 2004 as an exhibit to the Company' s Current Report on Form 8-K.
- (10) Filed on May 4, 2005 as an exhibit to the Company' s Quarterly Report on Form 10-Q for the quarter ended March 31, 2005.
- (11) Filed on November 8, 2005 as an exhibit to the Company' s Quarterly Report on Form 10-Q for the quarter ended September 30, 2005.
- (12) Filed on October 11, 2005 as an exhibit to the Company' s Current Report on Form 8-K.
- (13) Filed on November 4, 2005 as an exhibit to the Company' s Current Report on Form 8-K.
- (14) Filed on March 3, 2005 as an exhibit to the Company' s Annual Report on Form 10-K for the year ended December 31, 2004.

-
- (15) Filed on August 7, 2006 as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ending June 30, 2006.
 - (16) Filed on July 6, 2006 as an exhibit to the Company's Current Report on Form 8-K.
 - (17) Filed on November 3, 2006 as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2006.
 - (18) Filed on October 18, 2006 as an exhibit to the Company's Current Report on Form 8-K.
 - (19) Filed on July 31, 2006 as an exhibit to the Company's Current Report on Form 8-K.
 - (20) Filed on December 20, 2006 as an exhibit to the Company's Current Report on Form 8-K.
 - (21) Filed on November 19, 2002 as an exhibit to the Company's Current Report on Form 8-K.
 - (22) Filed on May 3, 2007 as an exhibit to the Company's Quarterly Report as Form 10-Q for the quarter ended March 31, 2007.
 - (23) Filed on August 6, 2007 as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007.
 - (24) Filed on February 16, 2007 as an exhibit to the Company's Current Report on Form 8-K.
 - (25) Filed on March 17, 2011 as an exhibit to the Company's Current Report on Form 8-K/A.
 - (26) Filed on February 28, 2007 as an exhibit to the Company's Current Report on Form 8-K.
 - (27) Filed on June 4, 2007 as an exhibit to the Company's Current Report on Form 8-K.
 - (28) Filed on May 8, 2008 as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2008.
 - (29) Filed on July 31, 2008 as an exhibit to the Company's Current Report on Form 8-K.
 - (30) Filed on November 6, 2008 as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2008.
 - (31) Filed on February 29, 2008 as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 2007.
 - (32) Filed on February 27, 2009 as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 2008.
 - (33) Filed on May 7, 2009 as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2009.
 - (34) Filed on June 18, 2009 as an exhibit to the Company's Current Report on Form 8-K.
 - (35) Filed on April 14, 2010 as an exhibit to the Company's Current Report on Form 8-K.
 - (36) Filed on May 3, 2010 as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2010.
 - (37) Filed on April 28, 2010 as Appendix A to the Company's Definitive Proxy Statement on Schedule 14A.
 - (38) Filed on October 19, 2010 as an exhibit to the Company's Current Report on Form 8-K.
 - (39) Filed on October 21, 2010 as an exhibit to the Company's Current Report on Form 8-K.
 - (40) Filed on February 25, 2010 as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 2009.
 - (41) Filed on December 29, 2011 as an exhibit to the Company's Annual Report on Form 10-K/A for the year ended December 31, 2010.
 - (42) Filed on May 6, 2011 as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2011.
 - (43) Filed on April 27, 2011 as Appendix A to the Company's Definitive Proxy Statement on Schedule 14A.
 - (44) Filed on August 4, 2011 as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2011.
 - (45) Filed on December 29, 2011 as an exhibit to the Company's Quarterly Report on Form 10-Q/A for the quarter ended June 30, 2011.
 - (46) Filed on January 17, 2012 as an exhibit to the Company's Quarterly Report on Form 10-Q/A for the quarter ended March 31, 2011.
 - (47) Filed on February 10, 2011 as an exhibit to the Company's Current Report on Form 8-K.

DAVITA INC.

MANAGEMENT' S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

Management is responsible for establishing and maintaining an adequate system of internal control over financial reporting designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles and which includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company' s assets that could have a material effect on the financial statements.

During the last fiscal year, the Company conducted an evaluation, under the oversight of the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company' s internal control over financial reporting. This evaluation was completed based on the criteria established in the report titled "Internal Control-Integrated Framework" issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

Based upon our evaluation under the COSO framework, we have concluded that the Company' s internal control over financial reporting was effective as of December 31, 2011.

The Company' s independent registered public accounting firm, KPMG LLP, has issued an attestation report on the Company' s internal control over financial reporting, which report is included in this Annual Report.

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Board of Directors and Shareholders

DaVita Inc.:

We have audited the accompanying consolidated balance sheets of DaVita Inc. and subsidiaries as of December 31, 2011 and 2010, and the related consolidated statements of income, equity and comprehensive income, and cash flows for each of the years in the three-year period ended December 31, 2011. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of DaVita Inc. and subsidiaries as of December 31, 2011 and 2010, and the results of their operations and their cash flows for each of the years in the three-year period ended December 31, 2011, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), DaVita Inc.'s internal control over financial reporting as of December 31, 2011, based on criteria established in *Internal Control-Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our report dated February 24, 2012 expressed an unqualified opinion on the effectiveness of the Company's internal control over financial reporting.

/s/ KPMG LLP

Seattle, Washington

February 24, 2012

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Board of Directors and Shareholders

DaVita Inc.:

We have audited DaVita Inc.'s internal control over financial reporting as of December 31, 2011, based on criteria established in *Internal Control-Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). DaVita Inc.'s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying "Management's Report on Internal Control Over Financial Reporting". Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, DaVita Inc. maintained, in all material respects, effective internal control over financial reporting as of December 31, 2011, based on criteria established in *Internal Control-Integrated Framework* issued by COSO.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of DaVita Inc. and subsidiaries as of December 31, 2011 and 2010, and the related consolidated statements of income, equity and comprehensive income, and cash flows for each of the years in the three-year period ended December 31, 2011, and our report dated February 24, 2012 expressed an unqualified opinion on those consolidated financial statements.

/s/ KPMG LLP

Seattle, Washington

February 24, 2012

DAVITA INC.

CONSOLIDATED STATEMENTS OF INCOME

(dollars in thousands, except per share data)

	Year ended December 31,		
	2011	2010	2009
Net operating revenues	\$6,982,214	\$6,438,050	\$6,100,648
Operating expenses and charges:			
Patient care costs	4,680,772	4,467,107	4,242,147
General and administrative	691,243	579,000	531,531
Depreciation and amortization	266,628	233,730	228,396
Provision for uncollectible accounts	197,565	170,652	161,388
Equity investment income	(8,776)	(8,999)	(2,442)
Goodwill impairment charge	24,000	-	-
Total operating expenses and charges	<u>5,851,432</u>	<u>5,441,490</u>	<u>5,161,020</u>
Operating income	1,130,782	996,560	939,628
Debt expense	(241,090)	(181,607)	(185,755)
Debt refinancing and redemption charges	-	(74,382)	-
Other income	2,982	3,419	3,706
Income from continuing operations before income taxes	892,674	743,990	757,579
Income tax expense	315,744	260,052	278,213
Income from continuing operations	576,930	483,938	479,366
Discontinued operations:			
Income from operations of discontinued operations, net of tax	1,221	281	393
Loss on disposal of discontinued operations, net of tax	(4,756)	-	-
Net income	573,395	484,219	479,759
Less: Net income attributable to noncontrolling interests	(95,394)	(78,536)	(57,075)
Net income attributable to DaVita Inc.	<u>\$478,001</u>	<u>\$405,683</u>	<u>\$422,684</u>
Earnings per share:			
Basic income from continuing operations per share attributable to DaVita Inc.	<u>\$5.09</u>	<u>\$3.99</u>	<u>\$4.07</u>
Basic net income per share attributable to DaVita Inc.	<u>\$5.05</u>	<u>\$4.00</u>	<u>\$4.08</u>
Diluted income from continuing operations per share attributable to DaVita Inc.	<u>\$4.99</u>	<u>\$3.93</u>	<u>\$4.05</u>
Diluted net income per share attributable to DaVita Inc.	<u>\$4.96</u>	<u>\$3.94</u>	<u>\$4.06</u>
Weighted average shares for earnings per share:			
Basic	<u>94,658,027</u>	<u>101,504,373</u>	<u>103,603,885</u>
Diluted	<u>96,532,110</u>	<u>103,059,171</u>	<u>104,167,685</u>
Amounts attributable to DaVita Inc.:			
Income from continuing operations	\$481,755	\$405,402	\$422,291
Discontinued operations	(3,754)	281	393
Net income	<u>\$478,001</u>	<u>\$405,683</u>	<u>\$422,684</u>

See notes to consolidated financial statements.

DAVITA INC.

CONSOLIDATED BALANCE SHEETS
(dollars in thousands, except per share data)

	December 31,	
	2011	2010
ASSETS		
Cash and cash equivalents	\$393,752	\$860,117
Short-term investments	17,399	23,003
Accounts receivable, less allowance of \$250,343 and \$235,629	1,195,163	1,048,976
Inventories	75,731	76,008
Other receivables	269,832	304,366
Other current assets	49,349	43,994
Income tax receivable	-	40,330
Deferred income taxes	280,382	226,060
Total current assets	2,281,608	2,622,854
Property and equipment, net	1,432,651	1,170,808
Amortizable intangibles, net	159,491	162,635
Equity investments	27,325	25,918
Long-term investments	9,890	8,848
Other long-term assets	34,231	32,054
Goodwill	4,946,976	4,091,307
	<u>\$8,892,172</u>	<u>\$8,114,424</u>
LIABILITIES AND EQUITY		
Accounts payable	\$289,653	\$181,033
Other liabilities	325,734	342,943
Accrued compensation and benefits	412,972	325,477
Current portion of long-term debt	87,345	74,892
Income taxes payable	37,412	-
Total current liabilities	1,153,116	924,345
Long-term debt	4,417,624	4,233,850
Other long-term liabilities	132,006	89,290
Alliance and product supply agreement, net	19,987	25,317
Deferred income taxes	423,098	421,436
Total liabilities	6,145,831	5,694,238
Commitments and contingencies		
Noncontrolling interests subject to put provisions	478,216	383,052
Equity:		
Preferred stock (\$0.001 par value, 5,000,000 shares authorized; none issued)		
Common stock (\$0.001 par value, 450,000,000 shares authorized; 134,862,283 shares issued; 93,641,363 and 96,001,535 shares outstanding)	135	135
Additional paid-in capital	596,300	620,546
Retained earnings	3,195,818	2,717,817
Treasury stock, at cost (41,220,920 and 38,860,748 shares)	(1,631,694)	(1,360,579)
Accumulated other comprehensive (loss) income	(19,484)	503
Total DaVita Inc. shareholders' equity	2,141,075	1,978,422
Noncontrolling interests not subject to put provisions	127,050	58,712
Total equity	<u>2,268,125</u>	<u>2,037,134</u>

\$8,892,172

\$8,114,424

See notes to consolidated financial statements.

F-5

DAVITA INC.

CONSOLIDATED STATEMENTS OF CASH FLOW
(dollars in thousands)

	Year ended December 31,		
	2011	2010	2009
Cash flows from operating activities:			
Net income	\$573,395	\$484,219	\$479,759
Adjustments to reconcile net income to cash provided by operating activities:			
Depreciation and amortization	267,315	234,378	228,986
Stock-based compensation expense	48,718	45,551	44,422
Tax benefits from stock award exercises	38,199	26,706	18,241
Excess tax benefits from stock award exercises	(20,834)	(6,283)	(6,950)
Deferred income taxes	53,438	75,399	50,869
Equity investment income, net	354	(3,298)	(204)
Loss on disposal of assets and other non-cash charges	20,329	9,585	20,945
Goodwill impairment charge	24,000	-	-
Debt refinancing and redemption charges	-	74,382	-
Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:			
Accounts receivable	(88,848)	55,379	(32,313)
Inventories	10,270	(3,892)	15,115
Other receivables and other current assets	53,697	(44,719)	(35,104)
Other long-term assets	2,039	901	7,288
Accounts payable	84,400	4,228	(104,879)
Accrued compensation and benefits	77,074	39,588	(9,138)
Other current liabilities	(51,979)	(111,444)	(43,543)
Income taxes	77,418	(45,737)	44,578
Other long-term liabilities	11,061	4,740	(11,362)
Net cash provided by operating activities	<u>1,180,046</u>	<u>839,683</u>	<u>666,710</u>
Cash flows from investing activities:			
Additions of property and equipment, net	(400,156)	(273,602)	(274,605)
Acquisitions	(1,077,442)	(188,502)	(87,617)
Proceeds from asset sales	75,183	22,727	7,697
Purchase of investments available-for-sale	(5,971)	(1,125)	(2,062)
Purchase of investments held-to-maturity	(37,628)	(56,615)	(22,664)
Proceeds from the sale of investments available-for-sale	1,149	900	16,693
Proceeds from maturities of investments held-to-maturity	47,695	59,932	16,380
Purchase of equity investments and other assets	(2,398)	(709)	(2,429)
Distributions received on equity investments	340	361	2,547
Net cash used in investing activities	<u>(1,399,228)</u>	<u>(436,633)</u>	<u>(346,060)</u>
Cash flows from financing activities:			
Borrowings	36,395,105	24,809,258	18,767,592
Payments on long-term debt	(36,249,584)	(24,134,502)	(18,828,824)
Interest rate cap premiums and other deferred financing costs	(17,861)	-	-
Debt refinancing costs including tender and call premiums	-	(113,810)	(42)
Purchase of treasury stock	(323,348)	(618,496)	(153,495)

Distributions to noncontrolling interests	(100,653)	(83,591)	(67,748)
Stock award exercises and other share issuances, net	11,316	53,760	67,908
Excess tax benefits from stock award exercises	20,834	6,283	6,950
Contributions from noncontrolling interests	21,010	9,510	13,071
Proceeds from sales of additional noncontrolling interests	9,687	3,410	9,375
Purchases from noncontrolling interests	(13,689)	(14,214)	(6,859)
Net cash used in financing activities	(247,183)	(82,392)	(192,072)
Net (decrease) increase in cash and cash equivalents	(466,365)	320,658	128,578
Cash and cash equivalents at beginning of year	860,117	539,459	410,881
Cash and cash equivalents at end of year	<u>\$393,752</u>	<u>\$860,117</u>	<u>\$539,459</u>

See notes to consolidated financial statements.

DAVITA INC.

CONSOLIDATED STATEMENTS OF EQUITY
AND
COMPREHENSIVE INCOME
(dollars and shares in thousands)

	Non-controlling interests subject to put provisions	DaVita Inc. Shareholders' Equity								Non-controlling interests not subject to put provisions
		Common stock				Treasury stock				
		Shares	Amount	Additional paid-in capital	Retained earnings	Shares	Amount	Accumulated other comprehensive income (loss)	Total	
Balance at December 31, 2008	\$291,397	134,862	\$ 135	\$584,358	\$1,889,450	(31,109)	\$(691,857)	\$ (14,339)	\$1,767,747	\$59,152
Comprehensive income:										
Net income	38,381				422,684				422,684	18,694
Unrealized losses on interest rate swaps, net of tax								(2,578)	(2,578)	
Less reclassification of net swap realized losses into net income, net of tax								10,542	10,542	
Unrealized gains on investments, net of tax								986	986	
Less reclassification of net investment realized gains into net income, net of tax								(159)	(159)	
Total comprehensive income										
Stock purchase shares issued				2,135		107	2,387		4,522	
Stock unit shares issued				(1,570)		69	1,570		-	
Stock options and SSARs exercised				15,598		2,036	48,055		63,653	
Stock-based compensation expense				44,422					44,422	
Excess tax benefits from stock awards exercised				6,150					6,150	
Distributions to noncontrolling interests	(44,277)									(23,471)
Contributions from noncontrolling interests	10,502									2,569
Sales and assumptions of additional noncontrolling interests	13,483			(529)					(529)	4,039
Purchases from noncontrolling interests	(2,594)			(3,721)					(3,721)	(544)
Changes in fair value of noncontrolling interests	24,819			(24,819)					(24,819)	-
Other adjustments	14			(339)					(339)	(1,346)
Purchase of treasury stock						(2,903)	(153,495)		(153,495)	
Balance at December 31, 2009	\$331,725	134,862	\$ 135	\$621,685	\$2,312,134	(31,800)	\$(793,340)	\$ (5,548)	\$2,135,066	\$59,093
Comprehensive income:										
Net income	52,589				405,683				405,683	25,947
Unrealized losses on interest rate swaps, net of tax								(134)	(134)	

Less reclassification of net swap realized losses into net income, net of tax			5,557	5,557
Unrealized gains on investments, net of tax			615	615
Less reclassification of net investment realized losses into net income, net of tax			13	13
Total comprehensive income				
Stock purchase shares issued	2,129	86	2,151	4,280
Stock unit shares issued	(875)	32	875	–
Stock options and SSARs exercised	455	1,740	48,231	48,686
Stock-based compensation expense	45,551			45,551

F-7

DAVITA INC.
CONSOLIDATED STATEMENTS OF EQUITY
AND
COMPREHENSIVE INCOME—(Continued)
(dollars and shares in thousands)

	Non-controlling interests subject to put provisions	DaVita Inc. Shareholders' Equity							Non-controlling interests not subject to put provisions	Comprehensive income	
		Common stock			Treasury stock						
		Shares	Amount	Additional paid-in capital	Retained earnings	Shares	Amount	Accumulated other comprehensive income (loss)			Total
Excess tax benefits from stock awards exercised				6,283					6,283		
Distributions to noncontrolling interests	(54,612)										(28,979)
Contributions from noncontrolling interests	5,439										4,071
Sales and assumptions of additional noncontrolling interests	4,059			(298)					(298)	2,308	
Purchases from noncontrolling interests	(4,949)			(5,537)					(5,537)	(3,728)	
Impact on fair value due to change in methodology	(24,571)			24,571					24,571		
Changes in fair value of noncontrolling interests	73,372			(73,372)					(73,372)		
Other adjustments				(46)					(46)		
Purchase of treasury stock						(8,919)	(618,496)		(618,496)		
Balance at December 31, 2010	\$383,052	134,862	\$ 135	\$620,546	\$2,717,817	(38,861)	\$(1,360,579)	\$ 503	\$1,978,422	\$58,712	
Comprehensive income:											
Net income	59,135				478,001				478,001	36,259	\$ 573,395
Unrealized losses on interest rate swap and cap agreements, net of tax								(29,049)	(29,049)		(29,049)
Less reclassification of net swap and cap agreements realized losses into net income, net of tax								9,721	9,721		9,721
Unrealized losses on investments, net of tax								(602)	(602)		(602)
Less reclassification of net investment								(57)	(57)		(57)

realized gains into net income, net of tax											
Total comprehensive income											<u>\$ 553,408</u>
Stock purchase shares issued		4,268		175	6,554			10,822			
Stock unit shares issued		(2,866)		78	2,866			-			
Stock options and SSARs exercised		(37,370)		1,182	42,813			5,443			
Stock-based compensation expense		48,718						48,718			
Excess tax benefits from stock awards exercised		20,834						20,834			
Distributions to noncontrolling interests	(61,343)									(39,310)	
Contributions from noncontrolling interests	12,547									8,463	
Sales and assumptions of additional noncontrolling interests	49,343		(1,299)					(1,299)	55,566		
Purchases from noncontrolling interests	(2,103)		(9,486)					(9,486)		(2,100)	
Changes in fair value of noncontrolling interests	63,762		(63,762)					(63,762)			
Expired put provision	(26,177)		16,717					16,717	9,460		
Purchase of treasury stock					(3,795)	(323,348)		(323,348)			
Balance at December 31, 2011	<u>\$478,216</u>	<u>134,862</u>	<u>\$ 135</u>	<u>\$596,300</u>	<u>\$3,195,818</u>	<u>(41,221)</u>	<u>\$(1,631,694)</u>	<u>\$ (19,484)</u>	<u>\$2,141,075</u>	<u>\$ 127,050</u>	

See notes to consolidated financial statements.

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(dollars in thousands, except per share data)

1. Organization and summary of significant accounting policies

Organization

DaVita Inc. principally operates kidney dialysis centers and provides related lab services primarily in outpatient dialysis centers and in contracted hospitals mainly across the United States. The Company also operates other ancillary services and strategic initiatives, which include the Company's international operations that relate primarily to its core business of providing kidney dialysis services. As of December 31, 2011, the Company operated or provided administrative services through a network of 1,809 outpatient dialysis centers located in the United States throughout 43 states and the District of Columbia, serving approximately 142,000 patients. In addition, as of December 31, 2011, the Company operated or provided administrative services to 11 outpatient dialysis centers located in three countries outside of the United States. The Company's U.S. dialysis and related lab services business qualifies as a separately reportable segment and all other ancillary services and strategic initiatives, including the Company's international operations, have been combined and disclosed in the other segments category.

Basis of presentation

These consolidated financial statements are prepared in accordance with United States generally accepted accounting principles. The financial statements include DaVita and its subsidiaries, partnerships and other entities in which it maintains a 100% or majority voting interest, another controlling financial interest, or of which it is the primary beneficiary (collectively, the Company). All significant intercompany transactions and balances have been eliminated. Non-marketable equity investments are recorded under the equity or cost method of accounting based upon whether the Company has significant influence over the investee. The Company has evaluated subsequent events through the date these consolidated financial statements were issued, and have included all necessary disclosures. For the Company's international subsidiaries, local currencies are their functional currencies. A translation adjustment results from the process of translating the Company's international subsidiaries' financial statements which are reflected at their functional currencies into the Company's reporting currency (USD). The translation adjustment as of and for the year ended December 31, 2011 was immaterial.

Use of estimates

The preparation of financial statements in conformity with United States generally accepted accounting principles requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and temporary equity. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management's best judgments at the time made. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends, or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies. Interim changes in estimates related to annual operating costs are applied prospectively within annual periods.

The most significant assumptions and estimates underlying these financial statements and accompanying notes involve revenue recognition and accounts receivable, impairments of long-lived assets and valuation adjustments, accounting for income taxes, quarterly and annual variable compensation accruals, purchase accounting valuation estimates, fair value estimates and stock-based compensation. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements.

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

Net operating revenues and accounts receivable

Revenues associated with Medicare and Medicaid programs are recognized based on: (a) the payment rates that are established by statute or regulation for the portion of the payment rates paid by the government payor (e.g., 80% for Medicare patients) and (b) for the portion not paid by the primary government payor, estimates of the amounts ultimately collectible from other government programs paying secondary coverage (e.g., Medicaid secondary coverage), the patient's commercial health plan secondary coverage, or the patient. Effective January 1, 2011, the Company's reimbursements from Medicare are now subject to certain variations under Medicare's new single bundled payment rate system, whereby reimbursements can be adjusted for certain patient characteristics and other factors. The Company's revenue recognition will depend upon its ability to effectively capture, document and bill for Medicare's base payment rate as well as these other variable factors. In addition, as a result of the potential range of variations that can occur in the Company's reimbursements from Medicare under the new single bundled payment rate system, the Company's revenue recognition is now subject to a greater degree of estimating risk.

Revenues associated with commercial health plans are estimated based on contractual terms for the patients under healthcare plans with which the Company has formal agreements, non-contracted health plan coverage terms if known, estimated secondary collections, historical collection experience, historical trends of refunds and payor payment adjustments (retractions), inefficiencies in the Company's billing and collection processes that can result in denied claims for payments, and regulatory compliance issues.

Operating revenues are recognized in the period services are provided. Revenues consist primarily of payments from Medicare, Medicaid and commercial health plans for dialysis and ancillary services provided to patients. A usual and customary fee schedule is maintained for the Company's dialysis treatments and other patient services; however, actual collectible revenue is normally recognized at a discount from the fee schedule.

Commercial revenue recognition also involves significant estimating risks. With many larger, commercial insurers the Company has several different contracts and payment arrangements, and these contracts often include only a subset of the Company's centers. It is often not possible to determine which contract, if any, should be applied prior to billing. In addition, for services provided by non-contracted centers, final collection may require specific negotiation of a payment amount, typically at a significant discount from the Company's usual and customary rates.

Effective January 1, 2011, services covered by Medicare are now subject to a greater degree of estimating risk under Medicare's new single bundled payment rate system, whereby reimbursements from Medicare can vary significantly depending upon certain patient characteristics and other variable factors. Prior to January 1, 2011, services covered by Medicare as well as Medicaid were less subject to estimating risks since both Medicare and Medicaid rates used a prospective payment method established in advance with definitive terms. Even with the new bundled payment rate system, Medicare payments for bad debt claims are still subject to individual center profitability, as established by cost reports, and require evidence of collection efforts. As a result, billing and collection of Medicare bad debt claims can be delayed significantly, and final payment is subject to audit.

Medicaid payments, when Medicaid coverage is secondary, can also be difficult to estimate. For many states, Medicaid payment terms and methods differ from Medicare, and may prevent accurate estimation of individual payment amounts prior to billing.

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

Net revenue recognition and allowances for uncollectible billings require the use of estimates of the amounts that will ultimately be realized considering, among other items, retroactive adjustments that may be associated with regulatory reviews, audits, billing reviews and other matters. The Company's policy is to write-off any uncollectible accounts receivable balance only after all collection efforts have been exhausted or when write-off is mandated by federal or state policies or required by certain payor contracts. It is also the Company's policy to write-off any accounts receivable balance associated with any payors or patients upon the Company receiving notification of a bankruptcy filing.

The Company's range of revenue estimating risk for the dialysis and related lab services segment is generally expected to be within 1% of its revenue. Changes in revenue estimates for prior periods are separately disclosed, if material.

Management and administrative support services are provided to outpatient dialysis centers and physician practices and certain other clinics that the Company does not own or in which the Company owns a minority equity investment interest. The management fees are principally determined as a percentage of the managed operations' revenues or cash collections and in some cases an additional component based upon a percentage of operating income. Management fees are included in net operating revenues when earned, and represent less than 1% of total consolidated operating revenues.

Other income

Other income includes interest income on cash investments and other non-operating gains from investment transactions.

Cash and cash equivalents

Cash equivalents are short-term highly liquid investments with maturities of three months or less at date of purchase.

Inventories

Inventories are stated at the lower of cost (first-in, first-out) or market and consist principally of pharmaceuticals and dialysis-related supplies. Rebates related to inventory purchases are recorded when earned and are based on certain qualification requirements based upon a variety of factors including future pricing levels by the manufacturer and data submission.

Property and equipment

Property and equipment is stated at cost less accumulated depreciation and amortization and is further reduced by any impairments. Maintenance and repairs are charged to expense as incurred. Depreciation and amortization expenses are computed using the straight-line method over the useful lives of the assets estimated as follows: buildings, 20 to 40 years; leasehold improvements, the shorter of their economic useful life or the expected lease term; and equipment and information systems, principally 3 to 8 years. Disposition gains and losses are included in current operating expenses.

Investments

Based upon the Company's intentions and strategy involving investments in debt and equity securities, the Company classifies certain debt securities as held-to-maturity and measures them at amortized cost. Based upon

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

the Company's other strategies involving investments, the Company classifies equity securities that have readily determinable fair values and certain other debt securities as available for sale and measures them at fair value. Unrealized gains or losses from available for sale investments are recorded in other comprehensive income until realized.

Amortizable intangibles

Amortizable intangible assets and liabilities include non-competition and similar agreements, lease agreements, hospital acute services contracts, deferred debt financing costs and the Alliance and Product Supply Agreement, each of which have finite useful lives. Non-competition and similar agreements are amortized over the terms of the agreements, typically ten years, using the straight-line method. Lease agreements and hospital acute service contracts are amortized on a straight-line basis over the term of the lease and the contract period, respectively. Deferred debt financing costs are amortized to debt expense over the term of the related debt using the effective interest method. The Alliance and Product Supply Agreement intangible liability is being amortized using the straight-line method over the term of the agreement, which is ten years.

Goodwill

Goodwill represents the difference between the fair value of acquired businesses and the fair value of the identifiable tangible and intangible net assets acquired. Goodwill is not amortized, but is assessed for valuation impairment as circumstances warrant and at least annually. An impairment charge would be recorded to the extent the carrying amount of goodwill exceeds its implied fair value. The Company operates several reporting units for goodwill impairment assessments. See Note 10 to the consolidated financial statements for further details.

Impairment of long-lived assets

Long-lived assets, including property and equipment, equity investments in non-consolidated businesses, and amortizable intangible assets with finite useful lives, are reviewed for possible impairment at least annually and whenever significant events or changes in circumstances indicate that an impairment may have occurred, including changes in the Company's business strategy and plans, changes in the quality or structure of its relationships with its partners and deteriorating operating performance of individual outpatient dialysis centers or other operations. An impairment is indicated when the sum of the expected future undiscounted net cash flows identifiable to an asset or asset group is less than its carrying amount. Impairment losses are measured based upon the difference between the actual or estimated fair values, which are based on market values, net realizable values or projections of discounted net cash flows, as appropriate, compared to the carrying amount of the asset. Impairment charges are included in operating expenses.

Income taxes

Federal and state income taxes are computed at current enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

The Company uses a recognition threshold of more-likely-than not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements.

Self insurance

The Company maintains insurance reserves for professional and general liability and workers' compensation in excess of certain individual and or aggregate amounts not covered by third-party carriers. The Company estimates the self-insured retention portion of professional and general liability and workers' compensation risks using third-party actuarial calculations that are based upon historical claims experience and expectations for future claims.

Noncontrolling interests

Noncontrolling interests represent the third-party's minority equity ownership interests in consolidated entities which are majority-owned by the Company. As of December 31, 2011, third parties held noncontrolling ownership interests in 196 consolidated entities.

Stock-based compensation

The Company's stock-based compensation awards are measured at their estimated fair value on the date of grant. Stock-based compensation expense recognized in a period represents the straight-line amortization during that period of the estimated grant date fair value of current and prior stock-based awards over their vesting terms, adjusted for expected forfeitures.

Interest rate swap and cap agreements

The Company has entered into several interest rate swap agreements as a means of hedging its exposure to and volatility from variable-based interest rate changes as part of its overall risk management strategy. These agreements are designated as cash flow hedges and are not held for trading or speculative purposes. The swap agreements have the economic effect of converting the LIBOR variable component of the Company's interest rate to fixed rates. In addition, in January 2011, the Company entered into several interest rate cap agreements that have the economic effect of capping the Company's maximum exposure to LIBOR variable interest rate changes on specific portions of the Company's other variable-based rate debt. See Note 13 to the consolidated financial statements for further details.

Fair value estimates

The Company currently measures the fair value of certain assets, liabilities and noncontrolling interests subject to put provisions (temporary equity) based upon certain valuation techniques that include observable or unobservable market inputs and assumptions that market participants would use in pricing these assets, liabilities and temporary equity. The Company also has classified its assets, liabilities and temporary equity into the appropriate fair value hierarchy levels as defined by the Financial Accounting Standards Board (FASB). See Note 23 to the consolidated financial statements for further details.

New accounting standards

On January 1, 2012, the Company adopted FASB's Accounting Standard Update (ASU) No. 2011-08, *Intangibles - Goodwill and Other*. This standard amends the current two-step goodwill impairment test required

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

under the existing accounting guidance. This amendment allows entities the option to first assess certain qualitative factors to ascertain whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount to determine if the two-step impairment test is necessary. If an entity concludes that certain events or circumstances prove that it is more likely than not that the fair value of a reporting unit is less than its carrying amount then an entity is required to proceed to step one of the two-step goodwill impairment test. This standard is effective during interim and annual periods beginning after December 15, 2011. The adoption of this standard did not have a material impact on the Company's consolidated financial statements.

On January 1, 2012, the Company adopted FASB's ASU No. 2011-07, *Health Care Entities-Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debts, and the Allowance for Doubtful Accounts*. This standard amends the current presentation and disclosure requirements for Health Care Entities that recognize significant amounts of patient service revenue at the time the services are rendered without assessing the patient's ability to pay. This standard requires health care entities to reclassify the provision for bad debts from an operating expense to a deduction from patient service revenues. In addition, this standard requires more disclosure on the policies for recognizing revenue, assessing bad debts, as well as quantitative and qualitative information regarding changes in the allowance for doubtful accounts. This standard is applied retrospectively to all prior periods presented and is effective during interim and annual periods beginning after December 15, 2011. The adoption of this standard will require the Company to change the presentation in its financial statements.

On January 1, 2012, the Company adopted FASB's ASU No. 2011-05, *Comprehensive Income - Presentation of Comprehensive Income*. This standard amends the current presentation requirements for comprehensive income by eliminating the presentation of the components of other comprehensive income within the statement of equity. This standard allows two options on how to present the various components of comprehensive income. These options are either to report the components of comprehensive income separately on the income statement or to present total other comprehensive income and the components of other comprehensive income in a separate statement. This standard does not change the items that must be reported in other comprehensive income or when an item must be reclassified into net income. This standard is applied retrospectively and is effective for fiscal years and interim periods within those years beginning after December 15, 2011. Early adoption is permitted. The adoption of this standard will require the Company to change the presentation in its financial statements.

On January 1, 2012, the Company adopted FASB's ASU No. 2011-04, *Fair Value Measurement*. This standard amends the current fair value measurement and disclosure requirements to improve comparability between U.S. GAAP and International Financial Reporting Standards (IFRS). The intent of this standard is to update the disclosures that describe several of the requirements in U.S. GAAP for measuring fair value and to enhance disclosures about fair value measurements which will improve consistency between U.S. GAAP and IFRS. This standard does not change the application of the requirements on fair value measurements and disclosures. This standard is applied prospectively and is effective during interim and annual periods beginning after December 15, 2011. The adoption of this standard did not have a material impact on the Company's consolidated financial statements.

2. Earnings per share

Basic net income per share is calculated by dividing net income attributable to DaVita Inc., net of the decrease (increase) in noncontrolling interest redemption rights in excess of fair value, by the weighted average number of common shares and vested stock units outstanding. Diluted net income per share includes the dilutive effect of outstanding stock-settled stock appreciation rights, stock options and unvested stock units (under the treasury stock method).

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

The reconciliations of the numerators and denominators used to calculate basic and diluted net income per share are as follows:

	Year ended December 31,		
	2011	2010	2009
	(shares in thousands)		
Basic:			
Income from continuing operations attributable to DaVita Inc.	\$481,755	\$405,402	\$422,291
Decrease (increase) in noncontrolling interest redemption rights in excess of fair value	335	(68)	(267)
Income from continuing operations for basic earnings per share calculation	\$482,090	\$405,334	\$422,024
Discontinued operations attributable to DaVita Inc.	(3,754)	281	393
Net income attributable to DaVita Inc. for basic earnings per share calculation	<u>\$478,336</u>	<u>\$405,615</u>	<u>\$422,417</u>
Weighted average shares outstanding during the period	94,655	101,497	103,595
Vested stock units	3	7	9
Weighted average shares for basic earnings per share calculation	<u>94,658</u>	<u>101,504</u>	<u>103,604</u>
Basic income from continuing operations per share attributable to DaVita Inc.	<u>\$5.09</u>	<u>\$3.99</u>	<u>\$4.07</u>
Basic net income per share attributable to DaVita Inc.	<u>\$5.05</u>	<u>\$4.00</u>	<u>\$4.08</u>
Diluted:			
Income from continuing operations attributable to DaVita Inc.	\$481,755	\$405,402	\$422,291
Decrease (increase) in noncontrolling interest redemption rights in excess of fair value	335	(68)	(267)
Income from continuing operations for diluted earnings per share calculation	\$482,090	\$405,334	\$422,024
Discontinued operations attributable to DaVita Inc.	(3,754)	281	393
Net income attributable to DaVita Inc. for diluted earnings per share calculation	<u>\$478,336</u>	<u>\$405,615</u>	<u>\$422,417</u>
Weighted average shares outstanding during the period	94,655	101,497	103,595
Vested stock units	3	7	9
Assumed incremental shares from stock plans	1,874	1,555	564
Weighted average shares for diluted earnings per share calculation	<u>96,532</u>	<u>103,059</u>	<u>104,168</u>
Diluted income from continuing operations per share attributable to DaVita Inc.	<u>\$4.99</u>	<u>\$3.93</u>	<u>\$4.05</u>
Diluted net income per share attributable to DaVita Inc.	<u>\$4.96</u>	<u>\$3.94</u>	<u>\$4.06</u>
Anti-dilutive stock-settled awards excluded from calculation (1)	<u>2,388</u>	<u>1,452</u>	<u>9,912</u>

- (1) Shares associated with stock-settled stock appreciation rights and stock options that are excluded from the diluted denominator calculation because they are anti-dilutive under the treasury stock method.

DAVITA INC.**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)**
(dollars in thousands, except per share data)**3. Accounts receivable**

Approximately 16% and 15% of the accounts receivable balances as of December 31, 2011 and 2010, respectively, were more than six months old, and there were no significant balances over one year old. Approximately 2% of the Company's accounts receivable as of December 31, 2011 and 2010, related to amounts due from patients. Accounts receivable are principally from Medicare and Medicaid programs and commercial insurance plans.

4. Other receivables

Other receivables were comprised of the following:

	December 31,	
	2011	2010
Supplier rebates and other non-trade receivables	\$195,426	\$238,156
Medicare bad debt claims	57,232	46,250
Operating advances under management and administrative services agreements	17,174	19,960
	<u>\$269,832</u>	<u>\$304,366</u>

Operating advances under management and administrative services agreements are generally unsecured.

5. Other current assets

Other current assets consist principally of prepaid expenses and operating deposits.

6. Property and equipment

Property and equipment were comprised of the following:

	December 31,	
	2011	2010
Land	\$23,004	\$23,182
Buildings	34,173	33,937
Leasehold improvements	1,266,499	1,106,935
Equipment and information systems	1,269,343	1,107,778
New center and capital asset projects in progress	144,124	38,721
	2,737,143	2,310,553
Less accumulated depreciation and amortization	(1,304,492)	(1,139,745)
	<u>\$1,432,651</u>	<u>\$1,170,808</u>

Depreciation and amortization expense on property and equipment was \$249,060, \$218,666 and \$213,657 for 2011, 2010 and 2009, respectively.

Interest on debt incurred during the development of new centers and other capital asset projects is capitalized as a component of the asset cost based on the respective in-process capital asset balances. Interest capitalized was \$4,887, \$2,621 and \$3,627 for 2011, 2010 and 2009, respectively.

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

7. Amortizable intangibles

Amortizable intangible assets were comprised of the following:

	December 31,	
	2011	2010
Noncompetition and other agreements	\$335,012	\$309,405
Lease agreements	8,081	8,466
Deferred debt financing costs	66,011	61,405
	409,104	379,276
Less accumulated amortization	(249,613)	(216,641)
Total amortizable intangible assets	\$159,491	\$162,635

Amortizable intangible liabilities were comprised of the following:

	December 31,	
	2011	2010
Alliance and product supply agreement commitment (See Note 22)	\$68,200	\$68,200
Less accumulated amortization	(48,213)	(42,883)
	\$19,987	\$25,317

Net amortization expense from noncompetition and other agreements and the amortizable intangible liabilities was \$17,568, \$15,064 and \$14,739 for 2011, 2010 and 2009, respectively. Lease agreements which are amortized to rent expense were \$361 in 2011, \$480 in 2010 and \$565 in 2009, respectively. Deferred debt issuance costs are amortized to debt expense as described in Note 13 to the consolidated financial statements.

Scheduled amortization charges from intangible assets and liabilities as of December 31, 2011 were as follows:

	Noncompetition and other agreements	Deferred debt financing costs	Alliance and Product Supply Agreement liability
2012	24,453	10,552	(5,330)
2013	21,928	10,260	(5,330)
2014	19,724	9,747	(5,330)
2015	15,761	8,514	(3,997)
2016	6,669	5,017	-
Thereafter	17,520	9,346	-

8. Equity investments

Equity investments in non-consolidated businesses were \$27,325 and \$25,918 at December 31, 2011 and 2010, respectively. During 2011, 2010 and 2009, the Company recognized income of \$8,776, \$8,999 and \$2,442, respectively, relating to equity investments in non-consolidated businesses under the equity method of accounting.

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

9. Investments in debt and equity securities

Based on the Company's intentions and strategy involving investments in debt and equity securities, the Company classifies certain debt securities as held-to-maturity and records them at amortized cost. Equity securities that have readily determinable fair values and other debt securities classified as available for sale are recorded at fair value.

The Company's investments consist of the following:

	December 31, 2011			December 31, 2010		
	Held to maturity	Available for sale	Total	Held to maturity	Available for sale	Total
Certificates of deposit, money market funds and U.S. treasury notes due within one year	\$11,754	\$-	\$11,754	\$21,803	\$-	\$21,803
Investments in mutual funds and NxStage common stock	-	15,535	15,535	-	10,048	10,048
	<u>\$11,754</u>	<u>\$15,535</u>	<u>\$27,289</u>	<u>\$21,803</u>	<u>\$10,048</u>	<u>\$31,851</u>
Short-term investments	\$11,754	\$5,645	\$17,399	\$21,803	\$1,200	\$23,003
Long-term investments	-	9,890	9,890	-	8,848	8,848
	<u>\$11,754</u>	<u>\$15,535</u>	<u>\$27,289</u>	<u>\$21,803</u>	<u>\$10,048</u>	<u>\$31,851</u>

The cost of the certificates of deposit and money market funds at December 31, 2011 and in addition, U.S. treasury notes at December 31, 2010, approximate fair value. As of December 31, 2011 and 2010, the available for sale investments included \$(255) and \$824, respectively, of gross pre-tax unrealized (loss) gains. During 2011 and 2010 the Company recorded gross pre-tax unrealized (loss) gains of \$(986) and \$1,007, respectively, in other comprehensive income associated with changes in the fair value of these investments. During 2011, the Company sold investments in mutual funds for net proceeds of \$1,149, and recognized a pre-tax gain of \$93, or \$57 after tax, that was previously recorded in other comprehensive income. During 2010, the Company sold investments in mutual funds for net proceeds of \$900, and recognized a pre-tax loss of \$22, or \$13 after tax, that was previously recorded in other comprehensive income.

In addition, the available for sale securities, as of December 31, 2011, include the fair value of NxStage Medical Inc. (NxStage) common stock totaling \$4,445, which is based upon quoted prices as reported by NASDAQ. Under the terms of the NxStage First National Service Provider Agreement effective July 22, 2010, the Company may, in lieu of a cash rebate, vest in warrants to purchase NxStage common stock based on achieving certain System One home patient growth targets by June 30, 2011, 2012 and 2013. The warrants are exercisable for up to a cumulative total of 5,500,000 shares of common stock over three years at an initial exercise price of \$14.22 per share. As of June 30, 2011, the Company earned warrants to purchase 250,000 shares of NxStage common stock and in October 2011, the Company exercised its right and purchased these shares for a total of \$3,555. In February 2012, the Company sold all 250,000 shares for approximately \$5,200.

The investments in mutual funds classified as available for sale are held within a trust to fund existing obligations associated with several of the Company's non-qualified deferred compensation plans.

As of December 31, 2011 and 2010, there were investments totaling \$7,224 and \$18,537, respectively, classified as held to maturity that were used to maintain certain capital requirements of the special needs plans of

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

VillageHealth, which is a wholly-owned subsidiary of the Company. As of December 31, 2009, the Company discontinued the VillageHealth special needs plans and is in process of paying out all incurred claims. During the fourth quarter of 2011, the Company received a total of \$11,313 from various state regulatory agencies for the release of certain investments that were previously held to maintain certain capital requirements.

10. Goodwill

Changes in the book value of goodwill were as follows:

	Year ended December 31,	
	2011	2010
Balance at January 1	\$4,091,307	\$3,951,196
Acquisitions	889,506	152,252
Divestitures	(9,837)	(12,128)
Impairment charge	(24,000)	-
Other adjustments	-	(13)
Balance at December 31	<u>\$4,946,976</u>	<u>\$4,091,307</u>

As of December 31, 2011, there was \$4,865,864 and \$81,112 of goodwill associated with the dialysis and related lab services business and the ancillary services and strategic initiatives, respectively.

As of December 31, 2010, there was \$4,022,365 and \$68,942 of goodwill associated with the dialysis and related lab services business and the ancillary services and strategic initiatives, respectively.

In the second quarter of 2011, the Company determined that circumstances indicated it was more likely than not that the fair value of one of its ancillary businesses, HCP, which provides infusion therapy services, was less than its carrying amount. The primary factor informing the Company's conclusion was the recent decline in the operating performance of HCP caused mainly by rapid expansion. This led management to revise its view of HCP's organizational growth capability and scale back significantly its plans for HCP's future growth initiatives and to update HCP's forecasts and current operating budgets accordingly. These revisions reflected the current and expected future cash flows that the Company believed market participants would use in determining the fair value of the HCP business. As a result, in the second quarter of 2011, the Company estimated that the carrying amount of goodwill related to HCP exceeded its implied fair value by \$24,000, resulting in a pre-tax goodwill impairment charge of that amount. As of December 31, 2011, after giving effect to this impairment charge, the Company has approximately \$32,000 of HCP goodwill remaining. During the fourth quarter of 2011, the Company finalized its calculation of this impairment charge, which did not change the goodwill impairment charge previously recorded.

11. Other liabilities

Other accrued liabilities were comprised of the following:

	December 31,	
	2011	2010
Payor refunds and retractions	\$193,966	\$216,655
Insurance and self-insurance accruals	69,962	65,950
Accrued interest	17,469	22,905
Accrued non-income tax liabilities	15,174	9,995
Other	<u>29,163</u>	<u>27,438</u>

\$325,734

\$342,943

F-19

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

12. Income taxes

A reconciliation of the beginning and ending liability for unrecognized tax benefits that do not meet the more-likely-than-not threshold were as follows:

	Year ended December 31,	
	2011	2010
Balance beginning	\$8,138	\$30,693
Additions for tax positions related to current year	2,052	1,515
Additions for tax positions related to prior years	786	69
Reductions for tax positions related to prior years	(2,033)	(24,139)
Balance ending	<u>\$8,943</u>	<u>\$8,138</u>

As of December 31, 2011, unrecognized tax benefits totaling \$8,943 would affect the Company's effective tax rate, if recognized.

The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense. At December 31, 2011 and 2010, the Company had approximately \$3,420 and \$3,177, respectively, accrued for interest and penalties related to unrecognized tax benefits, net of federal tax benefits.

The Company and its subsidiaries file U.S. federal income tax returns and various state returns. The Company is no longer subject to U.S. federal, state and local examinations by tax authorities for years before 2006.

Income tax expense consisted of the following:

	Year ended December 31,		
	2011	2010	2009
Current:			
Federal	\$217,885	\$153,502	\$193,181
State	44,403	31,338	34,415
Deferred:			
Federal	46,779	67,901	44,376
State	6,659	7,498	6,493
	<u>\$315,726</u>	<u>\$260,239</u>	<u>\$278,465</u>

The allocation of income tax expense was as follows:

	Year ended December 31,		
	2011	2010	2009
Continuing operations	\$315,744	\$260,052	\$278,213
Discontinued operations	675	187	252
Loss on discontinued operations	(693)	-	-
	<u>\$315,726</u>	<u>\$260,239</u>	<u>\$278,465</u>

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

Deferred tax assets and liabilities arising from temporary differences were as follows:

	December 31,	
	2011	2010
Receivables	\$125,159	\$110,332
Alliance and product supply agreement	7,775	9,849
Accrued liabilities	163,770	127,073
Net operating loss carryforwards	118,745	11,272
Other	64,120	49,096
Deferred tax assets	479,569	307,622
Valuation allowance	(15,642)	(10,998)
Net deferred tax assets	463,927	296,624
Intangible assets	(439,203)	(377,456)
Property and equipment	(164,404)	(110,472)
Other	(3,036)	(4,072)
Deferred tax liabilities	(606,643)	(492,000)
Net deferred tax liabilities	<u>\$ (142,716)</u>	<u>\$ (195,376)</u>

At December 31, 2011, the Company had federal net operating loss carryforwards of approximately \$288,604 that expire through 2031, and state net operating loss carryforwards of \$390,774 that expire through 2031. The increase in federal and state net operating loss carryforwards is a result of the acquisition of DSI Renal, Inc. The utilization of a portion of these losses may be limited in future years based on the profitability of certain entities. The valuation allowance increase of \$4,644 is primarily due to changes in the estimated tax benefit and utilization of federal and state operating losses.

The reconciliation between the Company's effective tax rate from continuing operations and the U.S. federal income tax rate is as follows:

	Year ended December 31,		
	2011	2010	2009
Federal income tax rate	35.0%	35.0%	35.0%
State taxes, net of federal benefit	4.1	3.9	3.7
Changes in deferred tax valuation allowances	(0.3)	(0.1)	0.2
Other	0.8	0.2	0.8
Impact of noncontrolling interests primarily attributable to non-tax paying entities	(4.2)	(4.0)	(3.0)
Effective tax rate	<u>35.4%</u>	<u>35.0%</u>	<u>36.7%</u>

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

13. Long-term debt

Long-term debt was comprised of the following:

	December 31,	
	2011	2010
Senior Secured Credit Facilities:		
Term Loan A	\$950,000	\$1,000,000
Term Loan A-2	199,500	–
Term Loan B	1,732,500	1,750,000
Senior notes	1,550,000	1,550,000
Acquisition obligations and other notes payable	37,447	9,049
Capital lease obligations	43,364	8,074
Total principal debt outstanding	4,512,811	4,317,123
Discount on long-term debt	(7,842)	(8,381)
	4,504,969	4,308,742
Less current portion	(87,345)	(74,892)
	\$4,417,624	\$4,233,850

Scheduled maturities of long-term debt at December 31, 2011 were as follows:

2012	87,345
2013	125,106
2014	176,910
2015	676,293
2016	1,858,567
Thereafter	1,588,590

Senior Secured Credit Facility

On August 26, 2011, the Company entered into an Increase Joinder Agreement under its existing Senior Secured Credit Agreement, as described below. Pursuant to the Increase Joinder Agreement, the Company increased the revolving credit facility by \$100,000, to a total of \$350,000, and entered into an additional \$200,000 Term Loan A-2. The new Term Loan A-2 required a principal payment of \$500 on December 31, 2011, and thereafter requires annual principal payments of \$2,000 with a balance of \$191,500 due in 2016, and bears interest at LIBOR (floor of 1.00%) plus an interest rate margin of 3.50% subject to a rating based step-down to 3.25%.

On October 20, 2010, the Company entered into a \$3,000,000 Senior Secured Credit Agreement (the Credit Agreement), consisting of a five year \$250,000 revolving line of credit, a five year \$1,000,000 Term Loan A and a six year \$1,750,000 Term Loan B. The Company also has the right to request an increase to the borrowing capacity to a total aggregate principal amount of not more than \$4,000,000 subject to bank participation. The revolving line of credit and the Term Loan A bore interest at LIBOR plus an interest rate margin of 2.75% until June 30, 2011, when the interest rate margin was reduced to 2.50%. The interest rate margin is still subject to adjustment depending upon the Company's leverage ratio and can range from 2.25% to 2.75%. The Term Loan A requires annual principal payments of \$50,000 in 2011, \$50,000 in 2012, \$100,000 in 2013, and \$150,000 in

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

2014, with the balance of \$650,000 due in 2015. The Term Loan B bears interest at LIBOR (floor of 1.50%) plus 3.00% subject to a ratings based step-down to 2.75%. The Term Loan B requires annual principal payments of \$17,500 in each year from 2011 through 2015 with the balance of \$1,662,500 due in 2016. The borrowings under the Credit Agreement are guaranteed by substantially all of the Company's direct and indirect wholly-owned domestic subsidiaries and are secured by substantially all of the Company's and its guarantors' assets. The Credit Agreement contains customary affirmative and negative covenants such as various restrictions on investments, acquisitions, the payment of dividends, redemptions and acquisitions of capital stock, capital expenditures and other indebtedness, as well as limitations on the amount of tangible net assets in non-guarantor subsidiaries. However, many of these restrictions will not apply as long as the Company's leverage ratio is below 3.50:1.00. In addition, the Credit Agreement requires compliance with financial covenants including an interest coverage ratio and a leverage ratio that determines the interest rate margins as described above.

On October 20, 2010, the Company also issued \$775,000 aggregate principal amount of 6 ³/₈% senior notes due 2018 and \$775,000 aggregate principal amount of 6 ⁵/₈% senior notes due 2020 (collectively the New Senior Notes). The New Senior Notes will pay interest on May 1 and November 1 of each year, beginning May 1, 2011. The New Senior Notes are unsecured senior obligations and rank equally to other unsecured senior indebtedness. The New Senior Notes are guaranteed by substantially all of the Company's direct and indirect wholly owned domestic subsidiaries. The Company may redeem some or all of the 6 ³/₈% senior notes at any time on or after November 1, 2013 at certain redemption prices and may redeem some or all of the 6 ⁵/₈% senior notes at any time on or after November 1, 2014 at certain redemption prices.

The Company received total proceeds of \$4,300,000 from these transactions, \$2,750,000 from the borrowings on Term Loan A and Term Loan B and an additional \$1,550,000 from the issuance of the New Senior Notes. The Company used a portion of the proceeds to pay-off the outstanding principal balances of its existing Senior Secured Credit Facilities plus accrued interest totaling \$1,795,363 and to purchase pursuant to a cash tender offer \$557,644 of the outstanding principal balances of the Company's \$700,000 6 ⁵/₈% senior notes due 2013 and \$730,827 of the outstanding balances of the Company's \$850,000 7 ¹/₄% senior subordinated notes due 2015, (the Existing Notes), plus accrued interest totaling \$1,297,215. The total amount paid for the Existing Notes was \$1,019.06 per \$1,000 principal amount of the 6 ⁵/₈% senior notes and \$1,038.75 per \$1,000 principal amount of the 7 ¹/₄% senior subordinated notes. This resulted in the Company paying a cash tender premium of \$38,933 in order to extinguish this portion of the Existing Notes. On November 19, 2010, the Company redeemed the remaining outstanding balance of the existing 6 ⁵/₈% senior notes of \$142,356 at 101.656% per \$1,000 and the remaining outstanding balance of the existing 7 ¹/₄% senior subordinated notes of \$119,173 at 103.625% per \$1,000 plus accrued interest totaling \$264,742. In addition, the Company paid a call premium totaling \$6,677. The Company also paid an additional \$74,431 in fees, discounts and other expenses. As a result of the above transactions, the Company received approximately \$823,000 in excess cash which it has been using for general purposes and other opportunities, including share repurchases, acquisitions and other growth investments.

In connection with these transactions, the Company expensed debt refinancing and redemption charges totaling \$70,255, which includes the write off of certain existing deferred financing costs and other new financing costs, the cash tender and call premiums, as described above and other expenses.

On June 7, 2010, the Company redeemed \$200,000 aggregate principal amount of its outstanding 6 ⁵/₈% senior notes due 2013, at a price of 101.656% plus accrued interest. As a result of this transaction, the Company expensed debt redemption charges of \$4,127, which includes the call premium and the net write-off of other finance costs.

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

Term Loans

Term Loan A, Term Loan A-2 and Term Loan B total outstanding borrowings can consist of various individual tranches that can range in maturity from one month to twelve months (currently all tranches are one month in duration). Each tranche for the Term Loan A bears interest at a LIBOR rate determined by the duration of such tranche plus an interest rate margin, currently 2.50%. The LIBOR variable component of the interest rate for each tranche is reset as such tranche matures and a new tranche is established. At December 31, 2011, the overall weighted average interest rate for the Term Loan A was determined based upon the LIBOR interest rates in effect for all of the individual tranches plus the interest rate margin. In January 2011, the Company entered into several interest rate swap agreements that had the economic effect of fixing all of the Term Loan A LIBOR variable component of the Company's interest rate, as described below. At December 31, 2011, the Term Loan A-2 bears interest at LIBOR (floor of 1.00%) plus an interest rate margin of 3.50% subject to a ratings based step-down to 3.25%. At December 31, 2011, the Term Loan B bears interest at LIBOR (floor of 1.50%) plus a margin of 3.00% subject to a ratings based step-down to 2.75%. The Company is subject to these LIBOR-based floors until such time as the LIBOR-based component of the interest rate exceeds 1.00% on the Term Loan A-2 and 1.50% on the Term Loan B. At such time, the Company will then be subject to LIBOR-based interest rate volatility on the LIBOR variable component of its interest rate and the overall weighted average interest rate for the Term Loan A-2 and Term Loan B will then be determined based upon the LIBOR interest rates in effect for all individual tranches plus the interest rate margin. In January 2011, the Company entered into several interest rate cap agreements that have the economic effect of capping the LIBOR variable component of the Company's interest rate at a maximum of 4.00% on \$1,250,000 of outstanding principal debt on the Term Loan B, as described below. The remaining \$483,000 outstanding principal balance of the Term Loan B is subject to LIBOR-based interest rate volatility above a floor of 1.50%.

During 2011 and 2010, the Company made mandatory principal payments totaling \$50,000 and \$65,625, respectively, on the current and previous outstanding Term Loan A. During 2011, the Company made principal payments totaling \$500 on the Term Loan A-2 and made principal payments totaling \$17,500 on the Term Loan B. During 2010, the Company did not make, nor was the Company required to make, any principal payments on the previous outstanding Term Loan B.

Revolving Lines of Credit

The Company has an undrawn revolving line under the Senior Secured Credit Facilities totaling \$350,000, of which approximately \$52,297 was committed for outstanding letters of credit.

Senior and Senior Subordinated Notes

The Company's senior notes, as of December 31, 2011 and 2010, consisted of \$775,000 of 6³/₈ senior notes due 2018 and \$775,000 of 6⁵/₈ senior notes due 2020, as discussed above.

Interest rate swaps and caps

In January 2011, the Company entered into several interest rate swap agreements as a means of hedging its exposure to and volatility from variable-based interest rate changes as part of its overall risk management strategy. These agreements are not held for trading or speculative purposes and have the economic effect of converting the LIBOR variable component of the Company's interest rate to a fixed rate. These swap agreements are designated as cash flow hedges, and as a result, hedge-effective gains or losses resulting from changes in the fair values of these swaps are reported in other comprehensive income until such time as each specific swap tranche is realized, at which time the amounts are reclassified into net income. Net amounts paid or received for each specific swap tranche that have settled have been reflected as adjustments to debt expense. In addition, in January 2011, the Company entered into several interest rate cap agreements that have the economic effect of capping the Company's maximum exposure to LIBOR variable interest rate changes on specific portions of the

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

Company's Term Loan B debt, as described below. These cap agreements are also designated as cash flow hedges and as a result changes in the fair values of these cap agreements are reported in other comprehensive income. The amortization of the original cap premium is recognized as a component of debt expense on a straight line basis over the term on the cap agreements. The swap and cap agreements do not contain credit-risk contingent features.

As of December 31, 2011, the Company maintained a total of nine interest rate swap agreements with amortizing notional amounts totaling \$950,000. These agreements had the economic effect of modifying the LIBOR variable component of the Company's interest rate on an equivalent amount of the Company's Term Loan A to fixed rates ranging from 1.59% to 1.64%, resulting in an overall weighted average effective interest rate of 4.11%, including the Term Loan A margin of 2.50%. The swap agreements expire by September 30, 2014 and require monthly interest payments. The Company estimates that approximately \$10,900 of existing unrealized pre-tax losses in other comprehensive income at December 31, 2011 will be reclassified into income over the next twelve months.

As of December 31, 2011, the Company maintained five interest rate cap agreements with notional amounts totaling \$1,250,000. These agreements have the economic effect of capping the LIBOR variable component of the Company's interest rate at a maximum of 4.00% on an equivalent amount of the Company's Term Loan B debt. The cap agreements expire on September 30, 2014.

During 2010, the Company had several interest rate swap agreements outstanding that had the economic effect of modifying the LIBOR variable component of the Company's interest rate on an equivalent amount of the Company's debt to fixed rates ranging from 4.05% to 4.70%, resulting in an overall weighted average effective interest rate of 5.84% on the hedged portion of the Company's Senior Secured Credit Facilities, including the margin of 1.50%. These agreements did not contain credit-risk contingent features and had expired as of September 30, 2010.

The following table summarizes the Company's derivative instruments as of December 31, 2011 and 2010:

<u>Derivatives designated as hedging instruments</u>	<u>Interest rate swap and cap agreements (liabilities and assets)</u>			
	<u>December 31, 2011</u>		<u>December 31, 2010</u>	
	<u>Balance sheet location</u>	<u>Fair value</u>	<u>Balance sheet location</u>	<u>Fair value</u>
Interest rate swap agreements	Other long-term liabilities	<u>\$23,145</u>	Other long-term liabilities	<u>\$ -</u>
Interest rate cap agreements	Other long-term assets	<u>\$1,381</u>	Other long-term assets	<u>\$ -</u>

The following table summarizes the effects of the Company's interest rate swap and cap agreements for the years ended December 31, 2011, 2010 and 2009:

<u>Derivatives designated as cash flow hedges</u>	<u>Amount of gains (losses) recognized in OCI on interest rate swap and cap agreements</u>			<u>Location of (losses) gains reclassified from accumulated OCI into income</u>	<u>Amount of gains (losses) reclassified from accumulated OCI into income</u>		
	<u>Years ended December 31,</u>	<u>Years ended December 31,</u>	<u>Years ended December 31,</u>		<u>Years ended December 31,</u>	<u>Years ended December 31,</u>	<u>Years ended December 31,</u>
	<u>2011</u>	<u>2010</u>	<u>2009</u>		<u>2011</u>	<u>2010</u>	<u>2009</u>
Interest rate swap agreements	\$(35,767)	\$(217)	\$(4,220)	Debt expense	\$(12,622)	\$(9,093)	\$(17,253)
Interest rate cap agreements	(11,777)	-	-	Debt expense	(3,289)	-	-
Tax benefit	<u>18,495</u>	<u>83</u>	<u>1,642</u>		<u>6,190</u>	<u>3,536</u>	<u>6,711</u>

Total	<u>\$(29,049)</u>	<u>\$(134)</u>	<u>\$(2,578)</u>	<u>\$(9,721)</u>	<u>\$(5,557)</u>	<u>\$(10,542)</u>
-------	-------------------	----------------	------------------	-------------------	------------------	-------------------

F-25

DAVITA INC.**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)**
(dollars in thousands, except per share data)

The Company's overall weighted average effective interest rate in 2011 was 5.28% and as of December 31, 2011 was 5.27%.

Debt expense

Debt expense consisted of interest expense of \$230,953, \$172,265 and \$176,100, including the amortization and accretion of debt discounts and premiums and the amortization of deferred financing costs of \$10,137, \$9,342 and \$9,655 for 2011, 2010 and 2009, respectively. The interest expense amounts are net of capitalized interest.

14. Leases

The majority of the Company's facilities are leased under non-cancelable operating leases, ranging in terms from five to 15 years, which contain renewal options of five to ten years at the fair rental value at the time of renewal. The Company leases are generally subject to periodic consumer price index increases or contain fixed escalation clauses. The Company also leases certain facilities and equipment under capital leases.

Future minimum lease payments under non-cancelable operating leases and capital leases are as follows:

	Operating leases	Capital leases
2012	258,336	4,620
2013	232,569	4,656
2014	211,544	4,510
2015	193,874	4,260
2016	176,063	4,239
Thereafter	635,608	42,335
	<u>\$1,707,994</u>	64,620
Less portion representing interest		(21,256)
Total capital lease obligations, including current portion		<u><u>\$43,364</u></u>

Rent expense under all operating leases for 2011, 2010, and 2009 was \$296,051, \$266,849 and \$248,154, respectively. Rent expense is recorded on a straight-line basis, over the term of the lease, for leases that contain fixed escalation clauses or include abatement provisions. Leasehold improvement incentives are deferred and amortized to rent expense over the term of the lease. The net book value of property and equipment under capital leases was \$41,514 and \$7,579 at December 31, 2011 and 2010, respectively. Capital lease obligations are included in long-term debt. See Note 13 to the consolidated financial statements.

15. Employee benefit plans

The Company has a savings plan for substantially all employees which has been established pursuant to the provisions of Section 401(k) of the Internal Revenue Code, or IRC. The plan allows for employees to contribute a percentage of their base annual salaries on a tax-deferred basis not to exceed IRC limitations. The Company does not provide any matching contributions.

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

The Company also maintains a voluntary compensation deferral plan, the DaVita Voluntary Deferral Plan. This plan is non-qualified and permits certain employees whose annualized base salary equals or exceeds a minimum annual threshold amount as set by the Company to elect to defer all or a portion of their annual bonus payment and up to 50% of their base salary into a deferral account maintained by the Company. Total contributions to this plan in 2011, 2010 and 2009 were \$2,416, \$1,125 and \$2,062, respectively. Deferred amounts are generally paid out in cash at the participant's election either in the first or second year following retirement or in a specified future period at least three to four years after the deferral election was effective. During 2011, 2010 and 2009 the Company distributed \$955, \$701 and \$601, respectively, to participants. Participants are credited with their proportional amount of annual earnings from the plan. The assets of this plan are held in a "rabbi trust" and as such are subject to the claims of the Company's general creditors in the event of its bankruptcy. As of December 31, 2011 and 2010, the total fair value of assets held in trust were \$9,796 and \$8,547, respectively.

As part of the acquisition of DVA Renal Healthcare on October 5, 2005, the Company acquired an Executive Retirement Plan for certain members of management. This plan is non-qualified and contributions to the plan were made at the discretion of DVA Renal Healthcare based upon a pre-determined percentage of a participant's base salary. Effective November 2005, all contributions to this plan were discontinued and the balance of the plan assets will be paid out upon termination of each individual participant. During 2011, 2010 and 2009, the Company distributed \$194, \$198 and \$241, respectively, to participants. As of December 31, 2011 and 2010, the total fair value of assets held in trust was \$1,294 and \$1,501, respectively.

The fair value of all of the assets held in plan trusts as of December 31, 2011, and 2010 totaled \$11,090 and \$10,048, respectively. These assets are available for sale and as such are recorded at fair market value with changes in the fair market values being recorded in other comprehensive income. Any fair market value changes to the corresponding liability balance will be recorded as compensation expense. See Note 9 to the consolidated financial statements.

Most of the Company's outstanding employee stock plan awards include a provision accelerating the vesting of the award in the event of a change of control. The Company also maintains a change of control protection program for its employees who do not have a significant number of stock awards, which has been in place since 2001, and which provides for cash bonuses to employees in the event of a change of control. Based on the market price of the Company's common stock and shares outstanding on December 31, 2011, these cash bonuses would total approximately \$277,000 if a control transaction occurred at that price and the Company's Board of Directors did not modify the program. This amount has not been accrued at December 31, 2011, and would only be accrued upon a change of control. These change of control provisions may affect the price an acquirer would be willing to pay for the Company.

16. Contingencies

The majority of the Company's revenues are from government programs and may be subject to adjustment as a result of: (1) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (2) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (3) differing opinions regarding a patient's medical diagnosis or the medical necessity of services provided; and (4) retroactive applications or interpretations of governmental requirements. In addition, the Company's revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

Inquiries by the Federal Government and Certain Related Civil Proceedings

2005 U.S. Attorney Investigation: In March 2005, the Company received a subpoena from the U.S. Attorney's Office for the Eastern District of Missouri in St. Louis. The subpoena required production of a wide range of documents relating to the Company's operations, including documents related to, among other things, pharmaceutical and other services provided to patients, relationships with pharmaceutical companies, and financial relationships with physicians and joint ventures. The subpoena covers the period from December 1, 1996 through March 2005. In October 2005, the Company received a follow-up request for additional documents related to specific medical director and joint venture arrangements. In February 2006, the Company received an additional subpoena for documents, including certain patient records relating to the administration and billing of EPO. In May 2007, the Company received a request for documents related to durable medical equipment and supply companies owned and operated by the Company. The Company cooperated with the inquiry and has produced the requested records. The subpoenas were issued in connection with a joint civil and criminal investigation. It is possible that criminal proceedings may be initiated against the Company in connection with this investigation. The Company has not received a communication from the St. Louis U.S. Attorney's Office on this matter in over two years.

Woodard Private Civil Suit: In February 2007, the Company received a request for information from the Office of Inspector General, U.S. Department of Health and Human Services, or OIG, for records relating to EPO claims submitted to Medicare. In August 2007, the Company received a subpoena from the OIG seeking similar documents. The requested documents relate to services provided from 2001 to 2004 by a number of the Company's centers. The request and subpoena were sent from the OIG's offices in Houston and Dallas, Texas. The Company cooperated with the inquiry and has produced all previously requested records to date. The Company was contacted by the U.S. Attorney's Office for the Eastern District of Texas, which stated that this was a civil investigation related to EPO claims. On July 6, 2009, the United States District Court for the Eastern District of Texas lifted the seal on the civil *qui tam* complaint related to these previous requests for information. The Company was subsequently served with a complaint by the relator, Ivey Woodard, purportedly on behalf of the federal government, under the *qui tam* provisions of the federal False Claims Act. The government did not intervene and is not actively pursuing this matter. The relator is pursuing the claims independently and the parties are engaged in active litigation. The complaint contains allegations relating to the Company's EPO practices for the period from 1992 through 2010 and seeks monetary damages and civil penalties as well as costs and expenses. The court has ruled that claims earlier than 1996 are beyond the statute of limitations. The Company believes that there is some overlap between the subject of this complaint and the review of EPO utilization in the 2005 U.S. Attorney investigation described above. The Company is vigorously defending this matter and intends to continue to do so. The Company can make no assurances as to the time or resources that will be needed to devote to this litigation or its final outcome.

Vainer Private Civil Suit: In December 2008, the Company received a subpoena for documents from the OIG relating to the pharmaceutical products Zemplar, Hectorol, Venofer, Ferrlecit and EPO, as well as other related matters. The subpoena covers the period from January 2003 to December 2008. The Company was in contact with the U.S. Attorney's Office for the Northern District of Georgia and the U.S. Department of Justice in Washington, DC, since November 2008 relating to this matter, and was advised that this was a civil inquiry. On June 17, 2009, the Company learned that the allegations underlying this inquiry were made as part of a civil complaint filed by individuals and brought pursuant to the *qui tam* provisions of the federal False Claims Act. On April 1, 2011, the United States District Court for the Northern District of Georgia ordered the case to be unsealed. At that time, the Department of Justice and U.S. Attorney's Office filed a notice of declination stating that the United States would not be intervening and not pursuing the relators' allegation in litigation. On July 25, 2011, the relators, Daniel Barbir and Dr. Alon Vainer, filed their amended complaint in the United States District

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

Court for the Northern District of Georgia, purportedly on behalf of the federal government. The allegations in the complaint relate to the Company's drug administration practices for Vitamin D and iron agents for a period from 2003 through 2010. The complaint seeks monetary damages and civil penalties as well as costs and expenses. The Company is vigorously defending this matter and intends to continue to do so. The Company can make no assurances as to the time or resources that will be needed to devote to this litigation or its final outcome.

2010 U.S. Attorney Physician Relationship Investigation: In May 2010, the Company received a subpoena from the OIG's office in Dallas, Texas. The subpoena covers the period from January 1, 2005 to May 2010, and seeks production of a wide range of documents relating to the Company's operations, including documents related to, among other things, financial relationships with physicians and joint ventures. The general subject matter of the inquiry appears to overlap with the 2005 U.S. Attorney Investigation described above. The Company met with representatives of the government to discuss the scope of the subpoena and the production of responsive documents. The Company has been advised that this is a civil investigation. The Company is cooperating with the inquiry and is producing the requested records. The Company can make no assurances as to the time or resources that will be needed to devote to this litigation or its final outcome.

2011 U.S. Attorney Physician Relationship Investigation: In August 2011, the Company announced it had learned that the U.S. Attorney's Office for the District of Colorado would be looking into certain activities of the Company in connection with information being provided to a grand jury. The Company announced further that it understood that this investigation was at a very preliminary stage, and while its precise scope was unclear, it appeared to overlap, at least in part, with the 2005 U.S. Attorney Investigation and 2010 U.S. Attorney Physician Relationship Investigation described above. Subsequent to the Company's announcement of this 2011 U.S. Attorney Physician Relationship Investigation, it received a subpoena for documents which substantially overlaps with the subpoena in the 2010 U.S. Attorney Physician Relationship Investigation described above and covers the period from January 2006 to September 2011. The Company is cooperating with the government and is producing the requested records. Certain current and former members of the Board and executives received subpoenas in November 2011 and thereafter to testify before the grand jury, and other Company representatives may also receive subpoenas for testimony related to this matter. The Company can make no assurances as to the time or resources that will be needed to devote to this litigation or its final outcome.

2011 U.S. Attorney Medicaid Investigation: In October 2011, the Company announced that it would be receiving a request for documents, which could include an administrative subpoena from the Office of Inspector General for the U.S. Department of Health and Human Services. Subsequent to the Company's announcement of this 2011 U.S. Attorney Medicaid Investigation, the Company received a request for documents in connection with the inquiry by the United States Attorney's Office for the Eastern District of New York. The request relates to payments for infusion drugs covered by Medicaid composite payments for dialysis. The Company believes this inquiry is civil in nature. The Company does not know the time period or scope. The Company understands that certain other providers that operate dialysis clinics in New York may be receiving or have received a similar request for documents. The Company intends to cooperate with the government to provide responsive documents.

Except for the private civil complaints filed by the relators as described above, to the Company's knowledge, no proceedings have been initiated against the Company at this time in connection with any of the inquiries by the federal government. Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved, it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators. Responding to the subpoenas or inquiries and defending the Company in the relator

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

proceedings will continue to require management's attention and significant legal expense. Any negative findings in the inquiries or relator proceedings could result in substantial financial penalties or awards against the Company, exclusion from future participation in the Medicare and Medicaid programs and, to the extent criminal proceedings may be initiated against the Company, possible criminal penalties. At this time, the Company cannot predict the ultimate outcome of these inquiries, or the potential outcome of the relators claims, or the potential range of damages, if any.

Other

The Company has received several notices of claims from commercial payors and other third parties related to historical billing practices and claims against DVA Renal Healthcare (formerly known as Gambro Healthcare), a subsidiary of the Company, related to historical Gambro Healthcare billing practices and other matters covered by its 2004 settlement agreement with the Department of Justice and certain agencies of the U.S. government. The Company has received no further indication that any of these claims are active, and some of them may be barred by applicable statutes of limitations. To the extent any of these claims might proceed, the Company intends to defend against them vigorously; however, the Company may not be successful and these claims may lead to litigation and any such litigation may be resolved unfavorably. At this time, the Company cannot predict the ultimate outcome of this matter or the potential range of damages, if any.

A wage and hour claim, which has been styled as a class action, is pending against the Company in the Superior Court of California. The Company was served with the complaint in this lawsuit in April 2008, and it has been amended since that time. The lawsuit, as amended, alleges that the Company failed to provide meal periods, failed to pay compensation in lieu of providing rest or meal periods, failed to pay overtime, and failed to comply with certain other California Labor Code requirements. In September 2011, the court denied the plaintiffs' motion for class certification. Plaintiffs have appealed that decision. The Company intends to continue to vigorously defend against these claims. Any potential settlement of these claims is not anticipated to be material to the Company's consolidated financial statements.

In October 2007, the Company was contacted by the Attorney General's Office for the State of Nevada. The Attorney General's Office informed the Company that it was conducting a civil and criminal investigation of the Company's operations in Nevada and that the investigation related to the billing of pharmaceuticals, including EPO. In February 2008, the Attorney General's Office informed the Company that the civil and criminal investigation had been discontinued. The Attorney General's Office further advised the Company that Nevada Medicaid intended to conduct audits of end stage renal disease (ESRD) dialysis providers in Nevada and such audits would relate to the issues that were the subjects of the investigation. To the Company's knowledge, no court proceedings have been initiated against the Company at this time. Any negative audit findings could result in a substantial repayment by the Company. At this time, the Company cannot predict the ultimate outcome of this matter or the potential range of damages, if any.

In June 2004, DVA Renal Healthcare was served with a complaint filed in the Superior Court of California by one of its former employees who worked for its California acute services program. The complaint, which is styled as a class action, alleges, among other things, that DVA Renal Healthcare failed to provide overtime wages, defined rest periods and meal periods, or compensation in lieu of such provisions and failed to comply with certain other California Labor Code requirements. The parties have reached an agreement, subject to approval by the court, which fully resolves this matter for an amount that did not materially impact the Company's financial results.

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

In addition to the foregoing, the Company is subject to claims and suits, including from time to time, contractual disputes and professional and general liability claims, as well as audits and investigations by various government entities, in the ordinary course of business. The Company believes that the ultimate resolution of any such pending proceedings, whether the underlying claims are covered by insurance or not, will not have a material adverse effect on its financial condition, results of operations or cash flows.

17. DaVita Inc. stock-based compensation and shareholders' equity

Stock-based compensation

Stock-based compensation recognized in a period represents the straight-line amortization during that period of the estimated grant-date fair value of stock-based awards over their vesting terms, adjusted for expected forfeitures. Shares issued upon exercise of stock awards are generally issued from shares held in treasury.

Stock-based compensation plans

On June 6, 2011, the Company's stockholders approved the DaVita Inc. 2011 Incentive Award Plan (the 2011 Plan), which constituted an amendment and restatement of the DaVita Inc. 2002 Equity Compensation Plan (the 2002 Plan, and jointly the Plan).

The 2011 Plan is the Company's omnibus equity compensation plan and provides for grants of stock-based awards to employees, directors and other individuals providing services to the Company, except that incentive stock options may only be awarded to employees. The 2011 Plan authorizes the Company to provide equity-based compensation in the form of stock options, stock appreciation rights, restricted stock units, restricted stock, and certain other performance-based awards, and is designed to enable the Company to grant equity and cash awards that qualify as performance-based compensation under Section 162(m) of the Internal Revenue Code. The 2011 Plan does not increase the number of shares authorized under the 2002 Plan, continues to mandate a maximum award term of five years, and continues to stipulate that stock appreciation rights and stock options be granted with prices not less than the fair market value on the date of grant. The 2011 Plan also continues to require that full share awards such as restricted stock units reduce shares available under the Plan at a rate of 3.0:1. The Company's nonqualified stock appreciation rights and stock units awarded under the Plan generally vest over 48 to 60 months from the date of grant. At December 31, 2011, there were 10,205,564 stock-settled stock appreciation rights, 10,000 cash-settled stock appreciation rights, 513,108 stock units outstanding under the Plan, and 8,405,431 shares available for future grants under the Plan.

On June 7, 2010, the Company's stockholders had previously approved an amendment and restatement of the 2002 Plan to increase the number of shares reserved to the Plan by 10,000,000 shares.

In connection with this 2010 amendment, the Board of Directors has committed to the Company's stockholders that over the three-year period commencing on April 1, 2010 it will not grant a number of shares subject to stock awards under the Plan, including stock options, stock appreciation rights, restricted stock units or other stock awards, at an average annual rate greater than 4.02% of the number of shares of the Company's common stock that management believes will be outstanding over such three-year period. This 4.02% rate is the average of the 2009 and 2010 three-year average median grant rate plus one standard deviation as published by RiskMetrics Group for the Russell 3000 companies in the GICS 3510 industry segment. Awards that are settled in cash, awards that are granted pursuant to stockholder approved exchange programs, awards sold under the Company's employee stock purchase plan and awards assumed or substituted in business combination transactions will be excluded from the Company's grant rate calculation. For purposes of calculating the number

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

of shares granted, any “full-value” awards (i.e., restricted stock, restricted stock unit, performance share or any other award that does not have an exercise price per share at least equal to the per share fair market value of the Company’s common stock on the grant date) will count as equivalent to 3.0 shares. The Company will publicly report its compliance with this three-year average annual grant rate commitment, and the data necessary to independently confirm it, in a public filing shortly after March 31, 2013.

Predecessor plans. Various prior stock-based compensation plans were terminated upon original shareholder approval of the 2002 Plan in 2002 and the 1999 Non-Executive Officer and Non-Director Equity Compensation Plan expired in 2009, both except with respect to option awards then outstanding. Stock options granted under these terminated plans were generally issued with exercise prices equal to the market price of the stock on the date of grant, vested over four years from the date of grant, and bore maximum award terms of five to 10 years. There were no stock awards remaining outstanding under these terminated plans as of December 31, 2011.

A combined summary of the status of awards under the Company’s stock-based compensation plans, including base shares for stock-settled stock appreciation rights and shares subject to stock option and stock unit awards, is as follows:

	Year ended December 31, 2011				
	Stock appreciation rights and stock options			Stock units	
	Awards	Weighted average exercise price	Weighted average remaining contractual life	Awards	Weighted average remaining contractual life
Outstanding at beginning of year	11,013,487	\$51.94		501,564	
Granted	2,707,500	82.17		150,246	
Exercised	(3,032,329)	51.46		(78,106)	
Cancelled	(483,094)	59.59		(60,596)	
Outstanding at end of period	<u>10,205,564</u>	<u>\$59.74</u>	<u>2.6</u>	<u>513,108</u>	<u>1.5</u>
Awards exercisable at end of period	<u>4,348,803</u>	<u>\$50.62</u>	<u>1.7</u>	<u>3,446</u>	<u>0.6</u>
Weighted-average fair value of awards granted during 2011	<u>\$21.93</u>			<u>\$85.28</u>	
Weighted-average fair value of awards granted during 2010	<u>\$15.87</u>			<u>\$62.85</u>	
Weighted-average fair value of awards granted during 2009	<u>\$12.08</u>			<u>\$54.31</u>	

Range of exercise prices	Awards outstanding	Weighted average exercise price	Awards exercisable	Weighted average exercise price
\$ 0.00- \$ 0.01	513,108	\$–	3,446	\$–
\$40.01- \$50.00	3,856,250	45.69	2,254,496	45.54
\$50.01- \$60.00	1,868,878	52.43	1,453,292	52.47
\$60.01- \$70.00	1,993,936	64.40	621,015	64.04
\$70.01- \$80.00	397,500	74.20	20,000	72.52
\$80.01- \$90.00	2,089,000	85.01	–	–
Total	<u>10,718,672</u>	<u>\$56.88</u>	<u>4,352,249</u>	<u>\$50.58</u>

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

The Company also granted 10,000 cash-settled stock appreciation rights in 2011 at a base price of \$79.57. These liability-classified awards remain outstanding but unvested at December 31, 2011, have no intrinsic value at that date, and have contributed \$0 to total stock-based compensation for 2011.

For the years ended December 31, 2011, 2010, and 2009, the aggregate intrinsic value of stock awards exercised was \$98,235, \$67,935 and \$46,896, respectively. At December 31, 2011, the aggregate intrinsic value of stock awards outstanding was \$222,347 and the aggregate intrinsic value of stock awards exercisable was \$109,791.

Estimated fair value of stock-based compensation awards

The Company has estimated the grant-date fair value of stock-settled stock appreciation rights awards and stock options using the Black-Scholes-Merton valuation model and stock unit awards at intrinsic value on the date of grant. The following assumptions were used in estimating these values and determining the total stock-based compensation attributable to the current period:

Expected term of the awards: The expected term of awards granted represents the period of time that they are expected to remain outstanding from the date of grant. The Company determines the expected term of its stock awards based on its historical experience with similar awards, considering the Company's historical exercise and post-vesting termination patterns, and the terms expected by peer companies in near industries.

Expected volatility: Expected volatility represents the volatility anticipated over the expected term of the award. The Company determines the expected volatility for its awards based on the volatility of the price of its common stock over the most recent retrospective period commensurate with the expected term of the award, considering the volatility expectations implied by the market price of its exchange-traded options and the volatilities expected by peer companies in near industries.

Expected dividend yield: The Company has not paid dividends on its common stock and does not currently expect to pay dividends during the term of stock awards granted.

Risk-free interest rate: The Company bases the expected risk-free interest rate on the implied yield currently available on stripped interest coupons of U.S. Treasury issues with a remaining term equivalent to the expected term of the award.

A summary of the weighted average valuation inputs described above used for estimating the grant-date fair value of stock options and stock-settled stock appreciation rights granted in the periods indicated is as follows:

	Year ended December 31,					
	2011		2010		2009	
Expected term	4.2 years		3.5 years		3.5 years	
Expected volatility	30	%	30	%	32	%
Expected dividend yield	0.0	%	0.0	%	0.0	%
Risk-free interest rate	1.6	%	1.7	%	1.8	%

The Company estimates expected forfeitures based upon historical experience with separate groups of employees that have exhibited similar forfeiture behavior in the past. Stock-based compensation expense is recorded only for awards that are expected to vest.

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

Employee stock purchase plan

The Employee Stock Purchase Plan entitles qualifying employees to purchase up to \$25 of the Company's common stock during each calendar year. The amounts used to purchase stock are accumulated through payroll withholdings or through optional lump sum payments made in advance of the first day of the purchase right period. This compensatory plan allows employees to purchase stock for the lesser of 100% of the fair market value on the first day of the purchase right period or 85% of the fair market value on the last day of the purchase right period. Purchase right periods begin on January 1 and July 1, and end on December 31. Payroll withholdings and lump-sum payments related to the plan, included in accrued compensation and benefits and used to purchase the Company's common stock for 2011, 2010 and 2009 participation periods, were \$5,889, \$4,933, and \$4,280, respectively. Shares purchased pursuant to the plan's 2011, 2010 and 2009 participation periods were 91,353, 83,865, and 86,213, respectively. At December 31, 2011, there were 787,497 shares remaining available for future grants under this plan.

The fair value of employees' purchase rights was estimated as of the beginning dates of the purchase right periods using the Black-Scholes-Merton valuation model with the following weighted average assumptions for purchase right periods in 2011, 2010 and 2009, respectively: expected volatility of 22%, 22% and 34%; risk-free interest rate of 0.5%, 0.3% and 0.2%, and no dividends. Using these assumptions, the weighted average estimated fair value of these purchase rights was \$17.20, \$13.80 and \$13.90 for 2011, 2010 and 2009, respectively.

Stock-based compensation expense and proceeds

For the years ended December 31, 2011, 2010 and 2009, the Company recognized \$48,718, \$45,551 and \$44,422, respectively, in stock-based compensation expense for stock settled-stock appreciation rights, stock options, stock units and discounted employee stock plan purchases, which is primarily included in general and administrative expenses. The estimated tax benefits recorded for this stock-based compensation in 2011, 2010 and 2009 were \$18,424, \$17,273 and \$16,810, respectively. As of December 31, 2011, there was \$91,305 of total estimated unrecognized compensation cost related to nonvested stock-settled compensation arrangements under the Company's equity compensation and stock purchase plans. The Company expects to recognize this cost over a weighted average remaining period of 1.4 years.

During the years ended December 31, 2011, 2010 and 2009, the Company received \$5,443, \$48,686 and \$63,653 in cash proceeds from stock option exercises and \$38,199, \$26,706 and \$18,241 in total actual tax benefits upon the exercise of stock awards, respectively.

Stock repurchases

During 2011 and 2010, the Company repurchased a total of 3,794,686 and 8,918,760 shares of its common stock for \$323,348 and \$618,496, or an average price of \$85.21 and \$69.35 per share, respectively, pursuant to previously announced authorizations by the Board of Directors. On November 3, 2010, the Company's Board of Directors authorized an additional \$800,000 of share repurchases of its common stock. As a result of these transactions, the total outstanding authorization for share repurchases as of December 31, 2011 was approximately \$358,200. The Company has not repurchased any additional shares of its common stock from January 1, 2012 through February 24, 2012. This stock repurchase program has no expiration date.

Shareholder rights plan

The Company's Board of Directors approved a shareholder rights plan on November 14, 2002. This plan provided a mechanism whereby the Board of Directors could take certain actions to dilute the ownership stake of a person or group which acquired, or announced a tender offer for, 15% or more of DaVita Inc.'s outstanding common stock.

DAVITA INC.**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)**
(dollars in thousands, except per share data)

On March 10, 2011, the Company and The Bank of New York Mellon Trust Company, N.A., as rights agent, entered into an amendment to this plan. This amendment accelerated the expiration of the rights issued under the plan from the close of business on November 14, 2012 to the close of business on March 10, 2011. Accordingly, as of the close of business on March 10, 2011, the rights issued under this plan expired and are no longer outstanding.

Charter documents & Delaware law

The Company's charter documents include provisions that may deter hostile takeovers, delay or prevent changes of control or changes in management, or limit the ability of stockholders to approve transactions that they may otherwise determine to be in their best interests. These include provisions prohibiting stockholders from acting by written consent, requiring 90 days advance notice of stockholder proposals or nominations to the Board of Directors and granting the Board of Directors the authority to issue up to five million shares of preferred stock and to determine the rights and preferences of the preferred stock without the need for further stockholder approval.

The Company is also subject to Section 203 of the Delaware General Corporation Law that, subject to exceptions, would prohibit the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period of three years following the date on which that stockholder became an interested stockholder. These restrictions may discourage, delay or prevent a change in the control of the Company.

Changes in DaVita Inc.'s ownership interest in consolidated subsidiaries

The effects of changes in DaVita Inc.'s ownership interest on the Company's equity are as follows:

	Year ended December 31, 2011	Year ended December 31, 2010	Year ended December 31, 2009
Net income attributable to DaVita Inc.	\$ 478,001	\$ 405,683	\$ 422,684
Decrease in paid-in capital for sales of noncontrolling interest in several joint ventures	(1,299)	(298)	(529)
Decrease in paid-in capital for the purchase of a noncontrolling interest in several joint ventures	(9,486)	(5,537)	(3,721)
Net transfer to noncontrolling interests	(10,785)	(5,835)	(4,250)
Change from net income attributable to DaVita Inc. and transfers to noncontrolling interests	<u>\$ 467,216</u>	<u>\$ 399,848</u>	<u>\$ 418,434</u>

In addition in 2011, 2010 and 2009, the Company also acquired additional ownership interests in several existing majority-owned joint ventures for \$13,689, \$14,214 and \$6,859, respectively.

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

18. Other comprehensive income

Charges and credits to other comprehensive income have been as follows:

	<u>2009</u>		
	<u>Before tax</u>	<u>Tax (expense)</u>	<u>Net-of-</u>
	<u>amount</u>	<u>benefit</u>	<u>tax</u>
Unrealized losses on interest rate swaps	\$(4,220)	\$ 1,642	\$(2,578)
Less reclassification of net swap realized losses into net income	17,253	(6,711)	10,542
Net swap activity	13,033	(5,069)	7,964
Unrealized gains on investments	1,614	(628)	986
Less reclassification of net investment realized gains into net income	(261)	102	(159)
Net investment activity	1,353	(526)	827
Total	\$14,386	\$ (5,595)	\$8,791

	<u>2010</u>		
	<u>Before tax</u>	<u>Tax (expense)</u>	<u>Net-of-</u>
	<u>amount</u>	<u>benefit</u>	<u>tax</u>
Unrealized losses on interest rate swaps	\$(217)	\$ 83	\$(134)
Less reclassification of net swap realized losses into net income	9,093	(3,536)	5,557
Net swap activity	8,876	(3,453)	5,423
Unrealized gains on investments	1,007	(392)	615
Less reclassification of net investment realized losses into net income	22	(9)	13
Net investment activity	1,029	(401)	628
Total	\$9,905	\$ (3,854)	\$6,051

	<u>2011</u>		
	<u>Before tax</u>	<u>Tax (expense)</u>	<u>Net-of-tax</u>
	<u>amount</u>	<u>benefit</u>	<u>amount</u>
Unrealized losses on interest rate swap and cap agreements	\$(47,544)	\$ 18,495	\$(29,049)
Less reclassification of net swap and cap agreements realized losses into net income	15,911	(6,190)	9,721
Net swap and cap agreements activity	(31,633)	12,305	(19,328)
Unrealized losses on investments	(986)	384	(602)
Less reclassification of net investment realized gains into net income	(93)	36	(57)
Net investment activity	(1,079)	420	(659)
Total	\$ (32,712)	\$ 12,725	\$ (19,987)

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

Changes in accumulated other comprehensive income (loss) has been as follows:

	Interest rate swap and cap agreements	Investment securities	Accumulated other comprehensive income
Balance December 31, 2009	\$(5,423)	\$ (125)	\$ (5,548)
Net activity	5,423	628	6,051
Balance December 31, 2010	\$-	\$ 503	\$ 503
Net activity	(19,328)	(659)	(19,987)
Balance December 31, 2011	<u>\$(19,328)</u>	<u>\$ (156)</u>	<u>\$ (19,484)</u>

19. Acquisitions

During 2011, 2010, and 2009, the Company acquired total dialysis and other businesses as follows:

	Year ended December 31,		
	2011	2010	2009
Cash paid, net of cash acquired	\$1,077,442	\$188,502	\$87,617
Deferred purchase price and other acquisition obligations	19,010	449	338
Aggregate purchase cost	<u>\$1,096,452</u>	<u>\$188,951</u>	<u>\$87,955</u>
Number of chronic dialysis centers acquired	<u>178</u>	<u>41</u>	<u>19</u>

The assets and liabilities for all acquisitions were recorded at their estimated fair values at the dates of the acquisitions and are included in the Company's financial statements and operating results from the effective dates of the acquisitions.

Acquisition of DSI Renal Inc.

On September 2, 2011, the Company completed its acquisition of all of the outstanding common stock of CDSI I Holding Company, Inc., the parent company of dialysis provider DSI Renal Inc. (DSI), pursuant to an agreement and plan of merger for approximately \$723,012 in net cash, plus the assumption of certain liabilities totaling approximately \$6,541, subject to certain post-closing adjustments. DSI had 113 outpatient dialysis centers that provide services to approximately 8,000 patients in 23 states. The Company also incurred approximately \$21,700 in transaction and integration costs during 2011 associated with this acquisition that are included in general and administrative expenses in the consolidated statements of income.

The initial purchase price allocation for the DSI acquisition is recorded at estimated fair values based upon the best information available to management and will be finalized when certain information arranged to be obtained has been received. In particular, certain income tax amounts are pending issuance of the final tax returns.

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

The following table summarizes the assets acquired and liabilities assumed in the transaction and recognized at the acquisition date at their estimated fair values, as well as the estimated fair value of the noncontrolling interests in DSI at that date:

Current assets	\$ 164,227
Property and equipment	67,080
Amortizable intangible and other long-term assets	6,523
Goodwill	500,662
Long-term deferred income taxes	79,420
Current liabilities assumed	(54,046)
Other long-term liabilities	(11,213)
Noncontrolling interests	(23,100)
	<u>\$729,553</u>

Amortizable intangible assets acquired in this acquisition had weighted average estimated useful lives of nine years.

Of the goodwill recognized in this acquisition, approximately \$262,000 is expected to be deductible for tax purposes over the next 15 years.

The noncontrolling interests acquired as part of the acquisition are stated at fair value based upon a third-party appraisal that was informed by implied multiples used in conjunction with the acquisition of the DSI group, as well as the Company's overall experience and contractual multiples typical for such arrangements.

The operating results of DSI are included in the Company's consolidated financial statements effective September 1, 2011.

Other acquisitions

During 2011, the Company acquired other dialysis related and other ancillary businesses consisting of 57 dialysis centers in the U.S., eight dialysis centers outside of the U.S. and one vascular access center for a total of \$354,430 in net cash and deferred purchase price of \$12,469. During 2010 and 2009, the Company acquired other dialysis businesses consisting of 41 centers and 19 centers for a total of \$188,951 and \$87,955, respectively, in cash and deferred purchase price obligations. The assets and liabilities for all acquisitions were recorded at their estimated fair market values at the dates of the acquisitions and are included in the Company's financial statements and operating results from the effective dates of the acquisitions.

The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values, as well as the estimated fair value of the noncontrolling interests assumed in these transactions:

	<u>Year ended December 31,</u>		
	<u>2011</u>	<u>2010</u>	<u>2009</u>
Tangible assets, principally leasehold improvements and equipment	\$32,649	\$21,257	\$11,140
Amortizable intangible assets	19,804	18,300	6,703
Goodwill	388,844	152,252	78,199
Noncontrolling interests assumed	(70,821)	(1,171)	(7,567)
Liabilities assumed	(3,577)	(1,687)	(520)
Aggregate purchase cost	<u>\$366,899</u>	<u>\$188,951</u>	<u>\$87,955</u>

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

Amortizable intangible assets acquired during 2011, 2010 and 2009 had weighted-average estimated useful lives of nine, nine and seven years, respectively. In 2011, 2010 and 2009, \$352,674, \$152,252 and \$78,199 of goodwill was associated with the dialysis and related lab services business. In addition, in 2011 \$36,170 of goodwill was associated with the other ancillary services and strategic initiatives. The total amount of goodwill deductible for tax purposes associated with these acquisitions for 2011, 2010, and 2009 was approximately \$298,000, \$154,000 and \$72,000, respectively.

Discontinued operations

Pursuant to a consent order issued by the Federal Trade Commission on September 2, 2011, the Company agreed to divest a total of 30 outpatient dialysis centers and several home-based dialysis programs in order to complete the acquisition of DSI. In conjunction with the consent order, on September 30, 2011, the Company completed the sale of 28 outpatient dialysis centers to Dialysis Newco, Inc. (Dialysis Newco), a portfolio company of Frazier Healthcare VI, L.P. and New Enterprise Associates 13, Limited Partnership pursuant to an asset purchase agreement dated August 26, 2011. Effective October 31, 2011, the Company also completed the sale of two additional outpatient dialysis centers to Dialysis Newco that were previously pending state regulatory approval. The Company anticipates receiving total net cash consideration of approximately \$82,000 for all of the outpatient dialysis centers that were divested. As part of this transaction, Dialysis Newco assumed specific liabilities related to the centers it acquired. All other liabilities were retained by the Company. The Company recorded a loss of approximately \$4,756, net of tax, during the year ended December 31, 2011 related to the divestiture of its historical DaVita centers.

The operating results of the historical DaVita divested centers are reflected as discontinued operations for all periods presented. In addition, the operating results of the DSI divested centers are reflected as discontinued operations in the consolidated financial statements beginning September 1, 2011.

The results from discontinued operations related to the dialysis and related lab services segment were as follows:

	Year ended December 31,		
	2011	2010	2009
Net operating revenues	\$16,648	\$9,341	\$8,152
Income before income taxes	1,896	468	645
Income tax expense	675	187	252
Income from discontinued operations	\$1,221	\$281	\$393

Net assets of discontinued operations related to the dialysis and related lab services segment as of September 30, 2011, were as follows:

Current assets	\$ 71,384
Property and equipment, net	5,183
Goodwill	7,999
Liabilities and noncontrolling interests	(836)
Net assets from discontinued operations	\$83,730

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

Pro forma financial information

The following summary, prepared on a pro forma basis, combines the results of operations as if all acquisitions and divestitures in 2011 and 2010 had been consummated as of the beginning of 2010, after including the impact of certain adjustments such as amortization of intangibles, interest expense on acquisition financing and income tax effects.

	Year ended December 31,	
	2011	2010
	(unaudited)	
Pro forma net revenues	\$7,309,901	\$6,983,641
Pro forma net income attributable to DaVita Inc.	520,625	471,635
Pro forma income from continuing operations attributable to DaVita Inc.	524,379	471,354
Pro forma basic net income per share attributable to DaVita Inc.	5.50	4.65
Pro forma diluted net income per share attributable to DaVita Inc.	5.39	4.58

20. Variable interest entities

The Company is required to consolidate each entity determined to be a variable interest entity for which the Company is the primary beneficiary. Variable interest entities (VIEs) typically include those for which the entity's equity is not sufficient to finance its activities without additional subordinated financial support; those for which the equity holders as a group lack the power to direct the activities that most significantly influence the entity's economic performance, the obligation to absorb the entity's expected losses, or the right to receive the entity's expected returns; or those for which the voting rights of some investors are not proportional to their obligations to absorb the entity's losses.

The Company is deemed to be the primary beneficiary of all the variable interest entities it is associated with. These VIEs are principally operating subsidiaries owned by related party nominee owners for the Company's benefit in jurisdictions in which the Company does not qualify for direct ownership under applicable regulations or joint ventures that require subordinated support in addition to their equity capital to finance operations. These include both dialysis operations and physician practice management entities.

Under the terms of the applicable arrangement, the Company bears substantially all of the economic risks and rewards of ownership for these operating VIEs. In some cases, the Company has contractual arrangements with its respective related party nominee owners which indemnify them from the economic losses, and entitle the Company to the economic benefits, that may result from ownership of these VIEs. DaVita Inc. manages these VIEs and provides operating and capital funding as necessary to accomplish their operational and strategic objectives.

Accordingly, since the Company bears the majority of the risks and rewards attendant to their ownership, the Company consolidates these VIEs as their primary beneficiary. Total assets of these consolidated operating VIEs were approximately \$7,000 and their liabilities to unrelated third parties were approximately \$5,000 at December 31, 2011.

The Company also sponsors certain deferred compensation plans whose trusts qualify as VIEs and as their primary beneficiary the Company consolidates each of these plans. The assets of these plans are recorded in short-term or long-term investments with matching offsetting liabilities in accrued compensation and benefits and other long-term liabilities. See Note 9 for disclosures on the assets of these consolidated non-qualified deferred compensation plans.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

21. Concentrations

Approximately 66% of the Company's total dialysis and related lab services revenues in 2011, 66% in 2010 and 65% in 2009 are from government-based programs, principally Medicare and Medicaid. Accounts receivable and other receivables, from Medicare, including Medicare-assigned plans, and Medicaid, including Medicaid-assigned plans, were approximately \$617,200 and \$554,300, respectively as of December 31, 2011 and 2010. No other single payor accounted for more than 5% of total accounts receivable.

EPO is a significant physician-prescribed pharmaceutical that is administered during dialysis and is provided by a sole supplier. The amount of EPO that is separately billable accounted for approximately 3% and 18% of the dialysis and related lab services net operating revenues in 2011 and 2010, respectively. As long as certain conditions are met by the Company, the agreement with Amgen limits their ability to unilaterally decide to increase the price it charges the Company for EPO.

22. Noncontrolling interests subject to put provisions and other commitments

Noncontrolling interests subject to put provisions

The Company has potential obligations to purchase the noncontrolling interests held by third parties in several of its joint ventures and non-wholly-owned subsidiaries. These obligations are in the form of put provisions and are exercisable at the third-party owners' discretion within specified periods as outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase the third-party owners' noncontrolling interests at either the appraised fair market value or a predetermined multiple of earnings or cash flow attributable to the noncontrolling interests put to the Company, which is intended to approximate fair value. The methodology the Company uses to estimate the fair values of noncontrolling interests subject to put provisions assumes either the higher of a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators, as well as other factors. During the second quarter of 2010, the Company refined its methodology used to estimate the fair value of noncontrolling interests subject to put provisions by eliminating an annual inflation factor that was previously applied to the put provisions until they became exercisable. The Company believes that eliminating an annual inflation factor will result in a better representation of the estimated actual fair value of the noncontrolling interests subject to put provisions as of the reporting date. The estimated fair values of the noncontrolling interests subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interests obligations may be settled will vary significantly depending upon market conditions including potential purchasers' access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners' noncontrolling interests. The amount of noncontrolling interests subject to put provisions that contractually employ a predetermined multiple of earnings rather than fair value are immaterial.

Additionally, the Company has certain other potential commitments to provide operating capital to several dialysis centers that are wholly-owned by third parties or centers in which the Company owns a minority equity investment as well as to physician-owned vascular access clinics that the Company operates under management and administrative service agreements of approximately \$4,000.

Certain consolidated joint ventures are contractually scheduled to dissolve after terms ranging from ten to fifty years. Accordingly, the noncontrolling interests in these joint ventures are considered mandatorily redeemable instruments, for which the classification and measurement requirements have been indefinitely deferred. Future distributions upon dissolution of these entities would be valued below the related noncontrolling interest carrying balances in the consolidated balance sheet.

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

Other commitments

In November 2011, the Company entered into a seven year Sourcing and Supply Agreement with Amgen USA Inc. that expires on December 31, 2018. Under terms of the agreement, the Company will purchase EPO in amounts necessary to meet no less than 90% of its requirements for erythropoiesis stimulations agents. The agreement replaces in its entirety the prior one-year supply agreement between the Company and Amgen that expired on December 31, 2011, and among other things, provides for discounted pricing and rebates for EPO. Some of the rebates are subject to various conditions including future pricing levels of EPO by Amgen and data submission by the Company. In the initial years of the agreement the total rebate opportunity is less than what was provided for in the agreement that expired at the end of 2011, however, the opportunity for the Company to earn discounts and rebates increases over the term of the agreement. The actual amount of EPO that the Company will purchase from Amgen will depend upon the amount of EPO administered during dialysis as prescribed by physicians and the overall number of patients that the Company serves.

In January 2010, the Company entered into an agreement with Fresenius which committed the Company to purchase a certain amount of dialysis equipment, parts and supplies from them through 2013. During 2011 and 2010, the Company purchased \$107,977 and \$103,183, respectively, of certain equipment, parts and supplies from Fresenius.

In July 2010, the Company announced that it will construct a new corporate headquarters in Denver, Colorado. In July 2010, the Company acquired the land and existing improvements for approximately \$12,000. Effective December 18, 2010, the Company entered into a construction agreement for the construction of the new building. The Company currently estimates the total construction costs and other project costs of the building will be approximately \$95,000. Construction began in early 2011, and is estimated to be completed in the second half of 2012. In 2011 and 2010, the Company paid construction costs and architecture and other design costs totaling approximately \$44,000 and \$5,000, respectively.

In conjunction with the acquisition of DVA Renal Healthcare, Inc., formerly known as Gambro Healthcare, Inc., which occurred in October 2005, the Company entered into an Alliance and Product Supply Agreement (the Product Supply Agreement) with Gambro AB and Gambro Renal Products, Inc (Gambro Renal Products). Because the Product Supply Agreement results in higher costs for most of the products covered by the Product Supply Agreement than would otherwise be available to the Company, the Product Supply Agreement represented an intangible liability initially valued at \$162,100 as of the acquisition date.

The Product Supply Agreement committed the Company to purchase a significant majority of its hemodialysis products, supplies and equipment at fixed prices through 2015. The agreement was amended in 2006 (the Amended Product Supply Agreement) to reduce the Company's purchase obligations for certain hemodialysis product supplies and equipment, and in 2007, the Company terminated its obligation to purchase certain dialysis machines under the Amended Product Supply Agreement. However, the Company continues to be subject to the Product Supply Agreement's requirements to purchase a majority of its hemodialysis non-equipment product supplies, such as dialyzers, from Gambro at fixed prices.

During 2011, 2010 and 2009, the Company purchased \$120,938, \$115,682 and \$87,983 of hemodialysis product supplies from Gambro Renal Products, representing 2% of the Company's total operating costs, for all years presented.

Other than operating leases disclosed in Note 14 to the consolidated financial statements, the letters of credit disclosed in Note 13 to the consolidated financial statements, and the arrangements as described above, the Company has no off balance sheet financing arrangements as of December 31, 2011.

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

23. Fair values of financial instruments

The Company measures the fair value of certain assets, liabilities and noncontrolling interests subject to put provisions (temporary equity) based upon certain valuation techniques that include observable or unobservable inputs and assumptions that market participants would use in pricing these assets, liabilities, temporary equity and commitments. The Company also has classified certain assets, liabilities and temporary equity that are measured at fair value into the appropriate fair value hierarchy levels as defined by FASB.

The following tables summarize the Company's assets, liabilities and temporary equity measured at fair value on a recurring basis as of December 31, 2011 and 2010:

	December 31, 2011			
	Total	Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Assets				
Available for sale securities	\$15,535	\$ 15,535	\$ -	\$ -
Interest rate cap agreements	\$1,381	\$ -	\$ 1,381	\$ -
Liabilities				
Interest rate swap agreements	\$23,145	\$ -	\$ 23,145	\$ -
Temporary equity				
Noncontrolling interests subject to put provisions	\$478,216	\$ -	\$ -	\$478,216

	December 31, 2010			
	Total	Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Assets				
Available for sale securities	\$10,048	\$ 10,048	\$ -	\$ -
Temporary equity				
Noncontrolling interests subject to put provisions	\$383,052	\$ -	\$ -	\$383,052

The available for sale securities represent investments in various open-ended registered investment companies, or mutual funds, and are recorded at fair value based upon quoted prices reported by each mutual fund. The available for sale securities also include the fair value of NxStage common stock based upon quoted market prices as reported by NASDAQ. See Note 9 to the consolidated financial statements for further discussion.

The interest rate swap and cap agreements are recorded at fair value based upon valuation models utilizing the income approach and commonly accepted valuation techniques that use inputs from closing prices for similar assets and liabilities in active markets as well as other relevant observable market inputs at quoted intervals such as current interest rates, forward yield curves, implied volatility and credit default swap pricing. The Company does not believe the ultimate amount that could be realized upon settlement of these

interest rate swap and cap agreements would be materially different than the fair values as currently reported. See Note 13 to the consolidated financial statements for further discussion.

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

See Note 22 to the consolidated financial statements for a discussion of the Company's methodology for estimating the fair value of noncontrolling interests subject to put obligations.

Other financial instruments consist primarily of cash, accounts receivable, accounts payable, other accrued liabilities and debt. The balances of the non-debt financial instruments are presented in the consolidated financial statements at December 31, 2011 and 2010 at their approximate fair values due to the short-term nature of their settlements. The carrying balance of the Company's Senior Secured Credit Facilities totaled \$2,874,158 as of December 31, 2011, and the fair value was \$2,860,465 based upon quoted market prices. The fair value of the Company's senior notes was approximately \$1,565,500 at December 31, 2011 based upon quoted market prices, as compared to the carrying amount of \$1,550,000.

24. Segment reporting

The Company operates principally as a dialysis and related lab services business but also operates other ancillary services and strategic initiatives. These ancillary services and strategic initiatives consist primarily of pharmacy services, infusion therapy services, disease management services, vascular access services, ESRD clinical research programs, physician services and the Company's international dialysis operations. For internal management reporting the dialysis and related lab services business and each of the ancillary services and strategic initiatives have been defined as separate operating segments by management since separate financial information is regularly produced and reviewed by the Company's chief operating decision maker in making decisions about allocating resources and assessing financial results. The Company's chief operating decision maker is its Chief Executive Officer. The U.S. dialysis and related lab services business qualifies as a separately reportable segment and all of the other ancillary services and strategic initiatives operating segments have been combined and disclosed in the other segments category.

The Company's operating segment financial information is prepared on an internal management reporting basis that the Chief Executive Officer uses to allocate resources and analyze the performance of the operating segments. For internal management reporting, segment operations include direct segment operating expenses with the exception of stock-based compensation expense and equity investment income. In addition, beginning in 2011, the ancillary services and strategic initiatives segment operations also include an allocation of corporate general and administrative expenses.

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

The following is a summary of segment revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income before income taxes:

	Year ended December 31,		
	2011	2010	2009
Segment revenues:			
Dialysis and related lab services (1)			
External sources	\$6,473,829	\$6,054,252	\$5,766,795
Intersegment revenues	11,141	9,300	16,782
Total dialysis and related lab services	<u>6,484,970</u>	<u>6,063,552</u>	<u>5,783,577</u>
Other - Ancillary services and strategic initiatives			
External sources (2)	\$508,385	\$383,798	\$333,853
Intersegment revenues	5,796	-	-
Total ancillary services and strategic initiatives	<u>514,181</u>	<u>383,798</u>	<u>333,853</u>
Total segment revenues	6,999,151	6,447,350	6,117,430
Elimination of intersegment revenues	(16,937)	(9,300)	(16,782)
Consolidated revenues	<u>\$6,982,214</u>	<u>\$6,438,050</u>	<u>\$6,100,648</u>
Segment operating margin (loss): (3)			
Dialysis and related lab services	\$1,224,672	\$1,038,698	\$993,834
Other-Ancillary services and strategic initiatives	(53,948)	(5,586)	(12,226)
Total segment margin	1,170,724	1,033,112	981,608
Reconciliation of segment operating margin to consolidated income before income taxes:			
Stock-based compensation	(48,718)	(45,551)	(44,422)
Equity investment income	8,776	8,999	2,442
Consolidated operating income	1,130,782	996,560	939,628
Debt expense	(241,090)	(181,607)	(185,755)
Debt refinancing and redemption charges	-	(74,382)	-
Other income	2,982	3,419	3,706
Consolidated income from continuing operations before income taxes	<u>\$892,674</u>	<u>\$743,990</u>	<u>\$757,579</u>

- (1) Includes management fees for providing management and administrative services to dialysis centers in which the Company either owns a minority equity investment or are wholly-owned by third parties.
- (2) Revenues from external sources in 2010 and 2009 that were previously eliminated within the ancillary services and strategic initiatives segment have now been reported as a component of revenue from external sources to conform to current year presentations.
- (3) Certain costs previously reported in the Ancillary Services and Strategic Initiatives have been reclassified to the dialysis and related lab services to conform to the current year presentation.

Depreciation and amortization expense for the dialysis and related lab services for 2011, 2010 and 2009 were \$259,685, \$227,029 and \$221,317, respectively, and were \$6,943, \$6,701 and \$7,079, respectively, for the ancillary services and strategic initiatives.

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

Summary of assets by segment is as follows:

	December 31,	
	2011	2010
Segment assets		
Dialysis and related lab services	\$8,588,671	\$7,862,882
Other—Ancillary services and strategic initiatives	276,176	225,624
Equity investments	27,325	25,918
Consolidated assets	<u>\$8,892,172</u>	<u>\$8,114,424</u>

In 2011 and 2010, the total amount of expenditures for property and equipment for the dialysis and related lab services were \$425,228 and \$271,559, respectively, and were \$10,692 and \$7,226, respectively, for the ancillary services and strategic initiatives.

25. Supplemental cash flow information

The table below provides supplemental cash flow information:

	Year ended December 31,		
	2011	2010	2009
Cash paid:			
Income taxes	\$145,687	\$207,265	\$161,671
Interest	236,446	190,949	186,280
Non-cash investing and financing activities:			
Fixed assets under capital lease obligations	35,764	3,983	—
Assets exchanged for equity investments	—	—	2,618
Assets received for additional noncontrolling interests	—	—	51
Issuance of noncontrolling interests	—	1,139	—

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

26. Selected quarterly financial data (unaudited)

	2011				2010			
	December 31	September 30	June 30	March 31	December 31	September 30	June 30	March 31
Net operating revenues	\$1,862,318	\$1,807,869	\$1,708,643	\$1,603,384	\$1,646,924	\$1,649,557	\$1,584,821	\$1,556,748
Operating income	330,112	318,712	246,624	235,334	255,258	256,745	242,512	242,045
Income from continuing operations before income taxes	269,149	258,662	187,283	177,580	132,215	218,014	195,469	198,292
Discontinued operations, net of tax.	(1,307)	(2,612)	253	131	93	(95)	(89)	372
Net income attributable to DaVita Inc.	\$148,123	\$135,361	\$100,015	\$94,502	\$69,020	\$119,387	\$107,853	\$109,423
Basic income from continuing operations per share attributable to DaVita Inc.	1.60	1.48	1.05	0.98	0.71	1.16	1.06	1.05
Basic net income per share attributable to DaVita Inc.	1.59	1.45	1.05	0.98	0.71	1.16	1.05	1.05
Diluted income from continuing operations per share attributable to DaVita Inc.	\$1.58	\$1.45	\$1.02	\$0.96	\$0.70	\$1.15	\$1.04	\$1.04
Diluted net income per share attributable to DaVita Inc.	\$1.56	\$1.42	\$1.03	\$0.96	\$0.70	\$1.15	\$1.04	\$1.04

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

27. Consolidating financial statements

The following information is presented in accordance with Rule 3-10 of Regulation S-X. The operating and investing activities of the separate legal entities included in the Company's consolidated financial statements are fully interdependent and integrated. Revenues and operating expenses of the separate legal entities include intercompany charges for management and other services. The senior notes were issued by the Company on October 20, 2010 and are guaranteed by substantially all of its direct and indirect domestic wholly-owned subsidiaries. Each of the guarantor subsidiaries has guaranteed the notes on a joint and several basis. However, the guarantor subsidiaries can be released from their obligations in the event of a sale or other disposition of all or substantially all of the assets of such subsidiary, if such subsidiary guarantor is designated as an unrestricted subsidiary or otherwise ceases to be a restricted subsidiary, and if such subsidiary guarantor no longer guaranties any other indebtedness of the Company. Non-wholly-owned subsidiaries, certain wholly-owned subsidiaries, foreign subsidiaries, joint ventures, partnerships and third parties are not guarantors of these obligations.

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

Consolidating Statements of Income

	<u>DaVita Inc.</u>	<u>Guarantor Subsidiaries</u>	<u>Non- Guarantor Subsidiaries</u>	<u>Consolidating Adjustments</u>	<u>Consolidated Total</u>
For the year ended December 31, 2011					
Net operating revenues	\$457,460	\$5,527,588	\$1,541,618	\$(544,452)	\$6,982,214
Operating expenses	301,255	4,827,005	1,267,624	(544,452)	5,851,432
Operating income	156,205	700,583	273,994	–	1,130,782
Debt (expense)	(242,730)	(218,182)	(9,215)	229,037	(241,090)
Other income, net	229,658	1,583	778	(229,037)	2,982
Income tax expense	56,681	248,139	10,924	–	315,744
Equity earnings in subsidiaries	391,549	184,404	–	(575,953)	–
Income from continuing operations	478,001	420,249	254,633	(575,953)	576,930
Discontinued operations net of (loss) gain on disposal of discontinued operations	–	(4,191)	656	–	(3,535)
Net income	478,001	416,058	255,289	(575,953)	573,395
Less: Net income attributable to noncontrolling interests	–	–	–	(95,394)	(95,394)
Net income attributable to DaVita Inc.	<u>\$478,001</u>	<u>\$416,058</u>	<u>\$255,289</u>	<u>\$(671,347)</u>	<u>\$478,001</u>
For the year ended December 31, 2010					
Net operating revenues	\$431,780	\$5,195,449	\$1,288,259	\$(477,438)	\$6,438,050
Operating expenses	259,302	4,615,716	1,043,910	(477,438)	5,441,490
Operating income	172,478	579,733	244,349	–	996,560
Debt (expense)	(257,243)	(163,034)	(1,277)	165,565	(255,989)
Other income, net	165,934	1,837	1,213	(165,565)	3,419
Income tax expense	31,656	220,867	7,529	–	260,052
Equity earnings in subsidiaries	356,170	157,278	–	(513,448)	–
Income from continuing operations	405,683	354,947	236,756	(513,448)	483,938
Income from operations of discontinued operations net of tax	–	172	109	–	281
Net income	405,683	355,119	236,865	(513,448)	484,219
Less: Net income attributable to noncontrolling interests	–	–	–	(78,536)	(78,536)
Net income attributable to DaVita Inc.	<u>\$405,683</u>	<u>\$355,119</u>	<u>\$236,865</u>	<u>\$(591,984)</u>	<u>\$405,683</u>
For the year ended December 31, 2009					
Net operating revenues	\$401,058	\$5,005,839	\$1,147,394	\$(453,643)	\$6,100,648
Operating expenses	246,578	4,375,032	993,053	(453,643)	5,161,020
Operating income	154,480	630,807	154,341	–	939,628
Debt (expense)	(188,109)	(181,853)	(1,721)	185,928	(185,755)
Other income, net	186,189	2,718	727	(185,928)	3,706
Income tax expense	60,414	218,618	(819)	–	278,213
Equity earnings in subsidiaries	330,538	94,964	–	(425,502)	–

Income from continuing operations	422,684	328,018	154,166	(425,502)	479,366
Income from operations of discontinued operations net of tax	<u>–</u>	<u>180</u>	<u>213</u>	<u>–</u>	<u>393</u>
Net income	422,684	328,198	154,379	(425,502)	479,759
Less: Net income attributable to noncontrolling interests	<u>–</u>	<u>–</u>	<u>–</u>	<u>(57,075)</u>	<u>(57,075)</u>
Net income attributable to DaVita Inc.	<u>\$422,684</u>	<u>\$328,198</u>	<u>\$154,379</u>	<u>\$(482,577)</u>	<u>\$422,684</u>

F-49

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

Consolidating Balance Sheets

	DaVita Inc.	Guarantor Subsidiaries	Non- Guarantor Subsidiaries	Consolidating Adjustments	Consolidated Total
As of December 31, 2011					
Cash and cash equivalents	\$365,276	\$-	\$28,476	\$-	\$393,752
Accounts receivable, net	-	926,041	269,122	-	1,195,163
Other current assets	14,665	598,721	79,307	-	692,693
Total current assets	379,941	1,524,762	376,905	-	2,281,608
Property and equipment, net	78,038	971,867	382,746	-	1,432,651
Amortizable intangible assets, net	53,276	95,900	10,315	-	159,491
Investments in subsidiaries	6,696,039	1,089,920	-	(7,785,959)	-
Intercompany receivables	-	472,200	253,447	(725,647)	-
Other long-term assets and investments	11,388	56,134	3,924	-	71,446
Goodwill	-	3,903,542	1,043,434	-	4,946,976
Total assets	<u>\$7,218,682</u>	<u>\$8,114,325</u>	<u>\$2,070,771</u>	<u>\$(8,511,606)</u>	<u>\$8,892,172</u>
Current liabilities	\$148,994	\$889,172	\$114,950	\$-	\$1,153,116
Intercompany payables	271,890	-	453,757	(725,647)	-
Long-term debt and other long-term liabilities	4,351,346	585,675	55,694	-	4,992,715
Noncontrolling interests subject to put provisions	305,377	-	-	172,839	478,216
Total DaVita Inc. shareholders' equity	2,141,075	6,639,478	1,146,481	(7,785,959)	2,141,075
Noncontrolling interest not subject to put provisions	-	-	299,889	(172,839)	127,050
Total equity	<u>2,141,075</u>	<u>6,639,478</u>	<u>1,446,370</u>	<u>(7,958,798)</u>	<u>2,268,125</u>
Total liabilities and equity	<u>\$7,218,682</u>	<u>\$8,114,325</u>	<u>\$2,070,771</u>	<u>\$(8,511,606)</u>	<u>\$8,892,172</u>
As of December 31, 2010					
Cash and cash equivalents	\$856,803	\$-	\$3,314	\$-	\$860,117
Accounts receivable, net	-	895,955	153,021	-	1,048,976
Other current assets	11,231	653,670	48,860	-	713,761
Total current assets	868,034	1,549,625	205,195	-	2,622,854
Property and equipment, net	30,409	888,927	251,472	-	1,170,808
Amortizable intangible assets, net	58,967	98,795	4,873	-	162,635
Investments in subsidiaries	6,154,398	555,579	-	(6,709,977)	-
Intercompany receivables	-	516,286	208,030	(724,316)	-
Other long-term assets and investments	8,951	56,996	873	-	66,820
Goodwill	-	3,731,983	359,324	-	4,091,307
Total assets	<u>\$7,120,759</u>	<u>\$7,398,191</u>	<u>\$1,029,767</u>	<u>\$(7,434,293)</u>	<u>\$8,114,424</u>
Current liabilities	\$61,384	\$786,114	\$76,847	\$-	\$924,345
Intercompany payables	611,919	-	112,397	(724,316)	-
Long-term debt and other long-term liabilities	4,210,703	539,620	19,570	-	4,769,893
Noncontrolling interests subject to put provisions	258,331	-	-	124,721	383,052
Total DaVita Inc. shareholders' equity	1,978,422	6,072,457	637,520	(6,709,977)	1,978,422
Noncontrolling interest not subject to put provisions	-	-	183,433	(124,721)	58,712

Total equity	<u>1,978,422</u>	<u>6,072,457</u>	<u>820,953</u>	<u>(6,834,698)</u>	<u>2,037,134</u>
Total liabilities and equity	<u>\$7,120,759</u>	<u>\$7,398,191</u>	<u>\$1,029,767</u>	<u>\$(7,434,293)</u>	<u>\$8,114,424</u>

F-50

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

Consolidating Statements of Cash Flows

	DaVita Inc.	Guarantor Subsidiaries	Non- Guarantor Subsidiaries	Consolidating Adjustments	Consolidated Total
For the year ended December 31, 2011					
Cash flows from operating activities:					
Net income.	\$478,001	\$416,058	\$255,289	\$(575,953)	\$573,395
Changes in operating assets and liabilities and non cash items included in net income	(268,798)	325,807	(26,311)	575,953	606,651
Net cash provided by operating activities	<u>209,203</u>	<u>741,865</u>	<u>228,978</u>	-	<u>1,180,046</u>
Cash flows from investing activities:					
Additions of property and equipment, net	(52,653)	(232,540)	(114,963)	-	(400,156)
Acquisitions	-	(1,048,136)	(29,306)	-	(1,077,442)
Proceeds from asset sales	-	75,183	-	-	75,183
Proceeds from investment sales and other items	(6,077)	9,264	-	-	3,187
Net cash used in by investing activities	<u>(58,730)</u>	<u>(1,196,229)</u>	<u>(144,269)</u>	-	<u>(1,399,228)</u>
Cash flows from financing activities:					
Long-term debt and related financing costs, net	113,762	(1,896)	15,794	-	127,660
Intercompany borrowing	(464,564)	460,262	4,302	-	-
Other items	(291,198)	(4,002)	(79,643)	-	(374,843)
Net cash (used in) provided by financing activities	<u>(642,000)</u>	<u>454,364</u>	<u>(59,547)</u>	-	<u>(247,183)</u>
Net (decrease) increase in cash and cash equivalents	(491,527)	-	25,162	-	(466,365)
Cash and cash equivalents at beginning of the year	856,803	-	3,314	-	860,117
Cash and cash equivalents at the end of the year	<u>\$365,276</u>	<u>\$-</u>	<u>\$28,476</u>	<u>\$-</u>	<u>\$393,752</u>
For the year ended December 31, 2010					
Cash flows from operating activities:					
Net income.	\$405,683	\$355,119	\$236,865	\$(513,448)	\$484,219
Changes in operating assets and liabilities and non cash items included in net income	(319,090)	136,348	24,758	513,448	355,464
Net cash provided by operating activities	<u>86,593</u>	<u>491,467</u>	<u>261,623</u>	-	<u>839,683</u>
Cash flows from investing activities:					
Additions of property and equipment, net	(24,118)	(199,147)	(50,337)	-	(273,602)
Acquisitions	-	(188,502)	-	-	(188,502)
Proceeds from asset sales	-	22,727	-	-	22,727
Proceeds from investment sales and other items	(470)	3,214	-	-	2,744

Net cash used in investing activities	<u>(24,588)</u>	<u>(361,708)</u>	<u>(50,337)</u>	<u>-</u>	<u>(436,633)</u>
---------------------------------------	------------------	-------------------	------------------	----------	-------------------

F-51

DAVITA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(dollars in thousands, except per share data)

Consolidating Statements of Cash Flows

	DaVita Inc.	Guarantor Subsidiaries	Non- Guarantor Subsidiaries	Consolidating Adjustments	Consolidated Total
For the year ended December 31, 2010					
Cash flows from financing activities:					
Long-term debt and related financing costs, net	563,350	1,987	(4,391)	-	560,946
Intercompany borrowing	255,351	(121,887)	(133,464)	-	-
Other items	(558,453)	(9,859)	(75,026)	-	(643,338)
Net cash provided by (used in) financing activities	<u>260,248</u>	<u>(129,759)</u>	<u>(212,881)</u>	-	<u>(82,392)</u>
Net increase (decrease) in cash and cash equivalents	322,253	-	(1,595)	-	320,658
Cash and cash equivalents at beginning of the year	<u>534,550</u>	-	<u>4,909</u>	-	<u>539,459</u>
Cash and cash equivalents at the end of the year	<u>\$856,803</u>	<u>\$-</u>	<u>\$3,314</u>	<u>\$-</u>	<u>\$860,117</u>
For the year ended December 31, 2009					
Cash flows from operating activities:					
Net income.	\$422,684	\$328,198	\$154,379	\$(425,502)	\$479,759
Changes in operating assets and liabilities and non cash items included in net income	<u>(257,591)</u>	<u>(58,813)</u>	<u>77,853</u>	<u>425,502</u>	<u>186,951</u>
Net cash provided by operating activities	<u>165,093</u>	<u>269,385</u>	<u>232,232</u>	-	<u>666,710</u>
Cash flows from investing activities:					
Additions of property and equipment, net	(1,748)	(207,738)	(65,119)	-	(274,605)
Acquisitions	-	(87,617)	-	-	(87,617)
Proceeds from asset sales	-	7,697	-	-	7,697
Proceeds from investment sales and other items	<u>11,631</u>	<u>(3,166)</u>	-	-	<u>8,465</u>
Net cash provided by (used in) investing activities	<u>9,883</u>	<u>(290,824)</u>	<u>(65,119)</u>	-	<u>(346,060)</u>
Cash flows from financing activities:					
Long-term debt	(60,619)	(1,962)	1,307	-	(61,274)
Intercompany borrowing	101,254	20,885	(122,139)	-	-
Other items	<u>(78,637)</u>	<u>2,516</u>	<u>(54,677)</u>	-	<u>(130,798)</u>
Net cash (used in) provided by financing activities	<u>(38,002)</u>	<u>21,439</u>	<u>(175,509)</u>	-	<u>(192,072)</u>
Net increase (decrease) in cash and cash equivalents	136,974	-	(8,396)	-	128,578
Cash and cash equivalents at beginning of the year	<u>397,576</u>	-	<u>13,305</u>	-	<u>410,881</u>
Cash and cash equivalents at the end of the year	<u>\$534,550</u>	<u>\$-</u>	<u>\$4,909</u>	<u>\$-</u>	<u>\$539,459</u>

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, we have duly caused this Annual Report on Form 10-K to be signed on our behalf by the undersigned, thereunto duly authorized, in the City of Denver, State of Colorado, on February 24, 2012.

DAVITA INC.

By: /s/ KENT J. THIRY
 Kent J. Thiry
 Chairman and Chief Executive Officer

KNOW ALL MEN BY THESE PRESENT, that each person whose signature appears below constitutes and appoints Kent J. Thiry, Luis A. Borgen, and Kim M. Rivera, and each of them his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

<u>Signature</u>	<u>Title</u>	<u>Date</u>
<u> /s/ KENT J. THIRY </u> Kent J. Thiry	Chairman and Chief Executive Officer (Principal Executive Officer)	February 24, 2012
<u> /s/ LUIS A. BORGEN </u> Luis A. Borgen	Chief Financial Officer (Principal Financial Officer)	February 24, 2012
<u> /s/ JAMES K. HILGER </u> James K. Hilger	Chief Accounting Officer (Principal Accounting Officer)	February 24, 2012
<u> /s/ PAMELA M. ARWAY </u> Pamela M. Arway	Director	February 24, 2012
<u> /s/ CHARLES G. BERG </u> Charles G. Berg	Director	February 24, 2012
<u> /s/ WILLARD W. BRITTAIN </u> Willard W. Brittain	Director	February 24, 2012
<u> /s/ CAROL A. DAVIDSON </u> Carol A. Davidson	Director	February 24, 2012
<u> /s/ PAUL J. DIAZ </u> Paul J. Diaz	Director	February 24, 2012

<u>Signature</u>	<u>Title</u>	<u>Date</u>
<u>/s/ PETER T. GRAUER</u> Peter T. Grauer	Director	February 24, 2012
<u>/s/ JOHN M. NEHRA</u> John M. Nehra	Director	February 24, 2012
<u>/s/ WILLIAM L. ROPER</u> William L. Roper	Director	February 24, 2012
<u>/s/ ROGER J. VALINE</u> Roger J. Valine	Director	February 24, 2012

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Board of Directors and Shareholders
DaVita Inc.:

Under date of February 24, 2012, we reported on the consolidated balance sheets of DaVita Inc. and subsidiaries as of December 31, 2011 and 2010, and the related consolidated statements of income, equity and comprehensive income, and cash flows for each of the years in the three-year period ended December 31, 2011, which are included in the Annual Report on Form 10-K. In connection with our audits of the aforementioned consolidated financial statements, we also audited the related consolidated financial statement Schedule II-Valuation and Qualifying Accounts included in the Annual Report on Form 10-K. This financial statement schedule is the responsibility of the Company's management. Our responsibility is to express an opinion on this financial statement schedule based on our audits.

In our opinion, such financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a whole, presents fairly, in all material respects, the information set forth therein.

/s/ KPMG LLP

Seattle, Washington
February 24, 2012

S-1

DAVITA INC.

SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS

<u>Description</u>	<u>Balance at beginning of year</u>	<u>DSI Renal Inc. Acquisition</u>	<u>Amounts charged to income</u>	<u>Amounts written off</u>	<u>Balance at end of year</u>
(in thousands)					
Allowance for uncollectible accounts:					
Year ended December 31, 2009	\$211,222	\$ -	\$161,786	\$143,691	\$229,317
Year ended December 31, 2010	\$229,317	\$ -	\$171,250	\$164,938	\$235,629
Year ended December 31, 2011	\$235,629	\$ 16,193	\$198,750	\$200,229	\$250,343

S-2

EXHIBIT INDEX

- 2.1 Stock Purchase Agreement dated as of December 6, 2004, among Gambro AB, Gambro, Inc. and DaVita Inc.(9)
- 2.2 Amended and Restated Asset Purchase Agreement effective as of July 28, 2005, by and among DaVita Inc., Gambro Healthcare, Inc. and Renal Advantage Inc., a Delaware corporation, formerly known as RenalAmerica, Inc.(12)
- 2.3 Agreement and Plan of Merger by and among DaVita Inc., DVA Acquisition Company, CDSI I Holding Company, Inc. and CDSI Representative LLC, dated as of February 4, 2011.(47)
- 3.1 Amended and Restated Certificate of Incorporation of Total Renal Care Holdings, Inc., or TRCH, dated December 4, 1995.(1)
- 3.2 Certificate of Amendment of Certificate of Incorporation of TRCH, dated February 26, 1998.(2)
- 3.3 Certificate of Amendment of Certificate of Incorporation of DaVita Inc. (formerly Total Renal Care Holdings, Inc.), dated October 5, 2000.(4)
- 3.4 Certificate of Amendment of Amended and Restated Certificate of Incorporation of DaVita Inc., as amended dated May 30, 2007.(23)
- 3.5 Amended and Restated Bylaws for DaVita Inc. dated as of March 10, 2011.(25)
- 4.1 Indenture for the 6 ⁵/₈% Senior Notes due 2013 dated as of March 22, 2005.(3)
- 4.2 Indenture for the 7 ¹/₄% Senior Subordinated Notes due 2015 dated as of March 22, 2005.(3)
- 4.3 First Supplemental Indenture, dated October 5, 2005, by and among DaVita Inc., the Guarantors, the persons named as Additional Guarantors and The Bank of New York Trust Company, N.A., as Trustee.(11)
- 4.4 First Supplemental Indenture, dated October 5, 2005, by and among DaVita Inc., the Guarantors, the persons named as Additional Guarantors and The Bank of New York Trust Company, N.A., as Trustee.(13)
- 4.5 Rights Agreement, dated as of November 14, 2002, between DaVita Inc. and the Bank of New York, as Rights Agent.(21)
- 4.6 Second Supplemental Indenture (Senior), dated February 9, 2007, by and among DaVita Inc., the Guarantors, the persons named as Additional Guarantors and The Bank of New York Trust Company, N.A., as Trustee.(22)
- 4.7 Second Supplemental Indenture (Senior Subordinated), dated February 9, 2007, by and among DaVita Inc., the Guarantors, the persons named as Additional Guarantors and The Bank of New York Trust Company, N.A., as Trustee.(22)
- 4.8 Registration Rights Agreement for the 6 ⁵/₈% Senior Notes due 2013 dated as of February 23, 2007.(26)
- 4.9 Third Supplemental Indenture, dated October 14, 2010, by and among DaVita Inc., the guarantors named therein and The Bank of New York Mellon Trust Company, N.A., as Trustee.(38)
- 4.10 Third Supplemental Indenture, dated October 14, 2010, by and among DaVita Inc., the guarantors named therein and The Bank of New York Mellon Trust Company, N.A., as Trustee.(38)
- 4.11 Indenture, dated October 20, 2010, by and among DaVita Inc., the guarantors named therein and The Bank of New York Mellon Trust Company, N.A., as Trustee.(39)
- 4.12 Indenture, dated October 20, 2010, by and among DaVita Inc., the guarantors named therein and The Bank of New York Mellon Trust Company, N.A., as Trustee.(39)

-
- 4.13 First Amendment to Rights Agreement, dated as of March 10, 2011, between DaVita Inc. and The Bank of New York Mellon Trust Company, N.A., as Rights Agent.(42)
- 10.1 Employment Agreement, dated as of October 19, 2009, by and between DaVita Inc. and Kim M. Rivera.(40)*
- 10.2 Employment Agreement, dated as of June 15, 2000, by and between DaVita Inc. and Joseph C. Mello.(6)*
- 10.3 Second Amendment to Mr. Mello' s Employment Agreement, effective December 12, 2008.(33)*
- 10.4 Employment Agreement, effective as of August 16, 2004, by and between DaVita Inc. and Tom Usilton.(7)*
- 10.5 Amendment to Mr. Usilton' s Employment Agreement, dated February 12, 2007.(24)*
- 10.6 Second Amendment to Mr. Usilton' s Employment Agreement, effective December 12, 2008.(32)*
- 10.7 Employment Agreement, effective as of November 18, 2004, by and between DaVita Inc. and Joseph Schohl.(14)*
- 10.8 Amendment to Mr. Schohl' s Employment Agreement, effective December 30, 2008.(32)*
- 10.9 Employment Agreement, dated as of October 31, 2005, effective October 24, 2005, by and between DaVita Inc. and Dennis Kogod.(13)*
- 10.10 Amendment to Mr. Kogod' s Employment Agreement, effective December 12, 2008.(32)*
- 10.11 Employment Agreement, effective September 22, 2005, by and between DaVita Inc. and James Hilger.(15)*
- 10.12 Amendment to Mr. Hilger' s Employment Agreement, effective December 12, 2008.(32)*
- 10.13 Employment Agreement effective February 13, 2008, by and between DaVita Inc. and Richard K. Whitney.(28)*
- 10.14 Amendment to Equity Award Agreement, entered into on December 11, 2009, between DaVita Inc. and Richard K. Whitney.(40)*
- 10.15 Amendment to Stock Appreciation Rights Agreements, effective November 2008, by and between DaVita Inc. and Richard K. Whitney.(36)*
- 10.16 Employment Agreement, effective July 25, 2008, between DaVita Inc. and Kent J. Thiry.(29)*
- 10.17 Employment Agreement, effective August 1, 2008, between DaVita Inc. and Allen Nissenson.(30)*
- 10.18 Employment Agreement, effective March 3, 2008, between DaVita Inc. and David Shapiro.(32)*
- 10.19 Amendment to Mr. Shapiro' s Employment Agreement, effective December 4, 2008.(32)*
- 10.20 Employment Agreement, effective March 17, 2010, by and between DaVita Inc. and Javier Rodriguez.(35)*
- 10.21 Employment Agreement, effective February 26, 2010, by and between DaVita Inc. and Luis Borgen.(36)*
- 10.22 Amendment to Mr. Borgen' s Employment Agreement, effective March 18, 2010.(36)*
- 10.23 Memorandum Relating to Bonus Structure for Kent J. Thiry.(36)*
- 10.24 Memorandum Relating to Bonus Structure for Dennis L. Kogod.(36)*
- 10.25 Memorandum Relating to Bonus Structure for Thomas O. Usilton, Jr.(36)*

10.26	Form of Indemnity Agreement.(20)*
10.27	Form of Indemnity Agreement.(14)*
10.28	Executive Incentive Plan (as Amended and Restated effective January 1, 2009).(34)*
10.29	Executive Retirement Plan.(32)*
10.30	Post-Retirement Deferred Compensation Arrangement.(14)*
10.31	Amendment No. 1 to Post Retirement Deferred Compensation Arrangement.(32)*
10.32	DaVita Voluntary Deferral Plan.(11)*
10.33	Deferred Bonus Plan (Prosperity Plan).(31)*
10.34	Amendment No. 1 to Deferred Bonus Plan (Prosperity Plan).(32)*
10.35	Amended and Restated Employee Stock Purchase Plan.(27)*
10.36	Severance Plan.(36)*
10.37	Change in Control Bonus Program.(32)*
10.38	First Amended and Restated Total Renal Care Holdings, Inc. 1999 Non-Executive Officer and Non-Director Equity Compensation Plan.(5)
10.39	Non-Management Director Compensation Philosophy and Plan.(28)*
10.40	Amended and Restated 2002 Equity Compensation Plan.(10)*
10.41	Amended and Restated 2002 Equity Compensation Plan.(19)*
10.42	Amended and Restated 2002 Equity Compensation Plan.(27)*
10.43	Amended and Restated 2002 Equity Compensation Plan.(32)*
10.44	DaVita Inc. 2002 Equity Compensation Plan.(37)*
10.45	Form of Non-Qualified Stock Option Agreement–Employee (DaVita Inc. 1999 Non-Executive Officer and Non-Director Equity Compensation Plan).(18)*
10.46	Form of Non-Qualified Stock Option Agreement–Employee (DaVita Inc. 2002 Equity Compensation Plan).(7)*
10.47	Form of Non-Qualified Stock Option Agreement–Employee (DaVita Inc. 2002 Equity Compensation Plan).(16)*
10.48	Form of Non-Qualified Stock Option Agreement–Employee (DaVita Inc. 2002 Equity Compensation Plan).(18)*
10.49	Form of Restricted Stock Units Agreement–Employee (DaVita Inc. 2002 Equity Compensation Plan).(7)*
10.50	Form of Restricted Stock Units Agreement–Employee (DaVita Inc. 2002 Equity Compensation Plan).(16)*
10.51	Form of Restricted Stock Units Agreement–Employee (DaVita Inc. 2002 Equity Compensation Plan).(18)*
10.52	Form of Restricted Stock Units Agreement–Employee (DaVita Inc. 2002 Equity Compensation Plan).(32)*
10.53	Form of Stock Appreciation Rights Agreement–Employee (DaVita Inc. 2002 Equity Compensation Plan).(16)*

-
- 10.54 Form of Stock Appreciation Rights Agreement–Employee (DaVita Inc. 2002 Equity Compensation Plan).(18)*
- 10.55 Form of Stock Appreciation Rights Agreement–Board (DaVita Inc. 2002 Equity Compensation Plan).(30)*
- 10.56 Form of Stock Appreciation Rights Agreement–Board members (DaVita Inc. 2011 Incentive Award Plan).(44)*
- 10.57 Form of Restricted Stock Units Agreement–Board (DaVita Inc. 2002 Equity Compensation Plan).(30)*
- 10.58 Form of Restricted Stock Units Agreement–Board members (DaVita Inc. 2011 Incentive Award Plan).(44)*
- 10.59 Form of Non-Qualified Stock Option Agreement–Board (DaVita Inc. 2002 Equity Compensation Plan).(30)*
- 10.60 Form of Stock Appreciation Rights Agreement–Executives (DaVita Inc. 2011 Incentive Award Plan).(44)*
- 10.61 Form of Restricted Stock Units Agreement–Executives (DaVita Inc. 2011 Incentive Award Plan).(44)*
- 10.62 Credit Agreement, dated as of October 5, 2005, among DaVita Inc., the Guarantors party thereto, the Lenders party thereto, Bank of America, N.A., Wachovia Bank, National Association, Bear Stearns Corporate Lending Inc., The Bank of New York, The Bank of Nova Scotia, The Royal Bank of Scotland plc, WestLB AG, New York Branch as Co-Documentation Agents, Credit Suisse, Cayman Islands Branch, as Syndication Agent, JPMorgan Chase Bank, N.A., as Administrative Agent and Collateral Agent, JPMorgan Securities Inc., as Sole Lead Arranger and Bookrunner and Credit Suisse, Cayman Islands Branch, as Co-Arranger.(11)
- 10.63 Credit Agreement, dated as of October 5, 2005, as Amended and Restated as of February 23, 2007, by and among DaVita Inc., the Guarantors party thereto, the Lenders party thereto and JPMorgan Chase Bank, N.A.(26)
- 10.64 Amendment Agreement, dated February 23, 2007, by and among DaVita Inc., the Guarantors party thereto, the Lenders party thereto and JPMorgan Chase Bank, N.A.(26)
- 10.65 Security Agreement, dated as of October 5, 2005, by DaVita Inc., the Guarantors party thereto and JPMorgan Chase Bank, N.A., as Collateral Agent.(11)
- 10.66 Credit Agreement, dated as of October 20, 2010, by and among DaVita Inc., the guarantors party thereto, the lenders party thereto, Credit Suisse AG, Barclays Bank PLC, Goldman Sachs Bank USA, Wells Fargo Bank, National Association, Credit Agricole Corporate and Investment Bank, RBC Capital Markets, Scotia Capital (USA) Inc., SunTrust Robinson Humphrey, Inc. and Union Bank, N.A., as Co-Documentation Agents, Bank of America, N.A., as Syndication Agent, JPMorgan Chase Bank, N.A., as Administrative Agent and Collateral Agent, and J.P. Morgan Securities LLC, Banc of America Securities LLC, Credit Suisse Securities (USA) LLC, Barclays Capital, Goldman Sachs Bank USA and Wells Fargo Securities, LLC, as Joint Lead Arrangers and Joint Bookrunners.(46)**
- 10.67 Perfection Certificate executed as of October 20, 2010 and delivered in connection with the closing of the Credit Agreement filed as Exhibit 10.66.(46)**
- 10.68 Corporate Integrity Agreement between the Office of Inspector General of the Department of Health and Human Services and Gambro Healthcare, Inc. effective as of December 1, 2004.(11)
- 10.69 Amended and Restated Alliance and Product Supply Agreement, dated as of August 25, 2006, among Gambro Renal Products, Inc., DaVita Inc. and Gambro AB.(17)**

10.70	Letter dated March 19, 2007 from Willard W. Brittain, Jr. to Peter T. Grauer, Lead Independent Director of the Company.(22)
10.71	Dialysis Organization Agreement between DaVita Inc. and Amgen USA Inc. dated December 20, 2007.(31)**
10.72	Dialysis Organization Agreement between DaVita Inc. and Amgen USA Inc. dated December 17, 2010.(41)**
10.73	DaVita Inc. 2011 Incentive Award Plan.(43)*
10.74	Amendment No. 2 to Dialysis Organization Agreement between DaVita Inc. and Amgen USA Inc. effective as of July 1, 2011.(45)**
10.75	Sourcing and Supply Agreement between DaVita Inc. and Amgen USA Inc. effective as of January 1, 2012.✓**
12.1	Computation of Ratio of Earnings to Fixed Charges.✓
14.1	DaVita Inc. Corporate Governance Code of Ethics.(8)
21.1	List of our subsidiaries.✓
23.1	Consent of KPMG LLP, independent registered public accounting firm.✓
24.1	Powers of Attorney with respect to DaVita. (Included on Page II-1).
31.1	Certification of the Chief Executive Officer, dated February 24, 2012, pursuant to Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.✓
31.2	Certification of the Chief Financial Officer, dated February 24, 2012, pursuant to Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.✓
32.1	Certification of the Chief Executive Officer, dated February 24, 2012, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.✓
32.2	Certification of the Chief Financial Officer, dated February 24, 2012, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.✓
101.INS	XBRL Instance Document.
101.SCH	XBRL Taxonomy Extension Schema Document.
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.

✓ Included in this filing.

* Management contract or executive compensation plan or arrangement.

** Portions of this exhibit are subject to a request for confidential treatment and have been redacted and filed separately with the SEC.

- (1) Filed on March 18, 1996 as an exhibit to the Company' s Transitional Report on Form 10-K for the transition period from June 1, 1995 to December 31, 1995.
- (2) Filed on March 31, 1998 as an exhibit to the Company' s Annual Report on Form 10-K for the year ended December 31, 1997.
- (3) Filed on March 25, 2005 as an exhibit to the Company' s Current Report on Form 8-K.
- (4) Filed on March 20, 2001 as an exhibit to the Company' s Annual Report on Form 10-K for the year ended December 31, 2000.

-
- (5) Filed on February 28, 2003 as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 2002.
 - (6) Filed on August 15, 2001 as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2001.
 - (7) Filed on November 8, 2004 as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2004.
 - (8) Filed on February 27, 2004 as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 2003.
 - (9) Filed on December 8, 2004 as an exhibit to the Company's Current Report on Form 8-K.
 - (10) Filed on May 4, 2005 as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2005.
 - (11) Filed on November 8, 2005 as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2005.
 - (12) Filed on October 11, 2005 as an exhibit to the Company's Current Report on Form 8-K.
 - (13) Filed on November 4, 2005 as an exhibit to the Company's Current Report on Form 8-K.
 - (14) Filed on March 3, 2005 as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 2004.
 - (15) Filed on August 7, 2006 as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ending June 30, 2006.
 - (16) Filed on July 6, 2006 as an exhibit to the Company's Current Report on Form 8-K.
 - (17) Filed on November 3, 2006 as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2006.
 - (18) Filed on October 18, 2006 as an exhibit to the Company's Current Report on Form 8-K.
 - (19) Filed on July 31, 2006 as an exhibit to the Company's Current Report on Form 8-K.
 - (20) Filed on December 20, 2006 as an exhibit to the Company's Current Report on Form 8-K.
 - (21) Filed on November 19, 2002 as an exhibit to the Company's Current Report on Form 8-K.
 - (22) Filed on May 3, 2007 as an exhibit to the Company's Quarterly Report as Form 10-Q for the quarter ended March 31, 2007.
 - (23) Filed on August 6, 2007 as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007.
 - (24) Filed on February 16, 2007 as an exhibit to the Company's Current Report on Form 8-K.
 - (25) Filed on March 17, 2011 as an exhibit to the Company's Current Report on Form 8-K/A.
 - (26) Filed on February 28, 2007 as an exhibit to the Company's Current Report on Form 8-K.
 - (27) Filed on June 4, 2007 as an exhibit to the Company's Current Report on Form 8-K.
 - (28) Filed on May 8, 2008 as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2008.
 - (29) Filed on July 31, 2008 as an exhibit to the Company's Current Report on Form 8-K.
 - (30) Filed on November 6, 2008 as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2008.
 - (31) Filed on February 29, 2008 as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 2007.
 - (32) Filed on February 27, 2009 as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 2008
 - (33) Filed on May 7, 2009 as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2009.
 - (34) Filed on June 18, 2009 as an exhibit to the Company's Current Report on Form 8-K.
 - (35) Filed on April 14, 2010 as an exhibit to the Company's Current Report on Form 8-K.
 - (36) Filed on May 3, 2010 as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2010.
 - (37) Filed on April 28, 2010 as Appendix A to the Company's Definitive Proxy Statement on Schedule 14A.
 - (38) Filed on October 19, 2010 as an exhibit to the Company's Current Report on Form 8-K.
 - (39) Filed on October 21, 2010 as an exhibit to the Company's Current Report on Form 8-K.

-
- (40) Filed on February 25, 2010 as an exhibit to the Company' s Annual Report on Form 10-K for the year ended December 31, 2009.
 - (41) Filed on December 29, 2011 as an exhibit to the Company' s Annual Report on Form 10-K/A for the year ended December 31, 2010.
 - (42) Filed on May 6, 2011 as an exhibit to the Company' s Quarterly Report on Form 10-Q for the quarter ended March 31, 2011.
 - (43) Filed on April 27, 2011 as Appendix A to the Company' s Definitive Proxy Statement on Schedule 14A.
 - (44) Filed on August 4, 2011 as an exhibit to the Company' s Quarterly Report on Form 10-Q for the quarter ended June 30, 2011.
 - (45) Filed on December 29, 2011 as an exhibit to the Company' s Quarterly Report on Form 10-Q/A for the quarter ended June 30, 2011.
 - (46) Filed on January 17, 2012 as an exhibit to the Company' s Quarterly Report on Form 10-Q/A for the quarter ended March 31, 2011.
 - (47) Filed on February 10, 2011 as an exhibit to the Company' s Current Report on Form 8-K.

SOURCING AND SUPPLY AGREEMENT

This Sourcing and Supply Agreement (this “Agreement”) is made by and between Amgen USA Inc. (“Amgen”), a wholly-owned subsidiary of Amgen Inc., and DaVita Inc. (“Dialysis Center”) to set forth the terms and conditions upon which Dialysis Center Purchasers shall purchase EPOGEN® (Epoetin alfa) and Amgen shall provide discounts and pay rebates to Dialysis Center on EPOGEN. Each of Amgen and Dialysis Center are referred to herein as a “Party” and together as the “Parties”. Amgen Inc. is a party to this Agreement for the purposes set forth in Sections 3.1, 8.2, 9.4, 9.5.1, and 11.14 of this Agreement. Capitalized terms used herein and not otherwise defined herein shall have the meaning set forth in Section 1.

RECITALS

WHEREAS, Amgen is a leading innovator in the field of ESAs with expertise in the field of anemia management and the ability to manufacture and supply safe and efficacious ESAs for the treatment of dialysis patients;

WHEREAS, Dialysis Center is a leading provider of dialysis services in the Territory with expertise in establishing and delivering state-of-the-art, quality-of-care standards, practices and procedures for the care of patients undergoing dialysis;

WHEREAS, Dialysis Center desires to select one ESA supplier to meet its primary ESA needs on a long term basis for patients undergoing dialysis;

WHEREAS, Dialysis Center has evaluated the ESAs available for commercial use and those in clinical development, including potential [DELETED] ESAs, and has determined that EPOGEN® (Epoetin alfa) will be its preferred ESA for managing anemia for patients undergoing dialysis;

WHEREAS, the Parties wish to enter into this Agreement to, among other things, provide for Dialysis Center’s selection of Amgen as the Dialysis Center Purchasers’ supplier of EPOGEN to meet the Dialysis Center Purchasers’ requirements for EPOGEN for the treatment of dialysis patients during the Term, on all of the terms provided herein;

WHEREAS, Dialysis Center seeks stable, predictable and competitive pricing over a seven year period, which it can achieve through the discounts, rebates and other price concessions set forth herein;

WHEREAS, in order to provide Dialysis Center with such pricing over a seven year period, Amgen will make substantial long-term investments and forego other potential opportunities to scale and schedule its manufacturing capacity and supply of EPOGEN for Dialysis Center Purchasers in accordance with Dialysis Center Purchasers’ anticipated demand for EPOGEN for use in the Territory as provided under this Agreement;

NOW THEREFORE, in consideration of the foregoing recitals and of the mutual promises and covenants set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, each Party hereby agrees as follows:

1. DEFINITIONS

When used with initial capitals herein, the following terms shall have the meaning ascribed to them below:

- 1.1. “Actual Supply Shortfall” has the meaning set forth in Section 2.5.

[DELETED] = Portions of this exhibit are subject to a request for confidential treatment and have been redacted and filed separately with the Securities and Exchange Commission.

-
- 1.2. “Added Dialysis Center Purchaser” has the meaning set forth in Section 2.8.2.
- 1.3. “Added Dialysis Center Purchaser Effective Date” has the meaning set forth in Section 2.8.2.
- 1.4. “Added Dialysis Center Purchaser Transaction Date” means with respect to each Added Dialysis Center Purchaser: (a) in the case of a new Dialysis Center Affiliate, the effective date of the acquisition or establishment of the new Dialysis Center Affiliate; or (b) in the case of a new Managed Center, the earlier of (i) the effective date of the contract pursuant to which a dialysis facility becomes a Managed Center or (ii) the date Dialysis Center first provides services to a dialysis facility that results in such facility becoming a Managed Center, in each case after the Term Start Date.
- 1.5. “Administrator” has the meaning set forth in Section 9.2.1.
- 1.6. “Affiliate” of a given entity shall mean an entity that controls, is controlled by, or under common control with such given entity. Control shall mean ownership of more than fifty percent (50%) of the voting stock of an entity or, for non-stock entities, the right to more than fifty percent (50%) of the profits of such entity.
- 1.7. “[DELETED]” has the meaning set forth in Section 2.5.1.
- 1.8. “Alternative ESA” means an ESA that is available for use in the Territory that is not EPOGEN or Aranesp.
- 1.9. “Alternative ESA Purchase Amount” has the meaning set forth in Section 2.1.1.
- 1.10. “Alternative ESA Purchase Event” has the meaning set forth in Section 2.1.1.
- 1.11. “Alternative ESA Purchase Event Share of Sales” shall be calculated as follows
- [DELETED]
- A = Committed Unit Purchases of Amgen ESAs during the [DELETED] which an Alternative ESA Purchase Event has occurred
- B = Committed Unit Purchases of Amgen ESAs during the [DELETED] which such Alternative ESA Purchase Event has occurred
- C = Committed Unit Purchases of Alternative ESAs during the [DELETED] which an Alternative ESA Purchase Event has occurred
- D = Committed Unit Purchases of Alternative ESAs during the [DELETED] which such Alternative ESA Purchase Event has occurred
- 1.12. “Amgen Business Representative” has the meaning set forth in Section 4.1.
- 1.13. “[DELETED]” means [DELETED] for use with patients receiving Dialysis Services, which [DELETED] is the subject of a written agreement between the Parties or their Affiliates.
- 1.14. “Amgen ESA Risk Evaluation Program” has the meaning set forth in Section 11.18.
- 1.15. “Amgen ESAs Share of Sales” shall mean Committed [DELETED] Purchases of Amgen ESAs during the Quarter divided by the sum of Committed [DELETED] Purchases of Amgen ESAs and Committed [DELETED] Purchases of Alternative ESAs during the Quarter.

Amgen ESAs Share of Sales Illustration:

Committed [DELETED] Purchases of Amgen ESAs

÷

Committed [DELETED] Purchases of Amgen ESAs + Committed [DELETED] Purchases
of Alternative ESAs

- 1.16. “Amgen Indemnitees” has the meaning set forth in Section 9.5.2.
- 1.17. “Appeal Procedures” has the meaning set forth in Section 9.2.3.
- 1.18. “Aranesp” means Amgen’s proprietary darbepoetin alfa product that is marketed by Amgen in the Territory under the trademark Aranesp®.
- 1.19. “Arbitrator” has the meaning set forth in Section 9.2.1.
- 1.20. “Authorized Removal Occurrence” has the meaning set forth in Section 2.8.3.
- 1.21. “Authorized Wholesalers” shall mean those wholesalers listed on Exhibit B, as such list may be modified pursuant to Section 2.7.
- 1.22. “Authorized Wholesaler List” has the meaning set forth in Section 2.7.
- 1.23. “Available EPOGEN SKUs” have the meaning set forth in Section 2.4.5.
- 1.24. “Award” has the meaning set forth in Section 9.2.3.
- 1.25. “Base Invoice Discount” means the base invoice discount described in Section 2.1 of Exhibit A.
- 1.26. “Base Rate Rebate” means the base rebate described in Section 3.1 of Exhibit A.
- 1.27. “Baseline [DELETED]” has the meaning set forth in Section 2.1.2.
- 1.28. “[DELETED] Rebate” means the [DELETED] rebate described in Section 3.2 of Exhibit A.
- 1.29. “Best Price” has the meaning set forth in Section 3.6.
- 1.30. “[DELETED] Rebate” means the [DELETED] rebate described in Section 3.3 of Exhibit A.
- 1.31. “Business Representatives” has the meaning set forth in Section 4.1.
- 1.32. “Certification” has the meaning set forth in Section 5.2.
- 1.33. “Committed [DELETED] Purchases of Amgen ESAs” means, for any period, the aggregate amounts in [DELETED] of EPOGEN and Aranesp purchased by all Dialysis Center Committed Purchasers during such period for use in providing Dialysis Services, net of product returns and adjustments, which aggregate [DELETED] data have been independently confirmed by Amgen through the Relevant Information.
- 1.34. “Committed [DELETED] Purchases of Alternative ESAs” means, for any period, the aggregate amounts in [DELETED] of all Alternative ESAs purchased by all Dialysis Center Committed Purchasers from any source during such period for use in providing Dialysis Services, (provided that any Alternative ESA provided to a Dialysis Center Committed Purchaser at no or nominal cost from any source shall be considered a purchase), adjusted to be an equivalent [DELETED] of EPOGEN (in [DELETED]) based on the [DELETED] (if the [DELETED] is clearly set forth therein) or otherwise as reasonably determined pursuant to Section 2.1.2, and which aggregate [DELETED] data have been independently confirmed by Amgen through the Relevant Information.

-
- 1.35. “Compensation Data” has the meaning set forth in Section 6.1.
- 1.36. “Confidential Information” has the meaning set forth in Section 11.14.
- 1.37. “Data” means the data set forth on Schedule 1 provided by Dialysis Center to Amgen pursuant to the terms and conditions of Section 5 and Exhibit A.
- 1.38. “Debarred Party” has the meaning set forth in Section 10.2.3.
- 1.39. “Designated Affiliates” shall mean any Affiliate of Dialysis Center listed on Exhibit C, as such list may be modified pursuant to Section 2.8.1.
- 1.40. “Designated Affiliates List” has the meaning set forth in Section 2.8.1.
- 1.41. “Dialysis Center Business Representative” has the meaning set forth in Section 4.1.
- 1.42. “Dialysis Center Committed Purchasers” has the meaning set forth in Section 2.8.5.
- 1.43. “Dialysis Center Committed Purchasers List” has the meaning set forth in Section 2.8.5.
- 1.44. “Dialysis Center Indemnitees” has the meaning set forth in Section 9.5.1.
- 1.45. “Dialysis Center Purchasers” shall mean Dialysis Center, the Designated Affiliates, and the Managed Centers. Dialysis Center Purchasers include Added Dialysis Center Purchasers from and after the Added Dialysis Center Purchaser Effective Date.
- 1.46. “Dialysis Services” means services related to the treatment of patients receiving renal dialysis, including hemodialysis, peritoneal dialysis, nocturnal dialysis, and home hemodialysis in the Territory during the Term.
- 1.47. “Disclosing Party” has the meaning set forth in Section 11.14.
- 1.48. “Discounts” means all rebates and discounts set forth on Exhibit A that may be earned by the Dialysis Center Purchasers pursuant to the terms and conditions set forth in this Agreement, which shall be earned, calculated and vested as provided in Exhibit A.
- 1.49. “Disputes” has the meaning set forth in Section 9.1.
- 1.50. “[DELETED]” has the meaning set forth in Section 2.1.2.
- 1.51. “EPOGEN” means Amgen’s proprietary epoetin alfa product that is marketed by Amgen in the Territory under the trademark EPOGEN®.
- 1.52. “EPOGEN Equivalent Quantity” has the meaning set forth in Section 2.1.1.
- 1.53. “ESAs” shall mean agents that stimulate erythropoiesis.
- 1.54. “FDA” has the meaning set forth in Section 8.3.
- 1.55. “FDA Website” has the meaning set forth in Section 11.18.
- 1.56. “Firm” has the meaning set forth in Section 3.2.
- 1.57. “Forecast Shortfall” has the meaning set forth in Section 2.4.2.
- 1.58. “Forecast Shortfall Amount” has the meaning set forth in Section 2.4.2.
- 1.59. “Force Majeure Event” has the meaning set forth in Section 11.8.
- 1.60. “Governmental Authority” shall mean in respect of any individual or entity, any government administrative agency, commission or other governmental authority, body or instrumentality, or any federal, state, or local governmental regulatory body having legal jurisdiction over that individual or entity.

-
- 1.61. “Gross Purchases of Amgen ESAs” means, for any period, the aggregate gross amounts paid for purchases of EPOGEN and Aranesp by all Dialysis Center Purchasers during such period for use in providing Dialysis Services, calculated by using [DELETED] in effect on each date of purchase, net of product returns and adjustments, which aggregate sales data have been independently confirmed by Amgen through the Relevant Information.
- 1.62. “Hearing” has the meaning set forth in Section 9.2.3.
- 1.63. “HIPAA” shall mean the Health Insurance Portability and Accountability Act of 1996 and its implementing regulations, each as may be amended.
- 1.64. “IMS” means IMS Health Incorporated, a Delaware corporation and its Affiliates.
- 1.65. “Indemnified Party” has the meaning set forth in Section 9.6.1.
- 1.66. “Indemnifying Party” has the meaning set forth in Section 9.6.1.
- 1.67. “Individually Identifiable Health Information” shall have the meaning specified in HIPAA.
- 1.68. “Initial [DELETED]” has the meaning set forth in Section 2.1.2.
- 1.69. “[DELETED]” means an [DELETED] for EPOGEN, Aranesp or an Alternative ESA, as applicable, based on its measured biological activity or effect.
- 1.70. “Joint Project” has the meaning set forth in Section 7.1.
- 1.71. “Joint Project Committee” has the meaning set forth in Section 7.1.
- 1.72. “Law” means, individually and collectively, any and all applicable laws, ordinances, rules, regulations, directives, administrative circulars, guidances and other pronouncements having the effect of law of any Governmental Authority.
- 1.73. “Liquidated Damages” has the meaning set forth in Section 10.3.
- 1.74. “Managed Center” shall mean a dialysis facility that is not an Affiliate of Dialysis Center but for which Dialysis Center or an Affiliate of Dialysis Center provides management services or administrative services in which it controls the selection or procurement of ESAs.
- 1.75. “Managed Centers List” has the meaning set forth in Section 2.8.1.
- 1.76. “Material Label Change” means a material amendment, change, revision, and/or modification to the Chronic Kidney Disease section of the Boxed Warning of the US prescribing information for EPOGEN as it relates to dialysis use.
- 1.77. “Minimum Forecast Commitment” has the meaning set forth in Section 2.4.2.
- 1.78. “[DELETED] Rebate” means the [DELETED] rebate described in Section 3.4 of Exhibit A.
- 1.79. “Non-Disclosing Party” has the meaning set forth in Section 11.14.
- 1.80. “Notice of Added Dialysis Center Purchaser” has the meaning set forth in Section 2.8.2.
- 1.81. “Objection Notice” has the meaning set forth in Section 3.2.
- 1.82. “Other Agreement(s)” has the meaning set forth in Section 2.2.
- 1.83. “Other Agreement Early Termination Date” has the meaning set forth in Section 2.2.
- 1.84. “Party” and “Parties” have the meaning set forth in the preamble hereto.
- 1.85. “[DELETED]” has the meaning set forth in Section 5.5.

-
- 1.86. “Permitted Percentage Variances” has the meaning set forth in Section 2.4.3.
- 1.87. “Permitted Variance Period” has the meaning set forth in Section 2.4.3.
- 1.88. “Policies and Procedures” has the meaning set forth in Section 2.8.6.
- 1.89. “Project Plan” has the meaning set forth in Section 7.1.
- 1.90. “Project Proposal” has the meaning set forth in Section 7.1.
- 1.91. “Purchase Commitment” has the meaning set forth in Section 2.1.
- 1.92. “Qualified Gross Purchases of EPOGEN” shall mean the amount of EPOGEN purchased by Dialysis Center Purchasers during the Term from an Authorized Wholesaler (or from Amgen pursuant to Section 2.7) for use in providing Dialysis Services, and confirmed by Amgen through sales tracking data. Qualified Gross Purchases of EPOGEN shall be calculated using the [DELETED] in effect at the time of the relevant purchase, net of product returns and adjustments.
- 1.93. “Quarter” shall mean each calendar quarter during the Term (*i.e.*, January 1 through March 31, April 1 through June 30, July 1 through September 30, and/or October 1 through December 31, as applicable).
- 1.94. “Recall” has the meaning set forth in Section 11.19.
- 1.95. “Relevant Information” means the Data, all sales tracking data, Self-Reported Purchase Data, Compensation Data and other relevant information, including relevant Third Party reporting agency data.
- 1.96. “Research Study” has the meaning set forth in Section 5.5.
- 1.97. “Rolling Forecast” has the meaning set forth in Section 2.4.1.
- 1.98. “Rolling Forecasts” has the meaning set forth in Section 2.4.1.
- 1.99. “Rules” has the meaning set forth in Section 9.2.1.
- 1.100. “Self-Reported Purchase Data” means all [DELETED] purchased of each ESA and the number of patients who received each such ESA from Dialysis Center Purchasers and such other related data as may be specified on Exhibit SR-1.
- 1.101. “[DELETED]” has the meaning set forth in Section 5.5.
- 1.102. “Supply Commitment” has the meaning set forth in Section 2.1.
- 1.103. “Supply Shortfall” has the meaning set forth in Section 2.5.
- 1.104. “Supply Shortfall Notice” has the meaning set forth in Section 2.5.
- 1.105. “Supply Shortfall Quarter” has the meaning set forth in Section 2.5.
- 1.106. “Term” means the period commencing on the Term Start Date and ending on the Term End Date.
- 1.107. “Term End Date” shall mean December 31, 2018.
- 1.108. “Term Start Date” shall mean January 1, 2012.
- 1.109. “Termination Date” means the date upon which this Agreement shall have been terminated in accordance with the terms and conditions of this Agreement pursuant to Section 10.2.
- 1.110. “Territory” means the United States, and its territories and possessions, including Puerto Rico.

-
- 1.111. “Third Party” means any individual or entity other than a Party or an Affiliate of a Party (or, in the case of Dialysis Center, a Managed Center).
- 1.112. “Third Party Claim(s)” has the meaning set forth in Section 9.5.1.
- 1.113. “[DELETED]” shall mean the [DELETED] for EPOGEN to [DELETED] as established by [DELETED] in its [DELETED] from time to time, not including prompt pay or other discounts, rebates, or reductions in [DELETED].

2. **PURCHASE AND SUPPLY COMMITMENTS**

- 2.1. Purchase and Supply Commitments. Subject to the terms and conditions of this Agreement, (i) the Dialysis Center Committed Purchasers shall purchase from Amgen through one or more Authorized Wholesalers those quantities of EPOGEN that are needed to meet an Amgen ESAs Share of Sales of at least ninety percent (90%) during each Quarter of the Term (the “Purchase Commitment”), and (ii) Amgen shall ensure that during each Quarter of the Term [DELETED] percent ([DELETED]%) of the [DELETED] for each such Quarter is available for purchase by the Dialysis Center Purchasers from one or more Authorized Wholesalers (the “Supply Commitment”). Subject to Section 2.3.2 and Section 2.3.3, Amgen acknowledges and agrees that nothing in this Agreement shall prohibit any Dialysis Center Committed Purchaser from purchasing an amount of EPOGEN necessary to satisfy the Purchase Commitment in a particular Quarter regardless of whether such EPOGEN was actually administered by the Dialysis Center Committed Purchasers to their patients for the provision of Dialysis Services during such Quarter.
- 2.1.1. *Alternative ESA Purchases*. If in any Quarter the Dialysis Center Committed Purchasers do not meet the Purchase Commitment (an “Alternative ESA Purchase Event”), then Dialysis Center shall (i) within thirty (30) days of the end of any such applicable Quarter provide notice to Amgen of such Alternative ESA Purchase Event, including the Committed [DELETED] Purchases of Alternative ESAs in such Quarter and (ii) within thirty (30) days of the end of the Quarter immediately following the Quarter in which the Alternative ESA Purchase Event occurred, the Committed [DELETED] Purchases of Alternative ESAs in such subsequent Quarter. If Dialysis Center provides such notice pursuant to this Section 2.1.1, or if Amgen, in its sole discretion, through the use of Relevant Information determines that there has been an Alternative ESA Purchase Event, then Amgen shall have the right to deliver to Dialysis Center a notice that sets forth the “EPOGEN Equivalent Quantity,” which shall be that quantity of EPOGEN (in [DELETED]) [DELETED] but for the Alternative ESA Purchase Event (based on the [DELETED] (if the [DELETED] is clearly set forth therein), or otherwise as reasonably determined by Amgen through the Relevant Information as set forth in Section 2.1.2). In the event the Alternative ESA Purchase Event Share of Sales is equal to or greater than ninety percent (90%), then Dialysis Center shall be deemed to have met the Purchase Commitment for the Quarter in which the Alternative ESA Purchase Event occurred. If the Alternative ESA Purchase Event Share of Sales is less than ninety percent (90%) for any reason, including a Force Majeure Event related to Dialysis Center and/or the Dialysis Center Purchasers, and not the result of a Supply Shortfall, then Amgen shall deliver to Dialysis Center a notice, and Dialysis Center shall pay to Amgen within thirty (30) days of its receipt of such notice, an amount (the “Alternative ESA Purchase Amount”) indicated by Amgen (as determined by Amgen based on the Relevant Information) in such notice equal to (a) the EPOGEN Equivalent Quantity multiplied by (b) [DELETED] of EPOGEN earned by the Dialysis Center Committed Purchasers during such

Quarter. At Amgen's option, any Alternative ESA Purchase Amount may be offset in whole or in part against any Discounts earned by the Dialysis Center Purchasers on Qualified Gross Purchases of EPOGEN in the applicable Quarter or any subsequent Quarter.

2.1.2. If a Party, in its reasonable discretion, feels that the Dialysis Center Committed Purchasers potentially may not meet the Purchase Commitment due to purchases of Alternative ESAs by the Dialysis Center Committed Purchasers in a Quarter, then Amgen shall in consultation with Dialysis Center determine the appropriate methodology to be used to determine the [DELETED] (in [DELETED]) of an Alternative ESA that was used by the Dialysis Center Committed Purchasers patients' during the applicable measurement period that is equivalent to a [DELETED] (in [DELETED]) of EPOGEN that was used by the Dialysis Center Committed Purchasers patients' during the applicable measurement period (the "[DELETED]") and Dialysis Center shall reasonably cooperate with Amgen and provide any other reasonable data, including [DELETED] of ESAs utilized during the applicable measurement period, necessary to complete the determination. If Dialysis Center has a reasonable objection to the methodology proposed by Amgen, the Parties shall appoint a mutually agreeable Third Party to determine the methodology to be used with the costs of such Third Party to be borne equally by the Parties. The initial [DELETED] for any particular Alternative ESA as determined by either the Parties or the Third Party appointed by the Parties, as applicable, pursuant to this Section 2.1.2 (the "Initial [DELETED]") shall only apply to the Quarter immediately preceding the Initial [DELETED]. The determination of the [DELETED] for each particular Alternative ESA shall be recalculated for each of the first [DELETED] after the Initial [DELETED] for such Alternative ESA and the calculation of the [DELETED] for such Alternative ESA after each Quarter during such [DELETED] period shall only apply to the immediately preceding Quarter after each such recalculation. The [DELETED] for a particular Alternative ESA for all periods after such [DELETED] period shall be the [DELETED] determined as of the end of the [DELETED] Quarter after the Initial [DELETED] for such Alternative ESA (the "Baseline [DELETED]"); provided, either Party may, no more frequently than once per calendar year, request a recalculation of the Baseline [DELETED], which recalculation shall be applied prospectively, if such Party reasonably believes that the Baseline [DELETED] has materially changed over time, in which event the requesting Party shall bear the costs of any Third Party appointed by the Parties in connection therewith.

2.2. Purchase Commitment Transition Period for Added Dialysis Center Purchasers. If, after the Term Start Date, there is a new Added Dialysis Center Purchaser pursuant to Section 2.8.2, that is a Dialysis Center Committed Purchaser, Dialysis Center shall use its commercially reasonable efforts to cause such Added Dialysis Center Purchaser to meet the Purchase Commitment as soon as practicable, but such Added Dialysis Center Purchaser shall not be obligated to meet the Purchase Commitment until [DELETED] days after the Added Dialysis Center Purchaser Effective Date. If, as of the Added Dialysis Center Purchaser Effective Date regarding an Added Dialysis Center Purchaser, such Added Dialysis Center Purchaser was a party to a written agreement with a Third Party which includes an obligation on the part of such Added Dialysis Center Purchaser to exclusively purchase an Alternative ESA to meet a majority of its ESA requirements for the provision of Dialysis Services in the Territory (an "Other Agreement(s)") and Dialysis Center can demonstrate via reasonable evidence to Amgen that such Other Agreement was entered into by such Added Dialysis Center Purchaser at least

[DELETED] days prior to the Added Dialysis Center Purchaser Transaction Date, then such Added Dialysis Center Purchaser shall not be subject to the Purchase Commitment until [DELETED] days after such time that such Other Agreement(s) can be terminated and/or amended to terminate such obligation with respect to the Alternative ESAs without such Added Dialysis Center Purchaser and/or Dialysis Center and/or any of its Affiliates paying any damages and/or other amounts to such Third Party (the “Other Agreement Early Termination Date”); provided that Dialysis Center shall use its best efforts to terminate such Other Agreement as soon Dialysis Center can do so without such Added Dialysis Center Purchaser and/or Dialysis Center and/or any of its Affiliates paying any damages and/or other amounts to such Third Party. Amgen shall not be obligated to meet the Supply Commitment for any Added Dialysis Center Purchaser until the expiration of the [DELETED] day period after the Added Dialysis Center Purchaser Effective Date or, in the case of an Added Dialysis Center Purchaser that is a party to an Other Agreement, [DELETED] days after the Other Agreement Early Termination Date.

2.3. Eligible Purchases.

- 2.3.1. Purchases from Authorized Wholesaler. Only purchases of EPOGEN made by a Dialysis Center Purchaser from an Authorized Wholesaler shall be eligible to receive the Discounts provided under this Agreement.
- 2.3.2. Own Use. The Dialysis Center Purchasers shall purchase EPOGEN under this Agreement solely for their own use in providing Dialysis Services, and only purchases made by Dialysis Center Purchasers for such use shall be eligible for the Discounts provided under this Agreement and shall be considered Committed [DELETED] Purchases of Amgen ESAs. Dialysis Center on behalf of itself and each other Dialysis Center Purchaser covenants that none of them shall seek to procure any of the Discounts available under this Agreement for any purchases of EPOGEN not for its or their use in providing Dialysis Services, and Dialysis Center shall promptly notify Amgen in the event Amgen shall have provided any Dialysis Center Purchaser with any Discounts hereunder for any EPOGEN that was not used by them for the provision of Dialysis Services.
- 2.3.3. Maximum Quarterly Purchase Increases. Notwithstanding any other provision of this Agreement, no Discounts earned by Dialysis Center shall apply to Qualified Gross Purchases of EPOGEN for any Quarter that exceed [DELETED] percent ([DELETED]%) of the Qualified Gross Purchases of EPOGEN in the immediately preceding Quarter unless Amgen, in its sole discretion, determines that such increase is necessary for Dialysis Center to meet its Purchase Commitment for any such Quarter. Such calculation shall be adjusted to remove from the calculation the effect of any change in [DELETED], or increases/decreases in the number of Dialysis Center Purchasers during the relevant comparison periods.

2.4. Quantity Forecasts and Minimum Forecast Commitment.

- 2.4.1. Rolling Forecast. Each Quarter during the Term, Dialysis Center shall submit in writing to Amgen a rolling [DELETED] month forecast setting forth on a month-by-month basis the aggregate quantities in [DELETED] of EPOGEN by Available EPOGEN SKU that Dialysis Center has determined in good faith are required for all Dialysis Center Purchasers for each month in the forecast period, starting with an initial [DELETED] month forecast beginning as of [DELETED] which shall be delivered to Amgen by [DELETED] (each, a “Rolling Forecast” and collectively the “Rolling Forecasts”). With the exception of the initial Rolling Forecast, Dialysis Center shall submit each Rolling Forecast by no later than the

[DELETED] of the [DELETED] of each Quarter during the Term (e.g., by [DELETED] Dialysis Center shall submit a Rolling Forecast for the [DELETED] month period from [DELETED] through [DELETED]). The Rolling Forecasts shall not reflect any EPOGEN requirements for periods after the Term End Date. If Dialysis Center has not timely delivered a Rolling Forecast as provided above, the Rolling Forecast previously in effect shall remain in effect for the periods covered thereby. The purpose of this [Section 2.4.1](#) is to allow Amgen adequate time to adjust its manufacturing planning and operations to properly reflect the anticipated mix of Available EPOGEN SKUs.

2.4.2. *Minimum Forecast Commitment.* Without reducing or limiting the Purchase Commitment set forth in [Section 2.1](#), the forecasted quantities of each Available EPOGEN SKU for months [DELETED] of each Rolling Forecast shall constitute the Dialysis Center Purchasers' aggregate minimum purchase commitment of [DELETED] of EPOGEN by Available EPOGEN SKU (the "[Minimum Forecast Commitment](#)"). If the Dialysis Center Purchasers purchase an aggregate quantity in [DELETED] of EPOGEN by Available EPOGEN SKU during any Quarter that is less than the Minimum Forecast Commitment for any such Quarter (the quantity of any such difference, the "[Forecast Shortfall](#)"), then Amgen shall notify Dialysis Center of the Forecast Shortfall in writing. If the Dialysis Center Purchasers purchase a quantity in [DELETED] of EPOGEN by Available EPOGEN SKU during the Quarter in which the Forecast Shortfall occurred and the immediately following Quarter in the aggregate that is less than the aggregate Minimum Forecast Commitments for such two Quarters, Amgen shall notify Dialysis Centers of such failure in writing, and within thirty (30) days of Dialysis Center's receipt of such notice, it shall pay to Amgen an amount equal to [DELETED] percent ([DELETED]%) of (i) the Forecast Shortfall for the applicable Quarter multiplied by (ii) [DELETED] less the Discounts per [DELETED] of EPOGEN for each Available EPOGEN SKU earned by the Dialysis Center Purchasers during such Quarter (the "[Forecast Shortfall Amount](#)"). At Amgen's option, any Forecast Shortfall Amount may be offset in whole or in part against any Discounts earned by the Dialysis Center Purchasers on purchases of EPOGEN in the applicable Quarter or any subsequent Quarter.

2.4.3. *Forecast Variance.* Each Rolling Forecast provided by Dialysis Center may [DELETED] quantities of each Available EPOGEN SKU only for new months [DELETED] and may [DELETED] quantities of each Available EPOGEN SKU in the new months [DELETED] from the corresponding months in the immediately prior Rolling Forecast by the "[Permitted Percentage Variances](#)" in the table below. The Permitted Percentage Variances for the months of each Rolling Forecast (the "[Permitted Variance Period](#)") are as follows:

Months	[DELETED]	[DELETED]	[DELETED]	[DELETED]	[DELETED]
Permitted Percentage Variance	[DELETED]%	[DELETED]%	[DELETED]%	[DELETED]%	[DELETED]%

If Dialysis Center submits a Rolling Forecast that contains a forecast for any month therein that is not in compliance with this [Section 2.4.3](#), Amgen shall have the right, in its sole discretion, to either (a) accept such forecast for any month

therein that is not in compliance with this Section; or (b) adjust such non-compliant forecasted quantity for any such month to increase or decrease the amount forecasted for such month by up to the minimum amount necessary to bring such forecasted quantity into compliance with this Section 2.4.3. Dialysis Center may, at any time for any good faith reason, request additional variances to the Permitted Percentage Variances and, in such event, the Parties shall work in good faith to accommodate such request; provided, however, that (i) in no event shall Amgen be liable for any resulting Supply Shortfall or Actual Supply Shortfall and (ii) Dialysis Center shall remain liable for any Forecast Shortfall that may occur. If in any Quarter during the Term, the Dialysis Center Purchasers have a Forecast Shortfall and the Parties have determined, after good faith discussions, that such Forecast Shortfall is the necessary result of a Material Label Change, then the Dialysis Center Purchasers shall not be liable for such Forecast Shortfall.

2.4.4. Good Faith Estimates. Each Rolling Forecast submitted by Dialysis Center shall represent good faith estimates of the Dialysis Center Purchasers' actual anticipated purchases of EPOGEN for the treatment of dialysis patients in the Territory and reasonable inventory requirements for EPOGEN in the Territory during the relevant timeframes.

2.4.5. Available EPOGEN SKUs. The Available EPOGEN SKU Schedule attached as Schedule 3 hereto sets forth the "Available EPOGEN SKUs" as of the Term Start Date. Amgen may add Available EPOGEN SKUs to, or remove Available EPOGEN SKUs (with respect to all purchasers of EPOGEN for free-standing dialysis clinics) from, the Available EPOGEN SKUs Schedule upon at least [DELETED] advance written notice to Dialysis Center; provided that Amgen may not remove any Available EPOGEN SKUs from the Available EPOGEN SKUs Schedule that accounted for [DELETED] percent ([DELETED]%) or more of the Qualified Gross Purchases of EPOGEN during the immediately preceding [DELETED] without the prior written consent of Dialysis Center, which consent may be withheld by Dialysis Center in its sole discretion, unless there is an Available EPOGEN SKU that corresponds to the same dosage, size and potency of the deleted Available EPOGEN SKU; and provided further that, notwithstanding the foregoing, Amgen may immediately remove any Available EPOGEN SKU should Amgen determine, in its sole discretion, that the removal of any such Available EPOGEN SKU is for safety or quality or similar reasons. The Parties shall mutually agree upon (a) the first period for which any such new Available EPOGEN SKU may be ordered by the Dialysis Center Purchasers and (b) any permitted adjustments to the EPOGEN SKU mix contained in Dialysis Center's then applicable Rolling Forecast to reflect any changes in the Available EPOGEN SKUs or as otherwise may be required due to any production shortfall applicable to all EPOGEN customers.

2.5. Supply Commitment Shortfalls. Dialysis Center shall promptly notify Amgen in writing (the "Supply Shortfall Notice") if a Dialysis Center Purchaser has not been able to purchase from the Authorized Wholesalers a quantity of EPOGEN in [DELETED] for any Available EPOGEN SKU that meets the Minimum Forecast Commitment for any Quarter for any reason, including as a result of a Force Majeure Event related to Amgen (a "Supply Shortfall Quarter"), setting forth in such notice the quantity of EPOGEN in [DELETED] by Available EPOGEN SKU representing such shortfall, including as a result of a Force Majeure Event related to Amgen (the "Supply Shortfall"). In the event of a

Supply Shortfall, Amgen shall not intentionally discriminate against any of the Dialysis Center Purchasers in its allocation of the available quantities of an Available EPOGEN SKU subject to such Supply Shortfall by making its allocation decisions, in whole or in part, on the basis of the prices, Discounts, and/or other financial terms offered to the Dialysis Center Purchasers pursuant to the terms and conditions of this Agreement. In no event shall the inability to obtain a particular Available EPOGEN SKU in a Minimum Forecast Commitment be deemed a Supply Shortfall, if a Dialysis Center Purchaser can purchase (i) the same quantity of EPOGEN in [DELETED] through other Available EPOGEN SKUs or (ii) Aranesp, other than with respect to use by physicians with privileges at a Dialysis Center Purchaser who have obtained approval through Dialysis Center's formulary exception process to use a "short-acting" Alternative ESA instead of Aranesp. If the Authorized Wholesalers are actually unable to supply the Dialysis Center Purchasers with a quantity of (i) EPOGEN or (ii) Aranesp equal to the Supply Shortfall within the time period reasonably required by the Dialysis Center Purchasers as set forth in the Supply Shortfall Notice, which in no event will be less than five (5) business days after Amgen's receipt of the applicable Supply Shortfall Notice, the Purchase Commitment shall be reduced by the quantity of any Supply Shortfall that actually occurs (the "Actual Supply Shortfall").

- 2.5.1. In the event of an Actual Supply Shortfall, Dialysis Center shall use good faith efforts to procure any Alternative ESAs from a Third Party at the [DELETED]. Dialysis Center shall deliver to Amgen a statement setting forth the aggregate [DELETED] (*i.e.*, the aggregate [DELETED] less all applicable discounts, rebates, chargebacks and other price adjustments) actually paid by the Dialysis Center Purchasers to any such Third Party for that quantity of Alternative ESAs purchased by such Dialysis Center Purchasers during the Supply Shortfall Quarter solely as a substitute for the Actual Supply Shortfall (the "[DELETED]"); provided that should Dialysis Center be subject to any confidentiality restrictions that Dialysis Center may have with any Third Party from which it procured Alternative ESAs, then the Parties agree to send such [DELETED] to the Firm to be verified. Amgen shall pay to Dialysis Center an amount of cash equal to the difference, if any, between (a) the [DELETED] and (b) the product of (i) (1) [DELETED] in effect for the Supply Shortfall Quarter less (2) the Discounts per [DELETED] of Available EPOGEN SKU earned by the Dialysis Center Purchasers in such Supply Shortfall Quarter multiplied by (ii) the Actual Supply Shortfall. Amgen shall also pay to Dialysis Center any incremental difference in the aggregate [DELETED] of Aranesp purchased by Dialysis Center Purchasers as a result of the Supply Shortfall compared to the aggregate [DELETED] of EPOGEN unless Amgen shall have notified Dialysis Center in advance that Dialysis Center Purchasers may purchase an Alternative ESA as opposed to Aranesp during the Actual Supply Shortfall.
- 2.5.2. Upon the completion of an Actual Supply Shortfall, the Purchase Commitment, with respect to the quantities of EPOGEN in [DELETED] of the Available EPOGEN SKUs that constitute the Actual Supply Shortfall shall be suspended for a period of [DELETED] days to allow the Dialysis Center Purchasers to transition back from any Alternative ESA's used by the Dialysis Center Purchasers during such Actual Supply Shortfall back to such applicable Available EPOGEN SKU.
- 2.5.3. Provided that Amgen complies with its obligations under Section 2.5.1, then Amgen will not be in breach of Section 2.1 and the Supply Commitment as a result of the Actual Supply Shortfall.

-
- 2.6. [DELETED]. The Dialysis Center Purchasers shall purchase EPOGEN from an Authorized Wholesaler at the then-prevailing [DELETED] (subject to any wholesaler markup, discount, services fees or other charges), and any Discounts shall be applied in accordance with the schedules and terms set forth in Exhibit A and this Agreement. Amgen reserves the right to change [DELETED] at any time, by any amount, without notice. Amgen shall promptly notify Dialysis Center of any change to [DELETED].
- 2.7. Authorized Wholesalers. Prior to the Term Start Date, Dialysis Center shall select one or more Authorized Wholesalers from the Authorized Wholesaler list prepared by Amgen and set forth on Exhibit B (as such list may be amended from time to time as provided in this Agreement, the “Authorized Wholesaler List”), and only such selected Authorized Wholesalers shall be Authorized Wholesalers for purposes of this Agreement. From and after the Term Start Date, Dialysis Center shall have the right to change its selection of Authorized Wholesalers from the Authorized Wholesaler List with thirty (30) days prior written notice to Amgen. Dialysis Center may request Amgen to add wholesalers to the Authorized Wholesaler List, and Amgen, at its sole discretion, shall have the right to determine whether to approve of such addition to the Authorized Wholesaler List. Amgen shall have the right to add or remove wholesalers from the Authorized Wholesaler List set forth on Exhibit B in the exercise of its commercially reasonable discretion by thirty (30) days prior written notice to Dialysis Center, provided that for any removal (a) Amgen removes such Authorized Wholesaler with respect to providing EPOGEN to all purchasers of EPOGEN for free standing dialysis clinics, or (b) such Authorized Wholesaler requests Amgen to remove it as an Authorized Wholesaler for Dialysis Center Purchasers. In the event of any removal of an Authorized Wholesaler from the Authorized Wholesaler List by Amgen, Amgen shall work with Dialysis Center to transition the Dialysis Center Purchasers’ purchases of EPOGEN to an alternative Authorized Wholesaler, and if no alternative Authorized Wholesaler exists at such time, the Parties shall use reasonable efforts to establish a direct purchasing relationship in any interim period between the removal of the removed Authorized Wholesaler and the initiation of purchases from a new Authorized Wholesaler, if no Authorized Wholesaler exists at such time. Any such direct purchasing relationship shall be subject to credit qualification and the approval by Amgen of an application for direct ship account. If the Dialysis Center Purchasers purchase EPOGEN directly from Amgen as contemplated in this Section 2.7, all purchases of EPOGEN made from Amgen by such Dialysis Center Purchasers shall be deemed Qualified Gross Purchases of EPOGEN and eligible for the Discounts.
- 2.8. Dialysis Center Purchasers
- 2.8.1. Designated Affiliates and Managed Centers. Only the Designated Affiliates listed on Exhibit C (as such list may be amended from time to time as provided in this Agreement, the “Designated Affiliates List”) and the Managed Centers set forth on Exhibit D (as such list may be amended from time to time as provided in this Agreement, the “Managed Centers List”) shall be Dialysis Center Purchasers for purposes of this Agreement. Dialysis Center shall promptly update and maintain the accuracy of the Designated Affiliates List and the Managed Centers List throughout the Term, but in no event later than thirty (30) days after the addition or removal of a Dialysis Center Purchaser pursuant to Section 2.8.2 or 2.8.3 below. Dialysis Center shall not acquire, divest, restructure, reorganize or reclassify its Affiliates or Managed Centers, or request any addition or removal of any Dialysis Center Purchaser, with the purpose or intent in whole or in part to avoid or eliminate its obligations or commitments, or the obligations and commitments of each of the Dialysis Center Purchasers set forth in this Agreement.

-
- 2.8.2. Addition of Dialysis Center Purchasers. After the Term Start Date, subject to Amgen's reasonable consent under this Section 2.8.2, all new Affiliates and Managed Centers in the Territory shall be added to this Agreement and become Dialysis Center Purchasers. Dialysis Center shall provide prior written notice to Amgen of each new Affiliate and Managed Center in the Territory (each a "Notice of Added Dialysis Center Purchaser"), which notice shall include the proposed Added Dialysis Center Purchaser Transaction Date, plus any additional information regarding the proposed Dialysis Center Purchaser that Amgen shall reasonably request. Upon Amgen's reasonable consent and subject to the terms and conditions of Section 2.2 with respect to the Purchase Commitment, the Designated Affiliates List and the Managed Centers List shall be amended to include such Affiliates or Managed Centers effective as of the later of (i) thirty (30) days from the date of Amgen's receipt of a Notice of Added Dialysis Center Purchaser or (ii) the applicable Added Dialysis Center Purchaser Transaction Date (each such effective date, the "Added Dialysis Center Purchaser Effective Date"), and each of the Affiliates and Managed Centers added by such amendments, an "Added Dialysis Center Purchaser"). The Designated Affiliates List and the Managed Centers List shall be amended without further action required of the Parties to reflect additions made in accordance with this Section 2.8.2.
- 2.8.3. Removal of Dialysis Center Purchasers. (A) Dialysis Center may remove Designated Affiliates from the Designated Affiliates List and Managed Centers from the Managed Center List only (i) upon the written consent of Amgen, which consent shall not be unreasonably withheld, conditioned, and/or delayed or (ii) upon thirty (30) days prior written notice to Amgen in the event such removal is a result of a (a) sale of all or substantially all of the assets or equity interests of a Designated Affiliate to a Third Party, whether by reorganization, merger, sales of assets, or sale of equity interests, (b) permanent closure of a Designated Affiliate facility or (c) termination of the relevant management agreement for a Managed Center that has ceased its management relationship with Dialysis Center and/or any Affiliate of Dialysis Center (each of the events described in this clause (ii), an "Authorized Removal Occurrence"). Dialysis Center shall provide Amgen written notice describing the nature of any requested removal, including the anticipated effective date of any Authorized Removal Occurrence, and such removal shall be effective thirty (30) days after Amgen has provided Dialysis Center with written consent to such removal or such earlier period as may be agreed to by Amgen or, in the event of an Authorized Removal Occurrence, the effective date of the Authorized Removal Occurrence.
- (B) Amgen shall also have the right to remove any Designated Affiliates from the Designated Affiliates List and any Managed Centers from the Managed Centers List upon thirty (30) days (or such shorter /period as may be required by Law or any Governmental Authority) written notice to Dialysis Center (a) that such removal is required by order of a court or Governmental Authority or (b) in instances in which Amgen determines, in its reasonable discretion, that such removal is required (i) to comply with Law or (ii) as a result of any such Designated Affiliate's or Managed Center's negligence or willful misconduct in the use or administration of EPOGEN.

(C) The Designated Affiliates List and the Managed Centers List shall be amended without further action required of the Parties to reflect removals made in accordance with this Section 2.8.3.

- 2.8.4. Adjustments to Rolling Forecast. Following the addition or removal of an Affiliate to or from the Designated Affiliates List or a Managed Center to or from the Managed Centers List, the Parties shall mutually agree in good faith to implement any reasonable and necessary adjustments to the Rolling Forecast to account for such addition or removal of an Affiliate to or from the Designated Affiliates List or a Managed Center to or from the Managed Centers List; provided, that Amgen shall have no obligation under Section 2.5 for an Actual Supply Shortfall in the event that any increase to the quantities of each Available EPOGEN SKU set forth in such adjusted Rolling Forecast is in excess of the applicable Permitted Percentage Variances.
- 2.8.5. Dialysis Center Committed Purchasers List. The Dialysis Center Purchasers as of the Term Start Date shall constitute the initial list of “Dialysis Center Committed Purchasers” as listed on Exhibit E (as such list may be amended from time to time as provided in this Agreement, the “Dialysis Center Committed Purchasers List”). Each Added Dialysis Center Purchaser shall automatically be added to the Dialysis Center Committed Purchasers List as of the Added Dialysis Center Purchaser Effective Date unless Amgen shall have provided notice to the contrary prior to the Added Dialysis Center Purchaser Effective Date. Any Dialysis Center Purchaser removed from the Designated Affiliates List or the Managed Center List in accordance with Section 2.8.3 shall automatically be removed from the Dialysis Center Committed Purchaser List as of the effective date of such removal from the Designated Affiliates List or the Managed Center List. Amgen shall have the right in its sole discretion to add or remove any Dialysis Center Purchasers from the Dialysis Center Committed Purchasers List upon at least fifteen (15) days’ written notice to Dialysis Center, effective as of the first day of the Quarter after the expiration of the fifteen (15) day notice period; provided, that Amgen shall work together with Dialysis Center to agree as to which specific Dialysis Center Purchasers will be added or removed and, in the event, the Parties are unable to agree in a reasonable time, Amgen may in its discretion add or remove specific Dialysis Center Purchasers that are not disproportionate in their use of Alternative ESAs compared to all Dialysis Center Purchasers. For avoidance of doubt, any Dialysis Center Committed Purchaser that is removed from the Dialysis Center Committed Purchasers List but remains on the Designated Affiliates List or the Managed Center List shall still be considered a Dialysis Center Purchaser.
- 2.8.6. Access to Dialysis Center Facilities. Amgen covenants and agrees that neither it nor any of its employees and/or agents shall have the right to access to any Individually Identifiable Health Information while accessing any of the Dialysis Center Purchasers’ . The Parties acknowledge and agree that (a) all of Dialysis Center’ s applicable policies and procedures regarding visitors and any updates thereto (the “Policies and Procedures”) that will be in effect during the Term are and will be available for viewing by Amgen and its employees and/or agents during the Term at <http://www.davita.com/about/vendor-policies> and (b) Amgen and its employees and/or agents shall have [DELETED] during [DELETED] to the Dialysis Center Purchasers’ facilities for the purpose of promoting and providing [DELETED] regarding [DELETED] and shall abide by all the Policies and Procedures during the Term to the extent that such Policies and Procedures have not changed since the

Term Start Date, other than as required by any applicable Law and/or generally accepted industry guidance covering vendor access to facilities, in a manner that would limit Amgen' s rights under this Section 2.8.6; provided, however, that, notwithstanding anything contained in the Policies and Procedures, Amgen' s employees and/or agents shall be permitted to utilize, without any pre-approval or review by Dialysis Center, any Amgen internally approved (i) [DELETED] materials that have been submitted to the FDA, (ii) [DELETED] materials, and (iii) [DELETED] materials, provided, such [DELETED] materials have been previously submitted to Dialysis Center' s Vice President of Clinical Management and Vendor Relations for approval and not objected to by Dialysis Center' s Vice President of Clinical Management and Vendor Relations within [DELETED] business days of such submission; and provided, further, that Amgen shall provide Dialysis Center' s Vice President of Clinical Management and Vendor Relations with copies of all materials to be utilized at the Dialysis Center Purchaser' s facilities prior to their first use at any facility of the Dialysis Center Purchasers.

3. **DISCOUNTS**

- 3.1. Earning, Calculating, Payment and Vesting of Discounts. All Discounts will be earned, calculated and vested as set forth in Exhibit A. For the purposes of calculating the Discounts hereunder, Qualified Gross Purchases of EPOGEN by any Dialysis Center Purchaser shall be deemed to be made on the date of invoice by an Authorized Wholesaler or Amgen pursuant to Section 2.7 to any such Dialysis Center Purchaser. The Discounts (other than invoice discounts) shall be paid in arrears by electronic funds transfer using information provided to Amgen by Dialysis Center as necessary to enable payment. All Discounts, excluding the Base Rate Rebate and the Base Invoice Discount, shall be conditioned upon material compliance with Section 2.8.6. Amgen Inc. hereby guarantees Amgen' s obligations to pay all Discounts earned by Dialysis Center hereunder.
- 3.2. Verification and Audit. Discounts (including any qualification criteria for any Discounts) specified herein and/or any other amounts paid by one Party to the other Party pursuant to this Agreement are subject to verification and audit of the relevant purchase and other data (including the Data, the Self-Reported Data and the Compensation Data), as reasonably necessary to calculate any amounts payable hereunder. Dialysis Center Purchasers shall maintain their books and records in accordance with U.S. generally accepted accounting principles, consistently applied. To the extent either Amgen or Dialysis Center, in its reasonable discretion, determines that it is necessary to verify and confirm the calculation of: (a) any Discount described in this Agreement in order to audit and assure compliance with the terms of this Agreement and/or (b) any other amount that one Party must pay to the other Party under this Agreement, the requesting Party shall provide written notice of same to the other Party (an "Objection Notice") setting forth in detail any and all items of disagreement related to such computation, statement, and/or amount that must be paid by one Party to the other Party. Amgen and Dialysis Center shall jointly engage (at the requesting Party' s sole cost and expense, subject to any reimbursement by the other Party as set forth below) and refer the items in dispute to a nationally recognized firm of independent, certified public accountants as to which Amgen and Dialysis Center mutually agree (the "Firm"), to resolve any disagreements. Amgen and Dialysis Center will direct the Firm to render a written determination within twenty (20) days of its retention, and Amgen and Dialysis Center and their respective employees and/or agents will cooperate with the Firm during its engagement. The Firm shall keep strictly confidential all data reviewed and information learned or obtained in

connection with resolving any Objection Notice and shall report to the requesting Party only the conclusion of its review without the disclosure of any Confidential Information. All reports of the Firm shall be made available to both Parties simultaneously, promptly upon completion, and shall be deemed to conclusively and definitively resolve the related Objection Notice, which shall be reimbursed (if applicable) in accordance with this Section 3.2. Any such audit shall be conducted during normal business hours, and so as not to unreasonably interfere with the business of Amgen and/or any of the Dialysis Center Purchasers. In the event any such audit is requested by Amgen and shows that Dialysis Center Purchasers have submitted incorrect information resulting in Dialysis Center receiving in excess of [DELETED] percent ([DELETED]%) of the amount to which it was entitled in any Quarter, Dialysis Center shall reimburse Amgen for the reasonable costs of such audit; otherwise, Amgen shall be responsible for the costs of such audit. In the event any such audit is requested by Dialysis Center and shows that Dialysis Center Purchasers have submitted correct information but have been underpaid by more than [DELETED] percent ([DELETED]%) of the amount to which they were entitled in any Quarter, Amgen shall reimburse Dialysis Center for the reasonable costs of such audit; otherwise, Dialysis Center shall be responsible for the costs of such audit. The determination of the Firm will be conclusive and binding upon Amgen and Dialysis Center. Following any audit that shows any over or underpayment hereunder, the relevant Party shall, within sixty (60) days, make payment to the other Party for the difference between the amount paid hereunder and the amount actually payable hereunder based upon the results of such audit.

3.3. Adjustments for Changes. In accordance with Section 2.8.2 and/or 2.8.3 above, in the event of an Affiliate' s addition to or deletion from the Designated Affiliates List or a Managed Center' s addition to or deletion from the Managed Centers List during any Quarter of the Term, Amgen shall adjust Qualified Gross Purchases of EPOGEN to account for such Affiliate' s addition to or deletion from the Designated Affiliates List or a Managed Center' s addition to or deletion from the Managed Centers List by adding or deleting such Designated Affiliates' or Managed Centers' , as applicable, purchases to or from the relevant Quarter or comparison Quarter (or portion thereof).

3.4. Treatment of Discounts and Rebates.

3.4.1. Dialysis Center agrees that Dialysis Center Purchasers shall properly disclose and account for all Discounts earned hereunder, in whatever form, in compliance with all applicable federal, state, and local Laws, including §1128B(b) of the Social Security Act, as amended and its implementing regulations. Dialysis Center agrees that, if required by such statutes or regulations, it (together with its Designated Affiliates) shall and it shall cause its Managed Centers to (i) claim the benefit of such Discount received in the fiscal year in which such Discount was earned or the year after, (ii) fully and accurately report the value of such Discount in any cost reports filed under Title XVIII or Title XIX of the Social Security Act, as amended or a state or local health care program, and (iii) provide, upon request by the U.S. Department of Health and Human Services or a state or local agency or any other federally funded state health care program, the information furnished to Dialysis Center Purchasers by Amgen concerning the amount or value of such Discount.

3.4.2. In order to assist Dialysis Center' s compliance with its obligations as set forth in Section 3.4.1 above, Amgen agrees that it will fully and accurately report all Discounts on the invoices or statements submitted to Dialysis Center and use reasonable efforts to inform Dialysis Center of its obligations to report all such Discounts to the extent specified by 42 C.F.R § 1001.952(h)(2)(ii)(A) or where the

value of a Discount is not known at the time of sale, Amgen shall fully and accurately report the existence of the Discount program on the invoices or statements submitted to Dialysis Center and use reasonable efforts to inform Dialysis Center of its obligations to report all such Discounts to the extent specified by 42 C.F.R § 1001.952(h)(2)(ii)(B), and when the value of the Discounts become known, provide Dialysis Center with documentation of the calculation of the Discount identifying the specific goods or services purchased to which the Discount will be applied, in accordance with Section 3.5 below.

- 3.5. Reports. Within ninety (90) days of the end of each Quarter, Amgen shall provide to Dialysis Center a statement of the Discounts earned hereunder with the itemization of EPOGEN purchases made in a particular Quarter, broken down for each Dialysis Center Purchaser and any other information that Dialysis Center may reasonably request that is reasonably available to Amgen and necessary for Dialysis Center to obtain in order to comply with its obligations hereunder. Dialysis Center agrees that it will provide such information to its Dialysis Center Purchasers in a timely manner in order to allow such Dialysis Center Purchasers to meet their reporting and other obligations hereunder and under applicable Law.
- 3.6. Best Price Limitation. At any time following the repeal, enactment or modification of any Law, policy, program memorandum, or the interpretation thereof, including a decision by the Centers for Medicare & Medicaid Services, that affects the definition of “Best Price” (which, for purposes of this Agreement, shall mean the price reported in Amgen’s Best Price Submission under Title XIX of the Social Security Act) or the methodology by which Best Price must be calculated, Amgen shall have the right, in its sole discretion, to determine the extent to which any [DELETED] to any Third Party due to such repeal, enactment, modification or decision may impact Amgen’s Best Price calculation under this Agreement alone or in combination with any other [DELETED] in other agreements with Dialysis Center or any Third Party. In the event that Amgen determines reasonably and in good faith that the then-existing [DELETED] under this Agreement establishes or would establish a new “Best Price,” Amgen shall have the right, in its sole discretion, upon the later of (a) the effective date of such repeal, enactment, modification or decision, or (b) notice to Dialysis Center, to [DELETED] the Discounts offered under this Agreement [DELETED], and shall promptly notify Dialysis Center of the [DELETED]; provided that the [DELETED] as adjusted by Amgen shall result in [DELETED] available to Dialysis Center which would [DELETED] the Best Price prior to the effective date of such repeal, enactment, modification or decision, calculated using the modified definition or methodology by which Best Price is to be calculated.

4. **GOVERNANCE**

- 4.1. Business Representatives. The “Business Representatives” shall be comprised of: (i) in the case of Amgen, Amgen’s General Manager of the Nephrology Business Unit (the “Amgen Business Representative”); and (ii) in the case of Dialysis Center, the Chief Operating Officer of DaVita Inc. (the “Dialysis Center Business Representative”). Each Business Representative shall be entitled to appoint designees who have been identified to the other Business Representative in writing and have equivalent authority to the Party’s Business Representative or have been expressly given all requisite authority by the Party’s Business Representative.
- 4.2. Responsibilities of Business Representatives. The Business Representatives shall be responsible for overseeing the Parties’ activities and conduct under this Agreement generally, and for ensuring an appropriate level of oversight. The Business Representatives shall meet in person, via teleconference or videoconference at such times as may be deemed necessary by the Parties).

5. **PATIENT AND PRODUCT DATA**

- 5.1. Data Submission. Dialysis Center shall deliver all Data to Amgen (or to a data collection vendor specified by Amgen) in the format and manner provided in Exhibit A and subject to the provisions of this Section 5. To the extent Amgen requests that Dialysis Center deliver Data to a data collection vendor, Amgen agrees to cause any such data collection vendor to adhere to and be bound by a substantially similar confidentiality obligation as is applicable to Amgen under this Agreement, and Amgen shall be liable for any failure by any such data collection vendor to act in accordance with such requirements.
- 5.2. HIPAA Compliance. Neither Party has the intent that Dialysis Center will provide Amgen (or any specified data collection vendor) any Data in violation of HIPAA. Accordingly, the Parties shall engage an appropriately qualified statistician, reasonably acceptable to each Party, who meets the requirements set forth in 45 C.F.R. § 164.514(b)(1) to review the Data and deliver a written certification that shall conclude that, subject to any conditions, requirements or assumptions set forth therein, each delivery of Data pursuant to this Agreement will meet the standards for “de-identification” under HIPAA (the “Certification”). In connection with the Certification, the Parties agree to use their commercially reasonable best efforts to facilitate the completion and delivery of such Certification to each Party in an expedited manner, and Amgen shall bear the pre-approved costs of such Certification. Notwithstanding anything in this Agreement to the contrary, in order to assure compliance, as determined by either Party in its reasonable discretion, with any existing Law relating to patient privacy of medical records, or at any time following the enactment of any Law relating to patient privacy of medical records that in any manner reforms, modifies, alters, restricts, or otherwise affects any of the Data received or to be received in connection with any of the Discounts contemplated under this Agreement, either Party may, upon thirty (30) days’ prior written notice, seek to amend this Agreement with respect to the affected Discount. Dialysis Center and Amgen shall meet and in good faith mutually agree to modify this Agreement to accommodate any such change in the Law, with the intent to, if possible, retain the essential terms of this Section 5 and the affected Discount and pricing structure of this Agreement.
- 5.3. Case Identifier. Dialysis Center shall consistently use a unique alpha-numeric code (which shall not be derived from Individually Identifiable Health Information) as a “case identifier” to track the care rendered to each individual patient over time, and such case identifier shall be included in the Data provided to Amgen. The key or list matching patient identities to their unique case identifiers shall not be provided to Amgen.
- 5.4. Data Use. Amgen and its Affiliates shall have the right to use Data (a) to support verification of the services under this Agreement, (b) for its [DELETED] and [DELETED], development of [DELETED], running [DELETED] analyses, overall analyses of how to improve treatment of patients on dialysis and creating tools by its marketing personnel, (c) in the aggregate for publications as part of a larger data set incorporating comparable clinical data received from other dialysis providers in the Territory and provided that no portion of such data shall be attributed to Dialysis Center or its Affiliates, and (d) for purposes of verifying the Dialysis Center Purchasers’ performance under this Agreement and the calculation of amounts payable hereunder, including verifying the Dialysis Center Purchasers’ Purchase Commitment performance under this Agreement and

calculating or determining the Dialysis Center Purchasers' eligibility to receive any Discount. Notwithstanding the foregoing, without Dialysis Center's prior written consent (such consent not to be unreasonably conditioned, withheld or delayed): Amgen and its Affiliates shall not (i) disclose to Third Parties the Data provided by Dialysis Center hereunder except (1) in any publication referenced in clause (c) above, (2) pursuant to public health activities, (3) to agents of Amgen bound by obligations of confidentiality no less restrictive than those contained in [Section 11.14](#) or (4) to other Third Parties as required by Law or regulation as determined in Amgen's discretion; and (ii) sell or resell any such data or derivative works thereof to any Third Party.

5.5. Clinical Research Studies. Dialysis Center and Amgen acknowledge that Dialysis Center, either directly or through DaVita Clinical Research, Inc., an Affiliate of Dialysis Center, may from time to time be engaged in research studies in which patients of the Dialysis Center Purchasers, may serve as clinical trial subjects (a "Research Study"). Notwithstanding any obligation of Dialysis Center in this Agreement to the contrary, including any requirement in [Section 3.5 of Exhibit A](#), Dialysis Center shall not be required to submit Data for any patients of the Dialysis Center Purchasers that are participating in a Research Study (a "[DELETED]"), but shall continue without limitation to be eligible for, and if earned receive, all Discounts granted pursuant to this Agreement, so long as (i) Dialysis Center notifies Amgen of the [DELETED] whose Data will not be delivered by Dialysis Center to Amgen as otherwise required by this Agreement as a result of such patient being a [DELETED], and (ii) the aggregate number of [DELETED] whose Data is excluded by Dialysis Center does not exceed the [DELETED]. For purposes of the foregoing, "[DELETED]" means [DELETED] percent ([DELETED]%) of the aggregate number of persons receiving treatment from the Dialysis Center Purchasers in any calendar month.

6. **OTHER DATA**

6.1. Compensation Data. Dialysis Center agrees that it shall provide the data, with respect to EPOGEN, set forth on [Schedule 2](#) attached hereto (the "Compensation Data") to Amgen in the electronic format set forth on [Schedule 2](#) on a calendar [DELETED] basis no later than the fourteenth (14th) day of the following calendar [DELETED] following the [DELETED] for which such Compensation Data is being provided. Amgen acknowledges, agrees and covenants that it shall only use the Compensation Data for sales force targeting and compensation. Dialysis Center and Amgen acknowledge and agree that the Compensation Data does not include and shall never include any Individually Identifiable Health Information of any patient of Dialysis Center Purchasers. Notwithstanding the foregoing, Amgen acknowledges and agrees that Dialysis Center shall only be required to deliver the Compensation Data to Amgen for as long as [DELETED]. Amgen shall indemnify, defend and hold harmless Dialysis Center from and against any and all loss, damage and/or expense (including reasonable attorney's fees) that it may suffer as a result of claims, demands, actions, proceedings, liabilities, costs or judgments, or threats thereof arising out of Dialysis Center's supply of the Compensation Data to Amgen.

6.2. Self-Reported Purchase Data. Dialysis Center, on behalf of the Dialysis Center Purchasers, acknowledges, covenants and agrees that it shall submit full and complete Self-Reported Purchase Data for each Quarter to Amgen within forty-five (45) days of the end of each such Quarter through a Purchase Data Submission Form attached here to as [Exhibit SR-1](#). [Exhibit SR-1](#) is subject to modification by mutual written agreement of the Parties. Dialysis Center on behalf of the Dialysis Center Purchasers shall submit [Exhibit SR-1](#) in an Excel file format electronically by e-mail to [DELETED] or in such other manner as may be specified by Amgen through written notification to Dialysis Center.

7. JOINT PROJECTS

7.1. Joint Projects. The Parties shall form a “Joint Project Committee” comprised of three (3) executives from each Party, one (1) of whom shall be a clinical executive, and shall be led by two (2) co-chairs, one (1) appointed by each of the Parties. During the Term, either Party may present to the Joint Project Committee one or more written proposals (a “Project Proposal”) for a project or projects to be undertaken jointly by the Parties related to the provision of Dialysis Services (a “Joint Project”), together with a draft project plan for the Joint Project (a “Project Plan”) which the Parties shall discuss in good faith. If the Parties agree in writing to undertake a Joint Project, the Parties shall jointly pursue such Joint Project in accordance with the Project Plan without any further approval action required by the Parties.

7.2. Joint Project Committee.

7.2.1. Joint Project Committee Responsibilities. The Joint Project Committee shall be responsible for the following:

- a) Reviewing and approving each new Project Proposal prior to adoption of any Joint Projects set forth in such new Project Proposal;
- b) Reviewing and approving changes to the Project Plans for existing Joint Projects prior to adoption of such changes;
- c) Providing for communication and discussion between the Parties to, as appropriate, coordinate and optimize the development activities of the Parties under each Joint Project;
- d) Reviewing and monitoring the activities and progress of the Parties against the Joint Projects;
- e) Communicating with the Business Representatives regarding all of the foregoing; and
- f) Such other matters as are appropriate to make operational the terms of this Agreement in respect of Joint Projects and as the Parties shall agree in writing.

7.2.2. Meetings. The Joint Project Committee shall meet in person, via teleconference or videoconference or otherwise, as frequently as deemed necessary by the Joint Project Committee. All Joint Project Committee meetings shall have at least one (1) member appointed by each Party in attendance.

7.2.3. Decision Making. The Joint Project Committee shall make decisions by a unanimous vote. The Parties shall use good faith, reasonable efforts to come to a complete agreement. In the event the Joint Project Committee fails to reach unanimity with respect to any matter, such matter shall be escalated to the Business Representatives.

8. WARRANTIES, REPRESENTATIONS AND COVENANTS

8.1. Power and Authority. Each Party represents and warrants to the other that this Agreement: (a) has been duly authorized, executed, and delivered by it, (b) constitutes a valid, legal, and binding agreement enforceable against it in accordance with the terms

contained herein, and (c) does not and shall not conflict with or violate any of its other contractual obligations, expressed or implied, to which it is a party or by which it may be bound.

- 8.2. Compliance with Law and Regulation. Amgen and Amgen Inc. shall, and Dialysis Center shall, comply with all applicable Laws related to the performance of their respective obligations under this Agreement. Each Party represents and warrants that (which representations and warranties shall be ongoing representations and warranties during the Term): (i) it is not currently named on any of the following lists: (A) HHS/OIG List of Excluded Individuals/Entities, (B) GSA List of Parties Excluded from Federal Programs, or (C) OFAC “SDN and Blocked Individuals” and (ii) it shall promptly notify the other Party in the event it becomes named on any of the following lists: (x) HHS/OIG List of Excluded Individuals/Entities, (y) GSA List of Parties Excluded from Federal Programs, or (z) OFAC “SDN and Blocked Individuals”.
- 8.3. Product. Amgen covenants and agrees that EPOGEN is not and will not be adulterated or misbranded within the meaning of the Federal Food, Drug and Cosmetic Act, as amended, or within the meaning of any applicable Law, or is or will be a product which may not be introduced in to interstate commerce. Amgen warrants that EPOGEN purchased pursuant to this Agreement (a) is manufactured, and up to the time of its receipt by Authorized Wholesalers is handled, stored, and transported in accordance with all applicable Laws, and meet all specifications for effectiveness and reliability as required by the United States Food and Drug Administration (the “FDA”), and (b) when used in accordance with the directions in its labeling is fit for the purposes and indications described in its labeling. Amgen warrants that the use of EPOGEN by Dialysis Center Purchasers shall not infringe upon any ownership rights of any other individual or entity or upon any patent, copyright, trademark or other intellectual property or proprietary right or trade secret of any individual or entity. Amgen agrees that as soon as practicable it will notify Dialysis Center of any material defect in EPOGEN delivered to any Dialysis Center Purchasers in accordance with applicable Law.
- 8.4. Data. Dialysis Center represents and warrants to Amgen that: (a) the Data, the Compensation Data, and the Self-Reported Purchase Data that the Dialysis Center Purchasers deliver to Amgen pursuant to Section 5 and Section 6 shall be: (i) prepared and delivered in accordance with the provisions of Section 5, Section 6 and Exhibit A and (ii) as complete and accurate as is reasonably obtainable in view of the Dialysis Center Purchasers’ customary method of compilation and the nature and accuracy of the Dialysis Center Purchasers’ resources; (b) the Dialysis Center Purchasers shall not knowingly and intentionally misrepresent any of the Data, the Compensation Data, and/or the Self-Reported Purchase Data provided by the Dialysis Center Purchasers to Amgen; and (c) Dialysis Center shall promptly notify Amgen in the event it has actual knowledge that any of the Data, the Compensation Data, and/or the Self-Reported Purchase Data is not complete and/or accurate.
- 8.5. Designated Affiliates List and Managed Centers List. Dialysis Center represents and warrants that the Designated Affiliates List and the Managed Centers List, as each of them is attached to this Agreement as of the Term Start Date (and as of any subsequent date that such lists are updated in accordance with the terms hereof) are complete and accurate lists of all Affiliates of Dialysis Center and Managed Centers of Dialysis Center providing Dialysis Services in the Territory as of the Term Start Date (and as of each such subsequent date).
- 8.6. Adverse Claims. Each Party represents and warrants to the other Party that, as of the execution of this Agreement, such Party has no actual knowledge of any legal claim or right to be asserted against the other Party or its Affiliates related to the negotiation or execution of this Agreement.

8.7. NO OTHER WARRANTIES. OTHER THAN THE WARRANTIES EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES, AND EACH PARTY EXPRESSLY DISCLAIMS, ALL OTHER WARRANTIES, STATUTORY, EXPRESS, AND/OR IMPLIED, INCLUDING THOSE OF MERCHANTABILITY AND/OR FITNESS FOR A PARTICULAR PURPOSE. EACH PARTY HEREBY EXPRESSLY WAIVES ANY AND ALL OTHER WARRANTIES, STATUTORY, EXPRESS, AND/OR IMPLIED, INCLUDING THOSE OF MERCHANTABILITY AND/OR FITNESS FOR A PARTICULAR PURPOSE.

9. **DISPUTE RESOLUTION, INSURANCE and INDEMNITY**

9.1. Escalation of Disputes to Business Representatives. The Parties recognize that claims, disputes or controversies arising out of or relating to this Agreement (“Disputes”) may occur from time to time. It is the objective of the Parties to establish procedures to facilitate the resolution of Disputes arising under this Agreement in an expedient manner by mutual cooperation and, if possible, without resort to litigation.

In the event of any Dispute, and prior to either Party (a) commencing any action in a court of law or under any Governmental Authority, or (b) taking any action to terminate this Agreement as provided in Section 10, the Parties shall first undertake that the employees of each Party with relevant expertise and authority with respect to a Dispute shall meet to discuss such Dispute within five (5) business days of a Party receiving notice of a Dispute (except in the case where delay in resolving any such Dispute would be materially prejudicial to a Party, in which case the Dispute will be referred directly to the Business Representatives). In the event the Parties are unable to resolve any such Dispute within thirty (30) business days of the initial meeting between the Parties, it shall be referred to the Business Representatives, who shall negotiate with one another in good faith to reach a good faith resolution of the Dispute; provided, that the Parties shall use commercially reasonable best efforts to expedite the resolution of any Disputes which by their nature need to be made quickly by the Business Representatives. In the event the Dispute cannot be resolved by the Business Representatives within fifteen (15) business days of the initial meeting between the Business Representatives or such other period of time as is mutually agreed to by the Parties, then, upon the written demand of either Party, the Dispute shall be subject to arbitration, as provided in Section 9.2. Pending resolution of any Dispute, both Parties will continue their performance under this Agreement of all obligations that are not the subject of any such Dispute. If there is a Dispute relating to any amount owed by either Party to the other Party, the undisputed portion of such amount shall be paid to the other Party in accordance with the terms hereof, and the Parties shall first attempt to resolve the disputed balance in accordance with this Section 9.1.

9.2. Arbitration.

9.2.1. Claims. Subject to Section 9.3 below, any Dispute that is not resolved under Section 9.1 within thirty (30) days after a Party’s initial written request for resolution, shall be resolved by final and binding arbitration administered by JAMS (the “Administrator”) in accordance with its Comprehensive Arbitration Rules and Procedures (the “Rules”), except to the extent any such Rule conflicts with the express provisions of this Section 9.2. (capitalized terms in this Section 9.2 used but not otherwise defined in this Agreement shall have the meanings provided in the Rules.) For Disputes valued at less than Five Million Dollars (\$5,000,000), the

Arbitration shall be conducted by one (1) neutral arbitrator (“Arbitrator”) selected in accordance with the Rules, provided that such Arbitrator shall not be a current or former employee or director, or a current stockholder, of either Party or any of their respective Affiliates. For Disputes valued at or more than Five Million Dollars (\$5,000,000), the Arbitration shall be conducted by a panel of three (3) neutral Arbitrators selected in accordance with the Rules, provided that any such Arbitrator shall not be a current or former employee or director, or a current stockholder, of either Party or any of their respective Affiliates. The Arbitration shall be held in Los Angeles, California.

- 9.2.2. Discovery. Within forty-five (45) days after selection of the Arbitrator(s), the Arbitrator(s) shall conduct the Preliminary Conference. In addressing any of the subjects within the scope of the Preliminary Conference, the Arbitrator(s) shall take into account both the needs of the Parties for an understanding of any legitimate issue raised in the Arbitration and the desirability of making discovery efficient and cost-effective. In that regard, the Parties agree to the application of the E-Discovery procedures set forth in Rule 16.2(c) of JAMS’ Expedited Procedures; provided that the Parties agree that the time limitations identified in Rule 16.2 of JAMS’ Expedited Procedures shall not be binding and the Arbitrator(s) shall set time limitations for discovery and depositions that are reasonable and necessary in light of the issues and matters raised in the Preliminary Conference. In no event shall the time limitations set by the Arbitrator(s) for discovery and depositions be shorter than the time periods for discovery and depositions that are set forth in Rule 16.2 of JAMS’ Expedited Procedures.
- 9.2.3. Hearing; Decision. The hearing (“Hearing”) shall commence within a reasonable time after the discovery cutoff. The Arbitrator(s) shall require that each Party submit concise written statements of position and shall permit the submission of rebuttal statements, subject to reasonable limitations on the length of such statements to be established by the Arbitrator(s). The Arbitrator(s) shall also permit the submission of expert reports. The Arbitrator(s) shall render the award (“Award”) within thirty (30) days after the Arbitrator(s) declares the Hearing closed, and the Award shall include a written statement describing the essential findings and conclusions on which the Award is based, including the calculation of any damages awarded. The Arbitrator(s) will, in rendering his, her or their decision, apply the substantive law of the State of California, without giving effect to its principles of conflicts of law, and without giving effect to any rules or laws relating to arbitration. The Award rendered by the Arbitrator(s) shall be final, binding and non-appealable, and judgment may be entered upon it in any court of competent jurisdiction. However, the Parties agree that the JAMS Optional Arbitration Appeal Procedures (“Appeal Procedures”) shall apply to the Arbitration, at the request by either Party in accordance with such Appeal Procedures. If a Party appeals the Award rendered by the Arbitrator(s), the Award issued by the Appeal Panel (as defined in such Appeal Procedures) shall be final, binding and non-appealable, and judgment may be entered upon it in any court of competent jurisdiction.
- 9.2.4. Costs. Each Party shall bear its own attorney’s fees, costs, and disbursements arising out of the Arbitration, and shall pay an equal share of the fees and costs of the Arbitrator(s); provided, however, the Arbitrator(s) shall be authorized to determine whether a Party is the prevailing party, and if so, to award to that prevailing party reimbursement for any or all of its reasonable attorneys’ fees, costs and disbursements (including, for example, expert witness fees and expenses, photocopy charges, travel expenses, etc.), and/or the fees and costs of the Administrator and the Arbitrator(s).

-
- 9.2.5. Confidentiality. Each Party acknowledges and agrees that: (a) any discovery pursuant to this Section 9.2, (b) the Hearing, (c) any and all documents exchanged or delivered in connection with the Hearing, settlement negotiations, and/or settlement terms, including the statements of position, rebuttal statements, and expert reports, (d) settlement negotiations and/or settlement terms, and (e) the Award shall be treated as Confidential Information and subject to the terms and conditions of Section 11.14.
- 9.3. Court Actions. Nothing contained in this Agreement shall deny either Party the right to seek injunctive or other equitable relief from a court of competent jurisdiction in the context of a bona fide emergency or prospective irreparable harm, and such an action may be filed and maintained notwithstanding any ongoing discussions between the Parties or any ongoing arbitration proceeding.
- 9.4. Insurance. Each Party shall secure and maintain in full force and effect throughout the Term (and following termination, to the extent necessary to cover any claims arising from this Agreement) commercial general liability insurance and product liability (in the case of Amgen only) which include contractual liability with limits of no less than [DELETED] dollars (\$[DELETED] USD); professional liability insurance (in the case of Dialysis Center only) with limits of no less than [DELETED] dollars (\$[DELETED] USD), and workers' compensation with statutory limits. Any limits on each of a Party's insurance coverage shall not be construed to create any limit on such Party's liability with respect to its obligations under this Agreement or otherwise. Each of the Parties shall have the right to satisfy its obligations under this Section 9.4 through self-insurance. Amgen Inc. hereby guarantees the performance of Amgen's obligations as set forth in this Section 9.4.
- 9.5. Indemnity.
- 9.5.1. *By Amgen*. Amgen agrees to indemnify, defend, and hold Dialysis Center, its officers, directors, agents and employees (collectively, the "Dialysis Center Indemnitees") harmless from and against any and all loss, damage and/or expense (including reasonable attorney's fees) that they may suffer as a result of Third Party claims, demands, actions, proceedings, liabilities, costs or judgments, or threats thereof ("Third Party Claim(s)") arising out of (i) any defect in the design and/or manufacture of EPOGEN or the storage and/or transportation of EPOGEN in Amgen's possession, including claims for property damage, loss of life, and/or bodily injury; and/or (ii) the breach by Amgen or Amgen Inc. of any of their respective warranties, representations, and/or covenants contained in this Agreement. Notwithstanding anything to the contrary contained herein, Amgen and Amgen Inc. shall not have any obligation to defend, indemnify, and/or hold the Dialysis Center Indemnitees harmless from any Third Party Claims arising out of the negligent acts and/or omissions and/or willful misconduct of the Dialysis Center Indemnitees. This indemnification shall survive the termination or expiration of this Agreement. Amgen Inc. hereby guarantees the performance of Amgen's obligations as set forth in this Section 9.5.1.
- 9.5.2. *By Dialysis Center*. Dialysis Center agrees to indemnify, defend, and hold Amgen, its officers, directors, agents and employees (collectively, the "Amgen Indemnitees") harmless from and against any and all Third Party Claims arising out of (i) any Dialysis Center Purchasers' administration, promotion or use of EPOGEN

purchased under this Agreement to its patients; (ii) any Dialysis Center Purchasers' failure to store and/or transport any EPOGEN in its possession in accordance with any applicable Law and/or labeling information; and/or (iii) the breach by Dialysis Center of any of its warranties, representations, and/or covenants contained in this Agreement. For purposes of the foregoing, the "administration" of EPOGEN by Dialysis Center shall mean the dispensing and handling by Dialysis Center and its employees of EPOGEN and the actual administration of EPOGEN to patients by Dialysis Center and its employees, but shall exclude physician prescriptions of EPOGEN to patients. Notwithstanding anything to the contrary contained herein, Dialysis Center shall not have any obligation to defend, indemnify, and/or hold the Amgen Indemnitees harmless from any Third Party Claims arising out of the negligent acts and/or omissions and/or willful misconduct of the Amgen Indemnitees. This indemnification shall survive the termination or expiration of this Agreement.

9.6. Procedure for Third Party Claims.

- 9.6.1. Notice. The Party receiving indemnification hereunder (the "Indemnified Party") shall give the Party providing indemnification hereunder (the "Indemnifying Party") written notice within fifteen (15) business days after the Indemnified Party receives notice of any Third Party Claim, subject to indemnification hereunder upon which such Indemnified Party intends to base a request for indemnification under Section 9.5.1 or Section 9.5.2. Failure to give any such notice shall not constitute a waiver of any right to indemnification or reduce in any way the indemnification available hereunder, except and only to the extent that as a result of such failure the Indemnifying Party demonstrates that it was directly and materially damaged as a result of such failure to give timely notice.
- 9.6.2. Control of Defense. The Indemnifying Party, at its expense, shall assume control of the defense and resolution of each Third Party Claim using legal counsel reasonably approved by the Indemnified Party and shall keep the Indemnified Party fully and timely informed of the progress of such defense and resolution. With respect to each Third Party Claim, the Indemnified Party shall have the right to retain independent legal counsel at its cost and monitor such Third Party Claim's defense and resolution. In such a case, the Indemnifying Party and its legal counsel shall fully cooperate with the Indemnified Party and its legal counsel in providing such information as the Indemnified Party may reasonably request. Notwithstanding this Section 9.6.2, the Indemnifying Party shall not be entitled to control, but may participate in, and the Indemnified Party shall be entitled to have sole control over and select counsel to conduct, the defense or settlement of each Third Party Claim that: (i) seeks a temporary restraining order, a preliminary or permanent injunction, and/or specific performance against the Indemnified Party, (ii) involves criminal allegations against the Indemnified Party, (iii) if unsuccessful, would set a precedent that would materially interfere with and/or have a material adverse effect on the business and/or financial condition of the Indemnified Party, and/or (iv) imposes liability on the part of the Indemnified Party for which the Indemnified Party is not entitled to indemnification hereunder. In such an event, the Indemnifying Party will still have all of its obligations hereunder with respect to any such affected Third Party Claims; provided that the Indemnified Party will not settle any such affected Third Party Claims without the prior written consent of the Indemnifying Party, which consent will not be unreasonably withheld, conditioned, and/or delayed by the Indemnifying Party.

-
- 9.6.3. *Representation.* If both the Indemnifying Party and the Indemnified Party are named parties in any Third Party Claim and representation of both Parties by the same legal counsel would be inappropriate due to the actual or potential differing interests between them, then the Indemnified Party, at the Indemnifying Party' s expense, shall have the right to be represented by separate counsel of the Indemnified Party' s choosing.
- 9.6.4. *Resolution.* The Indemnifying Party shall not settle, compromise or resolve any Third Party Claim without the written consent of the Indemnified Party; provided that, the Indemnifying Party may, without such consent, enter into any such judgment, settlement, compromise or resolution that relates solely to the payment of money damages, involves a full release of the Indemnified Party and does not result in any admission of any fault of the Indemnified Party with respect to such Third Party Claim.
- 9.6.5. *Payment.* Any final judgment entered or settlement agreed upon in the manner provided in this Section 9.6, as applicable, shall be binding upon the Indemnifying Party and shall conclusively be deemed to be an obligation with respect to which the Indemnified Party is entitled to prompt indemnification hereunder, if applicable. Payment of all amounts owing by the Indemnifying Party under this Section 9.6, as applicable, shall be made promptly upon a final settlement between the Indemnifying Party and the Indemnified Party or upon a final adjudication determined by the Arbitrator(s) that an indemnification obligation is owed by the Indemnifying Party to the Indemnified Party.

10. **TERM AND TERMINATION**

- 10.1. Term. This Agreement shall come into effect as of the Term Start Date and shall expire on the earlier of the Term End Date, or the Termination Date.
- 10.2. Termination for Cause. Amgen or Dialysis Center may terminate this Agreement only in the event of the following:
- 10.2.1. *Breach of Purchase Commitment.* The Parties acknowledge and agree that the Purchase Commitment is the principal value expected to be received by Amgen under this Agreement and it is the essential inducement for Amgen to enter into this Agreement, pursuant to which it has agreed, among other things, (a) to provide the Dialysis Center Purchasers for the duration of the Term the economic benefits of the Discounts provided for herein, (b) to make the Supply Commitment, which requires that Amgen commit facilities to the manufacture of EPOGEN at the expense of other Amgen uses and allocate significant resources to maintain its manufacturing capabilities and capacity at a commensurate level, (c) to assume the business risks and financial liability in respect of the representations, warranties and covenants made by it hereunder and (d) to forego potential other commercial opportunities in respect of its nephrology business. In the event that the Dialysis Center Committed Purchasers do not meet an Amgen ESAs Share of Sales of (i) at least [DELETED] percent ([DELETED]%) for [DELETED] or more [DELETED] during the Term with respect to which the Dialysis Center is required to pay the Alternative ESA Purchase Amount with respect to each of such [DELETED] in any [DELETED] period during the Term, or (ii) at least [DELETED] percent ([DELETED]%) in any [DELETED], then Amgen shall be entitled to terminate this Agreement immediately

upon written notice to Dialysis Center and, notwithstanding any other provision of this Agreement, thereupon either receive the “Liquidated Damages” defined below or exercise such other rights and remedies as may be allowed at law or in equity under applicable Law.

10.2.2. Termination for Failure to Supply. Dialysis Center may terminate this Agreement immediately upon written notice to Amgen in the event that Amgen has not been able to supply to Dialysis Center through one or more Authorized Wholesalers EPOGEN in [DELETED] (or Aranesp subject to the terms of Section 2.5) equal to at least [DELETED] percent ([DELETED]%) of the Minimum Forecast Commitment (other than as a result of one or more Force Majeure Events) for [DELETED].

10.2.3. Termination for Exclusion from Federal Health Care Program. Either Amgen or Dialysis Center may immediately terminate this Agreement upon written notice to the other Party in the event there is change in the other Party’s status which excludes it from participation in any “Federal health care program” (as defined under 42 U.S.C. § 1320a-7b(f)) (a “Debarred Party”), provided that no Party shall have the right to terminate this Agreement pursuant to this Section 10.2.3 if the Debarred Party can complete its obligations through, or otherwise transfer its obligations to, an Affiliate as permitted by applicable Law.

10.3. Liquidated Damages. The Parties acknowledge that Amgen’s actual damages in the event of a termination by Amgen, pursuant to Section 10.2.1 or Section 10.2.3, would be difficult to ascertain, and that the payment of the Liquidated Damages represents the best estimate of the amount of such damages by the Parties at this time. The Parties further expressly acknowledge and agree that the Liquidated Damages are intended not as a penalty, but as full liquidated damages, in the event of Amgen’s termination of this Agreement pursuant to Section 10.2.1 or Section 10.2.3 and as compensation for Amgen’s losses and other expenses associated with this Agreement.

For purposes of this Agreement, “Liquidated Damages” means, in addition to any amounts owed to Amgen under this Agreement, including for breach of the Purchase Commitment under Section 2.1, an amount in cash equal to [DELETED] percent ([DELETED] %) of the [DELETED] of Amgen’s projected [DELETED] for each remaining Quarter (including any fractional Quarters) in the Term, with such [DELETED] equal to A - B, grown Quarterly at a [DELETED] percent ([DELETED]%) annual rate and discounted on a Quarterly basis, at a rate equal to the average annual increase in [DELETED] for EPOGEN on an [DELETED] basis for all calendar years during the Term prior to the related [DELETED] calculation, where:

A = The average [DELETED] for the [DELETED] most recent Quarters prior to the Termination Date in which Dialysis Center satisfied the Purchase Commitment in full (or, if less than [DELETED] such Quarters exist, then “A” shall equal the average of the sum of (i) [DELETED] plus (ii) the [DELETED], for the [DELETED] most recent Quarters prior to the Termination Date); and

B = The average aggregate [DELETED] (other than the [DELETED] Rebate, the [DELETED] Rebate and the [DELETED] Rebate) earned by Dialysis Center Purchasers during the [DELETED] most recent Quarters prior to the Termination Date, regardless of whether Dialysis Center satisfied the Purchase Commitment in such Quarters.

10.4. Effect of Termination. Upon any termination or expiration of this Agreement, (a) any earned and vested Discounts shall be paid in accordance with the terms set forth in

Exhibit A, (b) any Alternative ESA Purchase Amounts shall be paid pursuant to Section 2.1.1, (c) any payments by Amgen owing to Dialysis Center under Section 2.5.1 shall be paid, (d) any payment by Dialysis Center owing to Amgen under Section 2.4.2 shall be paid and (e) the Liquidated Damages pursuant to Section 10.3 shall be paid. All Discounts available to Dialysis Center in the particular Quarter in which such termination occurs shall be paid to Dialysis Center based on an achievement of the eligibility and vesting requirements set forth in Exhibit A.

10.5. Survival. Any provision that, either expressly or by its nature is intended to survive this Agreement, shall survive any expiration or termination of this Agreement, including Sections 1, 3, 8, 9, 10, and 11.

11. MISCELLANEOUS

11.1. Amendment. Except as expressly set forth herein, no amendment of this Agreement shall be effective unless expressed in a writing signed by a duly authorized representative of each Party.

11.2. Assignment. Neither Party shall have the right to assign or otherwise transfer this Agreement, or any of its rights and obligations hereunder, in whole or in part, without the other Party's prior written consent, and any attempted assignment or transfer without such consent shall be void; provided, however, that Amgen may assign or otherwise transfer this Agreement and its rights and obligations hereunder to any of its Affiliates that is not in the business of providing Dialysis Services in the Territory. Notwithstanding the foregoing, each Party shall be obligated to assign and transfer this Agreement, without any required consent, to any Person to whom either such Party has transferred all or substantially all of its business relating to this Agreement, and the Parties agree that they shall take all reasonable and necessary actions in respect thereof including the execution and delivery of all appropriate instruments to effectuate such assignment and transfer of this Agreement; provided that any assignment and transfer of this Agreement by Amgen to any Person, a substantial portion of whose business consists of providing Dialysis Services in the Territory, shall require the prior written consent of Dialysis Center, which consent may be withheld by Dialysis Center in its sole and absolute discretion. This Agreement and the provisions hereof shall be binding upon, and inure to the benefit of, the Parties' permitted successors and assigns.

11.3. Modification of Law. If at any time following the Term Start Date, the enactment or modification of any Law occurs and, as a result, either Party's performance of its obligations under this Agreement would not comply with such Law, either Party may, upon notice to the other Party, recommend an amendment to modify this Agreement to address those provisions of the Agreement that may not comply with such Law. The Parties agree to use their commercially reasonable best efforts to modify this Agreement as necessary to bring it into compliance with the Law if that can be done while retaining, in all material respects, the essential rights and benefits of each Party under this Agreement, including the Purchase Commitment, the Supply Commitment, the collection, exchange and use of the Data and the ability for Dialysis Center Purchasers to earn the Discounts that the Dialysis Center Purchasers are eligible to receive hereunder. Promptly following the delivery of such notice describing the Law at issue and the proposed modifications to bring this Agreement into compliance with such Law, Dialysis Center and Amgen shall meet and in good faith seek to mutually agree to amend this Agreement to accommodate any such Law in accordance with this Section 11.3.

-
- 11.4. Conflicting Provisions. To the extent that any provisions of Amgen' s general or customary policies and procedures or any terms of any purchase order conflict with or are in addition to the terms of this Agreement or any Exhibit or Schedule attached hereto, the terms of this Agreement and its Exhibits and Schedules shall govern.
- 11.5. Construction. This Agreement shall be deemed to have been jointly drafted by the Parties, and no rule of strict construction shall apply against either Party. As used herein, the word "including" shall mean "including, without limitation."
- 11.6. Counterparts; Facsimile/PDF Signatures. This Agreement may be executed in one or more counterparts, each of which shall be considered an original. The Parties agree that facsimile or PDF transmission of original signatures shall constitute and be accepted as original signatures.
- 11.7. Currency. All amounts herein are set forth in United States Dollars.
- 11.8. Force Majeure. Except as provided in Section 2.1.1 or Section 2.5, neither Party will be liable for delays in performance or nonperformance of this Agreement or any covenant contained herein if such delay or nonperformance is a result of acts of God, acts of civil or military authority, acts of any Governmental Authority, civil disobedience or commotion, epidemics, war, terrorist acts, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe, inability to procure necessary raw materials in a commercially reasonable manner or default of suppliers or subcontractors or any events beyond the reasonable control and without the fault or negligence of a Party (all of the foregoing, a "Force Majeure Event"). Force Majeure Events shall not adversely affect Dialysis Center' s eligibility for any Discounts.
- 11.9. Further Assurances. Each Party shall perform all further acts reasonably requested by the other to effectuate the purposes of this Agreement, including obtaining the Certifications under Section 5 or obtaining purchase data necessary from third parties to calculate any amounts payable pursuant to Exhibit A.
- 11.10. Governing Law. This Agreement shall be governed by the laws of the State of California (without regard to its conflict of law rules) and, except as otherwise set forth in this Agreement, the Parties submit to the jurisdiction of the California courts, both state and federal.
- 11.11. Merger/No Reliance. This Agreement, together with the Schedules, and the Exhibits constitutes the entire agreement, written or oral, of the Parties as of the Term Start Date concerning the subject matter hereof. The Parties acknowledge that, in making the determination to enter into this Agreement or otherwise, they have not relied, in whole or in part, on any promise, information, understanding, guarantees, discussions, representation, or warranty, expressed or implied, not contained specifically in this Agreement. Without limiting the generality of the foregoing, the Parties agree that neither Party makes or has made any representation or warranty with respect to any potential changes in the dialysis segment or the use or pricing of ESAs in dialysis, including as a result of the introduction of Alternative ESAs (including [DELETED]) including the timing of such introduction(s), the pricing of such Alternative ESAs and their potential physician acceptance and impact on prescribing practices.
- 11.12. No Partnership. The relationship between Amgen and Dialysis Center is that of independent contractors, and not a partnership or an agency, franchise or other relationship. Neither Party shall have the authority to bind the other.

11.13. Notices. Any notice or other communication required or permitted hereunder (excluding purchase orders) shall be in writing and shall be deemed given or made five (5) days after deposit in the United States mail with proper postage for first-class registered or certified mail prepaid, return receipt requested, or when delivered personally or by facsimile (as shown by concurrent written transmission confirmation and confirmed by overnight mail), or one (1) day following traceable delivery to a nationally recognized overnight delivery service with instructions for overnight delivery, in each case addressed to the address set forth below, or at such designated address that either Party shall have furnished to the other in accordance with this Section 11.13:

If to Amgen:

Amgen USA Inc.
One Amgen Center Drive, [DELETED]
Thousand Oaks, CA 91320-1789
Attn: Specialist, Contracts & Pricing - Nephrology Business Unit
Fax: [DELETED]

with a copy to:

Amgen USA Inc.
One Amgen Center Drive, [DELETED]
Thousand Oaks, CA 91320-1789
Attn: General Counsel
Fax: [DELETED]

If to Amgen Inc.: Amgen Inc.

One Amgen Center Drive, [DELETED]
Thousand Oaks, CA 91320-1789
Attn: General Counsel
Fax No.: [DELETED]

If to Dialysis Center:

DaVita Inc.
1350 Old Bayshore Highway, Suite 777
Burlingame, California 94010
Attn: Vice-President of Purchasing
Fax No.: [DELETED]

with a copy to:

DaVita Inc.
1551 Wewatta Street
Denver, CO 80202
Attn: Chief Legal Officer
Fax No.: [DELETED]

11.14. Confidentiality. “Confidential Information” means any and all information provided by one Party and/or any of its Affiliates (including Managed Centers in the case of Dialysis Center) (the “Disclosing Party”) to the other Party and/or any of its Affiliates (including Managed Centers in the case of Dialysis Center) (the “Non-Disclosing Party”) which is identified in writing or orally as confidential by the Disclosing Party to the Non-Disclosing Party or given the nature of the information or circumstances surrounding its disclosure

reasonably should be considered as confidential, whether in written, computerized, oral, tangible or intangible, and/or other form. Nothing in this Section 11.14 shall prohibit, Amgen from using the Data, the Compensation Data, and/or the Self-Reported Purchase Data as provided in Section 5 and Section 6.

- 11.14.1. Confidentiality Covenants. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, the Non-Disclosing Party agrees that for the Term, and for a period of five (5) years following the Term, the Non-Disclosing Party will keep confidential and not publish or otherwise disclose to any Third Party or use for any purpose, other than in accordance with this Agreement, any Confidential Information, provided, however, that the Non-Disclosing Party may disclose any such Confidential Information to its directors, officers, employees, agents, consultants and advisors as necessary for the Non-Disclosing Party to carry out its rights and obligations under this Agreement on the condition that such directors, officers, employees, agents, consultants and advisors are bound by confidentiality provisions at least as restrictive as those contained in this Agreement. The confidentiality provisions contained in this Section 11.14 shall not apply to the extent that it can be established by the Non-Disclosing Party by competent proof that such Confidential Information:
- (a) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Non-Disclosing Party by the Disclosing Party; or
 - (b) became generally available to the public or otherwise part of the public domain after its disclosure to the Non-Disclosing Party by the Disclosing Party and other than through any act or omission of the Non-Disclosing Party in breach of this Agreement; or
 - (c) was independently discovered or developed by the Non-Disclosing Party without the use of or reference to the Confidential Information belonging to the Disclosing Party.
- 11.14.2. Retention and Destruction of Confidential Information. At any time upon the written request of the Disclosing Party the Non-Disclosing Party shall promptly return to the Disclosing Party or destroy all Confidential Information. Notwithstanding the return or destruction of the Confidential Information to the Disclosing Party or such other party as designated by the Disclosing Party to the Non-Disclosing Party, the Non-Disclosing Party covenants and agrees that it will continue to abide by its obligations hereunder with respect to any and all Confidential Information.
- 11.14.3. Disclosures Required By Law. In the event that the Non-Disclosing Party and/or any of its directors, officers, employees, agents, consultants and advisors that have received any Confidential Information is required by Law (e.g., by oral questions, interrogatories, request for information or documents, subpoena, civil investigative demand, or similar process) to disclose any Confidential Information, the Non-Disclosing Party agrees to (and shall cause each of its directors, officers, employees, agents, consultants and advisors that have received any Confidential Information to) provide the Disclosing Party with immediate written notice of any such disclosure of Confidential Information that is required by Law in order to provide the Disclosing Party with an opportunity to seek a protective order or other similar order with respect to such Confidential

Information. If disclosure of any Confidential Information is required by Law, the Non-Disclosing Party will (and will cause each of its directors, officers, employees, agents, consultants and advisors that have received any Confidential Information to) furnish only that portion of the Confidential Information which it is legally obligated to disclose by Law and consistent with the terms of any protective order or other similar order obtained by the Disclosing Party with respect to such Confidential Information required to be disclosed by Law.

- 11.14.4. Public Announcements; Authorized Disclosure. Neither Party shall make a public announcement or other public disclosure concerning this Agreement without the consent of the other Party, except that either Party may make such announcement or disclosure if it is required by applicable Law, reasonably necessary for any filings with any Governmental Authority or pursuant to the rules of any securities exchange or interdealer quotation system; provided, that the disclosing Party shall give reasonable prior advance notice of the proposed text of such announcement or disclosure to the other Party for its prior review and approval, which review and approval shall not be unreasonably conditioned, withheld or delayed. The proviso in the immediately preceding sentence shall not apply to Relevant Information included in any cost report filed under Title XVIII or Title XIX of the Social Security Act, or health care program of any Governmental Authority.
- 11.14.5. Confidential Terms. Notwithstanding the foregoing, each Party may disclose the terms of this Agreement in confidence under terms and conditions at least as restrictive as set forth herein on a need-to-know basis to its legal and financial advisors to the extent such disclosure shall be reasonably necessary in connection with such Party's activities as expressly permitted by this Agreement.
- 11.14.6. Enforcement. Each Party agrees that money damages alone would not be an adequate remedy for any breach of the terms and conditions of this Section 11.14. Therefore, in the event of a breach or threatened breach of this Section 11.14, the non-breaching Party may, in addition to other rights and remedies existing in its favor, apply to any court of competent jurisdiction for specific performance and/or injunctive and/or other relief in order to enforce and/or prevent any violation of the provisions of this Section 11.14 by the breaching Party (without proving monetary damages and/or posting a bond and/or other security).
- 11.15. Severability. Subject to the provisions of Section 11.3, if any one or more of the provisions of this Agreement is held to be invalid or unenforceable, the provisions shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof.
- 11.16. Waiver. No Party shall be deemed to have waived any right hereunder, unless such waiver is expressed in a writing signed by such Party.
- 11.17. Open Records. To the extent required by §1861(v)(1)(I) of the Social Security Act, as amended, the Parties will allow the U.S. Department of Health and Human Services, the U.S. Comptroller General and their duly authorized representatives, access to this Agreement and all books, documents and records necessary to certify the nature and extent of costs incurred pursuant to it during the Term and for four (4) years following the last date any EPOGEN or services are furnished under it. If Amgen carries out the duties of this Agreement through a subcontract worth \$10,000 or more over a 12-month period with a related organization, the subcontract shall also contain an access clause to

permit access by the U.S. Department of Health and Human Services, the U.S. Comptroller General, and their duly authorized representatives to the related organization's books and records.

- 11.18. Amgen's ESA Risk Evaluation and Mitigation Strategy Program. Dialysis Center and its Designated Affiliates and Managed Centers shall reasonably cooperate and comply with Amgen in Amgen's implementation of its ESA Risk Evaluation and Mitigation Strategy program as found at the FDA website: <http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM200105.pdf> ("the FDA Website") and which may be modified from time to time by the FDA (the "Amgen ESA Risk Evaluation Program"). Dialysis Center shall refer to the FDA Website for updates to the Amgen ESA Risk Evaluation Program.
- 11.19. Recall. In the event the FDA initiates a mandatory recall or Amgen initiates a recall, field market withdrawal, stock recovery, or other similar action with respect to EPOGEN (a "Recall"), the Dialysis Center Purchasers shall cooperate with Amgen in implementing the Recall consistent with applicable Law, any industry guidance issued by the FDA, and the terms or procedures of the Recall, including reasonable cooperation with any Amgen designated Third Party vendors.
- 11.20. Assumption of Risk. Each Party expressly accepts and assumes all risks that may arise out of or result from uncertainties or changes to the dialysis market including those resulting from the introduction of Alternative ESAs (including [DELETED]), including the timing of such introduction(s), the pricing of such Alternative ESAs and their potential physician acceptance and impact on prescribing practices.

The Parties have executed this Agreement by their designated representatives set forth below.

AMGEN USA INC.

DIALYSIS CENTER

By: /s/ Anthony C. Hooper
Name (print): Anthony C. Hooper
Title: Executive Vice President
Date: November 15, 2011

By: /s/ Dennis Kogod
Name (print): Dennis Kogod
Title: Chief Operating Officer
Date: November 15, 2011

Amgen Inc. with respect to certain provisions of this Agreement as set forth herein.

Amgen Inc.

By: /s/ Anthony C. Hooper
Name (print): Anthony C. Hooper
Title: Executive Vice President
Date: November 15, 2011

Exhibit A

Discount Terms and Conditions

1 **DEFINITIONS.** In addition to the defined terms set forth in Section 1 of this Agreement, the following terms, as used in this Exhibit A, shall have the meaning ascribed below.

[DELETED] Rebate Definitions

- 1.1 “Amgen Dialysis Contract” shall mean, as of any determination date, a contract between Amgen or one of its Affiliates and a Qualified Customer in effect as of such date that provides for such Qualified Customer to purchase EPOGEN for its commercial use in providing Dialysis Services in the Territory.
- 1.2 “Qualified Customer” shall mean a Third Party commercial enterprise collectively with all of its Affiliates and/or any dialysis facility in which a Third Party commercial enterprise and/or any of its Affiliates has an ownership interest of less than fifty percent (50%) but for which the Third Party commercial enterprise and/or any of its Affiliates provides management services or administrative services in which it controls the selection or procurement of ESAs (a) who has entered into an Amgen Dialysis Contract and (b) who is not exempt from consideration in the calculation of Best Price as defined by the Social Security Act at section 1927(c)(1)(C), as amended, and as implemented by regulation (e.g., any hospital participating in 340B Drug Pricing Program, any qualified state pharmaceutical assistance program, or any purchaser under the Federal Supply Schedule would not be a “Qualified Customer” for purposes of this Agreement).
- 1.3 “[DELETED]” shall mean for each [DELETED] of EPOGEN purchased by a Qualified Customer in any Quarter under an Amgen Dialysis Contract, the [DELETED] in effect on the date of purchase [DELETED] all of the discounts and rebates per [DELETED] of EPOGEN that, for such Quarter were actually earned by such Qualified Customer pursuant to the terms of such Amgen Dialysis Contract (regardless of the actual Quarter in which such discounts or rebates are actually paid to such Qualified Customer); provided, that if any such discounts and rebates once paid are subsequently returned, revised or withdrawn, including pursuant to any retroactive amendment of the Amgen Dialysis Contract or payment settlement (whether in such Quarter or any subsequent Quarter), the applicable “[DELETED]” shall be based on the discounts, rebates and chargebacks taking into full account such returns, revisions or withdrawals.

[DELETED] Rebate Definitions

- 1.4 “[DELETED] Rebate” shall mean the rebate described in Section 3.3 of this Exhibit A.

1.5 “[DELETED] Percentage” shall mean, at any date of determination, an amount equal to

$$\frac{((A - B) \text{ if } > 0)}{C}$$

Where

“A” equals [DELETED]

“B” equals [DELETED]

“C” equals [DELETED] in effect at the time of purchase

For example, a determination of [DELETED] Rebate Percentage would be as follows:

[DELETED] Rebate Percentage Illustration:

$$(([\text{DELETED}] - [\text{DELETED}]) \text{ if greater than zero})$$

÷

[DELETED] in effect at the time of purchase

- 1.6 “[DELETED]” shall mean a trial comparing the [DELETED] of patients receiving EPOGEN and the [DELETED] in connection with the provision of Dialysis Services.
- 1.7 “[DELETED] Price” shall mean the [DELETED] of the [DELETED] for the applicable Quarter as reported by the Centers for Medicare & Medicaid Services as mandated by the Patient Protection and Affordable Care Act, as amended and reconciled by the Healthcare and Education Reconciliation Act and implementing regulations and as adjusted to take into account the [DELETED] agreed to by the Parties or the results of the [DELETED], as applicable.
- 1.8 “[DELETED]” shall mean a [DELETED] product that has been approved by the FDA both as a [DELETED] and as [DELETED]. [DELETED] shall have the meanings ascribed to such terms in the Public Health Service Act (Title 42 U.S. Code, Chapter 6A), as such terms may be further defined by the FDA.

1.9 “[DELETED]” shall mean for each [DELETED] of EPOGEN purchased by a Dialysis Center Purchaser under this Agreement in any Quarter, the [DELETED] in effect on the date of purchase less for such Quarter (i) the Discounts that Dialysis Center is eligible to earn under this Agreement during the applicable Quarter, including the [DELETED] Rebate, the [DELETED] Rebate, and the [DELETED] Rebate, as applicable, and (ii) any other discount, rebate or other price adjustment received by a Dialysis Center Purchaser per [DELETED] of EPOGEN which is included in the “Best Price” reported in Amgen’s Best Price Submission under Title XIX of the Social Security Act in respect of such EPOGEN purchase.

1.10 “[DELETED]” shall mean, for any Quarter in which the [DELETED] Rebate is applied, an amount equal to $(A * B) + A$

Where

“A” equals the [DELETED] Price during such Quarter

“B” equals [DELETED]%

For example, a determination of [DELETED] would be as follows:

[DELETED] Illustration:

$$([\text{DELETED}] \text{ Price} * [\text{DELETED}]\%) + [\text{DELETED}] \text{ Price}$$

Dialysis Share of Sales Definitions

1.11 “Dialysis Market [DELETED] Purchases of [DELETED]” means, for any period, the aggregate [DELETED] paid for purchases of [DELETED] by all purchasers, including those by all Dialysis Center Purchasers, during such period for use in providing Dialysis Services, from any source measured using the prevailing [DELETED] as set by the product manufacturer in effect at the time of purchase to be determined by Amgen based on DDD™ data provided by IMS or if IMS’ DDD™ data is unavailable, by reliable alternative means to be determined by Amgen in Amgen’s reasonable discretion, subject to verification by Amgen.

1.12 “Dialysis Share of Sales” shall mean Dialysis Center Qualified [DELETED] Purchases [DELETED] during the Quarter divided by Dialysis Market [DELETED] Purchases of [DELETED] during the Quarter.

Dialysis Share of Sales Illustration:

$$\text{Dialysis Center Qualified [DELETED] Purchases of [DELETED]}$$

÷

$$\text{Dialysis Market [DELETED] Purchases of [DELETED]}$$

1.13 “Dialysis Share of Sales Requirement” shall mean, for any Quarter, that Dialysis Center had an aggregate Dialysis Share of Sales for any such Quarter and the immediately preceding Quarter that was equal to or greater than [DELETED] percent ([DELETED]%) in the aggregate for such two (2) Quarter period. It is not the intent of the Parties that a [DELETED] of any Alternative ESA (on a [DELETED] equivalent basis) that is significantly higher than the [DELETED] for EPOGEN should negatively

affect Dialysis Center' s attainment of the Dialysis Share of Sales Requirement. If at any time during a Quarter, an Alternative ESA is introduced with respect to the provision of Dialysis Services which has a [DELETED] for such Alternative ESA to [DELETED] as established by the manufacturer of such Alternative ESA that potentially is significantly greater than (on a [DELETED] equivalent basis) the [DELETED] for EPOGEN (a “[DELETED] Event”), Dialysis Center shall deliver a written notice to Amgen indicating that there has been a [DELETED] Event (a “[DELETED] Event Notice”). Within thirty (30) days after Amgen' s receipt of a [DELETED] Event Notice, the Parties shall meet and discuss in good faith any necessary changes, amendments, and/or adjustments to the calculation of the Dialysis Share of Sales Requirement to account for the impact of such [DELETED] Event on the Parties.

1.14 “Dialysis Center Qualified [DELETED] Purchases of [DELETED]” means, for any period, the aggregate [DELETED] paid for purchases of [DELETED] by all Dialysis Center Purchasers during such period for use in providing Dialysis Services, from any source measured using the prevailing [DELETED] as set by the product manufacturer in effect at the time of purchase to be determined by Amgen based on the DDD™ data provided by IMS or if IMS' DDD™ data is unavailable, by reliable alternative means to be determined by Amgen in Amgen' s sole discretion, subject to verification by Amgen.

1.15 “[DELETED] Event” has the meaning set forth in Section 1.13 of this Exhibit A.

1.16 “[DELETED] Event Notice” has the meaning set forth in Section 1.13 of this Exhibit A.

[DELETED] Share of Sales Definitions

1.17 “Dialysis Market [DELETED] Purchases of [DELETED] for [DELETED] Rebate” means, for any period, the aggregate [DELETED] paid for purchases of [DELETED] by all purchasers, but excluding all Dialysis Center Purchasers, during such period for use in providing Dialysis Services, from any source measured using the prevailing [DELETED] as set by the product manufacturer in effect at the time of purchase to be determined by Amgen based on data provided by a third-party reporting agency or if third-party reporting agency data is unavailable, by reliable alternative means to be determined by Amgen in Amgen' s sole reasonable discretion, subject to verification by the Parties.

1.18 “[DELETED] Share of Sales” shall mean Qualified [DELETED] Purchases of the [DELETED] during the Quarter divided by Dialysis Market [DELETED] Purchases of [DELETED] for [DELETED] Rebate during the Quarter.

[DELETED] Share of Sales Illustration:

Qualified [DELETED] Purchases of [DELETED]

÷

Dialysis Market [DELETED] Purchases of [DELETED] for [DELETED] Rebate

1.19 “Qualified [DELETED] Purchases of [DELETED]” means, for any period the aggregate [DELETED] paid for purchases of the applicable [DELETED] by all purchasers, but excluding all Dialysis Center Purchasers, during such period for use in providing Dialysis Services, from any source measured using the prevailing [DELETED] as set by the product manufacturer in effect at the time of purchase to be

determined by Amgen based on data provided by a third-party reporting agency or if third-party reporting agency data is unavailable, by some alternative means to be determined by Amgen in Amgen's sole discretion, subject to verification by Amgen.

[DELETED] Rebate Definitions

1.20 “[DELETED]” shall mean the applicable [DELETED] per [DELETED] of EPOGEN as set forth in the [DELETED] Table below.

[DELETED] Table

<u>Calendar Year</u>	<u>[DELETED]</u>
2012	\$(DELETED)
2013	\$(DELETED)
2014	\$(DELETED)
2015	\$(DELETED)
2016	\$(DELETED)
2017	\$(DELETED)
2018	\$(DELETED)

1.21 “[DELETED] Rebate Percentage” shall mean, at any date of determination, an amount equal to

$$\frac{((A - B) \text{ if } > 0)}{C}$$

Where

“A” equals [DELETED]

“B” equals [DELETED]

“C” equals [DELETED] in effect at the time of purchase

For example, a determination of the [DELETED] Rebate Percentage would be as follows:

[DELETED] Rebate Percentage Illustration:

$$(((\text{[DELETED]} - \text{[DELETED]}) \text{ if greater than zero})$$

÷

[DELETED] in effect at the time of purchase

[DELETED] Incentive Definitions

1.22 “[DELETED]” shall mean the [DELETED] incentive described in Section 3.5 of this Exhibit A.

1.23 Other. The Parties acknowledge and agree that (i) the aggregate [DELETED] paid for purchases of [DELETED] by all purchasers for use in providing Dialysis Services in the Territory include purchases by [DELETED] as well as other purchasers of ESAs for use in providing Dialysis Services, (ii) there may not be commercially available data comprising purchases of ESAs by all purchasers for use in providing Dialysis Services

in the Territory that Dialysis Center could access in order to understand and track the Dialysis Share of Sales on an ongoing basis, (iii) there is commercially available data comprising purchases of ESAs by [DELETED] in the Territory that Dialysis Center could access, (iv) the [DELETED] purchases of ESAs by [DELETED] in the Territory currently represents approximately [DELETED] percent ([DELETED]%) of [DELETED] purchases of ESAs by all purchases for use in providing Dialysis Services in the Territory, (v) for the sole and limited purpose of determining whether Dialysis Center shall have met the Dialysis Share of Sales requirement under Sections 3.2.1 and 3.4.1 of this Exhibit A, the aggregate [DELETED] paid for purchases of [DELETED] by all purchasers for use in providing Dialysis Services in the Territory shall be calculated as [DELETED] percent ([DELETED] %) of the aggregate [DELETED] purchases of ESAs by [DELETED] in the Territory and (vi) for the sole and limited purpose of determining whether the [DELETED] Share of Sales requirement under Section 3.3.1 and Section 3.3.2 of this Exhibit A has been met, (a) the aggregate [DELETED] paid for purchases of [DELETED] by all purchasers, but excluding all Dialysis Center Purchasers, for use in providing Dialysis Services in the Territory shall be calculated as [DELETED] percent ([DELETED] %) of the aggregate [DELETED] purchases of ESAs by [DELETED], but excluding all Dialysis Center Purchasers, in the Territory and (b) the aggregate [DELETED] paid for purchases of the applicable [DELETED] by all purchasers, but excluding all Dialysis Center Purchasers, for use in providing Dialysis Services in the Territory shall be calculated as [DELETED] percent ([DELETED]%) of the aggregate [DELETED] purchases of the applicable [DELETED] by [DELETED], but excluding all Dialysis Center Purchasers, in the Territory.

2 PRODUCT INVOICE DISCOUNTS

2.1 Base Invoice Discounts. Subject to the terms and conditions contained in the Agreement, Dialysis Center Purchasers shall be entitled to the Base Invoice Discount set forth in the following Base Invoice Discount Table, applied to [DELETED] in effect at the time of purchase of EPOGEN by Dialysis Center Purchasers under the Agreement, exclusive of any wholesaler markup, discount, service fees or other charges:

Base Invoice Discount Table

<u>PRODUCT</u>	<u>NDC</u>	<u>INVOICE DISCOUNT</u>
EPOGEN	All NDCs	[DELETED]%

3 PRODUCT REBATES

3.1 Base Rate Rebate. Dialysis Center shall earn a non-performance Base Rate Rebate for each Quarter during the Term in the manner described below in this Section 3.1.

3.1.1 Base Rate Rebate Calculation. Amgen shall calculate the amount of Dialysis Center’s Base Rate Rebate by multiplying Dialysis Center’s Qualified Gross Purchases of EPOGEN during a Quarter by the applicable Base Rate Rebate Percentage for the calendar year in which such Quarter occurs, according to the Base Rate Rebate Percentage Table below.

Base Rate Rebate Percentage Table

<u>Calendar Year</u>	<u>Base Rate Rebate Percentage</u>
2012	[DELETED] %
2013	[DELETED] %
2014	[DELETED] %
2015	[DELETED] %
2016	[DELETED] %
2017	[DELETED] %
2018	[DELETED] %

- 3.1.2 Payment of Base Rate Rebate. Amgen will pay the Base Rate Rebate within [DELETED] days after the end of the corresponding Quarter, provided Amgen is in receipt of all Relevant Information in a form acceptable to Amgen.
- 3.1.3 Vesting of Base Rate Rebate. The Base Rate Rebate for a given Quarter shall vest on the last day of such Quarter.
- 3.2 [DELETED] Rebate. Dialysis Center shall earn the [DELETED] Rebate, if any, for each Quarter during the Term provided it meets the requirements described below in this Section 3.2.
- 3.2.1 Eligibility for [DELETED] Rebate. Dialysis Center shall be eligible to receive the [DELETED] Rebate for any Quarter during the Term if each of the following shall have occurred in such Quarter: (a) Dialysis Center shall have met the Dialysis Share of Sales Requirement, (b) any Qualified Customer received a [DELETED] under an Amgen Dialysis Contract that is lower than the [DELETED] and (c) either (i) the aggregate net sales for all EPOGEN purchased by any such Qualified Customer who received a [DELETED] under an Amgen Dialysis Contract that is lower than the [DELETED] during such Quarter were greater than [DELETED] percent ([DELETED]%) of the aggregate net sales of EPOGEN to all purchasers in the Territory in such Quarter or (ii) the aggregate net sales for all EPOGEN purchased during such Quarter by all Qualified Customers in the aggregate who received a [DELETED] under an Amgen Dialysis Contract that is lower than the [DELETED] were greater than [DELETED] percent ([DELETED]%) of the aggregate net sales of EPOGEN to all purchasers in the Territory in such Quarter. Amgen's calculation of the [DELETED] Rebate shall not take into account any reallocation of discounts for purposes of any reports filed under Title XVIII or Title XIX of the Social Security Act, under any health care program of a Governmental Authority or pursuant to any other Law.

-
- 3.2.2 Calculation of [DELETED] Rebate. Amgen shall calculate the amount of Dialysis Center' s [DELETED] Rebate for any Quarter by taking the total of the [DELETED] minus the [DELETED], multiplied by the number of [DELETED] of EPOGEN purchased by all Dialysis Center Purchasers at a [DELETED] during such Quarter.

[DELETED] Rebate Illustration:

$$\begin{array}{c} ([DELETED] - [DELETED]) \\ \times \\ \text{Number of [DELETED] of EPOGEN purchased at [DELETED]} \end{array}$$

- 3.2.3 Payment of [DELETED] Rebate Amount. Amgen will pay the [DELETED] Rebate within [DELETED] days after the end of the corresponding Quarter, provided Amgen is in receipt of all Relevant Information in a form acceptable to Amgen.
- 3.2.4 Vesting of [DELETED] Rebate. The [DELETED] Rebate for a given Quarter shall vest on the last day of such Quarter.
- 3.3 [DELETED] Rebate. Dialysis Center shall earn a [DELETED] Rebate for each Quarter during the Term in the manner described below in this Section 3.3.
- 3.3.1 Trigger Event for [DELETED] Rebate. In the event that an [DELETED] had an [DELETED] Share of Sales of greater than [DELETED] percent ([DELETED]%) for [DELETED] consecutive Quarters during the Term, the Parties shall work together in good faith to determine a [DELETED] between the [DELETED] and EPOGEN. In the event the Parties are not able to determine a mutually agreed upon [DELETED] between the [DELETED] and EPOGEN within thirty (30) days of the end of the applicable Quarter at which the [DELETED] Rebate is at issue or such longer period of time as mutually agreed to by the Parties, the Parties shall work together in good faith to undertake a [DELETED], which [DELETED] shall be jointly funded by the Parties. If the Parties fail to agree on a design for the [DELETED], the Parties shall jointly appoint a mutually agreeable Third Party to design and undertake the [DELETED].
- 3.3.2 Qualification Criteria. If for a Quarter during the Term, an [DELETED] had an [DELETED] Share of Sales of greater than [DELETED] percent ([DELETED]%) for such Quarter and the immediately prior Quarter, then Dialysis Center shall be entitled to the [DELETED] Rebate for such Quarter, as calculated in Section 3.3.3 below.
- 3.3.3 [DELETED] Rebate Calculation. Amgen shall calculate the amount of Dialysis Center' s [DELETED] Rebate by multiplying the Qualified Gross Purchases of EPOGEN during the applicable Quarters by the applicable [DELETED] Rebate Percentage for such applicable Quarters.
- 3.3.4 Payment of [DELETED] Rebate. Amgen will pay the [DELETED] Rebate within [DELETED] days after the end of the corresponding Quarter, provided Amgen is in receipt of all Relevant Information in a form acceptable to Amgen and provided further, that in the event a final [DELETED] for the applicable [DELETED] has not been determined hereunder within thirty (30) days after the end of the applicable Quarter pursuant to Section 3.3.1 of this Exhibit A, such [DELETED] Rebate will be paid within [DELETED] days after the end of the Quarter in which a final [DELETED] for the applicable [DELETED] has been determined.

-
- 3.3.5 Vesting of [DELETED] Rebate. The [DELETED] Rebate for a given Quarter shall vest on the last day of such Quarter.
- 3.4 [DELETED] Rebate. Dialysis Center shall earn the [DELETED] Rebate for each Quarter during the Term in the manner described below in this Section 3.4
- 3.4.1 Qualification Criteria. If, for any Quarter during the Term, the [DELETED] exceeds the [DELETED] (“[DELETED] Trigger Event”), then Dialysis Center Purchasers shall be entitled to the [DELETED] Rebate as calculated in Section 3.4.2 below, provided that the Dialysis Share of Sales Requirement is met during such Quarter. Such [DELETED] Rebate shall apply to all purchases of EPOGEN by Dialysis Center Purchasers during such Quarter from the date of the [DELETED] Trigger Event until the date (if any) at which the [DELETED] is equal to or greater than the [DELETED].
- 3.4.2 Calculation of [DELETED] Rebate. Amgen shall calculate the amount of Dialysis Center’s [DELETED] Rebate by multiplying the Qualified Gross Purchases of EPOGEN during the applicable Quarter by the [DELETED] Rebate Percentage for such Quarter; provided, however, that in the event of an increase of [DELETED] other than on the first day of a calendar year, then the [DELETED] Rebate shall be reduced by an amount equal to the Qualified Gross Purchases of EPOGEN during such calendar year prior to the increase in [DELETED] multiplied by the [DELETED] minus the [DELETED].
- 3.4.3 Payment of [DELETED] Rebate. Amgen will pay such [DELETED] Rebate within [DELETED] days after the end of the corresponding Quarter, provided Amgen is in receipt of all Relevant Information in a form reasonably acceptable to Amgen.
- 3.4.4 Vesting of [DELETED] Rebate. The [DELETED] Rebate for a given Quarter shall vest on the last day of such Quarter.
- 3.5 [DELETED] Incentive. Dialysis Center shall earn the [DELETED] for each Quarter during the Term provided all Dialysis Center Purchasers provide to Amgen the Data set forth in Schedule 1 and provided Dialysis Center meets the requirements described below in this Section 3.5.
- 3.5.1 Submission of Data Requirement. Subject to the validity of a Certification as described in Section 5 of this Agreement, Dialysis Center Purchasers must provide to Amgen the Data in a machine readable format acceptable to Amgen (Excel; or text file that is tab delimited, comma delimited, colon delimited or space delimited including a line of column headers identifying the column contents and [DELETED], if applicable). The Data files shall contain record counts for each file contained in the data submission; provided, however, that Dialysis Center shall be required to submit such test results only for those dialysis patients whose test results are actually determined by laboratories owned and operated by Dialysis Center.
- 3.5.2 Calculation of [DELETED]. Provided Dialysis Center has fulfilled all requirements described in this Section 3.5 of this Exhibit A, Dialysis Center shall be eligible to receive a [DELETED] percent ([DELETED]%) [DELETED] payment. The [DELETED] will be calculated as a percentage of the Qualified Gross Purchases of EPOGEN during each Quarter.
- 3.5.3 Payment of [DELETED]. The Data must be submitted, on a calendar monthly basis by the last day of the following calendar month (or the next business day if such last day is not a business day). If the Data is received after such timeframe for any month within a given Quarter, the total Qualified Gross Purchases of EPOGEN during such month will be excluded from the calculation of the [DELETED] for that Quarter. Notwithstanding the

foregoing, if Amgen receives all required Data from a minimum of [DELETED] percent ([DELETED]%) of all Dialysis Center Purchasers within the time frame referenced above for any calendar month within a given Quarter, the total Qualified Gross Purchases of EPOGEN during such calendar month, will be included in the calculation of the [DELETED] for that Quarter; provided that for purposes of clarity, the [DELETED] percent ([DELETED]%) will not include Dialysis Center Purchasers that are acute facilities. Failure of Dialysis Center to qualify under this Section 3.5 of this Exhibit A during a particular Quarter shall not affect Dialysis Center's eligibility to qualify during any other Quarter, nor shall Dialysis Center's qualification during a particular Quarter automatically result in qualification during any other Quarter. If Amgen receives all required Data from less than [DELETED] percent ([DELETED]%) of Dialysis Center Purchasers for any calendar month within a given Quarter, no Qualified Gross Purchases of EPOGEN during such calendar month will be included in the calculation of the [DELETED] for that Quarter; provided, however, that if such [DELETED] percent ([DELETED]%) threshold is not met in any month due to the inclusion of *de novo* facilities that have not yet treated patients and/or inactive facilities, Amgen shall exclude any such facilities identified by Amgen and Dialysis Center from such month when calculating Dialysis Center's eligibility for the [DELETED] at the end of each Quarter. However, if Amgen determines that any Dialysis Center Purchaser is consistently not submitting the required Data, Amgen and Dialysis Center will work collaboratively in resolving such inconsistencies. Amgen will use commercially reasonable efforts to notify Dialysis Center in writing, no later than fifteen (15) business days after the receipt and acceptance by Amgen of the Data of the identity of all Dialysis Center Purchasers, if any, which have failed to meet the Data submission requirements for that month. Amgen reserves the right, in its sole discretion, to exclude any Qualified Gross Purchases of EPOGEN of any Dialysis Center Purchaser that is consistently non-reporting from the calculation of the [DELETED] for any relevant Quarter. Amgen will pay such [DELETED] within [DELETED] days after the end of the corresponding Quarter provided Amgen is in receipt of all Data in the form and in the time period described in Section 3.5.1 and this Section 3.5.3 of this Exhibit A. If the failure of Dialysis Center to deliver any of the Data is a result of a Certification not being valid due to Amgen's failure to satisfy any conditions, requirements or assumptions set forth in such Certification applicable to Amgen, then the [DELETED] shall still be available to Dialysis Center and payable by Amgen, in which case Dialysis Center shall deliver the Data to Amgen as soon as the Certification becomes valid. Upon a valid Certification being issued, Dialysis Center shall submit to Amgen all Data dating back to the date Dialysis Center stopped submitting the Data to Amgen within thirty (30) days.

3.5.4 Vesting of [DELETED]. The [DELETED] for a given Quarter shall vest on the last day of such Quarter.

4 **SUMMARY OF DISCOUNTS**

Provided Dialysis Center has fulfilled all Discount requirements, the total discount opportunity is as set forth in the Summary of Discounts Table below.

Summary of Discounts Table

	2012	2013	2014	2015	2016	2017	2018
Base Invoice							
Discount	[DELETED]%	[DELETED]%	[DELETED]%	[DELETED]%	[DELETED]%	[DELETED]%	[DELETED]%
Base Rate							
Rebate	[DELETED]%	[DELETED]%	[DELETED]%	[DELETED]%	[DELETED]%	[DELETED]%	[DELETED]%
[DELETED]							
Rebate	[DELETED]%	[DELETED]%	[DELETED]%	[DELETED]%	[DELETED]%	[DELETED]%	[DELETED]%
Total Discount							
Opportunity	[DELETED]%	[DELETED]%	[DELETED]%	[DELETED]%	[DELETED]%	[DELETED]%	[DELETED]%

Exhibit B

Authorized Wholesalers

The below represents a list of wholesalers authorized for participation under the attached Agreement. Any changes must be made in accordance with Section 2.7 of the Agreement. Only purchases from wholesalers set forth on this List (as may be modified pursuant to such Section 2.7) shall be eligible for the discounts and fees set forth in the Agreement. Notice(s) regarding pricing and membership alignment for the Agreement shall be sent to the wholesalers that Dialysis Center has designated for such notification below. In the absence of any such designation, Amgen shall send pricing and membership alignment notices for the Agreement to those Authorized Wholesalers as designated by Dialysis Center in its previously executed Agreement.

_____ American Medical Distributors, Div. of AmerisourceBergen Corporation
_____ American Medical Services, Div. of Henry Schein, Inc.
_____ AmerisourceBergen Corporation
_____ ASD Healthcare, Div. of AmerisourceBergen Specialty Group
_____ Belco Drug Corporation, Div of AmerisourceBergen Corporation
_____ Besse Medical Supply, Div. of AmerisourceBergen Specialty Group
_____ Borschow Hospital and Medical Supplies, Inc., Div of Cardinal Health, Inc.
_____ Cardinal Health Inc.
_____ Cesar Castillo, Inc.
_____ CuraScript Specialty Distribution (Priority Healthcare Distribution)
_____ Dakota Drug Inc.
_____ Dik Drug Company
_____ DMS Pharmaceutical Group Inc.
_____ Drogueria Central, Inc.
_____ Florida Infusion Services, Inc.
_____ Frank W. Kerr Company
_____ General Injectables & Vaccines, Div. of Henry Schein, Inc.
_____ HD Smith Wholesale Drug Company
_____ Henry Schein, Inc.
_____ J.M. Blanco, Div of AmerisourceBergen Corporation
_____ Kinray, Inc.
_____ McKesson Corporation
_____ McKesson Medical-Surgical Maine Inc., Div. of McKesson Medical-Surgical
_____ McKesson Medical-Surgical Minnesota Supply Inc., Div. of McKesson Medical
_____ Surgical
_____ McKesson Medical-Surgical, Div. of McKesson Corporation
_____ McKesson Specialty Care Distribution Corporation, Div. of McKesson Corporation
_____ Metro Medical Supply Inc.
_____ Morris & Dickson Company LLC
_____ N.C. Mutual Wholesale Drug Company
_____ Oncology Supply, Div. of AmerisourceBergen Specialty Group
_____ Rochester Drug Corporation (RDC)
_____ Smith Drug Company
_____ Value Drug Company

Exhibit C

Designated Affiliates List

Page 48 of 123

Exhibit C

Designated Affiliates List

Active count	TYPE	CTR #	CENTER NAME	LEGAL NAME	ADDRESS	ADDRESS	CITY	STATE	ZIP
1	Affiliated	398	Los Angeles Dialysis Center	Los Angeles Dialysis Center (LADC)	3901 S WESTERN AVE		LOS ANGELES	CA	90062-1112
2	Affiliated	613	Garfield	Garfield Hemodialysis Center	118 HILLIARD AVE		MONTEREY PARK	CA	91754-1118
3	Affiliated	614	Lynwood	Kidney Dialysis Care Unit (Lynwood)	3600 E MARTIN LUTHER KING JR BLVD		LYNWOOD	CA	90262-2607
4	Affiliated	615	Lakewood Dialysis-CA	Lakewood Dialysis-CA	4611 SILVA ST		LAKESWOOD	CA	90712-2512
5	Affiliated	616	Valley Dialysis	Valley Dialysis	16149 HART ST		VAN NUYS	CA	91406-3906
6	Affiliated	617	Downey Dialysis	Downey Dialysis	8630 FLORENCE AVE	STE 1	DOWNEY	CA	90240-4017
7	Affiliated	618	Covina Dialysis	Covina Dialysis	1547 W GARVEY AVE N		WEST COVINA	CA	91790-2139
8	Affiliated	625	Four Corners Farmington	Four Corners Farmington	801 W BROADWAY		FARMINGTON	NM	87401-5650
9	Affiliated	626	Tuba City Dialysis	Tuba City Dialysis	500 EDGEWATER DR	PO BOX 291	TUBA CITY	AZ	86045-2905
10	Affiliated	627	Camelback Dialysis Center	Camelback Dialysis Center (fka Scottsdale Dialysis Center)	7321 E OSBORN DR		SCOTTSDALE	AZ	85251-6418
11	Affiliated	630	Westbank	Westbank Chronic Renal Center	3631 BEHRMAN PLACE		NEW ORLEANS	LA	70114
12	Affiliated	632	Fleur de Lis	Fleur de Lis Dialysis (fka Tri-Parish)	5555 BULLARD AVE		NEW ORLEANS	LA	70128-3450
13	Affiliated	637	Desert Mountain	Desert Mountain Dialysis	9220 E MOUNTAIN VIEW RD	STE 15	SCOTTSDALE	AZ	85258-5134

14	Affiliated	638	Chinle	Chinle Dialysis	US HWY 191	PO BOX 879	CHINLE	AZ	86503-0879
15	Affiliated	648	Central City	Central City Dialysis Center	1300 MURCHISON DR	STE 32	EL PASO	TX	79902-4840
16	Affiliated	651	Federal Way	Federal Way Community Dialysis Center	1015 S 348TH ST		FEDERAL WAY	WA	98003-7078
17	Affiliated	663	Beverly Hills	Beverly Hills Dialysis Center	50 N LA CIENEGA BLVD	3RD FLOOR, STE 3	BEVERLY HILLS	CA	90211-2205
18	Affiliated	667	Walnut Creek	Walnut Creek Dialysis Center	404 N WIGET LN		WALNUT CREEK	CA	94598-2408
19	Affiliated	672	Norwalk	Norwalk Dialysis Center	12375 E IMPERIAL HWY	STE D3	NORWALK	CA	90650-3129
20	Affiliated	673	El Monte	Greater El Monte Dialysis Center	1938 TYLER AVE	STE J-168	SOUTH EL MONTE	CA	91733-3623
21	Affiliated	676	Bayonet Point	Bayonet Point-Hudson Kidney	14144 NEPHRON LN		HUDSON	FL	34667-6504
22	Affiliated	677	New Port Richey	New Port Richey Kidney Center	7421 RIDGE RD		PORT RICHEY	FL	34668-6933
23	Affiliated	678	Hernando	Hernando Kidney Center, Inc	2985 LANDOVER BLVD		SPRING HILL	FL	34608-7258
24	Affiliated	681	Woodbridge	CDC Of Woodbridge	2751 KILLARNEY DR		WOODBIDGE	VA	22192-4119
25	Affiliated	682	Manassas	CDC- Manassas Dialysis	10655 LOMOND DR	STE 11	MANASSAS	VA	20109-2877
26	Affiliated	683	Springfield	CDC- Springfield Dialysis	8350 TRAFORD LN	STE A	SPRINGFIELD	VA	22152-1671
27	Affiliated	684	Sterling	CDC-Sterling	46396 BENEDICT DR	STE 1	STERLING	VA	20164-6626
28	Affiliated	687	Alexandria	Springfield- Alexandria	5999 STEVENSON AVE	STE 1	ALEXANDRIA	VA	22304-3302

29	Affiliated	642	Statesboro	Nephrology Center of Statesboro fka Statesboro Dialysis	4B COLLEGE PLZ		STATESBORO	GA	30458-4928
30	Affiliated	643	Vidalia	Nephrology Center of Vidalia	1806 EDWINA DR		VIDALIA	GA	30474-8927
31	Affiliated	657	Papago Dialysis	Papago Dialysis Center (fka PD Central & Squaw Peak)	1401 N 24TH ST	STE 2	PHOENIX	AZ	85008-4638
32	Affiliated	658	Boca Raton	Boca Raton Artificial Kidney Center	998 NW 9TH CT		BOCA RATON	FL	33486-2214
33	Affiliated	644	Piedmont	Buckhead Dialysis	1575 NORTHSIDE DR NW	STE 365	ATLANTA	GA	30318-4210
34	Affiliated	311	Logan Square	Logan Square Dialysis Services	2659 N MILWAUKEE AVE	1ST FL	CHICAGO	IL	60647-1643
35	Affiliated	312	Lake County	Lake County Dialysis Services	918 S MILWAUKEE AVE		LIBERTYVILLE	IL	60048-3229
36	Affiliated	314	Lincoln Park	Lincoln Park Dialysis fka Lincoln Park Nephrology	3157 N LINCOLN AVE		CHICAGO	IL	60657-3111
37	Affiliated	318	Lincoln Pk- PD	Skyline Home Dialysis (fka Lincoln Park PD)	7009 W BELMONT AVE		CHICAGO	IL	60634-4533
38	Affiliated	670	West Palm Beach	Dialysis Associates of the Palm Beaches	2611 POINSETTIA AVE		WEST PALM BEACH	FL	33407-5919
39	Affiliated	693	Sunrise	Sunrise Dialysis Center	13039 HAWTHORNE BLVD		HAWTHORNE	CA	90250-4415
40	Affiliated	655	Kayenta	Kayenta Dialysis	PO BOX 217	US HWY 163 N	KAYENTA	AZ	86033-0217
41	Affiliated	321	Hyde Park	Emerald Dialysis (fka	710 W 43RD ST		CHICAGO	IL	60609-3435

				Hyde Park Kidney Center)						
42	Affiliated	322	Olympia Fields	Olympia Fields Dialysis Center	4557B LINCOLN HWY	STE B	MATTESON	IL	60443-2318	
43	Affiliated	351	CKD	Center for Kidney Disease at North Shore	1190 NW 95TH ST	STE 28	MIAMI	FL	33150-2065	
44	Affiliated	352	Venture	Center for Kidney Disease at Venture	16855 NE 2ND AVE	STE 25	N MIAMI BEACH	FL	33162-1744	
45	Affiliated	360	South Broward	South Broward Artificial Kidney	4401 HOLLYWOOD BLVD		HOLLYWOOD	FL	33021-6609	
46	Affiliated	688	East End	East End Dialysis Center	2201 E MAIN ST	STE 1	RICHMOND	VA	23223-7071	
47	Affiliated	354	Flamingo Park	Flamingo Park Kidney Cntr, Inc	901 E 10TH AVE	BAY 17	HIALEAH	FL	33010-3762	
48	Affiliated	355	Interamerican	InterAmerican Dialysis Center	7815 CORAL WAY	STE 115	MIAMI	FL	33155-6541	
49	Affiliated	356	Coral Gables Dialysis Center	Coral Gables Kidney Center (fka LeJeune)	3280 PONCE DE LEON BLVD		CORAL GABLES	FL	33134-7252	
50	Affiliated	370	Cielo Vista Dialysis	DaVita East Dialysis dba Cielo Vista Dialysis (fkaTotal Renal Care East Dialysis Center)	7200 GATEWAY BLVD E	STE B	EL PASO	TX	79915-1301	
51	Affiliated	371	West Texas Dialysis	DaVita West Dialysis Center dba West Texas (fkaTotal	5595 ALAMEDA AVE B	STE B	EL PASO	TX	79905	

				Renal Care West Dialysis Center)						
52	Affiliated	656	Shiprock	Shiprock Dialysis	PO BOX 2156	US HWY 491 N	SHIPROCK	NM	87420-2156	
53	Affiliated	202	Arden Hills	Arden Hills Dialysis Unit	3900 NORTHWOODS DR	STE 11	ARDEN HILLS	MN	55112-6911	
54	Affiliated	203	Burnsville	Burnsville Dialysis Unit	501 E NICOLLET BLVD	STE 15	BURNSVILLE	MN	55337-6784	
55	Affiliated	204	Coon Rapids	Coon Rapids Dialysis Unit	3960 COON RAPIDS BLVD NW	STE 39	COON RAPIDS	MN	55433-2598	
56	Affiliated	205	Edina	Edina Dialysis Unit	6550 YORK AVE S	STE 1	EDINA	MN	55435-2332	
57	Affiliated	206	Maplewood	Maplewood Dialysis Center	2785 WHITE BEAR AVE N	STE 21	MAPLEWOOD	MN	55109-1320	
58	Affiliated	207	Minneapolis	Minneapolis Dialysis Unit	825 S EIGHTH ST	STE SL42	MINNEAPOLIS	MN	55404-1208	
59	Affiliated	208	Minnetonka	Minnetonka Dialysis Unit	17809 HUTCHINS DR		MINNETONKA	MN	55345-4100	
60	Affiliated	209	St. Paul Dialysis	St. Paul Dialysis Unit	555 PARK ST	STE 18	SAINT PAUL	MN	55103-2192	
61	Affiliated	210	Special Needs	University Dialysis Unit Riverside (Minneapolis- Special Needs Dialysis)	1045 WESTGATE DR	STE 9	SAINT PAUL	MN	55114-1079	

62	Affiliated	211	West St. Paul	West St. Paul Dialysis	1555 LIVINGSTON AVE		WEST ST PAUL	MN	55118-3411
63	Affiliated	213	Cass Lake	Cass Lake Dialysis Unit	602 GRANT UTLEY ST	PO BOX 757	CASS LAKE	MN	56633-0757
64	Affiliated	215	Faribault	Faribault Dialysis Unit	201 LYNDALE AVE S	STE F	FARIBAULT	MN	55021-5758
65	Affiliated	217	Marshall	Marshall Dialysis Unit	300 S BRUCE ST	AVERA MARSHALL REGIONAL MEDICAL CENTER	MARSHALL	MN	56258-1934
66	Affiliated	218	Montevideo	Montevideo Dialysis Center	824 N 11TH ST	MONTEVIDEO HOSPITAL	MONTEVIDEO	MN	56265-1629
67	Affiliated	220	Pine City	TRC-Pine City (fka-Pine City Dialysis Unit)	129 6TH AVE SE	LAKESIDE MEDICAL CENTER	PINE CITY	MN	55063-1913
68	Affiliated	222	Red Wing	Red Wing Dialysis Unit	3028 N SERVICE DR		RED WING	MN	55066-1921
69	Affiliated	223	Redwood Falls	Redwood Falls Dialysis Center	100 FALLWOOD RD		REDWOOD FALLS	MN	56283-1828
70	Affiliated	240	Mitchell	Mitchell Dialysis	525 N FOSTER	QUEEN OF PEACE HOSPITAL	MITCHELL	SD	57301-2966
71	Affiliated	242	Rosebud	Rosebud Dialysis	1 SOLDIER CREEK RD		ROSEBUD	SD	57570-0610
72	Affiliated	243	Sioux Falls	Sioux Falls Dialysis Community Unit	1325 S CLIFF AVE	STE 46	SIOUX FALLS	SD	57105-1016
73	Affiliated	250	St. Croix Falls	St. Croix Falls Dialysis	744 E LOUISIANA ST		SAINT CROIX FALLS	WI	54024-9501
74	Affiliated	260	Hayward	Hayward Dialysis Center	21615 HESPERIAN BLVD	STE F	HAYWARD	CA	94541-7026
75	Affiliated	262	Pleasanton	Pleasanton Dialysis Center (HEMO) (fka Dublin)	5720 STONERIDGE MALL RD	STE 16	PLEASANTON	CA	94588-2882
76	Affiliated	263	Union City	Union City Dialysis Center (aka TRC- Union City)	32930 ALVARADO NILES RD	STE 3	UNION CITY	CA	94587-8101

77	Affiliated	264	East Bay - PD	East Bay Peritoneal Dialysis Center	13939 E 14TH ST	STE 11	SAN LEANDRO	CA	94578-2613
78	Affiliated	383	Greer	Greer Kidney Center	211 VILLAGE DR		GREER	SC	29651-1238
79	Affiliated	382	Upstate	Upstate Dialysis Center	308 MILLS AVE		GREENVILLE	SC	29605-4022
80	Affiliated	390	Kenner	Kenner Regional Dialysis Center	200 W ESPLANADE AVE	STE 1	KENNER	LA	70065-2473
81	Affiliated	689	Downtown Dialysis	Downtown Dialysis Center	821 N EUTAW ST	STE 41	BALTIMORE	MD	21201-6304
82	Affiliated	331	Eaton Canyon	Eaton Canyon Dialysis	2551 E WASHINGTON BLVD		PASADENA	CA	91107-1446
83	Affiliated	190	Georgetown	Georgetown on the Potomac	3223 K ST NW	STE 11	WASHINGTON	DC	20007-4412
84	Affiliated	395	St. Mary	Newtown Dialysis Center (fka St. Mary Dialysis)	60 BLACKSMITH RD		NEWTOWN	PA	18940-1847
85	Affiliated	393	Bertha Sirk	Bertha Sirk Dialysis Center	5820 YORK RD	STE 1	BALTIMORE	MD	21212-3620
86	Affiliated	394	Greenspring	Greenspring Dialysis Center	4701 MOUNT HOPE DR	STE C	BALTIMORE	MD	21215-3246
87	Affiliated	378	Houston Kidney - NW	Northwest Kidney Center (Houston)	11029 NORTHWEST FWY		HOUSTON	TX	77092-7311
88	Affiliated	379	NorthStar Dialysis	NorthStar Dialysis Center (fka North Houston Kidney Center)	380 W LITTLE YORK RD		HOUSTON	TX	77076-1303
89	Affiliated	363	Port Charlotte	Port Charlotte Artificial Kidney Center	4300 KINGS HWY STE 406		PORT CHARLOTTE	FL	33980
90	Affiliated	364	Gulf Coast PD	Gulf Coast Dialysis	3300 TAMIAMI TRL	STE 11A	PORT CHARLOTTE	FL	33952-8054
91	Affiliated	649	Loma Vista	Loma Vista Dialysis Center Partnership	1382 LOMALAND DR	STE A	EL PASO	TX	79935-5204
92	Affiliated	332	Paramount	Paramount Dialysis Center	8319 ALONDRA BLVD		PARAMOUNT	CA	90723-4403

93	Affiliated	334	East LA	Doctors Dialysis of East LA (aka East Los Angeles Dialysis)	950 S EASTERN AVE		LOS ANGELES	CA	90022-4801
94	Affiliated	335	Montebello	Doctors Dialysis of Montebello	1721 W WHITTIER BLVD		MONTEBELLO	CA	90640-4004
95	Affiliated	361	Pine Island	Pine Island Kidney Center	1871 N PINE ISLAND RD		PLANTATION	FL	33322-5208
96	Affiliated	365	Complete	Complete Dialysis Care	7850 W SAMPLE RD		MARGATE	FL	33065-4710
97	Affiliated	122	Lone Star Dialysis	Lone Star Dialysis (fka Hobby Dialysis)	8560 MONROE RD		HOUSTON	TX	77061-4815
98	Affiliated	255	Forest Lake	Forest Lake Dialysis	1068 S LAKE ST STE 11		FOREST LAKE	MN	55025-2633
99	Affiliated	690	USC Phase II	TRC/USC Dialysis Center	2310 ALCAZAR ST		LOS ANGELES	CA	90033-5327
100	Affiliated	396	TRC/Union Plaza Ctr	Union Plaza Dialysis Center	810 1ST ST NE STE 1		WASHINGTON	DC	20002-4227
101	Affiliated	130	Mid-Columbia Kidney	Mid Columbia Kidney Center	6825 BURDEN BLVD	STE A	PASCO	WA	99301-9584
102	Affiliated	131	Mt. Adams Kidney Ctr	Mt. Adams Kidney Center	3220 PICARD PL		SUNNYSIDE	WA	98944-8400
103	Affiliated	650	Lakewood	Lakewood Community Dialysis Center	5919 LAKEWOOD TOWNE CENTER BLVD SW	STE A	LAKEWOOD	WA	98499-6513
104	Affiliated	228	St. Paul Ramsey	St. Paul Capitol Dialysis	555 PARK ST STE 23		SAINT PAUL	MN	55103-2193
105	Affiliated	229	River City Dialysis	River City Dialysis (fka Lakeview Dialysis)	1970 NORTHWESTERN AVE S		STILLWATER	MN	55082-6567
106	Affiliated	231	Woodbury	Woodbury Dialysis	1850 WEIR DR STE 3		WOODBURY	MN	55125-2260
107	Affiliated	281	Alhambra	Alhambra Dialysis Center	1315 ALHAMBRA BLVD	STE 1	SACRAMENTO	CA	95816-5245
108	Affiliated	282	Antelope	Antelope Dialysis Center	6406 TUPELO DR STE A		CITRUS HEIGHTS	CA	95621-1780

109	Affiliated	283	Chico	Chico Dialysis Center (aka Chico Clinic)	530 COHASSET RD		CHICO	CA	95926-2212
110	Affiliated	285	North Clinic	Manzanita Dialysis Center (aka North Clinic)	4005 MANZANITA AVE	STE 17	CARMICHAEL	CA	95608-1779
111	Affiliated	286	Placerville	Cameron Park Dialysis (fka Placerville)	3311 COACH LN	STE C	CAMERON PARK	CA	95682
112	Affiliated	288	South Sacramento	South Sacramento Dialysis Center	7000 FRANKLIN BLVD	STE 88	SACRAMENTO	CA	95823-1838
113	Affiliated	289	Redding	Redding Dialysis Center	1876 PARK MARINA DR		REDDING	CA	96001-0913
114	Affiliated	291	Yuba City	Yuba City Dialysis Center	1525 PLUMAS CT	STE A	YUBA CITY	CA	95991-2971
115	Affiliated	292	University Clinic	University Dialysis Center	777 CAMPUS COMMONS RD	STE 1	SACRAMENTO	CA	95825-8344
116	Affiliated	372	Mesa Vista	Mesa Vista Dialysis Center (El Paso)	2400 N OREGON ST	STE C	EL PASO	TX	79902-3135
117	Affiliated	694	Hollywood	Hollywood Dialysis Center	5108 W SUNSET BLVD		LOS ANGELES	CA	90027-5708
118	Affiliated	697	UCLA Harbor	TRC/Harbor-UCLA MFI Total Renal Dialysis Center	21602 S VERMONT AVE		TORRANCE	CA	90502-1940
119	Affiliated	325	Brighton	Brighton Dialysis (fka Michigan Kidney Center of Brighton)	7960 GRAND RIVER RD	STE 21	BRIGHTON	MI	48114-7336
120	Affiliated	326	Macomb	Macomb Kidney Center (fka Macomb Dialysis)	28295 SCHOENHERR RD	STE A	WARREN	MI	48088-4300
121	Affiliated	327	North Oakland	North Oakland Dialysis	450 N TELEGRAPH RD	STE 6	PONTIAC	MI	48341-1037
122	Affiliated	328	Novi	Novi Dialysis	47250 W 10 MILE RD		NOVI	MI	48374-2932

123	Affiliated	329	Southfield	Cornerstone Dialysis (fka Southfield)	23857 GREENFIELD RD		SOUTHFIELD	MI	48075-3122
124	Affiliated	319	Children's Mem' l Hosp.	TRC Children's Dialysis Center aka Children's Chicago/ Children's Memorial Hospital	2611 N HALSTED ST		CHICAGO	IL	60614-2301
125	Affiliated	151	New Center	New Center Dialysis	3011 W GRAND BLVD	STE 65	DETROIT	MI	48202-3012
126	Affiliated	2003	Whittier	Whittier Dialysis Center (fka Whittier Hills)	10055 WHITTWOOD DR		WHITTIER	CA	90603-2313
127	Affiliated	357	Miami Lakes	Miami Lakes Artificial Kidney Center (ALTHIN)	14600 NW 60TH AVE		MIAMI LAKES	FL	33014-2811
128	Affiliated	571	Anson County	Dialysis Care of Anson County	923 E CASWELL ST		WADESBORO	NC	28170-2305

129	Affiliated	573	Edgecomb County	Dialysis Care of Edgecomb County	3206 WESTERN BLVD		TARBORO	NC	27886-1828
130	Affiliated	574	Franklin County	Dialysis Care of Franklin County	1706 NC HWY 39 N		LOUISBURG	NC	27549-8329
131	Affiliated	575	Hoke County	Dialysis Care of Hoke County	403 S MAIN ST		RAEFORD	NC	28376-3222
132	Affiliated	576	Martin County	Dialysis Care of Martin County	100 MEDICAL DR		WILLIAMSTON	NC	27892-2156
133	Affiliated	578	Montgomery County	Dialysis Care of Montgomery County (aka Montgomery)	323 W MAIN ST		BISCOE	NC	27209-9528
134	Affiliated	579	Moore County	Dialysis Care of Moore County (aka Pinehurst)	16 REGIONAL DR		PINEHURST	NC	28374-8850
135	Affiliated	580	Richmond County	Dialysis Care of Richmond County	771 CHERAW RD		HAMLET	NC	28345-7158
136	Affiliated	581	Rockingham County	Dialysis Care of Rockingham County	251 W KINGS HWY		EDEN	NC	27288-5009
137	Affiliated	582	Rowan County	Dialysis Care of Rowan County	111 DORSETT DR		SALISBURY	NC	28144-2278
138	Affiliated	583	Rutherford County	Dialysis Care of Rutherford County	226 COMMERCIAL ST		FOREST CITY	NC	28043-2851
139	Affiliated	399	Monterey Park	Monterey Park Dialysis Center	2560 CORPORATE PL	STE 1-11 BLDG D	MONTEREY PARK	CA	91754-7612
140	Affiliated	183	Mason Dixon	Mason-Dixon Baltimore County	9635-A LIBERTY RD	STE 1	RANDALLSTOWN	MD	21133-2436
141	Affiliated	184	Carrol County	Carroll County Dialysis Facility	412 MALCOLM DR	STE 31	WESTMINSTER	MD	21157-6167
142	Affiliated	167	South Brooklyn	South Brooklyn Nephrology Center	3915 AVENUE V	STE 14	BROOKLYN	NY	11234-5150
143	Affiliated	843	Phenix City	Phenix City Dialysis Center	1900 OPELIKA RD		PHENIX CITY	AL	36867-3640

144	Affiliated	876 Brea	Brea Dialysis Center	595 TAMARACK AVE	STE A	BREA	CA	92821-3125
145	Affiliated	878 Hemet	Hemet Dialysis Center	3050 W FLORIDA AVE		HEMET	CA	92545-3619
146	Affiliated	883 Temecula	Temecula Dialysis Center	40945 COUNTY CENTER DR	STE G	TEMECULA	CA	92591-6006
147	Affiliated	880 Riverside	Riverside Dialysis Center	4361 LATHAM ST	STE 1	RIVERSIDE	CA	92501-1767
148	Affiliated	870 Napa	Napa Dialysis Center	3900 BEL AIRE PLZ	STE C	NAPA	CA	94558-2823
149	Affiliated	875 Santa Ana	Santa Ana Dialysis Center	1820 E DEERE AVE		SANTA ANA	CA	92705-5721
150	Affiliated	879 Valley View Dialysis Center	Valley View Dialysis Center (aka Morneo Valley)	26900 CACTUS AVE		MORENO VALLEY	CA	92555-3912
151	Affiliated	884 Orange	Mainplace Dialysis Center (fka Orange Dialysis Center)	972 W TOWN AND COUNTRY RD		ORANGE	CA	92868-4714
152	Affiliated	882 San Bernadino	Mountain Vista Dialysis Center (fka San Bernadino Dailysis Center (Mountain Vista))	4041 NORTH UNIVERSITY PKWY		SAN BERNARDINO	CA	92407-1823
153	Affiliated	871 Lakeport	Lakeport Dialysis Center	804 11TH ST	STE 2	LAKEPORT	CA	95453-4102
154	Affiliated	873 Vacaville	Vacaville Dialysis Center	941 MERCHANT ST		VACAVILLE	CA	95688-5315
155	Affiliated	877 Corona	Corona Dialysis Center	1820 FULLERTON AVE	STE 18	CORONA	CA	92881-3147
156	Affiliated	872 Fairfield	Fairfield Dialysis Center	4660 CENTRAL WAY		FAIRFIELD	CA	94534-1803
157	Affiliated	902 Westminster	Westminster Dialysis Center (Federal Heights)	9053 HARLAN ST	STE 9	WESTMINSTER	CO	80031-2908

158	Affiliated	901	Aurora	Aurora Dialysis Center	1411 S POTOMAC ST	AMC II STE 1	AURORA	CO	80012-4536
159	Affiliated	900	Denver	Denver Dialysis Center	2900 DOWNING ST	STE C	DENVER	CO	80205-4699
160	Affiliated	903	Littleton	Littleton Dialysis Center	209 W COUNTY LINE RD		LITTLETON	CO	80129-1901
161	Affiliated	904	South Denver	South Denver Dialysis Center	850 E HARVARD AVE	STE 6	DENVER	CO	80210-5030
162	Affiliated	946	Lee Street Dialysis	Lee Street Dialysis (fka Grant Park Dialysis Center)	5155 LEE ST NE		WASHINGTON	DC	20019-4051
163	Affiliated	868	Leesburg	Leesburg Dialysis Center	801 E DIXIE AVE	STE 18A	LEESBURG	FL	34748-7699
164	Affiliated	866	Panama City	Panama City Dialysis Center	615 HIGHWAY 231		PANAMA CITY	FL	32405-4704
165	Affiliated	867	Marianna	Marianna Dialysis Center	2930 OPTIMIST DR		MARIANNA	FL	32448-7703
166	Affiliated	864	Venice	Venice Dialysis Center	816 PINEBROOK RD		VENICE	FL	34285-7103
167	Affiliated	827	Buena Vista	Buena Vista Dialysis Center	349 GENEVA RD		BUENA VISTA	GA	31803-1701
168	Affiliated	828	Decatur	Decatur Dialysis Center	1987 CANDLER RD		DECATUR	GA	30032-4212
169	Affiliated	825	Moultrie	Moultrie Dialysis Center	2419 S MAIN ST		MOULTRIE	GA	31768-6531
170	Affiliated	820	SW Atlanta	Southwest Atlanta Dialysis Center	3620 MARTIN LUTHER KING DR SW		ATLANTA	GA	30331-3711
171	Affiliated	818	Griffin	Griffin Dialysis Center	731 S 8TH ST		GRIFFIN	GA	30224-4818
172	Affiliated	826	Columbus	Columbus Dialysis Center	6228 BRADLEY PARK DR	STE B	COLUMBUS	GA	31904-3604
173	Affiliated	829	East Macon	East Macon Dialysis Center	165 EMERY HWY	STE 11	MACON	GA	31217-3666
174	Affiliated	817	Jonesboro	Jonesboro Dialysis Center	129 KING ST		JONESBORO	GA	30236-3656

175	Affiliated	824	Milledgeville	Milledgeville Dialysis Center	400 S WAYNE ST	MILLEDGEVILLE	GA	31061-3446
176	Affiliated	823	Fort Valley	Fort Valley Dialysis Center	557 BLUEBIRD BLVD	FORT VALLEY	GA	31030-5083
177	Affiliated	821	Midtown	Linden Dialysis (fka Midtown- Atlanta)	121 LINDEN AVE NE	ATLANTA	GA	30308-2432
178	Affiliated	953	E. St. Louis	Sauget Dialysis (fka East St. Louis Dialysis Center)	2061 GOOSE LAKE RD	SAUGET	IL	62206-2822
179	Affiliated	952	Granite City	Granite City Dialysis Center	9 AMERICAN VLG	GRANITE CITY	IL	62040-3706
180	Affiliated	937	Batesville	Batesville Dialysis Center Aka Renal Treatment Centers- Batesville	232 STATE ROAD 129 S	BATESVILLE	IN	47006-7694
181	Affiliated	938	Lawrenceburg	Lawrenceburg Dialysis Center	721 RUDOLPH WAY	GREENDALE	IN	47025-8378
182	Affiliated	939	Madison	Madison Dialysis Center	220 CLIFTY DR	MADISON	IN	47250-1669
183	Affiliated	836	Newton	Renal Treatment Center-Newton aka-Newton Dialysis Center	1223 WASHINGTON RD	NEWTON	KS	67114-4855
184	Affiliated	837	Derby	Renal Treatment Center-Derby aka Derby Dialysis Center	250 W RED POWELL DR	DERBY	KS	67037-2626
185	Affiliated	834	Winfield	Renal Treatment Center-Winfield aka, Winfield Dialysis Center	1315 E 4TH AVE	WINFIELD	KS	67156-2457
186	Affiliated	830	Wichita	Wichita Dialysis Center	909 N TOPEKA ST	WICHITA	KS	67214-3620
187	Affiliated	833	Garden City	Renal Treatment Center-Garden City Aka- Garden City Dialysis Center	401 N MAIN ST	GARDEN CITY	KS	67846-5429
188	Affiliated	831	E. Wichita	East Wichita Dialysis Center	320 N HILLSIDE ST	WICHITA	KS	67214-4918

189	Affiliated	832	Independence	Independence Dialysis Center	801 W MYRTLE ST		INDEPENDENCE	KS	67301-3239
190	Affiliated	835	Parson, KS	Parsons Dialysis Center	1902 S US HWY 59	BLDG B	PARSONS	KS	67357-4948
191	Affiliated	814	Wheaton	Wheaton Dialysis Center	11941 GEORGIA AVE		WHEATON	MD	20902
192	Affiliated	812	Rockville	Rockville Dialysis Center	14915 BROSCHART RD	STE 1	ROCKVILLE	MD	20850-3367
193	Affiliated	815	Owing Mills	Owings Mills Dialysis Center (fka-Renal Treatment Center-Owings Mills)	10 CROSSROADS DR	STE 11	OWINGS MILLS	MD	21117-5463
194	Affiliated	811	Berlin	Berlin Dialysis Center	314 FRANKLIN AVE	STE 36	BERLIN	MD	21811-1238
195	Affiliated	810	Easton	Easton Dialysis Center	402 MARVEL CT		EASTON	MD	21601-4052

196	Affiliated	813	Chestertown	Chestertown Dialysis Center (fka Renal Treatment Centers- Chestertown)	100 BROWN ST	CHESTERTOWN	MD 21620
197	Affiliated	951	Hope Again	Hope Again Dialysis Center- fka Kennett Dialysis Center	1207 STATE ROUTE VV	KENNETT	MO 63857-3823
198	Affiliated	950	Poplar Bluff	Bluff City Dialysis Center	2400 LUCY LEE STE E PKWY	POPLAR BLUFF	MO 63901-2429
199	Affiliated	949	Crystal City	Crystal City Dialysis Center	960 SO TRUMAN BLVD	CRYSTAL CITY	MO 63019-1329
200	Affiliated	947	St. Louis	St. Louis Dialysis Center (fka Renal Treatment Center-St. Louis)	2610 CLARK AVE	SAINT LOUIS	MO 63103-2502
201	Affiliated	944	Burlington	Burlington Dialysis	873 HEATHER RD	BURLINGTON	NC 27215-6288
202	Affiliated	838	Scottsbluff	Scottsbluff Dialysis Center	3812 AVENUE B	SCOTTSBLUFF	NE 69361-4780
203	Affiliated	802	Bridgewater	Bridgewater Dialysis Center (fka Renal Treatment Center- Bridgewater)	2121 US HWY 22	BOUND BROOK	NJ 08805-1546
204	Affiliated	845	West Las Vegas	Las Vegas Dialysis Center	150 S VALLEY VIEW BLVD	LAS VEGAS	NV 89107
205	Affiliated	846	North Las Vegas	North Las Vegas Dialysis Center	2300 MCDANIEL ST	NORTH LAS VEGAS	NV 89030-6318
206	Affiliated	940	Cincinnati	Eastgate Dialysis (fka Cincinnati)	4435 AICHOLTZ RD	CINCINNATI	OH 45245-1690
207	Affiliated	885	Tulsa	Tulsa Dialysis	4436 S HARVARD AVE	TULSA	OK 74135-2605

208	Affiliated	897	NW Bethany	Northwest Bethany Dialysis Center	7800 NW 23RD ST	STE A	BETHANY	OK	73008-4948
209	Affiliated	890	Duncan	Duncan Dialysis Center	2645 W ELK AVE		DUNCAN	OK	73533-1572
210	Affiliated	893	Shawnee	Shawnee Dialysis Center	4409 N KICKAPOO AVE	STE 113	SHAWNEE	OK	74804-1224
211	Affiliated	895	Stillwater	Stillwater Dialysis Center	406 E HALL OF FAME AVE	STE 3	STILLWATER	OK	74075-5447
212	Affiliated	955	Midwest City	Midwest City Dialysis Center	7221 E RENO AVE		MIDWEST CITY	OK	73110-4474
213	Affiliated	886	Broken Arrow	Broken Arrow Dialysis Center	1700 N 9TH ST		BROKEN ARROW	OK	74012
214	Affiliated	888	Tahlequah	Tahlequah Dialysis Center	1373 E BOONE ST		TAHLEQUAH	OK	74464-3330
215	Affiliated	899	Edmond	Edmond Dialysis	50 S BAUMANN AVE		EDMOND	OK	73034-5676
216	Affiliated	889	Altus	Altus Dialysis Center	205 S PARK LN	STE 13	ALTUS	OK	73521-5756
217	Affiliated	896	Elk City	Elk City Dialysis Center	1601 W 2ND ST		ELK CITY	OK	73644-4427
218	Affiliated	887	Claremore	Claremore Dialysis Center	202 E BLUE STARR DR		CLAREMORE	OK	74017-4223
219	Affiliated	891	Norman	Norman Dialysis Center	1818 W LINDSEY ST	STE 14 BLDG B	NORMAN	OK	73069-4159
220	Affiliated	862	Pocono	Pocono Dialysis Center	100 PLAZA CT	STE B	EAST STROUDSBURG	PA	18301-8258
221	Affiliated	861	Palmerton	Palmerton Dialysis Center	185 DELAWARE AVE	STE C	PALMERTON	PA	18071-1716
222	Affiliated	860	Jennersville	Jennersville Dialysis Center	1011 W BALTIMORE PIKE		WEST GROVE	PA	19390-9446
223	Affiliated	858	Lewistown	Lewistown Dialysis Center	611 ELECTRIC AVE		LEWISTOWN	PA	17044-1128
224	Affiliated	854	Lemoyne	Camp Hill Dialysis Center (fka Lemoyne Dialysis Center (York Hospital Acutes))	425 N 21ST ST	LOWER LEVEL	CAMP HILL	PA	17011-2223
225	Affiliated	856	Upland	Upland Dialysis Center	1 MEDICAL CENTER BLVD	STE 12	CHESTER	PA	19013-3902

226	Affiliated	848	South Philadelphia	So. Philadelphia Dialysis Center	109 DICKINSON ST	PHILADELPHIA	PA	19147-6107
227	Affiliated	857	Exton	Exton Dialysis Center	710 SPRINGDALE DR	EXTON	PA	19341-2828
228	Affiliated	847	Northeast Philadelphia	NE Philadelphia Dialysis Center	518 KNORR ST	PHILADELPHIA	PA	19111-4604
229	Affiliated	934	Longview	Longview Dialysis Center	425 N FREDONIA ST	LONGVIEW	TX	75601-6464
230	Affiliated	935	Marshall-RTC	Marshall Dialysis Center	1301 S WASHINGTON AVE	MARSHALL	TX	75670-6215
231	Affiliated	933	Conroe	Conroe Dialysis Center	500 MEDICAL CENTER BLVD STE 175	CONROE	TX	77304-2899
232	Affiliated	928	San Marcos	Hill Country Dialysis Center Of San Marcos	1820 PETER GARZA DR	SAN MARCOS	TX	78666-7407
233	Affiliated	923	Sherman	Sherman Dialysis Center	205 W LAMBERTH RD	SHERMAN	TX	75092-2659
234	Affiliated	932	Tomball	Tomball Dialysis Center	27720A TOMBALL PKWY	TOMBALL	TX	77375-
235	Affiliated	919	Cleveland	Cleveland Dialysis Center	600 E HOUSTON STE 63	CLEVELAND	TX	77327-4689
236	Affiliated	921	Livingston	Livingston Dialysis Center	209 W PARK	LIVINGSTON	TX	77351-7020
237	Affiliated	920	Kingwood	Kingwood Dialysis Center	2300 GREEN OAK DR STE 5	KINGWOOD	TX	77339-2053
238	Affiliated	930	North Houston	North Houston Dialysis Center	129 LITTLE YORK RD	HOUSTON	TX	77076-1020
239	Affiliated	926	Omni	Omni Dialysis Center (fka Hamilton Dialysis Center)	9350 KIRBY DR STE 11	HOUSTON	TX	77054-2528
240	Affiliated	925	Victoria	Victoria Dialysis Center	1405 VICTORIA STATION DR	VICTORIA	TX	77901-3092
241	Affiliated	922	Lufkin	Lufkin Dialysis Center	700 S JOHN REDDITT DR	LUFKIN	TX	75904-3145

242	Affiliated	927	Gonzales	Gonzales Dialysis Center	1406 N SARAH DEWITT DR		GONZALES	TX	78629-2702
243	Affiliated	924	Denison	Denison Dialysis Center	1220 REBA MCENTIRE LANE		DENISON	TX	75020-9057
244	Affiliated	918	South San Antonio	South San Antonio Dialysis Center	1313 SE MILITARY DR	STE 111	SAN ANTONIO	TX	78214-2850
245	Affiliated	913	Austin	Waterloo Dialysis Center (fka Austin Dialysis Center)	5310 BURNET RD	UNIT 122	AUSTIN	TX	78756-2003
246	Affiliated	916	S. Austin	El Milagro Dialysis Unit (fka South Austin Dialysis Center)	2800 S INTERSTATE HWY 35	STE 12	AUSTIN	TX	78704-5700
247	Affiliated	929	SW San Antonio	Southwest San Antonio Dialysis Center	7515 BARLITE BLVD		SAN ANTONIO	TX	78224-1311
248	Affiliated	936	Bedford	HEB Dialysis Center (Bedford)	1401 BROWN TRL	STE A	BEDFORD	TX	76022-6416
249	Affiliated	917	TRC Med Cntr	Med-Center Dialysis, fka Plaza Dialysis Center & Houston Kidney Center #376	5610 ALMEDA RD		HOUSTON	TX	77004-7515
250	Affiliated	908	Chesapeake	Chesapeake Dialysis Center	1400 CROSSWAYS BLVD	CROSSWAYS II STE 16	CHESAPEAKE	VA	23320-2839
251	Affiliated	912	Hopewell	Hopewell Dialysis Center	301 W BROADWAY AVE		HOPEWELL	VA	23860-2645
252	Affiliated	911	Newport News	Newport News Dialysis Center	711 79TH ST		NEWPORT NEWS	VA	23605-2767
253	Affiliated	907	Norfolk	Norfolk Dialysis Center	962 NORFOLK SQ		NORFOLK	VA	23502-3235
254	Affiliated	909	Virginia Beach	Virginia Beach Dialysis Center	740 INDEPENDENCE CIR		VIRGINIA BEACH	VA	23455-6438

255	Affiliated	171	Palmer	Palmer Dialysis Center	30 COMMUNITY DR	EASTON	PA	18045-2658
256	Affiliated	589	Burgaw	SEDC (NC II) Burgaw Dialysis Center	704 S DICKERSON ST	PO BOX 1391 BURGAW	NC	28425-4904
257	Affiliated	590	Elizabethtown	SEDC (NC II) Elizabethtown Dialysis Center	101 DIALYSIS DR	ELIZABETHTOWN	NC	28337-9048
258	Affiliated	591	Jacksonville	SEDC (NC II) Jacksonville Dialysis Center	14 OFFICE PARK DR	JACKSONVILLE	NC	28546-7325
259	Affiliated	592	Kenansville	SEDC (NC II) Kenansville Dialysis Center	305 BEASLEY ST	KENANSVILLE	NC	28349-8798
260	Affiliated	593	Shallotte	SEDC (NC II) Shallotte Dialysis Center	4770 SHALLOTTE AVE	SHALLOTTE	NC	28470-6596
261	Affiliated	594	Whiteville	SEDC (NC II) Whiteville Dialysis Center	608 PECAN LN	WHITEVILLE	NC	28472-2949
262	Affiliated	595	Wilmington	SEDC (NC II) Wilmington Dialysis Center	2215 YAUPON DR	WILMINGTON	NC	28401-7334

263	Affiliated	175	Deerfield	Deerfield Beach Artificial Kidney Center	1983 W HILLSBORO BLVD		DEERFIELD BEACH	FL	33442-1418
264	Affiliated	176	Pompano Beach	Pompano Beach Artificial Kidney Center	600 SW 3RD ST	STE 11	POMPANO BEACH	FL	33060-6936
265	Affiliated	177	Tamarack	Tamarac Artificial Kidney Center	7140 W MCNAB RD		TAMARAC	FL	33321-5306
266	Affiliated	168	Atlantic AKC	Atlantic Artificial Kidney Center	6 INDUSTRIAL WAY W	STE B	EATONTOWN	NJ	07724-2258
267	Affiliated	587	Rowan/ Kannapolis	Dialysis Care of Kannapolis	1607 N MAIN ST		KANNAPOLIS	NC	28081-2317
268	Affiliated	654	Cortez	Cortez Dialysis	610 E MAIN ST	STE C	CORTEZ	CO	81321-3308
269	Affiliated	142	West Bountiful 4/6/98	West Bountiful Dialysis	724 W 500 S	STE 3	WEST BOUNTIFUL	UT	84087-1471
270	Affiliated	187	Meherrin	Meherrin Dialysis Center	201A WEAVER AVE		EMPORIA	VA	23847-1248
271	Affiliated	436	Montclair	Montclair Dialysis Center	5050 PALO VERDE ST	STE 1	MONTCLAIR	CA	91763-2329
272	Affiliated	259	Pipestone	Pipestone Dialysis	916 4TH AVE SW		PIPESTONE	MN	56164-1054
273	Affiliated	236	Washington	Washington Dialysis Center	154 WASHINGTON PLZ		WASHINGTON	GA	30673-2074
274	Affiliated	235	Elberton	Elberton Dialysis Center	894 ELBERT ST		ELBERTON	GA	30635-2628
275	Affiliated	174	Gulf Breeze	Gulf Breeze Dialysis Center	1519 MAIN ST		DUNEDIN	FL	34698-4650
276	Affiliated	526	Asheville	Asheville Kidney Center	1600 CENTRE PARK DR		ASHEVILLE	NC	28805-6206
277	Affiliated	528	Sylva	Sylva Dialysis Center	655 ASHEVILLE HWY		SYLVA	NC	28779-2747

278	Affiliated	527 Hendersonville	Hendersonville Dialysis Center	500 BEVERLY HANKS CTR	HWY 25 N	HENDERSONVILLE NC	28792
279	Affiliated	389 Memorial	Memorial Dialysis	4427 S ROBERTSON ST		NEW ORLEANS LA	70115-6308
280	Affiliated	127 Warner Robbins	Dialysis Center of Middle Georgia- Warner Robins	509 N HOUSTON RD		WARNER ROBINS GA	31093-8844
281	Affiliated	126 Macon - Middle Georgia	Dialysis Center of Middle Georgia- Macon	747 2ND ST		MACON GA	31201-6835
282	Affiliated	344 Oakland PD	Oakland Peritoneal Dialysis Center (Piedmont PD)	5352 CLAREMONT AVE		OAKLAND CA	94618
283	Affiliated	384 Fairfax	Fairfax Dialysis Center	8501 ARLINGTON BLVD	STE 1	FAIRFAX VA	22031-4625
284	Affiliated	374 Houston SW	Houston Kidney Center Southwest	11111 BROOKLET DR	STE 1 BLDG 1	HOUSTON TX	77099-3555
285	Affiliated	545 Pikes Peak	Pikes Peak Dialysis Center	2002 LELARAY ST	STE 13	COLORADO SPRINGS CO	80909-2804
286	Affiliated	546 Printers Place	Printers Place Dialysis	2802 INTERNATIONAL CIR		COLORADO SPRINGS CO	80910-3127
287	Affiliated	541 Lakewood Colorado	Lakewood Dialysis Center	1750 PIERCE ST		LAKEWOOD CO	80214-1434
288	Affiliated	543 Boulder	Boulder Dialysis Center	2880 FOLSOM ST	STE 11	BOULDER CO	80304-3769
289	Affiliated	542 Thornton	Thornton Dialysis Center	8800 FOX DR		THORNTON CO	80260-6880
290	Affiliated	544 Arvada	Arvada Dialysis Center	9950 W 80TH AVE	STE 25	ARVADA CO	80005-3914

291	Affiliated	173 Ft. Lauderdale	CDC South-Ft Lauderdale Renal Associates	6264 N FEDERAL HWY		FORT LAUDERDALE	FL	33308-1904
292	Affiliated	380 Houston Cypress Station	Houston Kidney Center Cypress Station	221 FM 1960 RD W	STE H	HOUSTON	TX	77090-3537
293	Affiliated	169 Erie County	Cleve Hill Dialysis Center (Fka Cleve Hill Limited Partnership-Erie Dialysis &ECMC Dialysis Center At Cleve Hill)	1461 KENSINGTON AVE		BUFFALO	NY	14215-1436
294	Affiliated	430 UCLA Pediatrics	Century City Dialysis (fka UCLA, DaVita Westwood UCLA)	10630 SANTA MONICA BLVD		LOS ANGELES	CA	90025-4837
295	Affiliated	501 Bronx	Bronx Dialysis Center	1615 EASTCHESTER RD		BRONX	NY	10461-2603
296	Affiliated	502 Catskill	Catskill Dialysis Center	139 FORESTBURGH RD		MONTICELLO	NY	12701-2364
297	Affiliated	505 Riverdale	Riverdale Dialysis Center	170 W 233RD ST		BRONX	NY	10463-5639
298	Affiliated	506 South Bronx	South Bronx Dialysis Center	1940 WEBSTER AVE		BRONX	NY	10457-4261
299	Affiliated	507 Stanten Island	Richmond Kidney Center (Staten Island)	1366 VICTORY BLVD		STATEN ISLAND	NY	10301-3907
300	Affiliated	238 McDonough	McDonough Dialysis Center	114 DUNN ST		MCDONOUGH	GA	30253-2347
301	Affiliated	192 Milford	Delaware Valley Dialysis	102 DAVITA DR		MILFORD	PA	18337-9390

			Center (fka Milford)					
302	Affiliated	191 Honesdale	Honesdale Dialysis Center-NE Regional	RR 6 BOX 6636	STOURBRIDGE MALL	HONESDALE	PA	18431-9649
303	Affiliated	247 Memorial	Memorial Dialysis Center	11621 KATY FWY		HOUSTON	TX	77079-1801
304	Affiliated	246 Katy Dialysis Center	Grand Parkway Dialysis Center	403 W GRAND PKWY S	STE T	KATY	TX	77494-8358
305	Affiliated	245 Cyfair Dialysis Center	Cyfair Dialysis Center	9110 JONES RD	STE 11	HOUSTON	TX	77065-4489
306	Affiliated	165 Port Chester	Port Chester Dialysis and Renal Center	38 BULKLEY AVE		PORT CHESTER	NY	10573-3902
307	Affiliated	193 Franklin Dialysis	Franklin Dialysis Center	150 SOUTH INDEPENDENCE WEST	11 PUBLIC LEDGER BLDG	PHILADELPHIA	PA	19106-3413
308	Affiliated	156 Grand Blanc	Grand Blanc Dialysis Center	3625 GENESYS PKWY		GRAND BLANC	MI	48439-8070
309	Affiliated	397 Oxford Court	Oxford Court Dialysis	930 TOWN CENTER DR	STE G1	LANGHORNE	PA	19047-4260
310	Affiliated	348 Antioch	Antioch Dialysis	3100 DELTA FAIR BLVD		ANTIOCH	CA	94509-4001
311	Affiliated	401 North Palm Beach	North Palm Beach Dialysis Center	2841 PGA BLVD		PALM BEACH GARDENS	FL	33410-2910
312	Affiliated	277 Lodi	Lodi Dialysis Center	1610 W KETTLEMAN LN	STE D	LODI	CA	95242-4210
313	Affiliated	438 United	United Dialysis Center	3111 LONG BEACH BLVD		LONG BEACH	CA	90807-5015
314	Affiliated	437 Premier	Premier Dialysis Center	7612 ATLANTIC AVE		CUDAHY	CA	90201-5020
315	Affiliated	349 Salinas	Salinas Dialysis Center	955 BLANCO CIR	STE C	SALINAS	CA	93901-4452

316	Affiliated	428	Lowry I	Lowry Dialysis Center	7465 E 1ST AVE	STE A	DENVER	CO	80230-6877
317	Affiliated	154	Ypsilanti	Ypsilanti Dialysis	2766 WASHTENAW RD		YPSILANTI	MI	48197-1506
318	Affiliated	237	Eastpoint	East Point Dialysis	2669 CHURCH ST		EAST POINT	GA	30344-3115
319	Affiliated	520	Celia Dill	Celia Dill Dialysis Center	667 STONELEIGH AVE	STE 123 BARN OFFICE CENTER	CARMEL	NY	10512-2454
320	Affiliated	248	Elmbrook	Brookriver Dialysis	8101 BROOKRIVER DR		DALLAS	TX	75247-4003
321	Affiliated	402	Ocala East	OCALA Regional Kidney Center-East	2870 SE 1ST AVE		OCALA	FL	34471-0406
322	Affiliated	403	Ocala West	OCALA Regional Kidney Center-West	9401 SW HWY 200	BLDG 6	OCALA	FL	34481-9612
323	Affiliated	404	Ocala South	OCALA Regional Kidney Center-South	13940 N US HWY 441	BLDG 4	LADY LAKE	FL	32159-8908
324	Affiliated	417	Delta Sierra Dialysis	Delta-Sierra Dialysis Center	555 W BENJAMIN HOLT DR	STE 2	STOCKTON	CA	95207-3839
325	Affiliated	552	Olympic View	Olympic View Dialysis Center	125 16TH AVE E CSB	5TH FL	SEATTLE	WA	98112
326	Affiliated	148	Pratt	Pratt Dialysis Center	203 WATSON ST	STE 11	PRATT	KS	67124-3092
327	Affiliated	196	Buffalo	Renal Care of Buffalo	550 ORCHARD PARK RD		WEST SENECA	NY	14224-2646
328	Affiliated	555	Woodland	Woodland Dialysis Center	912 WOODLAND DR	STE B	ELIZABETHTOWN	KY	42701-2795
329	Affiliated	556	Taylor	Taylor County Dialysis Center	101 KINGSWOOD DR		CAMPBELLSVILLE	KY	42718-9634

330	Affiliated	491	Gary	Comprehensive Renal Care (CRC)-Gary	4802 BROADWAY	GARY	IN	46408-4509
331	Affiliated	492	Hammond	Comprehensive Renal Care (CRC)-Hammond	222 DOUGLAS ST	HAMMOND	IN	46320-1960
332	Affiliated	493	Valparaiso	Comprehensive Renal Care (CRC)-Valparaiso	606 E LINCOLNWAY	VALPARAISO	IN	46383-5728
333	Affiliated	494	Michigan City	Comprehensive Renal Care (CRC)-Michigan City	9836 WEST 400 NORTH	MICHIGAN CITY	IN	46360-2910
334	Affiliated	495	Munster	Comprehensive Renal Care (CRC)-Munster	9100 CALUMET AVE	MUNSTER	IN	46321-1737
335	Affiliated	497	South County-Deaconess	South County Dialysis (Deaconess)	4145 UNION RD	SAINT LOUIS	MO	63129-1064
336	Affiliated	266	South Hayward	South Hayward Dialysis Center	254 JACKSON ST	HAYWARD	CA	94544-1907
337	Affiliated	164	Dyker Heights	Dyker Heights Dialysis Center	1435 86TH ST	BROOKLYN	NY	11228-3435
338	Affiliated	152	Clarkston	Clarkston Dialysis Center	6770 DIXIE HWY STE 25	CLARKSTON	MI	48346-2089
339	Affiliated	534	Hudson Valley	Hudson Valley Dialysis Center	155 WHITE PLAINS RD	TARRYTOWN	NY	10591-5523
340	Affiliated	971	Central Tulsa	Central Tulsa Dialysis Center	1124 S SAINT LOUIS AVE	TULSA	OK	74120-5413
341	Affiliated	972	Okmulgee	Okmulgee Dialysis Center	201 SO DELAWARE AVE	OKMULGEE	OK	74447-5528
342	Affiliated	974	Muskogee	Muskogee Community Dialysis	2316 W SHAWNEE ST	MUSKOGEE	OK	74401-2228
343	Affiliated	975	Miami-Oklahoma	Tri-State Dialysis Center (fka Miami Dialysis Center (OK))	2510 N MAIN ST	MIAMI	OK	74354-1602

344	Affiliated	977	Stilwell	Stilwell Dialysis Center	80851 HWY 59		STILWELL	OK	74960
345	Affiliated	496	East Chicago	Comprehensive Renal Care (CRC)-East Chicago	4320 FIR ST	UNIT 44	EAST CHICAGO	IN	46312-3078
346	Affiliated	549	Bright Dialysis	Bright Dialysis (fka Fort Pierce Artificial Kidney Center, TRC of Fort Pierce-AKC)	1801 S 23RD ST	STE 1	FORT PIERCE	FL	34950-4830
347	Affiliated	153	Detroit	Detroit Dialysis Center (Eastern Market, Brewery Park Development)	2674 E JEFFERSON AVE		DETROIT	MI	48207-4129
348	Affiliated	166	White Plains	White Plains Dialysis Center	200 HAMILTON AVE	STE 13B	WHITE PLAINS	NY	10601-1859
349	Affiliated	337	Crescent Heights	Crescent Heights Dialysis Center	8151 BEVERLY BLVD		LOS ANGELES	CA	90048-4514
350	Affiliated	547	Pahrump Dialysis	Pahrump Dialysis Center	330 S LOLA LN	STE 1	PAHRUMP	NV	89048-0884
351	Affiliated	598	Cherokee Dialysis Center	Cherokee Dialysis Center	53 ECHOTA CHURCH RD		CHEROKEE	NC	28719-9702
352	Affiliated	444	Utah Valley	Utah Valley Dialysis Center	1055 N 500 W	STE 221	PROVO	UT	84604-3305
353	Affiliated	439	Washington Plaza	Washington Plaza Dialysis Center	516 E WASHINGTON BLVD	# 522	LOS ANGELES	CA	90015-3723
354	Affiliated	539	Commerce City	Commerce City Dialysis Center	6320 HOLLY ST		COMMERCE CITY	CO	80022-3325
355	Affiliated	251	Bloomington Dialysis	Bloomington Dialysis Unit of TRC (fka Richfield)	8591 LYNDALE AVE S		BLOOMINGTON	MN	55420-2237
356	Affiliated	133	Kent Community Dialysis	Kent Dialysis Center	21501 84TH AVE S		KENT	WA	98032-1960
357	Affiliated	278	Florin Dialysis	Florin Dialysis Center	7000 STOCKTON BLVD		SACRAMENTO	CA	95823-2312

358	Affiliated	540	South Las Vegas Dialysis	South Las Vegas Dialysis Center (Palms)	2250 S RANCHO DR	STE 115	LAS VEGAS	NV	89102-4456
359	Affiliated	538	Longmont Dialysis	Longmont Dialysis Center	1715 IRON HORSE DR	STE 17	LONGMONT	CO	80501-9617
360	Affiliated	500	Great Bridge	Great Bridge Dialysis (fka Chesapeake II)	745 BATTLEFIELD BLVD N	STE 1	CHESAPEAKE	VA	23320-0305
361	Affiliated	569	Weaverville Dialysis	Weaverville Dialysis Facility	329 MERRIMON AVE		WEAVERVILLE	NC	28787-9253
362	Affiliated	427	Lakewood Crossing	Lakewood Crossing Dialysis	1057 S WADSWORTH BLVD	STE 1	LAKESWOOD	CO	80226-4361
363	Affiliated	155	Jackson	Jackson Dialysis Center	234 W LOUIS GLICK HWY		JACKSON	MI	49201-1326
364	Affiliated	429	Englewood	Englewood Dialysis Center	3247 S LINCOLN ST		ENGLEWOOD	CO	80113-2505
365	Affiliated	387	Harford Road Dialysis	Harford Road Dialysis Center	5800 HARFORD RD		BALTIMORE	MD	21214-1847
366	Affiliated	179	Arcadia	Arcadia Dialysis Center	1341 E OAK ST		ARCADIA	FL	34266-8902
367	Affiliated	388	Richmond Community	Richmond Community Hospital Dialysis (fkaTRC @ Richmond Community/ Richmond II)	1510 N 28TH ST	STE 11	RICHMOND	VA	23223-5311
368	Affiliated	119	Henderson	Henderson Dialysis Center	1002 US HWY 79 N		HENDERSON	TX	75652-6008
369	Affiliated	253	Augusta	Nephrology Center of South Augusta	1631 GORDON HWY STE 1B		AUGUSTA	GA	30906
370	Affiliated	510	Boston Post Road	Boston Post Road Dialysis Center fka Co Op City Dialysis	4026 BOSTON RD		BRONX	NY	10475-1122
371	Affiliated	512	Peekskill	Peekskill Cortlandt Dialysis Center	2050 E MAIN ST	STE 15	CORTLANDT MANOR	NY	10567-2502

372	Affiliated	513	Queens	Queens Dialysis Center	11801 GUY R BREWER BLVD		JAMAICA	NY	11434-2101
373	Affiliated	517	Soundview	Soundview Dialysis Center	1622 BRUCKNER BLVD	STE 24	BRONX	NY	10473-4553
374	Affiliated	516	Port Washington	Port Washington Dialysis Center	50 SEAVIEW BLVD		PORT WASHINGTON	NY	11050-4615
375	Affiliated	515	Lynbrook	Lynbrook Dialysis Center	147 SCRANTON AVE		LYNBROOK	NY	11563-2808
376	Affiliated	518	Yonkers Dialysis Center	Yonkers Dialysis Center	575 YONKERS AVE		YONKERS	NY	10704-2601
377	Affiliated	537	IHS - Queens Village	Queens Village Dialysis Center	22202 HEMPSTEAD AVE	STE 17	QUEENS VILLAGE	NY	11429-2123
378	Affiliated	536	Coney Island - IHS	Sheepshead Bay Renal Care Center (fka Coney Island)	26 BRIGHTON 11TH ST		BROOKLYN	NY	11235-5304
379	Affiliated	521	Garden City I.H.S	Garden City Dialysis Center	1100 STEWART AVE	STE 2	GARDEN CITY	NY	11530-4839
380	Affiliated	267	Kenneth Hahn-I.R.A	Kenneth Hahn Plaza Dialysis Center (Willowbrook)	11854 S WILMINGTON AVE		LOS ANGELES	CA	90059-3016
381	Affiliated	279	North Highland	North Highlands Dialysis Center	4986 WATT AVE	STE F	NORTH HIGHLANDS	CA	95660-5182
382	Affiliated	294	TRC Orangevale	Orangevale Dialysis Center	9267 GREENBACK LN	STE A2	ORANGEVALE	CA	95662-4864
383	Affiliated	554	Forest Park Dialysis Center	Forest Park Dialysis Center	380 FOREST PKWY	STE C	FOREST PARK	GA	30297-2107
384	Affiliated	446	Grant Park Nursing Home Dialysis	Grant Park Dialysis (fka Grants Park Nursing Home)	5000 NANNIE HELEN BURROUGHS AVE NE		WASHINGTON	DC	20019-5506
385	Affiliated	455	Fourth Street Dialysis	Fourth Street Dialysis	3101 N 4TH ST	STE B	LONGVIEW	TX	75605-5146
386	Affiliated	274	Bay Breeze	Bay Breeze Dialysis	11465 ULMERTON RD		LARGO	FL	33778-1602

387	Affiliated	416	Hopi	Hopi Dialysis Center- fka First Mesa	PO BOX 964	HWY 264	POLACCA	AZ	86042
388	Affiliated	178	Orlando Dialysis	Orlando Dialysis	14050 TOWN LOOP BLVD	STE 14A	ORLANDO	FL	32837-6190
389	Affiliated	170	Celebration Dialysis	Celebration Dialysis	1154 CELEBRATION BLVD		CELEBRATION	FL	34747-4605
390	Affiliated	1500	Mt. Dora Dialysis	Mt. Dora Dialysis	2735 W OLD US HIGHWAY 441		MOUNT DORA	FL	32757-3526
391	Affiliated	1501	Lake Dialysis	Lake Dialysis	221 N 1ST ST		LEESBURG	FL	34748-5150
392	Affiliated	146	Puyallup Community Dialysis	Puyallup Dialysis Center	716 SOUTH HILL PARK DR	STE C	PUYALLUP	WA	98373-1445
393	Affiliated	562	Towson Dialysis	Dulaney Towson Dialysis Center	113 WEST RD	STE 21	TOWSON	MD	21204-2318
394	Affiliated	188	Purcellville	Purcellville Dialysis Center	280 N HATCHER AVE		PURCELLVILLE	VA	20132-3193
395	Affiliated	476	Iris City	Iris City Dialysis (aka Griffin)	521 N EXPRESSWAY	STE 159	GRIFFIN	GA	30223-2073
396	Affiliated	1521	Slidell Kidney Care	Slidell Kidney Care	1150 ROBERT BLVD	STE 24	SLIDELL	LA	70458-2005

397	Affiliated	385	Rivertowne Dialysis	Rivertowne Dialysis (fka Oxon Hill Dialysis)	6192 OXON HILL RD	1ST FL	OXON HILL	MD	20745-3114
398	Affiliated	477	Pearland Dialysis	Pearland Dialysis	6516 BROADWAY ST	STE 122	PEARLAND	TX	77581-7879
399	Affiliated	419	East Aurora Dialysis	East Aurora Dialysis (aka Aurora II)	482 S CHAMBERS RD		AURORA	CO	80017-2092
400	Affiliated	1507	Merrillville Dialysis	CRC- Merrillville Dialysis Center	9223 TAFT ST		MERRILLVILLE	IN	46410-6911
401	Affiliated	563	Bricktown Dialysis	Bricktown Dialysis Center	525 JACK MARTIN BLVD	FL 2	BRICK	NJ	08724-7735
402	Affiliated	423	Sapulpa	Sapulpa Dialysis (fka Jenks-Sapulpa)	9647 RIDGEVIEW ST		TULSA	OK	74131-6205
403	Affiliated	1526	Ellijay Dialysis	Ellijay Dialysis	449 INDUSTRIAL BLVD	STE 24	ELLIJAY	GA	30540-6724
404	Affiliated	1527	Gainesville Dialysis	Gainesville Dialysis	2545 FLINTRIDGE RD	STE 13	GAINESVILLE	GA	30501-7428
405	Affiliated	1528	Newnan Dialysis	Newnan Dialysis	1565 E HWY 34	STE 13	NEWNAN	GA	30265
406	Affiliated	405	Ocala Regional Kidney Center - North	OCALA North Dialysis Center	2620 W HWY 316		CITRA	FL	32113-3555
407	Affiliated	1516	Pin Oak Dialysis	Pin Oak Dialysis Center (aka Katy II)	1302 PIN OAK RD		KATY	TX	77494-6848
408	Affiliated	1523	Imperial Care Dialysis	Imperial Care Dialysis Center	4345 E IMPERIAL HWY		LYNWOOD	CA	90262-2318
409	Affiliated	1533	St. Louis Park Dialysis	St. Louis Park Dialysis Center	3505 LOUISIANA AVE S		ST LOUIS PARK	MN	55426-4121
410	Affiliated	1517	Minneapolis NE Dialysis	Minneapolis NE Dialysis	1049 10TH AVE SE		MINNEAPOLIS	MN	55414-1312
411	Affiliated	298	Flushing Dialysis	Flushing Dialysis Center	3469 PIERSON PL	STE A	FLUSHING	MI	48433-2413
412	Affiliated	1535	Dialysis Systems of Covington	Dialysis Systems of Covington	210 GREENBRIAR BLVD		COVINGTON	LA	70433-7235

413	Affiliated	1536	Dialysis Systems of Hammond	Dialysis Systems of Hammond	15799 PROFESSIONAL PLZ		HAMMOND	LA	70403-1452
414	Affiliated	433	Soledad Dialysis	Soledad Dialysis Center	901 LOS COCHES DR		SOLEDAD	CA	93960-2995
415	Affiliated	443	Lake Elsinore Dialysis	Lake Elsinore Dialysis	32291 MISSION TRL	BLDG S	LAKE ELSINORE	CA	92530
416	Affiliated	1511	Clinton Dialysis Center	Clinton Dialysis Center	150 S 31ST ST		CLINTON	OK	73601-9118
417	Affiliated	456	Bakers Ferry	Bakers Ferry Dialysis	3645 BAKERS FERRY RD SW		ATLANTA	GA	30331-3712
418	Affiliated	1509	Hermiston	Hermiston Community Dialysis Center	1155 W LINDA AVE		HERMISTON	OR	97838-9601
419	Affiliated	1539	Yakima	Yakima Dialysis Center	1221 N 16TH AVE		YAKIMA	WA	98902-1347
420	Affiliated	409	Madison	Madison Dialysis Center	302 HIGHWAY ST		MADISON	NC	27025-1672
421	Affiliated	1508	Swannanoa Dialysis	Swannanoa Dialysis Center (fka Black Mountain, NC)	2305 US HIGHWAY 70		SWANNANOA	NC	28778-8207
422	Affiliated	2009	NE Wichita Dialysis	NE Wichita Dialysis Center	2630 N WEBB RD	STE 1 BLDG 1	WICHITA	KS	67226-8174
423	Affiliated	2005	Chadbourn Dialysis	Chadbourn Dialysis Center (fkaColumbus County)	210 STRAWBERRY BLVD		CHADBOURN	NC	28431-1418
424	Affiliated	1506	Western Home Dialysis	Mile High Home Dialysis PD (fka Western Home)	1750 PIERCE ST	STE A	LAKEWOOD	CO	80214-1434
425	Affiliated	2019	Tustin Dialysis	Tustin Dialysis (aka Santa Ana)	2090 N TUSTIN AVE	STE 1	SANTA ANA	CA	92705-7869
426	Affiliated	182	Appomattox	Appomattox Dialysis (Petersburg)	15 W OLD ST		PETERSBURG	VA	23803-3221
427	Affiliated	2002	Maryville Dialysis	Maryville Dialysis	2130 VADALABENE DR		MARYVILLE	IL	62062-5632
428	Affiliated	2001	Mission Hills	Mission Hills Dialysis (aka Cristo Rey)	2700 N STANTON ST		EL PASO	TX	79902-2500

429	Affiliated	125	Moncrief	Moncrief Dialysis Partners	800 W 34TH ST	STE 11	AUSTIN	TX	78705-1144
430	Affiliated	295	Southfield West Dialysis	Southfield West Dialysis	21900 MELROSE AVE	STE 4	SOUTHFIELD	MI	48075-7967
431	Affiliated	525	Neptune Dialysis	Neptune Dialysis Center	2180 BRADLEY AVE		NEPTUNE	NJ	07753-4427
432	Affiliated	2014	Portsmouth Dialysis	Portsmouth Dialysis Center	2000 HIGH ST		PORTSMOUTH	VA	23704-3012
433	Affiliated	2016	Tokay Dialysis	Tokay Dialysis Center (fka East Lodi, CA)	312 S FAIRMONT AVE	STE A	LODI	CA	95240-3840
434	Affiliated	1504	Mt. Pocono Dialysis	Mt. Pocono Dialysis	100 COMMUNITY DR	STE 16	TOBYHANNA	PA	18466-8986
435	Affiliated	1544	Greater Portsmouth	Greater Portsmouth (aka Bon View Dialysis & Mid Town Hampton Road Dialysis)	3516 QUEEN ST		PORTSMOUTH	VA	23707-3238
436	Affiliated	1545	Peninsula Dialysis	Peninsula Dialysis Center (aka Immaculate Dialysis)	716 DENBIGH BLVD	STE D1 AND D2	NEWPORT NEWS	VA	23608-4414
437	Affiliated	1540	Saginaw Dialysis	Saginaw Dialysis	1527 E GENESEE AVE		SAGINAW	MI	48607-1755
438	Affiliated	1560	Churchview Dialysis	Churchview Dialysis	5970 CHURCHVIEW DR		ROCKFORD	IL	61107-2574
439	Affiliated	1562	Freeport Dialysis	Freeport Dialysis	1028 S KUNKLE BLVD		FREEPORT	IL	61032-6914
440	Affiliated	1563	Rockford Dialysis	Rockford Dialysis	3339 N ROCKTON AVE		ROCKFORD	IL	61103-2839
441	Affiliated	1564	Whiteside Dialysis	Whiteside Dialysis	2600 N LOCUST	STE D	STERLING	IL	61081-4602
442	Affiliated	2021	Pikesville Dialysis	Pikesville Dialysis	1500 REISTERSTOWN RD	STE 22	PIKESVILLE	MD	21208-3836
443	Affiliated	2000	Waynesville Dialysis	Waynesville Dialysis Center	11 PARK TERRACE DR		CLYDE	NC	28721-7445

				(fka Haywood, NC)						
444	Affiliated	296	Davison Dialysis	Davison Dialysis	1011 S STATE RD		DAVISON	MI	48423-1903	
445	Affiliated	1557	Flint Dialysis	Flint Dialysis Center	2 HURLEY PLZ	STE 115	FLINT	MI	48503-5904	
446	Affiliated	1558	Hallwood Dialysis	Hallwood Dialysis Center	4929 CLIO RD	STE B	FLINT	MI	48504-1886	
447	Affiliated	1559	Park Plaza Dialysis	Park Plaza Dialysis	G1075 N BALLENGER HWY		FLINT	MI	48504-4431	
448	Affiliated	1518	Rosemead Springs Dialysis	Rosemead Springs Dialysis Center	3212 ROSEMEAD BLVD		EL MONTE	CA	91731-2807	
449	Affiliated	2022	Scottsdale Dialysis	Scottsdale Dialysis Center	4725 N SCOTTSDALE RD	STE 1	SCOTTSDALE	AZ	85251-7621	
450	Affiliated	1570	Washington Parish Dialysis	Washington Parish Dialysis	724 WASHINGTON ST		FRANKLINTON	LA	70438-1790	
451	Affiliated	2027	Brookhollow Dialysis	Brookhollow Dialysis	4918 W 34TH ST		HOUSTON	TX	77092-6606	
452	Affiliated	2017	Creekside	Creekside Dialysis Center (fka So. Vacaville, CA)	141 PARKER ST		VACAVILLE	CA	95688-3921	
453	Affiliated	529	Middletown	Middletown Dialysis Center (fka-Red Bank)	500 STATE ROUTE 35	UNION SQUARE PLAZA	RED BANK	NJ	07701-5038	
454	Affiliated	1541	Southwest Ohio Dialysis	Southwest Ohio Dialysis (Xenia- SWORC)	215 S ALLISON AVE		XENIA	OH	45385-3694	
455	Affiliated	369	Oak Park	Oak Park Dialysis Center	13481 W 10 MILE RD		OAK PARK	MI	48237-4633	
456	Affiliated	2042	Eden Prairie	Eden Prairie Dialysis	14852 SCENIC HEIGHTS RD	STE 255 BLDG B	EDEN PRAIRIE	MN	55344-2320	
457	Affiliated	1530	Owensboro Dialysis	Owensboro Dialysis Center	1930 E PARRISH AVE		OWENSBORO	KY	42303-1443	
458	Affiliated	1531	Tell City Dialysis	CRC-Tell City Dialysis Center	1602 MAIN ST		TELL CITY	IN	47586-1310	
459	Affiliated	1576	Crestwood Dialysis	Crestwood Dialysis (fka	9901 WATSON RD	STE 125	SAINT LOUIS	MO	63126-1855	

Health Research
Group-St. Louis
(HRG))

460	Affiliated	2004	Copperfield Dialysis	Copperfield Dialysis (fka Cabarrus County-NC, and Concord)	1030 VINEHAVEN DR	CONCORD	NC	28025-2438
461	Affiliated	1572	Grand Island Dialysis	Grand Island Dialysis	603 S WEBB RD	GRAND ISLAND	NE	68803-5141
462	Affiliated	1573	Harlan Dialysis	Harlan Dialysis	1213 GARFIELD AVE	HARLAN	IA	51537-2057
463	Affiliated	1574	Shenandoah Dialysis	Shenandoah Dialysis	300 PERSHING AVE	SHENANDOAH	IA	51601-2355

464	Affiliated	2053	Germantown Dialysis	Germantown Dialysis	20111 CENTURY BLVD	STE C	GERMANTOWN MD	20874-9165
465	Affiliated	2051	Lamplighter Dialysis	Lamplighter Dialysis	12654 LAMPLIGHTER SQUARE		ST LOUIS MO	63128
466	Affiliated	1578	Kidney Care of Largo	Kidney Care of Largo	1300 MERCANTILE LN	STE 194	UPPER MARLBORO MD	20774
467	Affiliated	1579	Kidney Care of Laurel	Kidney Care of Laurel	14631 LAUREL BOWIE ROAD	UNITS 1-15	LAUREL MD	20707
468	Affiliated	2024	Durant Dialysis	Durant Dialysis Center	411 WESTSIDE DR		DURANT OK	74701-2932
469	Affiliated	2038	Palm Brook Dialysis	Palm Brook Dialysis Center	14664 N DEL WEBB BLVD		SUN CITY AZ	85351-2137
470	Affiliated	2043	Cambridge Dialysis	Cambridge Dialysis Center	300 BYRN ST		CAMBRIDGE MD	21613-1908
471	Affiliated	2059	Reston Dialysis Center	Reston Dialysis Center	1875 CAMPUS COMMONS DR	STE 11	RESTON VA	20191-1564
472	Affiliated	2040	Franconia Dialysis	Franconia Dialysis Centre	5695 KING CENTRE DRIVE		ALEXANDRIA VA	22315-5744
473	Affiliated	2041	Eagan Dialysis	Eagan Dialysis Unit	2750 BLUE WATER RD	SUITE 3	EAGAN MN	55121-1400
474	Affiliated	1594	Central Des Moines Dialysis	Central Des Moines Dialysis	1215 PLEASANT ST	STE 16	DES MOINES IA	50309-1409
475	Affiliated	1595	West Des Moines Dialysis	West Des Moines Dialysis	6800 LAKE DR	STE 185	WEST DES MOINES IA	50266-2544
476	Affiliated	1596	Creston Dialysis	Creston Dialysis	1700 W TOWNLINE ST		CRESTON IA	50801-1054
477	Affiliated	1597	Atlantic Dialysis	Atlantic Dialysis	1500 E 10TH ST		ATLANTIC IA	50022-1935
478	Affiliated	1598	Newton Dialysis	Newton Dialysis	204 N 4TH AVE E	STE 134	NEWTON IA	50208-3135
479	Affiliated	2046	Dialysis of Des Moines	Riverpoint Dialysis Unit	501 SW 7TH ST	STE B	DES MOINES IA	50309-4538
480	Affiliated	2060	Bellevue Dialysis	Bellevue Dialysis Center	3535 FACTORIA BLVD SE	STE 15	BELLEVUE WA	98006-1293

481	Affiliated	414	Somerset Dialysis	Somerset Dialysis Center	240 CHURCHILL AVE		SOMERSET	NJ	08873-3451
482	Affiliated	2031	East Ft. Lauderdale Dialysis	East Ft. Lauderdale Dialysis Center (fka No. Broward)	1301 S ANDREWS AVE	STE 11	FT LAUDERDALE	FL	33316-1823
483	Affiliated	1593	Spring Branch Dialysis	Spring Branch Dialysis	1425 BLALOCK	STE 1	HOUSTON	TX	77055-4446
484	Affiliated	1599	Battle Creek Dialysis	Battle Creek Dialysis	220 E GOODALE AVE		BATTLE CREEK	MI	49037-2728
485	Affiliated	2025	Hampton Avenue Dialysis	Hampton Avenue Dialysis-MO (Forest Park)	1425 HAMPTON AVE		SAINT LOUIS	MO	63139-3115
486	Affiliated	1605	Bogalusa Kidney Care	Bogalusa Kidney Care	2108 SOUTH AVE F		BOGALUSA	LA	70427
487	Affiliated	2055	Bardstown Dialysis	Bardstown Dialysis Center	210 W JOHN FITCH AVE		BARDSTOWN	KY	40004-1115
488	Affiliated	2050	Southern Pines	Southern Pines Dialysis Center	209 WINDSTAR PL		SOUTHERN PINES	NC	28387-7086
489	Affiliated	2030	Montclare Dialysis	Montclare Dialysis Center (aka Belmont Ave)	7009 W BELMONT AVE		CHICAGO	IL	60634-4533
490	Affiliated	2048	Southern Hills	Southern Hills Dialysis Center	9280 W SUNSET RD	STE 11	LAS VEGAS	NV	89148-4861
491	Affiliated	2068	Kilgore Dialysis	Kilgore Dialysis Center	209 HWY 42 NORTH		KILGORE	TX	75662-5019
492	Affiliated	2067	Brighton Dialysis	Brighton Dialysis	4700 E BROMLEY LN	STE 13	BRIGHTON	CO	80601-7821
493	Affiliated	2023	Union Gap	Union Gap Dialysis (aka Yakima)	1236 AHTANUM RIDGE DR	AHTANUM RIDGE BUSINESS PARK	UNION GAP	WA	98903-1813
494	Affiliated	2039	Dallas North Dialysis	Dallas North Dialysis Center (aka Greenville)	11886 GREENVILLE AVE	STE 1B	DALLAS	TX	75243-9743
495	Affiliated	2061	Grovepark Dialysis	Grovepark Dialysis Center (fka Jackson Dialysis)	794 MCDONOUGH RD		JACKSON	GA	30233-1572

496	Affiliated	1583	Eastern Kentucky Dialysis	Eastern Kentucky Dialysis	167 WEDDINGTON BRANCH RD		PIKEVILLE	KY	41501-3204
497	Affiliated	1584	Paintsville Dialysis	Paintsville Dialysis	4750 S KY ROUTE 321		HAGERHILL	KY	41222
498	Affiliated	1582	West Virginia Dialysis	West Virginia Dialysis	300 PROSPERITY LANE	STE 15	LOGAN	WV	25601-3494
499	Affiliated	2049	Reidsville Dialysis	Reidsville Dialysis	1307 FREEWAY DR		REIDSVILLE	NC	27320-7104
500	Affiliated	2034	Elk Grove Dialysis	Elk Grove Dialysis	9281 OFFICE PARK CIR	STE 15	ELK GROVE	CA	95758-8069
501	Affiliated	2035	Weston Dialysis	Weston Dialysis Center (fka Cleveland Clinic)	2685 EXECUTIVE PARK DR	STE 1	WESTON	FL	33331-3651
502	Affiliated	1600	McCook Dialysis	McCook Dialysis Center	801 W C ST		MCCOOK	NE	69001-3591
503	Affiliated	1601	Hastings Dialysis	Hastings Dialysis Center	1900 N SAINT JOSEPH AVE		HASTINGS	NE	68901-2652
504	Affiliated	1602	Capital City Dialysis	Capital City Dialysis	307 N 46TH ST		LINCOLN	NE	68503-3714
505	Affiliated	1616	Renal Care of Bowie	Renal Care of Bowie	4861 TELSA DRIVE	STES G-H	BOWIE	MD	20715-4318
506	Affiliated	1617	Renal Care of Takoma Park	Takoma Park Dialysis (fka Renal Care of Takoma Park)	1502 UNIVERSITY BLVD E		HYATTSVILLE	MD	20783
507	Affiliated	1618	Renal Care of Lanham	Renal Care of Lanham	8855 ANNAPOLIS RD	STE 2	LANHAM	MD	20706-2942
508	Affiliated	1619	Parma Dialysis	Parma Dialysis Center	6735 AMES RD		CLEVELAND	OH	44129-5601
509	Affiliated	1620	Middleburg Heights Dialysis	Middleburg Hts. Dialysis	7360 ENGLE RD		MIDDLEBURG HTS	OH	44130
510	Affiliated	1621	Rocky River Dialysis	Rocky River Dialysis	20220 CENTER RIDGE RD	STE 5	ROCKY RIVER	OH	44116-3567
511	Affiliated	1606	Diamond Valley Dialysis	Diamond Valley Dialysis	1030 E FLORIDA AVE		HEMET	CA	92543-4511
512	Affiliated	1607	Murrieta Dialysis	Murrieta Dialysis	25100 HANCOCK AVE	STE 11	MURRIETA	CA	92562-5973

513	Affiliated	2057	South Chico Dialysis	South Chico Dialysis Center	2345 FOREST AVE	CHICO	CA	95928-7641
514	Affiliated	2099	Dixon Kidney Center	Dixon Kidney Center	1131 N GALENA AVE	DIXON	IL	61021-1015
515	Affiliated	1640	Grand Rapids	PDI-Grand Rapids	801 CHERRY ST SE	GRAND RAPIDS	MI	49506-1440
516	Affiliated	1641	Grand Rapids East	PDI-Grand Rapids East	1230 EKHART ST NE	GRAND RAPIDS	MI	49503-1372
517	Affiliated	1642	Grand Haven	PDI-Grand Haven	16964 ROBBINS RD	GRAND HAVEN	MI	49417-2796
518	Affiliated	1644	Highland Park	PDI-Highland Park	64 VICTOR ST	HIGHLAND PARK	MI	48203-3128
519	Affiliated	1645	Cadieux	PDI-Cadieux	6150 CADIEUX ROAD	DETROIT	MI	48224-2006
520	Affiliated	1646	Montgomery	PDI- Montgomery	1001 FOREST AVE	MONTGOMERY	AL	36106-1181
521	Affiliated	1647	East Montgomery	PDI-East Montgomery	6890 WINTON BLOUNT BLVD	MONTGOMERY	AL	36117-3516
522	Affiliated	1648	Prattville	PDI-Prattville	1815 GLYNWOOD DR	PRATTVILLE	AL	36066-5584
523	Affiliated	1649	Elmore	PDI-Elmore	125 HOSPITAL DR	WETUMPKA	AL	36092-1626
524	Affiliated	1650	Fitchburg	PDI-Fitchburg	551 ELECTRIC AVE	FITCHBURG	MA	01420-5371
525	Affiliated	1652	Rocky Hill	PDI-Rocky Hill	30 WATERCHASE DR	ROCKY HILL	CT	06067-2110
526	Affiliated	1653	Middlesex	PDI-Middlesex Dialysis Center	100 MAIN ST STE A	MIDDLETOWN	CT	06457-3477
527	Affiliated	1655	Johnstown	PDI-Johnstown	344 BUDFIELD ST	JOHNSTOWN	PA	15904-3214
528	Affiliated	1656	Ebensburg	PDI-Ebensburg	236 JAMESWAY RD	EBENSBURG	PA	15931-4207
529	Affiliated	1657	Walnut Tower	PDI-Walnut Tower	834 WALNUT ST	PHILADELPHIA	PA	19107-5109
530	Affiliated	1659	Lancaster	PDI-Lancaster	1412 E KING ST	LANCASTER	PA	17602-3240

531	Affiliated	1660	Ephrata	PDI-Ephrata	67 W CHURCH ST		STEVENS	PA	17578-9203
532	Affiliated	2083	Pinecrest Dialysis	Pinecrest Dialysis (aka North Marshall-TX)	913 E PINECREST DR		MARSHALL	TX	75670-7309
533	Affiliated	551	Westwood Dialysis	Westwood Dialysis Center (aka West Seattle)	2615 SW TRENTON ST		SEATTLE	WA	98126-3745
534	Affiliated	2107	Louisville Dialysis	Louisville Dialysis	8037 DIXIE HWY		LOUISVILLE	KY	40258-1344
535	Affiliated	2018	Fair Oaks Dialysis	Fair Oaks Dialysis Center (fka Chantilly & Centreville)	3955 PENDER DR	ONE PENDER BUSINESS PARK	FAIRFAX	VA	22030-6091
536	Affiliated	421	Oak Cliff	Oak Cliff Dialysis	2000 S LLEWELLYN AVE		DALLAS	TX	75224-1804
537	Affiliated	2126	Gilmer Dialysis	Gilmer Dialysis Center	519 N WOOD ST		GILMER	TX	75644-1746
538	Affiliated	1608	Chicago Heights Dialysis	Chicago Heights Dialysis	177 W JOE ORR RD	STE B	CHICAGO HEIGHTS	IL	60411-1733
539	Affiliated	1623	East Georgia Dialysis	East Georgia Dialysis	450 GEORGIA AVE	STE A	STATESBORO	GA	30458-5590
540	Affiliated	1639	Northlake Dialysis	Northlake Dialysis	1350 MONTREAL RD	STE 2	TUCKER	GA	30084-8144
541	Affiliated	1680	Down River Dialysis	Downriver Kidney Center	5600 ALLEN RD		ALLEN PARK	MI	48101-2604
542	Affiliated	2063	Belcaro	Belcaro Dialysis Center	755 S COLORADO BLVD		DENVER	CO	80246-8005
543	Affiliated	2076	Sherwood Dialysis Center	Sherwood Dialysis Center	21035 SW PACIFIC HWY		SHERWOOD	OR	97140-8062
544	Affiliated	2054	Lonetree Dialysis	Lonetree Dialysis Center (aka Skyridge)	9777 MOUNT PYRAMID CT	STE 14	ENGLEWOOD	CO	80112-6017
545	Affiliated	2078	River Park Dialysis	River Park Dialysis (aka Conroe)	2010 S LOOP 336 W	STE 2	CONROE	TX	77304-3313
546	Affiliated	2058	Northshore Dialysis	Northshore Kidney Center (fka Slidell II)	106 MEDICAL CENTER DR		SLIDELL	LA	70461-5575

547	Affiliated	2036	Marysville Dialysis	Marysville Dialysis Center	1015 8TH ST		MARYSVILLE	CA	95901-5271
548	Affiliated	2070	West Georgia Dialysis	West Georgia Dialysis	1216 STARK AVE		COLUMBUS	GA	31906-2500
549	Affiliated	2102	East Dearborn Dialysis	Westland Dialysis (aka Canton)	36588 FORD RD		WESTLAND	MI	48185-3769
550	Affiliated	2045	Downtown Houston Dialysis	Downtown Houston Dialysis Center	2207 CRAWFORD ST		HOUSTON	TX	77002-8915
551	Affiliated	2066	Concord Dialysis	Concord Dialysis Center	2300 STANWELL DR	STE C	CONCORD	CA	94520-4841
552	Affiliated	2087	Pendleton Dialysis	Pendleton Dialysis (aka Clemson, Tri- County)	7703 HIGHWAY 76		PENDLETON	SC	29670-1818
553	Affiliated	2106	New Albany Dialysis	New Albany Dialysis	2669 CHARLESTON RD		NEW ALBANY	IN	47150-2573
554	Affiliated	1585	Whitesburg Dialysis	Whitesburg Dialysis	222 HOSPITAL RD	STE D	WHITESBURG	KY	41858-7627
555	Affiliated	2047	Jacinto Dialysis	Jacinto Dialysis Center (aka East Houston)	11515 MARKET STREET RD		HOUSTON	TX	77029-2305
556	Affiliated	2088	Transmountain Dialysis	Transmountain Dialysis (aka Northeast El Paso, Rushfair)	5255 WOODROW BEAN	STE B18	EL PASO	TX	79924-3832
557	Affiliated	2029	Southcrest Dialysis	Southcrest Dialysis (aka South Creek)	9001 S 101ST EAST AVE	STE 11	TULSA	OK	74133-5799
558	Affiliated	2071	Lake Hearn	Lake Hearn Dialysis (aka Dunwoody, Roswell, Northside)	1150 LAKE HEARN DR NE	STE 1	ATLANTA	GA	30342-1566
559	Affiliated	2118	Mt. Greenwood	Mt. Greenwood Dialysis	3401 W 111TH ST		CHICAGO	IL	60655-3329
560	Affiliated	2086	Citrus Valley Dialysis Center	Citrus Valley Dialysis (aka San Bernadino II)	894 HARDT STREET		SAN BERNARDINO	CA	92408-2854
561	Affiliated	2095	McDowell County Dialysis	McDowell County Dialysis Center	100 SPAULDING RD	STE 2	MARION	NC	28752-5116

562	Affiliated	2115	Leigh Dialysis Center	Leigh Dialysis Center (aka Leigh-Kempville-VA)	420 N CENTER DR	STE 128	NORFOLK	VA	23502-4019
563	Affiliated	2120	Dialysis of Lithonia	Dialysis of Lithonia	2485 PARK CENTRAL BLVD		DECATUR	GA	30035-3902
564	Affiliated	2114	Embassy Lake Artificial Kidney Center	Embassy Lake Artificial Kidney Center (fka Davie & South Broward AKC)	11011 SHERIDAN ST	STE 38	HOLLYWOOD	FL	33026-1505
565	Affiliated	2056	Sun City Dialysis	Sun City Dialysis (aka Texas Tech II)	600 NEWMAN ST		EL PASO	TX	79902-5543
566	Affiliated	1651	PDI Worcester	PDI-Worcester Dialysis	19 GLENNIE ST	STE A	WORCESTER	MA	01605-3918
567	Affiliated	2130	Davenport Dialysis Center	Davenport Dialysis Center (aka Haines City II)	45597 HIGHWAY 27	RIDGEVIEW PLAZA	DAVENPORT	FL	33897-4519
568	Affiliated	2081	Cinema Dialysis	Cinema Dialysis (aka OKC South)	3909 S WESTERN AVE		OKLAHOMA CITY	OK	73109-3405
569	Affiliated	2037	Greenwood Dialysis Center	Greenwood Dialysis Center (North Tulsa)	1345 N LANSING AVE		TULSA	OK	74106-5911
570	Affiliated	1712	TRC Alamosa Diakysis	Alamosa Dialysis	612 DEL SOL DR		ALAMOSA	CO	81101-8548
571	Affiliated	1682	South Austin	South Austin Dialysis	6114 S 1ST ST		AUSTIN	TX	78745-4008
572	Affiliated	2109	Durango Dialysis Center	Durango Dialysis Center	72 SUTTLE STREET	STE D	DURANGO	CO	81303-6829
573	Affiliated	1700	Bolivar Dialysis	Bolivar Dialysis	515 PECAN DR		BOLIVAR	TN	38008-1611
574	Affiliated	1701	Brownsville Dialysis	Brownsville Dialysis	380 N DUPREE AVE		BROWNSVILLE	TN	38012-2332
575	Affiliated	1702	Camden Dialysis	Camden Dialysis	168 W MAIN ST	STE A	CAMDEN	TN	38320-1767
576	Affiliated	1703	Collierville Dialysis	Collierville Dialysis	791 W POPLAR AVE		COLLIERVILLE	TN	38017-2543
577	Affiliated	1705	Galleria Dialysis	Galleria Dialysis	9160 HIGHWAY 64		LAKELAND	TN	38002-4766
578	Affiliated	1706	Humboldt Dialysis	Humboldt Dialysis	2214 OSBORNE ST		HUMBOLDT	TN	38343-3044

579	Affiliated	1707	Stonegate Dialysis	North Jackson Dialysis (fka Stonegate)	217 STERLING FARM DR	JACKSON	TN	38305-5727
580	Affiliated	1708	Lexington Dialysis	Lexington Dialysis	317 W CHURCH ST	LEXINGTON	TN	38351-2096
581	Affiliated	1709	Pickwick Dialysis	Pickwick Dialysis	121 PICKWICK ST	SAVANNAH	TN	38372-1953
582	Affiliated	1710	Selmer Dialysis	Selmer Dialysis	251 OAKGROVE RD	SELMER	TN	38375-1881
583	Affiliated	1713	Childs Dialysis	Childs Dialysis	101 MAIN ST	CHILDS	PA	18407-2614
584	Affiliated	1714	Dunmore Dialysis	Dunmore Dialysis	1212 O' NEIL HWY	DUNMORE	PA	18512-1717
585	Affiliated	1716	Old Forge Dialysis	Old Forge Dialysis	325 S MAIN ST	OLD FORGE	PA	18518-1677
586	Affiliated	1717	Scranton Dialysis	Scranton Dialysis	475 MORGAN HWY	SCRANTON	PA	18508-2605
587	Affiliated	1718	Tunkhannock Dialysis	Tunkhannock Dialysis	5950 SR 6	TUNKHANNOCK	PA	18657-7905
588	Affiliated	1725	East Evansville Dialysis	East Evansville Dialysis	1312 PROFESSIONAL BLVD	EVANSVILLE	IN	47714-8007
589	Affiliated	1726	North Evansville Dialysis	North Evansville Dialysis	1151 W BUENA VISTA RD	EVANSVILLE	IN	47710-3334
590	Affiliated	1728	Jasper Dialysis	Jasper Dialysis	721 W 13TH ST STE 15	JASPER	IN	47546-1856
591	Affiliated	1729	Daviess County Dialysis	Daviess County Dialysis	310 NE 14TH ST	WASHINGTON	IN	47501-2137
592	Affiliated	1730	Gardenside Dialysis	Gardenside Dialysis	70 N GARDENMILE RD	HENDERSON	KY	42420-5529
593	Affiliated	1732	PD Evansville Dialysis	East Evansville Dialysis PD	1312 PROFESSIONAL BLVD	EVANSVILLE	IN	47714-8007
594	Affiliated	2098	Meridian Dialysis Center	Meridian Dialysis Center (aka Bayshore)	201 W STE A FAIRMONT PKWY	LA PORTE	TX	77571-6303
595	Affiliated	2100	Sycamore Dialysis	Sycamore Dialysis (aka DeKalb)	2200 GATEWAY DR	SYCAMORE	IL	60178-3113
596	Affiliated	2104	Ballenger Pointe Dialysis	Ballenger Pointe Dialysis (aka West Flint)	2262 S BALLENGER HWY	FLINT	MI	48503-3447

597 Affiliated 2139 Leitchfield Leitchfield 912 WALLACE STE 16 LEITCHFIELD KY 42754-2405
Dialysis Dialysis AVE

Page 57 of 123

598	Affiliated	2097	Roxbury Dialysis Center	Roxbury Dialysis	622 ROXBURY RD	ROCKFORD	IL	61107-5089
599	Affiliated	2148	LaGrange Dialysis	La Grange Dialysis	240 PARKER DR	LA GRANGE	KY	40031-1200
600	Affiliated	2132	Des Moines East	East Des Moines Dialysis (aka Des Moines II)	1301 PENNSYLVANIA AVE STE 28	DES MOINES	IA	50316-2365
601	Affiliated	2119	Lake Villa Dialysis	Lake Villa Dialysis	37809 N IL ROUTE 59	LAKE VILLA	IL	60046-7332
602	Affiliated	159	Seneca Dialysis	Seneca County Dialysis	65 SAINT FRANCIS AVE	TIFFIN	OH	44883-3413
603	Affiliated	407	Perry	Perry Dialysis Center	1027 KEITH DR	PERRY	GA	31069-2948
604	Affiliated	661	Wilshire	Wilshire Dialysis	1212 WILSHIRE BLVD	LOS ANGELES	CA	90017-1902
605	Affiliated	692	University Park	University Park Dialysis Center	3986 S FIGUEROA ST	LOS ANGELES	CA	90037-1222
606	Affiliated	1720	Metro East Dialysis	Metro East Dialysis	5105 W MAIN ST	BELLEVILLE	IL	62226-4728
607	Affiliated	2196	Ocala Regional Kidney Centers	Ocala Regional Kidney Centers Home Dialysis Division PD	2860 SE 1ST AVE	OCALA	FL	34471-0406
608	Affiliated	2133	Little Village Dialysis	Little Village Dialysis (Chicago)	2335 W CERMAK RD	CHICAGO	IL	60608-3811
609	Affiliated	2112	Crossroads	Crossroads Dialysis (aka Fullerton Dialysis)	3214 YORBA LINDA BLVD	FULLERTON	CA	92831-1707
610	Affiliated	1727	Vincennes Dialysis	Vincennes Dialysis	700 WILLOW ST	VINCENNES	IN	47591-1028
611	Affiliated	1723	Spring Dialysis	Spring Dialysis	607 TIMBERDALE LN STE 1	HOUSTON	TX	77090-3043
612	Affiliated	2190	River Center	Rivercenter Dialysis (aka Central San Antonio)	1123 N MAIN AVE STE 15	SAN ANTONIO	TX	78212-4738

613	Affiliated	2193	Southcross Dialysis Center	Southcross Dialysis (aka SouthEast San Antonio)	4602 E SOUTHCROSS BLVD		SAN ANTONIO	TX	78222-4911
614	Affiliated	2125	Bonham Dialysis	Bonham Dialysis	201 W 5TH ST		BONHAM	TX	75418-4302
615	Affiliated	2192	Northwest Medical Center Dialysis	NW Medical Center Dialysis (aka NorthWest San Antonio)	5284 MEDICAL DR	STE 1	SAN ANTONIO	TX	78229-4849
616	Affiliated	2124	Ontario Dialysis	Ontario Dialysis (aka Dr. Handoko)	1950 S GROVE AVE	STE 11-15	ONTARIO	CA	91761-5693
617	Affiliated	1750	Chipley Community Dialysis	Chipley Dialysis	877 3RD ST	STE 2	CHIPLEY	FL	32428-1855
618	Affiliated	1751	North Ikalooosa	North Okaloosa Dialysis	320 REDSTONE AVE W		CRESTVIEW	FL	32536-6433
619	Affiliated	1752	West Florida Dialysis	West Florida Dialysis	8333 N DAVIS HWY	1ST FLOOR ATTN DIALYSIS ROOM	PENSACOLA	FL	32514-6049
620	Affiliated	1753	Santa Rosa Dialysis	Santa Rosa Dialysis	5819 HIGHWAY 90		MILTON	FL	32583-1763
621	Affiliated	1755	Atmore Dialysis	Atmore Dialysis Center	807 E CRAIG ST		ATMORE	AL	36502-3017
622	Affiliated	1756	South Baldwin Dialysis	South Baldwin Dialysis Center	150 W PEACHTREE AVE		FOLEY	AL	36535-2244
623	Affiliated	1731	Olney Dialysis	Olney Dialysis Center (aka Good Samaritan Hospital)	117 N BOONE ST		OLNEY	IL	62450-2109
624	Affiliated	2156	Lancaster Dialysis	Lancaster Dialysis	2424 W PLEASANT RUN RD		LANCASTER	TX	75146-4005
625	Affiliated	2136	Columbia Dialysis	RTC- Columbia Dialysis (MO)	1701 E BROADWAY	STE G12	COLUMBIA	MO	65201-8029

626	Affiliated	2194	Las Palmas Dialysis Center	Las Palmas Dialysis Center (aka West San Antonio)	803 CASTROVILLE RD	STE 415	SAN ANTONIO	TX	78237-3148
627	Affiliated	2116	South Shore Dialysis Center	South Shore Dialysis (aka Horizon)	212 GULF FWY S	STE G3	LEAGUE CITY	TX	77573-3957
628	Affiliated	2191	Marymount Dilaysis Center	Marymont Dialysis (aka NorthEast San Antonio)	2391 NE LOOP 410	STE 211	SAN ANTONIO	TX	78217-5675
629	Affiliated	1744	Fox River Dialysis	Fox River Dialysis	1910 RIVERSIDE DR		GREEN BAY	WI	54301-2319
630	Affiliated	1745	Titletown Dialysis	Titletown Dialysis	120 SIEGLER ST		GREEN BAY	WI	54303-2636
631	Affiliated	1746	Northwoods Dialysis	Green Bay Northwood Dialysis	W 7305 ELM AVENUE		SHAWANO	WI	54166-1024
632	Affiliated	1758	North Charleston Dialysis	North Charleston Dialysis	5900 RIVERS AVE	STE E	NORTH CHARLESTON	SC	29406
633	Affiliated	1759	Charleston County Dialysis	Faber Place Dialysis	3801 FABER PLACE DR		NORTH CHARLESTON	SC	29405-8533
634	Affiliated	1760	Goose Creek Dialysis	Goose Creek Dialysis	109 GREENLAND DR		GOOSE CREEK	SC	29445-5354
635	Affiliated	2501	Bridgeport Dialysis	Bridgeport Dialysis	900 MADISON AVE	STE 221	BRIDGEPORT	CT	06606-5534
636	Affiliated	2503	Greater Waterbury Dialysis	Greater Waterbury Dialysis	209 HIGHLAND AVE		WATERBURY	CT	06708-3026
637	Affiliated	2506	Shelton Dialysis	Shelton Dialysis	750 BRIDGEPORT AVE		SHELTON	CT	06484-4734
638	Affiliated	2508	Yuma Dialysis	Yuma Dialysis	2130 W 24TH ST		YUMA	AZ	85364-6122
639	Affiliated	2509	Pittsburgh Dialysis	Pittsburgh Dialysis	4312 PENN AVE		PITTSBURGH	PA	15224-1310
640	Affiliated	2510	Elizabeth Dialysis	Elizabeth Dialysis	201 MCKEESPORT RD		ELIZABETH	PA	15037-1623

641	Affiliated	2511	Brandon East Dialysis	Brandon East Dialysis	114 E BRANDON BLVD		BRANDON	FL	33511-5219
642	Affiliated	2513	North Rolling Road Dialysis	North Rolling Road Dialysis	1108 N ROLLING RD		BALTIMORE	MD	21228-3826
643	Affiliated	2521	Memphis South Dialysis	Memphis South Dialysis	1205 MARLIN RD		MEMPHIS	TN	38116-5812
644	Affiliated	2524	Hartford Dialysis	Hartford Dialysis	675 TOWER AVE	RENAL UNIT 2ND FL	HARTFORD	CT	6112
645	Affiliated	2538	New Orleans Uptown Dialysis	New Orleans Uptown Dialysis	1401 FOUCHER ST	4TH FLOOR DIALYSIS	NEW ORLEANS	LA	70115-3515
646	Affiliated	2540	Omaha West Dialysis	Omaha West Dialysis	13014 W DODGE RD		OMAHA	NE	68154-2148
647	Affiliated	2541	White Memorial Dialysis	East Los Angeles Plaza Dialysis (fka White Memorial)	1700 E CESAR E CHAVEZ AVE	STE L 1	LOS ANGELES	CA	90033-2424
648	Affiliated	2542	Imperial Dialysis	Imperial Dialysis	2738 W IMPERIAL HWY		INGLEWOOD	CA	90303-3111
649	Affiliated	2546	North Hollywood Dialysis	North Hollywood Dialysis	12126 VICTORY BLVD		NORTH HOLLYWOOD	CA	91606-3205
650	Affiliated	2555	Mountain View Dialysis	Mountain View Dialysis	2881 BUSINESS PARK CT	STE 13	LAS VEGAS	NV	89128-9019
651	Affiliated	2560	San Juan Capistrano South Dialysis	San Juan Capistrano South Dialysis	31736 RANCHO VIEJO RD	STE B	SAN JUAN CAPISTRANO	CA	92675-2783
652	Affiliated	2564	Mission Viejo Dialysis	Mission Viejo Dialysis	27640 MARGUERITE PKWY		MISSION VIEJO	CA	92692-3604
653	Affiliated	2568	HI-Desert Dialysis	HI-Desert Dialysis	58457 29 PALMS HWY	STE 12	YUCCA VALLEY	CA	92284-5879
654	Affiliated	2571	Banning Dialysis	Banning Dialysis	6090 W RAMSEY ST		BANNING	CA	92220-3052
655	Affiliated	2601	Rainbow City Dialysis	Rainbow City Dialysis	2800 RAINBOW DR		RAINBOW CITY	AL	35906-5811
656	Affiliated	2604	Gadsden Dialysis	Gadsden Dialysis	409 S 1ST ST		GADSDEN	AL	35901-5358

657	Affiliated	2605	Chateau Dialysis	Chateau Dialysis	720 VILLAGE RD	KENNER	LA	70065-2751
658	Affiliated	2606	Donaldsonville Dialysis	Donaldsonville Dialysis	101 PLIMSOL DR	DONALDSONVILLE	LA	70346-4357
659	Affiliated	2609	Dothan Dialysis	Dothan Dialysis	216 GRACELAND DR	DOTHAN	AL	36305-7346
660	Affiliated	2614	Birmingham East Dialysis	Birmingham East Dialysis	1105 E PARK DR	BIRMINGHAM	AL	35235-2560
661	Affiliated	2615	Tuscaloosa Dialysis	Tuscaloosa Dialysis	805 OLD MILL ST	TUSCALOOSA	AL	35401-7132
662	Affiliated	2616	Demopolis Dialysis	Demopolis Dialysis	511 S CEDAR AVE	DEMOPOLIS	AL	36732-2235
663	Affiliated	2623	Singing River Dialysis	Singing River Dialysis	4907 TELEPHONE RD	PASCAGOULA	MS	39567-1823
664	Affiliated	2624	Ocean Springs Dialysis	Ocean Springs Dialysis	13150 PONCE DE LEON DR	OCEAN SPRINGS	MS	39564-2460

665	Affiliated	2625	Lucedale Dialysis	Lucedale Dialysis	652 MANILA ST		LUCEDALE	MS	39452-5962
666	Affiliated	2707	Holmdel Dialysis	Holmdel Dialysis	668 N BEERS ST		HOLMDEL	NJ	07733-1526
667	Affiliated	2855	Alameda County Dialysis	Alameda County Dialysis	10700 MACARTHUR BLVD	STE 14	OAKLAND	CA	94605-5260
668	Affiliated	2908	Elizabeth City Dialysis	Elizabeth City Dialysis	1840 W CITY DR		ELIZABETH CITY	NC	27909-9632
669	Affiliated	2914	Cookeville Dialysis	Cookeville Dialysis	140 W 7TH ST		COOKEVILLE	TN	38501-1726
670	Affiliated	3001	Inglewood Dialysis	Inglewood Dialysis	125 E ARBOR VITAE ST		INGLEWOOD	CA	90301-3839
671	Affiliated	3002	Rome Dialysis	Rome Dialysis	15 JOHN MADDOX DR NW		ROME	GA	30165-1413
672	Affiliated	3004	Pomona Dialysis	Pomona Dialysis	2111 N GAREY AVE		POMONA	CA	91767-2328
673	Affiliated	3005	Oak Street Dialysis	Oak Street Dialysis (fka Valdosta)	2704 N OAK ST	BLDG H	VALDOSTA	GA	31602-1723
674	Affiliated	3006	Channelview Dialysis	Channelview Dialysis	777 SHELDON RD	STE C	CHANNELVIEW	TX	77530-3509
675	Affiliated	3007	Sagemont Dialysis	Sagemont Dialysis	10851 SCARSDALE BLVD	STE 2	HOUSTON	TX	77089-5738
676	Affiliated	3008	San Jacinto Dialysis	San Jacinto Dialysis	11430 EAST FWY	STE 33	HOUSTON	TX	77029-1959
677	Affiliated	3009	Victor Valley Dialysis	Victor Valley Dialysis	16049 KAMANA RD		APPLE VALLEY	CA	92307-1331
678	Affiliated	3010	Delran Dialysis	Delran Dialysis	8008 ROUTE 130		DELTRAN	NJ	08075-1869
679	Affiliated	3011	Central Houston Dialysis	Central Houston Dialysis	610 S WAYSIDE DR	UNIT B	HOUSTON	TX	77011-4605
680	Affiliated	3012	Southern Lane Dialysis	Southern Lane Dialysis	1840 SOUTHERN LN		DECATUR	GA	30033-4033
681	Affiliated	3013	Northumberland Dialysis	Northumberland Dialysis	103 W STATE ROUTE 61		MOUNT CARMEL	PA	17851-2539
682	Affiliated	3014	Pryor Dialysis	Pryor Dialysis	309 E GRAHAM AVE		PRYOR	OK	74361-2434
683	Affiliated	3015	Oklahoma City South Dialysis	Oklahoma City South Dialysis	5730 S MAY AVE		OKLAHOMA CITY	OK	73119-5604

684	Affiliated	3016	Abington Dialysis	Abington Dialysis	3940A COMMERCE AVE	WILLOW GROVE	PA	19090-1705
685	Affiliated	3017	Memphis Central Dialysis	Memphis Central Dialysis	889 LINDEN AVE	MEMPHIS	TN	38126-2412
686	Affiliated	3018	Memphis East Dialysis	Memphis East Dialysis	50 HUMPHREYS CTR	MEMPHIS	TN	38120-2372
687	Affiliated	3019	Clarksville Dialysis	Clarksville Dialysis	231 HILLCREST DR	CLARKSVILLE	TN	37043-5093
688	Affiliated	3020	Miami Campus Dialysis	Miami Campus Dialysis	1500 NW 12TH AVE	MIAMI	FL	33136-1028
689	Affiliated	3021	Orlando Dialysis	Orlando Dialysis	116 STURTEVANT ST	ORLANDO	FL	32806-2021
690	Affiliated	3024	Durham Dialysis	Durham Dialysis	601 FAYETTEVILLE ST	DURHAM	NC	27701-3910
691	Affiliated	3025	Candler County Dialysis	Candler County Dialysis	325 CEDAR ST	METTER	GA	30439-4043
692	Affiliated	3027	Kerrville Dialysis	Kerrville Dialysis	515 GRANADA PL	KERRVILLE	TX	78028-5992
693	Affiliated	3028	Floresville Dialysis	Floresville Dialysis	543 10TH ST	FLORESVILLE	TX	78114-3107
694	Affiliated	3029	Pearsall Dialysis	Pearsall Dialysis	1305 N OAK ST	PEARSALL	TX	78061-3414
695	Affiliated	3030	Nogales Dialysis	Nogales Dialysis	1231 W TARGET RANGE RD	NOGALES	AZ	85621-2417
696	Affiliated	3032	Wilson Dialysis	Wilson Dialysis	1605 MEDICAL PARK DR W	WILSON	NC	27893-2799
697	Affiliated	3033	Goldsboro Dialysis	Goldsboro Dialysis	2609 HOSPITAL RD	GOLDSBORO	NC	27534-9424
698	Affiliated	3034	Roxboro Dialysis	Roxboro Dialysis	718 RIDGE RD	ROXBORO	NC	27573-4508
699	Affiliated	3035	Boston Dialysis	Boston Dialysis	660 HARRISON AVE	BOSTON	MA	02118-2304
700	Affiliated	3037	Jesup Dialysis	Jesup Dialysis	301 PEACHTREE ST	JESUP	GA	31545-0245
701	Affiliated	3038	Sheffield Dialysis	Sheffield Dialysis	1120 S JACKSON HWY	SHEFFIELD	AL	35660-5777

702	Affiliated	3039	Berkeley Dialysis	Berkeley Dialysis	2920 TELEGRAPH AVE		BERKELEY	CA	94705-2031
703	Affiliated	3040	Douglas Dialysis	Douglas Dialysis	190 WESTSIDE DR	STE A	DOUGLAS	GA	31533-3534
704	Affiliated	3041	Hopkinsville Dialysis	Hopkinsville Dialysis	1914 S VIRGINIA ST		HOPKINSVILLE	KY	42240-3610
705	Affiliated	3042	Roxborough Dialysis	Roxborough Dialysis	5003 UMBRIA ST		PHILADELPHIA	PA	19128-4301
706	Affiliated	3043	New Haven Dialysis	New Haven Dialysis	100 CHURCH ST S	STE C	NEW HAVEN	CT	06519-1703
707	Affiliated	3044	Ocoee Dialysis	Ocoee Dialysis	11140 W COLONIAL DR	STE 5	OCOEE	FL	34761-3300
708	Affiliated	3045	Waverly Dialysis	Waverly Dialysis	407 E BALTIMORE PIKE		MORTON	PA	19070-1042
709	Affiliated	3046	Sells Dialysis	Sells Dialysis	PO BOX 3030	HWY 86 MILEPOST 113	SELLS	AZ	85634-3030
710	Affiliated	3047	Sierra Vista Dialysis	Sierra Vista Dialysis	629 N HIGHWAY 90	STE 6	SIERRA VISTA	AZ	85635-2257
711	Affiliated	3048	Callaghan Road Dialysis	San Antonio West Dialysis (fka Callaghan Road)	4530 CALLAGHAN RD		SAN ANTONIO	TX	78228
712	Affiliated	3049	Houston Dialysis	Houston Dialysis	7543 SOUTH FWY		HOUSTON	TX	77021-5928
713	Affiliated	3050	South Yuma Dialysis	South Yuma Dialysis	7179 E 31ST PLACE		YUMA	AZ	85365-8392
714	Affiliated	3052	Cherry Hill Dialysis	Cherry Hill Dialysis	1030 KINGS HWY N	STE 1	CHERRY HILL	NJ	08034-1907
715	Affiliated	3055	Escondido Dialysis	Escondido Dialysis	203 E 2ND AVE		ESCONDIDO	CA	92025-4212
716	Affiliated	3056	Brookline Dialysis	Brookline Dialysis	322 WASHINGTON ST		BROOKLINE	MA	02445-6850
717	Affiliated	3057	Reliant Dialysis	Reliant Dialysis	1335 LA CONCHA LN		HOUSTON	TX	77054-1809
718	Affiliated	3058	Fullerton Dialysis	Fullerton Dialysis	238 ORANGEFAIR MALL		FULLERTON	CA	92832-3037

719	Affiliated	3059	Huntington Beach Dialysis	Huntington Beach Dialysis	16892 BOLSA CHICA ST	STE 1	HUNTINGTON BEACH	CA	92649-3571
720	Affiliated	3060	Eastlake Dialysis	Eastlake Dialysis (fka South Dekalb)	1757 CANDLER RD		DECATUR	GA	30032-3276
721	Affiliated	3061	Mt. Olive Dialysis	Mt. Olive Dialysis	105 MICHAEL MARTIN RD		MOUNT OLIVE	NC	28365-1112
722	Affiliated	3062	Southwest San Antonio Dialysis	Southwest San Antonio Dialysis	1620 SOMERSET RD		SAN ANTONIO	TX	78211-3021
723	Affiliated	3064	North Loop East Dialysis	North Loop East Dialysis	7139 NORTH LOOP E		HOUSTON	TX	77028-5903
724	Affiliated	3065	Katy Cinco Ranch Dialysis	Katy Cinco Ranch Dialysis	1265 ROCK CANYON DR		KATY	TX	77450-3831
725	Affiliated	3067	Palm Springs Dialysis	Palm Springs Dialysis	1061 N INDIAN CANYON DR		PALM SPRINGS	CA	92262-4854
726	Affiliated	3069	Muskegon Dialysis	Muskegon Dialysis	1277 MERCY DR		MUSKEGON	MI	49444-4605
727	Affiliated	3070	Loomis Road Dialysis	Loomis Road Dialysis	4120 W LOOMIS RD		GREENFIELD	WI	53221-2052
728	Affiliated	3071	Ludington Dialysis	Ludington Dialysis	5 N ATKINSON DR	STE 11	LUDINGTON	MI	49431-2918
729	Affiliated	3073	Walterboro Dialysis	Walterboro Dialysis	302 RUBY ST		WALTERBORO	SC	29488-2758
730	Affiliated	3074	K Street Dialysis (fka GWU N Street Dialysis)	K Street Dialysis (fka GWU N Street Dialysis)	2131 K ST NW		WASHINGTON	DC	20037-1898
731	Affiliated	3075	GWU Southeast Dialysis	GWU Southeast Dialysis	3857A PENNSYLVANIA AVE SE		WASHINGTON	DC	20020-1309

732	Affiliated	3076	Lakeside Dialysis	Lakeside Dialysis	10401 HOSPITAL DR	STE G2	CLINTON	MD	20735-3113
733	Affiliated	3077	Summit Dialysis	Summit Dialysis	1139 SPRUCE DR		MOUNTAINSIDE	NJ	07092-2221
734	Affiliated	3078	Aiken Dialysis	Aiken Dialysis	775 MEDICAL PARK DR		AIKEN	SC	29801-6306
735	Affiliated	3092	Ozark Dialysis	Ozark Dialysis	214 HOSPITAL AVE		OZARK	AL	36360-2038
736	Affiliated	3094	Wylds Road Dialysis	Wylds Road Dialysis (fka Augusta South)	1815 WYLDs RD		AUGUSTA	GA	30909-4430
737	Affiliated	3104	Douglasville Dialysis	Douglasville Dialysis	3899 LONGVIEW DR		DOUGLASVILLE	GA	30135-1373
738	Affiliated	3106	Brunswick Dialysis	Brunswick Dialysis	53 SCRANTON CONNECTOR		BRUNSWICK	GA	31525-1862
739	Affiliated	3109	Benicia Dialysis	Benicia Dialysis	560 1ST ST	STE 13 BLDG D	BENICIA	CA	94510-3295
740	Affiliated	3111	Atlanta Dialysis	Atlanta Dialysis	567 NORTH AVE NE	STE 2	ATLANTA	GA	30308-2719
741	Affiliated	3115	Rolla Dialysis	Rolla Dialysis	1503 E 10TH ST		ROLLA	MO	65401-3696
742	Affiliated	3119	East Atlanta Dialysis	East Atlanta Dialysis	1308 MORELAND AVE SE		ATLANTA	GA	30316-3224
743	Affiliated	3120	Brunswick South Dialysis	Brunswick South Dialysis	2930 SPRINGDALE RD		BRUNSWICK	GA	31520
744	Affiliated	3121	Thomaston Dialysis	Thomaston Dialysis	1065 US HIGHWAY 19 NORTH		THOMASTON	GA	30286-2233
745	Affiliated	3128	Piedmont Dialysis	Piedmont Dialysis	105 COLLIER RD NW	STE B	ATLANTA	GA	30309-1730
746	Affiliated	3130	Athens West Dialysis	Athens West Dialysis	2047 PRINCE AVE	STE A	ATHENS	GA	30606-6033
747	Affiliated	3131	Florence Dialysis	Florence Dialysis	422 E DR HICKS BLVD	STE B	FLORENCE	AL	35630-5763
748	Affiliated	3138	Atwater Dialysis	Atwater Dialysis	1201 COMMERCE AVE		ATWATER	CA	95301
749	Affiliated	3143	North Merced Dialysis	Merced Dialysis	3150 G ST	STE A	MERCED	CA	95340-1346
750	Affiliated	3169	Wisconsin Avenue Dialysis	Wisconsin Avenue Dialysis	3801 W WISCONSIN AVE		MILWAUKEE	WI	53208-3155

751	Affiliated	3171	River Center Dialysis	River Center Dialysis	117 N JEFFERSON ST		MILWAUKEE	WI	53202-6160
752	Affiliated	3175	South Fulton Dialysis	South Fulton Dialysis	2685 METROPOLITAN PKWY SW	STE F	ATLANTA	GA	30315-7926
753	Affiliated	3201	Heartland Dialysis	Heartland Dialysis	925 NE 8TH ST		OKLAHOMA CITY	OK	73104-5800
754	Affiliated	3202	Hospital Hill Dialysis	Hospital Hill Dialysis	2250 HOLMES ST		KANSAS CITY	MO	64108-2639
755	Affiliated	3203	Tucson South Dialysis	Tucson South Dialysis	3662 S 16TH AVE		TUCSON	AZ	85713-6001
756	Affiliated	3204	Greene County Dialysis	Greene County Dialysis (AL)	544 US HIGHWAY 43		EUTAW	AL	35462-4017
757	Affiliated	3205	Fayette Dialysis	Fayette Dialysis	2450 TEMPLE AVE N		FAYETTE	AL	35555-1160
758	Affiliated	3206	Tuscaloosa University Dialysis	Tuscaloosa University Dialysis	220 15TH STREET		TUSCALOOSA	AL	35401
759	Affiliated	3207	Goldsboro South Dialysis	Goldsboro South Dialysis	1704 WAYNE MEMORIAL DR		GOLDSBORO	NC	27534-2240
760	Affiliated	3208	Orlando North Dialysis	Orlando North Dialysis	5135 ADANSON ST	STE 7	ORLANDO	FL	32804-1338
761	Affiliated	3209	UT Southwestern- Dallas Dialysis	UT Southwestern- Dallas Dialysis	204 E AIRPORT FREEWAY		IRVING	TX	75062
762	Affiliated	3210	San Diego South Dialysis	San Diego South Dialysis	995 GATEWAY CENTER WAY	STE 11	SAN DIEGO	CA	92102-4550
763	Affiliated	3211	Santa Monica Dialysis	Santa Monica Dialysis	1260 15TH ST	STE 12	SANTA MONICA	CA	90404-1136
764	Affiliated	3212	Airport Dialysis	Airport Dialysis	4632 W CENTURY BLVD		INGLEWOOD	CA	90304-1456
765	Affiliated	3220	Plantation Dialysis	Plantation Dialysis	7061 CYPRESS RD	STE 13	PLANTATION	FL	33317-2243
766	Affiliated	3224	Laurens County Dialysis	Laurens County Dialysis	2400 BELLEVUE RD	STE 8	DUBLIN	GA	31021-2856
767	Affiliated	3225	Ford Factory Square Dialysis	Ford Factory Square Dialysis	567 NORTH AVE NE	STE 1	ATLANTA	GA	30308-2719

768	Affiliated	3226	North Fulton Dialysis	North Fulton Dialysis	1250 NORTHMEADOW PKWY	STE 12	ROSWELL	GA	30076-4914
769	Affiliated	3228	Freehold Dialysis	Freehold Dialysis	300 CRAIG RD		MANALAPAN	NJ	07726-8742
770	Affiliated	3229	Neptune Dialysis	Neptune Route 66 Dialysis	3297 STATE ROUTE 66		NEPTUNE	NJ	07753-2762
771	Affiliated	3231	East Orange Dialysis	East Orange Dialysis	90 WASHINGTON ST	BSMT	EAST ORANGE	NJ	07017-1050
772	Affiliated	3234	UT Southwestern- Oakcliff Dialysis	UT Southwestern- Oakcliff Dialysis	610 WYNNEWOOD DR		DALLAS	TX	75224
773	Affiliated	3236	Atlanta West Dialysis	Atlanta West Dialysis	2538 MARTIN LUTHER KING JR DR SW		ATLANTA	GA	30311-1779
774	Affiliated	3237	Columbia University Dialysis Center	Columbia University Dialysis Center	60 HAVEN AVE		NEW YORK	NY	10032-2604
775	Affiliated	3238	Northeast Cambridge Dialysis	Northeast Cambridge Dialysis	799 CONCORD AVE		CAMBRIDGE	MA	02138-1048
776	Affiliated	3239	New Bedford Dialysis	New Bedford Dialysis	524 UNION ST		NEW BEDFORD	MA	02740-3546
777	Affiliated	3242	Weymouth Dialysis	Weymouth Dialysis	330 LIBBEY INDUSTRIAL PARK	STE 9	WEYMOUTH	MA	02189-3122
778	Affiliated	3243	Woburn Dialysis	Woburn Dialysis	23 WARREN AVE		WOBURN	MA	01801-7906
779	Affiliated	3248	Bryan Dialysis	College Station Dialysis (fka Bryan Dialysis)	701 UNIVERSITY DR E	STE 41	COLLEGE STATION	TX	77840-1866
780	Affiliated	3249	Brenham Dialysis	Brenham Dialysis	2815 HIGHWAY 36 SO		BRENHAM	TX	77833
781	Affiliated	3250	Huntsville Dialysis	Huntsville Dialysis	521 IH 45S	STE 2	HUNTSVILLE	TX	77340-5651
782	Affiliated	3252	Utica Avenue Dialysis Center	Utica Avenue Dialysis Center	1305 UTICA AVE		BROOKLYN	NY	11203-5911

783	Affiliated	3254	New London Dialysis	New London Dialysis	5 SHAWS COVE STE 1	NEW LONDON	CT	06320-4974
784	Affiliated	3258	Baxley Dialysis	Baxley Dialysis	539 FAIR ST	BAXLEY	GA	31513-0112
785	Affiliated	3261	Pascua Yaqui Tribe Dialysis	Pascua Yaqui Tribe Dialysis	7490 S CAMINO DE OESTE	TUCSON	AZ	85746-9308
786	Affiliated	3262	JHHS North Bond Street Dialysis	JHHS North Bond Street Dialysis	409 N CAROLINE ST	BALTIMORE	MD	21231-1003
787	Affiliated	3263	Syosset Kidney Center	Syosset Kidney Center	1 LOCUST LN	SYOSSET	NY	11791-4834
788	Affiliated	3264	Freeport Kidney Center	Freeport Kidney Center	267 W MERRICK RD	FREEPORT	NY	11520-3346
789	Affiliated	3265	Huntington Station Dialysis Center	HAKC- Huntington	256 BROADWAY	HUNTINGTON STATION	NY	11746-1403
790	Affiliated	3266	Medford Kidney Center	Medford Kidney Center	1725 N OCEAN AVE	MEDFORD	NY	11763-2649
791	Affiliated	3267	Blue Ash Dialysis	Blue Ash Dialysis	10600 MCKINLEY RD	CINCINNATI	OH	45242-3716
792	Affiliated	3269	Mt. Auburn Dialysis	Mt. Auburn Dialysis	2109 READING RD	CINCINNATI	OH	45202-1417
793	Affiliated	3272	Charlottesville Dialysis	Charlottesville Dialysis	1460 PANTOPS MOUNTAIN PLACE	CHARLOTTESVILLE	VA	22911
794	Affiliated	3273	Alexandria Dialysis	Alexandria Dialysis	5150 DUKE ST	ALEXANDRIA	VA	22304-2906
795	Affiliated	3275	Sebastian Dialysis	Sebastian Dialysis	1424 US HWY 1 STE C	SEBASTIAN	FL	32958-1619
796	Affiliated	3276	Crestview Hills Dialysis	Crestview Hills Dialysis	400 CENTERVIEW BLVD	CRESTVIEW HILLS	KY	41017-3478
797	Affiliated	3278	Washington Square Dialysis	Washington Square Dialysis	1112 WASHINGTON SQ	WASHINGTON	MO	63090-5336
798	Affiliated	3279	Florissant Dialysis	Florissant Dialysis	11687 W FLORISSANT AVE	FLORISSANT	MO	63033-6711

799	Affiliated	3282	Ithaca Dialysis Center	Ithaca Dialysis Center	201 DATES DR	STE 26	ITHACA	NY	14850-1345
800	Affiliated	3289	Fairfield Dialysis	Fairfield Dialysis	1210 HICKS BLVD		FAIRFIELD	OH	45014-1921
801	Affiliated	3290	Fairfield Home Training Dialysis	Fairfield Home Training Dialysis	1210 HICKS BLVD		FAIRFIELD	OH	45014-1921
802	Affiliated	3291	South Hill Dialysis	South Hill Dialysis	525 ALEXANDRIA PIKE	STE 12	SOUTHGATE	KY	41071-3243
803	Affiliated	3292	Silver Spring Dialysis	Silver Spring Dialysis	8412 GEORGIA AVE		SILVER SPRING	MD	20910-4406
804	Affiliated	3295	Philadelphia PMC Dialysis	Philadelphia PMC Dialysis	51 N 39TH ST		PHILADELPHIA	PA	19104-2640
805	Affiliated	3298	Tulare Dialysis	Tulare Dialysis	545 E TULARE AVE		TULARE	CA	93274-4220
806	Affiliated	3300	Visalia Dialysis	Visalia Dialysis	5429 W CYPRESS AVE		VISALIA	CA	93277-8341
807	Affiliated	3310	Falls Road Dialysis	Falls Road Dialysis	10753 FALLS RD	STE 115	LUTHERVILLE	MD	21093-4572
808	Affiliated	3312	Malden Dialysis	Wellington Circle Dialysis Center (fka Malden)	10 CABOT RD	STE 13B	MEDFORD	MA	02155-5173
809	Affiliated	3313	Salem Northeast Dialysis	Salem Northeast Dialysis (MA)	10 COLONIAL RD	STE 25	SALEM	MA	01970-2947
810	Affiliated	3314	Lexington	Lexington Prison Unit (OK)	15151 STATE HWY 39 E	PO BOX 26	LEXINGTON	OK	73051-0260
811	Affiliated	3315	Macon County Dialysis	Macon County Dialysis	1090 W MCKINLEY AVE		DECATUR	IL	62526-3208
812	Affiliated	3316	Effingham Dialysis	Effingham Dialysis	904 MEDICAL PARK DR	STE 1	EFFINGHAM	IL	62401-2193
813	Affiliated	3317	Jacksonville Dialysis	Jacksonville Dialysis	1515 W WALNUT ST		JACKSONVILLE	IL	62650-1150

814	Affiliated	3318	Litchfield Dialysis	Litchfield Dialysis	915 ST FRANCES WAY	LITCHFIELD	IL	62056-1775
815	Affiliated	3319	Mattoon Dialysis	Mattoon Dialysis	6051 DEVELOPMENT DR	CHARLESTON	IL	61920-9467
816	Affiliated	3320	Springfield Central Dialysis	Springfield Central Dialysis	932 N RUTLEDGE ST	SPRINGFIELD	IL	62702-3721
817	Affiliated	3321	Taylorville Dialysis	Taylorville Dialysis	901 W SPRESSER ST	TAYLORVILLE	IL	62568-1831
818	Affiliated	3322	Lincoln Dialysis	Lincoln Dialysis	2100 WEST FIFTH	LINCOLN	IL	62656-9115
819	Affiliated	3323	J. B. Zachary Dialysis Center	J. B. Zachary Dialysis Center	333 CASSELL DR STE 23	BALTIMORE	MD	21224-6815
820	Affiliated	3324	Whitesquare Dialysis	Whitesquare Dialysis	1 NASHUA CT STE E	BALTIMORE	MD	21221
821	Affiliated	3325	25th Street Dialysis	25th Street Dialysis	920 E 25TH ST	BALTIMORE	MD	21218-5503
822	Affiliated	3326	Perth Amboy Dialysis	Perth Amboy Dialysis	530 NEW BRUNSWICK AVE	PERTH AMBOY	NJ	08861-3654
823	Affiliated	3327	Old Bridge Dialysis	Old Bridge Dialysis	3 HOSPITAL PLZ STE 11	OLD BRIDGE	NJ	08857-3084
824	Affiliated	3328	Pear Tree Dialysis	Pear Tree Dialysis (fka Ukiah)	126 N ORCHARD AVE	UKIAH	CA	95482-4502
825	Affiliated	3334	Hubbard Road Dialysis	Hubbard Road Dialysis	1963 HUBBARD RD	MADISON	OH	44057-2105
826	Affiliated	3335	St. Charles Dialysis	St. Charles Dialysis	2125 BLUESTONE DR	SAINT CHARLES	MO	63303-6704
827	Affiliated	3336	Bel Air Dialysis	Bel Air Dialysis	2225 OLD EMMORTON RD STE 15	BEL AIR	MD	21015-6122
828	Affiliated	3339	Cedarburg Dialysis	Cedarburg Dialysis	N 54 W 6135 MILL ST	CEDARBURG	WI	53012-2021
829	Affiliated	3340	Western Hills Dialysis	Western Hills Dialysis	3267 WESTBOURNE DR	CINCINNATI	OH	45248-5130
830	Affiliated	3341	Winton Road Dialysis	Winton Road Dialysis	6550 WINTON RD	CINCINNATI	OH	45224-1327
831	Affiliated	3342	Stamford Dialysis	Stamford Dialysis	30 COMMERCE RD	STAMFORD	CT	06902-4550

832	Affiliated	3343	Boaz Dialysis	Boaz Dialysis	16 CENTRAL HENDERSON RD	BOAZ	AL	35957-5922
833	Affiliated	3344	Guernsey County Dialysis	Guernsey County Dialysis	1300 CLARK ST	CAMBRIDGE	OH	43725-8875
834	Affiliated	3345	Marietta Dialysis	Marietta Dialysis	1019 PIKE ST	MARIETTA	OH	45750-3500
835	Affiliated	3346	Zanesville Dialysis	Zanesville Dialysis	3120 NEWARK RD	ZANESVILLE	OH	43701-9659
836	Affiliated	3351	Orlando East Dialysis	Orlando East Dialysis	1160 S SEMORAN STE C BLVD	ORLANDO	FL	32807-1461
837	Affiliated	3352	Norwich Dialysis	Norwich Dialysis	113 SALEM TPKE	NORWICH	CT	06360-6484
838	Affiliated	3354	Columbus Dialysis	Columbus Dialysis	3830 OLENTANGY RIVER RD	COLUMBUS	OH	43214-5404
839	Affiliated	3362	Pasadena Dialysis	Pasadena Dialysis	8894 FORT STE 12 SMALLWOOD RD	PASADENA	MD	21122-7608
840	Affiliated	3369	Baltimore Geriatric & Rehab Dialysis Center	Baltimore Geriatric & Rehab Dialysis Center	4940 EASTERN FLOOR 5 AVE	BALTIMORE	MD	21224-2735
841	Affiliated	3373	Frederick Dialysis	Frederick Dialysis	140 THOMAS STE 1 JOHNSON DR	FREDERICK	MD	21702-4475
842	Affiliated	3376	Fayetteville Dialysis	Fayetteville Dialysis	1279 HIGHWAY 54 STE 11 W	FAYETTEVILLE	GA	30214-4551
843	Affiliated	3377	Birmingham Central Dialysis	Birmingham Central Dialysis	728 RICHARD ARRINGTON JR BLVD S	BIRMINGHAM	AL	35233-2106
844	Affiliated	3379	Birmingham North Dialysis	Birmingham North Dialysis	1917 32ND AVE N	BIRMINGHAM	AL	35207-3333
845	Affiliated	3380	Bessemer Dialysis	Bessemer Dialysis	901 W LAKE MALL	BESSEMER	AL	35020
846	Affiliated	3382	Ensley Dialysis	Ensley Dialysis	2630 AVENUE E	BIRMINGHAM	AL	35218-2163
847	Affiliated	3383	Sylacauga Dialysis	Sylacauga Dialysis	331 JAMES PAYTON BLVD	SYLACAUGA	AL	35150
848	Affiliated	3385	Branford Dialysis	Branford Dialysis	249 W MAIN ST	BRANFORD	CT	06405-4048

849	Affiliated	3386	Shrewsbury Dialysis	Shrewsbury Dialysis	7435 WATSON RD	STE 119	SAINTE LOUIS	MO	63119-4472
850	Affiliated	3389	Milford Dialysis	Milford Dialysis	470 BRIDGEPORT AVE		MILFORD	CT	06460-4167
851	Affiliated	3414	Cedartown Dialysis	Cedartown Dialysis	325 WEST AVE		CEDARTOWN	GA	30125-3439
852	Affiliated	3416	Brookfield Dialysis	Brookfield Dialysis	19395 W CAPITOL BLDG C DR		BROOKFIELD	WI	53045-2736
853	Affiliated	3417	Henrico County Dialysis	Henrico County Dialysis	5270 CHAMBERLAYNE RD		RICHMOND	VA	23227-2950
854	Affiliated	3418	St. Louis West Dialysis	St. Louis West Dialysis	400 N LINDBERGH BLVD		SAINTE LOUIS	MO	63141-7814
855	Affiliated	3420	Springfield Montvale Dialysis	Springfield Montvale Dialysis	2930 MONTVALE DR	STE A	SPRINGFIELD	IL	62704-5376
856	Affiliated	3422	South Norwalk Dialysis	South Norwalk Dialysis	31 STEVENS ST		NORWALK	CT	06850-3805
857	Affiliated	3425	Decatur East Wood Dialysis	Decatur East Wood Dialysis	794 E WOOD ST		DECATUR	IL	62523-1155
858	Affiliated	3426	Schaeffer Drive Dialysis	Schaeffer Drive Dialysis	18100 SCHAEFER HWY		DETROIT	MI	48235-2600
859	Affiliated	3427	Redford Dialysis	Redford Dialysis	22711 GRAND RIVER AVE		DETROIT	MI	48219-3113
860	Affiliated	3428	Kresge Dialysis	Kresge Dialysis	4145 CASS AVE		DETROIT	MI	48201-1707
861	Affiliated	3429	Motor City Dialysis	Motor City Dialysis	4727 SAINT ANTOINE ST	STE 11	DETROIT	MI	48201-1461
862	Affiliated	3431	Whitebridge Dialysis	Whitebridge Dialysis	103 WHITE BRIDGE PIKE	STE 6	NASHVILLE	TN	37209-4539
863	Affiliated	3432	Columbia Dialysis	Columbia Dialysis (TN)	1705 GROVE ST		COLUMBIA	TN	38401-3517
864	Affiliated	3433	Murfreesboro Dialysis	Murfreesboro Dialysis	1346 DOW ST		MURFREESBORO	TN	37130-2470
865	Affiliated	3434	Lawrenceburg Dialysis	Lawrenceburg Dialysis (TN)	2022 N LOCUST AVE		LAWRENCEBURG	TN	38464-2336

866	Affiliated	3436	Sumner Dialysis	Sumner Dialysis	300 STEAM PLANT RD	STE 27	GALLATIN	TN	37066-3019
867	Affiliated	3437	Cumberland Dialysis	Cumberland Dialysis	312 HOSPITAL DR	STE 5	MADISON	TN	37115-5037
868	Affiliated	3438	Williamson County Dialysis	Williamson County Dialysis	3983 CAROTHERS PKWY	STE E-4	FRANKLIN	TN	37067-5936
869	Affiliated	3441	Cumming Dialysis	Cumming Dialysis	911 MARKET PLACE BLVD	STE 3	CUMMING	GA	30041-7938
870	Affiliated	3443	Silverton Dialysis	Silverton Dialysis	6929 SILVERTON AVE		CINCINNATI	OH	45236-3701
871	Affiliated	3445	Atlanta South Dialysis	Atlanta South Dialysis	3158 EAST MAIN ST	STE A	EAST POINT	GA	30344-4800
872	Affiliated	3447	St. Petersburg Dialysis	St. Petersburg Dialysis	1117 ARLINGTON AVE N		ST PETERSBURG	FL	33705-1521
873	Affiliated	3449	Alton Dialysis	Alton Dialysis	3511 COLLEGE AVE		ALTON	IL	62002-5009
874	Affiliated	3451	Edison Dialysis	Edison Dialysis	29 MERIDIAN RD		EDISON	NJ	08820-2823
875	Affiliated	3452	Dundalk Dialysis	Dundalk Dialysis	14 COMMERCE ST		DUNDALK	MD	21222-4307
876	Affiliated	3454	Columbus East Dialysis	Columbus East Dialysis	299 OUTERBELT ST		COLUMBUS	OH	43213-1529
877	Affiliated	3455	Dallas East Dialysis	Dallas East Dialysis	3312 N BUCKNER BLVD	STE 213	DALLAS	TX	75228-5642
878	Affiliated	3456	San Ysidro Dialysis	San Ysidro Dialysis	1445 30TH ST	STE A	SAN DIEGO	CA	92154-3496
879	Affiliated	3457	Olathe Dialysis	Olathe Dialysis	732 W FRONTIER LN		OLATHE	KS	66061-7202
880	Affiliated	3459	Orange City Dialysis	Orange City Dialysis	242 TREEMONT DR	BLDG II	ORANGE CITY	FL	32763-7945
881	Affiliated	3460	Miami East Dialysis	Miami East Dialysis	1250 NW 7TH ST	STE 16	MIAMI	FL	33125-3744
882	Affiliated	3462	Temple Terrace Dialysis	Temple Terrace Dialysis	11306 N 53RD ST		TEMPLE TERRACE	FL	33617-2214

883	Affiliated	3463	Midlothian Dialysis	Midlothian Dialysis	14281 MIDLOTHIAN TPKE	BLDG B	MIDLOTHIAN	VA	23113-6560
884	Affiliated	3464	Christian County Dialysis	Christian County Dialysis	200 BURLEY AVE		HOPKINSVILLE	KY	42240-8725
885	Affiliated	3465	St. Louis West PD Dialysis	St. Louis West PD Dialysis	450 N LINDBERGH BLVD	STE 1C	CREVE COEUR	MO	63141-7858
886	Affiliated	3467	Atlanta Midtown Dialysis	Atlanta Midtown Dialysis PD	418 DECATUR ST SE	STE A	ATLANTA	GA	30312-1801
887	Affiliated	3468	Silverton Home Training Dialysis	Silverton Home Training Dialysis	6929 SILVERTON AVE		CINCINNATI	OH	45236-3701
888	Affiliated	3472	Philadelphia 42nd Street Dialysis	Philadelphia 42nd Street Dialysis	4126 WALNUT ST		PHILADELPHIA	PA	19104-3511
889	Affiliated	3473	Radnor Dialysis	Radnor Dialysis	250 KING OF PRUSSIA RD		RADNOR	PA	19087-5220
890	Affiliated	3475	St. Louis Dialysis	St. Louis Dialysis	324 DE BALIVIERE AVE		SAINT LOUIS	MO	63112-1804
891	Affiliated	3477	Elkins Park Dialysis	Wyncote Dialysis (fka Elkins Park)	1000 EASTON RD	STE 25	WYNCOTE	PA	19095-2934
892	Affiliated	3478	Mainland Dialysis	Mainland Dialysis	2600 GULF FWY		LA MARQUE	TX	77568-4922
893	Affiliated	3479	Island Dialysis	Island Dialysis	5920 BROADWAY ST		GALVESTON	TX	77551-4305
894	Affiliated	3481	Orlando Home Training Dialysis	Orlando Home Training Dialysis	116 STURTEVANT ST	STE 2	ORLANDO	FL	32806-2021
895	Affiliated	3482	Mechanicsville Dialysis	Mechanicsville Dialysis	8191 ATLEE RD		MECHANICSVILLE	VA	23116-1807
896	Affiliated	3484	San Diego East Dialysis	San Diego East Dialysis	292 EUCLID AVE	STE 1	SAN DIEGO	CA	92114-3629
897	Affiliated	3485	Russellville Dialysis	Russellville Dialysis	14897 HIGHWAY 43		RUSSELLVILLE	AL	35653-1954
898	Affiliated	3486	Encinitas Dialysis	Encinitas Dialysis	332 SANTA FE DR	STE 1	ENCINITAS	CA	92024-5143

899	Affiliated	3491	Rushville Dialysis	Rushville Dialysis	112 SULLIVAN DRIVE		RUSHVILLE	IL	62681-1293
900	Affiliated	3493	Plainfield Dialysis	Plainfield Dialysis	1200 RANDOLPH RD	MUHLENBURG CAMPUS	PLAINFIELD	NJ	07060-3361
901	Affiliated	3494	Parkersburg Dialysis	Parkersburg Dialysis	1824 MURDOCH AVE	STE 44	PARKERSBURG	WV	26101-3230
902	Affiliated	3497	Tucson South Central Dialysis	Tucson South Central Dialysis	2024 E IRVINGTON RD	STE 7	TUCSON	AZ	85714-1825
903	Affiliated	3499	Hazelwood Dialysis	Hazelwood Dialysis	637 DUNN RD		HAZELWOOD	MO	63042-1755
904	Affiliated	3503	Durham West Dialysis	Durham West Dialysis	4307 WESTERN PARK PL		DURHAM	NC	27705-1204
905	Affiliated	3504	Liberty Dialysis	Liberty Dialysis	2525 GLEN HENDREN DR		LIBERTY	MO	64068-9625
906	Affiliated	3506	Chino Dialysis	Chino Dialysis	4445 RIVERSIDE DR		CHINO	CA	91710-3961
907	Affiliated	3507	Greenview Dialysis	Greenview Dialysis	18544 W 8 MILE RD		SOUTHFIELD	MI	48075-4194
908	Affiliated	3508	Perry Dialysis	Perry Dialysis	118 W MAIN ST		PERRY	FL	32347-2656
909	Affiliated	3511	Ashtabula Dialysis	Ashtabula Dialysis	1614 W 19TH ST		ASHTABULA	OH	44004-3036
910	Affiliated	3513	Northland Dialysis	Northland Dialysis	2750 CLAY EDWARDS DR	STE 1	N KANSAS CITY	MO	64116-3257
911	Affiliated	3516	Lake St. Louis Dialysis	Lake St. Louis Dialysis	200 BREVCO PLZ	STE 21	LAKE SAINT LOUIS	MO	63367-2950
912	Affiliated	3517	Wyandotte West Dialysis	Wyandotte West Dialysis	8919 PARALLEL PKWY	STE 121	KANSAS CITY	KS	66112-1655
913	Affiliated	3518	Huntingdon Valley Dialysis	Temp CLSD- Huntingdon Valley Dialysis	769 HUNTINGDON PIKE	STE 18	HUNTINGDON VALLEY	PA	19006-8362
914	Affiliated	3519	Glendale Dialysis	Glendale Dialysis	1000 E PALMER AVE		GLENDALE	CA	91205-3532
915	Affiliated	3520	Toledo Dialysis	Toledo Dialysis	1614 S BYRNE RD		TOLEDO	OH	43614-3464
916	Affiliated	3523	Cameron Dialysis	Cameron Dialysis	1003 W 4TH ST		CAMERON	MO	64429-1466
917	Affiliated	3524	Omaha Central Dialysis	Omaha Central Dialysis	144 S 40TH ST		OMAHA	NE	68131-3004

918	Affiliated	3525	Chillicothe Dialysis	Chillicothe Dialysis	588 E BUSINESS 36		CHILLICOTHE	MO	64601-3721
919	Affiliated	4210	Council Bluffs Dialysis	Council Bluffs Dialysis Center	300 W BROADWAY	STE 15	COUNCIL BLUFFS	IA	51503-9077
920	Affiliated	3528	DeRidder Dialysis	DeRidder Dialysis	239 E 1ST ST		DERIDDER	LA	70634-4105
921	Affiliated	3530	Dodge County Dialysis	Dodge County Dialysis	1949 E 23RD AVE S		FREMONT	NE	68025-2452
922	Affiliated	3533	Omaha North Dialysis	Omaha North Dialysis	6572 AMES AVE		OMAHA	NE	68104-1931
923	Affiliated	3534	Omaha South Dialysis	Omaha South Dialysis	3427 L ST	STE 16	OMAHA	NE	68107-2577
924	Affiliated	3535	Lake Charles Southwest Dialysis	Lake Charles Southwest Dialysis	300 W 18th ST		LAKE CHARLES	LA	70601-7342
925	Affiliated	3536	St. Joseph Dialysis	St. Joseph Dialysis	5514 CORPORATE DR	STE 1	SAINT JOSEPH	MO	64507-7752
926	Affiliated	3537	Sulphur Dialysis	Sulphur Dialysis	944 BEGLIS PKWY		SULPHUR	LA	70663-5102
927	Affiliated	3539	Tipton County Dialysis	Tipton County Dialysis	107 TENNESSEE AVE		COVINGTON	TN	38019-3902
928	Affiliated	3540	Dyersburg Dialysis	Dyersburg Dialysis	1575 PARR AVE		DYERSBURG	TN	38024-3151
929	Affiliated	3544	Effingham North Dialysis	Effingham North Dialysis	301 N PINE ST		SPRINGFIELD	GA	31329-3076
930	Affiliated	3545	Westminster South Dialysis	Westminster South Dialysis	14014 MAGNOLIA ST.		WESTMINSTER	CA	92683-4736
931	Affiliated	3546	Williams Street Dialysis	Williams Street Dialysis	2812 WILLIAMS ST		SAVANNAH	GA	31404-4134
932	Affiliated	3547	DeRenne Dialysis	DeRenne Dialysis	5303 MONTGOMERY ST		SAVANNAH	GA	31405-5138

933	Affiliated	3548	Abercorn Dialysis	Abercorn Dialysis	11706 MERCY BLVD	STE 9	SAVANNAH	GA	31419-1751
934	Affiliated	3551	Fort Myers North Dialysis	Fort Myers North Dialysis	16101 N CLEVELAND AVE		N FT MYERS	FL	33903-2148
935	Affiliated	3552	Butler County Dialysis	Butler County Dialysis	3497 S DIXIE HWY		FRANKLIN	OH	45005-5717
936	Affiliated	3556	Willingboro	Willingboro Dialysis	230 VAN SCIVER PKWY		WILLINGBORO	NJ	08046-1131
937	Affiliated	3557	McKeesport West Dialysis	McKeesport West Dialysis	101 9TH ST		MCKEESPORT	PA	15132-3953
938	Affiliated	3559	College Dialysis	College Dialysis	6535 UNIVERSITY AVE		SAN DIEGO	CA	92115-5810
939	Affiliated	3560	Montezuma Dialysis	Montezuma Dialysis	114 DEVAUGHN AVE		MONTEZUMA	GA	31063-1708
940	Affiliated	3561	Romulus Dialysis	Romulus Dialysis	31470 ECORSE RD		ROMULUS	MI	48174-1963
941	Affiliated	3564	Wrightsville Dialysis	Wrightsville Dialysis	2240 W ELM ST		WRIGHTSVILLE	GA	31096-2016
942	Affiliated	3565	Tower Dialysis	Tower Dialysis	8635 W 3RD ST	STE 56W	LOS ANGELES	CA	90048-6110
943	Affiliated	3566	Columbus Downtown Dialysis	Columbus Downtown Dialysis	415 E MOUND ST		COLUMBUS	OH	43215-5512
944	Affiliated	3568	Charlotte East Dialysis	Charlotte East Dialysis	3204 N SHARON AMITY RD		CHARLOTTE	NC	28205-6541
945	Affiliated	3569	Carmel Mountain Dialysis	Carmel Mountain Dialysis	9850 CARMEL MOUNTAIN RD		SAN DIEGO	CA	92129-2892
946	Affiliated	3571	Lenexa Dialysis	Lenexa Dialysis	8630 HALSEY ST		LENEXA	KS	66215-2880
947	Affiliated	3577	Nashua Dialysis	Nashua Dialysis	38 TYLER ST	STE 1	NASHUA	NH	03060-2912
948	Affiliated	3580	Illini Renal Dialysis	Illini Renal Dialysis	507 E UNIVERSITY AVE		CHAMPAIGN	IL	61820-3828
949	Affiliated	3586	Loring Heights Dialysis	Loring Heights Dialysis	1575 NORTHSIDE DR NW	STE 45	ATLANTA	GA	30318-4211

950	Affiliated	3588	Forest Hills Dialysis	Forest Hills Dialysis	2693 FOREST HILLS RD SW		WILSON	NC	27893-8611
951	Affiliated	3589	St. Peters Dialysis	St. Peters Dialysis	300 FIRST EXECUTIVE AVE	STE A	SAINTE PETERS	MO	63376-1655
952	Affiliated	3591	Platte Woods Dialysis	Platte Woods Dialysis	7667 NW PRAIRIE VIEW RD		KANSAS CITY	MO	64151-1544
953	Affiliated	3593	Fresno North Dialysis	Fresno Palm Bluffs Dialysis (fka Fresno North)	770 W PINEDALE AVE		FRESNO	CA	93711-5744
954	Affiliated	3594	Middlesex County Dialysis	Burlington Regional Dialysis (fka Middlesex County)	31 MALL RD	STE 1B	BURLINGTON	MA	01803-4138
955	Affiliated	3596	Clearfield Dialysis	Clearfield Dialysis	1033 TURNPIKE AVE	STE 1	CLEARFIELD	PA	16830-3061
956	Affiliated	3597	Papillion Dialysis	Papillion Dialysis	1502 S WASHINGTON ST	STE 1	PAPILLION	NE	68046-3136
957	Affiliated	3598	Birmingham Home Training Dialysis	Birmingham Home Training Dialysis	2101 7TH AVE S		BIRMINGHAM	AL	35233-3105
958	Affiliated	3603	Bayou Dialysis	Magnolia Dialysis	210 E SPILLMAN ST		GONZALES	LA	70737-4604
959	Affiliated	3609	Radford Dialysis	Radford Dialysis	600 E MAIN ST	STE F	RADFORD	VA	24141-1826
960	Affiliated	3610	Eufaula Dialysis	Eufaula Dialysis	220 S ORANGE AVE		EUFAULA	AL	36027-1612
961	Affiliated	3612	Coshocton Dialysis	Coshocton Dialysis	1404 CHESTNUT ST EAST		COSHOCTON	OH	43812-1401
962	Affiliated	3614	Costa Mesa Dialysis	Costa Mesa Dialysis	1590 SCENIC AVE		COSTA MESA	CA	92626-1400
963	Affiliated	3615	Little Rock Dialysis	Central Little Rock Dialysis	5800 W 10TH ST	STE 51	LITTLE ROCK	AR	72204-1760
964	Affiliated	3619	Northport Dialysis	Northport Dialysis	2401 HOSPITAL DR		NORTHPORT	AL	35476-3392
965	Affiliated	3632	Pageland Dialysis	Pageland Dialysis	505A S PEARL ST		PAGELAND	SC	29728-2222

966	Affiliated	3633	Bakersfield South Dialysis	White Lane Dialysis (fka Bakersfield South)	7701 WHITE LN	STE D	BAKERSFIELD	CA	93309-0201
967	Affiliated	3634	Newaygo County Dialysis	Newaygo County Dialysis	1317 W MAIN ST		FREMONT	MI	49412-1478
968	Affiliated	3636	Cedar Lane Dialysis	Cedar Lane Dialysis	6334 CEDAR LN	STE 11	COLUMBIA	MD	21044-3898
969	Affiliated	3639	Torrington Dialysis	Torrington Dialysis	780 LITCHFIELD ST	STE 1	TORRINGTON	CT	06790-6268
970	Affiliated	3642	Janesville Dialysis	Janesville Dialysis	1305 WOODMAN RD		JANESVILLE	WI	53545-1068
971	Affiliated	3643	Bloomfield Dialysis	Bloomfield Dialysis	29 GRIFFIN RD S		BLOOMFIELD	CT	06002-1351
972	Affiliated	3645	Anthem Village Dialysis	Anthem Village Dialysis	2530 ANTHEM VILLAGE DR		HENDERSON	NV	89052-5548
973	Affiliated	3646	Glen Burnie Dialysis	Glen Burnie Dialysis	120 LANGLEY RD N		GLEN BURNIE	MD	21060-6578
974	Affiliated	3655	Melbourne Dialysis	Melbourne Dialysis	2235 S BABCOCK ST		MELBOURNE	FL	32901-5305
975	Affiliated	3656	St. Petersburg South Dialysis	St. Petersburg South Dialysis	2850 34TH ST S		ST PETERSBURG	FL	33711-3817
976	Affiliated	3663	Belpre Dialysis	Belpre Dialysis	2906 WASHINGTON BLVD		BELPRE	OH	45714-1848
977	Affiliated	3666	Stockton Home Training Dialysis	Stockton Home Training Dialysis	545 E CLEVELAND ST	STE A	STOCKTON	CA	95204-5535
978	Affiliated	3670	Rock Prairie Road Dialysis	Rock Prairie Road Dialysis	1605 ROCK PRAIRIE RD	STE 11	COLLEGE STATION	TX	77845-8358
979	Affiliated	3675	Market Street Dialysis	Market Street Dialysis	3701 MARKET ST	STE 1	PHILADELPHIA	PA	19104-5503
980	Affiliated	3677	Northwood	Northwood Dialysis (aka Toledo East)	611 LEMOYNE RD		NORTHWOOD	OH	43619-1811
981	Affiliated	3701	Tyson' s Corner Dialysis	Tyson' s Corner Dialysis	8391 OLD COURTHOUSE RD	STE 16	VIENNA	VA	22182-3819

982	Affiliated	3704	Southern Maryland Dialysis	Southern Maryland Dialysis	9211 STUART LN	4TH FL	CLINTON	MD	20735-2712
983	Affiliated	3707	Brentwood Dialysis	Brentwood Dialysis	1231 BRENTWOOD RD NE		WASHINGTON	DC	20018-1019
984	Affiliated	3708	Amelia Dialysis	Amelia Dialysis	15151 PATRICK HENRY HWY		AMELIA COURT HOUSE	VA	23002-4700
985	Affiliated	3714	Eighth Street Dialysis	Eighth Street Dialysis	300 8TH ST NE		WASHINGTON	DC	20002-6108
986	Affiliated	3715	Chester Dialysis	Chester Dialysis	10360 IRONBRIDGE RD		CHESTER	VA	23831-1425
987	Affiliated	3716	Howard County Dialysis	Howard County Dialysis	5999 HARPERS FARM RD	STE 11E	COLUMBIA	MD	21044-3023
988	Affiliated	3717	Catonsville Dialysis	Catonsville Dialysis	1581 SULPHUR SPRING RD	STE 112	BALTIMORE	MD	21227
989	Affiliated	3718	Mercy Dialysis	Mercy Dialysis	315 N CALVERT ST	STE 3	BALTIMORE	MD	21202-3611
990	Affiliated	3719	Harbor Park Dialysis	Harbor Park Dialysis	111 CHERRY HILL RD		BALTIMORE	MD	21225-1392
991	Affiliated	3732	Dabney Dialysis	Three Chopt Dialysis (fka Dabney)	8813 THREE CHOPT RD		RICHMOND	VA	23229
992	Affiliated	3733	Hioaks Dialysis	Hioaks Dialysis	671 HIOAKS RD	STE A	RICHMOND	VA	23225-4072
993	Affiliated	3757	Arlington Dialysis	Arlington Dialysis	4805 1st ST N		ARLINGTON	VA	22203
994	Affiliated	3759	Landover Dialysis	Landover Dialysis	1200 MERCANTILE LN	STE 15	UPPER MARLBORO	MD	20774-5389
995	Affiliated	3761	Staunton Dialysis	Staunton Dialysis	29 IDLEWOOD BLVD		STAUNTON	VA	24401-9355
996	Affiliated	3762	Covington Dialysis	Covington Dialysis	2504 VALLEY RIDGE RD		COVINGTON	VA	24426-6339
997	Affiliated	3763	Culpeper Dialysis	Culpeper Dialysis	430 SOUTHRIDGE PARKWAY		CULPEPER	VA	22701-3791

998	Affiliated	3764	Greenbrier Dialysis	Greenbrier Dialysis	129 SENECA TRL		LEWISBURG	WV	24901-1564
999	Affiliated	3765	Harrisonburg Dialysis	Harrisonburg Dialysis	871 CANTRELL AVE	STE 1	HARRISONBURG	VA	22801-4323

1000	Affiliated	3766	Lexington Dialysis	Lexington Dialysis	756 N LEE HWY		LEXINGTON	VA	24450-3724
1001	Affiliated	3802	Manteca Dialysis	Manteca Dialysis	1156 S MAIN ST		MANTECA	CA	95337-9505
1002	Affiliated	3804	Roseburg/Mercy Dialysis	Roseburg/ Mercy Dialysis	2599 NW EDENBOWER BLVD		ROSEBURG	OR	97471-6220
1003	Affiliated	3805	Daly City Dialysis	Daly City Dialysis	1498 SOUTHGATE AVE	STE 11	DALY CITY	CA	94015-4015
1004	Affiliated	3806	Vallejo Dialysis	Vallejo Dialysis	121 HOSPITAL DR		VALLEJO	CA	94589-2562
1005	Affiliated	3812	Salem Dialysis	Salem Dialysis (OR)	3550 LIBERTY RD S	STE 1	SALEM	OR	97302-5700
1006	Affiliated	3817	Fresno Dialysis	Fresno Dialysis	1111 E WARNER AVE		FRESNO	CA	93710-4030
1007	Affiliated	3818	Oakland Dialysis	Oakland Dialysis	5354 CLAREMONT AVE		OAKLAND	CA	94618-1035
1008	Affiliated	3820	Bakersfield Dialysis	Bakersfield Brimhall Dialysis (fka California Ave.)	8501 BRIMHALL RD	BLDG 5	BAKERSFIELD	CA	93311-2252
1009	Affiliated	3821	Northeast Bakersfield Dialysis	Northeast Dialysis (fka NE Bakersfield)	3761 MALL VIEW RD		BAKERSFIELD	CA	93306-3048
1010	Affiliated	3830	San Francisco Dialysis	San Francisco Dialysis	1499 WEBSTER ST		SAN FRANCISCO	CA	94115-3705
1011	Affiliated	3831	Hanford Dialysis	Hanford Dialysis	402 W 8TH ST		HANFORD	CA	93230-4536
1012	Affiliated	3840	San Pablo Dialysis	San Pablo Dialysis	14020 SAN PABLO AVE		SAN PABLO	CA	94806-3604
1013	Affiliated	3847	Chinatown Dialysis	Chinatown Dialysis	636 CLAY ST		SAN FRANCISCO	CA	94111-2502
1014	Affiliated	3849	El Cerrito Dialysis	El Cerrito Dialysis	10690 SAN PABLO AVE		EL CERRITO	CA	94530-2620
1015	Affiliated	3857	Tracy Dialysis	Tracy Dialysis	425 W BEVERLY PL	STE A	TRACY	CA	95376-3086
1016	Affiliated	3858	Salem North Dialysis	Salem North Dialysis (OR)	1220 LIBERTY ST NE		SALEM	OR	97301-7330

1017	Affiliated	3860	Auburn Dialysis	Auburn Dialysis	3126 PROFESSIONAL DR	STE 1	AUBURN	CA	95603-2411
1018	Affiliated	3861	Grass Valley Dialysis	Grass Valley Dialysis	360 CROWN POINT CIRCLE	STE 21	GRASS VALLEY	CA	95945-2543
1019	Affiliated	3901	Santee Dialysis	Santee Dialysis	228 BRADFORD BLVD		SANTEE	SC	29142-8677
1020	Affiliated	3903	Upland Dialysis	Upland Dialysis	600 N 13TH AVE		UPLAND	CA	91786-4957
1021	Affiliated	3906	Vance County Dialysis	Vance County Dialysis	854 S BECKFORD DR		HENDERSON	NC	27536-3487
1022	Affiliated	3907	Edenton Dialysis	Edenton Dialysis	703 LUKE ST		EDENTON	NC	27932-9694
1023	Affiliated	3909	Ahoskie Dialysis	Ahoskie Dialysis	129 HERTFORD COUNTY HIGH RD		AHOSKIE	NC	27910-8131
1024	Affiliated	3914	Allendale County Dialysis	Allendale County Dialysis	202 HAMPTON AVE N		FAIRFAX	SC	29827-4510
1025	Affiliated	3916	North Orangeburg Dialysis	North Orangeburg Dialysis	124 FIRE TOWER RD		ORANGEBURG	SC	29118-1443
1026	Affiliated	3917	South Orangeburg Dialysis	South Orangeburg Dialysis	1080 SUMMERS AVE		ORANGEBURG	SC	29115-4920
1027	Affiliated	3931	Greenwood Dialysis	Greenwood Dialysis	109 OVERLAND DR		GREENWOOD	SC	29646-4053
1028	Affiliated	3933	Union County Dialysis	Union County Dialysis	701 E ROOSEVELT BLVD	STE 4	MONROE	NC	28112-4107
1029	Affiliated	3934	South Charlotte Dialysis	South Charlotte Dialysis	6450 BANNINGTON RD		CHARLOTTE	NC	28226-1327
1030	Affiliated	3935	Lancaster SC Dialysis	Lancaster SC Dialysis	980 N WOODLAND DR	STE 1	LANCASTER	SC	29720-1964
1031	Affiliated	3952	Central Bamberg Dialysis	Central Bamberg Dialysis	67 SUNSET DR		BAMBERG	SC	29003-1181
1032	Affiliated	4001	West Tallahassee Dialysis	West Tallahassee Dialysis	2645 W TENNESSEE ST		TALLAHASSEE	FL	32304-2547

1033	Affiliated	4002	Daytona South Dialysis	Daytona South Dialysis	1801 S NOVA RD	STE 36	SOUTH DAYTONA	FL	32119-1775
1034	Affiliated	4003	Daytona Beach Dialysis	Daytona Beach Dialysis	578 HEALTH BLVD		DAYTONA BEACH	FL	32114-1492
1035	Affiliated	4004	West Tampa Dialysis	West Tampa Dialysis	4515 GEORGE RD	STE 3	TAMPA	FL	33634-7300
1036	Affiliated	4005	Fontana Dialysis	Fontana Dialysis	17590 FOOTHILL BLVD		FONTANA	CA	92335-8416
1037	Affiliated	4007	Fort Myers Dialysis	Fort Myers Dialysis	4220 EXECUTIVE CIRCLE	STE 38	FORT MYERS	FL	33916-7993
1038	Affiliated	4009	Lehigh Acres Dialysis	Lehigh Acres Dialysis	2719 4TH ST W		LEHIGH ACRES	FL	33971-1942
1039	Affiliated	4010	Los Banos Dialysis	Los Banos Dialysis	222 I ST		LOS BANOS	CA	93635-4132
1040	Affiliated	4013	Kissimmee Dialysis	Kissimmee Dialysis	802 N JOHN YOUNG PKWY		KISSIMMEE	FL	34741-4912
1041	Affiliated	4014	New Smyrna Beach Dialysis	New Smyrna Beach Dialysis	110 S ORANGE ST		NEW SMYRNA BEACH	FL	32168-7153
1042	Affiliated	4017	Lake Wales Dialysis	Lake Wales Dialysis	1125 BRYN MAWR AVE		LAKE WALES	FL	33853-4333
1043	Affiliated	4018	Dearborn Dialysis	Dearborn Dialysis	1185 MONROE ST		DEARBORN	MI	48124-2814
1044	Affiliated	4020	Greater Miami Dialysis	Greater Miami Dialysis	160 NW 176TH ST	STE 1	MIAMI	FL	33169-5023
1045	Affiliated	4021	Burbank Dialysis	Burbank Dialysis	1211 N SAN FERNANDO BLVD		BURBANK	CA	91504-4234
1046	Affiliated	4024	Lakeland Dialysis	Lakeland Dialysis	515 E BELLA VISTA ST		LAKELAND	FL	33805-3005
1047	Affiliated	4025	Burlington North Dialysis	Burlington North Dialysis	1164 E ROUTE 130		BURLINGTON	NJ	08016-2954
1048	Affiliated	4026	Delano Dialysis	Delano Dialysis	905 MAIN ST		DELANO	CA	93215-1729
1049	Affiliated	4027	Erie Dialysis	Erie Dialysis	350 E BAYFRONT PKWY	STE A	ERIE	PA	16507-2410
1050	Affiliated	4028	Homestead Dialysis	Homestead Dialysis	207 W 7TH AVE		W HOMESTEAD	PA	15120-1002
1051	Affiliated	4029	Plant City Dialysis	Plant City Dialysis	1211 W REYNOLDS ST		PLANT CITY	FL	33563-4321

1052	Affiliated	4030	Winter Haven Dialysis	Winter Haven Dialysis	1625 UNITY WAY NW		WINTER HAVEN	FL	33881
1053	Affiliated	4032	Charlotte Dialysis	Charlotte Dialysis	2321 W MOREHEAD ST	STE 12	CHARLOTTE	NC	28208-5145
1054	Affiliated	4034	McKeesport Dialysis	McKeesport Dialysis	2001 LINCOLN WAY	OAK PARK MALL	MCKEESPORT	PA	15131-2419
1055	Affiliated	4035	Broward Dialysis	Broward Dialysis	1500 N FEDERAL HWY	STE 1	FT LAUDERDALE	FL	33304-5600
1056	Affiliated	4036	Athens Dialysis	Athens Dialysis	15953 ATHENS LIMESTONE DR		ATHENS	AL	35613-2214
1057	Affiliated	4038	Bradenton Dialysis	Bradenton Dialysis	3501 CORTEZ RD W	STE 14	BRADENTON	FL	34210-3104
1058	Affiliated	4039	Deland Dialysis	Deland Dialysis	350 E NEW YORK AVE		DELAND	FL	32724-5510
1059	Affiliated	4040	Boynton/North Delray Dialysis	Boynton/North Delray Dialysis	2655 W ATLANTIC AVE		DELRAY BEACH	FL	33445-4400
1060	Affiliated	4041	Lake Worth Dialysis	Lake Worth Dialysis	2459 S CONGRESS AVE	STE 1	PALM SPRINGS	FL	33406-7616
1061	Affiliated	4042	Palm Coast Dialysis	Palm Coast Dialysis	13 KINGSWOOD DR	STE A	PALM COAST	FL	32137-4614
1062	Affiliated	4043	Fort Myers South Dialysis	Fort Myers South Dialysis	8570 GRANITE CT		FORT MYERS	FL	33908-4102
1063	Affiliated	4044	Woodburn Dialysis	Woodburn Dialysis	1840 NEWBERG HWY	STE 14	WOODBURN	OR	97071-3187
1064	Affiliated	4045	Four Freedoms	Four Freedoms Dialysis (fka Range Street)	289 SW RANGE AVE	STE A	MADISON	FL	32340-2351
1065	Affiliated	4046	West Philadelphia Dialysis	West Philadelphia Dialysis	7609 LINDBERGH BLVD		PHILADELPHIA	PA	19153-2301
1066	Affiliated	4048	Tucson West Dialysis	Tucson West Dialysis	1780 W ANKLAM RD		TUCSON	AZ	85745-2632

1067	Affiliated	4049	Tucson East Dialysis	Tucson East Dialysis	6420 E BROADWAY BLVD	STE C3	TUCSON	AZ	85710-3512
1068	Affiliated	4053	Tallahassee South Dialysis	Tallahassee South Dialysis	2410 S ADAMS ST		TALLAHASSEE	FL	32301-6325
1069	Affiliated	4054	Selma Dialysis	Selma Dialysis	2711 CINEMA WAY	STE 111	SELMA	CA	93662-2662
1070	Affiliated	4055	Hinesville Dialysis	Hinesville Dialysis	522 ELMA G MILES PKWY		HINESVILLE	GA	31313-4021
1071	Affiliated	4056	Los Angeles Downtown Dialysis	Los Angeles Downtown Dialysis	2021 S FLOWER ST		LOS ANGELES	CA	90007-1342
1072	Affiliated	4057	Anaheim Dialysis	Anaheim Dialysis	1107 W LA PALMA AVE		ANAHEIM	CA	92801-2804
1073	Affiliated	4058	Martinsville Dialysis	Martinsville Dialysis	33 BRIDGE ST S		MARTINSVILLE	VA	24112-6214
1074	Affiliated	4060	Jefferson Dialysis	Jefferson Dialysis	14 CLAIRTON BLVD		PITTSBURGH	PA	15236-3911
1075	Affiliated	4061	Saddleback Dialysis	Saddleback Dialysis	23141 PLAZA POINTE DR		LAGUNA HILLS	CA	92653-1425
1076	Affiliated	4064	Sun City Center Dialysis	Sun City Center Dialysis	783 CORTARO DR		RUSKIN	FL	33573-6812
1077	Affiliated	4065	Paris Dialysis	Paris Dialysis	32 STEUBENVILLE PK		PARIS	PA	15021
1078	Affiliated	4066	Central Tampa Dialysis	Central Tampa Dialysis	4204 N MACDILL AVE	SOUTH BLDG	TAMPA	FL	33607-6342
1079	Affiliated	4068	Zephyrhills Dialysis	Zephyrhills Dialysis	6610 STADIUM DR		ZEPHYRHILLS	FL	33542-7510
1080	Affiliated	4069	Bartow Dialysis	Bartow Dialysis	1190 E CHURCH ST		BARTOW	FL	33830-4117
1081	Affiliated	4070	Ormond Beach Dialysis	Ormond Beach Dialysis	495 S NOVA RD	STE 19	ORMOND BEACH	FL	32174-8444
1082	Affiliated	4071	Lakeland South Dialysis	Lakeland South Dialysis	5050 S FLORIDA AVE		LAKELAND	FL	33813-2501
1083	Affiliated	4072	St. Mary' s Dialysis	St. Mary' s Dialysis	2714 OSBORNE RD		ST MARY' S	GA	31558-4049
1084	Affiliated	4073	Miami North Dialysis	Miami North Dialysis	860 NE 125TH ST		NORTH MIAMI	FL	33161-5743

1085	Affiliated	4074	Naples Dialysis	Naples Dialysis	661 9TH ST N		NAPLES	FL	34102-8132
1086	Affiliated	4075	Bonita Springs Dialysis	Bonita Springs Dialysis	9134 BONITA BEACH RD SE		BONITA SPRINGS	FL	34135-4281
1087	Affiliated	4076	Orlando Southwest Dialysis	Orlando Southwest Dialysis	6925 LAKE ELLENOR DR	STE 65	ORLANDO	FL	32809-4670
1088	Affiliated	4088	Quincy Dialysis	Quincy Dialysis	878 STRONG RD		QUINCY	FL	32351-5243
1089	Affiliated	4089	Tallahassee Dialysis	Tallahassee Dialysis	1607 PHYSICIANS DR		TALLAHASSEE	FL	32308-4620
1090	Affiliated	4095	South Beach Dialysis	South Beach Dialysis	4701 N MERIDIAN AVE		MIAMI BEACH	FL	33140-2910
1091	Affiliated	4124	Americus Dialysis	Americus Dialysis	227 N LEE ST		AMERICUS	GA	31709-3525
1092	Affiliated	4204	Corry Dialysis	Corry Dialysis	300 YORK ST		CORRY	PA	16407-1420
1093	Affiliated	4208	Elizabethtown Dialysis	Elizabethtown Dialysis	844 N HANOVER ST		ELIZABETHTOWN	PA	17022-1303
1094	Affiliated	4209	Lumberton Dialysis	Lumberton Dialysis	668 MAIN ST		LUMBERTON	NJ	08048-5016
1095	Affiliated	4211	Cobbs Creek Dialysis	Cobbs Creek Dialysis	1700 S 60TH ST		PHILADELPHIA	PA	19142-1404
1096	Affiliated	4214	Westland Dialysis	Garden West Dialysis (fka Westland)	5715 N VENOY RD		WESTLAND	MI	48185-2830
1097	Affiliated	4215	Meadville Dialysis	Meadville Dialysis	19050 PARK AVENUE PLZ		MEADVILLE	PA	16335-4012
1098	Affiliated	4217	Bradford Dialysis	Bradford Dialysis	665 E MAIN ST		BRADFORD	PA	16701-1869
1099	Affiliated	4219	Southgate Dialysis	Southgate Dialysis	14752 NORTHLINE RD		SOUTHGATE	MI	48195-2467
1100	Affiliated	4223	Waynesburg Dialysis	Waynesburg Dialysis	248 ELM DR		WAYNESBURG	PA	15370-8269
1101	Affiliated	4224	Selinsgrove Dialysis	Selinsgrove Dialysis	1030 N SUSQUEHANNA TRAIL		SELINSGROVE	PA	17870-7767
1102	Affiliated	2153	Arlington Dialysis	Arlington Dialysis	1250 E PIONEER PKWY	STE 7	ARLINGTON	TX	76010-6423
1103	Affiliated	2154	Grapevine Dialysis	Grapevine Dialysis	1600 W NORTHWEST HWY	STE 1	GRAPEVINE	TX	76051-8131

1104	Affiliated	1740	Willow Dialysis	Willow Dialysis	1675 ALEX DR		WILMINGTON	OH	45177-2446
1105	Affiliated	1767	New Braunfels Dialysis	New Braunfels Dialysis	900 LOOP 337		NEW BRAUNFELS	TX	78130-3555
1106	Affiliated	2080	Chickasha Dialysis	Chickasha Dialysis	228 S 29TH ST		CHICKASHA	OK	73018-2502
1107	Affiliated	2184	Sugarloaf	Sugarloaf Dialysis (fka Lawrenceville)	1705 BELLE MEADE CT	STE 11	LAWRENCEVILLE	GA	30043-5895
1108	Affiliated	2166	Buford Dialysis	Buford Dialysis	1550 BUFORD HWY	STE 1E	BUFORD	GA	30518-3666
1109	Affiliated	1749	St. Louis Park PD	St. Louis Park Dialysis Center PD	3505 LOUISIANA AVE S		ST LOUIS PARK	MN	55426-4121
1110	Affiliated	1769	Front Royal Dialysis	Front Royal Dialysis	1077D N SHENANDOAH AVE		FRONT ROYAL	VA	22630-3546
1111	Affiliated	1770	Winchester Dialysis	Winchester Dialysis	2301 VALOR DR		WINCHESTER	VA	22601-6111
1112	Affiliated	2200	New Hope Dialysis	New Hope Dialysis (aka Minneapolis, Golden Valley)	5640 INTERNATIONAL PKWY		NEW HOPE	MN	55428-3047
1113	Affiliated	2175	Richfield Dialysis	Richfield Dialysis	6601 LYNDALE AVE S	STE 15	RICHFIELD	MN	55423-2490
1114	Affiliated	2162	Fairborne Dialysis	Fairborn Dialysis	3070 PRESIDENTIAL DR	STE A	FAIRBORN	OH	45324-6273
1115	Affiliated	1694	Benton Dialysis	Benton Dialysis	1151 ROUTE 14 W		BENTON	IL	62812-1500
1116	Affiliated	1695	Centralia Dialysis	Centralia Dialysis	1231 STATE ROUTE 161		CENTRALIA	IL	62801-6739
1117	Affiliated	1696	Marion Dialysis	Marion Dialysis	324 S 4TH ST		MARION	IL	62959-1241
1118	Affiliated	1697	Mount Vernon Dialysis	Mount Vernon Dialysis	1800 JEFFERSON AVE		MOUNT VERNON	IL	62864-4300
1119	Affiliated	2121	Bayou City Dialysis	Bayou City Dialysis (fka Hanson)	10655 EASTEX FWY		HOUSTON	TX	77093-4323
1120	Affiliated	2117	Metairie Dialysis Center	Metairie Dialysis	7100 AIRLINE DR		METAIRIE	LA	70003-5950

1121	Affiliated	1784	Stony Creek Dialysis	Stony Creek Dialysis	9115 S CICERO AVE		OAK LAWN	IL	60453-1895
1122	Affiliated	1785	Beverly Dialysis	Beverly Dialysis	8109 SOUTH WESTERN AVE		CHICAGO	IL	60620-5939
1123	Affiliated	2089	Summit Dialysis	Summit Dialysis Center	3150 POLK ST		HOUSTON	TX	77003-4631
1124	Affiliated	2212	Upper Valley Dialysis	Upper Valley Dialysis (fka West El Paso)	7933 N MESA ST	STE H	EL PASO	TX	79932-1699
1125	Affiliated	2134	Dallas County	Perry Dialysis (fka Dallas County)	610 10TH ST	STE L1	PERRY	IA	50220-2221
1126	Affiliated	1813	Nampa Dialysis Center	Nampa Dialysis	846 PARKCENTRE WAY		NAMPA	ID	83651-1790
1127	Affiliated	1814	Table Rock Dialysis	Table Rock Dialysis	5610 W GAGE ST	STE B	BOISE	ID	83706
1128	Affiliated	1815	Twin Falls Dialysis	Twin Falls Dialysis	1840 CANYON CREST DR		TWIN FALLS	ID	83301-3007
1129	Affiliated	1816	Burley Dialysis Center	Burley Dialysis	741 N OVERLAND AVE		BURLEY	ID	83318-3440
1130	Affiliated	1817	Gate City Dialysis Center	Gate City Dialysis	2001 BENCH RD		POCATELLO	ID	83201-2033
1131	Affiliated	1818	Four Rivers Dialysis	Four Rivers Dialysis	515 EAST LN		ONTARIO	OR	97914-3953
1132	Affiliated	2231	River Parishes	River Parishes Dialysis (aka La Place)	2880 W AIRLINE HWY		LA PLACE	LA	70068-2922
1133	Affiliated	2177	South Lincoln	South Lincoln Dialysis	3401 PLANTATION DR	STE 14	LINCOLN	NE	68516-4712

1134	Affiliated	2105	Rochester Hills	Rochester Hills Dialysis (aka Sterling Heights)	1886 W AUBURN RD	STE 1	ROCHESTER HILLS	MI	48309-3865
1135	Affiliated	2101	Willowbrook Dialysis	Willowbrook Dialysis	12120 JONES RD	STE G	HOUSTON	TX	77070-5280
1136	Affiliated	2195	Springhurst Dialysis	Springhurst Dialysis (aka Louisville)	10201 CHAMPION FARMS DR		LOUISVILLE	KY	40241-6150
1137	Affiliated	2012	Magnolia West	Magnolia West Dialysis (aka Riverside II)	11161 MAGNOLIA AVE		RIVERSIDE	CA	92505-3605
1138	Affiliated	2206	Garrisonville Dialysis	Garrisonville Dialysis	70 DOC STONE RD	STE 11	STAFFORD	VA	22556-4628
1139	Affiliated	2152	Strongsville Dialysis	Strongsville Dialysis	17792 PEARL RD		STRONGSVILLE	OH	44136-6909
1140	Affiliated	984	Summerlin Dialysis	Summerlin Dialysis Center, LV	653 N TOWN CENTER DR	STE 7 BLDG 2	LAS VEGAS	NV	89144-0503
1141	Affiliated	2127	Red Bluff Dialysis	Red Bluff Dialysis Center	2455 SISTER MARY COLUMBA DR		RED BLUFF	CA	96080-4364
1142	Affiliated	1638	Cobb Dialysis	Cobb Dialysis	3865 MEDICAL PARK DR		AUSTELL	GA	30106-1109
1143	Affiliated	1693	Paulding Dialysis	Paulding Dialysis	4019 JOHNS RD		DALLAS	GA	30132-3420
1144	Affiliated	1839	Sweetwater Dialysis	Sweetwater Dialysis	7117 S SWEETWATER RD		LITHIA SPRINGS	GA	30122-2446
1145	Affiliated	3671	Charlottesville North	Charlottesville North Dialysis	1800 TIMBERWOOD BLVD	STE C	CHARLOTTESVILLE	VA	22911-7544
1146	Affiliated	2186	Southern Crescent	Southern Crescent Dialysis Center (fka Riverdale)	275 UPPER RIVERDALE RD SW	STE B	RIVERDALE	GA	30274-2556
1147	Affiliated	2169	Meridian Park	Meridian Park Dialysis Center (fka Lake Oswego)	19255 SW 65TH AVE	STE 1	TUALATIN	OR	97062-9712

1148	Affiliated	1812	Treasure Valley Dialysis	Treasure Valley Dialysis	3525 E LOUISE ST	STE 155	MERIDIAN	ID	83642-6303
1149	Affiliated	3637	White Oak	White Oak Dialysis (Chronic)	5520 CHEVIOT RD	STE B	CINCINNATI	OH	45247-7069
1150	Affiliated	1786	Ash Tree	Ash Tree Dialysis	2666 N GROVE INDUSTRIAL DR		FRESNO	CA	93727-1552
1151	Affiliated	2242	Madera Dialysis	Almond Wood Dialysis (fka Madera)	501 E ALMOND AVE		MADERA	CA	93637-5661
1152	Affiliated	2209	Carrollton	Carrollton Dialysis	1544 VALWOOD PKWY	STE 114	CARROLLTON	TX	75006-8425
1153	Affiliated	2202	Edna Dialysis	Edna Dialysis	1008 N WELLS ST		EDNA	TX	77957-2153
1154	Affiliated	2208	Bear Creek Dialysis	Bear Creek Dialysis (fka Clay Road)	4978 HIGHWAY 6 N	STE I	HOUSTON	TX	77084-5282
1155	Affiliated	1820	Windham Dialysis	Windham Dialysis	375 TUCKIE RD	STE C	NORTH WINDHAM	CT	06256-1345
1156	Affiliated	1819	Vernon Dialysis	Vernon Dialysis	460 HARTFORD TPKE STE C		VERNON ROCKVILLE	CT	6066
1157	Affiliated	2092	Fountain Dialysis	Fountain Dialysis (aka Security)	6910 BANDLEY DR		FOUNTAIN	CO	80817-2617
1158	Affiliated	1846	Grand Junction	Grand Junction Dialysis Center	710 WELLINGTON AVE	STE 2	GRAND JUNCTION	CO	81501-6100
1159	Affiliated	2183	Fort Mill	Fort Mill Dialysis	1975 CAROLINA PLACE DR		FORT MILL	SC	29708-6922
1160	Affiliated	2215	Myrtle Beach	JV-Myrtle Beach Dialysis	3919 MAYFAIR ST		MYRTLE BEACH	SC	29577-5773
1161	Affiliated	2032	Oakwood	Oakwood Dialysis Center	148 HECTOR AVE		GRETNA	LA	70056-2531

1162	Affiliated	2168	SP Hillsboro	Hillsboro Dialysis	2500 NW 229TH AVE	STE 3 BLDG E	HILLSBORO	OR	97124-7516
1163	Affiliated	2269	Kettering	Kettering Dialysis	5721 BIGGER RD		KETTERING	OH	45440-2752
1164	Affiliated	2246	Mansfield	Mansfield Dialysis Center (aka Dallas)	987 N WALNUT CREEK DR	STE 11	MANSFIELD	TX	76063-8016
1165	Affiliated	2290	Cottage Grove	Cottage Grove Dialysis	8800 E POINT DOUGLAS RD S	STE 1	COTTAGE GROVE	MN	55016-4160
1166	Affiliated	2257	Scott County Dialysis	Scott County Dialysis	7456 S PARK DR		SAVAGE	MN	55378
1167	Affiliated	1773	Virginia Beach	Camelot Dialysis Center	1800 CAMELOT DR	STE 1	VIRGINIA BEACH	VA	23454-2440
1168	Affiliated	1627	Amelia Island	Amelia Island Dialysis	1525 LIME ST	STE 12	FERNANDINA BEACH	FL	32034-3015
1169	Affiliated	2179	Laurel Manor at the Villages	Laurel Manor Dialysis Center at the Villages	1950 LAUREL MANOR DR	STE 19	LADY LAKE	FL	32162-5603
1170	Affiliated	2160	East Dearborn	East Dearborn Dialysis	13200 W WARREN AVE		DEARBORN	MI	48126-2410
1171	Affiliated	1661	North Houston	PDI-North Houston	7115 NORTH LOOP E		HOUSTON	TX	77028-5948
1172	Affiliated	1663	South Houston	PDI-South Houston	5989 SOUTH LOOP E		HOUSTON	TX	77033-1017
1173	Affiliated	1856	Ralph McGill Dialysis Center	Ralph McGill Dialysis	418 DECATUR ST SE		ATLANTA	GA	30312-1801
1174	Affiliated	2144	Chelsea	Chelsea Dialysis	1620 COMMERCE PARK DR	STE 2	CHELSEA	MI	48118-2136
1175	Affiliated	2214	Smokey Mountain	Smoky Mountain Dialysis	1611 ANDREWS RD		MURPHY	NC	28906-5100
1176	Affiliated	3680	Miami Gardens	Miami Gardens Dialysis	3363 NW 167TH ST		MIAMI GARDENS	FL	33056-4254
1177	Affiliated	2222	Deerbrook	Deerbrook Dialysis	9660 FM 1960 BYPASS RD W		HUMBLE	TX	77338-4039

1178	Affiliated	2227	Downtown Dallas	DaVita Downtown Dallas Dialysis Center (fka Grove)	3515 SWISS AVE	STE A	DALLAS	TX	75204-6223
1179	Affiliated	2197	Henderson	Siena Henderson Dialysis Center	2865 SIENNA HEIGHTS DR	STE 141	HENDERSON	NV	89052-4168
1180	Affiliated	2292	Wyandotte	Wyandotte Central Dialysis	3737 STATE AVE		KANSAS CITY	KS	66102-3830
1181	Affiliated	2235	Westview	Westview Dialysis	3749 COMMERCIAL DR	LAFAYETTE PLACE SHOPPING CENTER	INDIANAPOLIS	IN	46222-1676
1182	Affiliated	2286	Garland	Garland Dialysis	776 E CENTERVILLE RD		GARLAND	TX	75041-4640
1183	Affiliated	2333	Aberdeen	Aberdeen Dialysis	780 W BEL AIR AVE		ABERDEEN	MD	21001-2236
1184	Affiliated	2259	Mountain Park	Mountain Park Dialysis	5235 MEMORIAL DR		STONE MOUNTAIN	GA	30083-3112
1185	Affiliated	2229	Downtown San Antonio	Downtown San Antonio Dialysis (Brooklyn St)	615 E QUINCY ST		SAN ANTONIO	TX	78215-1600
1186	Affiliated	2237	Medlock Bridge	Medlock Bridge Dialysis (aka Duluth)	10680 MEDLOCK BRIDGE RD	STE 13	DULUTH	GA	30097-8420
1187	Affiliated	2234	Greene County Dialysis	Greene County Dialysis Center (NC)	1025 KINGOLD BLVD		SNOW HILL	NC	28580-1616
1188	Affiliated	2243	West Broadway Dialysis	West Broadway Dialysis	720 W BROADWAY		LOUISVILLE	KY	40202-2240
1189	Affiliated	2072	St. Pauls Dialysis	St. Pauls Dialysis (aka Robeson County)	564 W MCLEAN ST		SAINT PAULS	NC	28384-1421

1190	Affiliated	2123	Carquinez Dialysis	Carquinez Dialysis (fka SW Vallejo)	125 CORPORATE PL	STE C	VALLEJO	CA	94590-6968
1191	Affiliated	2159	DaVita East	DaVita East Dialysis Clinic (fka La Bamba)	11989 PELLICANO DR		EL PASO	TX	79936-6287
1192	Affiliated	2187	Natomas	Natomas Dialysis	30 GOLDEN LAND CT	BLDG G	SACRAMENTO	CA	95834-2420
1193	Affiliated	2228	Tennessee Valley	Tennessee Valley Dialysis Center (aka Johnson City)	107 WOODLAWN DR	STE 2	JOHNSON CITY	TN	37604-6287
1194	Affiliated	2174	Turfway Dialysis	Turfway Dialysis (fka Florence)	11 SPIRAL DR	STE 15	FLORENCE	KY	41042-1394
1195	Affiliated	2291	Leavenworth	Leavenworth Dialysis	501 OAK ST		LEAVENWORTH	KS	66048-2646
1196	Affiliated	2270	Franklin Dialysis	Franklin Dialysis (IN)	1140 W JEFFERSON ST	STE A	FRANKLIN	IN	46131-2101
1197	Affiliated	2011	Norco	Norco Dialysis (fka Corona II)	1901 TOWN AND COUNTRY DR	STE 1	NORCO	CA	92860-3611
1198	Affiliated	2240	Andover	Andover Dialysis	488 S MAIN ST		ANDOVER	OH	44003-9602
1199	Affiliated	1863	Little Rock	Jacksonville Central Dialysis Center	400 T P WHITE DR		JACKSONVILLE	AR	72076-3287
1200	Affiliated	1864	North Little Rock Dialysis	North Little Rock Center	4505 E MCCAIN BLVD		NORTH LITTLE ROCK	AR	72117-2902

1201	Affiliated	2233	Anadarko	Anadarko Dialysis	412 SE 11TH STREET		ANADARKO	OK	73005-4442
1202	Affiliated	2331	Desert Springs	Desert Springs Dialysis	2110 E FLAMINGO RD	STE 18	LAS VEGAS	NV	89119-5191
1203	Affiliated	2213	Livingston	Vancouver Dialysis Center	9120 NE VANCOUVER MALL DR	STE 16	VANCOUVER	WA	98662-9401
1204	Affiliated	2300	Vancouver	Livingston TN Dialysis	308 OAK ST		LIVINGSTON	TN	38570-1729
1205	Affiliated	2225	Fenton Dialysis	Fenton Dialysis	17420 SILVER PKWY		FENTON	MI	48430-4429
1206	Affiliated	2332	Cold Spring	Cold Springs Dialysis	430 CROSS ROADS BLVD		COLD SPRING	KY	41076-2341
1207	Affiliated	2094	Yucaipa	Yucaipa Dialysis	33487 YUCAIPA BLVD		YUCAIPA	CA	92399-2064
1208	Affiliated	1900	Florida Renal Center	Florida Renal Center	3500 NW 7TH ST		MIAMI	FL	33125-4016
1209	Affiliated	2140	Harbor UCLA	Long Beach Harbor Dialysis (aka UCLA)	1075 E PACIFIC COAST HWY		LONG BEACH	CA	90806-5089
1210	Affiliated	2210	Seaton Drive	Seton Drive Dialysis (fka Greensprings II)	4800 SETON DR		BALTIMORE	MD	21215-3210
1211	Affiliated	1865	South Valley	South Valley Dialysis	17815 VENTURA BLVD	STE 1	ENCINO	CA	91316-3600
1212	Affiliated	2305	West Pensacola	West Pensacola Dialysis	598 N FAIRFIELD DR	STE 1	PENSACOLA	FL	32506-4320
1213	Affiliated	2073	Mar Vista	Mar Vista Dialysis Center (UCLA-Santa Monica)	2020 SANTA MONICA BLVD	STE 1	SANTA MONICA	CA	90404-2139
1214	Affiliated	2082	Riddle Dialysis	Riddle Dialysis	100 GRANITE DR	STE 16	MEDIA	PA	19063-5134
1215	Affiliated	2346	Uptown	Minneapolis Uptown Dialysis	3601 LYNDALE AVE S		MINNEAPOLIS	MN	55409-1103

1216	Affiliated	1907	Lake Griffith East Dialysis	Lake Griffin East Dialysis	401 E NORTH BLVD		LEESBURG	FL	34748-5256
1217	Affiliated	2170	West Linn	West Linn Dialysis	19056 WILLAMETTE DR		WEST LINN	OR	97068-1715
1218	Affiliated	2330	Cape Coral South Dialysis	Cape Coral South Dialysis	3046 DEL PRADO BLVD S	STE 4A	CAPE CORAL	FL	33904-7232
1219	Affiliated	2241	Ceres	Ceres Dialysis Center	1768 MITCHELL RD	STE 38	CERES	CA	95307-2156
1220	Affiliated	1862	Shaker Square	Shaker Square Dialysis	12800 SHAKER BLVD	STE 1	CLEVELAND	OH	44120-2004
1221	Affiliated	1906	St. Cloud Dialysis	St. Cloud Dialysis	4750 OLD CANOE CREEK RD		SAINT CLOUD	FL	34769-1430
1222	Affiliated	1915	Turlock Dialysis Center	Turlock Dialysis Center	50 W SYRACUSE AVE		TURLOCK	CA	95380-3143
1223	Affiliated	2268	Haymarket	Haymarket Dialysis (fka Gainesville)	14664 GAP WAY		GAINESVILLE	VA	20155-1683
1224	Affiliated	2272	Hackettstown	Hackettstown Dialysis	657 WILLOW GROVE ST	WEST WING MEDICAL PLAZA STE 22	HACKETTSTOWN	NJ	07840-1713
1225	Affiliated	2274	Regency	Regency Dialysis Center (fka Jacksonville)	9535 REGENCY SQUARE BLVD N		JACKSONVILLE	FL	32225-8128
1226	Affiliated	2149	Williamsburg	Williamsburg Dialysis (fka Yorktown)	500 SENTARA CIR	STE 13	WILLIAMSBURG	VA	23188-5727
1227	Affiliated	2141	Commerce Township	Commerce Township Dialysis	120 W COMMERCE RD		COMMERCE TOWNSHIP	MI	48382-3915
1228	Affiliated	2147	Kankakee	Kankakee County Dialysis	581 WILLIAM R LATHAM SR DR	STE 14	BOURBONNAIS	IL	60914-2439
1229	Affiliated	2283	Sandusky	Sandusky Dialysis Center	795 BARDSHAR RD		SANDUSKY	OH	44870-1505

1230	Affiliated	2252	Ionia	Ionia Dialysis	2622 HEARTLAND BLVD	IONIA	MI	48846-8757
1231	Affiliated	2289	Indian River	Indian River Dialysis Center	2150 45TH ST UNIT 12	VERO BEACH	FL	32967-6281
1232	Affiliated	2360	North Henry	North Henry Dialysis (fka Stockbridge)	5627 N HENRY BLVD STE 11	STOCKBRIDGE	GA	30281-3244
1233	Affiliated	2077	Tacoma Dialysis	Tacoma Dialysis Center	3401 S 19TH ST	TACOMA	WA	98405-1909
1234	Affiliated	1908	Hialeah Kidney Center I	Hialeah Artificial Kidney Center	2750 W 68TH STE 27 ST	HIALEAH	FL	33016-5450
1235	Affiliated	2315	St. Francis	Charter Colony Dialysis Center (fka St. Francis Dialysis)	2312 COLONY CROSSING PL	MIDLOTHIAN	VA	23112-4280
1236	Affiliated	2138	Bellflower	Bellflower Dialysis Center (aka Widerhorn)	15736 WOODRUFF AVE	BELLFLOWER	CA	90706-4018
1237	Affiliated	2301	Smyrna	Smyrna Dialysis	537 STONECREST PKWY	SMYRNA	TN	37167-6884
1238	Affiliated	2122	Clearlake	Clearlake Dialysis	14400 OLYMPIC DR	CLEARLAKE	CA	95422-8809
1239	Affiliated	1853	Dialysis Center of Erie	Dialysis Center of Erie	1641 SASSAFRAS ST	ERIE	PA	16502-1858
1240	Affiliated	1854	Warren Dialysis	Warren Dialysis	2 W CRESCENT PARK	WARREN	PA	16365-2111
1241	Affiliated	2322	Maysville	Maysville Dialysis	489 TUCKER DR	MAYSVILLE	KY	41056-9111
1242	Affiliated	2429	Fridley	East River Road Dialysis (fka Fridley Dialysis Unit)	5301 E RIVER STE 117 RD	FRIDLEY	MN	55421-3778

1243	Affiliated	2189	West Sacramento	West Sacramento Dialysis	3450 INDUSTRIAL BLVD	STE 1	WEST SACRAMENTO	CA	95691-5003
1244	Affiliated	2293	Anderson	Anderson Dialysis Center	7502 STATE RD	STE 116	CINCINNATI	OH	45255
1245	Affiliated	2383	North County	North St. Louis County Dialysis	13119 NEW HALLS FERRY RD		FLORISSANT	MO	63033-3228
1246	Affiliated	2439	Fargo	Fargo Dialysis Center	4474 23RD AVE S	STE M	FARGO	ND	58104-8795
1247	Affiliated	2008	Eastchester	Eastchester Road Dialysis Center (Bronx II)	1515 JARRETT PL		BRONX	NY	10461-2606
1248	Affiliated	2224	Fallon	Fallon Dialysis	1103 NEW RIVER PKWY		FALLON	NV	89406-6899
1249	Affiliated	2279	Clarksville North	Clarksville North Dialysis	3071 CLAY LEWIS RD		CLARKSVILLE	TN	37040-5141
1250	Affiliated	2308	Eaton	Eaton Dialysis	105 E WASHINGTON JACKSON RD		EATON	OH	45320-9789
1251	Affiliated	2447	Wallace	Wallace Dialysis	5650 S NC 41 HWY		WALLACE	NC	28466-6094
1252	Affiliated	2288	Central Kalazmazoo	Kalamazoo Central Dialysis	535 S BURDICK ST	STE 11	KALAMAZOO	MI	49007-5261
1253	Affiliated	2287	West Kalamazoo	Kalamazoo West Dialysis	1040 N 10TH ST		KALAMAZOO	MI	49009-6149
1254	Affiliated	1921	Bakersfield	Bakersfield Dialysis Center	5143 OFFICE PARK DR		BAKERSFIELD	CA	93309-0660
1255	Affiliated	1930	Antelope Valley	Antelope Valley Dialysis	1759 W AVENUE J	STE 12	LANCASTER	CA	93534-2703
1256	Affiliated	1931	Indian Wells Valley	Indian Wells Valley Dialysis	212 S RICHMOND RD		RIDGECREST	CA	93555-4434
1257	Affiliated	1932	Palmdale Regional	Palmdale Regional Dialysis	1643 E PALMDALE BLVD		PALMDALE	CA	93550-4847
1258	Affiliated	2185	South Star / Adamsville	Southstar Adamsville	3651 BAKERS FERRY RD SW		ATLANTA	GA	30331-3712

				Dialysis (fka Cascade)						
1259	Affiliated	2314	Union City	Union City Dialysis	6851 SHANNON PKWY	STE 2	UNION CITY	GA	30291-2049	
1260	Affiliated	2345	Waterbury	Waterbury Dialysis Center	150 MATTATUCK HEIGHTS RD		WATERBURY	CT	06705-3893	
1261	Affiliated	2421	Butler Farm	Butler Farm Dialysis (Hope II)	501 BUTLER FARM RD		HAMPTON	VA	23666-1777	
1262	Affiliated	2337	Blue Mtn Kidney Center	Blue Mountain Kidney Center (aka Wild Horse, Pendleton)	72556 COYOTE RD		PENDLETON	OR	97801-1002	
1263	Affiliated	2249	Talladega	Talladega Dialysis	726 BATTLE ST E	STE A	TALLADEGA	AL	35160-2583	
1264	Affiliated	2281	Athens East	Athens East Dialysis	2026 S MILLEDGE AVE	STE A2	ATHENS	GA	30605-6480	
1265	Affiliated	2412	Mayland	Mayland Dialysis Center (aka Spruce Pine)	575 ALTAPASS HWY		SPRUCE PINE	NC	28777-3012	
1266	Affiliated	2236	Salem	Salem Dialysis Center (IN)	1201 N JIM DAY RD	STE 13	SALEM	IN	47167-7219	
1267	Affiliated	2239	Lake Cliff	Lake Cliff Dialysis Center	805 N BECKLEY AVE		DALLAS	TX	75203-1612	

1268	Affiliated	2363	DVA Mid Cities Dialysis	Mid Cities Dialysis Center	117 E HARWOOD RD	HURST	TX	76054-3043
1269	Affiliated	2362	Boerne	Boerne Dialysis Center	1369 S MAIN ST STE 11	BOERNE	TX	78006-2860
1270	Affiliated	2318	Columbus West	Columbus West Dialysis	1395 GEORGESVILLE RD	COLUMBUS	OH	43228-3611
1271	Affiliated	2306	Point Place	Point Place Dialysis	4747 SUDER STE 17 AVE	TOLEDO	OH	43611-2869
1272	Affiliated	2350	Delhi Dialysis	Delhi Dialysis	5040 DELHI AVE	CINCINNATI	OH	45238-5388
1273	Affiliated	2253	Pataskala	Pataskala Dialysis Center	642 E BROAD ST	PATASKALA	OH	43062-7627
1274	Affiliated	2384	Eastland	Eastland Dialysis (fka Independence)	19101 E VALLEY STE E VIEW PKWY	INDEPENDENCE	MO	64055-6907
1275	Affiliated	2254	Wauseon	Wauseon Dialysis Center	721 S SHOOP AVE	WAUSEON	OH	43567-1729
1276	Affiliated	2327	Lebanon Dialysis	Lebanon Dialysis Center (Chronic Only)	918B COLUMBUS AVE	LEBANON	OH	45036-
1277	Affiliated	2460	Horton	Horton Dialysis	1901 EUCLID AVE	HORTON	KS	66439-1238
1278	Affiliated	2280	Lone Peak Dialysis	Lone Peak Dialysis	1175 E 50 S STE 111	AMERICAN FORK	UT	84003-2845
1279	Affiliated	2347	Mena	Mena Dialysis Center	1200 CRESTWOOD CIR	MENA	AR	71953-5516
1280	Affiliated	1941	FAYETTEVILLE DIALYSIS	Fayetteville Dialysis	509 E MILLSAP STE 111 RD	FAYETTEVILLE	AR	72703-4862
1281	Affiliated	1942	BENTONVILLE DIALYSIS	Bentonville Dialysis	1104 SE 30TH ST	BENTONVILLE	AR	72712-4290
1282	Affiliated	1943	SILOAM SPRINGS DIALYSIS	Siloam Springs Dialysis	500 S MOUNT STE 17 OLIVE ST	SILOAM SPRINGS	AR	72761-3602
1283	Affiliated	1944	SPRINGDALE DIALYSIS	Springdale Dialysis	708 QUANDT AVE	SPRINGDALE	AR	72764-5309

1284	Affiliated	2273	Grosse Pointe	Grosse Pointe Dialysis	18000 E WARREN AVE	STE 1	DETROIT	MI	48224-1336
1285	Affiliated	2448	Indy South Dialysis	Indy South Dialysis	972 EMERSON PKWY	STE E	GREENWOOD	IN	46143-6202
1286	Affiliated	2358	Greensburg Dialysis	Greensburg Dialysis	1531 N COMMERCE EAST DR	STE 6	GREENSBURG	IN	47240-3259
1287	Affiliated	2319	Grove City	Grove City Dialysis	4155 KELNOR DR		GROVE CITY	OH	43123-2960
1288	Affiliated	2338	West Beach	West Beach Dialysis Center	16201 PANAMA CITY BEACH HWY	STE 12	PANAMA CITY BEACH	FL	32413-5301
1289	Affiliated	2371	Birmingham	Center Point Dialysis (aka Birmingham Center)	2337 1ST ST NE		CENTER POINT	AL	35215-3619
1290	Affiliated	2445	Eureka	Eureka Dialysis Center	419 MERAMEC BLVD		EUREKA	MO	63025-3906
1291	Affiliated	2313	Tifton	Tifton Dialysis	624 LOVE AVE		TIFTON	GA	31794-4406
1292	Affiliated	2146	Woodlands	The Woodlands Dialysis	9301 PINECROFT DR	STE 13	SHENANDOAH	TX	77380-3178
1293	Affiliated	2266	Exeter	Exeter Dialysis	1116 W VISALIA RD	STE 16	EXETER	CA	93221-1482
1294	Affiliated	2396	Wayne County	Wayne County Dialysis (fka Fairfield)	303 NW 11TH ST	STE 1	FAIRFIELD	IL	62837-1203
1295	Affiliated	2415	Cordele Dialysis	Cordele Dialysis	1013 E 16TH AVE		CORDELE	GA	31015-1539
1296	Affiliated	2304	Winter Park	Winter Park Dialysis (aka Orlando)	3727 N GOLDENROD RD	STE 11	WINTER PARK	FL	32792-8611
1297	Affiliated	2449	Carmel	Carmel Dialysis	180 E CARMEL DR		CARMEL	IN	46032-2633
1298	Affiliated	2298	Corydon	Corydon Dialysis	1937 OLD HWY 135 NW		CORYDON	IN	47112-2013
1299	Affiliated	2382	Memphis Southeast	Memphis Southeast Dialysis (aka Midtown)	1805 MORIAH WOODS BLVD	STE 11	MEMPHIS	TN	38117-7119

1300	Affiliated	2399	Rim Country	Rim Country Dialysis	809 W LONGHORN RD		PAYSON	AZ	85541-4280
1301	Affiliated	2201	Cedar Park	Cedar Park Dialysis (fka North Austin)	1720 E WHITESTONE BLVD		CEDAR PARK	TX	78613-7640
1302	Affiliated	2368	Ellensburg	Ellensburg Dialysis	2101 W DOLARWAY RD	STE 1	ELLENSBURG	WA	98926-9310
1303	Affiliated	2260	Santa Fe Springs	Santa Fe Springs Dialysis	11147 WASHINGTON BLVD		WHITTIER	CA	90606-3007
1304	Affiliated	1950	Snapfinger Dialysis	Snapfinger Dialysis	5255 SNAPFINGER PARK DR	STE 115	DECATUR	GA	30035-4066
1305	Affiliated	1951	East Dekalb Dialysis	East DeKalb Dialysis	2801 CANDLER RD	STE 23	DECATUR	GA	30034-1429
1306	Affiliated	2258	Meadows East	Meadows East Dialysis	2529 SIX MILE LN		LOUISVILLE	KY	40220-2934
1307	Affiliated	2226	First Colony	First Colony Dialysis (aka Sugarland, Great Woods)	1447 HIGHWAY 6	STE 14	SUGAR LAND	TX	77478-5094
1308	Affiliated	1612	Coastal Kidney Center	Coastal Kidney Center	510 N MACARTHUR AVE		PANAMA CITY	FL	32401-3636
1309	Affiliated	2211	Clinton Township	Clinton Township Dailysis	15918 19 MILE RD	STE 11	CLINTON TOWNSHIP	MI	48038-1101
1310	Affiliated	2207	West Brook	Westbrook Dialysis (fka Palm Brook II)	13907 W CAMINO DEL SOL	STE 13	SUN CITY WEST	AZ	85375-4405
1311	Affiliated	1954	Johnson County	Johnson County Dialysis	10453 W 84TH TER		LENEXA	KS	66214-1641
1312	Affiliated	1956	Wyandotte County	Wyandotte County Dialysis	5001 STATE AVE		KANSAS CITY	KS	66102-3459
1313	Affiliated	2479	Maple Grove	Maple Grove Dialysis Unit	15655 GROVE CIR N		MAPLE GROVE	MN	55369-4489
1314	Affiliated	4336	East End	East End- Pittsburgh Dialysis (fka Wilkinsburg)	7714 PENN AVE PARK PLAZA		PITTSBURGH	PA	15221

1315	Affiliated	2493	Westminster II - North Metro	North Metro Dialysis Center (aka Denver, Westminster II)	12365 HURON ST	STE 5	WESTMINSTER	CO	80234-3498
1316	Affiliated	1960	Vidalia	Vidalia First Street Dialysis	906 E 1ST ST		VIDALIA	GA	30474-4207
1317	Affiliated	2357	Highland Park	Highland Park Dialysis	1559 W 7TH ST		SAINT PAUL	MN	55102-4238
1318	Affiliated	2367	Centennial Parkway	Centennial Dialysis Center	8775 DEER SPRINGS WAY		LAS VEGAS	NV	89149-0416
1319	Affiliated	2250	Lord Baltimore	Northwest Dialysis Center (aka Lord Baltimore, N. Rolling Road II, Owings Mills II)	2245 ROLLING RUN DR	STE 1	WINDSOR MILL	MD	21244-1858
1320	Affiliated	3944	North Charlotte	North Charlotte Dialysis	6620 OLD STATESVILLE RD		CHARLOTTE	NC	28269
1321	Affiliated	2410	Sun Ray Dialysis	Sun Ray Dialysis Unit (fka East St. Paul)	1758 OLD HUDSON RD	STE 1	SAINT PAUL	MN	55106-6161
1322	Affiliated	2425	Vandalia	Vandalia Dialysis	301 MATTES AVE		VANDALIA	IL	62471-2061
1323	Affiliated	2428	Westwood Hills	Westwood Hills Dialysis (fka Minneapolis, Excelsior)	7525 WAYZATA BLVD		SAINT LOUIS PARK	MN	55426-1621
1324	Affiliated	4305	Amery	Amery Dialysis	970 ELDEN AVE		AMERY	WI	54001-1448
1325	Affiliated	2434	Wadsworth	Wadsworth Dialysis	195 WADSWORTH RD	STE 32	WADSWORTH	OH	44281-9504
1326	Affiliated	2419	Dublin	Dublin Dialysis	6770 PERIMETER DR		DUBLIN	OH	43016-8063

1327	Affiliated	4314	Weber Valley	Weber Valley Dialysis (fka Ogden)	1920 W 250TH N		MARRIOTT- SLATERVILLE	UT	84404-9233
1328	Affiliated	2343	West Elk Grove	West Elk Grove Dialysis	2208 KAUSEN DR	STE 1	ELK GROVE	CA	95758-7174
1329	Affiliated	2355	Bedford Park	Bedford Park Dialysis Center	3119 WEBSTER AVE	1ST FLR	BRONX	NY	10467-4905
1330	Affiliated	1747	Cuero Lakeview Dialysis	Cuero Lakeview Dialysis	1105 E BROADWAY ST		CUERO	TX	77954
1331	Affiliated	1961	Madisonville Dialysis	Madisonville Dialysis Center	255 E NORTH ST		MADISONVILLE	KY	42431
1332	Affiliated	2467	Crescent City	Crescent City Dialysis Center	3909 BIENVILLE ST	STE B	NEW ORLEANS	LA	70119-5152
1333	Affiliated	4318	Callowhill	Callowhill Dialysis Center	313 CALLOWHILL ST		PHILADELPHIA	PA	19123-4103
1334	Affiliated	2406	Oak Creek	Oak Creek Dialysis (fka South Milwaukee)	8201 S HOWELL AVE	STE 6	OAK CREEK	WI	53154-8336

1335	Affiliated	4395	Leesburg Virginia	Leesburg Virginia Dialysis	224D CORNWALL ST NW	STE 1	LEESBURG	VA	20176-2700
1336	Affiliated	2386	Joy of Dixon	Joy of Dixon Dialysis Center	1640 N LINCOLN ST		DIXON	CA	95620-9255
1337	Affiliated	2137	Long Beach JV - Bixby Knolls	Bixby Knolls Dialysis (fka Long Beach)	3744 LONG BEACH BLVD		LONG BEACH	CA	90807-3310
1338	Affiliated	1790	Alliance Community Dialysis	Alliance Community Dialysis	270 E STATE ST	STE 11	ALLIANCE	OH	44601-4309
1339	Affiliated	1791	Belden Community Dialysis	Belden Community Dialysis	4685 FULTON DR NW		CANTON	OH	44718-2379
1340	Affiliated	1792	Mercy Canton Dialysis	Mercy Canton Dialysis	1320 MERCY DR NW		CANTON	OH	44708-2614
1341	Affiliated	2294	Marrero	Marrero Dialysis	1908 JUTLAND DR		HARVEY	LA	70058-2359
1342	Affiliated	2351	Miramar	Miramar Kidney Center	2501 DYKES RD	STE 2	MIRAMAR	FL	33027-4217
1343	Affiliated	2418	Chesterton	Chesterton Dialysis	711 PLAZA DR	STE 6	CHESTERTON	IN	46304-5506
1344	Affiliated	4368	St. John	St. John Dialysis	10033 WICKER AVE	STE 6	SAINT JOHN	IN	46373-8777
1345	Affiliated	2256	Princeton	Princeton Dialysis	2227 SHERMAN DR		PRINCETON	IN	47670-1062
1346	Affiliated	4332	Black Rock	Black Rock Dialysis (aka Faifield)	427 STILLSON RD		FAIRFIELD	CT	06824-3153
1347	Affiliated	2422	Williamstown	Williamstown Dialysis (fka Dry Ridge)	103 BARNES RD	STE A	WILLIAMSTOWN	KY	41097-9468
1348	Affiliated	4376	Renaissance	Renaissance Dialysis	1840 DARBY DR		FLORENCE	AL	35630-2623
1349	Affiliated	4360	Portage	Portage Dialysis	5823 US HIGHWAY 6		PORTAGE	IN	46368-4851
1350	Affiliated	2393	Opelika	Opelika Dialysis Center	2340 PEPPERELL PKWY		OPELIKA	AL	36801-6240

1351	Affiliated	2435	Urbana	Urbana Dialysis Center	1880 E US HIGHWAY 36		URBANA	OH	43078-9600
1352	Affiliated	1913	Port Lavaca Dialysis	Port Lavaca Dialysis	1300 N VIRGINIA ST	STE 12	PORT LAVACA	TX	77979-2512
1353	Affiliated	2276	Cornerhouse Dialysis	Cornerhouse Dialysis Center (aka Santa Clara)	2005 NAGLEE AVE		SAN JOSE	CA	95128-4801
1354	Affiliated	2167	Snellville	Snellville Dialysis	2135 MAIN ST E	STE 13	SNELLVILLE	GA	30078-6424
1355	Affiliated	4334	Bloomfield	Bloomfield- Pittsburgh Dialysis	5171 LIBERTY AVE	STE C	PITTSBURGH	PA	15224-2254
1356	Affiliated	2489	Pennsauken	Pennsauken Dialysis	7024 KAIGHNS AVE		PENNSAUKEN	NJ	08109-4417
1357	Affiliated	2433	Logan	Logan Dialysis	12880 GREY ST		LOGAN	OH	43138-9638
1358	Affiliated	2454	Forest Fair	Forest Fair Dialysis (fka Forest Park)	1145 KEMPER MEADOW DR		CINCINNATI	OH	45240-4118
1359	Affiliated	4307	Knoxville	Knoxville Central Dialysis	9141 CROSS PARK DR	STE 12	KNOXVILLE	TN	37923-4557
1360	Affiliated	4338	Kennestone	Kennestone Dialysis (aka Cobb II)	200 COBB PKWY N	STE 318 BLDG 3	MARIETTA	GA	30062-3558
1361	Affiliated	4343	Wiregrass Kidney Center	Wiregrass Kidney Center (fka Ross Circle)	1450 ROSS CLARK CIR		DOTHAN	AL	36301-4765
1362	Affiliated	2432	Memphis Downtown	Memphis Downtown Dialysis	2076 UNION AVE		MEMPHIS	TN	38104-4138
1363	Affiliated	3953	Marshville	Marshville Dialysis Center	7260 E MARSHVILLE BLVD		MARSHVILLE	NC	28103-1191
1364	Affiliated	4356	Shamrock	Shamrock Dialysis	1016 CLAXTON DAIRY RD	STE 1A	DUBLIN	GA	31021-7971
1365	Affiliated	4367	North Colorado Springs	North Colorado	6071 E WOODMEN RD	STE 1	COLORADO SPRINGS	CO	80923-2610

				Springs Dialysis						
1366	Affiliated	2466	Oakes	Oakes Dialysis	413 S 7TH ST		OAKES	ND	58474-1920	
1367	Affiliated	1976	Pinnacle Dialysis of Boca Raton	Pinnacle Dialysis of Boca Raton	2900 N STE 195 MILITARY TRL		BOCA RATON	FL	33431-6308	
1368	Affiliated	1980	Cedar Valley Dialysis	Cedar Valley Dialysis	1661 W RIDGEWAY AVE		WATERLOO	IA	50701-4541	
1369	Affiliated	1981	West Union Dialysis	West Union Dialysis	405 HIGHWAY 150 N		WEST UNION	IA	52175-1003	
1370	Affiliated	2161	Rockside	Rockside Dialysis (aka Independence, Parma II)	4801 ACORN DR		INDEPENDENCE	OH	44131-2566	
1371	Affiliated	2263	Sunset	Sunset Dialysis Center (fka Sunrise II)	3071 GOLD CANAL DR		RANCHO CORDOVA	CA	95670-6129	
1372	Affiliated	2442	Yosemite Street	Yosemite Street Dialysis	1650 W YOSEMITE AVE		MANTECA	CA	95337-5193	
1373	Affiliated	2335	Jedburg	Jedburg Dialysis	2897 W 5TH NORTH ST		SUMMERVILLE	SC	29483-9674	
1374	Affiliated	2441	Parker Dialysis	Parker Dialysis	10371 S PARK STE 18 GLENN WAY		PARKER	CO	80138-3885	
1375	Affiliated	2296	Northgate	Northgate Dialysis Center (aka San Rafael- Terra)	650 LAS GALLINAS AVE		SAN RAFAEL	CA	94903-3620	
1376	Affiliated	2271	The Nevada Center	The Nevada Dialysis Center (fka Warm Springs, Green Valley)	1510 W WARM STE 1 SPRINGS RD		HENDERSON	NV	89014-3586	
1377	Affiliated	2091	Aventura	Aventura Kidney Center	22 SW 11TH ST FLOOR 2		HALLANDALE BEACH	FL	33009-7038	
1378	Affiliated	2408	US Grant Dialysis	US Grant Dialysis (fka Georgetown,	458 HOME ST		GEORGETOWN	OH	45121-1408	

				Brown County)						
1379	Affiliated	4400	Arbor Place	Arbor Place Dialysis	9559 HIGHWAY 5	STE 1	DOUGLASVILLE	GA	30135-1573	
1380	Affiliated	4389	South Jacksonville	Jacksonville South Dialysis Center	14965 OLD SAINT AUGUSTINE RD	UNIT 114	JACKSONVILLE	FL	32258-9481	
1381	Affiliated	2385	Somerville	Somerville Dialysis	12475 US HIGHWAY 64		SOMERVILLE	TN	38068-6029	
1382	Affiliated	4321	District Heights	District Heights Dialysis (aka Pennsylvania Ave)	5701 SILVER HILL RD		DISTRICT HEIGHTS	MD	20747-1102	
1383	Affiliated	2414	Edwardsville	Edwardsville Dialysis	235 S BUCHANAN ST		EDWARDSVILLE	IL	62025-2108	
1384	Affiliated	2361	Broad St	South Broad Street Dialysis (aka S. Philadelphia II)	1172 S BROAD ST		PHILADELPHIA	PA	19146-3142	
1385	Affiliated	2342	Las Vegas Pediatrics	Las Vegas Pediatrics Dialysis (fka UMC Peds, DaVita Peds)	7271 W SAHARA AVE	STE 12	LAS VEGAS	NV	89117-2862	
1386	Affiliated	1990	Apopka Dialysis	Apopka Dialysis	640 EXECUTIVE PARK CT		APOPKA	FL	32703-6075	
1387	Affiliated	1991	Casselberry Dialysis	Casselberry Dialysis	4970 S US HWY 17/92		CASSELBERRY	FL	32707-3888	
1388	Affiliated	1992	Central Orlando Dialysis	Central Orlando Dialysis	2548 N ORANGE BLOSSOM TRL	STE 4	ORLANDO	FL	32804-4863	
1389	Affiliated	1993	Sanford Dialysis	Sanford Dialysis	1701 W 1ST ST		SANFORD	FL	32771-1605	
1390	Affiliated	1994	Winter Park Hemo Dialysis	Winter Park Hemo Dialysis	4100 METRIC DR	STE 3	WINTER PARK	FL	32792-6832	
1391	Affiliated	2173	Graham	Graham Dialysis Center	10219 196TH ST CT E	STE C	GRAHAM	WA	98338-7792	

1392	Affiliated	2316	Batavia	Batavia Dialysis	4000 GOLDEN AGE DR		BATAVIA	OH	45103-1913
1393	Affiliated	1967	Klamath Falls	Klamath Falls Dialysis	2230 N ELDORADO AVE		KLAMATH FALLS	OR	97601-6418
1394	Affiliated	2336	Longs	Longs Dialysis (fka Conway)	90 CLOVERLEAF DR	STE 36	LONGS	SC	29568-9262
1395	Affiliated	2452	Pooler	Pooler Dialysis	54 TRADERS WAY		POOLER	GA	31322-
1396	Affiliated	4380	Ohio Pike Dialysis	Ohio Pike Dialysis (aka Amelia)	1761 STATE ROUTE 125		AMELIA	OH	45102-2039
1397	Affiliated	2285	Canyon Springs	Canyon Springs Dialysis (aka Moreno Valley)	22555 ALESSANDRO BLVD		MORENO VALLEY	CA	92553-8533
1398	Affiliated	4306	Williamson	South Williamson Dialysis	204 APPALACHIAN PLAZA		SOUTH WILLIAMSON	KY	41503-9404
1399	Affiliated	4402	Gulf Shores	Gulf Shores Dialysis Center	3947 GULF SHORES PKWY	UNIT 15	GULF SHORES	AL	36542-2737
1400	Affiliated	2496	Las Vegas Multi-Care Five Star	Five Star Dialysis Center (fka Las Vegas Multi-Care)	2400 TECH CENTER CT		LAS VEGAS	NV	89128-0804
1401	Affiliated	4358	North Vernon	North Vernon Dialysis	2340 N STATE HWY 7		NORTH VERNON	IN	47265-7183

1402	Affiliated	4316	Olympia	Olympia Dialysis Center	335 COOPER POINT RD NW	STE 15	OLYMPIA	WA	98502-4436
1403	Affiliated	4335	Monroeville	Monroeville Dialysis	2690 MONROEVILLE BLVD		MONROEVILLE	PA	15146-2302
1404	Affiliated	2317	East Galbraith	East Galbraith Dialysis	3877 E GALBRAITH RD	BLDG C	CINCINNATI	OH	45236-1500
1405	Affiliated	2261	San Marcos	San Marcos Dialysis Center	2135 MONTIEL RD	BLDG B	SAN MARCOS	CA	92069-3511
1406	Affiliated	4408	Winter Garden	Winter Garden Dialysis	1222 WINTER GARDEN VINELAND RD	BLDG 3 STE 1	WINTER GARDEN	FL	34787
1407	Affiliated	1926	Bremer County Dialysis	Relo-Bremer County Dialysis (5022-Cedar Valley Waverly Dialysis)	220 10th ST SW		WAVERLY	IA	50677-2930
1408	Affiliated	1927	Black Hawk Dialysis	Black Hawk Dialysis (Waterloo)	3421 W 9TH ST		WATERLOO	IA	50702-5401
1409	Affiliated	2218	Downey Landing	Downey Landing Dialysis Center (aka Downey- Kaiser)	11611 BELLFLOWER BLVD		DOWNEY	CA	90241-5408
1410	Affiliated	2427	Tucson Central	Tucson Central Dialysis	2901 E GRANT RD		TUCSON	AZ	85716-2717
1411	Affiliated	4377	Hamburg	Hamburg Dialysis (fka Lexington)	1745 ALYSHEBA WAY		LEXINGTON	KY	40509-9013
1412	Affiliated	2150	Midtown Norfolk	Midtowne Norfolk Dialysis (aka Ghent II)	2201 COLONIAL AVE		NORFOLK	VA	23517-1928
1413	Affiliated	2394	Yonkers II	Yonkers East Dialysis Center	5 ODELL PLZ	STE 131	YONKERS	NY	10701-1406
1414	Affiliated	2364	Caldwell	Caldwell Dialysis Center	821 S SMEED PKWY		CALDWELL	ID	83605-5130
1415	Affiliated	2278	Hesperia	Hesperia Dialysis Center	14135 MAIN ST	UNIT 51	HESPERIA	CA	92345-8097
1416	Affiliated	2339	Sealy	Sealy Dialysis	2242 CHAMPIONSHIP DR		SEALY	TX	77474-8026

1417	Affiliated	2438	Hearne	Hearne Dialysis Center	106 CEDAR ST		HEARNE	TX	77859-2523
1418	Affiliated	1998	Stockton Kidney Center	Stockton Kidney Center	1523 E MARCH LN	STE 2	STOCKTON	CA	95210-5607
1419	Affiliated	5525	University of South Florida	USF Dialysis	10770 N 46TH ST		TAMPA	FL	33617-3465
1420	Affiliated	4424	Westborough	Westborough Dialysis Center (fka South San Francisco, Daly City)	925 EL CAMINO REAL		SOUTH SAN FRANCISCO	CA	94080-3203
1421	Affiliated	4359	Rush County	Rush County Dialysis	1400 N CHERRY ST		RUSHVILLE	IN	46173-1097
1422	Affiliated	4339	Defuniak Springs	Defuniak Springs Dialysis	1045 US HWY 331 S	DEFUNIAK SHOPPING PLAZA	DEFUNIAK SPRINGS	FL	32435-3375
1423	Affiliated	2181	Foster city	Foster City Dialysis (fka Belmont)	1261 E HILLSDALE BLVD	STE 2	FOSTER CITY	CA	94404-1236
1424	Affiliated	4427	Red Bank	Redbank Village Dialysis (Cincinnati)	3960 RED BANK RD	STE 16	CINCINNATI	OH	45227-3421
1425	Affiliated	4448	Southport	Southport Dialysis Center	1513 N HOWE ST	STE 15	SOUTHPORT	NC	28461-2770
1426	Affiliated	4446	Orlando Park	Orlando Park Dialysis	5397 W COLONIAL DR	STE 12	ORLANDO	FL	32808-7647
1427	Affiliated	4431	Harrisburg	Harrisburg Dialysis Center (aka Concord)	3310 PERRY ST		CONCORD	NC	28027-3901
1428	Affiliated	2352	Waycross	Satilla River Dialysis	308 CARSWELL AVE		WAYCROSS	GA	31501-4762
1429	Affiliated	4455	Timberlake	Timberlake Dialysis (Kansas City)	12110 HOLMES RD		KANSAS CITY	MO	64145-1707
1430	Affiliated	4447	Dexter	Dexter Dialysis	2010 N OUTER RD		DEXTER	MO	63841
1431	Affiliated	4426	Norwood	Norwood Dialysis (Cincinnati)	2300 WALL ST		CINCINNATI	OH	45212-2781
1432	Affiliated	4420	Peachtree City	Peachtree City Dialysis	2830 W HWY 54	BLDG 1 STE J AND K	PEACHTREE CITY	GA	30269-1026

1433	Affiliated	5516	Rogue Valley	Rogue Valley Dialysis	760 GOLF VIEW DR	UNIT 1	MEDFORD	OR	97504-9685
1434	Affiliated	5517	Redwood Dialysis	Redwood Dialysis	201 SW L ST		GRANTS PASS	OR	97526-2913
1435	Affiliated	4410	Tucker	Tucker Dialysis	4434 HUGH HOWELL RD		TUCKER	GA	30084-4905
1436	Affiliated	4386	Shepherdsville	Shepherdsville Dialysis Center	150 BROOKS WAY	STE 15	BROOKS	KY	40109-6105
1437	Affiliated	4399	Muscle Shoals	Muscle Shoals Dialysis	712 STATE ST		MUSCLE SHOALS	AL	35661-2940
1438	Affiliated	2463	Tel Huron	Tel-Huron Dialysis (fka Waterford)	225 SUMMIT DR		WATERFORD	MI	48328-3364
1439	Affiliated	2481	Cherry Valley	Cherry Valley Dialysis (aka Newark)	1627 W MAIN ST		NEWARK	OH	43055-1345
1440	Affiliated	2437	Taylor	Taylor Dialysis	3100 W 2ND ST		TAYLOR	TX	76574
1441	Affiliated	4430	Forrest City	Forrest City Dialysis	1501 N WASHINGTON ST		FORREST CITY	AR	72335-2152
1442	Affiliated	4309	Kaufman	Kaufman Dialysis	2851 MILLENNIUM DR		KAUFMAN	TX	75142-8865
1443	Affiliated	4348	Artesia	Artesia Dialysis	702 N 13TH ST		ARTESIA	NM	88210-1166
1444	Affiliated	2381	North Hills	North Hills Dialysis	7927 BOULEVARD 26		NORTH RICHLAND HILLS	TX	76180-7103
1445	Affiliated	4428	Millington	Millington Dialysis	8510 WILKINSVILLE RD	STE 121	MILLINGTON	TN	38053-1537
1446	Affiliated	5519	Adams County	Adams County Dialysis	436 N 10TH ST		QUINCY	IL	62301-4152
1447	Affiliated	5518	Hannibal	Hannibal Dialysis	3140 PALMYRA ROAD		HANNIBAL	MO	63401-2204
1448	Affiliated	5520	Pittsfield	Pittsfield Dialysis	640 W WASHINGTON ST		PITTSFIELD	IL	62363-1350
1449	Affiliated	4463	Villa of Waterbury	Villa of Waterbury (fka Kissker Microcenter)	929 WATERBURY FALLS DR		O' FALLON	MO	63368-2202

1450	Affiliated	2465	Washington DC Nursing Facility	Washington DC Nursing Facility	2425 25TH ST SE		WASHINGTON	DC	20020-3408
1451	Affiliated	4325	Moscow	Moscow Dialysis Center	212 RODEO DR	STE 11	MOSCOW	ID	83843-9798
1452	Affiliated	2402	Chinook Kidney Center	Chinook Kidney Center (aka Richland)	1315 AARON DR	BLDG C1	RICHLAND	WA	99352-4678
1453	Affiliated	4416	River' s Edge	Rivers Edge Dialysis (aka Athens)	1006 E STATE ST	STE B	ATHENS	OH	45701-2121
1454	Affiliated	5530	North Glendale Dialysis	North Glendale Dialysis	1505 WILSON TER STE 190		GLENDALE	CA	91206-4015
1455	Affiliated	4373	Everett	Everett Dialysis Center (fka Snohomish 2)	8130 EVERGREEN WAY		EVERETT	WA	98203-6419
1456	Affiliated	2069	Harbourview	Harbour View Dialysis (aka Churchland, Suffolk)	1039 CHAMPIONS WAY	BLDG 4	SUFFOLK	VA	23435-3761
1457	Affiliated	4357	Capelville	Capelville Dialysis Center	7008 E SHELBY DR		MEMPHIS	TN	38125-3416
1458	Affiliated	4485	San Leandro	San Leandro Dialysis (Bayfair Mall)	15555 E 14TH	STE 52	SAN LEANDRO	CA	94578-1900
1459	Affiliated	4317	Mill Creek	Mill Creek Dialysis Center (Snohomish/ Everett)	18001 BOTHELL EVERETT HWY	STE 112	BOTHELL	WA	98012-1661
1460	Affiliated	2470	Seaview	Seaview Dialysis Center	101 18TH ST SE		LONG BEACH	WA	98631
1461	Affiliated	2461	East Tampa	East Tampa Dialysis (Ybor City)	1701 E 9TH AVE		YBOR CITY	FL	33605-3801
1462	Affiliated	5522	Detroit Road Dialysis	Detroit Road Dialysis	7901 DETROIT AVE		CLEVELAND	OH	44102-2828
1463	Affiliated	5523	St V Quadrangle Dialysis	St V Quadrangle Dialysis	2302 COMMUNITY COLLEGE AVE		CLEVELAND	OH	44115-3117
1464	Affiliated	5524	Westshore Dialysis	Westshore Dialysis	29000 CENTER RIDGE RD		WESTLAKE	OH	44145-5293

1465	Affiliated	2468	Magnolia Dialysis Center Texas	Magnolia Dialysis Center	17649 FM 1488 RD		MAGNOLIA	TX	77354-5235
1466	Affiliated	4471	Highland County	Highland County Dialysis (Hillsboro)	120 ROBERTS LN	STE 4	HILLSBORO	OH	45133-7608
1467	Affiliated	4313	Rockwall	Rockwall Dialysis	2455 RIDGE RD	STE 11	ROCKWALL	TX	75087-5530
1468	Affiliated	4354	Great Northern	Villa of Great Northern (fka North Olmsted)	22710 FAIRVIEW CENTER DR	STE 1	FAIRVIEW PARK	OH	44126-3607

1469	Affiliated	2440	Ridgeland	Ridgeland Dialysis	112 WEATHERSBY ST		RIDGELAND	SC	29936-9514
1470	Affiliated	2334	Livermore	Livermore Dialysis	3201 DOOLAN RD	STE 175	LIVERMORE	CA	94551-9605
1471	Affiliated	2265	Westlake Daly city	Westlake Daly City Dialysis (fka Colma)	2201 JUNIPERO SERRA BLVD	STE 175	DALY CITY	CA	94014-1908
1472	Affiliated	4488	12th Street Covington	12th Street Covington Dialysis	1500 JAMES SIMPSON JR WAY	STE 11	COVINGTON	KY	41011
1473	Affiliated	4384	Bourbon County	Bourbon County Dialysis (fka Paris)	213 LETTON DR	PARIS TOWNE SQUARE	PARIS	KY	40361-2251
1474	Affiliated	2499	Calverton	Calverton Dialysis	4780 CORRIDOR PL	STE C	BELTSVILLE	MD	20705-1165
1475	Affiliated	2199	Aborn	Aborn Dialysis (fka East San Jose)	3162 S WHITE RD	STE 1	SAN JOSE	CA	95148-4019
1476	Affiliated	4438	Clermont	Clermont County Dialysis (Milford,Goshen)	5901 MONTCLAIR BLVD	STE 1	MILFORD	OH	45150-2547
1477	Affiliated	4365	Rita Ranch	Rita Ranch Dialysis (aka Tucson East II)	7355 S HOUGHTON RD	STE 11	TUCSON	AZ	85747-9379
1478	Affiliated	4333	Wake Forest	Wake Forest Dialysis Center	11001 INGLESIDE PL		RALEIGH	NC	27614-8577
1479	Affiliated	4472	Colonial Springs	Colonial Springs Dialysis (fka Powder Springs)	2840 EAST WEST CONNECTOR	STE 35	AUSTELL	GA	30106-6813
1480	Affiliated	2474	Central Dallas	DaVita Central Dallas Dialysis	9500 N CENTRAL EXPY		DALLAS	TX	75231-5002
1481	Affiliated	2188	Sanger	Sanger Sequoia Dialysis	2517 JENSEN AVE	BLDG B	SANGER	CA	93657-2251
1482	Affiliated	4421	Conyers	Conyers Dialysis	1501 MILSTEAD RD NE		CONYERS	GA	30012-3838
1483	Affiliated	4337	Duncanville	Duncanville Dialysis (Cedar Hill)	270 E HIGHWAY 67	STE 1	DUNCANVILLE	TX	75137-4428
1484	Affiliated	4417	Gateway	Gateway Dialysis (Ft.Myers)	5705 LEE BLVD		LEHIGH ACRES	FL	33971-6342

1485	Affiliated	4487	Derry	Derry Dialysis	1 ACTION BLVD	STE 2	LONDONDERRY NH	03053-3428
1486	Affiliated	4461	Villa of Wentzville Microcenter	Villa of Wentzville (Microcenter)	1126 W PEARCE BLVD	STE 116 & 118	WENTZVILLE MO	63385-1053
1487	Affiliated	1925	Buchanan County Dialysis	Buchanan County Dialysis (Independence)	1600 1ST ST E		INDEPENDENCE IA	50644-3155
1488	Affiliated	2450	Hoosier Hills	Hoosier Hills Dialysis	143 S KINGSTON DR		BLOOMINGTON IN	47408-6342
1489	Affiliated	4492	Palm Breeze	Palm Breeze Dialysis (fka North Port)	14942 TAMIAMI TRL	STE E	NORTH PORT FL	34287-2705
1490	Affiliated	4362	Big Oaks	Big Oaks Dialysis	5623 W TOUHY AVE		NILES IL	60714-4019
1491	Affiliated	4407	Pinellas West Shore	Pinellas West Shore Dialysis	3451 66TH ST N	STE A	ST PETERSBURG FL	33710-1568
1492	Affiliated	2267	Plano	Plano Dialysis	481 SHILOH RD	STE 1	PLANO TX	75074-7231
1493	Affiliated	4350	Fairview	Villa of Fairview Park (fka Fairview Park Dialysis)	19050 LORAIN RD		FAIRVIEW PARK OH	44126-1915
1494	Affiliated	2380	Ave Marisa	Ave Maria Dialysis (fka Immokalee)	5340 USEPPA DR		AVE MARIA FL	34142-5051
1495	Affiliated	5037	Warminster	Franklin Commons Dialysis (fka Warminster)	720 JOHNSVILLE BLVD	STE 8	WARMINSTER PA	18974-3546
1496	Affiliated	2446	Ripley	Ripley Dialysis Center	854 HWY 51 S		RIPLEY TN	38063-5536
1497	Affiliated	5538	St Charles / Riverbend	River Bend Dialysis (St. Charles Parish)	1057 PAUL MAILLARD RD	ST B135	LULING LA	70070-4349
1498	Affiliated	5570	Midwest Springfield	Midwest Springfield Dialysis	2200 N LIMESTONE ST STE 104		SPRINGFIELD OH	45503-2692
1499	Affiliated	5571	Midwest Fairborn	Midwest Fairborn Dialysis	1266 N BROAD ST		FAIRBORN OH	45324-5549
1500	Affiliated	5572	Midwest Urbana	Midwest Urbana Dialysis	1430 E US HIGHWAY 36		URBANA OH	43078-9112

1501	Affiliated	5531	Camarillo	Camarillo Dialysis	2438 N PONDEROSA DR STE C101	CAMARILLO	CA	93010-2465
1502	Affiliated	5532	Thousand Oaks	Thousand Oaks Dialysis	375 ROLLING OAKS DR STE 100	THOUSAND OAKS	CA	91361-1024
1503	Affiliated	5533	Simi Valley	Simi Valley Dialysis	2950 SYCAMORE DR STE 100	SIMI VALLEY	CA	93065-1210
1504	Affiliated	5534	Santa Paula	Santa Paula Dialysis	253 MARCH ST	SANTA PAULA	CA	93060-2511
1505	Affiliated	5548	Ventura	Ventura Dialysis	2705 LOMA VISTA RD STE 101	VENTURA	CA	93003-1596
1506	Affiliated	4468	Villa of St. John	Villa of St John (Crossing Microcenter- MO)	9030 SAINT CHARLES ROCK RD	SAINT LOUIS	MO	63114-4246
1507	Affiliated	4372	Whidbey Island	Whidbey Island Dialysis Center	32650 STATE RD BLDG E 20 STE 18	OAK HARBOR	WA	98277-2641
1508	Affiliated	4437	Baytown	Baytown Dialysis	4665 GARTH RD STE 9	BAYTOWN	TX	77521-2261
1509	Affiliated	2475	Highland Ranch	Highland Ranch Dialysis Center	7223 CHURCH ST STE A14	HIGHLAND	CA	92346-6837
1510	Affiliated	4474	Tiptonville	Tiptonville Dialysis	795 HAMRA ST	TIPTONVILLE	TN	38079-1663
1511	Affiliated	1902	Carabello	Carabello Dialysis Center	757 E WASHINGTON BLVD	LOS ANGELES	CA	90021-3016
1512	Affiliated	5573	Palmetto	Palmetto Dialysis	317 PROFESSIONAL PARK RD	CLINTON	SC	29325-7625
1513	Affiliated	5574	Greer South	Greer South Dialysis	3254 BRUSHY CREEK RD	GREER	SC	29650-1000
1514	Affiliated	5575	Greenville West End	Greenville West End Dialysis	605 S ACADEMY ST	GREENVILLE	SC	29601-2407
1515	Affiliated	5576	Fountain Inn	Fountain Inn Dialysis	298 CHAPMAN RD	FOUNTAIN INN	SC	29644-6129
1516	Affiliated	5558	Sellersville	Sellersville Dialysis	1112 OLD BETHLEHEM PIKE	SELLERSVILLE	PA	18960-1423

1517	Affiliated	5564	Humbolt Ridge	Humboldt Ridge Dialysis	2211 N HUMBOLDT BLVD		MILWAUKEE	WI	53212-3507
1518	Affiliated	5565	West Appleton	West Appleton Dialysis	10130 W APPLETON AVE	STE 5	MILWAUKEE	WI	53225-2579
1519	Affiliated	5566	Bay Shore	Bay Shore Dialysis	5650 N GREEN BAY AVE	STE 15	GLENDALE	WI	53209-4449
1520	Affiliated	5567	South Ridge	South Ridge Dialysis	4848 S 76TH ST	STE 1	GREENFIELD	WI	53220-4361
1521	Affiliated	5568	Bluemound	Bluemound Dialysis	601 N 99TH ST	STE 1	MILWAUKEE	WI	53226-4362
1522	Affiliated	4385	Versailles	Versailles Dialysis	480 LEXINGTON RD		VERSAILLES	KY	40383-1918
1523	Affiliated	5035	Magnolia Oaks	Magnolia Oaks Dialysis (aka Hinesville)	2377 HWY 196 W		HINESVILLE	GA	31313-8036
1524	Affiliated	4489	Mesa County	Mesa County Dialysis (Grand Junction)	561 25 RD	STE D	GRAND JUNCTION	CO	81505-1303
1525	Affiliated	297	West Bloomfield	West Bloomfield Dialysis	6010 W MAPLE RD	STE 215	WEST BLOOMFIELD	MI	48322-4406
1526	Affiliated	5550	Crystal Springs	Crystal Springs Dialysis	720 COG CIRCLE		CRYSTAL LAKE	IL	60014-7301
1527	Affiliated	5551	Cobblestone	Cobblestone Dialysis	934 CENTER ST	STE A	ELGIN	IL	60120-2125
1528	Affiliated	5586	Oak Springs	Oak Springs Dialysis	764 LOCUST AVE		WASHINGTON	PA	15301-2756
1529	Affiliated	5010	Maple Valley	Maple Valley Plaza Dialysis (Farmington)	649 MAPLE VALLEY DR		FARMINGTON	MO	63640-1993
1530	Affiliated	4433	Floyd Curl	Floyd Curl Dialysis (San Antonio)	9238 FLOYD CURL DR	STE 12	SAN ANTONIO	TX	78240-1691
1531	Affiliated	2387	Mission Valley	Mission Valley Dialysis (aka McAllen)	1203 ST CLAIRE BLVD 9B		MISSION	TX	78572-6601
1532	Affiliated	2180	Silver Lake	Silver Lake Dialysis	2723 W TEMPLE ST		LOS ANGELES	CA	90026-4723
1533	Affiliated	5578	Lake Park	Lake Park Dialysis	1531 E HYDE PARK BLVD		CHICAGO	IL	60615-3039

1534	Affiliated	5579	Stoney Island Dialysis	Stony Island Dialysis	8725 S STONY ISLAND AVE	CHICAGO	IL	60617-2709
1535	Affiliated	5580	Woodlawn Dialysis	Woodlawn Dialysis	1164 E 55TH ST	CHICAGO	IL	60615-5115

1536	Affiliated	4440	Jefferson Ave	Jefferson Avenue Dialysis (aka Village Parkway, Hampton)	11234 JEFFERSON AVE		NEWPORT NEWS VA	23601-2207
1537	Affiliated	4381	Robinson	Robinson Dialysis	1215 N ALLEN ST	STE B	ROBINSON IL	62454-1100
1538	Affiliated	4320	Gateway Plaza	Gateway Plaza Dialysis (aka Willowbrook)	1580 W ROSECRANS AVE		COMPTON CA	90222-3700
1539	Affiliated	4329	Pasadena Foothills	Pasadena Foothills Dialysis (fka Arcadia)	3722 E COLORADO BLVD		PASADENA CA	91107-3803
1540	Affiliated	914	Live Oak Dialysis	Live Oak Dialysis (fka San Antonio)	6700 RANDOLPH BLVD	STE 11	LIVE OAK TX	78233-4222
1541	Affiliated	5031	Frackville	Frackville Dialysis (aka JV_Pottsville)	801 SCHUYLKILL MALL		FRACKVILLE PA	17931-2524
1542	Affiliated	5038	Castor	Cottman Kidney Center (Castor, NE Philadelphia)	7198 CASTOR AVE		PHILADELPHIA PA	19149-1105
1543	Affiliated	4351	Villa of North Ridgeville	Villa of North Ridgeville	35143 CENTER RIDGE RD		NORTH RIDGEVILLE OH	44039-3089
1544	Affiliated	5503	Thorn Run Dialysis	Thorn Run Dialysis	1136 THORN RUN RD	STE J1	MOON TOWNSHIP PA	15108
1545	Affiliated	5504	Allegheny Valley	Allegheny Valley Dialysis	1620 PACIFIC AVE	HEIGHTS PLAZA SHOPPING CENTER	NATRONA HEIGHTS PA	15065-2101
1546	Affiliated	5506	Northside	Northside Dialysis (fka Allegheny General)	320 E NORTH AVE	4TH FL, SOUTH TOWER	PITTSBURGH PA	15212-4756
1547	Affiliated	5507	Somerset	Somerset County Dialysis	229 S KIMBERLY AVE	STE 1	SOMERSET PA	15501-2022

1548	Affiliated	4493	Carthage	Carthage Dialysis	165 SAVANNAH GARDENS DR	CARTHAGE	NC	28327
1549	Affiliated	2464	Riverwood Dialysis	Riverwood Dialysis (fka Nine Mile, Tree City & Southfield)	24467 W 10 MILE RD	SOUTHFIELD	MI	48033-2931
1550	Affiliated	4415	Burton	Burton Dialysis (fka Flint Northeast)	4015 DAVISON RD	BURTON	MI	48509-1401
1551	Affiliated	4490	Black Canyon	Black Canyon Dialysis (Montrose)	3421 S RIO GRANDE AVE	UNIT D MONTROSE	CO	81401-4840
1552	Affiliated	4394	Memphis Midtown	Memphis Midtown Dialysis	3430 SUMMER AVE	MEMPHIS	TN	38122-3610
1553	Affiliated	5539	Stonecrest Dialysis	Stonecrest Dialysis	1302 E STATE ST	ROCKFORD	IL	61104-2228
1554	Affiliated	4412	West Plano	West Plano Dialysis	5036 TENNYSON PKWY	PLANO	TX	75024-3002
1555	Affiliated	2217	Redwood City	Redwood City Dialysis (fka Palo Alto)	1000 MARSHALL ST	REDWOOD CITY	CA	94063-2027
1556	Affiliated	1592	State Fair	State Fair Dialysis	19800 WOODWARD AVE	DETROIT	MI	48203-5102
1557	Affiliated	5589	ADC of Ft Lauderdale	Advanced Dialysis Center of Fort Lauderdale	911 E OAKLAND PARK BLVD	OAKLAND PARK	FL	33334-2725
1558	Affiliated	5008	Dover	Dover Community Dialysis (New Philadelphia)	899 E IRON AVE	DOVER	OH	44622-2097
1559	Affiliated	5045	McMinnville	McMinnville Dialysis	200 NE NORTON LN	MCMINNVILLE	OR	97128-8470
1560	Affiliated	5007	Sparta	Sparta Dialysis	150 SAM WALTON DR	STE 8 SPARTA	TN	38583-8818
1561	Affiliated	4409	Kendall	Kendall Kidney Center (fka Dadeland)	8364 MILLS DR	STE 174 MIAMI	FL	33183-4806

1562	Affiliated	4397	Abbeville	Abbeville Dialysis	904 W GREENWOOD ST		ABBEVILLE	SC	29620
1563	Affiliated	2453	Delta View	Delta View Dialysis	1150 E LELAND RD		PITTSBURG	CA	94565-5319
1564	Affiliated	5013	Wolf River	Wolf River Dialysis (Germantown)	7990 TRINITY PL	STE 11	CORDOVA	TN	38018-7731
1565	Affiliated	5601	San Luis Obispo Dialysis	San Luis Obispo Dialysis	1043 MARSH ST		SAN LUIS OBISPO	CA	93401-3629
1566	Affiliated	5602	Templeton Dialysis	Templeton Dialysis	1310 LAS TABLAS RD	STE 11	TEMPLETON	CA	93465-9746
1567	Affiliated	5603	Pismo Beach Dialysis	Pismo Beach Dialysis	320 JAMES WAY	STE 11	PISMO BEACH	CA	93449-2813
1568	Affiliated	5583	Lincoln Way Dialysis	Lincoln Way Dialysis	1303 LINCOLN WAY STE A		WHITE OAK	PA	15131-1603
1569	Affiliated	5023	Grundy Center	Grundy Center Dialysis	101 E J AVENUE		GRUNDY CENTER	IA	50638-2031
1570	Affiliated	3862	Pickens County	Pickens County Dialysis	289 WILLIAM E HILL DR.	STE A	CARROLLTON	AL	35447
1571	Affiliated	5032	Willow Grove	Willow Grove Dialysis (Abington- Maplewood)	1849 DAVISVILLE RD		WILLOW GROVE	PA	19090-4111
1572	Affiliated	2255	Amherst	Amherst Dialysis (Lorain County)	3200 COOPER FOSTER PRK RD W		LORAIN	OH	44053-3654
1573	Affiliated	2220	South Fort Worth	South Fort Worth Dialysis	6260 SOUTHWEST BLVD		BENBROOK	TX	76109-6906
1574	Affiliated	5521	Jerseyville Dialysis	Jerseyville Dialysis	917 S STATE ST		JERSEYVILLE	IL	62052-2344
1575	Affiliated	5605	Independence County Dialysis	Independence County Dialysis	1700 HARRISON ST	STE F	BATESVILLE	AR	72501-7315
1576	Affiliated	5606	Jackson County Dialysis	Jackson County Dialysis	1912 MCLAIN ST	PRATT SQUARE	NEWPORT	AR	72112-3659
1577	Affiliated	5607	Searcy Dialysis	Searcy Dialysis	3208 LANGLEY DR		SEARCY	AR	72143-6020
1578	Affiliated	5608	Springhill Dialysis	Springhill Dialysis	3401 SPRINGHILL DR	STE 19	NORTH LITTLE ROCK	AR	72117-2925

1579	Affiliated	5609	Pulaski County Dialysis	Pulaski County Dialysis	202 JOHN HARDEN DR		JACKSONVILLE	AR	72076-3775
1580	Affiliated	5610	Little Rock Midtown Dialysis	Little Rock Midtown Dialysis	2 LILE CT	STE 12A	LITTLE ROCK	AR	72205-6241
1581	Affiliated	5611	Saline County Dialysis	Saline County Dialysis	1200 N MAIN ST	STE 2	BENTON	AR	72015-3341
1582	Affiliated	5612	Conway Dialysis	Conway Dialysis	2445 CHRISTINA LANE		CONWAY	AR	72034
1583	Affiliated	5614	Valley Baptist Harlingen Dialysis	Valley Baptist- Harlingen Dialysis	2220 HAINE DR STE 40		HARLINGEN	TX	78550-8584
1584	Affiliated	5615	Valley Baptist Raymondville Dialysis	Valley Baptist- Raymondville Dialysis	894 FM 3168		RAYMONDVILLE	TX	78580-4519
1585	Affiliated	2455	Hawaiian Gardens	Hawaiian Gardens Dialysis	12191 226TH ST		HAWAIIAN GARDENS	CA	90716-1510
1586	Affiliated	2310	Huntington park	Huntington Park Dialysis	5942 RUGBY AVE		HUNTINGTON PARK	CA	90255-2803
1587	Affiliated	2462	Poinciana	Poinciana Dialysis	1002 CYPRESS PKWY		KISSIMMEE	FL	34758-3328
1588	Affiliated	5005	Southtowns	Southtowns Dialysis (Hamburg)	4910 CAMP RD	STE 1	HAMBURG	NY	14075-2617
1589	Affiliated	5635	Parma Heights Dialysis	Parma Heights Dialysis	9050 N CHURCH DR		PARMA HEIGHTS	OH	44130-4701
1590	Affiliated	5636	Hilliard Dialysis	Hilliard Dialysis	19133 HILLIARD BLVD		ROCKY RIVER	OH	44116-2907
1591	Affiliated	5546	Pacific Dialysis	Pacific Dialysis	2351 CLAY ST	FL 4	SAN FRANCISCO	CA	94115-1931
1592	Affiliated	5547	Davies Dialysis	Davies Dialysis	45 CASTRO ST	SOUTH TOWER 2ND FL	SAN FRANCISCO	CA	94114-1032
1593	Affiliated	4486	Newburgh	Newburgh Dialysis	4311 HIGHWAY 261	STE A	NEWBURGH	IN	47630-2653
1594	Affiliated	5052	Enterprise	Enterprise Dialysis (fka Geneva)	6002 BOLL WEEVIL CIRCLE		ENTERPRISE	AL	36330-9420

1595	Affiliated	4387	State Line	State Line Dialysis	2049 E SHELBY DR	MEMPHIS	TN	38116-7639
1596	Affiliated	5108	Cape Coral North	Cape Coral North Dialysis	1315 SE 8TH TERRACE	CAPE CORAL	FL	33990-3213
1597	Affiliated	5044	Willard Ave	Willard Avenue Dialysis (Newington)	445E WILLARD AVE	NEWINGTON	CT	06111-2318
1598	Affiliated	4363	West Lawn	West Lawn Dialysis (aka Midway)	7000 S PULASKI RD	CHICAGO	IL	60629-5842
1599	Affiliated	4353	Villa of Lakewood	Villa of Lakewood (Northcoast)	14050 MADISON AVE	LAKESWOOD	OH	44107-4530
1600	Affiliated	5054	North Carrollton	North Carrollton Dialysis (Parkview)	195 PARKWOOD CIRCLE	CARROLLTON	GA	30117-8756
1601	Affiliated	5620	Sikeston Jaycee Regional Dialysis	Sikeston Jaycee Regional Dialysis	135 PLAZA DR STE 101	SIKESTON	MO	63801-5148
1602	Affiliated	2244	Radcliff	Radcliff Dialysis	180 E LINCOLN TRAIL BLVD	RADCLIFF	KY	40160-1254

1603	Affiliated	4452	McAfee	McAfee Dialysis (Candler Road Decatur)	1987 CANDLER RD	STE C	DECATUR	GA	30032-4212
1604	Affiliated	5036	Avon	Avon Dialysis (Indy West)	9210 ROCKVILLE RD	STE D	INDIANAPOLIS	IN	46234-2669
1605	Affiliated	2485	Anaheim West	Anaheim West Dialysis	1821 W LINCOLN AVE		ANAHEIM	CA	92801-6731
1606	Affiliated	5043	Port Saint Joe	Port Saint Joe Dialysis	3871 HIGHWAY 98 E	STE 11	PORT ST. JOE	FL	32456-5318
1607	Affiliated	5056	Hayward Mission Hills	Hayward Mission Hills Dialysis	1661 INDUSTRIAL PKWY W		HAYWARD	CA	94544-7046
1608	Affiliated	2472	Cypress Woods Northwest	Cypress Woods Northwest Dialysis (aka NW Houston)	20320 NORTHWEST FWY	STE 1	HOUSTON	TX	77065-
1609	Affiliated	5641	Willow Creek Dialysis	Willow Creek Dialysis	1139 WARWICK WAY		RACINE	WI	53406-5661
1610	Affiliated	5642	Harbor View Dialysis	Harbor View Dialysis	818 6TH ST		RACINE	WI	53403-1176
1611	Affiliated	4451	Red River	Red River Dialysis (fka Shreveport South)	9205 LINWOOD AVE		SHREVEPORT	LA	71106-7006
1612	Affiliated	2392	South Dade Kidney Center	South Dade Kidney Center (Coral Reef)	11040 SW 184TH ST		CUTLER BAY	FL	33157-6602
1613	Affiliated	5604	Niagara Falls Memorial Dialysis	Niagara Falls Memorial Dialysis (was NF Kidney Care Center)	621 10TH ST		NIAGARA FALLS	NY	14301-1813
1614	Affiliated	5617	Silverado Dialysis	Silverado Dialysis	1100 TRANCAS ST	STE 266 AND 267	NAPA	CA	94558-2921
1615	Affiliated	5621	Prairie River Dialysis	Prairie River Dialysis	601 S CENTER AVE		MERRILL	WI	54452-3404
1616	Affiliated	5622	Stevens Point Dialysis	Stevens Point Dialysis	900 ILLINOIS AVE	5th FLR	STEVENS POINT	WI	54481-2885

1617	Affiliated	5623	Grand Seasons Dialysis	Grand Seasons Dialysis	190 GRAND SEASONS DR		WAUPACA	WI	54981-8219
1618	Affiliated	5624	Wausau Dialysis	Wausau Dialysis	2600 STEWART AVE	STE 144	WAUSAU	WI	54401-1403
1619	Affiliated	5625	Pine Crest Dialysis	Pine Crest Dialysis	232 S COURTNEY ST	STE 2	RHINELANDER	WI	54501-3319
1620	Affiliated	5626	Meadow Lane Dialysis	Meadow Lane Dialysis	1120 PINE ST		STANLEY	WI	54768-1297
1621	Affiliated	5627	Wisconsin Rapids Dialysis	Wisconsin Rapids Dialysis	1041B HILL ST		WISCONSIN RAPIDS	WI	54494-5221
1622	Affiliated	5628	Marshfield Dialysis	Marshfield Dialysis	123 NORTHRIDGE ST		MARSHFIELD	WI	54449-8341
1623	Affiliated	5629	Northern Star Dialysis	Northern Star Dialysis	311 ELM ST		WOODRUFF	WI	54568-9190
1624	Affiliated	5632	Ames Mary Greeley Dialysis	Ames Mary Greeley Dialysis	2322 E 13TH ST		AMES	IA	50010-5669
1625	Affiliated	5633	Marshalltown Mary Greeley Dialysis	Marshalltown Mary Greeley Dialysis	3120 S 2ND ST		MARSHALLTOWN	IA	50158-4614
1626	Affiliated	5634	Iowa Falls Mary Greeley Dialysis	Iowa Falls Mary Greeley Dialysis	701 WASHINGTON AVE		IOWA FALLS	IA	50126-2100
1627	Affiliated	5649	Dialysis Center of Hutchinson	Dialysis Center of Hutchinson	1901 N WALDRON ST		HUTCHINSON	KS	67502-1129
1628	Affiliated	5650	Amarillo Dialysis	Amarillo Dialysis	8604 S COULTER ST		AMARILLO	TX	79119-7379
1629	Affiliated	4495	Sagemeadow	Sagemeadow Dialysis (Houston)	10923 SCARSDALE BLVD		HOUSTON	TX	77089-6024
1630	Affiliated	5009	McKinney	McKinney Dialysis	4717 MEDICAL CENTER DR		MCKINNEY	TX	75069-1870
1631	Affiliated	4499	Scottsburg	Scottsburg Dialysis	1619 W MCCLAIN AVE		SCOTTSBURG	IN	47170-1161
1632	Affiliated	2108	Snake River	Snake River Dialysis Center (fka Blackfoot)	1491 PARKWAY DR		BLACKFOOT	ID	83221-1667

1633	Affiliated	5034	Southpoint	Southpoint Dialysis (aka Durham South)	415 W NC HWY 54		DURHAM	NC	27713-7516
1634	Affiliated	5643	Burlingame Dialysis	Burlingame Dialysis	1720 EL CAMINO REAL	STE 12	BURLINGAME	CA	94010-3225
1635	Affiliated	5644	Mills Dialysis	Mills Dialysis	100 S SAN MATEO DR		SAN MATEO	CA	94401-3805
1636	Affiliated	5646	Stuebenville	Steubenville Dialysis	4000 JOHNSON RD		STEUBENVILLE	OH	43952-2300
1637	Affiliated	5656	Premiere Kidney Center of Newark	Premiere Kidney Center of Newark	65 SOUTH TERRACE AVE		NEWARK	OH	43055-1355
1638	Affiliated	5029	Calvine	Calvine Dialysis (Sacramento)	8243 E STOCKTON BLVD	STE 1	SACRAMENTO	CA	95828-8200
1639	Affiliated	4445	Durham Corners dialysis	Durham Corners Dialysis (South Plainfield)	241 DURHAM AVE		SOUTH PLAINFIELD	NJ	07080-2504
1640	Affiliated	4475	Mt Morris	Mt Morris Dialysis (aka North Flint)	6141 N. SAGINAW RD		MOUNT MORRIS	MI	48458-2403
1641	Affiliated	2176	Grandview	Grandview Dialysis	13812 S US HIGHWAY 71		GRANDVIEW	MO	64030-3685
1642	Affiliated	4450	Lemoore	Lemoore Dialysis	1345 W BUSH ST		LEMOORE	CA	93245-3303
1643	Affiliated	5663	Middlebrook Dialysis	Middlebrook Dialysis	12401 MIDDLEBROOK RD	STE 16	GERMANTOWN	MD	20874-1523
1644	Affiliated	5664	Catoctin Dialysis	Catoctin Dialysis	405 W 7TH ST		FREDERICK	MD	21701-4505
1645	Affiliated	5648	Central New York Dialysis Center	Central New York Dialysis Center	910 ERIE BLVD E		SYRACUSE	NY	13210-1060
1646	Affiliated	5014	South Jackson	South Jackson Dialysis	46 HARTS BRIDGE RD		JACKSON	TN	38301-7512
1647	Affiliated	2344	Los Alamitos	Los Alamitos Dialysis	4141 KATELLA AVE		LOS ALAMITOS	CA	90720-3406

1648	Affiliated	5048	Robbinsdale	Robbinsdale Dialysis	3461 W BROADWAY AVE		ROBBINSDALE	MN	55422-2955
1649	Affiliated	5557	Oxnard	Oxnard Dialysis	1900 OUTLET CENTER DR		OXNARD	CA	93036-0677
1650	Affiliated	4429	Marked Tree	DNVO- Marked Tree- AR	216 HESTER PARKER DR		MARKED TREE	AR	72365-2023
1651	Affiliated	5669	Louisa Dialysis	Louisa Dialysis	2145 HWY 2565		LOUISA	KY	41230
1652	Affiliated	5670	Point Pleasant Dialysis	Point Pleasant Dialysis	3683 OHIO RIVER DR		POINT PLEASANT	WV	25550
1653	Affiliated	6802	Marion	Renal Care of Marion (P150)	2921 HWY 77	SUITE #8	MARION	AR	72364-2368
1654	Affiliated	6803	Osceola	Osceola Dialysis (P151)	1420 W KEISER AVE		OSCEOLA	AR	72370-2800
1655	Affiliated	6805	Cottonwood	Cottonwood Dialysis (P153)	203 S CANDY LANE		COTTONWOOD	AZ	86326-8115
1656	Affiliated	6808	Prescott	Prescott Dialysis (P157)	980 WILLOW CREEK RD.	SUITE 11	PRESCOTT	AZ	86301-1619
1657	Affiliated	6811	Naples	Collier County Dialysis (P160)	6625 HILLWAY CIRCLE		NAPLES	FL	34112
1658	Affiliated	6813	Cartersville	Cartersville Renal Center (P162)	203 S TENNESSEE ST		CARTERSVILLE	GA	30120
1659	Affiliated	6816	Arlington Heights Renal Center	Arlington Heights Renal Center (P165)	17 W GOLF RD		ARLINGTON HEIGHTS	IL	60006
1660	Affiliated	6817	Hazel Crest Renal Center	Hazel Crest Renal Center (P166)	3470 W 183RD ST		HAZEL CREST	IL	60429
1661	Affiliated	6818	Loop Renal Center	Loop Renal Center (P167)	1101 S CANAL ST	11TH FLR	CHICAGO	IL	60607
1662	Affiliated	6819	Markham Renal Center	Markham Renal Center (P168)	3053 W 159TH ST		MARKHAM	IL	60426

1663	Affiliated	6821	South Holland Renal Center	South Holland Renal Center (P170)	16136 S PARK AVE.		SOUTH HOLLAND	IL	60473
1664	Affiliated	6822	Waukegan Renal Center	Waukegan Renal Center (P171)	1616 GRAND AVE.	STE. C	WAUKEGAN	IL	60085
1665	Affiliated	6936	Waukegan Home Renal Center	Waukegan Home Training (P172)	1616 GRAND AVE	STE F	WAUKEGAN	IL	60085
1666	Affiliated	6825	Baton Rouge	East Baton Rouge Dialysis (P174)	1333 ONEAL LANE		BATON ROUGE	LA	70816
1667	Affiliated	6826	Houma Renal Center	Houma Dialysis (P175)	108 PICONE RD		HOUMA	LA	70363
1668	Affiliated	6827	Amesbury	Amesbury Renal Center (P177)	24 MORRILL PLACE		AMESBURY	MA	1913
1669	Affiliated	6828	North Andover	North Andover Renal Center (P178)	201 SUTTON ST		NORTH ANDOVER	MA	1845

1670	Affiliated	6829	Canton	Canton Renal Center (P179)	620 E PEACE ST		CANTON	MS	39046-4729
1671	Affiliated	6830	Hazlehurst	Hazlehurst Dialysis (P180)	201 N HALEY ST		HAZLEHURST	MS	39083
1672	Affiliated	6831	Jackson North	Jackson North Dialysis (P181)	571 BEASLEY RD	SUITE B	JACKSON	MS	39206-3042
1673	Affiliated	6832	Jackson South	Jackson South Dialysis (P182)	2460 TERRY RD	SUITE 27-J	JACKSON	MS	39204-5767
1674	Affiliated	6833	Jackson Southwest	Jackson Southwest Dialysis (P183)	1828 RAYMOND RD		JACKSON	MS	39204-4126
1675	Affiliated	6834	Lexington	Renal Care of Lexington (P184)	22579 DEPOT STREET		LEXINGTON	MS	39095
1676	Affiliated	6835	Munroe Falls	Munroe Falls Dialysis (P185)	265 N MAIN ST		MUNROE FALLS	OH	44262
1677	Affiliated	6836	Summit	Summit Renal Center (P186)	73 MASSILLON ROAD		AKRON	OH	44312
1678	Affiliated	6837	White Ponds	White Ponds Dialysis (P187)	534 WHITE POND DRIVE	SUITE A	AKRON	OH	44320
1679	Affiliated	6838	Philadelphia	Memphis Street Renal Center (P189)	3310 24 MEMPHIS ST		PHILADELPHIA	PA	19134-4510
1680	Affiliated	6839	Memphis Central Renal Center	Renal Care of Central Memphis (P190)	1331 UNION AVE.	SUITE 11	MEMPHIS	TN	38104-7559
1681	Affiliated	6840	Memphis Graceland Renal Center	Memphis Graceland Renal Center (P191)	4180 AUBURN RD		MEMPHIS	TN	38116-6202
1682	Affiliated	6841	Memphis Midtown Renal Center	Renal Care of Midtown Memphis (P192)	1166 MONROE AVE.		MEMPHIS	TN	38104-6614
1683	Affiliated	6842	Memphis North Renal Center	Renal Care of Memphis North (P193)	4913 RALEIGH COMMON DR.	SUITE 1	MEMPHIS	TN	38128-2485
1684	Affiliated	6844	Whitehaven Renal Center	Whitehaven Renal Center (P195)	3420 ELVIS PRESLEY BLVD.		MEMPHIS	TN	38116-3260
1685	Affiliated	6846	Edinburg	Edinburg Renal Center (P197)	4302 S SUGAR RD	STE 15	EDINBURG	TX	78539-9140
1686	Affiliated	6847	McAllen	Dialysis Care of McAllen (P198)	411 LINDBERG AVE		MCALLEN	TX	78501-2921

1687	Affiliated	6848	Weslaco	Weslaco Renal Center (P199)	910 SOUTH UTAH		WESLACO	TX	78596-4270
1688	Affiliated	6849	Marlton	Marlton Dialysis Center (P200)	769 E ROUTE 70		MARLTON	NJ	08053-2341
1689	Affiliated	6850	Lawrenceville	Lawrenceville Renal Center (P201)	1840 PRINCETON AVE		LAWRENCEVILLE	NJ	8648
1690	Affiliated	6851	Austell Renal Center	Austell Renal Center (P202)	3642 MARATHON CIRCLE		AUSTELL	GA	30106-6821
1691	Affiliated	6852	Bartlett Renal Center	Bartlett Renal Center (P203_P290_P8203)	2920 COVINGTON PIKE		MEMPHIS	TN	38128-6007
1692	Affiliated	6854	Beaverton	Beaverton Dialysis Center (P206)	15050 SW SUITE J KOLL PARKWAY		BEAVERTON	OR	97006-6002
1693	Affiliated	6858	Walker County	Walker County Dialysis (P212)	589 HIGHWAY 78W		JASPER	AL	35501
1694	Affiliated	6861	Lakewood	Manatee County Dialysis (P215)	8470 COOPER CREEK BVLD		UNIVERSITY PARK	FL	34201
1695	Affiliated	6862	Canton	Northwest Georgia Dialysis (P216)	260 HOSPITAL RD		CANTON	GA	30114
1696	Affiliated	6863	Buffalo Grove	Buffalo Grove Renal Center	1291 W DUNDEE RD		BUFFALO GROVE	IL	60089
1697	Affiliated	6864	Evanston Renal Center	Evanston Renal Center (P219)	1715 CENTRAL ST		EVANSTON	IL	60201
1698	Affiliated	6865	Schaumburg Renal Center	Schaumburg Renal Center (P220)	1156 S. ROSELLE ROAD		SCHAUMBURG	IL	60193
1699	Affiliated	6937	Schaumburg Home Renal Center	Schaumburg Home Training (P270)	17 W GOLF RD		ARLINGTON HEIGHTS	IL	60005
1700	Affiliated	6866	Blue River Valley	Blue River Valley Renal Center (P222)	2309 S MILLER STREET	SUITE 1	SHELBYVILLE	IN	46176-9350
1701	Affiliated	6867	Central Fort Wayne	Central Fort Wayne Dialysis (P223)	1940 BLUFTON RD		FORT WAYNE	IN	46809-1307
1702	Affiliated	6869	Huntington	Renal Care of Huntington (P225)	3040 WEST PARK DRIVE		HUNTINGTON	IN	46750-8956
1703	Affiliated	6870	Lake Avenue Dialysis Renal Center	Lake Avenue Dialysis (P226)	3525 LAKE AVE	STE 4	FORT WAYNE	IN	46805-5545

1704	Affiliated	6871	Marion County	Marion County Dialysis (P229)	3834 S EMERSON AVE	BLDG B	INDIANAPOLIS	IN	46203-5902
1705	Affiliated	6873	Quad Counties Dialysis	Quad Counties Dialysis (P232)	528 NORTH GRANDSTAFF		AUBURN	IN	46706-1660
1706	Affiliated	6875	South Anthony	South Anthony Dialysis (P234)	7017 SOUTH ANTHONY BLVD.		FORT WAYNE	IN	46816-2016
1707	Affiliated	6876	Brandon	Brandon Renal Center (P235)	101 CHRISTIAN DR		BRANDON	MS	39042-2678
1708	Affiliated	6877	Carthage	Renal Care of Carthage (P236)	312 ELLIS STREET		CARTHAGE	MS	39051
1709	Affiliated	6878	Las Cruces Renal Center	Las Cruces Renal Center (P237)	3961 E LOHMAN AVE	STE 29	LAS CRUCES	NM	88011-8272
1710	Affiliated	6879	Northeast Portland	Northeast Portland Renal Center (P240)	703 NE HANCOCK ST		PORTLAND	OR	97212-3955
1711	Affiliated	6880	Oregon Kidney Center	Dialysis Care of Portland (P241)	5318 NE IRVING		PORTLAND	OR	97213
1712	Affiliated	6881	Sunnyside	Sunnyside Renal Center (P242)	6902 SE LAKE ROAD	SUITE 1	MILWAUKIE	OR	97267-2148
1713	Affiliated	6882	Willamette Valley	Williamette Valley Renal Center (P243)	1510 DIVISION STREET	SUITE 9	OREGON CITY	OR	97045-1572
1714	Affiliated	6883	Northern Philadelphia	Northern Philadelphia Dialysis (P244)	5933 N BROAD ST		PHILADELPHIA	PA	19141
1715	Affiliated	6884	North Providence Renal Center	North Providence Renal Center (P246)	1635 MINERAL SPRING AVE		NORTH PROVIDENCE	RI	02904-4025
1716	Affiliated	6889	Alice Renal Center	Alice Renal Center (P252)	2345 ALICE REGIONAL BLVD.		ALICE	TX	78332-7291
1717	Affiliated	6890	Beeville Renal Center	Beeville Renal Center (P253)	1905 NW FRONTAGE		BEEVILLE	TX	78102-2954
1718	Affiliated	6891	Brownsville	Brownsville Renal Center (P254)	2945 CENTRAL BLVD		BROWNSVILLE	TX	78520-8958
1719	Affiliated	6892	Corpus Christi Renal Center	Corpus Christi Dialysis (P255)	2733 SWANTNER DR		CORPUS CHRISTI	TX	78404-2832
1720	Affiliated	6893	Riverside Renal Center	Riverside Renal Center (P256)	13434 LEOPARD RD. SUITE A17		CORPUS CHRISTI	TX	78410-4466

1721	Affiliated	6894	South Texas Renal Center	South Texas Renal Center (P257)	4301 S PADRE ISLAND DR		CORPUS CHRISTI TX	78411-4433
1722	Affiliated	6896	South Central Renal Center	Morgan Avenue Dialysis (P258)	2222 S MORGAN AVE	SUITE 114	CORPUS CHRISTI TX	78405-1900
1723	Affiliated	6898	Northeast Texas	Dialysis Care of Greenville (P260)	4805 WESLEY ST		GREENVILLE TX	75401-5649
1724	Affiliated	6899	Downtown Spokane	Downtown Spokane Renal Center (P261)	601 W 5TH ST	SUITE F	SPOKANE WA	99205
1725	Affiliated	6900	North Spokane	North Spokane Renal Center (P262)	12610 E MARIBEAU PRKWY	STE 1	SPOKANE WA	99216
1726	Affiliated	6901	Spokane Valley	Spokane Valley Renal Center (P263)	12610 EAST MIRABEAU PKY	SUITE 1	SPOKANE WA	99208-1450
1727	Affiliated	6902	Kansas City	Kansas City Renal Center (P264)	4333 MADISON AVE		KANSAS CITY MO	64111-3429
1728	Affiliated	6903	Butler Renal Center	Butler Renal Center (P266)	601 W NURSERY		BUTLER MO	64730
1729	Affiliated	6904	Harrisonville	Harrisonville Renal Center (P267)	308 GALAXIE AVE		HARRISONVILLE MO	64701-2084
1730	Affiliated	6905	Marshall Renal Center	Marshall Renal Center (P268)	359 W MORGAN		MARSHALL MO	65340
1731	Affiliated	6907	Akron Renal Center	Akron Renal Center (P272)	525 EAST MARKET STREET		AKRON OH	44304-1619
1732	Affiliated	6908	Kendallville Renal Center	Kendallville Renal Center (P274)	602 SAWYER RD		KENDALLVILLE IN	46755-2566
1733	Affiliated	6909	Greenwood Holly Renal Center	Greenwood Holly Renal Center (P276)	1533 HOLLY RD		CORPUS CHRISTI TX	78417-2010
1734	Affiliated	6910	Plainfield Renal Center	Plainfield Renal Center (P278)	8110 NETWORK DR		PLAINFIELD IN	46168-9024
1735	Affiliated	6911	Green Valley Renal Center	Green Valley Dialysis (P279)	1489 W WARM SPRINGS RD	STE 122	HENDERSON NV	89014-7637
1736	Affiliated	6912	Las Vegas Renal Center	Las Vegas Renal Center (P280)	2333 RENAISSANCE DR		LAS VEGAS NV	89119-6191

1737	Affiliated	6913	Lees Summit Renal Center	Lees Summit Renal Center (P281)	100 NE MISSOURI RD	STE 1	LEE' S SUMMIT	MO	64086-4702
1738	Affiliated	6914	Westport Renal Center	Westport Renal Center (P282)	3947 BROADWAY STREET		KANSAS CITY	MO	64111-2516
1739	Affiliated	6915	Greensboro Dialysis Center	Greensboro Dialysis Center (P284)	1220 SILOAM RD		GREENSBORO	GA	30642-0390
1740	Affiliated	5057	Forest Landing	DNVO-Forest Landing Dialysis (Harford Cty, Havre de Grace)-MD	2220 COMMERCE AVE	STE 1	FOREST HILL	MD	21050
1741	Affiliated	5033	University City	DNVO-University City Dialysis (Philadelphia)-PA	3020 MARKET ST	STE 13	PHILADELPHIA	PA	19104-2999
1742	Affiliated	2411	Parkland	DNVO-Parkland Dialysis-WA	311 140TH ST SO		TACOMA	WA	98444
1743	Affiliated	5094	Shelbyville Road	DNVO JV-Shelbyville Road Dialysis (DuPont, Louisville)-KY	4600 SHELBYVILLE RD	STE 31	LOUISVILLE	KY	40207
1744	Affiliated	5106	Fort Wayne West Dialysis	DNVO JV-Fort Wayne South-IN	302 E PETTIT AVE		FORT WAYNE	IN	468063007
1745	Affiliated	5671	Suburban Dialysis	ACQ-5671-NY	1542 MAPLE RD		WILLIAMSVILLE	NY	14221
1746	Affiliated	5672	Gates Circle Dialysis	ACQ-5672-NY	3 GATES CIRCLE	1ST FLR	BUFFALO	NY	14209
1747	Affiliated	5673	Orchard Park Dialysis	ACQ-5673-NY	3801 TAYLOR RD		ORCHARD PARK	NY	14127
1748	Affiliated	2420	TC Jester	DNVO-TC Jester-TX	1800 W 26TH ST	STE 11	HOUSTON	TX	77008-1419
1749	Affiliated	4436	Champions	DNVO-Champions Dialysis (Houston)-TX	4427 FM 1960 W	STE D	HOUSTON	TX	77068-3409

1750	Affiliated	5083	Magic City Dialysis MMC	DNVO-Magic City Dialysis (Birmingham)-AL	300 22ND ST SO		BIRMINGHAM	AL	35233-2209
1751	Affiliated	5084	Steel City Dialysis	DNVO-Steel City Dialysis (Birmingham)-AL	1809 AVE H (ENSLEY)		BIRMINGHAM	AL	35218
1752	Affiliated	5081	Jewel Dialysis	DNVO-Jewel Dialysis (Camellia, Birmingham)-AL	514 WEST TOWN PLAZA		BESSEMER	AL	35020
1753	Affiliated	660	Crystal River	Crystal River Dialysis	7435 W GULF TO LAKE HWY		CRYSTAL RIVER	FL	34429-7834
1754	Affiliated	1936	Southwest Kidney	Estrella Dialysis Center	8410 W THOMAS RD	STE 1 BLDG 1	PHOENIX	AZ	85037-3356
1755	Affiliated	1937	Gilbert Dialysis	Gilbert Dialysis Center	5222 E BASELINE RD	STE 14	GILBERT	AZ	85234-2963
1756	Affiliated	1938	Tempe Dialysis	Tempe Dialysis Center	2149 E WARNER RD	STE 11	TEMPE	AZ	85284-3496
1757	Affiliated	1939	Phoenix Dialysis	Phoenix Dialysis Center	337 E CORONADO RD	STE 11	PHOENIX	AZ	85004-1582
1758	Affiliated	1949	Arrowhead Lakes Dialysis	Arrowhead Lakes Dialysis	20325 N 51ST AVE	BLDG 11, STE 186	GLENDALE	AZ	85308-4625
1759	Affiliated	1952	Mountain Vista Dialysis	Mountain Vista Dialysis Center of Arizona	10238 E HAMPTON AVE	STE 18	MESA	AZ	85209-3317
1760	Affiliated	1977	South Meadows Dialysis Center	South Meadows Dialysis Center	10085 DOUBLE R BLVD	STE 16	RENO	NV	89521-4867
1761	Affiliated	1978	Reno Dialysis Center	Reno Dialysis Center	1500 E 2ND ST	STE 11	RENO	NV	89502-1189
1762	Affiliated	1979	Carson City Dialysis Center	Carson City Dialysis Center	3246 N. CARSON ST	STE 11	CARSON CITY	NV	89706-0248
1763	Affiliated	844	Sparks	Sparks Dialysis Center	4860 VISTA BLVD	STE 1	SPARKS	NV	89436-2817
1764	Affiliated	2015	Sierra Rose Dialysis	Sierra Rose Dialysis Center	685 SIERRA ROSE DR		RENO	NV	89511-2060
1765	Affiliated	2325	Northwest Tucson	Northwest Tucson Dialysis	2945 W INA RD	STE 15	TUCSON	AZ	85741-2366

1766	Affiliated	4355 Mesa	Central Mesa Dialysis Center	1134 E UNIVERSITY DR	STE 11	MESA	AZ	85203-8048
1767	Affiliated	4371 Raven	Raven Dialysis Center	3540 E BASELINE RD	STE 11	PHOENIX	AZ	85042-9628
1768	Affiliated	4374 Brookwood	Brookwood Dialysis Center	8910 N 43RD AVE	STE 17	GLENDALE	AZ	85302-5340
1769	Affiliated	4405 Ocotillo	Ocotillo Dialysis	975 W CHANDLER HEIGHTS RD	UNIT 11	CHANDLER	AZ	85248-5724
1770	Affiliated	4364 Maryvale	Maryvale Dialysis Center	4845 W MCDOWELL RD	STE 1A, 2A, 3A	PHOENIX	AZ	85035-4076
	Affiliated	1995 Winter Park Home PD Dialysis	Winter Park Home PD Dialysis	4100 METRIC DR	STE 2	WINTER PARK	FL	32792-6832
	Affiliated	4302 Lockport HHD PD At Home	Lockport Home Dialysis-PD	16626 W 159TH ST	STE 73	LOCKPORT	IL	60441-8019
	Affiliated	1972 HHD 6183 and PD 1972 in Shreveport	Shreveport Home Dialysis PD	1560 IRVING PL		SHREVEPORT	LA	71101-4604
	Affiliated	5618 Home Dialysis of Dayton - South	Home Dialysis of Dayton- South	4700 SPRINGBORO PIKE	STE 3	MORAINES	OH	45439-1964
	Affiliated	5619 Home Dialysis of Dayton	Home Dialysis of Dayton	627 S EDWIN C MOSES BLVD	STE 2B	DAYTON	OH	45417-3474
	Affiliated	144 Timpanogos Dialysis Center	Timpanogos Dialysis	1055 N 500 W	STE 222	PROVO	UT	84604-3329
	Affiliated	216 HOME DIALYSIS UNIT	Home Dialysis /CAPD Unit	825 S 8TH ST STE 1202		MINNEAPOLIS	MN	55404
	Affiliated	284 MANZANITA HOME TRAINING CENTER	Manzanita Home Training Center (fka North CAPD)	4005 MANZANITA AVE	STE 18	CARMICHAEL	CA	95608-1779
	Affiliated	408 WICHITA DIALYSIS CENTER	Wichita Dialysis Center-PD Program	909 N TOPEKA ST		WICHITA	KS	67214-3620
	Affiliated	978 CENTRAL TULSA DIALYSIS CENTER	Central Tulsa PD	1124 S SAINT LOUIS AVE		TULSA	OK	74120-5413

Affiliated	1748	ST PAUL CAPITAL PD	St. Paul Capital Dialysis at Home-PD (fka Capital PD Program)	555 PARK ST	STE 110	SAINT PAUL	MN	55103-2110
Affiliated	1787	ASH TREE PD	Ash Tree PD	2666 N GROVE INDUSTRIAL DR		FRESNO	CA	93727-1552
Affiliated	1821	EMERALD DIALYSIS	Emerald Dialysis PD (fka Hyde Park PD)	710 W 43RD ST		CHICAGO	IL	60609-3435
Affiliated	1822	OLYMPIA FIELDS DIALYSIS	Olympia Fields PD	4557B LINCOLN HWY	STE B	MATTESON	IL	60443-2385
Affiliated	1823	LAKE COUNTY DIALYSIS	Lake County PD	918 S MILWAUKEE AVE		LIBERTYVILLE	IL	60048-3229
Affiliated	1825	COMPREHENSIVE RENAL CARE-GARY	CRC-Gary PD	4802 BROADWAY		GARY	IN	46408-4509
Affiliated	1826	COMPREHENSIVE RENAL CARE-HAMMOND	CRC-Hammond PD	222 DOUGLAS ST		HAMMOND	IN	46320-1960
Affiliated	1827	COMPREHENSIVE RENAL CARE-VALPARAISO	CRC-Valparaiso PD	606 E LINCOLNWAY		VALPARAISO	IN	46383-5728
Affiliated	1828	COMPREHENSIVE RENAL CARE-MICHIGAN CITY	CRC-Michigan City PD	9836 WEST 400 NORTH		MICHIGAN CITY	IN	46360-2910
Affiliated	1829	MERRILLVILLE PD	Merrillville Dialysis PD	9223 TAFT ST		MERRILLVILLE	IN	46410-6911
Affiliated	1833	NAMPA DIALYSIS CENTER	Nampa Dialysis PD	846 PARKCENTRE WAY		NAMPA	ID	83651-1790
Affiliated	1834	TABLE ROCK DIALYSIS CENTER	Table Rock Dialysis PD	5610 W GAGE ST		BOISE	ID	83706
Affiliated	1835	TWIN FALLS DIALYSIS CENTER	Twin Falls Dialysis PD	1840 CANYON CREST DR		TWIN FALLS	ID	83301-3007
Affiliated	1836	TREASURE VALLEY DIALYSIS CENTER	Treasure Valley Dialysis PD & Home	3525 E LOUISE DR	STE 155	MERIDIAN	ID	83642-6303

Affiliated	1837	GATE CITY DIALYSIS CENTER	Gate City Dialysis PD	2001 BENCH RD		POCATELLO	ID	83201-2033
Affiliated	1838	FOUR RIVERS DIALYSIS CENTER	Four Rivers Dialysis PD	515 EAST LN		ONTARIO	OR	97914-3953
Affiliated	1869	LOWRY DIALYSIS CENTER	Lowry Dialysis PD	7465 E 1ST AVE	STE A	DENVER	CO	80230-6877
Affiliated	1905	BURLEY DIALYSIS CENTER	Burley Dialysis PD	741 N OVERLAND AVE		BURLEY	ID	83318-3440
Affiliated	1909	TURFWAY PD DIALYSIS	Turfway PD Training	11 SPIRAL DR	STE 15A	FLORENCE	KY	41042-1394
Affiliated	1910	MARYVILLE DIALYSIS	Maryville Dialysis PD	2136B VADALABENE DR		MARYVILLE	IL	62062-5632
Affiliated	1917	PDL ANNEX-PD	PDL Annex-PD (PDL=Physician Dialysis Lancaster)	2110 HARRISBURG PIKE	STE 310	LANCASTER	PA	17601-2644
Affiliated	1924	KANKAKEE COUNTY DIALYSIS	Kankakee County Dialysis PD	581 WILLIAM R LATHAM SR DR	STE 104	BOURBONNAIS	IL	60914-2439
Affiliated	1946	SNAKE RIVER DIALYSIS PD	DNVO-Snake River Dialysis PD (fka Blackfoot)-ID	1491 PARKWAY DR		BLACKFOOT	ID	83221-1667

Affiliated	1953	NORTH HIGHLANDS DIALYSIS CENTER	North Highlands Dialysis Center PD	4986 WATT AVE STE C		NORTH HIGHLANDS	CA	95660-5182
Affiliated	1966	AMERY DIALYSIS	Amery Dialysis PD	970 ELDEN AVE		AMERY	WI	54001-1448
Affiliated	1975	KIDNEY HOME CENTER	Kidney HOME (Home Operations & Medical Education) Center PD	2245 ROLLING RUN DR	STE 4	WINDSOR MILL	MD	21244-1858
Affiliated	1988	MEMPHIS DOWNTOWN DIALYSIS	Memphis Downtown Dialysis PD	2076 UNION AVE	FL 2	MEMPHIS	TN	38104-4138
Affiliated	1989	PGH HOME MODALITY COE	Pittsburgh Home Modality Center of Excellence PD	5171 LIBERTY AVE	STE A	PITTSBURGH	PA	15224-2254
Affiliated	2223	LAKE VILLA DIALYSIS	Lake Villa Dialysis PD	37809 N IL RTE 59		LAKE VILLA	IL	60046-7332
Affiliated	2232	RICHFIELD DIALYSIS	Richfield PD Program	6601 LYNDAL AVE S	STE 150	RICHFIELD	MN	55423-2490
Affiliated	2297	TOKAY HOME DIALYSIS CENTER	Tokay Home Dialysis-PD	777 S HAM LN	STE L	LODI	CA	95242-3593
Affiliated	2302	SPIVEY PERITONEAL AND HOME DIALYSIS CENTER	Spivey Peritoneal Dialysis and Home Dialysis Center	1423 STOCKBRIDGE RD	STE B	JONESBORO	GA	30236-3740
Affiliated	2326	WARRENSVILLE HEIGHTS PD DIALYSIS	Warrensville Heights PD Dialysis	4200 WARRENSVILLE CENTER RD	STE 210	WARRENSVILLE HEIGHTS	OH	44122-7000
Affiliated	2340	EASTGATE HOME	Eastgate Home Training	4435 AICHOLTZ RD	STE 800B	CINCINNATI	OH	45245-1692
Affiliated	2366	WESLEY CHAPEL DIALYSIS	Wesley Chapel Dialysis (PD ONLY)	2255 GREEN HEDGES WAY		WESLEY CHAPEL	FL	33544-8183
Affiliated	2400	FRESNO PD	Fresno At Home Center- PD Only	568 E HERNDON AVE	STE 301	FRESNO	CA	93720-2989

Affiliated	2456	GRAND HOME DIALYSIS PD/HHD	Grand Home Dialysis (PD only)	14674 W MOUNTAIN VIEW BLVD	STE 204	SURPRISE	AZ	85374-2708
Affiliated	2458	WASHINGTON COUNTY DIALYSIS	Washington County Dialysis PD Only (fka Hagerstown)	1136 OPAL CT		HAGERSTOWN	MD	21740-5940
Affiliated	2477	SAN JOSE PD	San Jose At Home-PD Only (Freestanding)	4400 STEVENS CREEK BLVD	STE 50	SAN JOSE	CA	95129-1104
Affiliated	2483	FREMONT HOME TRAINING JV	DNVO- Fremont At Home PD/ HHD-CA	39355 CALIFORNIA AVE		FREMONT	CA	94538
Affiliated	2490	HOME DIALYSIS OPTIONS OF BALDWIN COUNTY	Home Dialysis Options of Baldwin County-PD Only	27880 N MAIN ST	STE A	DAPHNE	AL	36526-7080
Affiliated	3299	TRI COUNTIES HOME TRAINING	Tri Counties Home Dialysis	433 S BRIDGE ST		VISALIA	CA	93277-2801
Affiliated	3640	WHITE OAK HOME TRAINING DIALYSIS	White Oak Home Training	5520 CHEVIOT RD	STE B	CINCINNATI	OH	45247-7069
Affiliated	3683	BUTLER COUNTY HOME TRAINING DIALYSIS	Butler County Home Training	3497 S DIXIE HWY		FRANKLIN	OH	45005-5717
Affiliated	3727	HANFORD AT HOME DIALYSIS	Hanford Home Dialysis PD	900 N DOUTY ST		HANFORD	CA	93230-3918
Affiliated	3735	HIOAKS DIALYSIS PD	Hioaks Dialysis PD	681 HIOAKS RD	STE B	RICHMOND	VA	23225-4043
Affiliated	3891	MEMPHIS EAST DIALYSIS PD	Memphis East Dialysis PD	50 HUMPHREYS CTR	STE 28B	MEMPHIS	TN	38120-2369
Affiliated	3892	NASHVILLE HOME TRAINING DIALYSIS PD	Nashville Home Training Dialysis PD	1919 CHARLOTTE AVE	STE 200	NASHVILLE	TN	37203-2245
Affiliated	3989	DEARBORN HOME DIALYSIS	Dearborn Home Dialysis-PD	22030 PARK ST		DEARBORN	MI	48124-2854
Affiliated	4308	GALLERIA HOME TRAINING DIALYSIS	Galleria Home Training Dialysis PD	9045 HIGHWAY 64	STE 102	LAKELAND	TN	38002-8394

			(aka SW Tennessee)						
Affiliated	4310	GREATER TAMPA AT HOME	Greater Tampa At Home PD	4204 N MACDILL AVE	STE 1B NORTH BLDG	TAMPA	FL	33607-6364	
Affiliated	4315	LORAIN COUNTY HOME DIALYSIS	DNVO-Lorain County Home Dialysis HHD/ PD-OH	824 E BROAD ST		ELYRIA	OH	44035-6557	
Affiliated	4375	GARFIELD HOME PROGRAM	Garfield Home Program (PD Only)	228 N GARFIELD AVE	STE 301	MONTEREY PARK	CA	91754-1709	
Affiliated	4453	BINZ HOME TRAINING	Binz Home Training - PD only	1213 HERMANN DR	STE 180	HOUSTON	TX	77004-7018	
Affiliated	5021	FRANKLIN AT HOME PD	Franklin At Home PD	301 CALLOWHILL ST		PHILADELPHIA	PA	19123-4117	
Affiliated	5028	CALDWELL DIALYSIS CENTER PD	Caldwell Dialysis Center	821 S SMEED PKWY		CALDWELL	ID	83605-5130	
Affiliated	5170	FORT WAYNE HOME DIALYSIS	DNVO-Fort Wayne Home Dialysis (PD- HHD)-IN	3124 E STATE BLVD	STE 5B	FORT WAYNE	IN	46805-4763	
Affiliated	5556	VISALIA AT HOME	Visalia At Home PD	1120 N CHINOWTH ST		VISALIA	CA	93291-7896	
Affiliated	5569	BLUEMOUND PD	Bluemound PD	601 N 99TH ST STE 300		WAUWATOSA	WI	53226-4362	
Affiliated	5581	WOODLAWN HOME PROGRAM PD	Woodlawn Home Program PD Only	5841 S MARYLAND AVE	RM L-026	CHICAGO	IL	60637-1447	
Affiliated	5599	BEVERLY DIALYSIS PD	Beverly PD	8109 S WESTERN AVE		CHICAGO	IL	60620-5939	
Affiliated	5600	WOODLAWN PEDIATRIC HOME PROGRAM	Woodlawn Pediatrics Home Program PD Only	5841 S MARYLAND AVE L026		CHICAGO	IL	60615	
Affiliated	5616	SPRINGHILL HOME TRAINING DIALYSIS	Springhill Home Training (PD Only)	3401 SPRINGHILL DR	STE 330	NORTH LITTLE ROCK	AR	72117-2945	
Affiliated	5647	FIRST COLONIAL DAVITA PD	First Colonial DaVita PD	1157 FIRST COLONIAL RD	STE 200	VIRGINIA BEACH	VA	23454-2432	

Affiliated	5898	AMHERST AT HOME	Amherst At Home	3200 COOPER FOSTER PRK RD W		LORAIN	OH	44053-3654
Affiliated	5900	CATHERDRAL CITY AT HOME	DNVO JV-Cathedral City At Home-CA	30-885 DATE PALM DR		CATHEDRAL CITY	CA	92234-2958
Affiliated	5904	ROBBINSDALE AT HOME	Robbinsdale At Home	3461 WEST BROADWAY AVE		ROBBINSDALE	MN	55422-2955
Affiliated	5905	NORTH PALM BEACH AT HOME	North Palm Beach At Home	2841 PGA BLVD		PALM BEACH GARDENS	FL	33410-2910
Affiliated	5907	SOUTHTOWNS AT HOME	Southtowns At Home (Hamburg)	4910 CAMP RD	STE 100	HAMBURG	NY	14075-2617
Affiliated	5909	FORT WAYNE HOME AT HOME	DNVO-Fort Wayne Home At Home	3124 E STATE BLVD	STE 5B	FORT WAYNE	IN	46805-4763
Affiliated	5910	FORT WAYNE WEST AT HOME	DNVO JV-Fort Wayne West At Home	4916 ILLINOIS RD	STE 118	FORT WAYNE	IN	46804-5116
Affiliated	5913	WINCHESTER AT HOME	Winchester At Home	2301 VALOR DR		WINCHESTER	VA	22601-6111
Affiliated	5914	MARSHFIELD AT HOME	Marshfield At Home	123 NORTHRIDGE ST		MARSHFIELD	WI	54449-8341
Affiliated	5915	MOSCOW AT HOME	Moscow At Home	212 RODEO DR	STE 110	MOSCOW	ID	83843-9791
Affiliated	5919	AVON AT HOME	Avon At Home	9210 ROCKVILLE RD	STE D	INDIANAPOLIS	IN	46234-2670
Affiliated	5923	NORTHSIDE AT HOME	Northside At Home	320 E NORTH AVE	4TH FLOOR SOUTH TOWER	PITTSBURGH	PA	15212-4756
Affiliated	5926	PANAMA CITY AT HOME	Panama City At Home	615 HIGHWAY 231		PANAMA CITY	FL	32405-4704
Affiliated	5927	MAGNOLIA OAKS AT HOME	Magnolia Oaks At Home (aka Hinesville, Satilla River)	2377 HIGHWAY 196 W	BLDG A MAGNOLIA OAKS	HINESVILLE	GA	31313-8036
Affiliated	5928	WESTBANK AT HOME	Westbank At Home	3631 BEHRMAN PL		NEW ORLEANS	LA	70114-0906
Affiliated	5931	ROCKSIDE AT HOME	Rockside At Home	4801 ACORN DR		INDEPENDENCE	OH	44131-2566

Affiliated	5932	WADSWORTH AT HOME	Wadsworth At Home	195 WADSWORTH RD STE 302	FOUNDERS HALL 3RD FLOOR	WADSWORTH	OH	44281-9504
Affiliated	5933	WOODLAWN AT HOME HHD	Woodlawn Home Program At Home	5841 S MARYLAND AVE	RM L-026	CHICAGO	IL	60637-1447
Affiliated	5934	WESLEY CHAPEL AT HOME	Wesley Chapel At Home	2255 GREEN HEDGES WAY		WESLEY CHAPEL	FL	33544-8183
Affiliated	5935	THOUSAND OAKS AT HOME	Thousand Oaks At Home	375 ROLLING OAKS DR	STE 100	THOUSAND OAKS	CA	91361-1024
Affiliated	5936	SIMI VALLEY AT HOME	Simi Valley At Home	2950 SYCAMORE DR	STE 100	SIMI VALLEY	CA	93065-1210
Affiliated	5937	MIDWEST FAIRBORN AT HOME	Midwest Fairborn At Home	1266 N BROAD ST		FAIRBORN	OH	45324
Affiliated	5938	NORTH ST LOUIS COUNTY AT HOME	North St. Louis County At Home	13119 NEW HALLS FERRY RD		FLORISSANT	MO	63033-3228
Affiliated	5939	BLUEMOUND AT HOME	Bluemound At Home	601 N 99TH ST	STE 110	WAUWATOSA	WI	53226
Affiliated	5940	MESA COUNTY AT HOME	Mesa County At Home (Grand Junction)	561 25 RD	STE D	GRAND JUNCTION	CO	81505-1303
Affiliated	5942	PLANO AT HOME	Plano At Home	481 SHILOH RD	STE 100	PLANO	TX	75074-7231

Affiliated	5943	WEST BLOOMFIELD AT HOME	West Bloomfield At Home	6010 W MAPLE RD STE 215		WEST BLOOMFIELD	MI	48322-4406
Affiliated	5945	BINZ HOME TRAINING AT HOME	Binz Home Training At Home	1213 HERMANN DR STE 180		HOUSTON	TX	77004-7070
Affiliated	5947	HANNIBAL AT HOME	Hannibal At Home	3140 PALMYRA RD		HANNIBAL	MO	63401-2204
Affiliated	5949	BEVERLY AT HOME	Beverly At Home	8109 SOUTH WESTERN AVE		CHICAGO	IL	60620-5939
Affiliated	5950	NORTH JACKSON AT HOME	North Jackson At Home (fka Stonegate)	217 STERLING FARM DR		JACKSON	TN	38305-5727
Affiliated	5951	PORTAGE AT HOME	Portage At Home	5823 US HIGHWAY 6		PORTAGE	IN	46368-4851
Affiliated	5952	ROGUE VALLEY AT HOME	Rogue Valley At Home	760 GOLF VIEW DR UNIT 100		MEDFORD	OR	97504-9685
Affiliated	5953	EVERETT AT HOME	Everett At Home	8130 EVERGREEN WAY STE C		EVERETT	WA	98203-6419
Affiliated	5954	OLYMPIA AT HOME	Olympia At Home	335 COOPER POINT ROAD NW	SUITE 105	OLYMPIA	WA	98502-4436
Affiliated	5955	LORAIN COUNTY HOME AT HOME	DNVO-Lorain County Home At Home	824 EAST BROAD ST		ELYRIA	OH	44035-6559
Affiliated	5956	RENAISSANCE AT HOME	Renaissance At Home	1840 DARBY DR		FLORENCE	AL	35630-2623
Affiliated	5957	POOLER AT HOME	Pooler At Home	54 TRADERS WAY	LIVE OAK PLAZA	POOLER	GA	31322-4158
Affiliated	5958	GULF SHORES AT HOME	Gulf Shores At Home	3947 GULF SHORES PKWY	UNIT 150	GULF SHORES	AL	36542-2735
Affiliated	5959	FRANKLIN AT HOME	Franklin At Home	301 CALLOWHILL ST		PHILADELPHIA	PA	19123-4117
Affiliated	5961	RENO AT HOME	Reno At Home	1500 EAST 2ND STREET	STE 101, 106	RENO	NV	89502-1189
Affiliated	5963	JACKSONVILLE SOUTH AT HOME	Jacksonville South At Home	14965 OLD SAINT	UNIT 114	JACKSONVILLE	FL	32258-9481

				AUGUSTINE RD				
Affiliated	5964	LAKE ST LOUIS AT HOME	Lake St. Louis At Home	200 BREVCO PLZ	STE 202	LAKE ST LOUIS	MO	63367-2950
Affiliated	5965	UNION CITY AT HOME (GA)	Union City At Home (GA)	6851 SHANNON PARKWAY	STE 200	UNION CITY	GA	30291-2049
Affiliated	5966	WEBER VALLEY AT HOME	Weber Valley At Home	1920 W 250TH N		MARRIOTT- SLATERVILLE	UT	84404-9233
Affiliated	5968	PARKER DIALYSIS CENTER	Parker At Home	10371 S PARK GLENN WAY	STE 180	PARKER	CO	80138-3871
Affiliated	5971	KENNESTONE AT HOME	Kennestone At Home	200 COBB PKWY N	STE 318	MARIETTA	GA	30062-3558
Affiliated	5973	NORTH COLORADO SPRINGS AT HOME	North Colorado Springs At Home	6071 E WOODMEN RD	STE 100	COLORADO SPRINGS	CO	80923-2610
Affiliated	5974	PGH HOME MODALITY COD/HHD	Pittsburgh Home Modality Center of Excellence At Home	5171 LIBERTY AVE	STE A	PITTSBURGH	PA	15224-2254
Affiliated	5977	FRESNO AT HOME CENTER	Fresno At Home Center-HHD Only	568 E HERNDON AVE	STE 301	FRESNO	CA	93720-2989
Affiliated	5978	BLUFF CITY AT HOME	Bluff City At Home	2400 LUCY LEE PKWY	STE E	POPLAR BLUFF	MO	63901-2427
Affiliated	5979	NORTH METRO AT HOME	North Metro At Home	12365 HURON ST	STE 500	WESTMINSTER	CO	80234-3498
Affiliated	5980	FIVE STAR AT HOME	Five Star At Home (fka Las Vegas Multi- Care)	2400 TECH CENTER CT		LAS VEGAS	NV	89128-0804
Affiliated	5981	KIDNEY HOME AT HOME	Kidney HOME (Home Operations & Medical Education) At Home	2245 ROLLING RUN DR	STE 3	WINDSOR MILL	MD	21244-1858
Affiliated	5982	FARGO AT HOME	Fargo At Home	4474 23RD AVE S	STE M	FARGO	ND	58104-8795

Affiliated	5983	GALLERIA HOME TRAINING AT HOME	Galleria Home Training At Home	9045 HIGHWAY 64	STE 102	LAKELAND	TN	38002-8394
Affiliated	5986	BELDEN COMMUNITY AT HOME	Belden Community At Home	4685 FULTON DR NW		CANTON	OH	44718-2379
Affiliated	5987	MAINPLACE AT HOME	Mainplace At Home	972 W TOWN AND COUNTRY RD		ORANGE	CA	92868-4714
Affiliated	5988	PENNSAUKEN AT HOME	Pennsauken At Home	7024 KAIGHNS AVE		PENNSAUKEN	NJ	08109-4417
Affiliated	5989	JEDBURG AT HOME	Jedburg At Home	2897 W 5TH NORTH ST		SUMMERVILLE	SC	29483-9674
Affiliated	5993	CAPE CORAL SOUTH AT HOME	Cape Coral South At Home	3046 DEL PRADO BLVD S	STE 4A	CAPE CORAL	FL	33904-7232
Affiliated	5994	GREATER TAMPA HOME AT HOME	Greater Tampa At Home	4204 N MACDILL AVE	STE 1B NORTH BLDG	TAMPA	FL	33607-6364
Affiliated	5995	ATHENS EAST AT HOME	Athens East At Home	2026 S MILLEDGE AVE	STE A2	ATHENS	GA	30605-6480
Affiliated	5996	UNIVERSITY UNIT RIVERSIDE AT HOME	University Unit Riverside At Home	1045 WESTGATE DR	STE 90	SAINT PAUL	MN	55114-1079
Affiliated	5997	WOODRIDGE AT HOME	Woodridge Home At Home	7425 JANES AVE	STE 103	WOODRIDGE	IL	60517-2356
Affiliated	5998	INDY SOUTH AT HOME	Indy South At Home	972 EMERSON PKWY	STE E	GREENWOOD	IN	46143-6202
Affiliated	5999	LOCKPORT HOME AT HOME	Lockport Home Dialysis At Home	16626 W 159TH ST	STE 703	LOCKPORT	IL	60441-8019
Affiliated	6000	CAMELBACK AT HOME HEMO	Camelback Dialysis At Home	7321 E OSBORN DR		SCOTTSDALE	AZ	85251-6418
Affiliated	6002	WEST BOUNTIFUL DIALYSIS AT HOME	West Bountiful Dialysis At Home	724 W 500 S	STE 300	WEST BOUNTIFUL	UT	84087-1471

Affiliated	6002	WEST BOUNTIFUL DIALYSIS AT HOME	West Bountiful Dialysis At Home	724 W 500 S STE 300	WEST BOUNTIFUL	UT	84087-1471
Affiliated	6004	CORNERSTONE DIALYSIS AT HOME	Cornerstone Dialysis At Home	23857 GREENFIELD RD	SOUTHFIELD	MI	48075-3122
Affiliated	6006	DIALYSIS CARE OF MOORE COUNTY AT HOME	Dialysis Care of Moore County At Home (aka Pinehurst)	16 REGIONAL DR	PINEHURST	NC	28374-8850
Affiliated	6007	HOME DIALYSIS AT HOME	Home Dialysis At Home (Minneapolis)	825 S 8TH ST STE 1224	MINNEAPOLIS	MN	55404-1223
Affiliated	6009	ST PAUL CAPITOL DIALYSIS AT HOME	St Paul Capital Dialysis At Home	555 PARK ST STE 210	SAINT PAUL	MN	55103-2193
Affiliated	6011	BALLENGER PT AT HOME	Ballenger Pt. At Home	2262 S BALLENGER HWY	FLINT	MI	48503-3447
Affiliated	6012	LAKEWOOD AT HOME	Lakewood At Home	1750 PIERCE ST	LAKEWOOD	CO	80214-1434
Affiliated	6013	MED-CENTER AT HOME	Med-Center at Home	7580 FANNIN ST	HOUSTON	TX	77054-1939
Affiliated	6014	UTAH VALLEY DIALYSIS AT HOME	Utah Valley Dialysis At Home	1055 N 500 W STE 221	PROVO	UT	84604-3305
Affiliated	6015	LOWRY AT HOME	Lowry At Home	7465 E 1ST AVE	DENVER	CO	80230-6877
Affiliated	6016	MANZANITA AT HOME	Manzanita At Home	4005 MANZANITA AVE	CARMICHAEL	CA	95608-1779
Affiliated	6017	FIRST COLONIAL DAVITA AT HOME	First Colonial DaVita At Home	1157 FIRST COLONIAL RD	VIRGINIA BEACH	VA	23454-2432
Affiliated	6019	LAKEWOOD WASHINGTON AT HOME	Lakewood Washington At Home	5919 LAKEWOOD TOWNE CENTER BLVD SW	LAKEWOOD	WA	98499-6513

Affiliated	6020	GRAPEVINE AT HOME	Grapevine At Home	1600 W NORTHWEST HWY	STE 100	GRAPEVINE TX	76051-8131
Affiliated	6021	GRAND RAPIDS AT HOME (CHERRY STREET)	Grand Rapids At Home (Cherry Street)	801 CHERRY ST SE		GRAND RAPIDS MI	49506-1440
Affiliated	6022	FEDERAL WAY AT HOME	Federal Way At Home	1015 S 348TH ST		FEDERAL WAY WA	98003-7078
Affiliated	6023	CENTURY CITY AT HOME	Century City At Home	10630 SANTA MONICA BLVD		LOS ANGELES CA	90025
Affiliated	6024	REDDING AT HOME	Redding At Home	1876 PARK MARINA DR		REDDING CA	96001-0913
Affiliated	6025	OLYMPIA FIELDS AT HOME	Olympia Fields At Home	4557B LINCOLN HWY	STE B	MATTESON IL	60443-2318
Affiliated	6026	MT VERNON AT HOME	Mount Vernon At Home	1800 JEFFERSON AVE		MOUNT VERNON IL	62864-4300
Affiliated	6028	YAKIMA AT HOME	Yakima At Home	1221 N 16TH AVE		YAKIMA WA	98902-1347
Affiliated	6029	MID-COLUMBIA AT HOME	Mid Columbia At Home	6825 BURDEN BLVD	STE A	PASCO WA	99301-9584
Affiliated	6030	GEORGETOWN ON THE POTOMAC AT HOME	Georgetown on the Potomac At Home	3323 K STREET NW	SUITE 110	WASHINGTON DC	20007
Affiliated	6031	SIOUX FALLS AT HOME	Sioux Falls At Home	800 E 21ST ST		SIOUX FALLS SD	57105-1016

Affiliated	6032	HILLSBORO AT HOME	Hillsboro At Home	2500 NW 229TH AVE	STE 300 BLDG E	HILLSBORO	OR	97124-7516
Affiliated	6033	PIKES PEAK AT HOME	Pikes Peak At Home	2002 LELARAY ST	STE 130	COLORADO SPRINGS	CO	80909-2804
Affiliated	6034	WALNUT CREEK AT HOME	Walnut Creek At Home	400 N WIGET LN		WALNUT CREEK	CA	94598-2408
Affiliated	6035	SAN ANTONIO AT HOME	San Antonio At Home	5284 MEDICAL DR	STE 100	SAN ANTONIO	TX	78229-4849
Affiliated	6036	SANTA ROSA AT HOME	Santa Rosa At Home	5819 HIGHWAY 90		MILTON	FL	32583-1763
Affiliated	6037	DUNMORE AT HOME	Dunmore At Home	1212 ONEILL HWY		DUNMORE	PA	18512-1717
Affiliated	6038	PALMERTON AT HOME	Palmerton At Home	185 DELAWARE AVE	STE C	PALMERTON	PA	18071-1716
Affiliated	6039	LONGVIEW AT HOME	Longview At Home	425 N FREDONIA ST		LONGVIEW	TX	75601-6464
Affiliated	6040	JB ZACHARY AT HOME	JB Zachary At Home	333 CASSELL DR	STE 2300	BALTIMORE	MD	21224-6815
Affiliated	6041	MEMPHIS EAST AT HOME	Memphis East At Home	50 HUMPHREYS CTR	STE 28B	MEMPHIS	TN	38120-2369
Affiliated	6042	PLAINFIELD AT HOME	Plainfield At Home	1200 RANDOLPH RD	KENYAN HOUSE	PLAINFIELD	NJ	07060-3361
Affiliated	6045	CHARLOTTE AT HOME	Charlotte (NC) At Home	2321 W MOREHEAD ST	STE 102	CHARLOTTE	NC	28208-5145
Affiliated	6046	DALY CITY AT HOME	Daly City At Home	1498 SOUTHGATE AVE	STE 101	DALY CITY	CA	94015-4015
Affiliated	6047	SALEM AT HOME	Salem At Home (OR)	3550 LIBERTY RD S	STE 100	SALEM	OR	97302-5700
Affiliated	6048	OMAHA WEST AT HOME	Omaha West At Home	13014 W DODGE RD		OMAHA	NE	68154-2148
Affiliated	6049	TUCSON EAST AT HOME	Tucson East At Home	6420 E BROADWAY BLVD	STE C300	TUCSON	AZ	85710-3512
Affiliated	6050	WHITE OAK AT HOME	White Oak At Home	5520 CHEVIOT RD	STE B	CINCINNATI	OH	45247-7069
Affiliated	6051	BELPRE AT HOME	Belpre At Home	2906 WASHINGTON BLVD		BELPRE	OH	45714-1848
Affiliated	6052	BIRMINGHAM AT HOME	Birmingham At Home	2101 7TH AVE S		BIRMINGHAM	AL	35233-3105

Affiliated	6053	STAMFORD AT HOME	Stamford At Home	30 COMMERCE RD		STAMFORD	CT	06902-4506
Affiliated	6054	WHITEBRIDGE AT HOME	Whitebridge At Home	103 WHITE BRIDGE PIKE	STE 6	NASHVILLE	TN	37209-4539
Affiliated	6055	ZANESVILLE AT HOME	Zanesville At Home	3120 NEWARK RD		ZANESVILLE	OH	43701-9659
Affiliated	6056	TYSON' S CORNER AT HOME	Tyson' s Corner At Home	8391 OLD COURTHOUSE RD	STE 160	VIENNA	VA	22182-3819
Affiliated	6057	BRADFORD AT HOME	Bradford At Home	665 E MAIN ST		BRADFORD	PA	16701-1869
Affiliated	6059	NORTHLAND AT HOME	Northland At Home	2750 CLAY EDWARDS DR	STE 515	N KANSAS CITY	MO	64116-3258
Affiliated	6060	LAKE WORTH AT HOME	Lake Worth At Home	2459 S CONGRESS AVE	STE 100	PALM SPRINGS	FL	33406-7616
Affiliated	6061	MEADVILLE AT HOME	Meadville At Home	19050 PARK AVENUE PLZ		MEADVILLE	PA	16335-4012
Affiliated	6063	WILLINGBORO AT HOME	Willingboro At Home	230 VAN SCIVER PKWY		WILLINGBORO	NJ	08046-1131
Affiliated	6064	DERENNE AT HOME	DeRenne At Home	5303 MONTGOMERY ST		SAVANNAH	GA	31405-5138
Affiliated	6065	BRUNSWICK AT HOME	Brunswick At Home	53 SCRANTON CONNECTOR		BRUNSWICK	GA	31525-1862
Affiliated	6067	AIKEN AT HOME	Aiken At Home	775 MEDICAL PARK DR		AIKEN	SC	29801-6306
Affiliated	6068	BRIDGEPORT AT HOME	Bridgeport At Home	900 MADISON AVE		BRIDGEPORT	CT	06606-5534
Affiliated	6069	ST PETERSBURG AT HOME	St Petersburg At Home	2850 34TH ST S		ST PETERSBURG	FL	33711-3817
Affiliated	6070	DENISON AT HOME	Denison At Home	1220 REBA MACENTIRE LN		DENISON	TX	75020-9057
Affiliated	6072	ATLANTIC AT HOME	Atlantic At Home	6 INDUSTRIAL WAY W	STE B	EATONTOWN	NJ	07724-2258
Affiliated	6073	NEWTOWN AT HOME	Newtown At Home (fka St. Mary)	60 BLACKSMITH RD		NEWTOWN	PA	18940-1847
Affiliated	6075	FOX RIVER AT HOME	Fox River At Home	1910 RIVERSIDE DR		GREEN BAY	WI	54301-2319
Affiliated	6076	TOKAY AT HOME	Tokay At Home	777 S HAM LN	STE L	LODI	CA	95242-3593

Affiliated	6077	CAPITAL CITY AT HOME	Capital City At Home	307 N 46TH ST		LINCOLN	NE	68503-3714
Affiliated	6081	GREATER MIAMI AT HOME	Greater Miami At Home	160 NW 176TH ST	STE 100	MIAMI	FL	33169-5023
Affiliated	6083	EFFINGHAM AT HOME	Effingham At Home	904 MEDICAL PARK DR	STE 1	EFFINGHAM	IL	62401-2193
Affiliated	6084	SPRINGFIELD CENTRAL AT HOME	Springfield Central At Home	932 N RUTLEDGE ST		SPRINGFIELD	IL	62702-3721
Affiliated	6085	DECATUR EAST WOOD AT HOME	Decatur East Wood At Home	794 E WOOD ST		DECATUR	IL	62523-1155
Affiliated	6086	ILLINI AT HOME	Illini At Home	507 E UNIVERSITY AVE		CHAMPAIGN	IL	61820-3828
Affiliated	6087	JANESVILLE AT HOME	Janesville At Home	1305 WOODMAN RD		JANESVILLE	WI	53545-1068
Affiliated	6088	NEW HAVEN AT HOME	New Haven At Home	100 CHURCH ST S	STE C	NEW HAVEN	CT	06519-1703
Affiliated	6089	NASHUA AT HOME	Nashua At Home	38 TYLER ST	STE 100	NASHUA	NH	03060-2912
Affiliated	6090	EAST EVANSVILLE AT HOME	East Evansville At Home	1312 PROFESSIONAL BLVD		EVANSVILLE	IN	47714-8007
Affiliated	6095	BROOKRIVER AT HOME	Brookriver At Home	8101 BROOKRIVER DR		DALLAS	TX	75247-4003
Affiliated	6098	METRO EAST AT HOME	Metro East At Home	5105 W MAIN ST		BELLEVILLE	IL	62226-4728
Affiliated	6099	MARION AT HOME	Marion At Home	324 S 4TH ST		MARION	IL	62959-1241
Affiliated	6100	ROXBURY AT HOME	Roxbury At Home	622 ROXBURY RD		ROCKFORD	IL	61107-5089
Affiliated	6101	SYCAMORE AT HOME	Sycamore At Home	2200 GATEWAY DR		SYCAMORE	IL	60178-3113
Affiliated	6103	WESTVIEW AT HOME	Westview At Home	3749 COMMERCIAL DR	STE B	INDIANAPOLIS	IN	46222-1676
Affiliated	6105	OCALA AT HOME	Ocala At Home	2860 SE 1ST AVE		OCALA	FL	34471-0406
Affiliated	6106	COMPLETE CARE AT HOME	Complete Care At Home	7850 W SAMPLE RD		MARGATE	FL	33065-4710

Affiliated	6107	INTERAMERICAN AT HOME	InterAmerican At Home	7815 CORAL WAY	STE 115	MIAMI	FL	33155-6541
Affiliated	6109	PURCELLVILLE AT HOME	Purcellville At Home	280 N HATCHER AVE		PURCELLVILLE	VA	20132-3193
Affiliated	6110	TABLE ROCK AT HOME	Table Rock At Home	5610 GAGE ST	STE B	BOISE	ID	83706
Affiliated	6111	TWIN FALLS AT HOME	Twin Falls At Home	1840 CANYON CREST DR		TWIN FALLS	ID	83301-3007
Affiliated	6113	FOUR RIVERS AT HOME	Four Rivers At Home	515 EAST LN		ONTARIO	OR	97914-3953
Affiliated	6114	OLYMPIC VIEW AT HOME	Olympic View At Home	125 16TH AVE E	FL 5	SEATTLE	WA	98112-5211
Affiliated	6115	SPIVEY AT HOME	Spivey At Home	1423 STOCKBRIDGE RD	STE B	JONESBORO	GA	30236-3740
Affiliated	6116	EAST DES MOINES AT HOME	East Des Moines At Home	1301 PENNSYLVANIA AVE	STE 208	DES MOINES	IA	50316-2365
Affiliated	6118	KETTERING AT HOME	Kettering At Home	5721 BIGGER RD		KETTERING	OH	45440-2752
Affiliated	6119	CITRUS VALLEY AT HOME	Citrus Valley At Home	894 HARDT ST		SAN BERNARDINO	CA	92408-2854
Affiliated	6124	MERIDIAN PARK AT HOME	Meridian Park At Home	19255 SW 65TH AVE	STE 100	TUALATIN	OR	97062-9712

Affiliated	6125	MARYVILLE AT HOME	Maryville At Home	2136B VADALABENE DR		MARYVILLE	IL	62062-5632
Affiliated	6128	PDI-WORCESTER AT HOME	PDI-Worcester At Home	19 GLENNIE ST	STE A	WORCESTER	MA	01605-3918
Affiliated	6129	PDI-ROCKY HILL AT HOME	PDI-Rocky Hill At Home	30 WATERCHASE DR		ROCKY HILL	CT	06067-2110
Affiliated	6133	WICHITA AT HOME	Wichita At Home	909 N TOPEKA ST		WICHITA	KS	67214-3620
Affiliated	6134	ASHEVILLE KIDNEY AT HOME	Asheville Kidney At Home	1600 CENTERPARK DR		ASHEVILLE	NC	28805-6206
Affiliated	6136	STRONGSVILLE AT HOME	Strongsville At Home	17792 PEARL RD		STRONGSVILLE	OH	44136-6909
Affiliated	6137	BATON ROUGE AT HOME	DSI Divest-Baton Rouge At Home	3888 NORTH BLVD	STE 101	BATON ROUGE	LA	70806-3824
Affiliated	6138	WEST BROADWAY DIALYSIS AT HOME	West Broadway At Home	720 W BROADWAY	STE 200	LOUISVILLE	KY	40202-3245
Affiliated	6140	BRONX AT HOME	Bronx At Home	1615 EASTCHESTER RD		BRONX	NY	10461-2603
Affiliated	6142	CLEVE HILL AT HOME	Cleve Hill At Home	1461 KENSINGTON AVE		BUFFALO	NY	14215-1436
Affiliated	6144	WHITE PLAINS AT HOME	White Plains At Home	200 HAMILTON AVE	STE 13B	WHITE PLAINS	NY	10601-1859
Affiliated	6146	LAKE VILLA AT HOME	Lake Villa At Home	37809 N IL ROUTE 59		LAKE VILLA	IL	60046-7332
Affiliated	6148	TULSA AT HOME	Tulsa At Home	4436 S HARVARD AVE		TULSA	OK	74135-2605
Affiliated	6151	LITHONIA AT HOME	Lithonia At Home	2485 PARK CENTRAL BLVD		DECATUR	GA	30035-3902
Affiliated	6152	LANHAM AT HOME	Lanham At Home	8855 ANNAPOLIS RD	STE 200	LANHAM	MD	20706-2919
Affiliated	6153	HAMMOND AT HOME	Hammond At Home	222 DOUGLAS ST		HAMMOND	IN	46320-1960

Affiliated	6156	UNION CITY CENTER AT HOME (CA)	Union City Center At Home (CA)	32930 ALVARADO NILES RD	STE 300	UNION CITY	CA	94587-8101
Affiliated	6157	CHICO AT HOME	Chico At Home	530 COHASSET RD		CHICO	CA	95926-2212
Affiliated	6158	MONTCLAIR AT HOME	Montclair At Home	5050 PALO VERDE ST	STE 100	MONTCLAIR	CA	91763-2333
Affiliated	6161	PDI - LANCASTER AT HOME	PDI-Lancaster At Home	1412 E KING ST		LANCASTER	PA	17602-3240
Affiliated	6162	PDI JOHNSTOWN AT HOME	PDI-Johnstown At Home	344 BUDFIELD ST		JOHNSTOWN	PA	15904-3214
Affiliated	6163	CAMP HILL AT HOME	Camp Hill At Home	425 N 21ST ST	PLAZA 21 BLDG 1ST FL	CAMP HILL	PA	17011-2202
Affiliated	6164	PDI MONTGOMERY AT HOME	PDI- Montgomery At Home	1001 FOREST AVE		MONTGOMERY	AL	36106-1181
Affiliated	6165	FAIRFAX AT HOME	Fairfax At Home	8501 ARLINGTON BLVD	STE 100	FAIRFAX	VA	22031-4625
Affiliated	6170	WEST SACRAMENTO AT HOME	West Sacramento At Home	3450 INDUSTRIAL BLVD	STE 100	WEST SACRAMENTO	CA	95691-5003
Affiliated	6171	EAST MACON AT HOME	East Macon At Home	165 EMERY HWY	STE 101	MACON	GA	31217-3666
Affiliated	6178	GERMANTOWN AT HOME	Germantown At Home	20111 CENTURY BLVD	STE C	GERMANTOWN	MD	20874-9165
Affiliated	6180	SEDC- WILMINGTON AT HOME	SEDC- Wilmington (NC) At Home	2215 YAUPON DR		WILMINGTON	NC	28401-7334
Affiliated	6182	HERMISTON COMMUNITY AT HOME	Hermiston Community At Home	1155 W LINDA AVE		HERMISTON	OR	97838-9601
Affiliated	6183	SHREVEPORT HHD LA	Shreveport Home Dialysis At Home	1560 IRVING PL		SHREVEPORT	LA	71101-4604
Affiliated	6184	DOWNTOWN SAN ANTONIO AT HOME	Downtown San Antonio At Home	615 E QUINCY ST		SAN ANTONIO	TX	78212
Affiliated	6186	COLUMBIA MO AT HOME	RTC-Columbia (MO) At Home	1701 E BROADWAY	STE G102	COLUMBIA	MO	65201-8029

Affiliated	6188	REGENCY AT HOME	Regency At Home (fka Jacksonville)	9535 REGENCY SQUARE BLVD N		JACKSONVILLE	FL	32225-8128
Affiliated	6193	WEST GEORGIA AT HOME	West Georgia At Home (fka Columbus (GA))	1216 STARK AVE		COLUMBUS	GA	31906-2500
Affiliated	6194	BUFORD AT HOME	Buford At Home	1550 BUFORD HWY	STE 1E	BUFORD	GA	30518-3666
Affiliated	6195	KALAMAZOO WEST AT HOME	Kalamazoo West At Home	1040 N 10TH ST		KALAMAZOO	MI	49009-6149
Affiliated	6196	SOUTH VALLEY AT HOME	South Valley At Home	17815 VENTURA BLVD	STE 100	ENCINO	CA	91316-3600
Affiliated	6204	QUEENS VILLAGE AT HOME	Queens Village At Home	22202 HEMPSTEAD AVE	STE 170	QUEENS VILLAGE	NY	11429-2123
Affiliated	6207	LANSING AT HOME-MI	Lansing Home Hemodialysis At Home	1675 WATERTOWER PL	STE 700	EAST LANSING	MI	48823-6397
Affiliated	6208	SOUTH COUNTY AT HOME	South County At Home (Deaconess)	4145 UNION RD		SAINT LOUIS	MO	63129-1064
Affiliated	6211	TACOMA AT HOME	Tacoma At Home	3401 S 19TH ST		TACOMA	WA	98405-1909
Affiliated	6213	CEDAR PARK AT HOME	Cedar Park At Home (fka North Austin)	1720 E WHITESTONE BLVD		CEDAR PARK	TX	78613-7640
Affiliated	6214	SOUTH FORT WORTH DIALYSIS AT HOME	South Fort Worth At Home	6260 SOUTHWEST BLVD		BENBROOK	TX	76109-6906
Affiliated	6215	THE WOODLANDS AT HOME	DNVO-The Woodlands At Home	9301 PINECROFT DR		SHENANDOAH	TX	77380-3179
Affiliated	6218	ARROWHEAD LAKES AT HOME	Arrowhead Lakes At Home	20325 N 51ST AVE	STE 184 BLDG 11	GLENDALE	AZ	85308-4625
Affiliated	6220	COLUMBUS WEST HOME TRAINING	Columbus West Home Training At Home	1391 GEORGESVILLE RD		COLUMBUS	OH	43228-3611
Affiliated	6221	RICHMOND KIDNEY	Richmond Kidney Center	1366 VICTORY BLVD		STATEN ISLAND	NY	10301-3907

		CENTER AT HOME	At Home (Staten Island)						
Affiliated	6225	DIALYSIS CARE OF KANNAPOLIS AT HOME	Dialysis Care of Kannapolis At Home	1607 N MAIN ST		KANNAPOLIS	NC	28081-2317	
Affiliated	6226	BUTLER-FARM AT HOME	Butler Farm At Home	501 BUTLER FARM RD	STE A	HAMPTON	VA	23666-1777	
Affiliated	6228	NEW PORT RICHEY AT HOME	New Port Richey Kidney At Home	7421 RIDGE RD		PORT RICHEY	FL	34668-6933	
Affiliated	6229	GRAND HOME AT HOME	Grand Home At Home	14674 W MOUNTAIN VIEW BLVD	STE 204	SURPRISE	AZ	85374-2708	
Affiliated	6230	WILLIAMSBURG AT HOME	Williamsburg At Home (fka Yorktown)	500 SENTARA CIR	STE 103	WILLIAMSBURG	VA	23188-5727	
Affiliated	6231	BALDWIN COUNTY AT HOME	Home Dialysis Options of Baldwin County At Home	27880 N MAIN ST	STE A	DAPHNE	AL	36526-7080	
Affiliated	6232	CLINTON TOWNSHIP AT HOME	Clinton Township at Home	15918 19 MILE RD	STE 110	CLINTON TOWNSHIP	MI	48038-1101	
Affiliated	6233	GROSSE POINTE AT HOME	Grosse Pointe At Home	18000 E WARREN AVE	STE 100	DETROIT	MI	48224-1336	
Affiliated	6234	GREENSBURG AT HOME	Greensburg At Home	1531 N COMMERCE EAST DR	STE 6	GREENSBURG	IN	47240-3259	
Affiliated	6236	GULF BREEZE AT HOME	Gulf Breeze At Home	1519 MAIN ST		DUNEDIN	FL	34698-4650	
Affiliated	6237	JACKSONVILLE CENTRAL AT HOME	Jacksonville Central At Home	400 T P WHITE DR		JACKSONVILLE	AR	72076-3287	
Affiliated	6238	SAN JOSE AT HOME	San Jose At Home (Freestanding)	4400 STEVENS CREEK BLVD	STE 50	SAN JOSE	CA	95129-1104	
Affiliated	6243	ORLANDO AT HOME	Orlando At Home (0178)	14050 TOWN LOOP BLVD	STE 104B	ORLANDO	FL	32837-6190	
Affiliated	6244	KENNEDY HOME DIALYSIS-AT HOME	Kennedy Home Dialysis-At Home	5509 N CUMBERLAND AVE	STE 515	CHICAGO	IL	60656-4702	

Affiliated	6245	YPSILANTI AT HOME	Ypsilanti At Home	2762 WASHTEAW RD		YPSILANTI	MI	48197-1506
Affiliated	6246	JACKSONVILLE AT HOME	SEDC (NC II) Jacksonville At Home	14 OFFICE PARK DR		JACKSONVILLE	NC	28546-7325
Affiliated	6247	LEBANON AT HOME	Lebanon At Home	918 COLUMBUS AVE	STE 2 UNIT B	LEBANON	OH	45036-1402
Affiliated	6248	SLIDELL KIDNEY CARE AT HOME	Slidell Kidney Care At Home	1150 ROBERT BLVD	STE 240	SLIDELL	LA	70458-2005
Affiliated	6249	WATERBURY AT HOME	Waterbury At Home	150 MATTATUCK HEIGHTS RD		WATERBURY	CT	06705-3893
Affiliated	6251	WHITE LANE AT HOME	White Lane At Home	7701 WHITE LN	STE D	BAKERSFIELD	CA	93309-0201

Affiliated 6253	HANFORD AT HOME	Hanford At Home	900 N DOUTY ST		HANFORD	CA 93230-3918
Affiliated 6254	ANAHEIM AT HOME	Anaheim At Home	1107 W LA PALMA AVE		ANAHEIM	CA 92801-2804
Affiliated 6255	MERCED AT HOME	Merced At Home	3150 NORTH G ST	STE B	MERCED	CA 95340-1346
Affiliated 6257	ST JOSEPH AT HOME	St. Joseph At Home	5514 CORPORATE DR	STE 100	SAINT JOSEPH	MO 64507-7752
Affiliated 6258	CENTRAL LITTLE ROCK AT HOME	Central Little Rock At Home	5800 W 10TH ST	STE 510	LITTLE ROCK	AR 72204-1760
Affiliated 6260	DURHAM WEST AT HOME	Durham West At Home	4307 WESTERN PARK PL	STE 101	DURHAM	NC 27705-1204
Affiliated 6262	TOLEDO AT HOME	Toledo At Home	1614 S BYRNE RD		TOLEDO	OH 43614-3464
Affiliated 6263	HIOAKS AT HOME	Hioaks At Home	681 HIOAKS RD	STE D	RICHMOND	VA 23225-4043
Affiliated 6264	ELIZABETH AT HOME	Elizabeth At Home	201 MCKEESPORT RD		ELIZABETH	PA 15037-1623
Affiliated 6265	ABINGTON AT HOME	Abington At Home	3940A COMMERCE AVE		WILLOW GROVE	PA 19090-1705
Affiliated 6267	NORTH ORANGEBURG AT HOME	North Orangeburg At Home	124 FIRE TOWER RD		ORANGEBURG	SC 29118-1401
Affiliated 6268	DEARBORN HOME DIALYSIS - AT HOME	Dearborn Home Dialysis-At Home	22030 PARK ST		DEARBORN	MI 48124-2854
Affiliated 6269	OCEAN SPRINGS AT HOME	Ocean Springs At Home	13150 PONCE DEL LEON		OCEAN SPRINGS	MS 39564-2460
Affiliated 6270	HAKC - HUNTINGTON AT HOME	HAKC- Huntington At Home	256 BROADWAY		HUNTINGTON STATION	NY 11746-1403
Affiliated 6271	42ND ST AT HOME	Philadelphia 42nd Street At Home	4126 WALNUT ST		PHILADELPHIA	PA 19104-3511
Affiliated 6275	CHARLOTTESVILLE NORTH AT HOME	Charlottesville North At Home	1800 TIMBERWOOD BLVD	STE C	CHARLOTTESVILLE	VA 22911-7544
Affiliated 6276	HEARTLAND AT HOME	Heartland At Home	925 NE 8TH ST		OKLAHOMA CITY	OK 73104-5800

Affiliated	6278	LAKELAND SOUTH AT HOME	Lakeland South At Home	5050 S FLORIDA AVE	STE 1	LAKELAND	FL	33813-2501
Affiliated	6282	RAINBOW CITY AT HOME	Rainbow City At Home	2800 RAINBOW DR		RAINBOW CITY	AL	35906-5811
Affiliated	6283	ATHENS AT HOME	Athens At Home	15953 ATHENS LIMESTONE DR	STE 15	ATHENS	AL	35613-2214
Affiliated	6284	SYLACAUGA AT HOME	Sylacauga At Home	331 JAMES PAYTON BLVD		SYLACAUGA	AL	35150
Affiliated	6287	PITTSBURGH AT HOME	Pittsburgh At Home	4312 PENN AVE		PITTSBURGH	PA	15224-1310
Affiliated	6289	RADNOR AT HOME	Radnor At Home	250 KING OF PRUSSIA RD		RADNOR	PA	19087-5220
Affiliated	6291	RADFORD AT HOME	Radford At Home	600 E MAIN ST	STE B	RADFORD	VA	24141-1826
Affiliated	6292	HARRISONBURG AT HOME	Harrisonburg At Home	871 CANTRELL AVE	STE 100	HARRISONBURG	VA	22801-4323
Affiliated	6293	KERRVILLE AT HOME	Kerrville At Home	515 GRANADA PL		KERRVILLE	TX	78028-5992
Affiliated	6294	WEST TALLAHASSEE AT HOME	West Tallahassee At Home	2645 W TENNESSEE ST	STE 8	TALLAHASSEE	FL	32304-2521
Affiliated	6295	ROME AT HOME	Rome At Home	15 JOHN MADDOX DR NW		ROME	GA	30165-1413
Affiliated	6297	ST LOUIS WEST AT HOME	St. Louis West At Home	450 N LINDBERGH BLVD	STE 100C	CREVE COEUR	MO	63141-7858
Affiliated	6298	COOKEVILLE AT HOME	Cookeville At Home	140 W 7TH ST		COOKEVILLE	TN	38501-1726
Affiliated	6300	DOTHAN AT HOME	Dothan At Home	216 GRACELAND DR		DOTHAN	AL	36305-7346
Affiliated	6302	HENRICO COUNTY AT HOME	Henrico County At Home	5270 CHAMBERLAYNE RD		RICHMOND	VA	23227-2950
Affiliated	6303	WEYMOUTH CLINIC AT HOME	Weymouth At Home	330 LIBBEY INDUSTRIAL PKWY	STE 900	WEYMOUTH	MA	02189-3122
Affiliated	6304	ERIE AT HOME	Erie At Home	350 E BAYFRONT PKWY	STE A	ERIE	PA	16507-2410
Affiliated	6305	WILSON AT HOME	Wilson At Home	1605 MEDICAL PARK DR W		WILSON	NC	27893-2799

Affiliated	6306	NORTH FULTON AT HOME	North Fulton At Home	1250 NORTHMEADOW PKWY	STE 120	ROSWELL	GA	30076-4914
Affiliated	6311	BRADENTON AT HOME	Bradenton At Home	3501 CORTEZ RD W	STE 104	BRADENTON	FL	34210-3104
Affiliated	6312	COLUMBIA UNIVERSITY AT HOME	Columbia University At Home	60 HAVEN AVENUE		NEW YORK	NY	10032-2604
Affiliated	6313	NEW BEDFORD AT HOME	New Bedford At Home	524 UNION ST		NEW BEDFORD	MA	02740-3546
Affiliated	6314	MUSKEGON AT HOME	Muskegon At Home	1277 MERCY DR		MUSKEGON	MI	49444-4605
Affiliated	6315	WELLINGTON CIRCLE AT HOME	Wellington Circle At Home	10 CABOT RD	STE 103B	MEDFORD	MA	02155-5173
Affiliated	6316	FREDERICK AT HOME	Frederick At Home	140 THOMAS JOHNSON DR	STE 100	FREDERICK	MD	21702-4475
Affiliated	6317	SELINSGROVE AT HOME	Selinsgrove At Home	1030 N SUSQUEHANNA TRL		SELINSGROVE	PA	17870-7767
Affiliated	6318	LAKE CHARLES SOUTHWEST AT HOME	Lake Charles Southwest At Home	300 18th ST		LAKE CHARLES	LA	70601-7342
Affiliated	6319	LENEXA AT HOME	Lenexa At Home	8630 HALSEY ST		LENEXA	KS	66215-2880
Affiliated	6321	NASHVILLE HOME TRAINING AT HOME	Nashville Home Training At Home	1919 CHARLOTTE AVE	STE 200	NASHVILLE	TN	37203-2245
Affiliated	6322	GOLDSBORO AT HOME	Goldsboro At Home	2609 HOSPITAL RD		GOLDSBORO	NC	27534-9424
Affiliated	6323	MIAMI CAMPUS AT HOME	Miami Campus At Home	1500 NW 12TH AVE	STE 106	MIAMI	FL	33136-1028
Affiliated	6324	DAYTONA BEACH AT HOME	Daytona Beach At Home	578 HEALTH BLVD		DAYTONA BEACH	FL	32114-1492
Affiliated	6325	GRASS VALLEY AT HOME	Grass Valley At Home	360 CROWN POINT CIR	STE 210	GRASS VALLEY	CA	95945-2543
Affiliated	6326	POMONA AT HOME	Pomona At Home	2111 NORTH GAREY AVENUE		POMONA	CA	91767

Affiliated	6327	MID ATLANTA HOME AT HOME	MidAtlanta Home At Home	418 DECATUR ST SE	SUITE B	ATLANTA	GA	30312-1801
Affiliated	6328	MARTINSVILLE AT HOME	Martinsville Dialysis	33 BRIDGE ST S		MARTINSVILLE	VA	24112-6214
Affiliated	6329	HUBBARD ROAD AT HOME	Hubbard Road At Home	1963 HUBBARD RD		MADISON	OH	44057
Affiliated	6350	PLAINFIELD RENAL CENTER AT HOME	Plainfield Renal At Home (P278)	8110 NETWORK DR		PLAINFIELD	IN	46168-9024
Affiliated	6351	NORTH ANDOVER RENAL CENTER AT HOME	North Andover Renal At Home (P178)	201 SUTTON ST		NORTH ANDOVER	MA	1845
Affiliated	6352	JACKSON NORTH DIALYSIS AT HOME	Jackson North At Home (P181)	571 BEASLEY RD	STE B	JACKSON	MS	39206-3042
Affiliated	6353	SUMMIT RENAL AT HOME	Summit Renal At Home (P186)	73 MASSILLON RD		AKRON	OH	44312-1028
Affiliated	6354	MARLTON DIALYSIS AT HOME	Marlton At Home (P200)	769 E RTE 70		MARLTON	NJ	08053-2341
Affiliated	6355	CENTRAL FORT WAYNE DIALYSIS AT HOME	Central Fort Wayne At Home (P223)	1940 BLUFTON RD		FORT WAYNE	IN	46809-1307
Affiliated	6356	LAS CRUCES RENAL CENTER AT HOME	Las Cruces Renal At Home (P237)	3961 E LOHMAN AVE	STE 29	LAS CRUCES	NM	88011-8272
Affiliated	6357	NORTHEAST PORTLAND RENAL CENTER AT HOME	Northeast Portland Renal At Home (P240)	703 NE HANCOCK ST		PORTLAND	OR	97212-3955
Affiliated	6358	KANSAS CITY RENAL CENTER AT HOME	Kansas City Renal At Home (P264)	4333 MADISON AVE		KANSAS CITY	MO	64111-3429
Affiliated	6359	COASTAL DIALYSIS AT HOME	South Texas Renal At Home (P257)	4300 S PADRE ISLAND DR		CORPUS CHRISTI	TX	78411-4433
Affiliated	6360	NORTH SPOKANE RENAL CENTER AT HOME	North Spokane Renal At Home (P262)	12610 E MARIBEAU PRKWY	STE 100	SPOKANE	WA	99216

Affiliated 5659 TEMPE DIALYSIS PD	Tempe Dialysis Center PD	2149 EAST WARNER RD	STE 109	TEMPE	AZ 85284-3496
Affiliated 5660 ARROWHEAD LAKES DIALYSIS PD	Arrowhead Lakes Dialysis PD	20325 N 51ST AVE	BLDG 11, STE 184	GLENDALE	AZ 85308-4625

Affiliated	5916	SHAKER SQUARE AT HOME	Shaker Square At Home	12800 SHAKER BLVD	STE 1	CLEVELAND	OH	44120-2004
Affiliated	6130	SIERRA ROSE AT HOME	Sierra Rose At Home	685 SIERRA ROSE DR		RENO	NV	89511-2060
Affiliated	6217	TEMPE AT HOME	Tempe At Home	2149 E WARNER RD	STE 109	TEMPE	AZ	85284-3496
Affiliated	6281	TUSCALOOSA AT HOME	Tuscaloosa At Home	805 OLD MILL ST		TUSCALOOSA	AL	35401-7132

TEMPORARY CLOSURES

(Included above are several centers that have temporarily suspended operations for a variety of reasons, but are scheduled to resume operations within the coming few months)

- 614 Lynwood
- 643 Vidalia
- 3518 Huntingdon Valley
Dialysis
- 626 Tuba City
- 903 Littleton

Exhibit D

Managed Centers List

Page 82 of 123

Exhibit D

Managed Centers List

Active

<u>count</u>	<u>TYPE</u>	<u>CTR #</u>	<u>CENTER NAME</u>	<u>LEGAL NAME</u>	<u>ADDRESS</u>	<u>ADDRESS</u>	<u>CITY</u>	<u>STATE</u>	<u>ZIP</u>
1771	Administrative Services	181	Childrens Hospital	MGD-Children' s National Medical Center	111 MICHIGAN AVE NW		WASHINGTON	DC	20010-2916
1772	Administrative Services	1624	Renal Care Seat Pleasant	MGD-Renal Care of Seat Pleasant	6274 CENTRAL AVE		SEAT PLEASANT	MD	20743
1773	Administrative Services	1715	Moses Taylor Hospital Renal Unit	Moses Taylor Hospital Renal Unit	700 QUINCY AVE		SCRANTON	PA	18510-1724
1774	Administrative Services	3330	Aurora Medical Group - Fond du Lac	Aurora Medical Group-Fond du Lac	210 WISCONSIN AMERICAN DR	ATTN DAVITA DIALYSIS (WEST END OF BLDG)	FOND DU LAC	WI	54937-2999
1775	Administrative Services	3331	Aurora Medical Group - Sheboygan	Aurora Medical Group-Sheboygan	2414 KOHLER MEMORIAL DR		SHEBOYGAN	WI	53081-3129
1776	Administrative Services	3338	Aurora Medical Group - Lake Geneva	Aurora Medical Group-Lake Geneva	146 E GENEVA SQ		LAKE GENEVA	WI	53147-9694
1777	Administrative Services	3555	Aurora Medical Group - Marinette Dialysis	Aurora Medical Group-Marinette Dialysis	4061 OLD PESHTIGO RD		MARINETTE	WI	54143
1778	Administrative Services	3607	Aurora Medical Group - Brown County Dialysis	Aurora Medical Group-Brown County Dialysis	1751 DECKNER AVE		GREEN BAY	WI	54302-2630
1779	Administrative Services	3641	Aurora Medical Group - Sturgeon Bay Dialysis	Aurora Medical Group-Sturgeon Bay Dialysis	108 S 10TH AVE		STURGEON BAY	WI	54235-1802

1780	Administrative Services	3653	Aurora Medical Group - Oshkosh West Dialysis	Aurora Medical Group-Oshkosh West Dialysis	855 N WESTHAVEN DR		OSHKOSH	WI	54904-7668
1781	Administrative Services	3665	Aurora Medical Group - Manitowoc Dialysis	Aurora Medical Group-Manitowoc Dialysis	601 REED AVE		MANITOWOC	WI	54220-2026
1782	Administrative Services	3672	Aurora Medical Group - Wautoma Dialysis	Aurora Medical Group-Wautoma Dialysis	900 EAST DIVISION ST		WAUTOMA	WI	54982-6944
1783	Administrative Services	1868	Maize Dialysis	Maize Dialysis Center	10001 GRADY AVE		MAIZE	KS	67101
1784	Administrative Services	1912	Kidney Dialysis Center	MGD-Kidney Dialysis Center, LLC (MMG Macon)	640 MARTIN LUTHER KING JR BLVD		MACON	GA	31201-3206
	Administrative Services	6079	MAGNOLIA WEST AT HOME	Magnolia West At Home	11161 MAGNOLIA AVE	STE B	RIVERSIDE	CA	92505-3605
	Administrative Services	1903	Riverside PD Central NAMG	Riverside PD Central	3660 PARK SIERRA DR	STE 18	RIVERSIDE	CA	92505-3071

Exhibit E

Dialysis Center Committed Purchasers List

Page 84 of 123

Exhibit E

Dialysis Center Committed Purchasers List

Active									
count	TYPE	CTR #	CENTER NAME	LEGAL NAME	ADDRESS	ADDRESS	CITY	STATE	ZIP
1	Affiliated	398	Los Angeles Dialysis Center	Los Angeles Dialysis Center (LADC)	3901 S WESTERN AVE		LOS ANGELES	CA	90062-1112
2	Affiliated	613	Garfield	Garfield Hemodialysis Center	118 HILLIARD AVE		MONTEREY PARK	CA	91754-1118
3	Affiliated	614	Lynwood	Kidney Dialysis Care Unit (Lynwood)	3600 E MARTIN LUTHER KING JR BLVD		LYNWOOD	CA	90262-2607
4	Affiliated	615	Lakewood Dialysis-CA	Lakewood Dialysis-CA	4611 SILVA ST		LAKESWOOD	CA	90712-2512
5	Affiliated	616	Valley Dialysis	Valley Dialysis	16149 HART ST		VAN NUYS	CA	91406-3906
6	Affiliated	617	Downey Dialysis	Downey Dialysis	8630 FLORENCE AVE	STE 1	DOWNEY	CA	90240-4017
7	Affiliated	618	Covina Dialysis	Covina Dialysis	1547 W GARVEY AVE N		WEST COVINA	CA	91790-2139
8	Affiliated	625	Four Corners Farmington	Four Corners Farmington	801 W BROADWAY		FARMINGTON	NM	87401-5650
9	Affiliated	626	Tuba City Dialysis	Tuba City Dialysis	500 EDGEWATER DR	PO BOX 291	TUBA CITY	AZ	86045-2905
10	Affiliated	627	Camelback Dialysis Center	Camelback Dialysis Center (fka Scottsdale Dialysis Center)	7321 E OSBORN DR		SCOTTSDALE	AZ	85251-6418
11	Affiliated	630	Westbank	Westbank Chronic Renal Center	3631 BEHRMAN PLACE		NEW ORLEANS	LA	70114
12	Affiliated	632	Fleur de Lis	Fleur de Lis Dialysis (fka Tri-Parish)	5555 BULLARD AVE		NEW ORLEANS	LA	70128-3450
13	Affiliated	637	Desert Mountain	Desert Mountain Dialysis	9220 E MOUNTAIN VIEW RD	STE 15	SCOTTSDALE	AZ	85258-5134

14	Affiliated	638	Chinle	Chinle Dialysis	US HWY 191	PO BOX 879	CHINLE	AZ	86503-0879
15	Affiliated	648	Central City	Central City Dialysis Center	1300 MURCHISON DR	STE 32	EL PASO	TX	79902-4840
16	Affiliated	651	Federal Way	Federal Way Community Dialysis Center	1015 S 348TH ST		FEDERAL WAY	WA	98003-7078
17	Affiliated	663	Beverly Hills	Beverly Hills Dialysis Center	50 N LA CIENEGA BLVD	3RD FLOOR, STE 3	BEVERLY HILLS	CA	90211-2205
18	Affiliated	667	Walnut Creek	Walnut Creek Dialysis Center	404 N WIGET LN		WALNUT CREEK	CA	94598-2408
19	Affiliated	672	Norwalk	Norwalk Dialysis Center	12375 E IMPERIAL HWY	STE D3	NORWALK	CA	90650-3129
20	Affiliated	673	El Monte	Greater El Monte Dialysis Center	1938 TYLER AVE	STE J-168	SOUTH EL MONTE	CA	91733-3623
21	Affiliated	676	Bayonet Point	Bayonet Point- Hudson Kidney	14144 NEPHRON LN		HUDSON	FL	34667-6504
22	Affiliated	677	New Port Richey	New Port Richey Kidney Center	7421 RIDGE RD		PORT RICHEY	FL	34668-6933
23	Affiliated	678	Hernando	Hernando Kidney Center, Inc	2985 LANDOVER BLVD		SPRING HILL	FL	34608-7258
24	Affiliated	681	Woodbridge	CDC Of Woodbridge	2751 KILLARNEY DR		WOODBIDGE	VA	22192-4119
25	Affiliated	682	Manassas	CDC- Manassas Dialysis	10655 LOMOND DR	STE 11	MANASSAS	VA	20109-2877
26	Affiliated	683	Springfield	CDC- Springfield Dialysis	8350 TRAFORD LN	STE A	SPRINGFIELD	VA	22152-1671
27	Affiliated	684	Sterling	CDC-Sterling	46396 BENEDICT DR	STE 1	STERLING	VA	20164-6626
28	Affiliated	687	Alexandria	Springfield- Alexandria	5999 STEVENSON AVE	STE 1	ALEXANDRIA	VA	22304-3302
29	Affiliated	642	Statesboro	Nephrology Center of	4B COLLEGE PLZ		STATESBORO	GA	30458-4928

				Statesboro fka Statesboro Dialysis					
30	Affiliated	643	Vidalia	Nephrology Center of Vidalia	1806 EDWINA DR		VIDALIA	GA	30474-8927
31	Affiliated	657	Papago Dialysis	Papago Dialysis Center (fka PD Central & Squaw Peak)	1401 N 24TH ST STE 2		PHOENIX	AZ	85008-4638
32	Affiliated	658	Boca Raton	Boca Raton Artificial Kidney Center	998 NW 9TH CT		BOCA RATON	FL	33486-2214
33	Affiliated	644	Piedmont	Buckhead Dialysis	1575 NORTHSIDE DR NW	STE 365	ATLANTA	GA	30318-4210
34	Affiliated	311	Logan Square	Logan Square Dialysis Services	2659 N MILWAUKEE AVE	1ST FL	CHICAGO	IL	60647-1643
35	Affiliated	312	Lake County	Lake County Dialysis Services	918 S MILWAUKEE AVE		LIBERTYVILLE	IL	60048-3229
36	Affiliated	314	Lincoln Park	Lincoln Park Dialysis fka Lincoln Park Nephrology	3157 N LINCOLN AVE		CHICAGO	IL	60657-3111
37	Affiliated	318	Lincoln Pk-PD	Skyline Home Dialysis (fka Lincoln Park PD)	7009 W BELMONT AVE		CHICAGO	IL	60634-4533
38	Affiliated	670	West Palm Beach	Dialysis Associates of the Palm Beaches	2611 POINSETTIA AVE		WEST PALM BEACH	FL	33407-5919
39	Affiliated	693	Sunrise	Sunrise Dialysis Center	13039 HAWTHORNE BLVD		HAWTHORNE	CA	90250-4415
40	Affiliated	655	Kayenta	Kayenta Dialysis	PO BOX 217 N	US HWY 163	KAYENTA	AZ	86033-0217
41	Affiliated	321	Hyde Park	Emerald Dialysis (fka Hyde Park Kidney Center)	710 W 43RD ST		CHICAGO	IL	60609-3435

42	Affiliated	322	Olympia Fields	Olympia Fields Dialysis Center	4557B LINCOLN HWY	STE B	MATTESON	IL	60443-2318
43	Affiliated	351	CKD	Center for Kidney Disease at North Shore	1190 NW 95TH ST	STE 28	MIAMI	FL	33150-2065
44	Affiliated	352	Venture	Center for Kidney Disease at Venture	16855 NE 2ND AVE	STE 25	N MIAMI BEACH	FL	33162-1744
45	Affiliated	360	South Broward	South Broward Artificial Kidney	4401 HOLLYWOOD BLVD		HOLLYWOOD	FL	33021-6609
46	Affiliated	688	East End	East End Dialysis Center	2201 E MAIN ST	STE 1	RICHMOND	VA	23223-7071
47	Affiliated	354	Flamingo Park	Flamingo Park Kidney Cntr, Inc	901 E 10TH AVE	BAY 17	HIALEAH	FL	33010-3762
48	Affiliated	355	Interamerican	InterAmerican Dialysis Center	7815 CORAL WAY	STE 115	MIAMI	FL	33155-6541
49	Affiliated	356	Coral Gables Dialysis Center	Coral Gables Kidney Center (fka LeJeune)	3280 PONCE DE LEON BLVD		CORAL GABLES	FL	33134-7252
50	Affiliated	370	Cielo Vista Dialysis	DaVita East Dialysis dba Cielo Vista Dialysis (fkaTotal Renal Care East Dialysis Center)	7200 GATEWAY BLVD E	STE B	EL PASO	TX	79915-1301
51	Affiliated	371	West Texas Dialysis	DaVita West Dialysis Center dba West Texas (fkaTotal Renal Care West Dialysis Center)	5595 ALAMEDA AVE B	STE B	EL PASO	TX	79905
52	Affiliated	656	Shiprock	Shiprock Dialysis	PO BOX 2156	US HWY 491 N	SHIPROCK	NM	87420-2156
53	Affiliated	202	Arden Hills	Arden Hills Dialysis Unit	3900 NORTHWOODS DR	STE 11	ARDEN HILLS	MN	55112-6911

54	Affiliated	203	Burnsville	Burnsville Dialysis Unit	501 E NICOLLET BLVD	STE 15	BURNSVILLE	MN	55337-6784
55	Affiliated	204	Coon Rapids	Coon Rapids Dialysis Unit	3960 COON RAPIDS BLVD NW	STE 39	COON RAPIDS	MN	55433-2598
56	Affiliated	205	Edina	Edina Dialysis Unit	6550 YORK AVE S	STE 1	EDINA	MN	55435-2332
57	Affiliated	206	Maplewood	Maplewood Dialysis Center	2785 WHITE BEAR AVE N	STE 21	MAPLEWOOD	MN	55109-1320
58	Affiliated	207	Minneapolis	Minneapolis Dialysis Unit	825 S EIGHTH ST	STE SL42	MINNEAPOLIS	MN	55404-1208
59	Affiliated	208	Minnetonka	Minnetonka Dialysis Unit	17809 HUTCHINS DR		MINNETONKA	MN	55345-4100
60	Affiliated	209	St. Paul Dialysis	St. Paul Dialysis Unit	555 PARK ST	STE 18	SAINT PAUL	MN	55103-2192
61	Affiliated	210	Special Needs	University Dialysis Unit Riverside (Minneapolis- Special Needs Dialysis)	1045 WESTGATE DR	STE 9	SAINT PAUL	MN	55114-1079

62	Affiliated	211	West St. Paul	West St. Paul Dialysis	1555 LIVINGSTON AVE		WEST ST PAUL	MN	55118-3411
63	Affiliated	213	Cass Lake	Cass Lake Dialysis Unit	602 GRANT UTLEY ST	PO BOX 757	CASS LAKE	MN	56633-0757
64	Affiliated	215	Faribault	Faribault Dialysis Unit	201 LYNDALE AVE S	STE F	FARIBAULT	MN	55021-5758
65	Affiliated	217	Marshall	Marshall Dialysis Unit	300 S BRUCE ST	AVERA MARSHALL REGIONAL MEDICAL CENTER	MARSHALL	MN	56258-1934
66	Affiliated	218	Montevideo	Montevideo Dialysis Center	824 N 11TH ST	MONTEVIDEO HOSPITAL	MONTEVIDEO	MN	56265-1629
67	Affiliated	220	Pine City	TRC-Pine City (fka-Pine City Dialysis Unit)	129 6TH AVE SE	LAKESIDE MEDICAL CENTER	PINE CITY	MN	55063-1913
68	Affiliated	222	Red Wing	Red Wing Dialysis Unit	3028 N SERVICE DR		RED WING	MN	55066-1921
69	Affiliated	223	Redwood Falls	Redwood Falls Dialysis Center	100 FALLWOOD RD		REDWOOD FALLS	MN	56283-1828
70	Affiliated	240	Mitchell	Mitchell Dialysis	525 N FOSTER	QUEEN OF PEACE HOSPITAL	MITCHELL	SD	57301-2966
71	Affiliated	242	Rosebud	Rosebud Dialysis	1 SOLDIER CREEK RD		ROSEBUD	SD	57570-0610
72	Affiliated	243	Sioux Falls	Sioux Falls Dialysis Community Unit	1325 S CLIFF AVE	STE 46	SIOUX FALLS	SD	57105-1016
73	Affiliated	250	St. Croix Falls	St. Croix Falls Dialysis	744 E LOUISIANA ST		SAINT CROIX FALLS	WI	54024-9501
74	Affiliated	260	Hayward	Hayward Dialysis Center	21615 HESPERIAN BLVD	STE F	HAYWARD	CA	94541-7026
75	Affiliated	262	Pleasanton	Pleasanton Dialysis Center (HEMO) (fka Dublin)	5720 STONERIDGE MALL RD	STE 16	PLEASANTON	CA	94588-2882
76	Affiliated	263	Union City	Union City Dialysis Center	32930 ALVARADO NILES RD	STE 3	UNION CITY	CA	94587-8101

				(aka TRC- Union City)								
77	Affiliated	264	East Bay - PD	East Bay Peritoneal Dialysis Center	13939 E 14TH ST	STE 11	SAN LEANDRO	CA	94578-2613			
78	Affiliated	383	Greer	Greer Kidney Center	211 VILLAGE DR		GREER	SC	29651-1238			
79	Affiliated	382	Upstate	Upstate Dialysis Center	308 MILLS AVE		GREENVILLE	SC	29605-4022			
80	Affiliated	390	Kenner	Kenner Regional Dialysis Center	200 W ESPLANADE AVE	STE 1	KENNER	LA	70065-2473			
81	Affiliated	689	Downtown Dialysis	Downtown Dialysis Center	821 N EUTAW ST	STE 41	BALTIMORE	MD	21201-6304			
82	Affiliated	331	Eaton Canyon	Eaton Canyon Dialysis	2551 E WASHINGTON BLVD		PASADENA	CA	91107-1446			
83	Affiliated	190	Georgetown	Georgetown on the Potomac	3223 K ST NW	STE 11	WASHINGTON	DC	20007-4412			
84	Affiliated	395	St. Mary	Newtown Dialysis Center (fka St. Mary Dialysis)	60 BLACKSMITH RD		NEWTOWN	PA	18940-1847			
85	Affiliated	393	Bertha Sirk	Bertha Sirk Dialysis Center	5820 YORK RD	STE 1	BALTIMORE	MD	21212-3620			
86	Affiliated	394	Greenspring	Greenspring Dialysis Center	4701 MOUNT HOPE DR	STE C	BALTIMORE	MD	21215-3246			
87	Affiliated	378	Houston Kidney - NW	Northwest Kidney Center (Houston)	11029 NORTHWEST FWY		HOUSTON	TX	77092-7311			
88	Affiliated	379	NorthStar Dialysis	NorthStar Dialysis Center (fka North Houston Kidney Center)	380 W LITTLE YORK RD		HOUSTON	TX	77076-1303			
89	Affiliated	363	Port Charlotte	Port Charlotte Artificial Kidney Center	4300 KINGS HWY STE 406		PORT CHARLOTTE	FL	33980			
90	Affiliated	364	Gulf Coast PD	Gulf Coast Dialysis	3300 TAMIAMI TRL	STE 11A	PORT CHARLOTTE	FL	33952-8054			
91	Affiliated	649	Loma Vista	Loma Vista Dialysis Center Partnership	1382 LOMALAND DR	STE A	EL PASO	TX	79935-5204			

92	Affiliated	332	Paramount	Paramount Dialysis Center	8319 ALONDRA BLVD		PARAMOUNT	CA	90723-4403
93	Affiliated	334	East LA	Doctors Dialysis of East LA (aka East Los Angeles Dialysis)	950 S EASTERN AVE		LOS ANGELES	CA	90022-4801
94	Affiliated	335	Montebello	Doctors Dialysis of Montebello	1721 W WHITTIER BLVD		MONTEBELLO	CA	90640-4004
95	Affiliated	361	Pine Island	Pine Island Kidney Center	1871 N PINE ISLAND RD		PLANTATION	FL	33322-5208
96	Affiliated	365	Complete	Complete Dialysis Care	7850 W SAMPLE RD		MARGATE	FL	33065-4710
97	Affiliated	122	Lone Star Dialysis	Lone Star Dialysis (fka Hobby Dialysis)	8560 MONROE RD		HOUSTON	TX	77061-4815
98	Affiliated	255	Forest Lake	Forest Lake Dialysis	1068 S LAKE ST	STE 11	FOREST LAKE	MN	55025-2633
99	Affiliated	690	USC Phase II	TRC/USC Dialysis Center	2310 ALCAZAR ST		LOS ANGELES	CA	90033-5327
100	Affiliated	396	TRC/Union Plaza Ctr	Union Plaza Dialysis Center	810 1ST ST NE	STE 1	WASHINGTON	DC	20002-4227
101	Affiliated	130	Mid-Columbia Kidney	Mid Columbia Kidney Center	6825 BURDEN BLVD	STE A	PASCO	WA	99301-9584
102	Affiliated	131	Mt. Adams Kidney Ctr	Mt. Adams Kidney Center	3220 PICARD PL		SUNNYSIDE	WA	98944-8400
103	Affiliated	650	Lakewood	Lakewood Community Dialysis Center	5919 LAKEWOOD TOWNE CENTER BLVD SW	STE A	LAKESIDE	WA	98499-6513
104	Affiliated	228	St. Paul Ramsey	St. Paul Capitol Dialysis	555 PARK ST	STE 23	SAINT PAUL	MN	55103-2193
105	Affiliated	229	River City Dialysis	River City Dialysis (fka Lakeview Dialysis)	1970 NORTHWESTERN AVE S		STILLWATER	MN	55082-6567
106	Affiliated	231	Woodbury	Woodbury Dialysis	1850 WEIR DR	STE 3	WOODBURY	MN	55125-2260
107	Affiliated	281	Alhambra	Alhambra Dialysis Center	1315 ALHAMBRA BLVD	STE 1	SACRAMENTO	CA	95816-5245
108	Affiliated	282	Antelope	Antelope Dialysis Center	6406 TUPELO DR	STE A	CITRUS HEIGHTS	CA	95621-1780

109	Affiliated	283	Chico	Chico Dialysis Center (aka Chico Clinic)	530 COHASSET RD		CHICO	CA	95926-2212
110	Affiliated	285	North Clinic	Manzanita Dialysis Center (aka North Clinic)	4005 MANZANITA AVE	STE 17	CARMICHAEL	CA	95608-1779
111	Affiliated	286	Placerville	Cameron Park Dialysis (fka Placerville)	3311 COACH LN	STE C	CAMERON PARK	CA	95682
112	Affiliated	288	South Sacramento	South Sacramento Dialysis Center	7000 FRANKLIN BLVD	STE 88	SACRAMENTO	CA	95823-1838
113	Affiliated	289	Redding	Redding Dialysis Center	1876 PARK MARINA DR		REDDING	CA	96001-0913
114	Affiliated	291	Yuba City	Yuba City Dialysis Center	1525 PLUMAS CT	STE A	YUBA CITY	CA	95991-2971
115	Affiliated	292	University Clinic	University Dialysis Center	777 CAMPUS COMMONS RD	STE 1	SACRAMENTO	CA	95825-8344
116	Affiliated	372	Mesa Vista	Mesa Vista Dialysis Center (El Paso)	2400 N OREGON ST	STE C	EL PASO	TX	79902-3135
117	Affiliated	694	Hollywood	Hollywood Dialysis Center	5108 W SUNSET BLVD		LOS ANGELES	CA	90027-5708
118	Affiliated	697	UCLA Harbor	TRC/Harbor-UCLA MFI Total Renal Dialysis Center	21602 S VERMONT AVE		TORRANCE	CA	90502-1940
119	Affiliated	325	Brighton	Brighton Dialysis (fka Michigan Kidney Center of Brighton)	7960 GRAND RIVER RD	STE 21	BRIGHTON	MI	48114-7336
120	Affiliated	326	Macomb	Macomb Kidney Center (fka Macomb Dialysis)	28295 SCHOENHERR RD	STE A	WARREN	MI	48088-4300
121	Affiliated	327	North Oakland	North Oakland Dialysis	450 N TELEGRAPH RD	STE 6	PONTIAC	MI	48341-1037
122	Affiliated	328	Novi	Novi Dialysis	47250 W 10 MILE RD		NOVI	MI	48374-2932

123	Affiliated	329	Southfield	Cornerstone Dialysis (fka Southfield)	23857 GREENFIELD RD		SOUTHFIELD	MI	48075-3122
124	Affiliated	319	Children' s Mem' l Hosp.	TRC Children' s Dialysis Center aka Children' s Chicago/ Children' s Memorial Hospital	2611 N HALSTED ST		CHICAGO	IL	60614-2301
125	Affiliated	151	New Center	New Center Dialysis	3011 W GRAND BLVD	STE 65	DETROIT	MI	48202-3012
126	Affiliated	2003	Whittier	Whittier Dialysis Center (fka Whittier Hills)	10055 WHITTWOOD DR		WHITTIER	CA	90603-2313
127	Affiliated	357	Miami Lakes	Miami Lakes Artificial Kidney Center (ALTHIN)	14600 NW 60TH AVE		MIAMI LAKES	FL	33014-2811
128	Affiliated	571	Anson County	Dialysis Care of Anson County	923 E CASWELL ST		WADESBORO	NC	28170-2305

129	Affiliated	573	Edgecomb County	Dialysis Care of Edgecomb County	3206 WESTERN BLVD	TARBORO	NC	27886-1828	
130	Affiliated	574	Franklin County	Dialysis Care of Franklin County	1706 NC HWY 39 N	LOUISBURG	NC	27549-8329	
131	Affiliated	575	Hoke County	Dialysis Care of Hoke County	403 S MAIN ST	RAEFORD	NC	28376-3222	
132	Affiliated	576	Martin County	Dialysis Care of Martin County	100 MEDICAL DR	WILLIAMSTON	NC	27892-2156	
133	Affiliated	578	Montgomery County	Dialysis Care of Montgomery County (aka Montgomery)	323 W MAIN ST	BISCOE	NC	27209-9528	
134	Affiliated	579	Moore County	Dialysis Care of Moore County (aka Pinehurst)	16 REGIONAL DR	PINEHURST	NC	28374-8850	
135	Affiliated	580	Richmond County	Dialysis Care of Richmond County	771 CHERAW RD	HAMLET	NC	28345-7158	
136	Affiliated	581	Rockingham County	Dialysis Care of Rockingham County	251 W KINGS HWY	EDEN	NC	27288-5009	
137	Affiliated	582	Rowan County	Dialysis Care of Rowan County	111 DORSETT DR	SALISBURY	NC	28144-2278	
138	Affiliated	583	Rutherford County	Dialysis Care of Rutherford County	226 COMMERCIAL ST	FOREST CITY	NC	28043-2851	
139	Affiliated	399	Monterey Park	Monterey Park Dialysis Center	2560 CORPORATE PL	STE 1-11 BLDG D	MONTEREY PARK	CA	91754-7612
140	Affiliated	183	Mason Dixon	Mason-Dixon Baltimore County	9635-A LIBERTY RD	STE 1	RANDALLSTOWN	MD	21133-2436
141	Affiliated	184	Carrol County	Carroll County Dialysis Facility	412 MALCOLM DR	STE 31	WESTMINSTER	MD	21157-6167

142	Affiliated	167	South Brooklyn	South Brooklyn Nephrology Center	3915 AVENUE V	STE 14	BROOKLYN	NY	11234-5150
143	Affiliated	843	Phenix City	Phenix City Dialysis Center	1900 OPELIKA RD		PHENIX CITY	AL	36867-3640
144	Affiliated	876	Brea	Brea Dialysis Center	595 TAMARACK AVE	STE A	BREA	CA	92821-3125
145	Affiliated	878	Hemet	Hemet Dialysis Center	3050 W FLORIDA AVE		HEMET	CA	92545-3619
146	Affiliated	883	Temecula	Temecula Dialysis Center	40945 COUNTY CENTER DR	STE G	TEMECULA	CA	92591-6006
147	Affiliated	880	Riverside	Riverside Dialysis Center	4361 LATHAM ST	STE 1	RIVERSIDE	CA	92501-1767
148	Affiliated	870	Napa	Napa Dialysis Center	3900 BEL AIRE PLZ	STE C	NAPA	CA	94558-2823
149	Affiliated	875	Santa Ana	Santa Ana Dialysis Center	1820 E DEERE AVE		SANTA ANA	CA	92705-5721
150	Affiliated	879	Valley View Dialysis Center	Valley View Dialysis Center (aka Morneo Valley)	26900 CACTUS AVE		MORENO VALLEY	CA	92555-3912
151	Affiliated	884	Orange	Mainplace Dialysis Center (fka Orange Dialysis Center)	972 W TOWN AND COUNTRY RD		ORANGE	CA	92868-4714
152	Affiliated	882	San Bernadino	Mountain Vista Dialysis Center (fka San Bernadino Dailysis Center (Mountain Vista))	4041 NORTH UNIVERSITY PKWY		SAN BERNARDINO	CA	92407-1823
153	Affiliated	871	Lakeport	Lakeport Dialysis Center	804 11TH ST	STE 2	LAKEPORT	CA	95453-4102
154	Affiliated	873	Vacaville	Vacaville Dialysis Center	941 MERCHANT ST		VACAVILLE	CA	95688-5315
155	Affiliated	877	Corona	Corona Dialysis Center	1820 FULLERTON AVE	STE 18	CORONA	CA	92881-3147

156	Affiliated	872	Fairfield	Fairfield Dialysis Center	4660 CENTRAL WAY		FAIRFIELD	CA	94534-1803
157	Affiliated	902	Westminster	Westminster Dialysis Center (Federal Heights)	9053 HARLAN STE 9 ST		WESTMINSTER	CO	80031-2908
158	Affiliated	901	Aurora	Aurora Dialysis Center	1411 S AMC II STE 1 POTOMAC ST		AURORA	CO	80012-4536
159	Affiliated	900	Denver	Denver Dialysis Center	2900 STE C DOWNING ST		DENVER	CO	80205-4699
160	Affiliated	903	Littleton	Littleton Dialysis Center	209 W COUNTY LINE RD		LITTLETON	CO	80129-1901
161	Affiliated	904	South Denver	South Denver Dialysis Center	850 E STE 6 HARVARD AVE		DENVER	CO	80210-5030
162	Affiliated	946	Lee Street Dialysis	Lee Street Dialysis (fka Grant Park Dialysis Center)	5155 LEE ST NE		WASHINGTON	DC	20019-4051
163	Affiliated	868	Leesburg	Leesburg Dialysis Center	801 E DIXIE STE 18A AVE		LEESBURG	FL	34748-7699
164	Affiliated	866	Panama City	Panama City Dialysis Center	615 HIGHWAY 231		PANAMA CITY	FL	32405-4704
165	Affiliated	867	Marianna	Marianna Dialysis Center	2930 OPTIMIST DR		MARIANNA	FL	32448-7703
166	Affiliated	864	Venice	Venice Dialysis Center	816 PINEBROOK RD		VENICE	FL	34285-7103
167	Affiliated	827	Buena Vista	Buena Vista Dialysis Center	349 GENEVA RD		BUENA VISTA	GA	31803-1701
168	Affiliated	828	Decatur	Decatur Dialysis Center	1987 CANDLER RD		DECATUR	GA	30032-4212
169	Affiliated	825	Moultrie	Moultrie Dialysis Center	2419 S MAIN ST		MOULTRIE	GA	31768-6531
170	Affiliated	820	SW Atlanta	Southwest Atlanta Dialysis Center	3620 MARTIN LUTHER KING DR SW		ATLANTA	GA	30331-3711
171	Affiliated	818	Griffin	Griffin Dialysis Center	731 S 8TH ST		GRIFFIN	GA	30224-4818

172	Affiliated	826	Columbus	Columbus Dialysis Center	6228 BRADLEY PARK DR	STE B	COLUMBUS	GA	31904-3604
173	Affiliated	829	East Macon	East Macon Dialysis Center	165 EMERY HWY	STE 11	MACON	GA	31217-3666
174	Affiliated	817	Jonesboro	Jonesboro Dialysis Center	129 KING ST		JONESBORO	GA	30236-3656
175	Affiliated	824	Milledgeville	Milledgeville Dialysis Center	400 S WAYNE ST		MILLEDGEVILLE	GA	31061-3446
176	Affiliated	823	Fort Valley	Fort Valley Dialysis Center	557 BLUEBIRD BLVD		FORT VALLEY	GA	31030-5083
177	Affiliated	821	Midtown	Linden Dialysis (fka Midtown- Atlanta)	121 LINDEN AVE NE		ATLANTA	GA	30308-2432
178	Affiliated	953	E. St. Louis	Sauget Dialysis (fka East St. Louis Dialysis Center)	2061 GOOSE LAKE RD		SAUGET	IL	62206-2822
179	Affiliated	952	Granite City	Granite City Dialysis Center	9 AMERICAN VLG		GRANITE CITY	IL	62040-3706
180	Affiliated	937	Batesville	Batesville Dialysis Center Aka Renal Treatment Centers- Batesville	232 STATE ROAD 129 S		BATESVILLE	IN	47006-7694
181	Affiliated	938	Lawrenceburg	Lawrenceburg Dialysis Center	721 RUDOLPH WAY		GREENDALE	IN	47025-8378
182	Affiliated	939	Madison	Madison Dialysis Center	220 CLIFTY DR	UNIT K	MADISON	IN	47250-1669
183	Affiliated	836	Newton	Renal Treatment Center-Newton aka-Newton Dialysis Center	1223 WASHINGTON RD		NEWTON	KS	67114-4855
184	Affiliated	837	Derby	Renal Treatment Center-Derby aka Derby Dialysis Center	250 W RED POWELL DR		DERBY	KS	67037-2626
185	Affiliated	834	Winfield	Renal Treatment Center-	1315 E 4TH AVE		WINFIELD	KS	67156-2457

			Winfield aka, Winfield Dialysis Center					
186	Affiliated	830	Wichita	Wichita	909 N TOPEKA		WICHITA	KS 67214-3620
			Dialysis Center	ST				
187	Affiliated	833	Garden City	Renal	401 N MAIN		GARDEN CITY	KS 67846-5429
			Treatment	ST				
			Center-Garden					
			City Aka-					
			Garden City					
			Dialysis Center					
188	Affiliated	831	E. Wichita	East Wichita	320 N		WICHITA	KS 67214-4918
			Dialysis Center	HILLSIDE ST				
189	Affiliated	832	Independence	Independence	801 W		INDEPENDENCE	KS 67301-3239
			Dialysis Center	MYRTLE ST				
190	Affiliated	835	Parson, KS	Parsons	1902 S US	BLDG B	PARSONS	KS 67357-4948
			Dialysis Center	HWY 59				
191	Affiliated	814	Wheaton	Wheaton	11941		WHEATON	MD 20902
			Dialysis Center	GEORGIA AVE				
192	Affiliated	812	Rockville	Rockville	14915	STE 1	ROCKVILLE	MD 20850-3367
			Dialysis Center	BROSCART				
				RD				
193	Affiliated	815	Owing Mills	Owings Mills	10	STE 11	OWINGS MILLS	MD 21117-5463
			Dialysis Center	CROSSROADS				
			(fka-Renal	DR				
			Treatment					
			Center-Owings					
			Mills)					
194	Affiliated	811	Berlin	Berlin Dialysis	314	STE 36	BERLIN	MD 21811-1238
			Center	FRANKLIN				
				AVE				
195	Affiliated	810	Easton	Easton Dialysis	402 MARVEL		EASTON	MD 21601-4052
			Center	CT				

196	Affiliated	813	Chestertown	Chestertown Dialysis Center (fka Renal Treatment Centers- Chestertown)	100 BROWN ST	CHESTERTOWN	MD 21620
197	Affiliated	951	Hope Again	Hope Again Dialysis Center- fka Kennett Dialysis Center	1207 STATE ROUTE VV	KENNETT	MO 63857-3823
198	Affiliated	950	Poplar Bluff	Bluff City Dialysis Center	2400 LUCY LEE STE E PKWY	POPLAR BLUFF	MO 63901-2429
199	Affiliated	949	Crystal City	Crystal City Dialysis Center	960 SO TRUMAN BLVD	CRYSTAL CITY	MO 63019-1329
200	Affiliated	947	St. Louis	St. Louis Dialysis Center (fka Renal Treatment Center-St. Louis)	2610 CLARK AVE	SAINT LOUIS	MO 63103-2502
201	Affiliated	944	Burlington	Burlington Dialysis Center	873 HEATHER RD	BURLINGTON	NC 27215-6288
202	Affiliated	838	Scottsbluff	Scottsbluff Dialysis Center	3812 AVENUE B	SCOTTSBLUFF	NE 69361-4780
203	Affiliated	802	Bridgewater	Bridgewater Dialysis Center (fka Renal Treatment Center- Bridgewater)	2121 US HWY 22	BOUND BROOK	NJ 08805-1546
204	Affiliated	845	West Las Vegas	Las Vegas Dialysis Center	150 S VALLEY VIEW BLVD	LAS VEGAS	NV 89107
205	Affiliated	846	North Las Vegas	North Las Vegas Dialysis Center	2300 MCDANIEL ST	NORTH LAS VEGAS	NV 89030-6318

206	Affiliated	940 Cincinnati	Eastgate Dialysis (fka Cincinnati)	4435 AICHOLTZ RD		CINCINNATI	OH	45245-1690
207	Affiliated	885 Tulsa	Tulsa Dialysis	4436 S HARVARD AVE		TULSA	OK	74135-2605
208	Affiliated	897 NW Bethany	Northwest Bethany Dialysis Center	7800 NW 23RD ST	STE A	BETHANY	OK	73008-4948
209	Affiliated	890 Duncan	Duncan Dialysis Center	2645 W ELK AVE		DUNCAN	OK	73533-1572
210	Affiliated	893 Shawnee	Shawnee Dialysis Center	4409 N KICKAPOO AVE	STE 113	SHAWNEE	OK	74804-1224
211	Affiliated	895 Stillwater	Stillwater Dialysis Center	406 E HALL OF FAME AVE	STE 3	STILLWATER	OK	74075-5447
212	Affiliated	955 Midwest City	Midwest City Dialysis Center	7221 E RENO AVE		MIDWEST CITY	OK	73110-4474
213	Affiliated	886 Broken Arrow	Broken Arrow Dialysis Center	1700 N 9TH ST		BROKEN ARROW	OK	74012
214	Affiliated	888 Tahlequah	Tahlequah Dialysis Center	1373 E BOONE ST		TAHLEQUAH	OK	74464-3330
215	Affiliated	899 Edmond	Edmond Dialysis	50 S BAUMANN AVE		EDMOND	OK	73034-5676
216	Affiliated	889 Altus	Altus Dialysis Center	205 S PARK LN	STE 13	ALTUS	OK	73521-5756
217	Affiliated	896 Elk City	Elk City Dialysis Center	1601 W 2ND ST		ELK CITY	OK	73644-4427
218	Affiliated	887 Claremore	Claremore Dialysis Center	202 E BLUE STARR DR		CLAREMORE	OK	74017-4223
219	Affiliated	891 Norman	Norman Dialysis Center	1818 W LINDSEY ST	STE 14 BLDG B	NORMAN	OK	73069-4159
220	Affiliated	862 Pocono	Pocono Dialysis Center	100 PLAZA CT	STE B	EAST STROUDSBURG	PA	18301-8258

221	Affiliated	861	Palmerton	Palmerton Dialysis Center	185 DELAWARE AVE	STE C	PALMERTON	PA	18071-1716
222	Affiliated	860	Jennersville	Jennersville Dialysis Center	1011 W BALTIMORE PIKE		WEST GROVE	PA	19390-9446
223	Affiliated	858	Lewistown	Lewistown Dialysis Center	611 ELECTRIC AVE		LEWISTOWN	PA	17044-1128
224	Affiliated	854	Lemoyne	Camp Hill Dialysis Center (fka Lemoyne Dialysis Center (York Hospital Acutes))	425 N 21ST ST	LOWER LEVEL	CAMP HILL	PA	17011-2223
225	Affiliated	856	Upland	Upland Dialysis Center	1 MEDICAL CENTER BLVD	STE 12	CHESTER	PA	19013-3902
226	Affiliated	848	South Philadelphia	So. Philadelphia Dialysis Center	109 DICKINSON ST		PHILADELPHIA	PA	19147-6107
227	Affiliated	857	Exton	Exton Dialysis Center	710 SPRINGDALE DR		EXTON	PA	19341-2828
228	Affiliated	847	Northeast Philadelphia	NE Philadelphia Dialysis Center	518 KNORR ST		PHILADELPHIA	PA	19111-4604
229	Affiliated	934	Longview	Longview Dialysis Center	425 N FREDONIA ST		LONGVIEW	TX	75601-6464
230	Affiliated	935	Marshall-RTC	Marshall Dialysis Center	1301 S WASHINGTON AVE		MARSHALL	TX	75670-6215
231	Affiliated	933	Conroe	Conroe Dialysis Center	500 MEDICAL CENTER BLVD	STE 175	CONROE	TX	77304-2899
232	Affiliated	928	San Marcos	Hill Country Dialysis Center Of San Marcos	1820 PETER GARZA DR		SAN MARCOS	TX	78666-7407

233	Affiliated 923	Sherman	Sherman Dialysis Center	205 W LAMBERTH RD	SHERMAN	TX	75092-2659
234	Affiliated 932	Tomball	Tomball Dialysis Center	27720A TOMBALL PKWY	TOMBALL	TX	77375-
235	Affiliated 919	Cleveland	Cleveland Dialysis Center	600 E HOUSTON STE 63	CLEVELAND	TX	77327-4689
236	Affiliated 921	Livingston	Livingston Dialysis Center	209 W PARK	LIVINGSTON	TX	77351-7020
237	Affiliated 920	Kingwood	Kingwood Dialysis Center	2300 GREEN STE 5 OAK DR	KINGWOOD	TX	77339-2053
238	Affiliated 930	North Houston	North Houston Dialysis Center	129 LITTLE YORK RD	HOUSTON	TX	77076-1020
239	Affiliated 926	Omni	Omni Dialysis Center (fka Hamilton Dialysis Center)	9350 KIRBY DR STE 11	HOUSTON	TX	77054-2528
240	Affiliated 925	Victoria	Victoria Dialysis Center	1405 VICTORIA STATION DR	VICTORIA	TX	77901-3092
241	Affiliated 922	Lufkin	Lufkin Dialysis Center	700 S JOHN REDDITT DR	LUFKIN	TX	75904-3145
242	Affiliated 927	Gonzales	Gonzales Dialysis Center	1406 N SARAH DEWITT DR	GONZALES	TX	78629-2702
243	Affiliated 924	Denison	Denison Dialysis Center	1220 REBA MCENTIRE LANE	DENISON	TX	75020-9057
244	Affiliated 918	South San Antonio	South San Antonio Dialysis Center	1313 SE STE 111 MILITARY DR	SAN ANTONIO	TX	78214-2850
245	Affiliated 913	Austin	Waterloo Dialysis Center (fka Austin	5310 BURNET UNIT 122 RD	AUSTIN	TX	78756-2003

			Dialysis Center)					
246	Affiliated	916 S. Austin	El Milagro Dialysis Unit (fka South Austin Dialysis Center)	2800 S INTERSTATE HWY 35	STE 12	AUSTIN	TX	78704-5700
247	Affiliated	929 SW San Antonio	Southwest San Antonio Dialysis Center	7515 BARLITE BLVD		SAN ANTONIO	TX	78224-1311
248	Affiliated	936 Bedford	HEB Dialysis Center (Bedford)	1401 BROWN TRL	STE A	BEDFORD	TX	76022-6416
249	Affiliated	917 TRC Med Cntr	Med-Center Dialysis, fka Plaza Dialysis Center & Houston Kidney Center #376	5610 ALMEDA RD		HOUSTON	TX	77004-7515
250	Affiliated	908 Chesapeake	Chesapeake Dialysis Center	1400 CROSSWAYS BLVD	CROSSWAYS II STE 16	CHESAPEAKE	VA	23320-2839
251	Affiliated	912 Hopewell	Hopewell Dialysis Center	301 W BROADWAY AVE		HOPEWELL	VA	23860-2645
252	Affiliated	911 Newport News	Newport News Dialysis Center	711 79TH ST		NEWPORT NEWS	VA	23605-2767
253	Affiliated	907 Norfolk	Norfolk Dialysis Center	962 NORFOLK SQ		NORFOLK	VA	23502-3235
254	Affiliated	909 Virginia Beach	Virginia Beach Dialysis Center	740 INDEPENDENCE CIR		VIRGINIA BEACH	VA	23455-6438
255	Affiliated	171 Palmer	Palmer Dialysis Center	30 COMMUNITY DR		EASTON	PA	18045-2658
256	Affiliated	589 Burgaw	SEDC (NC II) Burgaw Dialysis Center	704 S DICKERSON ST	PO BOX 1391	BURGAW	NC	28425-4904

257	Affiliated	590	Elizabethtown	SEDC (NC II)	101 DIALYSIS Elizabethtown DR Dialysis Center	ELIZABETHTOWN NC	28337-9048
258	Affiliated	591	Jacksonville	SEDC (NC II)	14 OFFICE PARK Jacksonville DR Dialysis Center	JACKSONVILLE NC	28546-7325
259	Affiliated	592	Kenansville	SEDC (NC II)	305 BEASLEY Kenansville ST Dialysis Center	KENANSVILLE NC	28349-8798
260	Affiliated	593	Shallotte	SEDC (NC II)	4770 Shallotte SHALLOTTE Dialysis AVE Center	SHALLOTTE NC	28470-6596
261	Affiliated	594	Whiteville	SEDC (NC II)	608 PECAN LN Whiteville Dialysis Center	WHITEVILLE NC	28472-2949
262	Affiliated	595	Wilmington	SEDC (NC II)	2215 YAUPON Wilmington DR Dialysis Center	WILMINGTON NC	28401-7334

263	Affiliated	175 Deerfield	Deerfield Beach Artificial Kidney Center	1983 W HILLSBORO BLVD		DEERFIELD BEACH	FL	33442-1418
264	Affiliated	176 Pompano Beach	Pompano Beach Artificial Kidney Center	600 SW 3RD ST	STE 11	POMPANO BEACH	FL	33060-6936
265	Affiliated	177 Tamarack	Tamarac Artificial Kidney Center	7140 W MCNAB RD		TAMARAC	FL	33321-5306
266	Affiliated	168 Atlantic AKC	Atlantic Artificial Kidney Center	6 INDUSTRIAL WAY W	STE B	EATONTOWN	NJ	07724-2258
267	Affiliated	587 Rowan/Kannapolis	Dialysis Care of Kannapolis	1607 N MAIN ST		KANNAPOLIS	NC	28081-2317
268	Affiliated	654 Cortez	Cortez Dialysis	610 E MAIN ST	STE C	CORTEZ	CO	81321-3308
269	Affiliated	142 West Bountiful 4/6/98	West Bountiful Dialysis	724 W 500 S	STE 3	WEST BOUNTIFUL	UT	84087-1471
270	Affiliated	187 Meherrin	Meherrin Dialysis Center	201A WEAVER AVE		EMPORIA	VA	23847-1248
271	Affiliated	436 Montclair	Montclair Dialysis Center	5050 PALO VERDE ST	STE 1	MONTCLAIR	CA	91763-2329
272	Affiliated	259 Pipestone	Pipestone Dialysis	916 4TH AVE SW		PIPESTONE	MN	56164-1054
273	Affiliated	236 Washington	Washington Dialysis Center	154 WASHINGTON PLZ		WASHINGTON	GA	30673-2074
274	Affiliated	235 Elberton	Elberton Dialysis Center	894 ELBERT ST		ELBERTON	GA	30635-2628
275	Affiliated	174 Gulf Breeze	Gulf Breeze Dialysis Center	1519 MAIN ST		DUNEDIN	FL	34698-4650
276	Affiliated	526 Asheville	Asheville Kidney Center	1600 CENTRE PARK DR		ASHEVILLE	NC	28805-6206
277	Affiliated	528 Sylva	Sylva Dialysis Center	655 ASHEVILLE HWY		SYLVA	NC	28779-2747

278	Affiliated	527 Hendersonville	Hendersonville Dialysis Center	500 BEVERLY HANKS CTR	HWY 25 N	HENDERSONVILLE NC	28792
279	Affiliated	389 Memorial	Memorial Dialysis	4427 S ROBERTSON ST		NEW ORLEANS LA	70115-6308
280	Affiliated	127 Warner Robbins	Dialysis Center of Middle Georgia- Warner Robins	509 N HOUSTON RD		WARNER ROBINS GA	31093-8844
281	Affiliated	126 Macon - Middle Georgia	Dialysis Center of Middle Georgia- Macon	747 2ND ST		MACON GA	31201-6835
282	Affiliated	344 Oakland PD	Oakland Peritoneal Dialysis Center (Piedmont PD)	5352 CLAREMONT AVE		OAKLAND CA	94618
283	Affiliated	384 Fairfax	Fairfax Dialysis Center	8501 ARLINGTON BLVD	STE 1	FAIRFAX VA	22031-4625
284	Affiliated	374 Houston SW	Houston Kidney Center Southwest	11111 BROOKLET DR	STE 1 BLDG 1	HOUSTON TX	77099-3555
285	Affiliated	545 Pikes Peak	Pikes Peak Dialysis Center	2002 LELARAY ST	STE 13	COLORADO SPRINGS CO	80909-2804
286	Affiliated	546 Printers Place	Printers Place Dialysis	2802 INTERNATIONAL CIR		COLORADO SPRINGS CO	80910-3127
287	Affiliated	541 Lakewood Colorado	Lakewood Dialysis Center	1750 PIERCE ST		LAKEWOOD CO	80214-1434
288	Affiliated	543 Boulder	Boulder Dialysis Center	2880 FOLSOM ST	STE 11	BOULDER CO	80304-3769
289	Affiliated	542 Thornton	Thornton Dialysis Center	8800 FOX DR		THORNTON CO	80260-6880
290	Affiliated	544 Arvada	Arvada Dialysis Center	9950 W 80TH AVE	STE 25	ARVADA CO	80005-3914

291	Affiliated	173 Ft. Lauderdale	CDC South-Ft Lauderdale Renal Associates	6264 N FEDERAL HWY		FORT LAUDERDALE	FL	33308-1904
292	Affiliated	380 Houston Cypress Station	Houston Kidney Center Cypress Station	221 FM 1960 RD W	STE H	HOUSTON	TX	77090-3537
293	Affiliated	169 Erie County	Cleve Hill Dialysis Center (Fka Cleve Hill Limited Partnership-Erie Dialysis &ECMC Dialysis Center At Cleve Hill)	1461 KENSINGTON AVE		BUFFALO	NY	14215-1436
294	Affiliated	430 UCLA Pediatrics	Century City Dialysis (fka UCLA, DaVita Westwood UCLA)	10630 SANTA MONICA BLVD		LOS ANGELES	CA	90025-4837
295	Affiliated	501 Bronx	Bronx Dialysis Center	1615 EASTCHESTER RD		BRONX	NY	10461-2603
296	Affiliated	502 Catskill	Catskill Dialysis Center	139 FORESTBURGH RD		MONTICELLO	NY	12701-2364
297	Affiliated	505 Riverdale	Riverdale Dialysis Center	170 W 233RD ST		BRONX	NY	10463-5639
298	Affiliated	506 South Bronx	South Bronx Dialysis Center	1940 WEBSTER AVE		BRONX	NY	10457-4261
299	Affiliated	507 Stanten Island	Richmond Kidney Center (Staten Island)	1366 VICTORY BLVD		STATEN ISLAND	NY	10301-3907
300	Affiliated	238 McDonough	McDonough Dialysis Center	114 DUNN ST		MCDONOUGH	GA	30253-2347
301	Affiliated	192 Milford	Delaware Valley Dialysis	102 DAVITA DR		MILFORD	PA	18337-9390

			Center (fka Milford)					
302	Affiliated	191 Honesdale	Honesdale Dialysis Center-NE Regional	RR 6 BOX 6636	STOURBRIDGE MALL	HONESDALE	PA	18431-9649
303	Affiliated	247 Memorial	Memorial Dialysis Center	11621 KATY FWY		HOUSTON	TX	77079-1801
304	Affiliated	246 Katy Dialysis Center	Grand Parkway Dialysis Center	403 W GRAND PKWY S	STE T	KATY	TX	77494-8358
305	Affiliated	245 Cyfair Dialysis Center	Cyfair Dialysis Center	9110 JONES RD	STE 11	HOUSTON	TX	77065-4489
306	Affiliated	165 Port Chester	Port Chester Dialysis and Renal Center	38 BULKLEY AVE		PORT CHESTER	NY	10573-3902
307	Affiliated	193 Franklin Dialysis	Franklin Dialysis Center	150 SOUTH INDEPENDENCE WEST	11 PUBLIC LEDGER BLDG	PHILADELPHIA	PA	19106-3413
308	Affiliated	156 Grand Blanc	Grand Blanc Dialysis Center	3625 GENESYS PKWY		GRAND BLANC	MI	48439-8070
309	Affiliated	397 Oxford Court	Oxford Court Dialysis	930 TOWN CENTER DR	STE G1	LANGHORNE	PA	19047-4260
310	Affiliated	348 Antioch	Antioch Dialysis	3100 DELTA FAIR BLVD		ANTIOCH	CA	94509-4001
311	Affiliated	401 North Palm Beach	North Palm Beach Dialysis Center	2841 PGA BLVD		PALM BEACH GARDENS	FL	33410-2910
312	Affiliated	277 Lodi	Lodi Dialysis Center	1610 W KETTLEMAN LN	STE D	LODI	CA	95242-4210
313	Affiliated	438 United	United Dialysis Center	3111 LONG BEACH BLVD		LONG BEACH	CA	90807-5015
314	Affiliated	437 Premier	Premier Dialysis Center	7612 ATLANTIC AVE		CUDAHY	CA	90201-5020
315	Affiliated	349 Salinas	Salinas Dialysis Center	955 BLANCO CIR	STE C	SALINAS	CA	93901-4452

316	Affiliated	428	Lowry I	Lowry Dialysis Center	7465 E 1ST AVE	STE A	DENVER	CO	80230-6877
317	Affiliated	154	Ypsilanti	Ypsilanti Dialysis	2766 WASHTENAW RD		YPSILANTI	MI	48197-1506
318	Affiliated	237	Eastpoint	East Point Dialysis	2669 CHURCH ST		EAST POINT	GA	30344-3115
319	Affiliated	520	Celia Dill	Celia Dill Dialysis Center	667 STONELEIGH AVE	STE 123 BARN OFFICE CENTER	CARMEL	NY	10512-2454
320	Affiliated	248	Elmbrook	Brookriver Dialysis	8101 BROOKRIVER DR		DALLAS	TX	75247-4003
321	Affiliated	402	Ocala East	OCALA Regional Kidney Center-East	2870 SE 1ST AVE		OCALA	FL	34471-0406
322	Affiliated	403	Ocala West	OCALA Regional Kidney Center-West	9401 SW HWY 200	BLDG 6	OCALA	FL	34481-9612
323	Affiliated	404	Ocala South	OCALA Regional Kidney Center-South	13940 N US HWY 441	BLDG 4	LADY LAKE	FL	32159-8908
324	Affiliated	417	Delta Sierra Dialysis	Delta-Sierra Dialysis Center	555 W BENJAMIN HOLT DR	STE 2	STOCKTON	CA	95207-3839
325	Affiliated	552	Olympic View	Olympic View Dialysis Center	125 16TH AVE E CSB	5TH FL	SEATTLE	WA	98112
326	Affiliated	148	Pratt	Pratt Dialysis Center	203 WATSON ST	STE 11	PRATT	KS	67124-3092
327	Affiliated	196	Buffalo	Renal Care of Buffalo	550 ORCHARD PARK RD		WEST SENECA	NY	14224-2646
328	Affiliated	555	Woodland	Woodland Dialysis Center	912 WOODLAND DR	STE B	ELIZABETHTOWN	KY	42701-2795
329	Affiliated	556	Taylor	Taylor County Dialysis Center	101 KINGSWOOD DR		CAMPBELLSVILLE	KY	42718-9634

330	Affiliated	491	Gary	Comprehensive Renal Care (CRC)-Gary	4802 BROADWAY	GARY	IN	46408-4509
331	Affiliated	492	Hammond	Comprehensive Renal Care (CRC)-Hammond	222 DOUGLAS ST	HAMMOND	IN	46320-1960
332	Affiliated	493	Valparaiso	Comprehensive Renal Care (CRC)-Valparaiso	606 E LINCOLNWAY	VALPARAISO	IN	46383-5728
333	Affiliated	494	Michigan City	Comprehensive Renal Care (CRC)-Michigan City	9836 WEST 400 NORTH	MICHIGAN CITY	IN	46360-2910
334	Affiliated	495	Munster	Comprehensive Renal Care (CRC)-Munster	9100 CALUMET AVE	MUNSTER	IN	46321-1737
335	Affiliated	497	South County-Deaconess	South County Dialysis (Deaconess)	4145 UNION RD	SAINT LOUIS	MO	63129-1064
336	Affiliated	266	South Hayward	South Hayward Dialysis Center	254 JACKSON ST	HAYWARD	CA	94544-1907
337	Affiliated	164	Dyker Heights	Dyker Heights Dialysis Center	1435 86TH ST	BROOKLYN	NY	11228-3435
338	Affiliated	152	Clarkston	Clarkston Dialysis Center	6770 DIXIE STE 25 HWY	CLARKSTON	MI	48346-2089
339	Affiliated	534	Hudson Valley	Hudson Valley Dialysis Center	155 WHITE PLAINS RD	TARRYTOWN	NY	10591-5523
340	Affiliated	971	Central Tulsa	Central Tulsa Dialysis Center	1124 S SAINT LOUIS AVE	TULSA	OK	74120-5413
341	Affiliated	972	Okmulgee	Okmulgee Dialysis Center	201 SO DELAWARE AVE	OKMULGEE	OK	74447-5528
342	Affiliated	974	Muskogee	Muskogee Community Dialysis	2316 W SHAWNEE ST	MUSKOGEE	OK	74401-2228
343	Affiliated	975	Miami-Oklahoma	Tri-State Dialysis Center (fka Miami Dialysis Center (OK))	2510 N MAIN ST	MIAMI	OK	74354-1602

344	Affiliated	977	Stilwell	Stilwell Dialysis Center	80851 HWY 59		STILWELL	OK	74960
345	Affiliated	496	East Chicago	Comprehensive Renal Care (CRC)-East Chicago	4320 FIR ST	UNIT 44	EAST CHICAGO	IN	46312-3078
346	Affiliated	549	Bright Dialysis	Bright Dialysis (fka Fort Pierce Artificial Kidney Center, TRC of Fort Pierce-AKC)	1801 S 23RD ST	STE 1	FORT PIERCE	FL	34950-4830
347	Affiliated	153	Detroit	Detroit Dialysis Center (Eastern Market, Brewery Park Development)	2674 E JEFFERSON AVE		DETROIT	MI	48207-4129
348	Affiliated	166	White Plains	White Plains Dialysis Center	200 HAMILTON AVE	STE 13B	WHITE PLAINS	NY	10601-1859
349	Affiliated	337	Crescent Heights	Crescent Heights Dialysis Center	8151 BEVERLY BLVD		LOS ANGELES	CA	90048-4514
350	Affiliated	547	Pahrump Dialysis	Pahrump Dialysis Center	330 S LOLA LN	STE 1	PAHRUMP	NV	89048-0884
351	Affiliated	598	Cherokee Dialysis Center	Cherokee Dialysis Center	53 ECHOTA CHURCH RD		CHEROKEE	NC	28719-9702
352	Affiliated	444	Utah Valley	Utah Valley Dialysis Center	1055 N 500 W	STE 221	PROVO	UT	84604-3305
353	Affiliated	439	Washington Plaza	Washington Plaza Dialysis Center	516 E WASHINGTON BLVD	# 522	LOS ANGELES	CA	90015-3723
354	Affiliated	539	Commerce City	Commerce City Dialysis Center	6320 HOLLY ST		COMMERCE CITY	CO	80022-3325
355	Affiliated	251	Bloomington Dialysis	Bloomington Dialysis Unit of TRC (fka Richfield)	8591 LYNDAL AVE S		BLOOMINGTON	MN	55420-2237
356	Affiliated	133	Kent Community Dialysis	Kent Dialysis Center	21501 84TH AVE S		KENT	WA	98032-1960
357	Affiliated	278	Florin Dialysis	Florin Dialysis Center	7000 STOCKTON BLVD		SACRAMENTO	CA	95823-2312

358	Affiliated	540	South Las Vegas Dialysis	South Las Vegas Dialysis Center (Palms)	2250 S RANCHO DR	STE 115	LAS VEGAS	NV	89102-4456
359	Affiliated	538	Longmont Dialysis	Longmont Dialysis Center	1715 IRON HORSE DR	STE 17	LONGMONT	CO	80501-9617
360	Affiliated	500	Great Bridge	Great Bridge Dialysis (fka Chesapeake II)	745 BATTLEFIELD BLVD N	STE 1	CHESAPEAKE	VA	23320-0305
361	Affiliated	569	Weaverville Dialysis	Weaverville Dialysis Facility	329 MERRIMON AVE		WEAVERVILLE	NC	28787-9253
362	Affiliated	427	Lakewood Crossing	Lakewood Crossing Dialysis	1057 S WADSWORTH BLVD	STE 1	LAKWOOD	CO	80226-4361
363	Affiliated	155	Jackson	Jackson Dialysis Center	234 W LOUIS GLICK HWY		JACKSON	MI	49201-1326
364	Affiliated	429	Englewood	Englewood Dialysis Center	3247 S LINCOLN ST		ENGLEWOOD	CO	80113-2505
365	Affiliated	387	Harford Road Dialysis	Harford Road Dialysis Center	5800 HARFORD RD		BALTIMORE	MD	21214-1847
366	Affiliated	179	Arcadia	Arcadia Dialysis Center	1341 E OAK ST		ARCADIA	FL	34266-8902
367	Affiliated	388	Richmond Community	Richmond Community Hospital Dialysis (fkaTRC @ Richmond Community/ Richmond II)	1510 N 28TH ST	STE 11	RICHMOND	VA	23223-5311
368	Affiliated	119	Henderson	Henderson Dialysis Center	1002 US HWY 79 N		HENDERSON	TX	75652-6008
369	Affiliated	253	Augusta	Nephrology Center of South Augusta	1631 GORDON HWY STE 1B		AUGUSTA	GA	30906
370	Affiliated	510	Boston Post Road	Boston Post Road Dialysis Center fka Co Op City Dialysis	4026 BOSTON RD		BRONX	NY	10475-1122
371	Affiliated	512	Peekskill	Peekskill Cortlandt Dialysis Center	2050 E MAIN ST	STE 15	CORTLANDT MANOR	NY	10567-2502

372	Affiliated	513	Queens	Queens Dialysis Center	11801 GUY R BREWER BLVD		JAMAICA	NY	11434-2101
373	Affiliated	517	Soundview	Soundview Dialysis Center	1622 BRUCKNER BLVD	STE 24	BRONX	NY	10473-4553
374	Affiliated	516	Port Washington	Port Washington Dialysis Center	50 SEAVIEW BLVD		PORT WASHINGTON	NY	11050-4615
375	Affiliated	515	Lynbrook	Lynbrook Dialysis Center	147 SCRANTON AVE		LYNBROOK	NY	11563-2808
376	Affiliated	518	Yonkers Dialysis Center	Yonkers Dialysis Center	575 YONKERS AVE		YONKERS	NY	10704-2601
377	Affiliated	537	IHS - Queens Village	Queens Village Dialysis Center	22202 HEMPSTEAD AVE	STE 17	QUEENS VILLAGE	NY	11429-2123
378	Affiliated	536	Coney Island - IHS	Sheepshead Bay Renal Care Center (fka Coney Island)	26 BRIGHTON 11TH ST		BROOKLYN	NY	11235-5304
379	Affiliated	521	Garden City I.H.S	Garden City Dialysis Center	1100 STEWART AVE	STE 2	GARDEN CITY	NY	11530-4839
380	Affiliated	267	Kenneth Hahn-I.R.A	Kenneth Hahn Plaza Dialysis Center (Willowbrook)	11854 S WILMINGTON AVE		LOS ANGELES	CA	90059-3016
381	Affiliated	279	North Highland	North Highlands Dialysis Center	4986 WATT AVE	STE F	NORTH HIGHLANDS	CA	95660-5182
382	Affiliated	294	TRC Orangevale	Orangevale Dialysis Center	9267 GREENBACK LN	STE A2	ORANGEVALE	CA	95662-4864
383	Affiliated	554	Forest Park Dialysis Center	Forest Park Dialysis Center	380 FOREST PKWY	STE C	FOREST PARK	GA	30297-2107
384	Affiliated	446	Grant Park Nursing Home Dialysis	Grant Park Dialysis (fka Grants Park Nursing Home)	5000 NANNIE HELEN BURROUGHS AVE NE		WASHINGTON	DC	20019-5506
385	Affiliated	455	Fourth Street Dialysis	Fourth Street Dialysis	3101 N 4TH ST	STE B	LONGVIEW	TX	75605-5146
386	Affiliated	274	Bay Breeze	Bay Breeze Dialysis	11465 ULMERTON RD		LARGO	FL	33778-1602

387	Affiliated	416	Hopi	Hopi Dialysis Center- fka First Mesa	PO BOX 964	HWY 264	POLACCA	AZ	86042
388	Affiliated	178	Orlando Dialysis	Orlando Dialysis	14050 TOWN LOOP BLVD	STE 14A	ORLANDO	FL	32837-6190
389	Affiliated	170	Celebration Dialysis	Celebration Dialysis	1154 CELEBRATION BLVD		CELEBRATION	FL	34747-4605
390	Affiliated	1500	Mt. Dora Dialysis	Mt. Dora Dialysis	2735 W OLD US HIGHWAY 441		MOUNT DORA	FL	32757-3526
391	Affiliated	1501	Lake Dialysis	Lake Dialysis	221 N 1ST ST		LEESBURG	FL	34748-5150
392	Affiliated	146	Puyallup Community Dialysis	Puyallup Dialysis Center	716 SOUTH HILL PARK DR	STE C	PUYALLUP	WA	98373-1445
393	Affiliated	562	Towson Dialysis	Dulaney Towson Dialysis Center	113 WEST RD	STE 21	TOWSON	MD	21204-2318
394	Affiliated	188	Purcellville	Purcellville Dialysis Center	280 N HATCHER AVE		PURCELLVILLE	VA	20132-3193
395	Affiliated	476	Iris City	Iris City Dialysis (aka Griffin)	521 N EXPRESSWAY	STE 159	GRIFFIN	GA	30223-2073
396	Affiliated	1521	Slidell Kidney Care	Slidell Kidney Care	1150 ROBERT BLVD	STE 24	SLIDELL	LA	70458-2005

397	Affiliated	385	Rivertowne Dialysis	Rivertowne Dialysis (fka Oxon Hill Dialysis)	6192 OXON HILL RD	1ST FL	OXON HILL	MD	20745-3114
398	Affiliated	477	Pearland Dialysis	Pearland Dialysis	6516 BROADWAY ST	STE 122	PEARLAND	TX	77581-7879
399	Affiliated	419	East Aurora Dialysis	East Aurora Dialysis (aka Aurora II)	482 S CHAMBERS RD		AURORA	CO	80017-2092
400	Affiliated	1507	Merrillville Dialysis	CRC- Merrillville Dialysis Center	9223 TAFT ST		MERRILLVILLE	IN	46410-6911
401	Affiliated	563	Bricktown Dialysis	Bricktown Dialysis Center	525 JACK MARTIN BLVD	FL 2	BRICK	NJ	08724-7735
402	Affiliated	423	Sapulpa	Sapulpa Dialysis (fka Jenks-Sapulpa)	9647 RIDGEVIEW ST		TULSA	OK	74131-6205
403	Affiliated	1526	Ellijay Dialysis	Ellijay Dialysis	449 INDUSTRIAL BLVD	STE 24	ELLIJAY	GA	30540-6724
404	Affiliated	1527	Gainesville Dialysis	Gainesville Dialysis	2545 FLINTRIDGE RD	STE 13	GAINESVILLE	GA	30501-7428
405	Affiliated	1528	Newnan Dialysis	Newnan Dialysis	1565 E HWY 34	STE 13	NEWNAN	GA	30265
406	Affiliated	405	Ocala Regional Kidney Center - North	OCALA North Dialysis Center	2620 W HWY 316		CITRA	FL	32113-3555
407	Affiliated	1516	Pin Oak Dialysis	Pin Oak Dialysis Center (aka Katy II)	1302 PIN OAK RD		KATY	TX	77494-6848
408	Affiliated	1523	Imperial Care Dialysis	Imperial Care Dialysis Center	4345 E IMPERIAL HWY		LYNWOOD	CA	90262-2318
409	Affiliated	1533	St. Louis Park Dialysis	St. Louis Park Dialysis Center	3505 LOUISIANA AVE S		ST LOUIS PARK	MN	55426-4121
410	Affiliated	1517	Minneapolis NE Dialysis	Minneapolis NE Dialysis	1049 10TH AVE SE		MINNEAPOLIS	MN	55414-1312
411	Affiliated	298	Flushing Dialysis	Flushing Dialysis Center	3469 PIERSON PL	STE A	FLUSHING	MI	48433-2413

412	Affiliated	1535	Dialysis Systems of Covington	Dialysis Systems of Covington	210 GREENBRIAR BLVD		COVINGTON	LA	70433-7235
413	Affiliated	1536	Dialysis Systems of Hammond	Dialysis Systems of Hammond	15799 PROFESSIONAL PLZ		HAMMOND	LA	70403-1452
414	Affiliated	433	Soledad Dialysis	Soledad Dialysis Center	901 LOS COCHES DR		SOLEDAD	CA	93960-2995
415	Affiliated	443	Lake Elsinore Dialysis	Lake Elsinore Dialysis	32291 MISSION TRL	BLDG S	LAKE ELSINORE	CA	92530
416	Affiliated	1511	Clinton Dialysis Center	Clinton Dialysis Center	150 S 31ST ST		CLINTON	OK	73601-9118
417	Affiliated	456	Bakers Ferry	Bakers Ferry Dialysis	3645 BAKERS FERRY RD SW		ATLANTA	GA	30331-3712
418	Affiliated	1509	Hermiston	Hermiston Community Dialysis Center	1155 W LINDA AVE		HERMISTON	OR	97838-9601
419	Affiliated	1539	Yakima	Yakima Dialysis Center	1221 N 16TH AVE		YAKIMA	WA	98902-1347
420	Affiliated	409	Madison	Madison Dialysis Center	302 HIGHWAY ST		MADISON	NC	27025-1672
421	Affiliated	1508	Swannanoa Dialysis	Swannanoa Dialysis Center (fka Black Mountain, NC)	2305 US HIGHWAY 70		SWANNANOA	NC	28778-8207
422	Affiliated	2009	NE Wichita Dialysis	NE Wichita Dialysis Center	2630 N WEBB RD	STE 1 BLDG 1	WICHITA	KS	67226-8174
423	Affiliated	2005	Chadbourn Dialysis	Chadbourn Dialysis Center (fkaColumbus County)	210 STRAWBERRY BLVD		CHADBOURN	NC	28431-1418
424	Affiliated	1506	Western Home Dialysis	Mile High Home Dialysis PD (fka Western Home)	1750 PIERCE ST	STE A	LAKESWOOD	CO	80214-1434
425	Affiliated	2019	Tustin Dialysis	Tustin Dialysis (aka Santa Ana)	2090 N TUSTIN AVE	STE 1	SANTA ANA	CA	92705-7869
426	Affiliated	182	Appomattox	Appomattox Dialysis (Petersburg)	15 W OLD ST		PETERSBURG	VA	23803-3221
427	Affiliated	2002	Maryville Dialysis	Maryville Dialysis	2130 VADALABENE DR		MARYVILLE	IL	62062-5632

428	Affiliated	2001	Mission Hills	Mission Hills Dialysis (aka Cristo Rey)	2700 N STANTON ST		EL PASO	TX	79902-2500
429	Affiliated	125	Moncrief	Moncrief Dialysis Partners	800 W 34TH ST	STE 11	AUSTIN	TX	78705-1144
430	Affiliated	295	Southfield West Dialysis	Southfield West Dialysis	21900 MELROSE AVE	STE 4	SOUTHFIELD	MI	48075-7967
431	Affiliated	525	Neptune Dialysis	Neptune Dialysis Center	2180 BRADLEY AVE		NEPTUNE	NJ	07753-4427
432	Affiliated	2014	Portsmouth Dialysis	Portsmouth Dialysis Center	2000 HIGH ST		PORTSMOUTH	VA	23704-3012
433	Affiliated	2016	Tokay Dialysis	Tokay Dialysis Center (fka East Lodi, CA)	312 S FAIRMONT AVE	STE A	LODI	CA	95240-3840
434	Affiliated	1504	Mt. Pocono Dialysis	Mt. Pocono Dialysis	100 COMMUNITY DR	STE 16	TOBYHANNA	PA	18466-8986
435	Affiliated	1544	Greater Portsmouth	Greater Portsmouth (aka Bon View Dialysis & Mid Town Hampton Road Dialysis)	3516 QUEEN ST		PORTSMOUTH	VA	23707-3238
436	Affiliated	1545	Peninsula Dialysis	Peninsula Dialysis Center (aka Immaculate Dialysis)	716 DENBIGH BLVD	STE D1 AND D2	NEWPORT NEWS	VA	23608-4414
437	Affiliated	1540	Saginaw Dialysis	Saginaw Dialysis	1527 E GENESEE AVE		SAGINAW	MI	48607-1755
438	Affiliated	1560	Churchview Dialysis	Churchview Dialysis	5970 CHURCHVIEW DR		ROCKFORD	IL	61107-2574
439	Affiliated	1562	Freeport Dialysis	Freeport Dialysis	1028 S KUNKLE BLVD		FREEPORT	IL	61032-6914
440	Affiliated	1563	Rockford Dialysis	Rockford Dialysis	3339 N ROCKTON AVE		ROCKFORD	IL	61103-2839
441	Affiliated	1564	Whiteside Dialysis	Whiteside Dialysis	2600 N LOCUST	STE D	STERLING	IL	61081-4602
442	Affiliated	2021	Pikesville Dialysis	Pikesville Dialysis	1500 REISTERSTOWN RD	STE 22	PIKESVILLE	MD	21208-3836

443	Affiliated	2000	Waynesville Dialysis	Waynesville Dialysis Center (fka Haywood, NC)	11 PARK TERRACE DR		CLYDE	NC	28721-7445
444	Affiliated	296	Davison Dialysis	Davison Dialysis	1011 S STATE RD		DAVISON	MI	48423-1903
445	Affiliated	1557	Flint Dialysis	Flint Dialysis Center	2 HURLEY PLZ	STE 115	FLINT	MI	48503-5904
446	Affiliated	1558	Hallwood Dialysis	Hallwood Dialysis Center	4929 CLIO RD	STE B	FLINT	MI	48504-1886
447	Affiliated	1559	Park Plaza Dialysis	Park Plaza Dialysis	G1075 N BALLENGER HWY		FLINT	MI	48504-4431
448	Affiliated	1518	Rosemead Springs Dialysis	Rosemead Springs Dialysis Center	3212 ROSEMEAD BLVD		EL MONTE	CA	91731-2807
449	Affiliated	2022	Scottsdale Dialysis	Scottsdale Dialysis Center	4725 N SCOTTSDALE RD	STE 1	SCOTTSDALE	AZ	85251-7621
450	Affiliated	1570	Washington Parish Dialysis	Washington Parish Dialysis	724 WASHINGTON ST		FRANKLINTON	LA	70438-1790
451	Affiliated	2027	Brookhollow Dialysis	Brookhollow Dialysis	4918 W 34TH ST		HOUSTON	TX	77092-6606
452	Affiliated	2017	Creekside	Creekside Dialysis Center (fka So. Vacaville, CA)	141 PARKER ST		VACAVILLE	CA	95688-3921
453	Affiliated	529	Middletown	Middletown Dialysis Center (fka-Red Bank)	500 STATE ROUTE 35	UNION SQUARE PLAZA	RED BANK	NJ	07701-5038
454	Affiliated	1541	Southwest Ohio Dialysis	Southwest Ohio Dialysis (Xenia- SWORC)	215 S ALLISON AVE		XENIA	OH	45385-3694
455	Affiliated	369	Oak Park	Oak Park Dialysis Center	13481 W 10 MILE RD		OAK PARK	MI	48237-4633
456	Affiliated	2042	Eden Prairie	Eden Prairie Dialysis	14852 SCENIC HEIGHTS RD	STE 255 BLDG B	EDEN PRAIRIE	MN	55344-2320
457	Affiliated	1530	Owensboro Dialysis	Owensboro Dialysis Center	1930 E PARRISH AVE		OWENSBORO	KY	42303-1443
458	Affiliated	1531	Tell City Dialysis	CRC-Tell City Dialysis Center	1602 MAIN ST		TELL CITY	IN	47586-1310

459	Affiliated	1576	Crestwood Dialysis	Crestwood Dialysis (fka Health Research Group-St. Louis (HRG))	9901 WATSON RD	STE 125	SAINT LOUIS	MO	63126-1855
460	Affiliated	2004	Copperfield Dialysis	Copperfield Dialysis (fka Cabarrus County-NC, and Concord)	1030 VINEHAVEN DR		CONCORD	NC	28025-2438
461	Affiliated	1572	Grand Island Dialysis	Grand Island Dialysis	603 S WEBB RD		GRAND ISLAND	NE	68803-5141
462	Affiliated	1573	Harlan Dialysis	Harlan Dialysis	1213 GARFIELD AVE		HARLAN	IA	51537-2057
463	Affiliated	1574	Shenandoah Dialysis	Shenandoah Dialysis	300 PERSHING AVE		SHENANDOAH	IA	51601-2355

464	Affiliated	2053	Germantown Dialysis	Germantown Dialysis	20111 CENTURY BLVD	STE C	GERMANTOWN MD	20874-9165
465	Affiliated	2051	Lamplighter Dialysis	Lamplighter Dialysis	12654 LAMPLIGHTER SQUARE		ST LOUIS MO	63128
466	Affiliated	1578	Kidney Care of Largo	Kidney Care of Largo	1300 MERCANTILE LN	STE 194	UPPER MARLBORO MD	20774
467	Affiliated	1579	Kidney Care of Laurel	Kidney Care of Laurel	14631 LAUREL BOWIE ROAD	UNITS 1-15	LAUREL MD	20707
468	Affiliated	2024	Durant Dialysis	Durant Dialysis Center	411 WESTSIDE DR		DURANT OK	74701-2932
469	Affiliated	2038	Palm Brook Dialysis	Palm Brook Dialysis Center	14664 N DEL WEBB BLVD		SUN CITY AZ	85351-2137
470	Affiliated	2043	Cambridge Dialysis	Cambridge Dialysis Center	300 BYRN ST		CAMBRIDGE MD	21613-1908
471	Affiliated	2059	Reston Dialysis Center	Reston Dialysis Center	1875 CAMPUS COMMONS DR	STE 11	RESTON VA	20191-1564
472	Affiliated	2040	Franconia Dialysis	Franconia Dialysis Centre	5695 KING CENTRE DRIVE		ALEXANDRIA VA	22315-5744
473	Affiliated	2041	Eagan Dialysis	Eagan Dialysis Unit	2750 BLUE WATER RD	SUITE 3	EAGAN MN	55121-1400
474	Affiliated	1594	Central Des Moines Dialysis	Central Des Moines Dialysis	1215 PLEASANT ST	STE 16	DES MOINES IA	50309-1409
475	Affiliated	1595	West Des Moines Dialysis	West Des Moines Dialysis	6800 LAKE DR	STE 185	WEST DES MOINES IA	50266-2544
476	Affiliated	1596	Creston Dialysis	Creston Dialysis	1700 W TOWNLINE ST		CRESTON IA	50801-1054
477	Affiliated	1597	Atlantic Dialysis	Atlantic Dialysis	1500 E 10TH ST		ATLANTIC IA	50022-1935
478	Affiliated	1598	Newton Dialysis	Newton Dialysis	204 N 4TH AVE E	STE 134	NEWTON IA	50208-3135
479	Affiliated	2046	Dialysis of Des Moines	Riverpoint Dialysis Unit	501 SW 7TH ST	STE B	DES MOINES IA	50309-4538
480	Affiliated	2060	Bellevue Dialysis	Bellevue Dialysis Center	3535 FACTORIA BLVD SE	STE 15	BELLEVUE WA	98006-1293

481	Affiliated	414	Somerset Dialysis	Somerset Dialysis Center	240 CHURCHILL AVE		SOMERSET	NJ	08873-3451
482	Affiliated	2031	East Ft. Lauderdale Dialysis	East Ft. Lauderdale Dialysis Center (fka No. Broward)	1301 S ANDREWS AVE	STE 11	FT LAUDERDALE	FL	33316-1823
483	Affiliated	1593	Spring Branch Dialysis	Spring Branch Dialysis	1425 BLALOCK	STE 1	HOUSTON	TX	77055-4446
484	Affiliated	1599	Battle Creek Dialysis	Battle Creek Dialysis	220 E GOODALE AVE		BATTLE CREEK	MI	49037-2728
485	Affiliated	2025	Hampton Avenue Dialysis	Hampton Avenue Dialysis-MO (Forest Park)	1425 HAMPTON AVE		SAINT LOUIS	MO	63139-3115
486	Affiliated	1605	Bogalusa Kidney Care	Bogalusa Kidney Care	2108 SOUTH AVE F		BOGALUSA	LA	70427
487	Affiliated	2055	Bardstown Dialysis	Bardstown Dialysis Center	210 W JOHN FITCH AVE		BARDSTOWN	KY	40004-1115
488	Affiliated	2050	Southern Pines	Southern Pines Dialysis Center	209 WINDSTAR PL		SOUTHERN PINES	NC	28387-7086
489	Affiliated	2030	Montclare Dialysis	Montclare Dialysis Center (aka Belmont Ave)	7009 W BELMONT AVE		CHICAGO	IL	60634-4533
490	Affiliated	2048	Southern Hills	Southern Hills Dialysis Center	9280 W SUNSET RD	STE 11	LAS VEGAS	NV	89148-4861
491	Affiliated	2068	Kilgore Dialysis	Kilgore Dialysis Center	209 HWY 42 NORTH		KILGORE	TX	75662-5019
492	Affiliated	2067	Brighton Dialysis	Brighton Dialysis	4700 E BROMLEY LN	STE 13	BRIGHTON	CO	80601-7821
493	Affiliated	2023	Union Gap	Union Gap Dialysis (aka Yakima)	1236 AHTANUM RIDGE DR	AHTANUM RIDGE BUSINESS PARK	UNION GAP	WA	98903-1813
494	Affiliated	2039	Dallas North Dialysis	Dallas North Dialysis Center (aka Greenville)	11886 GREENVILLE AVE	STE 1B	DALLAS	TX	75243-9743
495	Affiliated	2061	Grovepark Dialysis	Grovepark Dialysis Center (fka Jackson Dialysis)	794 MCDONOUGH RD		JACKSON	GA	30233-1572

496	Affiliated	1583	Eastern Kentucky Dialysis	Eastern Kentucky Dialysis	167 WEDDINGTON BRANCH RD		PIKEVILLE	KY	41501-3204
497	Affiliated	1584	Paintsville Dialysis	Paintsville Dialysis	4750 S KY ROUTE 321		HAGERHILL	KY	41222
498	Affiliated	1582	West Virginia Dialysis	West Virginia Dialysis	300 PROSPERITY LANE	STE 15	LOGAN	WV	25601-3494
499	Affiliated	2049	Reidsville Dialysis	Reidsville Dialysis	1307 FREEWAY DR		REIDSVILLE	NC	27320-7104
500	Affiliated	2034	Elk Grove Dialysis	Elk Grove Dialysis	9281 OFFICE PARK CIR	STE 15	ELK GROVE	CA	95758-8069
501	Affiliated	2035	Weston Dialysis	Weston Dialysis Center (fka Cleveland Clinic)	2685 EXECUTIVE PARK DR	STE 1	WESTON	FL	33331-3651
502	Affiliated	1600	McCook Dialysis	McCook Dialysis Center	801 W C ST		MCCOOK	NE	69001-3591
503	Affiliated	1601	Hastings Dialysis	Hastings Dialysis Center	1900 N SAINT JOSEPH AVE		HASTINGS	NE	68901-2652
504	Affiliated	1602	Capital City Dialysis	Capital City Dialysis	307 N 46TH ST		LINCOLN	NE	68503-3714
505	Affiliated	1616	Renal Care of Bowie	Renal Care of Bowie	4861 TELSA DRIVE	STES G-H	BOWIE	MD	20715-4318
506	Affiliated	1617	Renal Care of Takoma Park	Takoma Park Dialysis (fka Renal Care of Takoma Park)	1502 UNIVERSITY BLVD E		HYATTSVILLE	MD	20783
507	Affiliated	1618	Renal Care of Lanham	Renal Care of Lanham	8855 ANNAPOLIS RD	STE 2	LANHAM	MD	20706-2942
508	Affiliated	1619	Parma Dialysis	Parma Dialysis Center	6735 AMES RD		CLEVELAND	OH	44129-5601
509	Affiliated	1620	Middleburg Heights Dialysis	Middleburg Hts. Dialysis	7360 ENGLE RD		MIDDLEBURG HTS	OH	44130
510	Affiliated	1621	Rocky River Dialysis	Rocky River Dialysis	20220 CENTER RIDGE RD	STE 5	ROCKY RIVER	OH	44116-3567
511	Affiliated	1606	Diamond Valley Dialysis	Diamond Valley Dialysis	1030 E FLORIDA AVE		HEMET	CA	92543-4511
512	Affiliated	1607	Murrieta Dialysis	Murrieta Dialysis	25100 HANCOCK AVE	STE 11	MURRIETA	CA	92562-5973

513	Affiliated	2057	South Chico Dialysis	South Chico Dialysis Center	2345 FOREST AVE	CHICO	CA	95928-7641
514	Affiliated	2099	Dixon Kidney Center	Dixon Kidney Center	1131 N GALENA AVE	DIXON	IL	61021-1015
515	Affiliated	1640	Grand Rapids	PDI-Grand Rapids	801 CHERRY ST SE	GRAND RAPIDS	MI	49506-1440
516	Affiliated	1641	Grand Rapids East	PDI-Grand Rapids East	1230 EKHART ST NE	GRAND RAPIDS	MI	49503-1372
517	Affiliated	1642	Grand Haven	PDI-Grand Haven	16964 ROBBINS RD	GRAND HAVEN	MI	49417-2796
518	Affiliated	1644	Highland Park	PDI-Highland Park	64 VICTOR ST	HIGHLAND PARK	MI	48203-3128
519	Affiliated	1645	Cadieux	PDI-Cadieux	6150 CADIEUX ROAD	DETROIT	MI	48224-2006
520	Affiliated	1646	Montgomery	PDI- Montgomery	1001 FOREST AVE	MONTGOMERY	AL	36106-1181
521	Affiliated	1647	East Montgomery	PDI-East Montgomery	6890 WINTON BLOUNT BLVD	MONTGOMERY	AL	36117-3516
522	Affiliated	1648	Prattville	PDI-Prattville	1815 GLYNWOOD DR	PRATTVILLE	AL	36066-5584
523	Affiliated	1649	Elmore	PDI-Elmore	125 HOSPITAL DR	WETUMPKA	AL	36092-1626
524	Affiliated	1650	Fitchburg	PDI-Fitchburg	551 ELECTRIC AVE	FITCHBURG	MA	01420-5371
525	Affiliated	1652	Rocky Hill	PDI-Rocky Hill	30 WATERCHASE DR	ROCKY HILL	CT	06067-2110
526	Affiliated	1653	Middlesex	PDI-Middlesex Dialysis Center	100 MAIN ST STE A	MIDDLETOWN	CT	06457-3477
527	Affiliated	1655	Johnstown	PDI-Johnstown	344 BUDFIELD ST	JOHNSTOWN	PA	15904-3214
528	Affiliated	1656	Ebensburg	PDI-Ebensburg	236 JAMESWAY RD	EBENSBURG	PA	15931-4207
529	Affiliated	1657	Walnut Tower	PDI-Walnut Tower	834 WALNUT ST	PHILADELPHIA	PA	19107-5109
530	Affiliated	1659	Lancaster	PDI-Lancaster	1412 E KING ST	LANCASTER	PA	17602-3240

531	Affiliated	1660	Ephrata	PDI-Ephrata	67 W CHURCH ST		STEVENS	PA	17578-9203
532	Affiliated	2083	Pinecrest Dialysis	Pinecrest Dialysis (aka North Marshall-TX)	913 E PINECREST DR		MARSHALL	TX	75670-7309
533	Affiliated	551	Westwood Dialysis	Westwood Dialysis Center (aka West Seattle)	2615 SW TRENTON ST		SEATTLE	WA	98126-3745
534	Affiliated	2107	Louisville Dialysis	Louisville Dialysis	8037 DIXIE HWY		LOUISVILLE	KY	40258-1344
535	Affiliated	2018	Fair Oaks Dialysis	Fair Oaks Dialysis Center (fka Chantilly & Centreville)	3955 PENDER DR	ONE PENDER BUSINESS PARK	FAIRFAX	VA	22030-6091
536	Affiliated	421	Oak Cliff	Oak Cliff Dialysis	2000 S LLEWELLYN AVE		DALLAS	TX	75224-1804
537	Affiliated	2126	Gilmer Dialysis	Gilmer Dialysis Center	519 N WOOD ST		GILMER	TX	75644-1746
538	Affiliated	1608	Chicago Heights Dialysis	Chicago Heights Dialysis	177 W JOE ORR RD	STE B	CHICAGO HEIGHTS	IL	60411-1733
539	Affiliated	1623	East Georgia Dialysis	East Georgia Dialysis	450 GEORGIA AVE	STE A	STATESBORO	GA	30458-5590
540	Affiliated	1639	Northlake Dialysis	Northlake Dialysis	1350 MONTREAL RD	STE 2	TUCKER	GA	30084-8144
541	Affiliated	1680	Down River Dialysis	Downriver Kidney Center	5600 ALLEN RD		ALLEN PARK	MI	48101-2604
542	Affiliated	2063	Belcaro	Belcaro Dialysis Center	755 S COLORADO BLVD		DENVER	CO	80246-8005
543	Affiliated	2076	Sherwood Dialysis Center	Sherwood Dialysis Center	21035 SW PACIFIC HWY		SHERWOOD	OR	97140-8062
544	Affiliated	2054	Lonetree Dialysis	Lonetree Dialysis Center (aka Skyridge)	9777 MOUNT PYRAMID CT	STE 14	ENGLEWOOD	CO	80112-6017
545	Affiliated	2078	River Park Dialysis	River Park Dialysis (aka Conroe)	2010 S LOOP 336 W	STE 2	CONROE	TX	77304-3313
546	Affiliated	2058	Northshore Dialysis	Northshore Kidney Center (fka Slidell II)	106 MEDICAL CENTER DR		SLIDELL	LA	70461-5575

547	Affiliated	2036	Marysville Dialysis	Marysville Dialysis Center	1015 8TH ST		MARYSVILLE	CA	95901-5271
548	Affiliated	2070	West Georgia Dialysis	West Georgia Dialysis	1216 STARK AVE		COLUMBUS	GA	31906-2500
549	Affiliated	2102	East Dearborn Dialysis	Westland Dialysis (aka Canton)	36588 FORD RD		WESTLAND	MI	48185-3769
550	Affiliated	2045	Downtown Houston Dialysis	Downtown Houston Dialysis Center	2207 CRAWFORD ST		HOUSTON	TX	77002-8915
551	Affiliated	2066	Concord Dialysis	Concord Dialysis Center	2300 STANWELL DR	STE C	CONCORD	CA	94520-4841
552	Affiliated	2087	Pendleton Dialysis	Pendleton Dialysis (aka Clemson, Tri- County)	7703 HIGHWAY 76		PENDLETON	SC	29670-1818
553	Affiliated	2106	New Albany Dialysis	New Albany Dialysis	2669 CHARLESTON RD		NEW ALBANY	IN	47150-2573
554	Affiliated	1585	Whitesburg Dialysis	Whitesburg Dialysis	222 HOSPITAL RD	STE D	WHITESBURG	KY	41858-7627
555	Affiliated	2047	Jacinto Dialysis	Jacinto Dialysis Center (aka East Houston)	11515 MARKET STREET RD		HOUSTON	TX	77029-2305
556	Affiliated	2088	Transmountain Dialysis	Transmountain Dialysis (aka Northeast El Paso, Rushfair)	5255 WOODROW BEAN	STE B18	EL PASO	TX	79924-3832
557	Affiliated	2029	Southcrest Dialysis	Southcrest Dialysis (aka South Creek)	9001 S 101ST EAST AVE	STE 11	TULSA	OK	74133-5799
558	Affiliated	2071	Lake Hearn	Lake Hearn Dialysis (aka Dunwoody, Roswell, Northside)	1150 LAKE HEARN DR NE	STE 1	ATLANTA	GA	30342-1566
559	Affiliated	2118	Mt. Greenwood	Mt. Greenwood Dialysis	3401 W 111TH ST		CHICAGO	IL	60655-3329
560	Affiliated	2086	Citrus Valley Dialysis Center	Citrus Valley Dialysis (aka San Bernadino II)	894 HARDT STREET		SAN BERNARDINO	CA	92408-2854
561	Affiliated	2095	McDowell County Dialysis	McDowell County Dialysis Center	100 SPAULDING RD	STE 2	MARION	NC	28752-5116

562	Affiliated	2115	Leigh Dialysis Center	Leigh Dialysis Center (aka Leigh-Kempville-VA)	420 N CENTER DR	STE 128	NORFOLK	VA	23502-4019
563	Affiliated	2120	Dialysis of Lithonia	Dialysis of Lithonia	2485 PARK CENTRAL BLVD		DECATUR	GA	30035-3902
564	Affiliated	2114	Embassy Lake Artificial Kidney Center	Embassy Lake Artificial Kidney Center (fka Davie & South Broward AKC)	11011 SHERIDAN ST	STE 38	HOLLYWOOD	FL	33026-1505
565	Affiliated	2056	Sun City Dialysis	Sun City Dialysis (aka Texas Tech II)	600 NEWMAN ST		EL PASO	TX	79902-5543
566	Affiliated	1651	PDI Worcester	PDI-Worcester Dialysis	19 GLENNIE ST	STE A	WORCESTER	MA	01605-3918
567	Affiliated	2130	Davenport Dialysis Center	Davenport Dialysis Center (aka Haines City II)	45597 HIGHWAY 27	RIDGEVIEW PLAZA	DAVENPORT	FL	33897-4519
568	Affiliated	2081	Cinema Dialysis	Cinema Dialysis (aka OKC South)	3909 S WESTERN AVE		OKLAHOMA CITY	OK	73109-3405
569	Affiliated	2037	Greenwood Dialysis Center	Greenwood Dialysis Center (North Tulsa)	1345 N LANSING AVE		TULSA	OK	74106-5911
570	Affiliated	1712	TRC Alamosa Diakysis	Alamosa Dialysis	612 DEL SOL DR		ALAMOSA	CO	81101-8548
571	Affiliated	1682	South Austin	South Austin Dialysis	6114 S 1ST ST		AUSTIN	TX	78745-4008
572	Affiliated	2109	Durango Dialysis Center	Durango Dialysis Center	72 SUTTLE STREET	STE D	DURANGO	CO	81303-6829
573	Affiliated	1700	Bolivar Dialysis	Bolivar Dialysis	515 PECAN DR		BOLIVAR	TN	38008-1611
574	Affiliated	1701	Brownsville Dialysis	Brownsville Dialysis	380 N DUPREE AVE		BROWNSVILLE	TN	38012-2332
575	Affiliated	1702	Camden Dialysis	Camden Dialysis	168 W MAIN ST	STE A	CAMDEN	TN	38320-1767
576	Affiliated	1703	Collierville Dialysis	Collierville Dialysis	791 W POPLAR AVE		COLLIERVILLE	TN	38017-2543
577	Affiliated	1705	Galleria Dialysis	Galleria Dialysis	9160 HIGHWAY 64		LAKELAND	TN	38002-4766
578	Affiliated	1706	Humboldt Dialysis	Humboldt Dialysis	2214 OSBORNE ST		HUMBOLDT	TN	38343-3044

579	Affiliated	1707	Stonegate Dialysis	North Jackson Dialysis (fka Stonegate)	217 STERLING FARM DR	JACKSON	TN	38305-5727
580	Affiliated	1708	Lexington Dialysis	Lexington Dialysis	317 W CHURCH ST	LEXINGTON	TN	38351-2096
581	Affiliated	1709	Pickwick Dialysis	Pickwick Dialysis	121 PICKWICK ST	SAVANNAH	TN	38372-1953
582	Affiliated	1710	Selmer Dialysis	Selmer Dialysis	251 OAKGROVE RD	SELMER	TN	38375-1881
583	Affiliated	1713	Childs Dialysis	Childs Dialysis	101 MAIN ST	CHILDS	PA	18407-2614
584	Affiliated	1714	Dunmore Dialysis	Dunmore Dialysis	1212 O' NEIL HWY	DUNMORE	PA	18512-1717
585	Affiliated	1716	Old Forge Dialysis	Old Forge Dialysis	325 S MAIN ST	OLD FORGE	PA	18518-1677
586	Affiliated	1717	Scranton Dialysis	Scranton Dialysis	475 MORGAN HWY	SCRANTON	PA	18508-2605
587	Affiliated	1718	Tunkhannock Dialysis	Tunkhannock Dialysis	5950 SR 6	TUNKHANNOCK	PA	18657-7905
588	Affiliated	1725	East Evansville Dialysis	East Evansville Dialysis	1312 PROFESSIONAL BLVD	EVANSVILLE	IN	47714-8007
589	Affiliated	1726	North Evansville Dialysis	North Evansville Dialysis	1151 W BUENA VISTA RD	EVANSVILLE	IN	47710-3334
590	Affiliated	1728	Jasper Dialysis	Jasper Dialysis	721 W 13TH ST STE 15	JASPER	IN	47546-1856
591	Affiliated	1729	Daviess County Dialysis	Daviess County Dialysis	310 NE 14TH ST	WASHINGTON	IN	47501-2137
592	Affiliated	1730	Gardenside Dialysis	Gardenside Dialysis	70 N GARDENMILE RD	HENDERSON	KY	42420-5529
593	Affiliated	1732	PD Evansville Dialysis	East Evansville Dialysis PD	1312 PROFESSIONAL BLVD	EVANSVILLE	IN	47714-8007
594	Affiliated	2098	Meridian Dialysis Center	Meridian Dialysis Center (aka Bayshore)	201 W STE A FAIRMONT PKWY	LA PORTE	TX	77571-6303
595	Affiliated	2100	Sycamore Dialysis	Sycamore Dialysis (aka DeKalb)	2200 GATEWAY DR	SYCAMORE	IL	60178-3113
596	Affiliated	2104	Ballenger Pointe Dialysis	Ballenger Pointe Dialysis (aka West Flint)	2262 S BALLENGER HWY	FLINT	MI	48503-3447

597 Affiliated 2139 Leitchfield Leitchfield 912 WALLACE STE 16 LEITCHFIELD KY 42754-2405
Dialysis Dialysis AVE

Page 93 of 123

598	Affiliated	2097	Roxbury Dialysis Center	Roxbury Dialysis	622 ROXBURY RD	ROCKFORD	IL	61107-5089
599	Affiliated	2148	LaGrange Dialysis	La Grange Dialysis	240 PARKER DR	LA GRANGE	KY	40031-1200
600	Affiliated	2132	Des Moines East	East Des Moines Dialysis (aka Des Moines II)	1301 PENNSYLVANIA AVE STE 28	DES MOINES	IA	50316-2365
601	Affiliated	2119	Lake Villa Dialysis	Lake Villa Dialysis	37809 N IL ROUTE 59	LAKE VILLA	IL	60046-7332
602	Affiliated	159	Seneca Dialysis	Seneca County Dialysis	65 SAINT FRANCIS AVE	TIFFIN	OH	44883-3413
603	Affiliated	407	Perry	Perry Dialysis Center	1027 KEITH DR	PERRY	GA	31069-2948
604	Affiliated	661	Wilshire	Wilshire Dialysis	1212 WILSHIRE BLVD	LOS ANGELES	CA	90017-1902
605	Affiliated	692	University Park	University Park Dialysis Center	3986 S FIGUEROA ST	LOS ANGELES	CA	90037-1222
606	Affiliated	1720	Metro East Dialysis	Metro East Dialysis	5105 W MAIN ST	BELLEVILLE	IL	62226-4728
607	Affiliated	2196	Ocala Regional Kidney Centers	Ocala Regional Kidney Centers Home Dialysis Division PD	2860 SE 1ST AVE	OCALA	FL	34471-0406
608	Affiliated	2133	Little Village Dialysis	Little Village Dialysis (Chicago)	2335 W CERMAK RD	CHICAGO	IL	60608-3811
609	Affiliated	2112	Crossroads	Crossroads Dialysis (aka Fullerton Dialysis)	3214 YORBA LINDA BLVD	FULLERTON	CA	92831-1707
610	Affiliated	1727	Vincennes Dialysis	Vincennes Dialysis	700 WILLOW ST	VINCENNES	IN	47591-1028
611	Affiliated	1723	Spring Dialysis	Spring Dialysis	607 TIMBERDALE LN STE 1	HOUSTON	TX	77090-3043
612	Affiliated	2190	River Center	Rivercenter Dialysis (aka	1123 N MAIN AVE STE 15	SAN ANTONIO	TX	78212-4738

613	Affiliated	2193	Southcross Dialysis Center	Central San Antonio) Southcross Dialysis (aka SouthEast San Antonio)	4602 E SOUTHCROSS BLVD		SAN ANTONIO	TX	78222-4911
614	Affiliated	2125	Bonham Dialysis	Bonham Dialysis	201 W 5TH ST		BONHAM	TX	75418-4302
615	Affiliated	2192	Northwest Medical Center Dialysis	NW Medical Center Dialysis (aka NorthWest San Antonio)	5284 MEDICAL DR	STE 1	SAN ANTONIO	TX	78229-4849
616	Affiliated	2124	Ontario Dialysis	Ontario Dialysis (aka Dr. Handoko)	1950 S GROVE AVE	STE 11-15	ONTARIO	CA	91761-5693
617	Affiliated	1750	Chipley Community Dialysis	Chipley Dialysis	877 3RD ST	STE 2	CHIPLEY	FL	32428-1855
618	Affiliated	1751	North Okaloosa	North Okaloosa Dialysis	320 REDSTONE AVE W		CRESTVIEW	FL	32536-6433
619	Affiliated	1752	West Florida Dialysis	West Florida Dialysis	8333 N DAVIS HWY	1ST FLOOR ATTN DIALYSIS ROOM	PENSACOLA	FL	32514-6049
620	Affiliated	1753	Santa Rosa Dialysis	Santa Rosa Dialysis	5819 HIGHWAY 90		MILTON	FL	32583-1763
621	Affiliated	1755	Atmore Dialysis	Atmore Dialysis Center	807 E CRAIG ST		ATMORE	AL	36502-3017
622	Affiliated	1756	South Baldwin Dialysis	South Baldwin Dialysis Center	150 W PEACHTREE AVE		FOLEY	AL	36535-2244
623	Affiliated	1731	Olney Dialysis	Olney Dialysis Center (aka Good Samaritan Hospital)	117 N BOONE ST		OLNEY	IL	62450-2109
624	Affiliated	2156	Lancaster Dialysis	Lancaster Dialysis	2424 W PLEASANT RUN RD		LANCASTER	TX	75146-4005

625	Affiliated	2136	Columbia Dialysis	RTC- Columbia Dialysis (MO)	1701 E BROADWAY	STE G12	COLUMBIA	MO	65201-8029
626	Affiliated	2194	Las Palmas Dialysis Center	Las Palmas Dialysis Center (aka West San Antonio)	803 CASTROVILLE RD	STE 415	SAN ANTONIO	TX	78237-3148
627	Affiliated	2116	South Shore Dialysis Center	South Shore Dialysis (aka Horizon)	212 GULF FWY S	STE G3	LEAGUE CITY	TX	77573-3957
628	Affiliated	2191	Marymount Dilaysis Center	Marymont Dialysis (aka NorthEast San Antonio)	2391 NE LOOP 410	STE 211	SAN ANTONIO	TX	78217-5675
629	Affiliated	1744	Fox River Dialysis	Fox River Dialysis	1910 RIVERSIDE DR		GREEN BAY	WI	54301-2319
630	Affiliated	1745	Titletown Dialysis	Titletown Dialysis	120 SIEGLER ST		GREEN BAY	WI	54303-2636
631	Affiliated	1746	Northwoods Dialysis	Green Bay Northwood Dialysis	W 7305 ELM AVENUE		SHAWANO	WI	54166-1024
632	Affiliated	1758	North Charleston Dialysis	North Charleston Dialysis	5900 RIVERS AVE	STE E	NORTH CHARLESTON	SC	29406
633	Affiliated	1759	Charleston County Dialysis	Faber Place Dialysis	3801 FABER PLACE DR		NORTH CHARLESTON	SC	29405-8533
634	Affiliated	1760	Goose Creek Dialysis	Goose Creek Dialysis	109 GREENLAND DR		GOOSE CREEK	SC	29445-5354
635	Affiliated	2501	Bridgeport Dialysis	Bridgeport Dialysis	900 MADISON AVE	STE 221	BRIDGEPORT	CT	06606-5534
636	Affiliated	2503	Greater Waterbury Dialysis	Greater Waterbury Dialysis	209 HIGHLAND AVE		WATERBURY	CT	06708-3026
637	Affiliated	2506	Shelton Dialysis	Shelton Dialysis	750 BRIDGEPORT AVE		SHELTON	CT	06484-4734
638	Affiliated	2508	Yuma Dialysis	Yuma Dialysis	2130 W 24TH ST		YUMA	AZ	85364-6122
639	Affiliated	2509	Pittsburgh Dialysis	Pittsburgh Dialysis	4312 PENN AVE		PITTSBURGH	PA	15224-1310

640	Affiliated	2510	Elizabeth Dialysis	Elizabeth Dialysis	201 MCKEESPORT RD		ELIZABETH	PA	15037-1623
641	Affiliated	2511	Brandon East Dialysis	Brandon East Dialysis	114 E BRANDON BLVD		BRANDON	FL	33511-5219
642	Affiliated	2513	North Rolling Road Dialysis	North Rolling Road Dialysis	1108 N ROLLING RD		BALTIMORE	MD	21228-3826
643	Affiliated	2521	Memphis South Dialysis	Memphis South Dialysis	1205 MARLIN RD		MEMPHIS	TN	38116-5812
644	Affiliated	2524	Hartford Dialysis	Hartford Dialysis	675 TOWER AVE	RENAL UNIT 2ND FL	HARTFORD	CT	6112
645	Affiliated	2538	New Orleans Uptown Dialysis	New Orleans Uptown Dialysis	1401 FOUCHER ST	4TH FLOOR DIALYSIS	NEW ORLEANS	LA	70115-3515
646	Affiliated	2540	Omaha West Dialysis	Omaha West Dialysis	13014 W DODGE RD		OMAHA	NE	68154-2148
647	Affiliated	2541	White Memorial Dialysis	East Los Angeles Plaza Dialysis (fka White Memorial)	1700 E CESAR E CHAVEZ AVE	STE L 1	LOS ANGELES	CA	90033-2424
648	Affiliated	2542	Imperial Dialysis	Imperial Dialysis	2738 W IMPERIAL HWY		INGLEWOOD	CA	90303-3111
649	Affiliated	2546	North Hollywood Dialysis	North Hollywood Dialysis	12126 VICTORY BLVD		NORTH HOLLYWOOD	CA	91606-3205
650	Affiliated	2555	Mountain View Dialysis	Mountain View Dialysis	2881 BUSINESS PARK CT	STE 13	LAS VEGAS	NV	89128-9019
651	Affiliated	2560	San Juan Capistrano South Dialysis	San Juan Capistrano South Dialysis	31736 RANCHO VIEJO RD	STE B	SAN JUAN CAPISTRANO	CA	92675-2783
652	Affiliated	2564	Mission Viejo Dialysis	Mission Viejo Dialysis	27640 MARGUERITE PKWY		MISSION VIEJO	CA	92692-3604
653	Affiliated	2568	HI-Desert Dialysis	HI-Desert Dialysis	58457 29 PALMS HWY	STE 12	YUCCA VALLEY	CA	92284-5879
654	Affiliated	2571	Banning Dialysis	Banning Dialysis	6090 W RAMSEY ST		BANNING	CA	92220-3052
655	Affiliated	2601	Rainbow City Dialysis	Rainbow City Dialysis	2800 RAINBOW DR		RAINBOW CITY	AL	35906-5811

656	Affiliated	2604	Gadsden Dialysis	Gadsden Dialysis	409 S 1ST ST	GADSDEN	AL	35901-5358
657	Affiliated	2605	Chateau Dialysis	Chateau Dialysis	720 VILLAGE RD	KENNER	LA	70065-2751
658	Affiliated	2606	Donaldsonville Dialysis	Donaldsonville Dialysis	101 PLIMSOL DR	DONALDSONVILLE	LA	70346-4357
659	Affiliated	2609	Dothan Dialysis	Dothan Dialysis	216 GRACELAND DR	DOTHAN	AL	36305-7346
660	Affiliated	2614	Birmingham East Dialysis	Birmingham East Dialysis	1105 E PARK DR	BIRMINGHAM	AL	35235-2560
661	Affiliated	2615	Tuscaloosa Dialysis	Tuscaloosa Dialysis	805 OLD MILL ST	TUSCALOOSA	AL	35401-7132
662	Affiliated	2616	Demopolis Dialysis	Demopolis Dialysis	511 S CEDAR AVE	DEMOPOLIS	AL	36732-2235
663	Affiliated	2623	Singing River Dialysis	Singing River Dialysis	4907 TELEPHONE RD	PASCAGOULA	MS	39567-1823
664	Affiliated	2624	Ocean Springs Dialysis	Ocean Springs Dialysis	13150 PONCE DE LEON DR	OCEAN SPRINGS	MS	39564-2460

665	Affiliated	2625	Lucedale Dialysis	Lucedale Dialysis	652 MANILA ST		LUCEDALE	MS	39452-5962
666	Affiliated	2707	Holmdel Dialysis	Holmdel Dialysis	668 N BEERS ST		HOLMDEL	NJ	07733-1526
667	Affiliated	2855	Alameda County Dialysis	Alameda County Dialysis	10700 MACARTHUR BLVD	STE 14	OAKLAND	CA	94605-5260
668	Affiliated	2908	Elizabeth City Dialysis	Elizabeth City Dialysis	1840 W CITY DR		ELIZABETH CITY	NC	27909-9632
669	Affiliated	2914	Cookeville Dialysis	Cookeville Dialysis	140 W 7TH ST		COOKEVILLE	TN	38501-1726
670	Affiliated	3001	Inglewood Dialysis	Inglewood Dialysis	125 E ARBOR VITAE ST		INGLEWOOD	CA	90301-3839
671	Affiliated	3002	Rome Dialysis	Rome Dialysis	15 JOHN MADDOX DR NW		ROME	GA	30165-1413
672	Affiliated	3004	Pomona Dialysis	Pomona Dialysis	2111 N GAREY AVE		POMONA	CA	91767-2328
673	Affiliated	3005	Oak Street Dialysis	Oak Street Dialysis (fka Valdosta)	2704 N OAK ST	BLDG H	VALDOSTA	GA	31602-1723
674	Affiliated	3006	Channelview Dialysis	Channelview Dialysis	777 SHELDON RD	STE C	CHANNELVIEW	TX	77530-3509
675	Affiliated	3007	Sagemont Dialysis	Sagemont Dialysis	10851 SCARSDALE BLVD	STE 2	HOUSTON	TX	77089-5738
676	Affiliated	3008	San Jacinto Dialysis	San Jacinto Dialysis	11430 EAST FWY	STE 33	HOUSTON	TX	77029-1959
677	Affiliated	3009	Victor Valley Dialysis	Victor Valley Dialysis	16049 KAMANA RD		APPLE VALLEY	CA	92307-1331
678	Affiliated	3010	Delran Dialysis	Delran Dialysis	8008 ROUTE 130		DELTRAN	NJ	08075-1869
679	Affiliated	3011	Central Houston Dialysis	Central Houston Dialysis	610 S WAYSIDE DR	UNIT B	HOUSTON	TX	77011-4605
680	Affiliated	3012	Southern Lane Dialysis	Southern Lane Dialysis	1840 SOUTHERN LN		DECATUR	GA	30033-4033
681	Affiliated	3013	Northumberland Dialysis	Northumberland Dialysis	103 W STATE ROUTE 61		MOUNT CARMEL	PA	17851-2539
682	Affiliated	3014	Pryor Dialysis	Pryor Dialysis	309 E GRAHAM AVE		PRYOR	OK	74361-2434

683	Affiliated	3015	Oklahoma City South Dialysis	Oklahoma City South Dialysis	5730 S MAY AVE	OKLAHOMA CITY	OK	73119-5604
684	Affiliated	3016	Abington Dialysis	Abington Dialysis	3940A COMMERCE AVE	WILLOW GROVE	PA	19090-1705
685	Affiliated	3017	Memphis Central Dialysis	Memphis Central Dialysis	889 LINDEN AVE	MEMPHIS	TN	38126-2412
686	Affiliated	3018	Memphis East Dialysis	Memphis East Dialysis	50 HUMPHREYS STE 42 CTR	MEMPHIS	TN	38120-2372
687	Affiliated	3019	Clarksville Dialysis	Clarksville Dialysis	231 HILLCREST DR	CLARKSVILLE	TN	37043-5093
688	Affiliated	3020	Miami Campus Dialysis	Miami Campus Dialysis	1500 NW 12TH STE 16 AVE	MIAMI	FL	33136-1028
689	Affiliated	3021	Orlando Dialysis	Orlando Dialysis	116 STURTEVANT ST	ORLANDO	FL	32806-2021
690	Affiliated	3024	Durham Dialysis	Durham Dialysis	601 FAYETTEVILLE ST	DURHAM	NC	27701-3910
691	Affiliated	3025	Candler County Dialysis	Candler County Dialysis	325 CEDAR ST	METTER	GA	30439-4043
692	Affiliated	3027	Kerrville Dialysis	Kerrville Dialysis	515 GRANADA PL	KERRVILLE	TX	78028-5992
693	Affiliated	3028	Floresville Dialysis	Floresville Dialysis	543 10TH ST	FLORESVILLE	TX	78114-3107
694	Affiliated	3029	Pearsall Dialysis	Pearsall Dialysis	1305 N OAK ST	PEARSALL	TX	78061-3414
695	Affiliated	3030	Nogales Dialysis	Nogales Dialysis	1231 W TARGET RANGE RD	NOGALES	AZ	85621-2417
696	Affiliated	3032	Wilson Dialysis	Wilson Dialysis	1605 MEDICAL PARK DR W	WILSON	NC	27893-2799
697	Affiliated	3033	Goldsboro Dialysis	Goldsboro Dialysis	2609 HOSPITAL RD	GOLDSBORO	NC	27534-9424
698	Affiliated	3034	Roxboro Dialysis	Roxboro Dialysis	718 RIDGE RD	ROXBORO	NC	27573-4508
699	Affiliated	3035	Boston Dialysis	Boston Dialysis	660 HARRISON AVE	BOSTON	MA	02118-2304
700	Affiliated	3037	Jesup Dialysis	Jesup Dialysis	301 PEACHTREE ST	JESUP	GA	31545-0245
701	Affiliated	3038	Sheffield Dialysis	Sheffield Dialysis	1120 S JACKSON HWY ST 17	SHEFFIELD	AL	35660-5777

702	Affiliated	3039	Berkeley Dialysis	Berkeley Dialysis	2920 TELEGRAPH AVE		BERKELEY	CA	94705-2031
703	Affiliated	3040	Douglas Dialysis	Douglas Dialysis	190 WESTSIDE DR	STE A	DOUGLAS	GA	31533-3534
704	Affiliated	3041	Hopkinsville Dialysis	Hopkinsville Dialysis	1914 S VIRGINIA ST		HOPKINSVILLE	KY	42240-3610
705	Affiliated	3042	Roxborough Dialysis	Roxborough Dialysis	5003 UMBRIA ST		PHILADELPHIA	PA	19128-4301
706	Affiliated	3043	New Haven Dialysis	New Haven Dialysis	100 CHURCH ST S	STE C	NEW HAVEN	CT	06519-1703
707	Affiliated	3044	Ocoee Dialysis	Ocoee Dialysis	11140 W COLONIAL DR	STE 5	OCOEE	FL	34761-3300
708	Affiliated	3045	Waverly Dialysis	Waverly Dialysis	407 E BALTIMORE PIKE		MORTON	PA	19070-1042
709	Affiliated	3046	Sells Dialysis	Sells Dialysis	PO BOX 3030	HWY 86 MILEPOST 113	SELLS	AZ	85634-3030
710	Affiliated	3047	Sierra Vista Dialysis	Sierra Vista Dialysis	629 N HIGHWAY 90	STE 6	SIERRA VISTA	AZ	85635-2257
711	Affiliated	3048	Callaghan Road Dialysis	San Antonio West Dialysis (fka Callaghan Road)	4530 CALLAGHAN RD		SAN ANTONIO	TX	78228
712	Affiliated	3049	Houston Dialysis	Houston Dialysis	7543 SOUTH FWY		HOUSTON	TX	77021-5928
713	Affiliated	3050	South Yuma Dialysis	South Yuma Dialysis	7179 E 31ST PLACE		YUMA	AZ	85365-8392
714	Affiliated	3052	Cherry Hill Dialysis	Cherry Hill Dialysis	1030 KINGS HWY N	STE 1	CHERRY HILL	NJ	08034-1907
715	Affiliated	3055	Escondido Dialysis	Escondido Dialysis	203 E 2ND AVE		ESCONDIDO	CA	92025-4212
716	Affiliated	3056	Brookline Dialysis	Brookline Dialysis	322 WASHINGTON ST		BROOKLINE	MA	02445-6850
717	Affiliated	3057	Reliant Dialysis	Reliant Dialysis	1335 LA CONCHA LN		HOUSTON	TX	77054-1809
718	Affiliated	3058	Fullerton Dialysis	Fullerton Dialysis	238 ORANGEFAIR MALL		FULLERTON	CA	92832-3037

719	Affiliated	3059	Huntington Beach Dialysis	Huntington Beach Dialysis	16892 BOLSA CHICA ST	STE 1	HUNTINGTON BEACH	CA	92649-3571
720	Affiliated	3060	Eastlake Dialysis	Eastlake Dialysis (fka South Dekalb)	1757 CANDLER RD		DECATUR	GA	30032-3276
721	Affiliated	3061	Mt. Olive Dialysis	Mt. Olive Dialysis	105 MICHAEL MARTIN RD		MOUNT OLIVE	NC	28365-1112
722	Affiliated	3062	Southwest San Antonio Dialysis	Southwest San Antonio Dialysis	1620 SOMERSET RD		SAN ANTONIO	TX	78211-3021
723	Affiliated	3064	North Loop East Dialysis	North Loop East Dialysis	7139 NORTH LOOP E		HOUSTON	TX	77028-5903
724	Affiliated	3065	Katy Cinco Ranch Dialysis	Katy Cinco Ranch Dialysis	1265 ROCK CANYON DR		KATY	TX	77450-3831
725	Affiliated	3067	Palm Springs Dialysis	Palm Springs Dialysis	1061 N INDIAN CANYON DR		PALM SPRINGS	CA	92262-4854
726	Affiliated	3069	Muskegon Dialysis	Muskegon Dialysis	1277 MERCY DR		MUSKEGON	MI	49444-4605
727	Affiliated	3070	Loomis Road Dialysis	Loomis Road Dialysis	4120 W LOOMIS RD		GREENFIELD	WI	53221-2052
728	Affiliated	3071	Ludington Dialysis	Ludington Dialysis	5 N ATKINSON DR	STE 11	LUDINGTON	MI	49431-2918
729	Affiliated	3073	Walterboro Dialysis	Walterboro Dialysis	302 RUBY ST		WALTERBORO	SC	29488-2758
730	Affiliated	3074	K Street Dialysis (fka GWU N Street Dialysis)	K Street Dialysis (fka GWU N Street Dialysis)	2131 K ST NW		WASHINGTON	DC	20037-1898
731	Affiliated	3075	GWU Southeast Dialysis	GWU Southeast Dialysis	3857A PENNSYLVANIA AVE SE		WASHINGTON	DC	20020-1309

732	Affiliated	3076	Lakeside Dialysis	Lakeside Dialysis	10401 HOSPITAL DR	STE G2	CLINTON	MD	20735-3113
733	Affiliated	3077	Summit Dialysis	Summit Dialysis	1139 SPRUCE DR		MOUNTAINSIDE	NJ	07092-2221
734	Affiliated	3078	Aiken Dialysis	Aiken Dialysis	775 MEDICAL PARK DR		AIKEN	SC	29801-6306
735	Affiliated	3092	Ozark Dialysis	Ozark Dialysis	214 HOSPITAL AVE		OZARK	AL	36360-2038
736	Affiliated	3094	Wylds Road Dialysis	Wylds Road Dialysis (fka Augusta South)	1815 WYLDs RD		AUGUSTA	GA	30909-4430
737	Affiliated	3104	Douglasville Dialysis	Douglasville Dialysis	3899 LONGVIEW DR		DOUGLASVILLE	GA	30135-1373
738	Affiliated	3106	Brunswick Dialysis	Brunswick Dialysis	53 SCRANTON CONNECTOR		BRUNSWICK	GA	31525-1862
739	Affiliated	3109	Benicia Dialysis	Benicia Dialysis	560 1ST ST	STE 13 BLDG D	BENICIA	CA	94510-3295
740	Affiliated	3111	Atlanta Dialysis	Atlanta Dialysis	567 NORTH AVE NE	STE 2	ATLANTA	GA	30308-2719
741	Affiliated	3115	Rolla Dialysis	Rolla Dialysis	1503 E 10TH ST		ROLLA	MO	65401-3696
742	Affiliated	3119	East Atlanta Dialysis	East Atlanta Dialysis	1308 MORELAND AVE SE		ATLANTA	GA	30316-3224
743	Affiliated	3120	Brunswick South Dialysis	Brunswick South Dialysis	2930 SPRINGDALE RD		BRUNSWICK	GA	31520
744	Affiliated	3121	Thomaston Dialysis	Thomaston Dialysis	1065 US HIGHWAY 19 NORTH		THOMASTON	GA	30286-2233
745	Affiliated	3128	Piedmont Dialysis	Piedmont Dialysis	105 COLLIER RD NW	STE B	ATLANTA	GA	30309-1730
746	Affiliated	3130	Athens West Dialysis	Athens West Dialysis	2047 PRINCE AVE	STE A	ATHENS	GA	30606-6033
747	Affiliated	3131	Florence Dialysis	Florence Dialysis	422 E DR HICKS BLVD	STE B	FLORENCE	AL	35630-5763
748	Affiliated	3138	Atwater Dialysis	Atwater Dialysis	1201 COMMERCE AVE		ATWATER	CA	95301
749	Affiliated	3143	North Merced Dialysis	Merced Dialysis	3150 G ST	STE A	MERCED	CA	95340-1346
750	Affiliated	3169	Wisconsin Avenue Dialysis	Wisconsin Avenue Dialysis	3801 W WISCONSIN AVE		MILWAUKEE	WI	53208-3155

751	Affiliated	3171	River Center Dialysis	River Center Dialysis	117 N JEFFERSON ST		MILWAUKEE	WI	53202-6160
752	Affiliated	3175	South Fulton Dialysis	South Fulton Dialysis	2685 METROPOLITAN PKWY SW	STE F	ATLANTA	GA	30315-7926
753	Affiliated	3201	Heartland Dialysis	Heartland Dialysis	925 NE 8TH ST		OKLAHOMA CITY	OK	73104-5800
754	Affiliated	3202	Hospital Hill Dialysis	Hospital Hill Dialysis	2250 HOLMES ST		KANSAS CITY	MO	64108-2639
755	Affiliated	3203	Tucson South Dialysis	Tucson South Dialysis	3662 S 16TH AVE		TUCSON	AZ	85713-6001
756	Affiliated	3204	Greene County Dialysis	Greene County Dialysis (AL)	544 US HIGHWAY 43		EUTAW	AL	35462-4017
757	Affiliated	3205	Fayette Dialysis	Fayette Dialysis	2450 TEMPLE AVE N		FAYETTE	AL	35555-1160
758	Affiliated	3206	Tuscaloosa University Dialysis	Tuscaloosa University Dialysis	220 15TH STREET		TUSCALOOSA	AL	35401
759	Affiliated	3207	Goldsboro South Dialysis	Goldsboro South Dialysis	1704 WAYNE MEMORIAL DR		GOLDSBORO	NC	27534-2240
760	Affiliated	3208	Orlando North Dialysis	Orlando North Dialysis	5135 ADANSON ST	STE 7	ORLANDO	FL	32804-1338
761	Affiliated	3209	UT Southwestern- Dallas Dialysis	UT Southwestern- Dallas Dialysis	204 E AIRPORT FREEWAY		IRVING	TX	75062
762	Affiliated	3210	San Diego South Dialysis	San Diego South Dialysis	995 GATEWAY CENTER WAY	STE 11	SAN DIEGO	CA	92102-4550
763	Affiliated	3211	Santa Monica Dialysis	Santa Monica Dialysis	1260 15TH ST	STE 12	SANTA MONICA	CA	90404-1136
764	Affiliated	3212	Airport Dialysis	Airport Dialysis	4632 W CENTURY BLVD		INGLEWOOD	CA	90304-1456
765	Affiliated	3220	Plantation Dialysis	Plantation Dialysis	7061 CYPRESS RD	STE 13	PLANTATION	FL	33317-2243
766	Affiliated	3224	Laurens County Dialysis	Laurens County Dialysis	2400 BELLEVUE RD	STE 8	DUBLIN	GA	31021-2856
767	Affiliated	3225	Ford Factory Square Dialysis	Ford Factory Square Dialysis	567 NORTH AVE NE	STE 1	ATLANTA	GA	30308-2719

768	Affiliated	3226	North Fulton Dialysis	North Fulton Dialysis	1250 NORTHMEADOW PKWY	STE 12	ROSWELL	GA	30076-4914
769	Affiliated	3228	Freehold Dialysis	Freehold Dialysis	300 CRAIG RD		MANALAPAN	NJ	07726-8742
770	Affiliated	3229	Neptune Dialysis	Neptune Route 66 Dialysis	3297 STATE ROUTE 66		NEPTUNE	NJ	07753-2762
771	Affiliated	3231	East Orange Dialysis	East Orange Dialysis	90 WASHINGTON ST	BSMT	EAST ORANGE	NJ	07017-1050
772	Affiliated	3234	UT Southwestern- Oakcliff Dialysis	UT Southwestern- Oakcliff Dialysis	610 WYNNEWOOD DR		DALLAS	TX	75224
773	Affiliated	3236	Atlanta West Dialysis	Atlanta West Dialysis	2538 MARTIN LUTHER KING JR DR SW		ATLANTA	GA	30311-1779
774	Affiliated	3237	Columbia University Dialysis Center	Columbia University Dialysis Center	60 HAVEN AVE		NEW YORK	NY	10032-2604
775	Affiliated	3238	Northeast Cambridge Dialysis	Northeast Cambridge Dialysis	799 CONCORD AVE		CAMBRIDGE	MA	02138-1048
776	Affiliated	3239	New Bedford Dialysis	New Bedford Dialysis	524 UNION ST		NEW BEDFORD	MA	02740-3546
777	Affiliated	3242	Weymouth Dialysis	Weymouth Dialysis	330 LIBBEY INDUSTRIAL PARK	STE 9	WEYMOUTH	MA	02189-3122
778	Affiliated	3243	Woburn Dialysis	Woburn Dialysis	23 WARREN AVE		WOBURN	MA	01801-7906
779	Affiliated	3248	Bryan Dialysis	College Station Dialysis (fka Bryan Dialysis)	701 UNIVERSITY DR E	STE 41	COLLEGE STATION	TX	77840-1866
780	Affiliated	3249	Brenham Dialysis	Brenham Dialysis	2815 HIGHWAY 36 SO		BRENHAM	TX	77833
781	Affiliated	3250	Huntsville Dialysis	Huntsville Dialysis	521 IH 45S	STE 2	HUNTSVILLE	TX	77340-5651
782	Affiliated	3252	Utica Avenue Dialysis Center	Utica Avenue Dialysis Center	1305 UTICA AVE		BROOKLYN	NY	11203-5911

783	Affiliated	3254	New London Dialysis	New London Dialysis	5 SHAWS COVE STE 1	NEW LONDON	CT	06320-4974
784	Affiliated	3258	Baxley Dialysis	Baxley Dialysis	539 FAIR ST	BAXLEY	GA	31513-0112
785	Affiliated	3261	Pascua Yaqui Tribe Dialysis	Pascua Yaqui Tribe Dialysis	7490 S CAMINO DE OESTE	TUCSON	AZ	85746-9308
786	Affiliated	3262	JHHS North Bond Street Dialysis	JHHS North Bond Street Dialysis	409 N CAROLINE ST	BALTIMORE	MD	21231-1003
787	Affiliated	3263	Syosset Kidney Center	Syosset Kidney Center	1 LOCUST LN	SYOSSET	NY	11791-4834
788	Affiliated	3264	Freeport Kidney Center	Freeport Kidney Center	267 W MERRICK RD	FREEPORT	NY	11520-3346
789	Affiliated	3265	Huntington Station Dialysis Center	HAKC- Huntington	256 BROADWAY	HUNTINGTON STATION	NY	11746-1403
790	Affiliated	3266	Medford Kidney Center	Medford Kidney Center	1725 N OCEAN AVE	MEDFORD	NY	11763-2649
791	Affiliated	3267	Blue Ash Dialysis	Blue Ash Dialysis	10600 MCKINLEY RD	CINCINNATI	OH	45242-3716
792	Affiliated	3269	Mt. Auburn Dialysis	Mt. Auburn Dialysis	2109 READING RD	CINCINNATI	OH	45202-1417
793	Affiliated	3272	Charlottesville Dialysis	Charlottesville Dialysis	1460 PANTOPS MOUNTAIN PLACE	CHARLOTTESVILLE	VA	22911
794	Affiliated	3273	Alexandria Dialysis	Alexandria Dialysis	5150 DUKE ST	ALEXANDRIA	VA	22304-2906
795	Affiliated	3275	Sebastian Dialysis	Sebastian Dialysis	1424 US HWY 1 STE C	SEBASTIAN	FL	32958-1619
796	Affiliated	3276	Crestview Hills Dialysis	Crestview Hills Dialysis	400 CENTERVIEW BLVD	CRESTVIEW HILLS	KY	41017-3478
797	Affiliated	3278	Washington Square Dialysis	Washington Square Dialysis	1112 WASHINGTON SQ	WASHINGTON	MO	63090-5336
798	Affiliated	3279	Florissant Dialysis	Florissant Dialysis	11687 W FLORISSANT AVE	FLORISSANT	MO	63033-6711

799	Affiliated	3282	Ithaca Dialysis Center	Ithaca Dialysis Center	201 DATES DR	STE 26	ITHACA	NY	14850-1345
800	Affiliated	3289	Fairfield Dialysis	Fairfield Dialysis	1210 HICKS BLVD		FAIRFIELD	OH	45014-1921
801	Affiliated	3290	Fairfield Home Training Dialysis	Fairfield Home Training Dialysis	1210 HICKS BLVD		FAIRFIELD	OH	45014-1921
802	Affiliated	3291	South Hill Dialysis	South Hill Dialysis	525 ALEXANDRIA PIKE	STE 12	SOUTHGATE	KY	41071-3243
803	Affiliated	3292	Silver Spring Dialysis	Silver Spring Dialysis	8412 GEORGIA AVE		SILVER SPRING	MD	20910-4406
804	Affiliated	3295	Philadelphia PMC Dialysis	Philadelphia PMC Dialysis	51 N 39TH ST		PHILADELPHIA	PA	19104-2640
805	Affiliated	3298	Tulare Dialysis	Tulare Dialysis	545 E TULARE AVE		TULARE	CA	93274-4220
806	Affiliated	3300	Visalia Dialysis	Visalia Dialysis	5429 W CYPRESS AVE		VISALIA	CA	93277-8341
807	Affiliated	3310	Falls Road Dialysis	Falls Road Dialysis	10753 FALLS RD	STE 115	LUTHERVILLE	MD	21093-4572
808	Affiliated	3312	Malden Dialysis	Wellington Circle Dialysis Center (fka Malden)	10 CABOT RD	STE 13B	MEDFORD	MA	02155-5173
809	Affiliated	3313	Salem Northeast Dialysis	Salem Northeast Dialysis (MA)	10 COLONIAL RD	STE 25	SALEM	MA	01970-2947
810	Affiliated	3314	Lexington	Lexington Prison Unit (OK)	15151 STATE HWY 39 E	PO BOX 26	LEXINGTON	OK	73051-0260
811	Affiliated	3315	Macon County Dialysis	Macon County Dialysis	1090 W MCKINLEY AVE		DECATUR	IL	62526-3208
812	Affiliated	3316	Effingham Dialysis	Effingham Dialysis	904 MEDICAL PARK DR	STE 1	EFFINGHAM	IL	62401-2193
813	Affiliated	3317	Jacksonville Dialysis	Jacksonville Dialysis	1515 W WALNUT ST		JACKSONVILLE	IL	62650-1150

814	Affiliated	3318	Litchfield Dialysis	Litchfield Dialysis	915 ST FRANCES WAY	LITCHFIELD	IL	62056-1775
815	Affiliated	3319	Mattoon Dialysis	Mattoon Dialysis	6051 DEVELOPMENT DR	CHARLESTON	IL	61920-9467
816	Affiliated	3320	Springfield Central Dialysis	Springfield Central Dialysis	932 N RUTLEDGE ST	SPRINGFIELD	IL	62702-3721
817	Affiliated	3321	Taylorville Dialysis	Taylorville Dialysis	901 W SPRESSER ST	TAYLORVILLE	IL	62568-1831
818	Affiliated	3322	Lincoln Dialysis	Lincoln Dialysis	2100 WEST FIFTH	LINCOLN	IL	62656-9115
819	Affiliated	3323	J. B. Zachary Dialysis Center	J. B. Zachary Dialysis Center	333 CASSELL DR STE 23	BALTIMORE	MD	21224-6815
820	Affiliated	3324	Whitesquare Dialysis	Whitesquare Dialysis	1 NASHUA CT STE E	BALTIMORE	MD	21221
821	Affiliated	3325	25th Street Dialysis	25th Street Dialysis	920 E 25TH ST	BALTIMORE	MD	21218-5503
822	Affiliated	3326	Perth Amboy Dialysis	Perth Amboy Dialysis	530 NEW BRUNSWICK AVE	PERTH AMBOY	NJ	08861-3654
823	Affiliated	3327	Old Bridge Dialysis	Old Bridge Dialysis	3 HOSPITAL PLZ STE 11	OLD BRIDGE	NJ	08857-3084
824	Affiliated	3328	Pear Tree Dialysis	Pear Tree Dialysis (fka Ukiah)	126 N ORCHARD AVE	UKIAH	CA	95482-4502
825	Affiliated	3334	Hubbard Road Dialysis	Hubbard Road Dialysis	1963 HUBBARD RD	MADISON	OH	44057-2105
826	Affiliated	3335	St. Charles Dialysis	St. Charles Dialysis	2125 BLUESTONE DR	SAINT CHARLES	MO	63303-6704
827	Affiliated	3336	Bel Air Dialysis	Bel Air Dialysis	2225 OLD EMMORTON RD STE 15	BEL AIR	MD	21015-6122
828	Affiliated	3339	Cedarburg Dialysis	Cedarburg Dialysis	N 54 W 6135 MILL ST	CEDARBURG	WI	53012-2021
829	Affiliated	3340	Western Hills Dialysis	Western Hills Dialysis	3267 WESTBOURNE DR	CINCINNATI	OH	45248-5130
830	Affiliated	3341	Winton Road Dialysis	Winton Road Dialysis	6550 WINTON RD	CINCINNATI	OH	45224-1327
831	Affiliated	3342	Stamford Dialysis	Stamford Dialysis	30 COMMERCE RD	STAMFORD	CT	06902-4550

832	Affiliated	3343	Boaz Dialysis	Boaz Dialysis	16 CENTRAL HENDERSON RD	BOAZ	AL	35957-5922
833	Affiliated	3344	Guernsey County Dialysis	Guernsey County Dialysis	1300 CLARK ST	CAMBRIDGE	OH	43725-8875
834	Affiliated	3345	Marietta Dialysis	Marietta Dialysis	1019 PIKE ST	MARIETTA	OH	45750-3500
835	Affiliated	3346	Zanesville Dialysis	Zanesville Dialysis	3120 NEWARK RD	ZANESVILLE	OH	43701-9659
836	Affiliated	3351	Orlando East Dialysis	Orlando East Dialysis	1160 S SEMORAN STE C BLVD	ORLANDO	FL	32807-1461
837	Affiliated	3352	Norwich Dialysis	Norwich Dialysis	113 SALEM TPKE	NORWICH	CT	06360-6484
838	Affiliated	3354	Columbus Dialysis	Columbus Dialysis	3830 OLENTANGY RIVER RD	COLUMBUS	OH	43214-5404
839	Affiliated	3362	Pasadena Dialysis	Pasadena Dialysis	8894 FORT STE 12 SMALLWOOD RD	PASADENA	MD	21122-7608
840	Affiliated	3369	Baltimore Geriatric & Rehab Dialysis Center	Baltimore Geriatric & Rehab Dialysis Center	4940 EASTERN FLOOR 5 AVE	BALTIMORE	MD	21224-2735
841	Affiliated	3373	Frederick Dialysis	Frederick Dialysis	140 THOMAS STE 1 JOHNSON DR	FREDERICK	MD	21702-4475
842	Affiliated	3376	Fayetteville Dialysis	Fayetteville Dialysis	1279 HIGHWAY 54 STE 11 W	FAYETTEVILLE	GA	30214-4551
843	Affiliated	3377	Birmingham Central Dialysis	Birmingham Central Dialysis	728 RICHARD ARRINGTON JR BLVD S	BIRMINGHAM	AL	35233-2106
844	Affiliated	3379	Birmingham North Dialysis	Birmingham North Dialysis	1917 32ND AVE N	BIRMINGHAM	AL	35207-3333
845	Affiliated	3380	Bessemer Dialysis	Bessemer Dialysis	901 W LAKE MALL	BESSEMER	AL	35020
846	Affiliated	3382	Ensley Dialysis	Ensley Dialysis	2630 AVENUE E	BIRMINGHAM	AL	35218-2163
847	Affiliated	3383	Sylacauga Dialysis	Sylacauga Dialysis	331 JAMES PAYTON BLVD	SYLACAUGA	AL	35150
848	Affiliated	3385	Branford Dialysis	Branford Dialysis	249 W MAIN ST	BRANFORD	CT	06405-4048

849	Affiliated	3386	Shrewsbury Dialysis	Shrewsbury Dialysis	7435 WATSON RD STE 119	SAINT LOUIS	MO	63119-4472
850	Affiliated	3389	Milford Dialysis	Milford Dialysis	470 BRIDGEPORT AVE	MILFORD	CT	06460-4167
851	Affiliated	3414	Cedartown Dialysis	Cedartown Dialysis	325 WEST AVE	CEDARTOWN	GA	30125-3439
852	Affiliated	3416	Brookfield Dialysis	Brookfield Dialysis	19395 W CAPITOL BLDG C DR	BROOKFIELD	WI	53045-2736
853	Affiliated	3417	Henrico County Dialysis	Henrico County Dialysis	5270 CHAMBERLAYNE RD	RICHMOND	VA	23227-2950
854	Affiliated	3418	St. Louis West Dialysis	St. Louis West Dialysis	400 N LINDBERGH BLVD	SAINT LOUIS	MO	63141-7814
855	Affiliated	3420	Springfield Montvale Dialysis	Springfield Montvale Dialysis	2930 MONTVALE STE A DR	SPRINGFIELD	IL	62704-5376
856	Affiliated	3422	South Norwalk Dialysis	South Norwalk Dialysis	31 STEVENS ST	NORWALK	CT	06850-3805
857	Affiliated	3425	Decatur East Wood Dialysis	Decatur East Wood Dialysis	794 E WOOD ST	DECATUR	IL	62523-1155
858	Affiliated	3426	Schaeffer Drive Dialysis	Schaeffer Drive Dialysis	18100 SCHAEFER HWY	DETROIT	MI	48235-2600
859	Affiliated	3427	Redford Dialysis	Redford Dialysis	22711 GRAND RIVER AVE	DETROIT	MI	48219-3113
860	Affiliated	3428	Kresge Dialysis	Kresge Dialysis	4145 CASS AVE	DETROIT	MI	48201-1707
861	Affiliated	3429	Motor City Dialysis	Motor City Dialysis	4727 SAINT ANTOINE ST STE 11	DETROIT	MI	48201-1461
862	Affiliated	3431	Whitebridge Dialysis	Whitebridge Dialysis	103 WHITE BRIDGE PIKE STE 6	NASHVILLE	TN	37209-4539
863	Affiliated	3432	Columbia Dialysis	Columbia Dialysis (TN)	1705 GROVE ST	COLUMBIA	TN	38401-3517
864	Affiliated	3433	Murfreesboro Dialysis	Murfreesboro Dialysis	1346 DOW ST	MURFREESBORO	TN	37130-2470
865	Affiliated	3434	Lawrenceburg Dialysis	Lawrenceburg Dialysis (TN)	2022 N LOCUST AVE	LAWRENCEBURG	TN	38464-2336

866	Affiliated	3436	Sumner Dialysis	Sumner Dialysis	300 STEAM PLANT RD	STE 27	GALLATIN	TN	37066-3019
867	Affiliated	3437	Cumberland Dialysis	Cumberland Dialysis	312 HOSPITAL DR	STE 5	MADISON	TN	37115-5037
868	Affiliated	3438	Williamson County Dialysis	Williamson County Dialysis	3983 CAROTHERS PKWY	STE E-4	FRANKLIN	TN	37067-5936
869	Affiliated	3441	Cumming Dialysis	Cumming Dialysis	911 MARKET PLACE BLVD	STE 3	CUMMING	GA	30041-7938
870	Affiliated	3443	Silverton Dialysis	Silverton Dialysis	6929 SILVERTON AVE		CINCINNATI	OH	45236-3701
871	Affiliated	3445	Atlanta South Dialysis	Atlanta South Dialysis	3158 EAST MAIN ST	STE A	EAST POINT	GA	30344-4800
872	Affiliated	3447	St. Petersburg Dialysis	St. Petersburg Dialysis	1117 ARLINGTON AVE N		ST PETERSBURG	FL	33705-1521
873	Affiliated	3449	Alton Dialysis	Alton Dialysis	3511 COLLEGE AVE		ALTON	IL	62002-5009
874	Affiliated	3451	Edison Dialysis	Edison Dialysis	29 MERIDIAN RD		EDISON	NJ	08820-2823
875	Affiliated	3452	Dundalk Dialysis	Dundalk Dialysis	14 COMMERCE ST		DUNDALK	MD	21222-4307
876	Affiliated	3454	Columbus East Dialysis	Columbus East Dialysis	299 OUTERBELT ST		COLUMBUS	OH	43213-1529
877	Affiliated	3455	Dallas East Dialysis	Dallas East Dialysis	3312 N BUCKNER BLVD	STE 213	DALLAS	TX	75228-5642
878	Affiliated	3456	San Ysidro Dialysis	San Ysidro Dialysis	1445 30TH ST	STE A	SAN DIEGO	CA	92154-3496
879	Affiliated	3457	Olathe Dialysis	Olathe Dialysis	732 W FRONTIER LN		OLATHE	KS	66061-7202
880	Affiliated	3459	Orange City Dialysis	Orange City Dialysis	242 TREEMONT DR	BLDG II	ORANGE CITY	FL	32763-7945
881	Affiliated	3460	Miami East Dialysis	Miami East Dialysis	1250 NW 7TH ST	STE 16	MIAMI	FL	33125-3744
882	Affiliated	3462	Temple Terrace Dialysis	Temple Terrace Dialysis	11306 N 53RD ST		TEMPLE TERRACE	FL	33617-2214

883	Affiliated	3463	Midlothian Dialysis	Midlothian Dialysis	14281 MIDLOTHIAN TPKE	BLDG B	MIDLOTHIAN	VA	23113-6560
884	Affiliated	3464	Christian County Dialysis	Christian County Dialysis	200 BURLEY AVE		HOPKINSVILLE	KY	42240-8725
885	Affiliated	3465	St. Louis West PD Dialysis	St. Louis West PD Dialysis	450 N LINDBERGH BLVD	STE 1C	CREVE COEUR	MO	63141-7858
886	Affiliated	3467	Atlanta Midtown Dialysis	Atlanta Midtown Dialysis PD	418 DECATUR ST SE	STE A	ATLANTA	GA	30312-1801
887	Affiliated	3468	Silverton Home Training Dialysis	Silverton Home Training Dialysis	6929 SILVERTON AVE		CINCINNATI	OH	45236-3701
888	Affiliated	3472	Philadelphia 42nd Street Dialysis	Philadelphia 42nd Street Dialysis	4126 WALNUT ST		PHILADELPHIA	PA	19104-3511
889	Affiliated	3473	Radnor Dialysis	Radnor Dialysis	250 KING OF PRUSSIA RD		RADNOR	PA	19087-5220
890	Affiliated	3475	St. Louis Dialysis	St. Louis Dialysis	324 DE BALIVIERE AVE		SAINT LOUIS	MO	63112-1804
891	Affiliated	3477	Elkins Park Dialysis	Wyncote Dialysis (fka Elkins Park)	1000 EASTON RD	STE 25	WYNCOTE	PA	19095-2934
892	Affiliated	3478	Mainland Dialysis	Mainland Dialysis	2600 GULF FWY		LA MARQUE	TX	77568-4922
893	Affiliated	3479	Island Dialysis	Island Dialysis	5920 BROADWAY ST		GALVESTON	TX	77551-4305
894	Affiliated	3481	Orlando Home Training Dialysis	Orlando Home Training Dialysis	116 STURTEVANT ST	STE 2	ORLANDO	FL	32806-2021
895	Affiliated	3482	Mechanicsville Dialysis	Mechanicsville Dialysis	8191 ATLEE RD		MECHANICSVILLE	VA	23116-1807
896	Affiliated	3484	San Diego East Dialysis	San Diego East Dialysis	292 EUCLID AVE	STE 1	SAN DIEGO	CA	92114-3629
897	Affiliated	3485	Russellville Dialysis	Russellville Dialysis	14897 HIGHWAY 43		RUSSELLVILLE	AL	35653-1954
898	Affiliated	3486	Encinitas Dialysis	Encinitas Dialysis	332 SANTA FE DR	STE 1	ENCINITAS	CA	92024-5143

899	Affiliated	3491	Rushville Dialysis	Rushville Dialysis	112 SULLIVAN DRIVE		RUSHVILLE	IL	62681-1293
900	Affiliated	3493	Plainfield Dialysis	Plainfield Dialysis	1200 RANDOLPH RD	MUHLENBURG CAMPUS	PLAINFIELD	NJ	07060-3361
901	Affiliated	3494	Parkersburg Dialysis	Parkersburg Dialysis	1824 MURDOCH AVE	STE 44	PARKERSBURG	WV	26101-3230
902	Affiliated	3497	Tucson South Central Dialysis	Tucson South Central Dialysis	2024 E IRVINGTON RD	STE 7	TUCSON	AZ	85714-1825
903	Affiliated	3499	Hazelwood Dialysis	Hazelwood Dialysis	637 DUNN RD		HAZELWOOD	MO	63042-1755
904	Affiliated	3503	Durham West Dialysis	Durham West Dialysis	4307 WESTERN PARK PL		DURHAM	NC	27705-1204
905	Affiliated	3504	Liberty Dialysis	Liberty Dialysis	2525 GLEN HENDREN DR		LIBERTY	MO	64068-9625
906	Affiliated	3506	Chino Dialysis	Chino Dialysis	4445 RIVERSIDE DR		CHINO	CA	91710-3961
907	Affiliated	3507	Greenview Dialysis	Greenview Dialysis	18544 W 8 MILE RD		SOUTHFIELD	MI	48075-4194
908	Affiliated	3508	Perry Dialysis	Perry Dialysis	118 W MAIN ST		PERRY	FL	32347-2656
909	Affiliated	3511	Ashtabula Dialysis	Ashtabula Dialysis	1614 W 19TH ST		ASHTABULA	OH	44004-3036
910	Affiliated	3513	Northland Dialysis	Northland Dialysis	2750 CLAY EDWARDS DR	STE 1	N KANSAS CITY	MO	64116-3257
911	Affiliated	3516	Lake St. Louis Dialysis	Lake St. Louis Dialysis	200 BREVCO PLZ	STE 21	LAKE SAINT LOUIS	MO	63367-2950
912	Affiliated	3517	Wyandotte West Dialysis	Wyandotte West Dialysis	8919 PARALLEL PKWY	STE 121	KANSAS CITY	KS	66112-1655
913	Affiliated	3518	Huntingdon Valley Dialysis	Temp CLSD- Huntingdon Valley Dialysis	769 HUNTINGDON PIKE	STE 18	HUNTINGDON VALLEY	PA	19006-8362
914	Affiliated	3519	Glendale Dialysis	Glendale Dialysis	1000 E PALMER AVE		GLENDALE	CA	91205-3532
915	Affiliated	3520	Toledo Dialysis	Toledo Dialysis	1614 S BYRNE RD		TOLEDO	OH	43614-3464
916	Affiliated	3523	Cameron Dialysis	Cameron Dialysis	1003 W 4TH ST		CAMERON	MO	64429-1466
917	Affiliated	3524	Omaha Central Dialysis	Omaha Central Dialysis	144 S 40TH ST		OMAHA	NE	68131-3004

918	Affiliated	3525	Chillicothe Dialysis	Chillicothe Dialysis	588 E BUSINESS 36		CHILLICOTHE	MO	64601-3721
919	Affiliated	4210	Council Bluffs Dialysis	Council Bluffs Dialysis Center	300 W BROADWAY	STE 15	COUNCIL BLUFFS	IA	51503-9077
920	Affiliated	3528	DeRidder Dialysis	DeRidder Dialysis	239 E 1ST ST		DERIDDER	LA	70634-4105
921	Affiliated	3530	Dodge County Dialysis	Dodge County Dialysis	1949 E 23RD AVE S		FREMONT	NE	68025-2452
922	Affiliated	3533	Omaha North Dialysis	Omaha North Dialysis	6572 AMES AVE		OMAHA	NE	68104-1931
923	Affiliated	3534	Omaha South Dialysis	Omaha South Dialysis	3427 L ST	STE 16	OMAHA	NE	68107-2577
924	Affiliated	3535	Lake Charles Southwest Dialysis	Lake Charles Southwest Dialysis	300 W 18th ST		LAKE CHARLES	LA	70601-7342
925	Affiliated	3536	St. Joseph Dialysis	St. Joseph Dialysis	5514 CORPORATE DR	STE 1	SAINT JOSEPH	MO	64507-7752
926	Affiliated	3537	Sulphur Dialysis	Sulphur Dialysis	944 BEGLIS PKWY		SULPHUR	LA	70663-5102
927	Affiliated	3539	Tipton County Dialysis	Tipton County Dialysis	107 TENNESSEE AVE		COVINGTON	TN	38019-3902
928	Affiliated	3540	Dyersburg Dialysis	Dyersburg Dialysis	1575 PARR AVE		DYERSBURG	TN	38024-3151
929	Affiliated	3544	Effingham North Dialysis	Effingham North Dialysis	301 N PINE ST		SPRINGFIELD	GA	31329-3076
930	Affiliated	3545	Westminster South Dialysis	Westminster South Dialysis	14014 MAGNOLIA ST.		WESTMINSTER	CA	92683-4736
931	Affiliated	3546	Williams Street Dialysis	Williams Street Dialysis	2812 WILLIAMS ST		SAVANNAH	GA	31404-4134
932	Affiliated	3547	DeRenne Dialysis	DeRenne Dialysis	5303 MONTGOMERY ST		SAVANNAH	GA	31405-5138

933	Affiliated	3548	Abercorn Dialysis	Abercorn Dialysis	11706 MERCY BLVD	STE 9	SAVANNAH	GA	31419-1751
934	Affiliated	3551	Fort Myers North Dialysis	Fort Myers North Dialysis	16101 N CLEVELAND AVE		N FT MYERS	FL	33903-2148
935	Affiliated	3552	Butler County Dialysis	Butler County Dialysis	3497 S DIXIE HWY		FRANKLIN	OH	45005-5717
936	Affiliated	3556	Willingboro	Willingboro Dialysis	230 VAN SCIVER PKWY		WILLINGBORO	NJ	08046-1131
937	Affiliated	3557	McKeesport West Dialysis	McKeesport West Dialysis	101 9TH ST		MCKEESPORT	PA	15132-3953
938	Affiliated	3559	College Dialysis	College Dialysis	6535 UNIVERSITY AVE		SAN DIEGO	CA	92115-5810
939	Affiliated	3560	Montezuma Dialysis	Montezuma Dialysis	114 DEVAUGHN AVE		MONTEZUMA	GA	31063-1708
940	Affiliated	3561	Romulus Dialysis	Romulus Dialysis	31470 ECORSE RD		ROMULUS	MI	48174-1963
941	Affiliated	3564	Wrightsville Dialysis	Wrightsville Dialysis	2240 W ELM ST		WRIGHTSVILLE	GA	31096-2016
942	Affiliated	3565	Tower Dialysis	Tower Dialysis	8635 W 3RD ST	STE 56W	LOS ANGELES	CA	90048-6110
943	Affiliated	3566	Columbus Downtown Dialysis	Columbus Downtown Dialysis	415 E MOUND ST		COLUMBUS	OH	43215-5512
944	Affiliated	3568	Charlotte East Dialysis	Charlotte East Dialysis	3204 N SHARON AMITY RD		CHARLOTTE	NC	28205-6541
945	Affiliated	3569	Carmel Mountain Dialysis	Carmel Mountain Dialysis	9850 CARMEL MOUNTAIN RD		SAN DIEGO	CA	92129-2892
946	Affiliated	3571	Lenexa Dialysis	Lenexa Dialysis	8630 HALSEY ST		LENEXA	KS	66215-2880
947	Affiliated	3577	Nashua Dialysis	Nashua Dialysis	38 TYLER ST	STE 1	NASHUA	NH	03060-2912
948	Affiliated	3580	Illini Renal Dialysis	Illini Renal Dialysis	507 E UNIVERSITY AVE		CHAMPAIGN	IL	61820-3828

949	Affiliated	3586	Loring Heights Dialysis	Loring Heights Dialysis	1575 NORTHSIDE DR NW	STE 45	ATLANTA	GA	30318-4211
950	Affiliated	3588	Forest Hills Dialysis	Forest Hills Dialysis	2693 FOREST HILLS RD SW		WILSON	NC	27893-8611
951	Affiliated	3589	St. Peters Dialysis	St. Peters Dialysis	300 FIRST EXECUTIVE AVE	STE A	SAINT PETERS	MO	63376-1655
952	Affiliated	3591	Platte Woods Dialysis	Platte Woods Dialysis	7667 NW PRAIRIE VIEW RD		KANSAS CITY	MO	64151-1544
953	Affiliated	3593	Fresno North Dialysis	Fresno Palm Bluffs Dialysis (fka Fresno North)	770 W PINEDALE AVE		FRESNO	CA	93711-5744
954	Affiliated	3594	Middlesex County Dialysis	Burlington Regional Dialysis (fka Middlesex County)	31 MALL RD	STE 1B	BURLINGTON	MA	01803-4138
955	Affiliated	3596	Clearfield Dialysis	Clearfield Dialysis	1033 TURNPIKE AVE	STE 1	CLEARFIELD	PA	16830-3061
956	Affiliated	3597	Papillion Dialysis	Papillion Dialysis	1502 S WASHINGTON ST	STE 1	PAPILLION	NE	68046-3136
957	Affiliated	3598	Birmingham Home Training Dialysis	Birmingham Home Training Dialysis	2101 7TH AVE S		BIRMINGHAM	AL	35233-3105
958	Affiliated	3603	Bayou Dialysis	Magnolia Dialysis	210 E SPILLMAN ST		GONZALES	LA	70737-4604
959	Affiliated	3609	Radford Dialysis	Radford Dialysis	600 E MAIN ST	STE F	RADFORD	VA	24141-1826
960	Affiliated	3610	Eufaula Dialysis	Eufaula Dialysis	220 S ORANGE AVE		EUFAULA	AL	36027-1612
961	Affiliated	3612	Coshocton Dialysis	Coshocton Dialysis	1404 CHESTNUT ST EAST		COSHOCTON	OH	43812-1401
962	Affiliated	3614	Costa Mesa Dialysis	Costa Mesa Dialysis	1590 SCENIC AVE		COSTA MESA	CA	92626-1400
963	Affiliated	3615	Little Rock Dialysis	Central Little Rock Dialysis	5800 W 10TH ST	STE 51	LITTLE ROCK	AR	72204-1760

964	Affiliated	3619	Northport Dialysis	Northport Dialysis	2401 HOSPITAL DR		NORTHPORT	AL	35476-3392
965	Affiliated	3632	Pageland Dialysis	Pageland Dialysis	505A S PEARL ST		PAGELAND	SC	29728-2222
966	Affiliated	3633	Bakersfield South Dialysis	White Lane Dialysis (fka Bakersfield South)	7701 WHITE LN	STE D	BAKERSFIELD	CA	93309-0201
967	Affiliated	3634	Newaygo County Dialysis	Newaygo County Dialysis	1317 W MAIN ST		FREMONT	MI	49412-1478
968	Affiliated	3636	Cedar Lane Dialysis	Cedar Lane Dialysis	6334 CEDAR LN	STE 11	COLUMBIA	MD	21044-3898
969	Affiliated	3639	Torrington Dialysis	Torrington Dialysis	780 LITCHFIELD ST	STE 1	TORRINGTON	CT	06790-6268
970	Affiliated	3642	Janesville Dialysis	Janesville Dialysis	1305 WOODMAN RD		JANESVILLE	WI	53545-1068
971	Affiliated	3643	Bloomfield Dialysis	Bloomfield Dialysis	29 GRIFFIN RD S		BLOOMFIELD	CT	06002-1351
972	Affiliated	3645	Anthem Village Dialysis	Anthem Village Dialysis	2530 ANTHEM VILLAGE DR		HENDERSON	NV	89052-5548
973	Affiliated	3646	Glen Burnie Dialysis	Glen Burnie Dialysis	120 LANGLEY RD N		GLEN BURNIE	MD	21060-6578
974	Affiliated	3655	Melbourne Dialysis	Melbourne Dialysis	2235 S BABCOCK ST		MELBOURNE	FL	32901-5305
975	Affiliated	3656	St. Petersburg South Dialysis	St. Petersburg South Dialysis	2850 34TH ST S		ST PETERSBURG	FL	33711-3817
976	Affiliated	3663	Belpre Dialysis	Belpre Dialysis	2906 WASHINGTON BLVD		BELPRE	OH	45714-1848
977	Affiliated	3666	Stockton Home Training Dialysis	Stockton Home Training Dialysis	545 E CLEVELAND ST	STE A	STOCKTON	CA	95204-5535
978	Affiliated	3670	Rock Prairie Road Dialysis	Rock Prairie Road Dialysis	1605 ROCK PRAIRIE RD	STE 11	COLLEGE STATION	TX	77845-8358
979	Affiliated	3675	Market Street Dialysis	Market Street Dialysis	3701 MARKET ST	STE 1	PHILADELPHIA	PA	19104-5503

980	Affiliated	3677	Northwood	Northwood Dialysis (aka Toledo East)	611 LEMOYNE RD		NORTHWOOD	OH	43619-1811
981	Affiliated	3701	Tyson' s Corner Dialysis	Tyson' s Corner Dialysis	8391 OLD COURTHOUSE RD	STE 16	VIENNA	VA	22182-3819
982	Affiliated	3704	Southern Maryland Dialysis	Southern Maryland Dialysis	9211 STUART LN	4TH FL	CLINTON	MD	20735-2712
983	Affiliated	3707	Brentwood Dialysis	Brentwood Dialysis	1231 BRENTWOOD RD NE		WASHINGTON	DC	20018-1019
984	Affiliated	3708	Amelia Dialysis	Amelia Dialysis	15151 PATRICK HENRY HWY		AMELIA COURT HOUSE	VA	23002-4700
985	Affiliated	3714	Eighth Street Dialysis	Eighth Street Dialysis	300 8TH ST NE		WASHINGTON	DC	20002-6108
986	Affiliated	3715	Chester Dialysis	Chester Dialysis	10360 IRONBRIDGE RD		CHESTER	VA	23831-1425
987	Affiliated	3716	Howard County Dialysis	Howard County Dialysis	5999 HARPERS FARM RD	STE 11E	COLUMBIA	MD	21044-3023
988	Affiliated	3717	Catonsville Dialysis	Catonsville Dialysis	1581 SULPHUR SPRING RD	STE 112	BALTIMORE	MD	21227
989	Affiliated	3718	Mercy Dialysis	Mercy Dialysis	315 N CALVERT ST	STE 3	BALTIMORE	MD	21202-3611
990	Affiliated	3719	Harbor Park Dialysis	Harbor Park Dialysis	111 CHERRY HILL RD		BALTIMORE	MD	21225-1392
991	Affiliated	3732	Dabney Dialysis	Three Chopt Dialysis (fka Dabney)	8813 THREE CHOPT RD		RICHMOND	VA	23229
992	Affiliated	3733	Hioaks Dialysis	Hioaks Dialysis	671 HIOAKS RD	STE A	RICHMOND	VA	23225-4072
993	Affiliated	3757	Arlington Dialysis	Arlington Dialysis	4805 1st ST N		ARLINGTON	VA	22203
994	Affiliated	3759	Landover Dialysis	Landover Dialysis	1200 MERCANTILE LN	STE 15	UPPER MARLBORO	MD	20774-5389
995	Affiliated	3761	Staunton Dialysis	Staunton Dialysis	29 IDLEWOOD BLVD		STAUNTON	VA	24401-9355

996	Affiliated	3762	Covington Dialysis	Covington Dialysis	2504 VALLEY RIDGE RD		COVINGTON	VA	24426-6339
997	Affiliated	3763	Culpeper Dialysis	Culpeper Dialysis	430 SOUTHRIDGE PARKWAY		CULPEPER	VA	22701-3791
998	Affiliated	3764	Greenbrier Dialysis	Greenbrier Dialysis	129 SENECA TRL		LEWISBURG	WV	24901-1564
999	Affiliated	3765	Harrisonburg Dialysis	Harrisonburg Dialysis	871 CANTRELL AVE	STE 1	HARRISONBURG	VA	22801-4323

1000	Affiliated	3766	Lexington Dialysis	Lexington Dialysis	756 N LEE HWY		LEXINGTON	VA	24450-3724
1001	Affiliated	3802	Manteca Dialysis	Manteca Dialysis	1156 S MAIN ST		MANTECA	CA	95337-9505
1002	Affiliated	3804	Roseburg/Mercy Dialysis	Roseburg/ Mercy Dialysis	2599 NW EDENBOWER BLVD		ROSEBURG	OR	97471-6220
1003	Affiliated	3805	Daly City Dialysis	Daly City Dialysis	1498 SOUTHGATE AVE	STE 11	DALY CITY	CA	94015-4015
1004	Affiliated	3806	Vallejo Dialysis	Vallejo Dialysis	121 HOSPITAL DR		VALLEJO	CA	94589-2562
1005	Affiliated	3812	Salem Dialysis	Salem Dialysis (OR)	3550 LIBERTY RD S	STE 1	SALEM	OR	97302-5700
1006	Affiliated	3817	Fresno Dialysis	Fresno Dialysis	1111 E WARNER AVE		FRESNO	CA	93710-4030
1007	Affiliated	3818	Oakland Dialysis	Oakland Dialysis	5354 CLAREMONT AVE		OAKLAND	CA	94618-1035
1008	Affiliated	3820	Bakersfield Dialysis	Bakersfield Brimhall Dialysis (fka California Ave.)	8501 BRIMHALL RD	BLDG 5	BAKERSFIELD	CA	93311-2252
1009	Affiliated	3821	Northeast Bakersfield Dialysis	Northeast Dialysis (fka NE Bakersfield)	3761 MALL VIEW RD		BAKERSFIELD	CA	93306-3048
1010	Affiliated	3830	San Francisco Dialysis	San Francisco Dialysis	1499 WEBSTER ST		SAN FRANCISCO	CA	94115-3705
1011	Affiliated	3831	Hanford Dialysis	Hanford Dialysis	402 W 8TH ST		HANFORD	CA	93230-4536
1012	Affiliated	3840	San Pablo Dialysis	San Pablo Dialysis	14020 SAN PABLO AVE		SAN PABLO	CA	94806-3604
1013	Affiliated	3847	Chinatown Dialysis	Chinatown Dialysis	636 CLAY ST		SAN FRANCISCO	CA	94111-2502
1014	Affiliated	3849	El Cerrito Dialysis	El Cerrito Dialysis	10690 SAN PABLO AVE		EL CERRITO	CA	94530-2620
1015	Affiliated	3857	Tracy Dialysis	Tracy Dialysis	425 W BEVERLY PL	STE A	TRACY	CA	95376-3086
1016	Affiliated	3858	Salem North Dialysis	Salem North Dialysis (OR)	1220 LIBERTY ST NE		SALEM	OR	97301-7330

1017	Affiliated	3860	Auburn Dialysis	Auburn Dialysis	3126 PROFESSIONAL DR	STE 1	AUBURN	CA	95603-2411
1018	Affiliated	3861	Grass Valley Dialysis	Grass Valley Dialysis	360 CROWN POINT CIRCLE	STE 21	GRASS VALLEY	CA	95945-2543
1019	Affiliated	3901	Santee Dialysis	Santee Dialysis	228 BRADFORD BLVD		SANTEE	SC	29142-8677
1020	Affiliated	3903	Upland Dialysis	Upland Dialysis	600 N 13TH AVE		UPLAND	CA	91786-4957
1021	Affiliated	3906	Vance County Dialysis	Vance County Dialysis	854 S BECKFORD DR		HENDERSON	NC	27536-3487
1022	Affiliated	3907	Edenton Dialysis	Edenton Dialysis	703 LUKE ST		EDENTON	NC	27932-9694
1023	Affiliated	3909	Ahoskie Dialysis	Ahoskie Dialysis	129 HERTFORD COUNTY HIGH RD		AHOSKIE	NC	27910-8131
1024	Affiliated	3914	Allendale County Dialysis	Allendale County Dialysis	202 HAMPTON AVE N		FAIRFAX	SC	29827-4510
1025	Affiliated	3916	North Orangeburg Dialysis	North Orangeburg Dialysis	124 FIRE TOWER RD		ORANGEBURG	SC	29118-1443
1026	Affiliated	3917	South Orangeburg Dialysis	South Orangeburg Dialysis	1080 SUMMERS AVE		ORANGEBURG	SC	29115-4920
1027	Affiliated	3931	Greenwood Dialysis	Greenwood Dialysis	109 OVERLAND DR		GREENWOOD	SC	29646-4053
1028	Affiliated	3933	Union County Dialysis	Union County Dialysis	701 E ROOSEVELT BLVD	STE 4	MONROE	NC	28112-4107
1029	Affiliated	3934	South Charlotte Dialysis	South Charlotte Dialysis	6450 BANNINGTON RD		CHARLOTTE	NC	28226-1327
1030	Affiliated	3935	Lancaster SC Dialysis	Lancaster SC Dialysis	980 N WOODLAND DR	STE 1	LANCASTER	SC	29720-1964
1031	Affiliated	3952	Central Bamberg Dialysis	Central Bamberg Dialysis	67 SUNSET DR		BAMBERG	SC	29003-1181
1032	Affiliated	4001	West Tallahassee Dialysis	West Tallahassee Dialysis	2645 W TENNESSEE ST		TALLAHASSEE	FL	32304-2547

1033	Affiliated	4002	Daytona South Dialysis	Daytona South Dialysis	1801 S NOVA RD	STE 36	SOUTH DAYTONA	FL	32119-1775
1034	Affiliated	4003	Daytona Beach Dialysis	Daytona Beach Dialysis	578 HEALTH BLVD		DAYTONA BEACH	FL	32114-1492
1035	Affiliated	4004	West Tampa Dialysis	West Tampa Dialysis	4515 GEORGE RD	STE 3	TAMPA	FL	33634-7300
1036	Affiliated	4005	Fontana Dialysis	Fontana Dialysis	17590 FOOTHILL BLVD		FONTANA	CA	92335-8416
1037	Affiliated	4007	Fort Myers Dialysis	Fort Myers Dialysis	4220 EXECUTIVE CIRCLE	STE 38	FORT MYERS	FL	33916-7993
1038	Affiliated	4009	Lehigh Acres Dialysis	Lehigh Acres Dialysis	2719 4TH ST W		LEHIGH ACRES	FL	33971-1942
1039	Affiliated	4010	Los Banos Dialysis	Los Banos Dialysis	222 I ST		LOS BANOS	CA	93635-4132
1040	Affiliated	4013	Kissimmee Dialysis	Kissimmee Dialysis	802 N JOHN YOUNG PKWY		KISSIMMEE	FL	34741-4912
1041	Affiliated	4014	New Smyrna Beach Dialysis	New Smyrna Beach Dialysis	110 S ORANGE ST		NEW SMYRNA BEACH	FL	32168-7153
1042	Affiliated	4017	Lake Wales Dialysis	Lake Wales Dialysis	1125 BRYN MAWR AVE		LAKE WALES	FL	33853-4333
1043	Affiliated	4018	Dearborn Dialysis	Dearborn Dialysis	1185 MONROE ST		DEARBORN	MI	48124-2814
1044	Affiliated	4020	Greater Miami Dialysis	Greater Miami Dialysis	160 NW 176TH ST	STE 1	MIAMI	FL	33169-5023
1045	Affiliated	4021	Burbank Dialysis	Burbank Dialysis	1211 N SAN FERNANDO BLVD		BURBANK	CA	91504-4234
1046	Affiliated	4024	Lakeland Dialysis	Lakeland Dialysis	515 E BELLA VISTA ST		LAKELAND	FL	33805-3005
1047	Affiliated	4025	Burlington North Dialysis	Burlington North Dialysis	1164 E ROUTE 130		BURLINGTON	NJ	08016-2954
1048	Affiliated	4026	Delano Dialysis	Delano Dialysis	905 MAIN ST		DELANO	CA	93215-1729
1049	Affiliated	4027	Erie Dialysis	Erie Dialysis	350 E BAYFRONT PKWY	STE A	ERIE	PA	16507-2410
1050	Affiliated	4028	Homestead Dialysis	Homestead Dialysis	207 W 7TH AVE		W HOMESTEAD	PA	15120-1002
1051	Affiliated	4029	Plant City Dialysis	Plant City Dialysis	1211 W REYNOLDS ST		PLANT CITY	FL	33563-4321

1052	Affiliated	4030	Winter Haven Dialysis	Winter Haven Dialysis	1625 UNITY WAY NW		WINTER HAVEN	FL	33881
1053	Affiliated	4032	Charlotte Dialysis	Charlotte Dialysis	2321 W MOREHEAD ST	STE 12	CHARLOTTE	NC	28208-5145
1054	Affiliated	4034	McKeesport Dialysis	McKeesport Dialysis	2001 LINCOLN WAY	OAK PARK MALL	MCKEESPORT	PA	15131-2419
1055	Affiliated	4035	Broward Dialysis	Broward Dialysis	1500 N FEDERAL HWY	STE 1	FT LAUDERDALE	FL	33304-5600
1056	Affiliated	4036	Athens Dialysis	Athens Dialysis	15953 ATHENS LIMESTONE DR		ATHENS	AL	35613-2214
1057	Affiliated	4038	Bradenton Dialysis	Bradenton Dialysis	3501 CORTEZ RD W	STE 14	BRADENTON	FL	34210-3104
1058	Affiliated	4039	Deland Dialysis	Deland Dialysis	350 E NEW YORK AVE		DELAND	FL	32724-5510
1059	Affiliated	4040	Boynton/North Delray Dialysis	Boynton/North Delray Dialysis	2655 W ATLANTIC AVE		DELRAY BEACH	FL	33445-4400
1060	Affiliated	4041	Lake Worth Dialysis	Lake Worth Dialysis	2459 S CONGRESS AVE	STE 1	PALM SPRINGS	FL	33406-7616
1061	Affiliated	4042	Palm Coast Dialysis	Palm Coast Dialysis	13 KINGSWOOD DR	STE A	PALM COAST	FL	32137-4614
1062	Affiliated	4043	Fort Myers South Dialysis	Fort Myers South Dialysis	8570 GRANITE CT		FORT MYERS	FL	33908-4102
1063	Affiliated	4044	Woodburn Dialysis	Woodburn Dialysis	1840 NEWBERG HWY	STE 14	WOODBURN	OR	97071-3187
1064	Affiliated	4045	Four Freedoms	Four Freedoms Dialysis (fka Range Street)	289 SW RANGE AVE	STE A	MADISON	FL	32340-2351
1065	Affiliated	4046	West Philadelphia Dialysis	West Philadelphia Dialysis	7609 LINDBERGH BLVD		PHILADELPHIA	PA	19153-2301
1066	Affiliated	4048	Tucson West Dialysis	Tucson West Dialysis	1780 W ANKLAM RD		TUCSON	AZ	85745-2632

1067	Affiliated	4049	Tucson East Dialysis	Tucson East Dialysis	6420 E BROADWAY BLVD	STE C3	TUCSON	AZ	85710-3512
1068	Affiliated	4053	Tallahassee South Dialysis	Tallahassee South Dialysis	2410 S ADAMS ST		TALLAHASSEE	FL	32301-6325
1069	Affiliated	4054	Selma Dialysis	Selma Dialysis	2711 CINEMA WAY	STE 111	SELMA	CA	93662-2662
1070	Affiliated	4055	Hinesville Dialysis	Hinesville Dialysis	522 ELMA G MILES PKWY		HINESVILLE	GA	31313-4021
1071	Affiliated	4056	Los Angeles Downtown Dialysis	Los Angeles Downtown Dialysis	2021 S FLOWER ST		LOS ANGELES	CA	90007-1342
1072	Affiliated	4057	Anaheim Dialysis	Anaheim Dialysis	1107 W LA PALMA AVE		ANAHEIM	CA	92801-2804
1073	Affiliated	4058	Martinsville Dialysis	Martinsville Dialysis	33 BRIDGE ST S		MARTINSVILLE	VA	24112-6214
1074	Affiliated	4060	Jefferson Dialysis	Jefferson Dialysis	14 CLAIRTON BLVD		PITTSBURGH	PA	15236-3911
1075	Affiliated	4061	Saddleback Dialysis	Saddleback Dialysis	23141 PLAZA POINTE DR		LAGUNA HILLS	CA	92653-1425
1076	Affiliated	4064	Sun City Center Dialysis	Sun City Center Dialysis	783 CORTARO DR		RUSKIN	FL	33573-6812
1077	Affiliated	4065	Paris Dialysis	Paris Dialysis	32 STEUBENVILLE PK		PARIS	PA	15021
1078	Affiliated	4066	Central Tampa Dialysis	Central Tampa Dialysis	4204 N MACDILL AVE	SOUTH BLDG	TAMPA	FL	33607-6342
1079	Affiliated	4068	Zephyrhills Dialysis	Zephyrhills Dialysis	6610 STADIUM DR		ZEPHYRHILLS	FL	33542-7510
1080	Affiliated	4069	Bartow Dialysis	Bartow Dialysis	1190 E CHURCH ST		BARTOW	FL	33830-4117
1081	Affiliated	4070	Ormond Beach Dialysis	Ormond Beach Dialysis	495 S NOVA RD	STE 19	ORMOND BEACH	FL	32174-8444
1082	Affiliated	4071	Lakeland South Dialysis	Lakeland South Dialysis	5050 S FLORIDA AVE		LAKELAND	FL	33813-2501
1083	Affiliated	4072	St. Mary' s Dialysis	St. Mary' s Dialysis	2714 OSBORNE RD		ST MARY' S	GA	31558-4049
1084	Affiliated	4073	Miami North Dialysis	Miami North Dialysis	860 NE 125TH ST		NORTH MIAMI	FL	33161-5743

1085	Affiliated	4074	Naples Dialysis	Naples Dialysis	661 9TH ST N	NAPLES	FL	34102-8132
1086	Affiliated	4075	Bonita Springs Dialysis	Bonita Springs Dialysis	9134 BONITA BEACH RD SE	BONITA SPRINGS	FL	34135-4281
1087	Affiliated	4076	Orlando Southwest Dialysis	Orlando Southwest Dialysis	6925 LAKE ELLENOR DR	ORLANDO	FL	32809-4670
1088	Affiliated	4088	Quincy Dialysis	Quincy Dialysis	878 STRONG RD	QUINCY	FL	32351-5243
1089	Affiliated	4089	Tallahassee Dialysis	Tallahassee Dialysis	1607 PHYSICIANS DR	TALLAHASSEE	FL	32308-4620
1090	Affiliated	4095	South Beach Dialysis	South Beach Dialysis	4701 N MERIDIAN AVE	MIAMI BEACH	FL	33140-2910
1091	Affiliated	4124	Americus Dialysis	Americus Dialysis	227 N LEE ST	AMERICUS	GA	31709-3525
1092	Affiliated	4204	Corry Dialysis	Corry Dialysis	300 YORK ST	CORRY	PA	16407-1420
1093	Affiliated	4208	Elizabethtown Dialysis	Elizabethtown Dialysis	844 N HANOVER ST	ELIZABETHTOWN	PA	17022-1303
1094	Affiliated	4209	Lumberton Dialysis	Lumberton Dialysis	668 MAIN ST	LUMBERTON	NJ	08048-5016
1095	Affiliated	4211	Cobbs Creek Dialysis	Cobbs Creek Dialysis	1700 S 60TH ST	PHILADELPHIA	PA	19142-1404
1096	Affiliated	4214	Westland Dialysis	Garden West Dialysis (fka Westland)	5715 N VENOY RD	WESTLAND	MI	48185-2830
1097	Affiliated	4215	Meadville Dialysis	Meadville Dialysis	19050 PARK AVENUE PLZ	MEADVILLE	PA	16335-4012
1098	Affiliated	4217	Bradford Dialysis	Bradford Dialysis	665 E MAIN ST	BRADFORD	PA	16701-1869
1099	Affiliated	4219	Southgate Dialysis	Southgate Dialysis	14752 NORTHLINE RD	SOUTHGATE	MI	48195-2467
1100	Affiliated	4223	Waynesburg Dialysis	Waynesburg Dialysis	248 ELM DR	WAYNESBURG	PA	15370-8269
1101	Affiliated	4224	Selinsgrove Dialysis	Selinsgrove Dialysis	1030 N SUSQUEHANNA TRAIL	SELINSGROVE	PA	17870-7767
1102	Affiliated	2153	Arlington Dialysis	Arlington Dialysis	1250 E PIONEER PKWY	ARLINGTON	TX	76010-6423
1103	Affiliated	2154	Grapevine Dialysis	Grapevine Dialysis	1600 W NORTHWEST HWY	GRAPEVINE	TX	76051-8131

1104	Affiliated	1740	Willow Dialysis	Willow Dialysis	1675 ALEX DR		WILMINGTON	OH	45177-2446
1105	Affiliated	1767	New Braunfels Dialysis	New Braunfels Dialysis	900 LOOP 337		NEW BRAUNFELS	TX	78130-3555
1106	Affiliated	2080	Chickasha Dialysis	Chickasha Dialysis	228 S 29TH ST		CHICKASHA	OK	73018-2502
1107	Affiliated	2184	Sugarloaf	Sugarloaf Dialysis (fka Lawrenceville)	1705 BELLE MEADE CT	STE 11	LAWRENCEVILLE	GA	30043-5895
1108	Affiliated	2166	Buford Dialysis	Buford Dialysis	1550 BUFORD HWY	STE 1E	BUFORD	GA	30518-3666
1109	Affiliated	1749	St. Louis Park PD	St. Louis Park Dialysis Center PD	3505 LOUISIANA AVE S		ST LOUIS PARK	MN	55426-4121
1110	Affiliated	1769	Front Royal Dialysis	Front Royal Dialysis	1077D N SHENANDOAH AVE		FRONT ROYAL	VA	22630-3546
1111	Affiliated	1770	Winchester Dialysis	Winchester Dialysis	2301 VALOR DR		WINCHESTER	VA	22601-6111
1112	Affiliated	2200	New Hope Dialysis	New Hope Dialysis (aka Minneapolis, Golden Valley)	5640 INTERNATIONAL PKWY		NEW HOPE	MN	55428-3047
1113	Affiliated	2175	Richfield Dialysis	Richfield Dialysis	6601 LYNDALE AVE S	STE 15	RICHFIELD	MN	55423-2490
1114	Affiliated	2162	Fairborne Dialysis	Fairborn Dialysis	3070 PRESIDENTIAL DR	STE A	FAIRBORN	OH	45324-6273
1115	Affiliated	1694	Benton Dialysis	Benton Dialysis	1151 ROUTE 14 W		BENTON	IL	62812-1500
1116	Affiliated	1695	Centralia Dialysis	Centralia Dialysis	1231 STATE ROUTE 161		CENTRALIA	IL	62801-6739
1117	Affiliated	1696	Marion Dialysis	Marion Dialysis	324 S 4TH ST		MARION	IL	62959-1241
1118	Affiliated	1697	Mount Vernon Dialysis	Mount Vernon Dialysis	1800 JEFFERSON AVE		MOUNT VERNON	IL	62864-4300
1119	Affiliated	2121	Bayou City Dialysis	Bayou City Dialysis (fka Hanson)	10655 EASTEX FWY		HOUSTON	TX	77093-4323
1120	Affiliated	2117	Metairie Dialysis Center	Metairie Dialysis	7100 AIRLINE DR		METAIRIE	LA	70003-5950

1121	Affiliated	1784	Stony Creek Dialysis	Stony Creek Dialysis	9115 S CICERO AVE		OAK LAWN	IL	60453-1895
1122	Affiliated	1785	Beverly Dialysis	Beverly Dialysis	8109 SOUTH WESTERN AVE		CHICAGO	IL	60620-5939
1123	Affiliated	2089	Summit Dialysis	Summit Dialysis Center	3150 POLK ST		HOUSTON	TX	77003-4631
1124	Affiliated	2212	Upper Valley Dialysis	Upper Valley Dialysis (fka West El Paso)	7933 N MESA ST	STE H	EL PASO	TX	79932-1699
1125	Affiliated	2134	Dallas County	Perry Dialysis (fka Dallas County)	610 10TH ST	STE L1	PERRY	IA	50220-2221
1126	Affiliated	1813	Nampa Dialysis Center	Nampa Dialysis	846 PARKCENTRE WAY		NAMPA	ID	83651-1790
1127	Affiliated	1814	Table Rock Dialysis	Table Rock Dialysis	5610 W GAGE ST	STE B	BOISE	ID	83706
1128	Affiliated	1815	Twin Falls Dialysis	Twin Falls Dialysis	1840 CANYON CREST DR		TWIN FALLS	ID	83301-3007
1129	Affiliated	1816	Burley Dialysis Center	Burley Dialysis	741 N OVERLAND AVE		BURLEY	ID	83318-3440
1130	Affiliated	1817	Gate City Dialysis Center	Gate City Dialysis	2001 BENCH RD		POCATELLO	ID	83201-2033
1131	Affiliated	1818	Four Rivers Dialysis	Four Rivers Dialysis	515 EAST LN		ONTARIO	OR	97914-3953
1132	Affiliated	2231	River Parishes	River Parishes Dialysis (aka La Place)	2880 W AIRLINE HWY		LA PLACE	LA	70068-2922
1133	Affiliated	2177	South Lincoln	South Lincoln Dialysis	3401 PLANTATION DR	STE 14	LINCOLN	NE	68516-4712

1134	Affiliated	2105	Rochester Hills	Rochester Hills Dialysis (aka Sterling Heights)	1886 W AUBURN RD	STE 1	ROCHESTER HILLS	MI	48309-3865
1135	Affiliated	2101	Willowbrook Dialysis	Willowbrook Dialysis	12120 JONES RD	STE G	HOUSTON	TX	77070-5280
1136	Affiliated	2195	Springhurst Dialysis	Springhurst Dialysis (aka Louisville)	10201 CHAMPION FARMS DR		LOUISVILLE	KY	40241-6150
1137	Affiliated	2012	Magnolia West	Magnolia West Dialysis (aka Riverside II)	11161 MAGNOLIA AVE		RIVERSIDE	CA	92505-3605
1138	Affiliated	2206	Garrisonville Dialysis	Garrisonville Dialysis	70 DOC STONE RD	STE 11	STAFFORD	VA	22556-4628
1139	Affiliated	2152	Strongsville Dialysis	Strongsville Dialysis	17792 PEARL RD		STRONGSVILLE	OH	44136-6909
1140	Affiliated	984	Summerlin Dialysis	Summerlin Dialysis Center, LV	653 N TOWN CENTER DR	STE 7 BLDG 2	LAS VEGAS	NV	89144-0503
1141	Affiliated	2127	Red Bluff Dialysis	Red Bluff Dialysis Center	2455 SISTER MARY COLUMBA DR		RED BLUFF	CA	96080-4364
1142	Affiliated	1638	Cobb Dialysis	Cobb Dialysis	3865 MEDICAL PARK DR		AUSTELL	GA	30106-1109
1143	Affiliated	1693	Paulding Dialysis	Paulding Dialysis	4019 JOHNS RD		DALLAS	GA	30132-3420
1144	Affiliated	1839	Sweetwater Dialysis	Sweetwater Dialysis	7117 S SWEETWATER RD		LITHIA SPRINGS	GA	30122-2446
1145	Affiliated	3671	Charlottesville North	Charlottesville North Dialysis	1800 TIMBERWOOD BLVD	STE C	CHARLOTTESVILLE	VA	22911-7544
1146	Affiliated	2186	Southern Crescent	Southern Crescent Dialysis Center (fka Riverdale)	275 UPPER RIVERDALE RD SW	STE B	RIVERDALE	GA	30274-2556
1147	Affiliated	2169	Meridian Park	Meridian Park Dialysis Center (fka Lake Oswego)	19255 SW 65TH AVE	STE 1	TUALATIN	OR	97062-9712

1148	Affiliated	1812	Treasure Valley Dialysis	Treasure Valley Dialysis	3525 E LOUISE ST	STE 155	MERIDIAN	ID	83642-6303
1149	Affiliated	3637	White Oak	White Oak Dialysis (Chronic)	5520 CHEVIOT RD	STE B	CINCINNATI	OH	45247-7069
1150	Affiliated	1786	Ash Tree	Ash Tree Dialysis	2666 N GROVE INDUSTRIAL DR		FRESNO	CA	93727-1552
1151	Affiliated	2242	Madera Dialysis	Almond Wood Dialysis (fka Madera)	501 E ALMOND AVE		MADERA	CA	93637-5661
1152	Affiliated	2209	Carrollton	Carrollton Dialysis	1544 VALWOOD PKWY	STE 114	CARROLLTON	TX	75006-8425
1153	Affiliated	2202	Edna Dialysis	Edna Dialysis	1008 N WELLS ST		EDNA	TX	77957-2153
1154	Affiliated	2208	Bear Creek Dialysis	Bear Creek Dialysis (fka Clay Road)	4978 HIGHWAY 6 N	STE I	HOUSTON	TX	77084-5282
1155	Affiliated	1820	Windham Dialysis	Windham Dialysis	375 TUCKIE RD	STE C	NORTH WINDHAM	CT	06256-1345
1156	Affiliated	1819	Vernon Dialysis	Vernon Dialysis	460 HARTFORD TPKE STE C		VERNON ROCKVILLE	CT	6066
1157	Affiliated	2092	Fountain Dialysis	Fountain Dialysis (aka Security)	6910 BANDLEY DR		FOUNTAIN	CO	80817-2617
1158	Affiliated	1846	Grand Junction	Grand Junction Dialysis Center	710 WELLINGTON AVE	STE 2	GRAND JUNCTION	CO	81501-6100
1159	Affiliated	2183	Fort Mill	Fort Mill Dialysis	1975 CAROLINA PLACE DR		FORT MILL	SC	29708-6922
1160	Affiliated	2215	Myrtle Beach	JV-Myrtle Beach Dialysis	3919 MAYFAIR ST		MYRTLE BEACH	SC	29577-5773
1161	Affiliated	2032	Oakwood	Oakwood Dialysis Center	148 HECTOR AVE		GRETNA	LA	70056-2531

1162	Affiliated	2168	SP Hillsboro	Hillsboro Dialysis	2500 NW 229TH AVE	STE 3 BLDG E	HILLSBORO	OR	97124-7516
1163	Affiliated	2269	Kettering	Kettering Dialysis	5721 BIGGER RD		KETTERING	OH	45440-2752
1164	Affiliated	2246	Mansfield	Mansfield Dialysis Center (aka Dallas)	987 N WALNUT CREEK DR	STE 11	MANSFIELD	TX	76063-8016
1165	Affiliated	2290	Cottage Grove	Cottage Grove Dialysis	8800 E POINT DOUGLAS RD S	STE 1	COTTAGE GROVE	MN	55016-4160
1166	Affiliated	2257	Scott County Dialysis	Scott County Dialysis	7456 S PARK DR		SAVAGE	MN	55378
1167	Affiliated	1773	Virginia Beach	Camelot Dialysis Center	1800 CAMELOT DR	STE 1	VIRGINIA BEACH	VA	23454-2440
1168	Affiliated	1627	Amelia Island	Amelia Island Dialysis	1525 LIME ST	STE 12	FERNANDINA BEACH	FL	32034-3015
1169	Affiliated	2179	Laurel Manor at the Villages	Laurel Manor Dialysis Center at the Villages	1950 LAUREL MANOR DR	STE 19	LADY LAKE	FL	32162-5603
1170	Affiliated	2160	East Dearborn	East Dearborn Dialysis	13200 W WARREN AVE		DEARBORN	MI	48126-2410
1171	Affiliated	1661	North Houston	PDI-North Houston	7115 NORTH LOOP E		HOUSTON	TX	77028-5948
1172	Affiliated	1663	South Houston	PDI-South Houston	5989 SOUTH LOOP E		HOUSTON	TX	77033-1017
1173	Affiliated	1856	Ralph McGill Dialysis Center	Ralph McGill Dialysis	418 DECATUR ST SE		ATLANTA	GA	30312-1801
1174	Affiliated	2144	Chelsea	Chelsea Dialysis	1620 COMMERCE PARK DR	STE 2	CHELSEA	MI	48118-2136
1175	Affiliated	2214	Smokey Mountain	Smoky Mountain Dialysis	1611 ANDREWS RD		MURPHY	NC	28906-5100
1176	Affiliated	3680	Miami Gardens	Miami Gardens Dialysis	3363 NW 167TH ST		MIAMI GARDENS	FL	33056-4254
1177	Affiliated	2222	Deerbrook	Deerbrook Dialysis	9660 FM 1960 BYPASS RD W		HUMBLE	TX	77338-4039

1178	Affiliated	2227	Downtown Dallas	DaVita Downtown Dallas Dialysis Center (fka Grove)	3515 SWISS AVE	STE A	DALLAS	TX	75204-6223
1179	Affiliated	2197	Henderson	Siena Henderson Dialysis Center	2865 SIENNA HEIGHTS DR	STE 141	HENDERSON	NV	89052-4168
1180	Affiliated	2292	Wyandotte	Wyandotte Central Dialysis	3737 STATE AVE		KANSAS CITY	KS	66102-3830
1181	Affiliated	2235	Westview	Westview Dialysis	3749 COMMERCIAL DR	LAFAYETTE PLACE SHOPPING CENTER	INDIANAPOLIS	IN	46222-1676
1182	Affiliated	2286	Garland	Garland Dialysis	776 E CENTERVILLE RD		GARLAND	TX	75041-4640
1183	Affiliated	2333	Aberdeen	Aberdeen Dialysis	780 W BEL AIR AVE		ABERDEEN	MD	21001-2236
1184	Affiliated	2259	Mountain Park	Mountain Park Dialysis	5235 MEMORIAL DR		STONE MOUNTAIN	GA	30083-3112
1185	Affiliated	2229	Downtown San Antonio	Downtown San Antonio Dialysis (Brooklyn St)	615 E QUINCY ST		SAN ANTONIO	TX	78215-1600
1186	Affiliated	2237	Medlock Bridge	Medlock Bridge Dialysis (aka Duluth)	10680 MEDLOCK BRIDGE RD	STE 13	DULUTH	GA	30097-8420
1187	Affiliated	2234	Greene County Dialysis	Greene County Dialysis Center (NC)	1025 KINGOLD BLVD		SNOW HILL	NC	28580-1616
1188	Affiliated	2243	West Broadway Dialysis	West Broadway Dialysis	720 W BROADWAY		LOUISVILLE	KY	40202-2240
1189	Affiliated	2072	St. Pauls Dialysis	St. Pauls Dialysis (aka Robeson County)	564 W MCLEAN ST		SAINT PAULS	NC	28384-1421

1190	Affiliated	2123	Carquinez Dialysis	Carquinez Dialysis (fka SW Vallejo)	125 CORPORATE PL	STE C	VALLEJO	CA	94590-6968
1191	Affiliated	2159	DaVita East	DaVita East Dialysis Clinic (fka La Bamba)	11989 PELLICANO DR		EL PASO	TX	79936-6287
1192	Affiliated	2187	Natomas	Natomas Dialysis	30 GOLDEN LAND CT	BLDG G	SACRAMENTO	CA	95834-2420
1193	Affiliated	2228	Tennessee Valley	Tennessee Valley Dialysis Center (aka Johnson City)	107 WOODLAWN DR	STE 2	JOHNSON CITY	TN	37604-6287
1194	Affiliated	2174	Turfway Dialysis	Turfway Dialysis (fka Florence)	11 SPIRAL DR	STE 15	FLORENCE	KY	41042-1394
1195	Affiliated	2291	Leavenworth	Leavenworth Dialysis	501 OAK ST		LEAVENWORTH	KS	66048-2646
1196	Affiliated	2270	Franklin Dialysis	Franklin Dialysis (IN)	1140 W JEFFERSON ST	STE A	FRANKLIN	IN	46131-2101
1197	Affiliated	2011	Norco	Norco Dialysis (fka Corona II)	1901 TOWN AND COUNTRY DR	STE 1	NORCO	CA	92860-3611
1198	Affiliated	2240	Andover	Andover Dialysis	488 S MAIN ST		ANDOVER	OH	44003-9602
1199	Affiliated	1863	Little Rock	Jacksonville Central Dialysis Center	400 T P WHITE DR		JACKSONVILLE	AR	72076-3287
1200	Affiliated	1864	North Little Rock Dialysis	North Little Rock Center	4505 E MCCAIN BLVD		NORTH LITTLE ROCK	AR	72117-2902

1201	Affiliated	2233	Anadarko	Anadarko Dialysis	412 SE 11TH STREET		ANADARKO	OK	73005-4442
1202	Affiliated	2331	Desert Springs	Desert Springs Dialysis	2110 E FLAMINGO RD	STE 18	LAS VEGAS	NV	89119-5191
1203	Affiliated	2213	Livingston	Vancouver Dialysis Center	9120 NE VANCOUVER MALL DR	STE 16	VANCOUVER	WA	98662-9401
1204	Affiliated	2300	Vancouver	Livingston TN Dialysis	308 OAK ST		LIVINGSTON	TN	38570-1729
1205	Affiliated	2225	Fenton	Fenton Dialysis	17420 SILVER PKWY		FENTON	MI	48430-4429
1206	Affiliated	2332	Cold Spring	Cold Springs Dialysis	430 CROSS ROADS BLVD		COLD SPRING	KY	41076-2341
1207	Affiliated	2094	Yucaipa	Yucaipa Dialysis	33487 YUCAIPA BLVD		YUCAIPA	CA	92399-2064
1208	Affiliated	1900	Florida Renal Center	Florida Renal Center	3500 NW 7TH ST		MIAMI	FL	33125-4016
1209	Affiliated	2140	Harbor UCLA	Long Beach Harbor Dialysis (aka UCLA)	1075 E PACIFIC COAST HWY		LONG BEACH	CA	90806-5089
1210	Affiliated	2210	Seaton Drive	Seton Drive Dialysis (fka Greensprings II)	4800 SETON DR		BALTIMORE	MD	21215-3210
1211	Affiliated	1865	South Valley	South Valley Dialysis	17815 VENTURA BLVD	STE 1	ENCINO	CA	91316-3600
1212	Affiliated	2305	West Pensacola	West Pensacola Dialysis	598 N FAIRFIELD DR	STE 1	PENSACOLA	FL	32506-4320
1213	Affiliated	2073	Mar Vista	Mar Vista Dialysis Center (UCLA-Santa Monica)	2020 SANTA MONICA BLVD	STE 1	SANTA MONICA	CA	90404-2139
1214	Affiliated	2082	Riddle Dialysis	Riddle Dialysis	100 GRANITE DR	STE 16	MEDIA	PA	19063-5134
1215	Affiliated	2346	Uptown	Minneapolis Uptown Dialysis	3601 LYNDALE AVE S		MINNEAPOLIS	MN	55409-1103
1216	Affiliated	1907	Lake Griffith East Dialysis	Lake Griffin East Dialysis	401 E NORTH BLVD		LEESBURG	FL	34748-5256

1217	Affiliated	2170	West Linn	West Linn Dialysis	19056 WILLAMETTE DR		WEST LINN	OR	97068-1715
1218	Affiliated	2330	Cape Coral South	Cape Coral South Dialysis	3046 DEL PRADO BLVD S	STE 4A	CAPE CORAL	FL	33904-7232
1219	Affiliated	2241	Ceres	Ceres Dialysis Center	1768 MITCHELL RD	STE 38	CERES	CA	95307-2156
1220	Affiliated	1862	Shaker Square	Shaker Square Dialysis	12800 SHAKER BLVD	STE 1	CLEVELAND	OH	44120-2004
1221	Affiliated	1906	St. Cloud Dialysis	St. Cloud Dialysis	4750 OLD CANOE CREEK RD		SAINT CLOUD	FL	34769-1430
1222	Affiliated	1915	Turlock Dialysis Center	Turlock Dialysis Center	50 W SYRACUSE AVE		TURLOCK	CA	95380-3143
1223	Affiliated	2268	Haymarket	Haymarket Dialysis (fka Gainesville)	14664 GAP WAY		GAINESVILLE	VA	20155-1683
1224	Affiliated	2272	Hackettstown	Hackettstown Dialysis	657 WILLOW GROVE ST	WEST WING MEDICAL PLAZA STE 22	HACKETTSTOWN	NJ	07840-1713
1225	Affiliated	2274	Regency	Regency Dialysis Center (fka Jacksonville)	9535 REGENCY SQUARE BLVD N		JACKSONVILLE	FL	32225-8128
1226	Affiliated	2149	Williamsburg	Williamsburg Dialysis (fka Yorktown)	500 SENTARA CIR	STE 13	WILLIAMSBURG	VA	23188-5727
1227	Affiliated	2141	Commerce Township	Commerce Township Dialysis	120 W COMMERCE RD		COMMERCE TOWNSHIP	MI	48382-3915
1228	Affiliated	2147	Kankakee	Kankakee County Dialysis	581 WILLIAM R LATHAM SR DR	STE 14	BOURBONNAIS	IL	60914-2439
1229	Affiliated	2283	Sandusky	Sandusky Dialysis Center	795 BARDSHAR RD		SANDUSKY	OH	44870-1505
1230	Affiliated	2252	Ionia	Ionia Dialysis	2622 HEARTLAND BLVD		IONIA	MI	48846-8757

1231	Affiliated	2289	Indian River	Indian River Dialysis Center	2150 45TH ST UNIT 12	VERO BEACH	FL	32967-6281
1232	Affiliated	2360	North Henry	North Henry Dialysis (fka Stockbridge)	5627 N HENRY BLVD STE 11	STOCKBRIDGE	GA	30281-3244
1233	Affiliated	2077	Tacoma Dialysis	Tacoma Dialysis Center	3401 S 19TH ST	TACOMA	WA	98405-1909
1234	Affiliated	1908	Hialeah Kidney Center I	Hialeah Artificial Kidney Center	2750 W 68TH ST STE 27	HIALEAH	FL	33016-5450
1235	Affiliated	2315	St. Francis	Charter Colony Dialysis Center (fka St. Francis Dialysis)	2312 COLONY CROSSING PL	MIDLOTHIAN	VA	23112-4280
1236	Affiliated	2138	Bellflower	Bellflower Dialysis Center (aka Widerhorn)	15736 WOODRUFF AVE	BELFLOWER	CA	90706-4018
1237	Affiliated	2301	Smyrna	Smyrna Dialysis	537 STONECREST PKWY	SMYRNA	TN	37167-6884
1238	Affiliated	2122	Clearlake	Clearlake Dialysis	14400 OLYMPIC DR	CLEARLAKE	CA	95422-8809
1239	Affiliated	1853	Dialysis Center of Erie	Dialysis Center of Erie	1641 SASSAFRAS ST	ERIE	PA	16502-1858
1240	Affiliated	1854	Warren Dialysis	Warren Dialysis	2 W CRESCENT PARK	WARREN	PA	16365-2111
1241	Affiliated	2322	Maysville	Maysville Dialysis	489 TUCKER DR	MAYSVILLE	KY	41056-9111
1242	Affiliated	2429	Fridley	East River Road Dialysis (fka Fridley Dialysis Unit)	5301 E RIVER RD STE 117	FRIDLEY	MN	55421-3778
1243	Affiliated	2189	West Sacramento	West Sacramento Dialysis	3450 INDUSTRIAL BLVD STE 1	WEST SACRAMENTO	CA	95691-5003
1244	Affiliated	2293	Anderson	Anderson Dialysis Center	7502 STATE RD STE 116	CINCINNATI	OH	45255
1245	Affiliated	2383	North County	North St. Louis County Dialysis	13119 NEW HALLS FERRY RD	FLORISSANT	MO	63033-3228

1246	Affiliated	2439	Fargo	Fargo Dialysis Center	4474 23RD AVE S	STE M	FARGO	ND	58104-8795
1247	Affiliated	2008	Eastchester	Eastchester Road Dialysis Center (Bronx II)	1515 JARRETT PL		BRONX	NY	10461-2606
1248	Affiliated	2224	Fallon	Fallon Dialysis	1103 NEW RIVER PKWY		FALLON	NV	89406-6899
1249	Affiliated	2279	Clarksville North	Clarksville North Dialysis	3071 CLAY LEWIS RD		CLARKSVILLE	TN	37040-5141
1250	Affiliated	2308	Eaton	Eaton Dialysis	105 E WASHINGTON JACKSON RD		EATON	OH	45320-9789
1251	Affiliated	2447	Wallace	Wallace Dialysis	5650 S NC 41 HWY		WALLACE	NC	28466-6094
1252	Affiliated	2288	Central Kalazmazoo	Kalamazoo Central Dialysis	535 S BURDICK ST	STE 11	KALAMAZOO	MI	49007-5261
1253	Affiliated	2287	West Kalamazoo	Kalamazoo West Dialysis	1040 N 10TH ST		KALAMAZOO	MI	49009-6149
1254	Affiliated	1921	Bakersfield	Bakersfield Dialysis Center	5143 OFFICE PARK DR		BAKERSFIELD	CA	93309-0660
1255	Affiliated	1930	Antelope Valley	Antelope Valley Dialysis	1759 W AVENUE J	STE 12	LANCASTER	CA	93534-2703
1256	Affiliated	1931	Indian Wells Valley	Indian Wells Valley Dialysis	212 S RICHMOND RD		RIDGECREST	CA	93555-4434
1257	Affiliated	1932	Palmdale Regional	Palmdale Regional Dialysis	1643 E PALMDALE BLVD		PALMDALE	CA	93550-4847
1258	Affiliated	2185	South Star / Adamsville	Southstar Adamsville Dialysis (fka Cascade)	3651 BAKERS FERRY RD SW		ATLANTA	GA	30331-3712
1259	Affiliated	2314	Union City	Union City Dialysis	6851 SHANNON PKWY	STE 2	UNION CITY	GA	30291-2049
1260	Affiliated	2345	Waterbury	Waterbury Dialysis Center	150 MATTATUCK HEIGHTS RD		WATERBURY	CT	06705-3893
1261	Affiliated	2421	Butler Farm	Butler Farm Dialysis (Hope II)	501 BUTLER FARM RD		HAMPTON	VA	23666-1777

1262	Affiliated	2337	Blue Mtn Kidney Center	Blue Mountain Kidney Center (aka Wild Horse, Pendleton)	72556 COYOTE RD		PENDLETON	OR	97801-1002
1263	Affiliated	2249	Talladega	Talladega Dialysis	726 BATTLE ST E	STE A	TALLADEGA	AL	35160-2583
1264	Affiliated	2281	Athens East	Athens East Dialysis	2026 S MILLEDGE AVE	STE A2	ATHENS	GA	30605-6480
1265	Affiliated	2412	Mayland	Mayland Dialysis Center (aka Spruce Pine)	575 ALTAPASS HWY		SPRUCE PINE	NC	28777-3012
1266	Affiliated	2236	Salem	Salem Dialysis Center (IN)	1201 N JIM DAY RD	STE 13	SALEM	IN	47167-7219
1267	Affiliated	2239	Lake Cliff	Lake Cliff Dialysis Center	805 N BECKLEY AVE		DALLAS	TX	75203-1612

1268	Affiliated	2363	DVA Mid Cities Dialysis	Mid Cities Dialysis Center	117 E HARWOOD RD	HURST	TX	76054-3043
1269	Affiliated	2362	Boerne	Boerne Dialysis Center	1369 S MAIN ST STE 11	BOERNE	TX	78006-2860
1270	Affiliated	2318	Columbus West	Columbus West Dialysis	1395 GEORGESVILLE RD	COLUMBUS	OH	43228-3611
1271	Affiliated	2306	Point Place	Point Place Dialysis	4747 SUDER STE 17 AVE	TOLEDO	OH	43611-2869
1272	Affiliated	2350	Delhi Dialysis	Delhi Dialysis	5040 DELHI AVE	CINCINNATI	OH	45238-5388
1273	Affiliated	2253	Pataskala	Pataskala Dialysis Center	642 E BROAD ST	PATASKALA	OH	43062-7627
1274	Affiliated	2384	Eastland	Eastland Dialysis (fka Independence)	19101 E VALLEY STE E VIEW PKWY	INDEPENDENCE	MO	64055-6907
1275	Affiliated	2254	Wauseon	Wauseon Dialysis Center	721 S SHOOP AVE	WAUSEON	OH	43567-1729
1276	Affiliated	2327	Lebanon Dialysis	Lebanon Dialysis Center (Chronic Only)	918B COLUMBUS AVE	LEBANON	OH	45036-
1277	Affiliated	2460	Horton	Horton Dialysis	1901 EUCLID AVE	HORTON	KS	66439-1238
1278	Affiliated	2280	Lone Peak Dialysis	Lone Peak Dialysis	1175 E 50 S STE 111	AMERICAN FORK	UT	84003-2845
1279	Affiliated	2347	Mena	Mena Dialysis Center	1200 CRESTWOOD CIR	MENA	AR	71953-5516
1280	Affiliated	1941	FAYETTEVILLE DIALYSIS	Fayetteville Dialysis	509 E MILLSAP STE 111 RD	FAYETTEVILLE	AR	72703-4862
1281	Affiliated	1942	BENTONVILLE DIALYSIS	Bentonville Dialysis	1104 SE 30TH ST	BENTONVILLE	AR	72712-4290
1282	Affiliated	1943	SILOAM SPRINGS DIALYSIS	Siloam Springs Dialysis	500 S MOUNT STE 17 OLIVE ST	SILOAM SPRINGS	AR	72761-3602
1283	Affiliated	1944	SPRINGDALE DIALYSIS	Springdale Dialysis	708 QUANDT AVE	SPRINGDALE	AR	72764-5309

1284	Affiliated	2273	Grosse Pointe	Grosse Pointe Dialysis	18000 E WARREN AVE	STE 1	DETROIT	MI	48224-1336
1285	Affiliated	2448	Indy South Dialysis	Indy South Dialysis	972 EMERSON PKWY	STE E	GREENWOOD	IN	46143-6202
1286	Affiliated	2358	Greensburg Dialysis	Greensburg Dialysis	1531 N COMMERCE EAST DR	STE 6	GREENSBURG	IN	47240-3259
1287	Affiliated	2319	Grove City	Grove City Dialysis	4155 KELNOR DR		GROVE CITY	OH	43123-2960
1288	Affiliated	2338	West Beach	West Beach Dialysis Center	16201 PANAMA CITY BEACH HWY	STE 12	PANAMA CITY BEACH	FL	32413-5301
1289	Affiliated	2371	Birmingham	Center Point Dialysis (aka Birmingham Center)	2337 1ST ST NE		CENTER POINT	AL	35215-3619
1290	Affiliated	2445	Eureka	Eureka Dialysis Center	419 MERAMEC BLVD		EUREKA	MO	63025-3906
1291	Affiliated	2313	Tifton	Tifton Dialysis	624 LOVE AVE		TIFTON	GA	31794-4406
1292	Affiliated	2146	Woodlands	The Woodlands Dialysis	9301 PINECROFT DR	STE 13	SHENANDOAH	TX	77380-3178
1293	Affiliated	2266	Exeter	Exeter Dialysis	1116 W VISALIA RD	STE 16	EXETER	CA	93221-1482
1294	Affiliated	2396	Wayne County	Wayne County Dialysis (fka Fairfield)	303 NW 11TH ST	STE 1	FAIRFIELD	IL	62837-1203
1295	Affiliated	2415	Cordele Dialysis	Cordele Dialysis	1013 E 16TH AVE		CORDELE	GA	31015-1539
1296	Affiliated	2304	Winter Park	Winter Park Dialysis (aka Orlando)	3727 N GOLDENROD RD	STE 11	WINTER PARK	FL	32792-8611
1297	Affiliated	2449	Carmel	Carmel Dialysis	180 E CARMEL DR		CARMEL	IN	46032-2633
1298	Affiliated	2298	Corydon	Corydon Dialysis	1937 OLD HWY 135 NW		CORYDON	IN	47112-2013
1299	Affiliated	2382	Memphis Southeast	Memphis Southeast Dialysis (aka Midtown)	1805 MORIAH WOODS BLVD	STE 11	MEMPHIS	TN	38117-7119

1300	Affiliated	2399	Rim Country	Rim Country Dialysis	809 W LONGHORN RD		PAYSON	AZ	85541-4280
1301	Affiliated	2201	Cedar Park	Cedar Park Dialysis (fka North Austin)	1720 E WHITESTONE BLVD		CEDAR PARK	TX	78613-7640
1302	Affiliated	2368	Ellensburg	Ellensburg Dialysis	2101 W DOLARWAY RD	STE 1	ELLENSBURG	WA	98926-9310
1303	Affiliated	2260	Santa Fe Springs	Santa Fe Springs Dialysis	11147 WASHINGTON BLVD		WHITTIER	CA	90606-3007
1304	Affiliated	1950	Snapfinger Dialysis	Snapfinger Dialysis	5255 SNAPFINGER PARK DR	STE 115	DECATUR	GA	30035-4066
1305	Affiliated	1951	East Dekalb Dialysis	East DeKalb Dialysis	2801 CANDLER RD	STE 23	DECATUR	GA	30034-1429
1306	Affiliated	2258	Meadows East	Meadows East Dialysis	2529 SIX MILE LN		LOUISVILLE	KY	40220-2934
1307	Affiliated	2226	First Colony	First Colony Dialysis (aka Sugarland, Great Woods)	1447 HIGHWAY 6	STE 14	SUGAR LAND	TX	77478-5094
1308	Affiliated	1612	Coastal Kidney Center	Coastal Kidney Center	510 N MACARTHUR AVE		PANAMA CITY	FL	32401-3636
1309	Affiliated	2211	Clinton Township	Clinton Township Dailysis	15918 19 MILE RD	STE 11	CLINTON TOWNSHIP	MI	48038-1101
1310	Affiliated	2207	West Brook	Westbrook Dialysis (fka Palm Brook II)	13907 W CAMINO DEL SOL	STE 13	SUN CITY WEST	AZ	85375-4405
1311	Affiliated	1954	Johnson County	Johnson County Dialysis	10453 W 84TH TER		LENEXA	KS	66214-1641
1312	Affiliated	1956	Wyandotte County	Wyandotte County Dialysis	5001 STATE AVE		KANSAS CITY	KS	66102-3459
1313	Affiliated	2479	Maple Grove	Maple Grove Dialysis Unit	15655 GROVE CIR N		MAPLE GROVE	MN	55369-4489
1314	Affiliated	4336	East End	East End- Pittsburgh Dialysis (fka Wilkinsburg)	7714 PENN AVE PARK PLAZA		PITTSBURGH	PA	15221

1315	Affiliated	2493	Westminster II - North Metro	North Metro Dialysis Center (aka Denver, Westminster II)	12365 HURON ST	STE 5	WESTMINSTER	CO	80234-3498
1316	Affiliated	1960	Vidalia	Vidalia First Street Dialysis	906 E 1ST ST		VIDALIA	GA	30474-4207
1317	Affiliated	2357	Highland Park	Highland Park Dialysis	1559 W 7TH ST		SAINT PAUL	MN	55102-4238
1318	Affiliated	2367	Centennial Parkway	Centennial Dialysis Center	8775 DEER SPRINGS WAY		LAS VEGAS	NV	89149-0416
1319	Affiliated	2250	Lord Baltimore	Northwest Dialysis Center (aka Lord Baltimore, N. Rolling Road II, Owings Mills II)	2245 ROLLING RUN DR	STE 1	WINDSOR MILL	MD	21244-1858
1320	Affiliated	3944	North Charlotte	North Charlotte Dialysis	6620 OLD STATESVILLE RD		CHARLOTTE	NC	28269
1321	Affiliated	2410	Sun Ray Dialysis	Sun Ray Dialysis Unit (fka East St. Paul)	1758 OLD HUDSON RD	STE 1	SAINT PAUL	MN	55106-6161
1322	Affiliated	2425	Vandalia	Vandalia Dialysis	301 MATTES AVE		VANDALIA	IL	62471-2061
1323	Affiliated	2428	Westwood Hills	Westwood Hills Dialysis (fka Minneapolis, Excelsior)	7525 WAYZATA BLVD		SAINT LOUIS PARK	MN	55426-1621
1324	Affiliated	4305	Amery	Amery Dialysis	970 ELDEN AVE		AMERY	WI	54001-1448
1325	Affiliated	2434	Wadsworth	Wadsworth Dialysis	195 WADSWORTH RD	STE 32	WADSWORTH	OH	44281-9504
1326	Affiliated	2419	Dublin	Dublin Dialysis	6770 PERIMETER DR		DUBLIN	OH	43016-8063

1327	Affiliated	4314	Weber Valley	Weber Valley Dialysis (fka Ogden)	1920 W 250TH N		MARRIOTT- SLATERVILLE	UT	84404-9233
1328	Affiliated	2343	West Elk Grove	West Elk Grove Dialysis	2208 KAUSEN DR	STE 1	ELK GROVE	CA	95758-7174
1329	Affiliated	2355	Bedford Park	Bedford Park Dialysis Center	3119 WEBSTER AVE	1ST FLR	BRONX	NY	10467-4905
1330	Affiliated	1747	Cuero Lakeview Dialysis	Cuero Lakeview Dialysis	1105 E BROADWAY ST		CUERO	TX	77954
1331	Affiliated	1961	Madisonville Dialysis	Madisonville Dialysis Center	255 E NORTH ST		MADISONVILLE	KY	42431
1332	Affiliated	2467	Crescent City	Crescent City Dialysis Center	3909 BIENVILLE ST	STE B	NEW ORLEANS	LA	70119-5152
1333	Affiliated	4318	Callowhill	Callowhill Dialysis Center	313 CALLOWHILL ST		PHILADELPHIA	PA	19123-4103
1334	Affiliated	2406	Oak Creek	Oak Creek Dialysis (fka South Milwaukee)	8201 S HOWELL AVE	STE 6	OAK CREEK	WI	53154-8336

1335	Affiliated	4395	Leesburg Virginia	Leesburg Virginia Dialysis	224D CORNWALL ST NW	STE 1	LEESBURG	VA	20176-2700
1336	Affiliated	2386	Joy of Dixon	Joy of Dixon Dialysis Center	1640 N LINCOLN ST		DIXON	CA	95620-9255
1337	Affiliated	2137	Long Beach JV - Bixby Knolls	Bixby Knolls Dialysis (fka Long Beach)	3744 LONG BEACH BLVD		LONG BEACH	CA	90807-3310
1338	Affiliated	1790	Alliance Community Dialysis	Alliance Community Dialysis	270 E STATE ST	STE 11	ALLIANCE	OH	44601-4309
1339	Affiliated	1791	Belden Community Dialysis	Belden Community Dialysis	4685 FULTON DR NW		CANTON	OH	44718-2379
1340	Affiliated	1792	Mercy Canton Dialysis	Mercy Canton Dialysis	1320 MERCY DR NW		CANTON	OH	44708-2614
1341	Affiliated	2294	Marrero	Marrero Dialysis	1908 JUTLAND DR		HARVEY	LA	70058-2359
1342	Affiliated	2351	Miramar	Miramar Kidney Center	2501 DYKES RD	STE 2	MIRAMAR	FL	33027-4217
1343	Affiliated	2418	Chesterton	Chesterton Dialysis	711 PLAZA DR	STE 6	CHESTERTON	IN	46304-5506
1344	Affiliated	4368	St. John	St. John Dialysis	10033 WICKER AVE	STE 6	SAINT JOHN	IN	46373-8777
1345	Affiliated	2256	Princeton	Princeton Dialysis	2227 SHERMAN DR		PRINCETON	IN	47670-1062
1346	Affiliated	4332	Black Rock	Black Rock Dialysis (aka Fairfield)	427 STILLSON RD		FAIRFIELD	CT	06824-3153
1347	Affiliated	2422	Williamstown	Williamstown Dialysis (fka Dry Ridge)	103 BARNES RD	STE A	WILLIAMSTOWN	KY	41097-9468
1348	Affiliated	4376	Renaissance	Renaissance Dialysis	1840 DARBY DR		FLORENCE	AL	35630-2623
1349	Affiliated	4360	Portage	Portage Dialysis	5823 US HIGHWAY 6		PORTAGE	IN	46368-4851
1350	Affiliated	2393	Opelika	Opelika Dialysis Center	2340 PEPPERELL PKWY		OPELIKA	AL	36801-6240

1351	Affiliated	2435	Urbana	Urbana Dialysis Center	1880 E US HIGHWAY 36		URBANA	OH	43078-9600
1352	Affiliated	1913	Port Lavaca Dialysis	Port Lavaca Dialysis	1300 N VIRGINIA ST	STE 12	PORT LAVACA	TX	77979-2512
1353	Affiliated	2276	Cornerhouse Dialysis	Cornerhouse Dialysis Center (aka Santa Clara)	2005 NAGLEE AVE		SAN JOSE	CA	95128-4801
1354	Affiliated	2167	Snellville	Snellville Dialysis	2135 MAIN ST E	STE 13	SNELLVILLE	GA	30078-6424
1355	Affiliated	4334	Bloomfield	Bloomfield- Pittsburgh Dialysis	5171 LIBERTY AVE	STE C	PITTSBURGH	PA	15224-2254
1356	Affiliated	2489	Pennsauken	Pennsauken Dialysis	7024 KAIGHNS AVE		PENNSAUKEN	NJ	08109-4417
1357	Affiliated	2433	Logan	Logan Dialysis	12880 GREY ST		LOGAN	OH	43138-9638
1358	Affiliated	2454	Forest Fair	Forest Fair Dialysis (fka Forest Park)	1145 KEMPER MEADOW DR		CINCINNATI	OH	45240-4118
1359	Affiliated	4307	Knoxville	Knoxville Central Dialysis	9141 CROSS PARK DR	STE 12	KNOXVILLE	TN	37923-4557
1360	Affiliated	4338	Kennestone	Kennestone Dialysis (aka Cobb II)	200 COBB PKWY N	STE 318 BLDG 3	MARIETTA	GA	30062-3558
1361	Affiliated	4343	Wiregrass Kidney Center	Wiregrass Kidney Center (fka Ross Circle)	1450 ROSS CLARK CIR		DOTHAN	AL	36301-4765
1362	Affiliated	2432	Memphis Downtown	Memphis Downtown Dialysis	2076 UNION AVE		MEMPHIS	TN	38104-4138
1363	Affiliated	3953	Marshville	Marshville Dialysis Center	7260 E MARSHVILLE BLVD		MARSHVILLE	NC	28103-1191
1364	Affiliated	4356	Shamrock	Shamrock Dialysis	1016 CLAXTON DAIRY RD	STE 1A	DUBLIN	GA	31021-7971
1365	Affiliated	4367	North Colorado Springs	North Colorado	6071 E WOODMEN RD	STE 1	COLORADO SPRINGS	CO	80923-2610

				Springs Dialysis						
1366	Affiliated	2466	Oakes	Oakes Dialysis	413 S 7TH ST		OAKES	ND	58474-1920	
1367	Affiliated	1976	Pinnacle Dialysis of Boca Raton	Pinnacle Dialysis of Boca Raton	2900 N STE 195 MILITARY TRL		BOCA RATON	FL	33431-6308	
1368	Affiliated	1980	Cedar Valley Dialysis	Cedar Valley Dialysis	1661 W RIDGEWAY AVE		WATERLOO	IA	50701-4541	
1369	Affiliated	1981	West Union Dialysis	West Union Dialysis	405 HIGHWAY 150 N		WEST UNION	IA	52175-1003	
1370	Affiliated	2161	Rockside	Rockside Dialysis (aka Independence, Parma II)	4801 ACORN DR		INDEPENDENCE	OH	44131-2566	
1371	Affiliated	2263	Sunset	Sunset Dialysis Center (fka Sunrise II)	3071 GOLD CANAL DR		RANCHO CORDOVA	CA	95670-6129	
1372	Affiliated	2442	Yosemite Street	Yosemite Street Dialysis	1650 W YOSEMITE AVE		MANTECA	CA	95337-5193	
1373	Affiliated	2335	Jedburg	Jedburg Dialysis	2897 W 5TH NORTH ST		SUMMERVILLE	SC	29483-9674	
1374	Affiliated	2441	Parker Dialysis	Parker Dialysis	10371 S PARK STE 18 GLENN WAY		PARKER	CO	80138-3885	
1375	Affiliated	2296	Northgate	Northgate Dialysis Center (aka San Rafael- Terra)	650 LAS GALLINAS AVE		SAN RAFAEL	CA	94903-3620	
1376	Affiliated	2271	The Nevada Center	The Nevada Dialysis Center (fka Warm Springs, Green Valley)	1510 W WARM STE 1 SPRINGS RD		HENDERSON	NV	89014-3586	
1377	Affiliated	2091	Aventura	Aventura Kidney Center	22 SW 11TH ST FLOOR 2		HALLANDALE BEACH	FL	33009-7038	
1378	Affiliated	2408	US Grant Dialysis	US Grant Dialysis (fka Georgetown,	458 HOME ST		GEORGETOWN	OH	45121-1408	

				Brown County)						
1379	Affiliated	4400	Arbor Place	Arbor Place Dialysis	9559 HIGHWAY 5	STE 1	DOUGLASVILLE	GA	30135-1573	
1380	Affiliated	4389	South Jacksonville	Jacksonville South Dialysis Center	14965 OLD SAINT AUGUSTINE RD	UNIT 114	JACKSONVILLE	FL	32258-9481	
1381	Affiliated	2385	Somerville	Somerville Dialysis	12475 US HIGHWAY 64		SOMERVILLE	TN	38068-6029	
1382	Affiliated	4321	District Heights	District Heights Dialysis (aka Pennsylvania Ave)	5701 SILVER HILL RD		DISTRICT HEIGHTS	MD	20747-1102	
1383	Affiliated	2414	Edwardsville	Edwardsville Dialysis	235 S BUCHANAN ST		EDWARDSVILLE	IL	62025-2108	
1384	Affiliated	2361	Broad St	South Broad Street Dialysis (aka S. Philadelphia II)	1172 S BROAD ST		PHILADELPHIA	PA	19146-3142	
1385	Affiliated	2342	Las Vegas Pediatrics	Las Vegas Pediatrics Dialysis (fka UMC Peds, DaVita Peds)	7271 W SAHARA AVE	STE 12	LAS VEGAS	NV	89117-2862	
1386	Affiliated	1990	Apopka Dialysis	Apopka Dialysis	640 EXECUTIVE PARK CT		APOPKA	FL	32703-6075	
1387	Affiliated	1991	Casselberry Dialysis	Casselberry Dialysis	4970 S US HWY 17/92		CASSELBERRY	FL	32707-3888	
1388	Affiliated	1992	Central Orlando Dialysis	Central Orlando Dialysis	2548 N ORANGE BLOSSOM TRL	STE 4	ORLANDO	FL	32804-4863	
1389	Affiliated	1993	Sanford Dialysis	Sanford Dialysis	1701 W 1ST ST		SANFORD	FL	32771-1605	
1390	Affiliated	1994	Winter Park Hemo Dialysis	Winter Park Hemo Dialysis	4100 METRIC DR	STE 3	WINTER PARK	FL	32792-6832	
1391	Affiliated	2173	Graham	Graham Dialysis Center	10219 196TH ST CT E	STE C	GRAHAM	WA	98338-7792	

1392	Affiliated	2316	Batavia	Batavia Dialysis	4000 GOLDEN AGE DR		BATAVIA	OH	45103-1913
1393	Affiliated	1967	Klamath Falls	Klamath Falls Dialysis	2230 N ELDORADO AVE		KLAMATH FALLS	OR	97601-6418
1394	Affiliated	2336	Longs	Longs Dialysis (fka Conway)	90 CLOVERLEAF DR	STE 36	LONGS	SC	29568-9262
1395	Affiliated	2452	Pooler	Pooler Dialysis	54 TRADERS WAY		POOLER	GA	31322-
1396	Affiliated	4380	Ohio Pike Dialysis	Ohio Pike Dialysis (aka Amelia)	1761 STATE ROUTE 125		AMELIA	OH	45102-2039
1397	Affiliated	2285	Canyon Springs	Canyon Springs Dialysis (aka Moreno Valley)	22555 ALESSANDRO BLVD		MORENO VALLEY	CA	92553-8533
1398	Affiliated	4306	Williamson	South Williamson Dialysis	204 APPALACHIAN PLAZA		SOUTH WILLIAMSON	KY	41503-9404
1399	Affiliated	4402	Gulf Shores	Gulf Shores Dialysis Center	3947 GULF SHORES PKWY	UNIT 15	GULF SHORES	AL	36542-2737
1400	Affiliated	2496	Las Vegas Multi-Care Five Star	Five Star Dialysis Center (fka Las Vegas Multi-Care)	2400 TECH CENTER CT		LAS VEGAS	NV	89128-0804
1401	Affiliated	4358	North Vernon	North Vernon Dialysis	2340 N STATE HWY 7		NORTH VERNON	IN	47265-7183

1402	Affiliated	4316	Olympia	Olympia Dialysis Center	335 COOPER POINT RD NW	STE 15	OLYMPIA	WA	98502-4436
1403	Affiliated	4335	Monroeville	Monroeville Dialysis	2690 MONROEVILLE BLVD		MONROEVILLE	PA	15146-2302
1404	Affiliated	2317	East Galbraith	East Galbraith Dialysis	3877 E GALBRAITH RD	BLDG C	CINCINNATI	OH	45236-1500
1405	Affiliated	2261	San Marcos	San Marcos Dialysis Center	2135 MONTIEL RD	BLDG B	SAN MARCOS	CA	92069-3511
1406	Affiliated	4408	Winter Garden	Winter Garden Dialysis	1222 WINTER GARDEN VINELAND RD	BLDG 3 STE 1	WINTER GARDEN	FL	34787
1407	Affiliated	1926	Bremer County Dialysis	Relo-Bremer County Dialysis (5022-Cedar Valley Waverly Dialysis)	220 10th ST SW		WAVERLY	IA	50677-2930
1408	Affiliated	1927	Black Hawk Dialysis	Black Hawk Dialysis (Waterloo)	3421 W 9TH ST		WATERLOO	IA	50702-5401
1409	Affiliated	2218	Downey Landing	Downey Landing Dialysis Center (aka Downey- Kaiser)	11611 BELLFLOWER BLVD		DOWNEY	CA	90241-5408
1410	Affiliated	2427	Tucson Central	Tucson Central Dialysis	2901 E GRANT RD		TUCSON	AZ	85716-2717
1411	Affiliated	4377	Hamburg	Hamburg Dialysis (fka Lexington)	1745 ALYSHEBA WAY		LEXINGTON	KY	40509-9013
1412	Affiliated	2150	Midtown Norfolk	Midtowne Norfolk Dialysis (aka Ghent II)	2201 COLONIAL AVE		NORFOLK	VA	23517-1928
1413	Affiliated	2394	Yonkers II	Yonkers East Dialysis Center	5 ODELL PLZ	STE 131	YONKERS	NY	10701-1406
1414	Affiliated	2364	Caldwell	Caldwell Dialysis Center	821 S SMEED PKWY		CALDWELL	ID	83605-5130
1415	Affiliated	2278	Hesperia	Hesperia Dialysis Center	14135 MAIN ST	UNIT 51	HESPERIA	CA	92345-8097
1416	Affiliated	2339	Sealy	Sealy Dialysis	2242 CHAMPIONSHIP DR		SEALY	TX	77474-8026

1417	Affiliated	2438	Hearne	Hearne Dialysis Center	106 CEDAR ST		HEARNE	TX	77859-2523
1418	Affiliated	1998	Stockton Kidney Center	Stockton Kidney Center	1523 E MARCH LN	STE 2	STOCKTON	CA	95210-5607
1419	Affiliated	5525	University of South Florida	USF Dialysis	10770 N 46TH ST	STE A100	TAMPA	FL	33617-3465
1420	Affiliated	4424	Westborough	Westborough Dialysis Center (fka South San Francisco, Daly City)	925 EL CAMINO REAL		SOUTH SAN FRANCISCO	CA	94080-3203
1421	Affiliated	4359	Rush County	Rush County Dialysis	1400 N CHERRY ST		RUSHVILLE	IN	46173-1097
1422	Affiliated	4339	Defuniak Springs	Defuniak Springs Dialysis	1045 US HWY 331 S	DEFUNIAK SHOPPING PLAZA	DEFUNIAK SPRINGS	FL	32435-3375
1423	Affiliated	2181	Foster city	Foster City Dialysis (fka Belmont)	1261 E HILLSDALE BLVD	STE 2	FOSTER CITY	CA	94404-1236
1424	Affiliated	4427	Red Bank	Redbank Village Dialysis (Cincinnati)	3960 RED BANK RD	STE 16	CINCINNATI	OH	45227-3421
1425	Affiliated	4448	Southport	Southport Dialysis Center	1513 N HOWE ST	STE 15	SOUTHPORT	NC	28461-2770
1426	Affiliated	4446	Orlando Park	Orlando Park Dialysis	5397 W COLONIAL DR	STE 12	ORLANDO	FL	32808-7647
1427	Affiliated	4431	Harrisburg	Harrisburg Dialysis Center (aka Concord)	3310 PERRY ST		CONCORD	NC	28027-3901
1428	Affiliated	2352	Waycross	Satilla River Dialysis	308 CARSWELL AVE		WAYCROSS	GA	31501-4762
1429	Affiliated	4455	Timberlake	Timberlake Dialysis (Kansas City)	12110 HOLMES RD		KANSAS CITY	MO	64145-1707
1430	Affiliated	4447	Dexter	Dexter Dialysis	2010 N OUTER RD		DEXTER	MO	63841
1431	Affiliated	4426	Norwood	Norwood Dialysis (Cincinnati)	2300 WALL ST		CINCINNATI	OH	45212-2781
1432	Affiliated	4420	Peachtree City	Peachtree City Dialysis	2830 W HWY 54	BLDG 1 STE J AND K	PEACHTREE CITY	GA	30269-1026

1433	Affiliated	5516	Rogue Valley	Rogue Valley Dialysis	760 GOLF VIEW UNIT 1 DR	MEDFORD	OR	97504-9685
1434	Affiliated	5517	Redwood Dialysis	Redwood Dialysis	201 SW L ST	GRANTS PASS	OR	97526-2913
1435	Affiliated	4410	Tucker	Tucker Dialysis	4434 HUGH HOWELL RD	TUCKER	GA	30084-4905
1436	Affiliated	4386	Shepherdsville	Shepherdsville Dialysis Center	150 BROOKS STE 15 WAY	BROOKS	KY	40109-6105
1437	Affiliated	4399	Muscle Shoals	Muscle Shoals Dialysis	712 STATE ST	MUSCLE SHOALS	AL	35661-2940
1438	Affiliated	2463	Tel Huron	Tel-Huron Dialysis (fka Waterford)	225 SUMMIT DR	WATERFORD	MI	48328-3364
1439	Affiliated	2481	Cherry Valley	Cherry Valley Dialysis (aka Newark)	1627 W MAIN ST	NEWARK	OH	43055-1345
1440	Affiliated	2437	Taylor	Taylor Dialysis	3100 W 2ND ST	TAYLOR	TX	76574
1441	Affiliated	4430	Forrest City	Forrest City Dialysis	1501 N WASHINGTON ST	FORREST CITY	AR	72335-2152
1442	Affiliated	4309	Kaufman	Kaufman Dialysis	2851 MILLENNIUM DR	KAUFMAN	TX	75142-8865
1443	Affiliated	4348	Artesia	Artesia Dialysis	702 N 13TH ST	ARTESIA	NM	88210-1166
1444	Affiliated	2381	North Hills	North Hills Dialysis	7927 BOULEVARD 26	NORTH RICHLAND HILLS	TX	76180-7103
1445	Affiliated	4428	Millington	Millington Dialysis	8510 WILKINSVILLE RD	MILLINGTON	TN	38053-1537
1446	Affiliated	5519	Adams County	Adams County Dialysis	436 N 10TH ST	QUINCY	IL	62301-4152
1447	Affiliated	5518	Hannibal	Hannibal Dialysis	3140 PALMYRA ROAD	HANNIBAL	MO	63401-2204
1448	Affiliated	5520	Pittsfield	Pittsfield Dialysis	640 W WASHINGTON ST	PITTSFIELD	IL	62363-1350
1449	Affiliated	4463	Villa of Waterbury	Villa of Waterbury (fka Kissker Microcenter)	929 WATERBURY FALLS DR	O' FALLON	MO	63368-2202

1450	Affiliated	2465	Washington DC Nursing Facility	Washington DC Nursing Facility	2425 25TH ST SE		WASHINGTON DC	20020-3408
1451	Affiliated	4325	Moscow	Moscow Dialysis Center	212 RODEO DR STE 11		MOSCOW ID	83843-9798
1452	Affiliated	2402	Chinook Kidney Center	Chinook Kidney Center (aka Richland)	1315 AARON DR BLDG C1		RICHLAND WA	99352-4678
1453	Affiliated	4416	River' s Edge	Rivers Edge Dialysis (aka Athens)	1006 E STATE ST STE B		ATHENS OH	45701-2121
1454	Affiliated	5530	North Glendale Dialysis	North Glendale Dialysis	1505 WILSON TER STE 190		GLENDALE CA	91206-4015
1455	Affiliated	4373	Everett	Everett Dialysis Center (fka Snohomish 2)	8130 EVERGREEN WAY		EVERETT WA	98203-6419
1456	Affiliated	2069	Harbourview	Harbour View Dialysis (aka Churchland, Suffolk)	1039 CHAMPIONS WAY	BLDG 4	SUFFOLK VA	23435-3761
1457	Affiliated	4357	Capelville	Capelville Dialysis Center	7008 E SHELBY DR		MEMPHIS TN	38125-3416
1458	Affiliated	4485	San Leandro	San Leandro Dialysis (Bayfair Mall)	15555 E 14TH STE 52		SAN LEANDRO CA	94578-1900
1459	Affiliated	4317	Mill Creek	Mill Creek Dialysis Center (Snohomish/ Everett)	18001 BOTHELL EVERETT HWY	STE 112	BOTHELL WA	98012-1661
1460	Affiliated	2470	Seaview	Seaview Dialysis Center	101 18TH ST SE		LONG BEACH WA	98631
1461	Affiliated	2461	East Tampa	East Tampa Dialysis (Ybor City)	1701 E 9TH AVE		YBOR CITY FL	33605-3801
1462	Affiliated	5522	Detroit Road Dialysis	Detroit Road Dialysis	7901 DETROIT AVE		CLEVELAND OH	44102-2828
1463	Affiliated	5523	St V Quadrangle Dialysis	St V Quadrangle Dialysis	2302 COMMUNITY COLLEGE AVE		CLEVELAND OH	44115-3117
1464	Affiliated	5524	Westshore Dialysis	Westshore Dialysis	29000 CENTER RIDGE RD		WESTLAKE OH	44145-5293

1465	Affiliated	2468	Magnolia Dialysis Center Texas	Magnolia Dialysis Center	17649 FM 1488 RD		MAGNOLIA	TX	77354-5235
1466	Affiliated	4471	Highland County	Highland County Dialysis (Hillsboro)	120 ROBERTS LN	STE 4	HILLSBORO	OH	45133-7608
1467	Affiliated	4313	Rockwall	Rockwall Dialysis	2455 RIDGE RD	STE 11	ROCKWALL	TX	75087-5530
1468	Affiliated	4354	Great Northern	Villa of Great Northern (fka North Olmsted)	22710 FAIRVIEW CENTER DR	STE 1	FAIRVIEW PARK	OH	44126-3607

1469	Affiliated	2440	Ridgeland	Ridgeland Dialysis	112 WEATHERSBY ST		RIDGELAND	SC	29936-9514
1470	Affiliated	2334	Livermore	Livermore Dialysis	3201 DOOLAN RD	STE 175	LIVERMORE	CA	94551-9605
1471	Affiliated	2265	Westlake Daly city	Westlake Daly City Dialysis (fka Colma)	2201 JUNIPERO SERRA BLVD	STE 175	DALY CITY	CA	94014-1908
1472	Affiliated	4488	12th Street Covington	12th Street Covington Dialysis	1500 JAMES SIMPSON JR WAY	STE 11	COVINGTON	KY	41011
1473	Affiliated	4384	Bourbon County	Bourbon County Dialysis (fka Paris)	213 LETTON DR	PARIS TOWNE SQUARE	PARIS	KY	40361-2251
1474	Affiliated	2499	Calverton	Calverton Dialysis	4780 CORRIDOR PL	STE C	BELTSVILLE	MD	20705-1165
1475	Affiliated	2199	Aborn	Aborn Dialysis (fka East San Jose)	3162 S WHITE RD	STE 1	SAN JOSE	CA	95148-4019
1476	Affiliated	4438	Clermont	Clermont County Dialysis (Milford,Goshen)	5901 MONTCLAIR BLVD	STE 1	MILFORD	OH	45150-2547
1477	Affiliated	4365	Rita Ranch	Rita Ranch Dialysis (aka Tucson East II)	7355 S HOUGHTON RD	STE 11	TUCSON	AZ	85747-9379
1478	Affiliated	4333	Wake Forest	Wake Forest Dialysis Center	11001 INGLESIDE PL		RALEIGH	NC	27614-8577
1479	Affiliated	4472	Colonial Springs	Colonial Springs Dialysis (fka Powder Springs)	2840 EAST WEST CONNECTOR	STE 35	AUSTELL	GA	30106-6813
1480	Affiliated	2474	Central Dallas	DaVita Central Dallas Dialysis	9500 N CENTRAL EXPY		DALLAS	TX	75231-5002
1481	Affiliated	2188	Sanger	Sanger Sequoia Dialysis	2517 JENSEN AVE	BLDG B	SANGER	CA	93657-2251
1482	Affiliated	4421	Conyers	Conyers Dialysis	1501 MILSTEAD RD NE		CONYERS	GA	30012-3838
1483	Affiliated	4337	Duncanville	Duncanville Dialysis (Cedar Hill)	270 E HIGHWAY 67	STE 1	DUNCANVILLE	TX	75137-4428
1484	Affiliated	4417	Gateway	Gateway Dialysis (Ft.Myers)	5705 LEE BLVD		LEHIGH ACRES	FL	33971-6342

1485	Affiliated	4487	Derry	Derry Dialysis	1 ACTION BLVD	STE 2	LONDONDERRY NH	03053-3428
1486	Affiliated	4461	Villa of Wentzville Microcenter	Villa of Wentzville (Microcenter)	1126 W PEARCE BLVD	STE 116 & 118	WENTZVILLE MO	63385-1053
1487	Affiliated	1925	Buchanan County Dialysis	Buchanan County Dialysis (Independence)	1600 1ST ST E		INDEPENDENCE IA	50644-3155
1488	Affiliated	2450	Hoosier Hills	Hoosier Hills Dialysis	143 S KINGSTON DR		BLOOMINGTON IN	47408-6342
1489	Affiliated	4492	Palm Breeze	Palm Breeze Dialysis (fka North Port)	14942 TAMIAMI TRL	STE E	NORTH PORT FL	34287-2705
1490	Affiliated	4362	Big Oaks	Big Oaks Dialysis	5623 W TOUHY AVE		NILES IL	60714-4019
1491	Affiliated	4407	Pinellas West Shore	Pinellas West Shore Dialysis	3451 66TH ST N	STE A	ST PETERSBURG FL	33710-1568
1492	Affiliated	2267	Plano	Plano Dialysis	481 SHILOH RD	STE 1	PLANO TX	75074-7231
1493	Affiliated	4350	Fairview	Villa of Fairview Park (fka Fairview Park Dialysis)	19050 LORAIN RD		FAIRVIEW PARK OH	44126-1915
1494	Affiliated	2380	Ave Marisa	Ave Maria Dialysis (fka Immokalee)	5340 USEPPA DR		AVE MARIA FL	34142-5051
1495	Affiliated	5037	Warminster	Franklin Commons Dialysis (fka Warminster)	720 JOHNSVILLE BLVD	STE 8	WARMINSTER PA	18974-3546
1496	Affiliated	2446	Ripley	Ripley Dialysis Center	854 HWY 51 S		RIPLEY TN	38063-5536
1497	Affiliated	5538	St Charles / Riverbend	River Bend Dialysis (St. Charles Parish)	1057 PAUL MAILLARD RD	ST B135	LULING LA	70070-4349
1498	Affiliated	5570	Midwest Springfield	Midwest Springfield Dialysis	2200 N LIMESTONE ST STE 104		SPRINGFIELD OH	45503-2692
1499	Affiliated	5571	Midwest Fairborn	Midwest Fairborn Dialysis	1266 N BROAD ST		FAIRBORN OH	45324-5549
1500	Affiliated	5572	Midwest Urbana	Midwest Urbana Dialysis	1430 E US HIGHWAY 36		URBANA OH	43078-9112

1501	Affiliated	5531	Camarillo	Camarillo Dialysis	2438 N PONDEROSA DR STE C101	CAMARILLO	CA	93010-2465
1502	Affiliated	5532	Thousand Oaks	Thousand Oaks Dialysis	375 ROLLING OAKS DR STE 100	THOUSAND OAKS	CA	91361-1024
1503	Affiliated	5533	Simi Valley	Simi Valley Dialysis	2950 SYCAMORE DR STE 100	SIMI VALLEY	CA	93065-1210
1504	Affiliated	5534	Santa Paula	Santa Paula Dialysis	253 MARCH ST	SANTA PAULA	CA	93060-2511
1505	Affiliated	5548	Ventura	Ventura Dialysis	2705 LOMA VISTA RD STE 101	VENTURA	CA	93003-1596
1506	Affiliated	4468	Villa of St. John	Villa of St John (Crossing Microcenter- MO)	9030 SAINT CHARLES ROCK RD	SAINT LOUIS	MO	63114-4246
1507	Affiliated	4372	Whidbey Island	Whidbey Island Dialysis Center	32650 STATE RD BLDG E STE 20 18	OAK HARBOR	WA	98277-2641
1508	Affiliated	4437	Baytown	Baytown Dialysis	4665 GARTH RD STE 9	BAYTOWN	TX	77521-2261
1509	Affiliated	2475	Highland Ranch	Highland Ranch Dialysis Center	7223 CHURCH ST STE A14	HIGHLAND	CA	92346-6837
1510	Affiliated	4474	Tiptonville	Tiptonville Dialysis	795 HAMRA ST	TIPTONVILLE	TN	38079-1663
1511	Affiliated	1902	Carabello	Carabello Dialysis Center	757 E WASHINGTON BLVD	LOS ANGELES	CA	90021-3016
1512	Affiliated	5573	Palmetto	Palmetto Dialysis	317 PROFESSIONAL PARK RD	CLINTON	SC	29325-7625
1513	Affiliated	5574	Greer South	Greer South Dialysis	3254 BRUSHY CREEK RD	GREER	SC	29650-1000
1514	Affiliated	5575	Greenville West End	Greenville West End Dialysis	605 S ACADEMY ST	GREENVILLE	SC	29601-2407
1515	Affiliated	5576	Fountain Inn	Fountain Inn Dialysis	298 CHAPMAN RD	FOUNTAIN INN	SC	29644-6129
1516	Affiliated	5558	Sellersville	Sellersville Dialysis	1112 OLD BETHLEHEM PIKE	SELLERSVILLE	PA	18960-1423

1517	Affiliated	5564	Humbolt Ridge	Humboldt Ridge Dialysis	2211 N HUMBOLDT BLVD		MILWAUKEE	WI	53212-3507
1518	Affiliated	5565	West Appleton	West Appleton Dialysis	10130 W APPLETON AVE	STE 5	MILWAUKEE	WI	53225-2579
1519	Affiliated	5566	Bay Shore	Bay Shore Dialysis	5650 N GREEN BAY AVE	STE 15	GLENDALE	WI	53209-4449
1520	Affiliated	5567	South Ridge	South Ridge Dialysis	4848 S 76TH ST	STE 1	GREENFIELD	WI	53220-4361
1521	Affiliated	5568	Bluemound	Bluemound Dialysis	601 N 99TH ST	STE 1	MILWAUKEE	WI	53226-4362
1522	Affiliated	4385	Versailles	Versailles Dialysis	480 LEXINGTON RD		VERSAILLES	KY	40383-1918
1523	Affiliated	5035	Magnolia Oaks	Magnolia Oaks Dialysis (aka Hinesville)	2377 HWY 196 W		HINESVILLE	GA	31313-8036
1524	Affiliated	4489	Mesa County	Mesa County Dialysis (Grand Junction)	561 25 RD	STE D	GRAND JUNCTION	CO	81505-1303
1525	Affiliated	297	West Bloomfield	West Bloomfield Dialysis	6010 W MAPLE RD	STE 215	WEST BLOOMFIELD	MI	48322-4406
1526	Affiliated	5550	Crystal Springs	Crystal Springs Dialysis	720 COG CIRCLE		CRYSTAL LAKE	IL	60014-7301
1527	Affiliated	5551	Cobblestone	Cobblestone Dialysis	934 CENTER ST	STE A	ELGIN	IL	60120-2125
1528	Affiliated	5586	Oak Springs	Oak Springs Dialysis	764 LOCUST AVE		WASHINGTON	PA	15301-2756
1529	Affiliated	5010	Maple Valley Plaza	Maple Valley Plaza Dialysis (Farmington)	649 MAPLE VALLEY DR		FARMINGTON	MO	63640-1993
1530	Affiliated	4433	Floyd Curl	Floyd Curl Dialysis (San Antonio)	9238 FLOYD CURL DR	STE 12	SAN ANTONIO	TX	78240-1691
1531	Affiliated	2387	Mission Valley	Mission Valley Dialysis (aka McAllen)	1203 ST CLAIRE BLVD 9B		MISSION	TX	78572-6601
1532	Affiliated	2180	Silver Lake	Silver Lake Dialysis	2723 W TEMPLE ST		LOS ANGELES	CA	90026-4723
1533	Affiliated	5578	Lake Park	Lake Park Dialysis	1531 E HYDE PARK BLVD		CHICAGO	IL	60615-3039

1534	Affiliated	5579	Stoney Island Dialysis	Stony Island Dialysis	8725 S STONY ISLAND AVE	CHICAGO	IL	60617-2709
1535	Affiliated	5580	Woodlawn Dialysis	Woodlawn Dialysis	1164 E 55TH ST	CHICAGO	IL	60615-5115

1536	Affiliated	4440	Jefferson Ave	Jefferson Avenue Dialysis (aka Village Parkway, Hampton)	11234 JEFFERSON AVE		NEWPORT NEWS VA	23601-2207
1537	Affiliated	4381	Robinson	Robinson Dialysis	1215 N ALLEN ST	STE B	ROBINSON IL	62454-1100
1538	Affiliated	4320	Gateway Plaza	Gateway Plaza Dialysis (aka Willowbrook)	1580 W ROSECRANS AVE		COMPTON CA	90222-3700
1539	Affiliated	4329	Pasadena Foothills	Pasadena Foothills Dialysis (fka Arcadia)	3722 E COLORADO BLVD		PASADENA CA	91107-3803
1540	Affiliated	914	Live Oak Dialysis	Live Oak Dialysis (fka San Antonio)	6700 RANDOLPH BLVD	STE 11	LIVE OAK TX	78233-4222
1541	Affiliated	5031	Frackville	Frackville Dialysis (aka JV_Pottsville)	801 SCHUYLKILL MALL		FRACKVILLE PA	17931-2524
1542	Affiliated	5038	Castor	Cottman Kidney Center (Castor, NE Philadelphia)	7198 CASTOR AVE		PHILADELPHIA PA	19149-1105
1543	Affiliated	4351	Villa of North Ridgeville	Villa of North Ridgeville	35143 CENTER RIDGE RD		NORTH RIDGEVILLE OH	44039-3089
1544	Affiliated	5503	Thorn Run Dialysis	Thorn Run Dialysis	1136 THORN RUN RD	STE J1	MOON TOWNSHIP PA	15108
1545	Affiliated	5504	Allegheny Valley	Allegheny Valley Dialysis	1620 PACIFIC AVE	HEIGHTS PLAZA SHOPPING CENTER	NATRONA HEIGHTS PA	15065-2101
1546	Affiliated	5506	Northside	Northside Dialysis (fka Allegheny General)	320 E NORTH AVE	4TH FL, SOUTH TOWER	PITTSBURGH PA	15212-4756
1547	Affiliated	5507	Somerset	Somerset County Dialysis	229 S KIMBERLY AVE	STE 1	SOMERSET PA	15501-2022

1548	Affiliated	4493	Carthage	Carthage Dialysis	165 SAVANNAH GARDENS DR	CARTHAGE	NC	28327
1549	Affiliated	2464	Riverwood Dialysis	Riverwood Dialysis (fka Nine Mile, Tree City & Southfield)	24467 W 10 MILE RD	SOUTHFIELD	MI	48033-2931
1550	Affiliated	4415	Burton	Burton Dialysis (fka Flint Northeast)	4015 DAVISON RD	BURTON	MI	48509-1401
1551	Affiliated	4490	Black Canyon	Black Canyon Dialysis (Montrose)	3421 S RIO GRANDE AVE	UNIT D MONTROSE	CO	81401-4840
1552	Affiliated	4394	Memphis Midtown	Memphis Midtown Dialysis	3430 SUMMER AVE	MEMPHIS	TN	38122-3610
1553	Affiliated	5539	Stonecrest Dialysis	Stonecrest Dialysis	1302 E STATE ST	ROCKFORD	IL	61104-2228
1554	Affiliated	4412	West Plano	West Plano Dialysis	5036 TENNYSON PKWY	PLANO	TX	75024-3002
1555	Affiliated	2217	Redwood City	Redwood City Dialysis (fka Palo Alto)	1000 MARSHALL ST	REDWOOD CITY	CA	94063-2027
1556	Affiliated	1592	State Fair	State Fair Dialysis	19800 WOODWARD AVE	DETROIT	MI	48203-5102
1557	Affiliated	5589	ADC of Ft Lauderdale	Advanced Dialysis Center of Fort Lauderdale	911 E OAKLAND PARK BLVD	OAKLAND PARK	FL	33334-2725
1558	Affiliated	5008	Dover	Dover Community Dialysis (New Philadelphia)	899 E IRON AVE	DOVER	OH	44622-2097
1559	Affiliated	5045	McMinnville	McMinnville Dialysis	200 NE NORTON LN	MCMINNVILLE	OR	97128-8470
1560	Affiliated	5007	Sparta	Sparta Dialysis	150 SAM WALTON DR	STE 8 SPARTA	TN	38583-8818
1561	Affiliated	4409	Kendall	Kendall Kidney Center (fka Dadeland)	8364 MILLS DR	STE 174 MIAMI	FL	33183-4806

1562	Affiliated	4397	Abbeville	Abbeville Dialysis	904 W GREENWOOD ST		ABBEVILLE	SC	29620
1563	Affiliated	2453	Delta View	Delta View Dialysis	1150 E LELAND RD		PITTSBURG	CA	94565-5319
1564	Affiliated	5013	Wolf River	Wolf River Dialysis (Germantown)	7990 TRINITY PL	STE 11	CORDOVA	TN	38018-7731
1565	Affiliated	5601	San Luis Obispo Dialysis	San Luis Obispo Dialysis	1043 MARSH ST		SAN LUIS OBISPO	CA	93401-3629
1566	Affiliated	5602	Templeton Dialysis	Templeton Dialysis	1310 LAS TABLAS RD	STE 11	TEMPLETON	CA	93465-9746
1567	Affiliated	5603	Pismo Beach Dialysis	Pismo Beach Dialysis	320 JAMES WAY	STE 11	PISMO BEACH	CA	93449-2813
1568	Affiliated	5583	Lincoln Way Dialysis	Lincoln Way Dialysis	1303 LINCOLN WAY STE A		WHITE OAK	PA	15131-1603
1569	Affiliated	5023	Grundy Center	Grundy Center Dialysis	101 E J AVENUE		GRUNDY CENTER	IA	50638-2031
1570	Affiliated	3862	Pickens County	Pickens County Dialysis	289 WILLIAM E HILL DR.	STE A	CARROLLTON	AL	35447
1571	Affiliated	5032	Willow Grove	Willow Grove Dialysis (Abington- Maplewood)	1849 DAVISVILLE RD		WILLOW GROVE	PA	19090-4111
1572	Affiliated	2255	Amherst	Amherst Dialysis (Lorain County)	3200 COOPER FOSTER PRK RD W		LORAIN	OH	44053-3654
1573	Affiliated	2220	South Fort Worth	South Fort Worth Dialysis	6260 SOUTHWEST BLVD		BENBROOK	TX	76109-6906
1574	Affiliated	5521	Jerseyville Dialysis	Jerseyville Dialysis	917 S STATE ST		JERSEYVILLE	IL	62052-2344
1575	Affiliated	5605	Independence County Dialysis	Independence County Dialysis	1700 HARRISON ST	STE F	BATESVILLE	AR	72501-7315
1576	Affiliated	5606	Jackson County Dialysis	Jackson County Dialysis	1912 MCLAIN ST	PRATT SQUARE	NEWPORT	AR	72112-3659
1577	Affiliated	5607	Searcy Dialysis	Searcy Dialysis	3208 LANGLEY DR		SEARCY	AR	72143-6020
1578	Affiliated	5608	Springhill Dialysis	Springhill Dialysis	3401 SPRINGHILL DR	STE 19	NORTH LITTLE ROCK	AR	72117-2925

1579	Affiliated	5609	Pulaski County Dialysis	Pulaski County Dialysis	202 JOHN HARDEN DR		JACKSONVILLE	AR	72076-3775
1580	Affiliated	5610	Little Rock Midtown Dialysis	Little Rock Midtown Dialysis	2 LILE CT	STE 12A	LITTLE ROCK	AR	72205-6241
1581	Affiliated	5611	Saline County Dialysis	Saline County Dialysis	1200 N MAIN ST	STE 2	BENTON	AR	72015-3341
1582	Affiliated	5612	Conway Dialysis	Conway Dialysis	2445 CHRISTINA LANE		CONWAY	AR	72034
1583	Affiliated	5614	Valley Baptist Harlingen Dialysis	Valley Baptist- Harlingen Dialysis	2220 HAINE DR STE 40		HARLINGEN	TX	78550-8584
1584	Affiliated	5615	Valley Baptist Raymondville Dialysis	Valley Baptist- Raymondville Dialysis	894 FM 3168		RAYMONDVILLE	TX	78580-4519
1585	Affiliated	2455	Hawaiian Gardens	Hawaiian Gardens Dialysis	12191 226TH ST		HAWAIIAN GARDENS	CA	90716-1510
1586	Affiliated	2310	Huntington park	Huntington Park Dialysis	5942 RUGBY AVE		HUNTINGTON PARK	CA	90255-2803
1587	Affiliated	2462	Poinciana	Poinciana Dialysis	1002 CYPRESS PKWY		KISSIMMEE	FL	34758-3328
1588	Affiliated	5005	Southtowns	Southtowns Dialysis (Hamburg)	4910 CAMP RD	STE 1	HAMBURG	NY	14075-2617
1589	Affiliated	5635	Parma Heights Dialysis	Parma Heights Dialysis	9050 N CHURCH DR		PARMA HEIGHTS	OH	44130-4701
1590	Affiliated	5636	Hilliard Dialysis	Hilliard Dialysis	19133 HILLIARD BLVD		ROCKY RIVER	OH	44116-2907
1591	Affiliated	5546	Pacific Dialysis	Pacific Dialysis	2351 CLAY ST	FL 4	SAN FRANCISCO	CA	94115-1931
1592	Affiliated	5547	Davies Dialysis	Davies Dialysis	45 CASTRO ST	SOUTH TOWER 2ND FL	SAN FRANCISCO	CA	94114-1032
1593	Affiliated	4486	Newburgh	Newburgh Dialysis	4311 HIGHWAY 261	STE A	NEWBURGH	IN	47630-2653
1594	Affiliated	5052	Enterprise	Enterprise Dialysis (fka Geneva)	6002 BOLL WEEVIL CIRCLE		ENTERPRISE	AL	36330-9420

1595	Affiliated	4387	State Line	State Line Dialysis	2049 E SHELBY DR	MEMPHIS	TN	38116-7639
1596	Affiliated	5108	Cape Coral North	Cape Coral North Dialysis	1315 SE 8TH TERRACE	CAPE CORAL	FL	33990-3213
1597	Affiliated	5044	Willard Ave	Willard Avenue Dialysis (Newington)	445E WILLARD AVE	NEWINGTON	CT	06111-2318
1598	Affiliated	4363	West Lawn	West Lawn Dialysis (aka Midway)	7000 S PULASKI RD	CHICAGO	IL	60629-5842
1599	Affiliated	4353	Villa of Lakewood	Villa of Lakewood (Northcoast)	14050 MADISON AVE	LAKESWOOD	OH	44107-4530
1600	Affiliated	5054	North Carrollton	North Carrollton Dialysis (Parkview)	195 PARKWOOD CIRCLE	CARROLLTON	GA	30117-8756
1601	Affiliated	5620	Sikeston Jaycee Regional Dialysis	Sikeston Jaycee Regional Dialysis	135 PLAZA DR STE 101	SIKESTON	MO	63801-5148
1602	Affiliated	2244	Radcliff	Radcliff Dialysis	180 E LINCOLN TRAIL BLVD	RADCLIFF	KY	40160-1254

1603	Affiliated	4452	McAfee	McAfee Dialysis (Candler Road Decatur)	1987 CANDLER RD	STE C	DECATUR	GA	30032-4212
1604	Affiliated	5036	Avon	Avon Dialysis (Indy West)	9210 ROCKVILLE RD	STE D	INDIANAPOLIS	IN	46234-2669
1605	Affiliated	2485	Anaheim West	Anaheim West Dialysis	1821 W LINCOLN AVE		ANAHEIM	CA	92801-6731
1606	Affiliated	5043	Port Saint Joe	Port Saint Joe Dialysis	3871 HIGHWAY 98 E	STE 11	PORT ST. JOE	FL	32456-5318
1607	Affiliated	5056	Hayward Mission Hills	Hayward Mission Hills Dialysis	1661 INDUSTRIAL PKWY W		HAYWARD	CA	94544-7046
1608	Affiliated	2472	Cypress Woods Northwest	Cypress Woods Northwest Dialysis (aka NW Houston)	20320 NORTHWEST FWY	STE 1	HOUSTON	TX	77065-
1609	Affiliated	5641	Willow Creek Dialysis	Willow Creek Dialysis	1139 WARWICK WAY		RACINE	WI	53406-5661
1610	Affiliated	5642	Harbor View Dialysis	Harbor View Dialysis	818 6TH ST		RACINE	WI	53403-1176
1611	Affiliated	4451	Red River	Red River Dialysis (fka Shreveport South)	9205 LINWOOD AVE		SHREVEPORT	LA	71106-7006
1612	Affiliated	2392	South Dade Kidney Center	South Dade Kidney Center (Coral Reef)	11040 SW 184TH ST		CUTLER BAY	FL	33157-6602
1613	Affiliated	5604	Niagara Falls Memorial Dialysis	Niagara Falls Memorial Dialysis (was NF Kidney Care Center)	621 10TH ST		NIAGARA FALLS	NY	14301-1813
1614	Affiliated	5617	Silverado Dialysis	Silverado Dialysis	1100 TRANCAS ST	STE 266 AND 267	NAPA	CA	94558-2921
1615	Affiliated	5621	Prairie River Dialysis	Prairie River Dialysis	601 S CENTER AVE		MERRILL	WI	54452-3404
1616	Affiliated	5622	Stevens Point Dialysis	Stevens Point Dialysis	900 ILLINOIS AVE	5th FLR	STEVENS POINT	WI	54481-2885
1617	Affiliated	5623	Grand Seasons Dialysis	Grand Seasons Dialysis	190 GRAND SEASONS DR		WAUPACA	WI	54981-8219

1618	Affiliated	5624	Wausau Dialysis	Wausau Dialysis	2600 STEWART AVE	STE 144	WAUSAU	WI	54401-1403
1619	Affiliated	5625	Pine Crest Dialysis	Pine Crest Dialysis	232 S COURTNEY ST	STE 2	RHINELANDER	WI	54501-3319
1620	Affiliated	5626	Meadow Lane Dialysis	Meadow Lane Dialysis	1120 PINE ST		STANLEY	WI	54768-1297
1621	Affiliated	5627	Wisconsin Rapids Dialysis	Wisconsin Rapids Dialysis	1041B HILL ST		WISCONSIN RAPIDS	WI	54494-5221
1622	Affiliated	5628	Marshfield Dialysis	Marshfield Dialysis	123 NORTHRIDGE ST		MARSHFIELD	WI	54449-8341
1623	Affiliated	5629	Northern Star Dialysis	Northern Star Dialysis	311 ELM ST		WOODRUFF	WI	54568-9190
1624	Affiliated	5632	Ames Mary Greeley Dialysis	Ames Mary Greeley Dialysis	2322 E 13TH ST		AMES	IA	50010-5669
1625	Affiliated	5633	Marshalltown Mary Greeley Dialysis	Marshalltown Mary Greeley Dialysis	3120 S 2ND ST		MARSHALLTOWN	IA	50158-4614
1626	Affiliated	5634	Iowa Falls Mary Greeley Dialysis	Iowa Falls Mary Greeley Dialysis	701 WASHINGTON AVE		IOWA FALLS	IA	50126-2100
1627	Affiliated	5649	Dialysis Center of Hutchinson	Dialysis Center of Hutchinson	1901 N WALDRON ST		HUTCHINSON	KS	67502-1129
1628	Affiliated	5650	Amarillo Dialysis	Amarillo Dialysis	8604 S COULTER ST		AMARILLO	TX	79119-7379
1629	Affiliated	4495	Sagemeadow Dialysis (Houston)	Sagemeadow Dialysis (Houston)	10923 SCARSDALE BLVD		HOUSTON	TX	77089-6024
1630	Affiliated	5009	McKinney Dialysis	McKinney Dialysis	4717 MEDICAL CENTER DR		MCKINNEY	TX	75069-1870
1631	Affiliated	4499	Scottsburg Dialysis	Scottsburg Dialysis	1619 W MCCLAIN AVE		SCOTTSBURG	IN	47170-1161
1632	Affiliated	2108	Snake River Dialysis Center (fka Blackfoot)	Snake River Dialysis Center (fka Blackfoot)	1491 PARKWAY DR		BLACKFOOT	ID	83221-1667
1633	Affiliated	5034	Southpoint Dialysis (aka Durham South)	Southpoint Dialysis (aka Durham South)	415 W NC HWY 54		DURHAM	NC	27713-7516

1634	Affiliated	5643	Burlingame Dialysis	Burlingame Dialysis	1720 EL CAMINO REAL	STE 12	BURLINGAME	CA	94010-3225
1635	Affiliated	5644	Mills Dialysis	Mills Dialysis	100 S SAN MATEO DR		SAN MATEO	CA	94401-3805
1636	Affiliated	5646	Stuebenville	Stuebenville Dialysis	4000 JOHNSON RD		STUEBENVILLE	OH	43952-2300
1637	Affiliated	5656	Premiere Kidney Center of Newark	Premiere Kidney Center of Newark	65 SOUTH TERRACE AVE		NEWARK	OH	43055-1355
1638	Affiliated	5029	Calvine	Calvine Dialysis (Sacramento)	8243 E STOCKTON BLVD	STE 1	SACRAMENTO	CA	95828-8200
1639	Affiliated	4445	Durham Corners dialysis	Durham Corners Dialysis (South Plainfield)	241 DURHAM AVE		SOUTH PLAINFIELD	NJ	07080-2504
1640	Affiliated	4475	Mt Morris	Mt Morris Dialysis (aka North Flint)	6141 N. SAGINAW RD		MOUNT MORRIS	MI	48458-2403
1641	Affiliated	2176	Grandview	Grandview Dialysis	13812 S US HIGHWAY 71		GRANDVIEW	MO	64030-3685
1642	Affiliated	4450	Lemoore	Lemoore Dialysis	1345 W BUSH ST		LEMOORE	CA	93245-3303
1643	Affiliated	5663	Middlebrook Dialysis	Middlebrook Dialysis	12401 MIDDLEBROOK RD	STE 16	GERMANTOWN	MD	20874-1523
1644	Affiliated	5664	Catoctin Dialysis	Catoctin Dialysis	405 W 7TH ST		FREDERICK	MD	21701-4505
1645	Affiliated	5648	Central New York Dialysis Center	Central New York Dialysis Center	910 ERIE BLVD E		SYRACUSE	NY	13210-1060
1646	Affiliated	5014	South Jackson	South Jackson Dialysis	46 HARTS BRIDGE RD		JACKSON	TN	38301-7512
1647	Affiliated	2344	Los Alamitos	Los Alamitos Dialysis	4141 KATELLA AVE		LOS ALAMITOS	CA	90720-3406
1648	Affiliated	5048	Robbinsdale	Robbinsdale Dialysis	3461 W BROADWAY AVE		ROBBINSDALE	MN	55422-2955
1649	Affiliated	5557	Oxnard	Oxnard Dialysis	1900 OUTLET CENTER DR		OXNARD	CA	93036-0677
1650	Affiliated	4429	Marked Tree	DNVO-Marked Tree-AR	216 HESTER PARKER DR		MARKED TREE	AR	72365-2023

1651	Affiliated	5669	Louisa Dialysis	Louisa Dialysis	2145 HWY 2565		LOUISA	KY	41230
1652	Affiliated	5670	Point Pleasant Dialysis	Point Pleasant Dialysis	3683 OHIO RIVER DR		POINT PLEASANT	WV	25550
1653	Affiliated	6802	Marion	Renal Care of Marion (P150)	2921 HWY 77	SUITE #8	MARION	AR	72364-2368
1654	Affiliated	6803	Osceola	Osceola Dialysis (P151)	1420 W KEISER AVE		OSCEOLA	AR	72370-2800
1655	Affiliated	6805	Cottonwood	Cottonwood Dialysis (P153)	203 S CANDY LANE		COTTONWOOD	AZ	86326-8115
1656	Affiliated	6808	Prescott	Prescott Dialysis (P157)	980 WILLOW CREEK RD.	SUITE 11	PRESCOTT	AZ	86301-1619
1657	Affiliated	6811	Naples	Collier County Dialysis (P160)	6625 HILLWAY CIRCLE		NAPLES	FL	34112
1658	Affiliated	6813	Cartersville	Cartersville Renal Center (P162)	203 S TENNESSEE ST		CARTERSVILLE	GA	30120
1659	Affiliated	6816	Arlington Heights Renal Center	Arlington Heights Renal Center (P165)	17 W GOLF RD		ARLINGTON HEIGHTS	IL	60006
1660	Affiliated	6817	Hazel Crest Renal Center	Hazel Crest Renal Center (P166)	3470 W 183RD ST		HAZEL CREST	IL	60429
1661	Affiliated	6818	Loop Renal Center	Loop Renal Center (P167)	1101 S CANAL ST	11TH FLR	CHICAGO	IL	60607
1662	Affiliated	6819	Markham Renal Center	Markham Renal Center (P168)	3053 W 159TH ST		MARKHAM	IL	60426
1663	Affiliated	6821	South Holland Renal Center	South Holland Renal Center (P170)	16136 S PARK AVE.		SOUTH HOLLAND	IL	60473
1664	Affiliated	6822	Waukegan Renal Center	Waukegan Renal Center (P171)	1616 GRAND AVE.	STE. C	WAUKEGAN	IL	60085
1665	Affiliated	6936	Waukegan Home Renal Center	Waukegan Home Training (P172)	1616 GRAND AVE	STE F	WAUKEGAN	IL	60085
1666	Affiliated	6825	Baton Rouge	East Baton Rouge Dialysis (P174)	1333 ONEAL LANE		BATON ROUGE	LA	70816
1667	Affiliated	6826	Houma Renal Center	Houma Dialysis (P175)	108 PICONE RD		HOUMA	LA	70363

1668	Affiliated	6827	Amesbury	Amesbury Renal Center (P177)	24 MORRILL PLACE	AMESBURY	MA 1913
1669	Affiliated	6828	North Andover	North Andover Renal Center (P178)	201 SUTTON ST	NORTH ANDOVER	MA 1845

1670	Affiliated	6829	Canton	Canton Renal Center (P179)	620 E PEACE ST		CANTON	MS	39046-4729
1671	Affiliated	6830	Hazlehurst	Hazlehurst Dialysis (P180)	201 N HALEY ST		HAZLEHURST	MS	39083
1672	Affiliated	6831	Jackson North	Jackson North Dialysis (P181)	571 BEASLEY RD	SUITE B	JACKSON	MS	39206-3042
1673	Affiliated	6832	Jackson South	Jackson South Dialysis (P182)	2460 TERRY RD	SUITE 27-J	JACKSON	MS	39204-5767
1674	Affiliated	6833	Jackson Southwest	Jackson Southwest Dialysis (P183)	1828 RAYMOND RD		JACKSON	MS	39204-4126
1675	Affiliated	6834	Lexington	Renal Care of Lexington (P184)	22579 DEPOT STREET		LEXINGTON	MS	39095
1676	Affiliated	6835	Munroe Falls	Munroe Falls Dialysis (P185)	265 N MAIN ST		MUNROE FALLS	OH	44262
1677	Affiliated	6836	Summit	Summit Renal Center (P186)	73 MASSILLON ROAD		AKRON	OH	44312
1678	Affiliated	6837	White Ponds	White Ponds Dialysis (P187)	534 WHITE POND DRIVE	SUITE A	AKRON	OH	44320
1679	Affiliated	6838	Philadelphia	Memphis Street Renal Center (P189)	3310 24 MEMPHIS ST		PHILADELPHIA	PA	19134-4510
1680	Affiliated	6839	Memphis Central Renal Center	Renal Care of Central Memphis (P190)	1331 UNION AVE.	SUITE 11	MEMPHIS	TN	38104-7559
1681	Affiliated	6840	Memphis Graceland Renal Center	Memphis Graceland Renal Center (P191)	4180 AUBURN RD		MEMPHIS	TN	38116-6202
1682	Affiliated	6841	Memphis Midtown Renal Center	Renal Care of Midtown Memphis (P192)	1166 MONROE AVE.		MEMPHIS	TN	38104-6614
1683	Affiliated	6842	Memphis North Renal Center	Renal Care of Memphis North (P193)	4913 RALEIGH COMMON DR.	SUITE 1	MEMPHIS	TN	38128-2485
1684	Affiliated	6844	Whitehaven Renal Center	Whitehaven Renal Center (P195)	3420 ELVIS PRESLEY BLVD.		MEMPHIS	TN	38116-3260
1685	Affiliated	6846	Edinburg	Edinburg Renal Center (P197)	4302 S SUGAR RD	STE 15	EDINBURG	TX	78539-9140
1686	Affiliated	6847	McAllen	Dialysis Care of McAllen (P198)	411 LINDBERG AVE		MCALLEN	TX	78501-2921

1687	Affiliated	6848	Weslaco	Weslaco Renal Center (P199)	910 SOUTH UTAH		WESLACO	TX	78596-4270
1688	Affiliated	6849	Marlton	Marlton Dialysis Center (P200)	769 E ROUTE 70		MARLTON	NJ	08053-2341
1689	Affiliated	6850	Lawrenceville	Lawrenceville Renal Center (P201)	1840 PRINCETON AVE		LAWRENCEVILLE	NJ	8648
1690	Affiliated	6851	Austell Renal Center	Austell Renal Center (P202)	3642 MARATHON CIRCLE		AUSTELL	GA	30106-6821
1691	Affiliated	6852	Bartlett Renal Center	Bartlett Renal Center (P203_P290_P8203)	2920 COVINGTON PIKE		MEMPHIS	TN	38128-6007
1692	Affiliated	6854	Beaverton	Beaverton Dialysis Center (P206)	15050 SW SUITE J KOLL PARKWAY		BEAVERTON	OR	97006-6002
1693	Affiliated	6858	Walker County	Walker County Dialysis (P212)	589 HIGHWAY 78W		JASPER	AL	35501
1694	Affiliated	6861	Lakewood	Manatee County Dialysis (P215)	8470 COOPER CREEK BVLD		UNIVERSITY PARK	FL	34201
1695	Affiliated	6862	Canton	Northwest Georgia Dialysis (P216)	260 HOSPITAL RD		CANTON	GA	30114
1696	Affiliated	6863	Buffalo Grove	Buffalo Grove Renal Center (P218)	1291 W DUNDEE RD		BUFFALO GROVE	IL	60089
1697	Affiliated	6864	Evanston	Evanston Renal Center (P219)	1715 CENTRAL ST		EVANSTON	IL	60201
1698	Affiliated	6865	Schaumburg	Schaumburg Renal Center (P220)	1156 S. ROSELLE ROAD		SCHAUMBURG	IL	60193
1699	Affiliated	6937	Schaumburg	Schaumburg Home Renal Center (P270)	17 W GOLF RD		ARLINGTON HEIGHTS	IL	60005
1700	Affiliated	6866	Blue River Valley	Blue River Valley Renal Center (P222)	2309 S MILLER SUITE 1 STREET		SHELBYVILLE	IN	46176-9350
1701	Affiliated	6867	Central Fort Wayne	Central Fort Wayne Dialysis (P223)	1940 BLUFTON RD		FORT WAYNE	IN	46809-1307
1702	Affiliated	6869	Huntington	Renal Care of Huntington (P225)	3040 WEST PARK DRIVE		HUNTINGTON	IN	46750-8956

1703	Affiliated	6870	Lake Avenue Dialysis Renal Center	Lake Avenue Dialysis (P226)	3525 LAKE AVE	STE 4	FORT WAYNE	IN	46805-5545
1704	Affiliated	6871	Marion County	Marion County Dialysis (P229)	3834 S EMERSON AVE	BLDG B	INDIANAPOLIS	IN	46203-5902
1705	Affiliated	6873	Quad Counties Dialysis	Quad Counties Dialysis (P232)	528 NORTH GRANDSTAFF		AUBURN	IN	46706-1660
1706	Affiliated	6875	South Anthony	South Anthony Dialysis (P234)	7017 SOUTH ANTHONY BLVD.		FORT WAYNE	IN	46816-2016
1707	Affiliated	6876	Brandon	Brandon Renal Center (P235)	101 CHRISTIAN DR		BRANDON	MS	39042-2678
1708	Affiliated	6877	Carthage	Renal Care of Carthage (P236)	312 ELLIS STREET		CARTHAGE	MS	39051
1709	Affiliated	6878	Las Cruces Renal Center	Las Cruces Renal Center (P237)	3961 E LOHMAN AVE	STE 29	LAS CRUCES	NM	88011-8272
1710	Affiliated	6879	Northeast Portland	Northeast Portland Renal Center (P240)	703 NE HANCOCK ST		PORTLAND	OR	97212-3955
1711	Affiliated	6880	Oregon Kidney Center	Dialysis Care of Portland (P241)	5318 NE IRVING		PORTLAND	OR	97213
1712	Affiliated	6881	Sunnyside	Sunnyside Renal Center (P242)	6902 SE LAKE ROAD	SUITE 1	MILWAUKIE	OR	97267-2148
1713	Affiliated	6882	Willamette Valley	Williamette Valley Renal Center (P243)	1510 DIVISION STREET	SUITE 9	OREGON CITY	OR	97045-1572
1714	Affiliated	6883	Northern Philadelphia	Northern Philadelphia Dialysis (P244)	5933 N BROAD ST		PHILADELPHIA	PA	19141
1715	Affiliated	6884	North Providence Renal Center	North Providence Renal Center (P246)	1635 MINERAL SPRING AVE		NORTH PROVIDENCE	RI	02904-4025
1716	Affiliated	6889	Alice Renal Center	Alice Renal Center (P252)	2345 ALICE REGIONAL BLVD.		ALICE	TX	78332-7291
1717	Affiliated	6890	Beeville Renal Center	Beeville Renal Center (P253)	1905 NW FRONTAGE		BEEVILLE	TX	78102-2954
1718	Affiliated	6891	Brownsville	Brownsville Renal Center (P254)	2945 CENTRAL BLVD		BROWNSVILLE	TX	78520-8958

1719	Affiliated	6892	Corpus Christi Renal Center	Corpus Christi Dialysis (P255)	2733 SWANTNER DR		CORPUS CHRISTI TX	78404-2832
1720	Affiliated	6893	Riverside Renal Center	Riverside Renal Center (P256)	13434 LEOPARD RD. SUITE A17		CORPUS CHRISTI TX	78410-4466
1721	Affiliated	6894	South Texas Renal Center	South Texas Renal Center (P257)	4301 S PADRE ISLAND DR		CORPUS CHRISTI TX	78411-4433
1722	Affiliated	6896	South Central Renal Center	Morgan Avenue Dialysis (P258)	2222 S MORGAN AVE	SUITE 114	CORPUS CHRISTI TX	78405-1900
1723	Affiliated	6898	Northeast Texas	Dialylsis Care of Greenville (P260)	4805 WESLEY ST		GREENVILLE TX	75401-5649
1724	Affiliated	6899	Downtown Spokane	Downtown Spokane Renal Center (P261)	601 W 5TH ST	SUITE F	SPOKANE WA	99205
1725	Affiliated	6900	North Spokane	North Spokane Renal Center (P262)	12610 E MARIBEAU PRKWY	STE 1	SPOKANE WA	99216
1726	Affiliated	6901	Spokane Valley	Spokane Valley Renal Center (P263)	12610 EAST MIRABEAU PKY	SUITE 1	SPOKANE WA	99208-1450
1727	Affiliated	6902	Kansas City	Kansas City Renal Center (P264)	4333 MADISON AVE		KANSAS CITY MO	64111-3429
1728	Affiliated	6903	Butler Renal Center	Butler Renal Center (P266)	601 W NURSERY		BUTLER MO	64730
1729	Affiliated	6904	Harrisonville	Harrisonville Renal Center (P267)	308 GALAXIE AVE		HARRISONVILLE MO	64701-2084
1730	Affiliated	6905	Marshall Renal Center	Marshall Renal Center (P268)	359 W MORGAN		MARSHALL MO	65340
1731	Affiliated	6907	Akron Renal Center	Akron Renal Center (P272)	525 EAST MARKET STREET		AKRON OH	44304-1619
1732	Affiliated	6908	Kendallville Renal Center	Kendallville Renal Center (P274)	602 SAWYER RD		KENDALLVILLE IN	46755-2566
1733	Affiliated	6909	Greenwood Holly Renal Center	Greenwood Holly Renal Center (P276)	1533 HOLLY RD		CORPUS CHRISTI TX	78417-2010
1734	Affiliated	6910	Plainfield Renal Center	Plainfield Renal Center (P278)	8110 NETWORK DR		PLAINFIELD IN	46168-9024
1735	Affiliated	6911	Green Valley Renal Center	Green Valley Dialysis (P279)	1489 W WARM SPRINGS RD	STE 122	HENDERSON NV	89014-7637

1736	Affiliated	6912	Las Vegas Renal Center	Las Vegas Renal Center (P280)	2333 RENAISSANCE DR	LAS VEGAS	NV 89119-6191
------	------------	------	---------------------------	----------------------------------	---------------------------	-----------	---------------

Page 110 of 123

1737	Affiliated	6913 Lees Summit Renal Center	Lees Summit Renal Center (P281)	100 NE MISSOURI RD	STE 1	LEE' S SUMMIT	MO	64086-4702
1738	Affiliated	6914 Westport Renal Center	Westport Renal Center (P282)	3947 BROADWAY STREET		KANSAS CITY	MO	64111-2516
1739	Affiliated	6915 Greensboro Dialysis Center	Greensboro Dialysis Center (P284)	1220 SILOAM RD		GREENSBORO	GA	30642-0390
1740	Affiliated	5057 Forest Landing	DNVO-Forest Landing Dialysis (Harford Cty, Havre de Grace)-MD	2220 COMMERCE AVE	STE 1	FOREST HILL	MD	21050
1741	Affiliated	5033 University City	DNVO-University City Dialysis (Philadelphia)-PA	3020 MARKET ST	STE 13	PHILADELPHIA	PA	19104-2999
1742	Affiliated	2411 Parkland	DNVO-Parkland Dialysis-WA	311 140TH ST SO		TACOMA	WA	98444
1743	Affiliated	5094 Shelbyville Road	DNVO JV-Shelbyville Road Dialysis (DuPont, Louisville)-KY	4600 SHELBYVILLE RD	STE 31	LOUISVILLE	KY	40207
1744	Affiliated	5106 Fort Wayne West Dialysis	DNVO JV-Fort Wayne South-IN	302 E PETTIT AVE		FORT WAYNE	IN	468063007
1745	Affiliated	5671 Suburban Dialysis	ACQ-5671-NY	1542 MAPLE RD		WILLIAMSVILLE NY		14221
1746	Affiliated	5672 Gates Circle Dialysis	ACQ-5672-NY	3 GATES CIRCLE	1ST FLR	BUFFALO	NY	14209
1747	Affiliated	5673 Orchard Park Dialysis	ACQ-5673-NY	3801 TAYLOR RD		ORCHARD PARK NY		14127
1748	Affiliated	2420 TC Jester	DNVO-TC Jester-TX	1800 W 26TH ST	STE 11	HOUSTON	TX	77008-1419
1749	Affiliated	4436 Champions	DNVO-Champions Dialysis (Houston)-TX	4427 FM 1960 W	STE D	HOUSTON	TX	77068-3409

1750	Affiliated	5083 Magic City Dialysis MMC	DNVO-Magic City Dialysis (Birmingham)-AL	300 22ND ST SO		BIRMINGHAM	AL	35233-2209
1751	Affiliated	5084 Steel City Dialysis	DNVO-Steel City Dialysis (Birmingham)-AL	1809 AVE H (ENSLEY)		BIRMINGHAM	AL	35218
1752	Affiliated	5081 Jewel Dialysis	DNVO-Jewel Dialysis (Camellia, Birmingham)-AL	514 WEST TOWN PLAZA		BESSEMER	AL	35020
1753	Affiliated	660 Crystal River	Crystal River Dialysis	7435 W GULF TO LAKE HWY		CRYSTAL RIVER	FL	34429-7834
1754	Affiliated	1936 Southwest Kidney	Estrella Dialysis Center	8410 W THOMAS RD	STE 1 BLDG 1	PHOENIX	AZ	85037-3356
1755	Affiliated	1937 Gilbert Dialysis	Gilbert Dialysis Center	5222 E BASELINE RD	STE 14	GILBERT	AZ	85234-2963
1756	Affiliated	1938 Tempe Dialysis	Tempe Dialysis Center	2149 E WARNER RD	STE 11	TEMPE	AZ	85284-3496
1757	Affiliated	1939 Phoenix Dialysis	Phoenix Dialysis Center	337 E CORONADO RD	STE 11	PHOENIX	AZ	85004-1582
1758	Affiliated	1949 Arrowhead Lakes Dialysis	Arrowhead Lakes Dialysis	20325 N 51ST AVE	BLDG 11, STE 186	GLENDALE	AZ	85308-4625
1759	Affiliated	1952 Mountain Vista Dialysis	Mountain Vista Dialysis Center of Arizona	10238 E HAMPTON AVE	STE 18	MESA	AZ	85209-3317
1760	Affiliated	1977 South Meadows Dialysis Center	South Meadows Dialysis Center	10085 DOUBLE R BLVD	STE 16	RENO	NV	89521-4867
1761	Affiliated	1978 Reno Dialysis Center	Reno Dialysis Center	1500 E 2ND ST	STE 11	RENO	NV	89502-1189
1762	Affiliated	1979 Carson City Dialysis Center	Carson City Dialysis Center	3246 N. CARSON ST	STE 11	CARSON CITY	NV	89706-0248
1763	Affiliated	844 Sparks	Sparks Dialysis Center	4860 VISTA BLVD	STE 1	SPARKS	NV	89436-2817
1764	Affiliated	2015 Sierra Rose Dialysis	Sierra Rose Dialysis Center	685 SIERRA ROSE DR		RENO	NV	89511-2060

1765	Affiliated	2325 Northwest Tucson	Northwest Tucson Dialysis	2945 W INA RD	STE 15	TUCSON	AZ	85741-2366
1766	Affiliated	4355 Mesa	Central Mesa Dialysis Center	1134 E UNIVERSITY DR	STE 11	MESA	AZ	85203-8048
1767	Affiliated	4371 Raven	Raven Dialysis Center	3540 E BASELINE RD	STE 11	PHOENIX	AZ	85042-9628
1768	Affiliated	4374 Brookwood	Brookwood Dialysis Center	8910 N 43RD AVE	STE 17	GLENDALE	AZ	85302-5340
1769	Affiliated	4405 Ocotillo	Ocotillo Dialysis	975 W CHANDLER HEIGHTS RD	UNIT 11	CHANDLER	AZ	85248-5724
1770	Affiliated	4364 Maryvale	Maryvale Dialysis Center	4845 W MCDOWELL RD	STE 1A, 2A, 3A	PHOENIX	AZ	85035-4076
1771	Administrative Services	181 Childrens Hospital	MGD-Children's National Medical Center	111 MICHIGAN AVE NW		WASHINGTON	DC	20010-2916
1772	Administrative Services	1624 Renal Care Seat Pleasant	MGD-Renal Care of Seat Pleasant	6274 CENTRAL AVE		SEAT PLEASANT	MD	20743
1773	Administrative Services	1715 Moses Taylor Hospital Renal Unit	Moses Taylor Hospital Renal Unit	700 QUINCY AVE		SCRANTON	PA	18510-1724
1774	Administrative Services	3330 Aurora Medical Group - Fond du Lac	Aurora Medical Group-Fond du Lac	210 WISCONSIN AMERICAN DR	ATTN DAVITA DIALYSIS (WEST END OF BLDG)	FOND DU LAC	WI	54937-2999
1775	Administrative Services	3331 Aurora Medical Group - Sheboygan	Aurora Medical Group-Sheboygan	2414 KOHLER MEMORIAL DR		SHEBOYGAN	WI	53081-3129
1776	Administrative Services	3338 Aurora Medical Group - Lake Geneva	Aurora Medical Group-Lake Geneva	146 E GENEVA SQ		LAKE GENEVA	WI	53147-9694
1777	Administrative Services	3555 Aurora Medical Group - Marinette Dialysis	Aurora Medical Group-	4061 OLD PESHTIGO RD		MARINETTE	WI	54143

			Marinette Dialysis					
1778	Administrative Services	3607	Aurora Medical Group - Brown County Dialysis	Aurora Medical Group-Brown County Dialysis	1751 DECKNER AVE		GREEN BAY	WI 54302-2630
1779	Administrative Services	3641	Aurora Medical Group - Sturgeon Bay Dialysis	Aurora Medical Group-Sturgeon Bay Dialysis	108 S 10TH AVE		STURGEON BAY	WI 54235-1802
1780	Administrative Services	3653	Aurora Medical Group - Oshkosh West Dialysis	Aurora Medical Group-Oshkosh West Dialysis	855 N WESTHAVEN DR		OSHKOSH	WI 54904-7668
1781	Administrative Services	3665	Aurora Medical Group - Manitowoc Dialysis	Aurora Medical Group-Manitowoc Dialysis	601 REED AVE		MANITOWOC	WI 54220-2026
1782	Administrative Services	3672	Aurora Medical Group - Wautoma Dialysis	Aurora Medical Group-Wautoma Dialysis	900 EAST DIVISION ST		WAUTOMA	WI 54982-6944
1783	Administrative Services	1868	Maize Dialysis	Maize Dialysis Center	10001 GRADY AVE		MAIZE	KS 67101
1784	Administrative Services	1912	Kidney Dialysis Center	MGD-Kidney Dialysis Center, LLC (MMG Macon)	640 MARTIN LUTHER KING JR BLVD		MACON	GA 31201-3206
	Administrative Services	6079	MAGNOLIA WEST AT HOME	Magnolia West At Home	11161 MAGNOLIA AVE	STE B	RIVERSIDE	CA 92505-3605
	Administrative Services	1903	Riverside PD Central NAMG	Riverside PD Central	3660 PARK SIERRA DR	STE 18	RIVERSIDE	CA 92505-3071
	Affiliated	1995	Winter Park Home PD Dialysis	Winter Park Home PD Dialysis	4100 METRIC DR	STE 2	WINTER PARK	FL 32792-6832
	Affiliated	4302	Lockport HHD PD At Home	Lockport Home Dialysis-PD	16626 W 159TH ST	STE 73	LOCKPORT	IL 60441-8019

Affiliated	1972 HHD 6183 and PD 1972 in Shreveport	Shreveport Home Dialysis PD	1560 IRVING PL		SHREVEPORT	LA 71101-4604
Affiliated	5618 Home Dialysis of Dayton - South	Home Dialysis of Dayton- South	4700 SPRINGBORO PIKE	STE 3	MORaine	OH 45439-1964
Affiliated	5619 Home Dialysis of Dayton	Home Dialysis of Dayton	627 S EDWIN C MOSES BLVD	STE 2B	DAYTON	OH 45417-3474
Affiliated	144 Timpanogos Dialysis Center	Timpanogos Dialysis	1055 N 500 W	STE 222	PROVO	UT 84604-3329
Affiliated	216 HOME DIALYSIS UNIT	Home Dialysis /CAPD Unit	825 S 8TH ST STE 1202		MINNEAPOLIS	MN 55404
Affiliated	284 MANZANITA HOME TRAINING CENTER	Manzanita Home Training Center (fka North CAPD)	4005 MANZANITA AVE	STE 18	CARMICHAEL	CA 95608-1779
Affiliated	408 WICHITA DIALYSIS CENTER	Wichita Dialysis Center-PD Program	909 N TOPEKA ST		WICHITA	KS 67214-3620
Affiliated	978 CENTRAL TULSA DIALYSIS CENTER	Central Tulsa PD	1124 S SAINT LOUIS AVE		TULSA	OK 74120-5413
Affiliated	1748 ST PAUL CAPITAL PD	St. Paul Capital Dialysis at Home-PD (fka Capital PD Program)	555 PARK ST	STE 110	SAINT PAUL	MN 55103-2110
Affiliated	1787 ASH TREE PD	Ash Tree PD	2666 N GROVE INDUSTRIAL DR		FRESNO	CA 93727-1552
Affiliated	1821 EMERALD DIALYSIS	Emerald Dialysis PD (fka Hyde Park PD)	710 W 43RD ST		CHICAGO	IL 60609-3435
Affiliated	1822 OLYMPIA FIELDS DIALYSIS	Olympia Fields PD	4557B LINCOLN HWY	STE B	MATTESON	IL 60443-2385
Affiliated	1823 LAKE COUNTY DIALYSIS	Lake County PD	918 S MILWAUKEE AVE		LIBERTYVILLE	IL 60048-3229

Affiliated	1825 COMPREHENSIVE CRC-Gary PD 4802	GARY	IN 46408-4509
	RENAL CARE- BROADWAY		
	GARY		
Affiliated	1826 COMPREHENSIVE CRC- 222 DOUGLAS	HAMMOND	IN 46320-1960
	RENAL CARE- Hammond PD ST		
	HAMMOND		

Affiliated	1827	COMPREHENSIVE RENAL CARE- VALPARAISO	CRC-Valparaiso PD	606 E LINCOLNWAY	VALPARAISO	IN	46383-5728
Affiliated	1828	COMPREHENSIVE RENAL CARE- MICHIGAN CITY	CRC-Michigan City PD	9836 WEST 400 NORTH	MICHIGAN CITY	IN	46360-2910
Affiliated	1829	MERRILLVILLE PD	Merrillville Dialysis PD	9223 TAFT ST	MERRILLVILLE	IN	46410-6911
Affiliated	1833	NAMPA DIALYSIS CENTER	Nampa Dialysis PD	846 PARKCENTRE WAY	NAMPA	ID	83651-1790
Affiliated	1834	TABLE ROCK DIALYSIS CENTER	Table Rock Dialysis PD	5610 W GAGE ST	BOISE	ID	83706
Affiliated	1835	TWIN FALLS DIALYSIS CENTER	Twin Falls Dialysis PD	1840 CANYON CREST DR	TWIN FALLS	ID	83301-3007
Affiliated	1836	TREASURE VALLEY DIALYSIS CENTER	Treasure Valley Dialysis PD & Home	3525 E LOUISE DR	STE 155 MERIDIAN	ID	83642-6303
Affiliated	1837	GATE CITY DIALYSIS CENTER	Gate City Dialysis PD	2001 BENCH RD	POCATELLO	ID	83201-2033
Affiliated	1838	FOUR RIVERS DIALYSIS CENTER	Four Rivers Dialysis PD	515 EAST LN	ONTARIO	OR	97914-3953
Affiliated	1869	LOWRY DIALYSIS CENTER	Lowry Dialysis PD	7465 E 1ST AVE	STE A DENVER	CO	80230-6877
Affiliated	1905	BURLEY DIALYSIS CENTER	Burley Dialysis PD	741 N OVERLAND AVE	BURLEY	ID	83318-3440
Affiliated	1909	TURFWAY PD DIALYSIS	Turfway PD Training	11 SPIRAL DR	STE 15A FLORENCE	KY	41042-1394
Affiliated	1910	MARYVILLE DIALYSIS	Maryville Dialysis PD	2136B VADALABENE DR	MARYVILLE	IL	62062-5632
Affiliated	1917	PDL ANNEX-PD	PDL Annex-PD (PDL=Physician Dialysis Lancaster)	2110 HARRISBURG PIKE	STE 310 LANCASTER	PA	17601-2644

Affiliated	1924	KANKAKEE COUNTY DIALYSIS	Kankakee County Dialysis PD	581 WILLIAM R LATHAM SR DR	STE 104	BOURBONNAIS IL	60914-2439
Affiliated	1946	SNAKE RIVER DIALYSIS PD	DNVO-Snake River Dialysis PD (fka Blackfoot)-ID	1491 PARKWAY DR		BLACKFOOT ID	83221-1667
Affiliated	1953	NORTH HIGHLANDS DIALYSIS CENTER	North Highlands Dialysis Center PD	4986 WATT AVE	STE C	NORTH HIGHLANDS CA	95660-5182
Affiliated	1966	AMERY DIALYSIS	Amery Dialysis PD	970 ELDEN AVE		AMERY WI	54001-1448
Affiliated	1975	KIDNEY HOME CENTER	Kidney HOME (Home Operations & Medical Education) Center PD	2245 ROLLING RUN DR	STE 4	WINDSOR MILL MD	21244-1858
Affiliated	1988	MEMPHIS DOWNTOWN DIALYSIS	Memphis Downtown Dialysis PD	2076 UNION AVE	FL 2	MEMPHIS TN	38104-4138
Affiliated	1989	PGH HOME MODALITY COE	Pittsburgh Home Modality Center of Excellence PD	5171 LIBERTY AVE	STE A	PITTSBURGH PA	15224-2254
Affiliated	2223	LAKE VILLA DIALYSIS	Lake Villa Dialysis PD	37809 N IL RTE 59		LAKE VILLA IL	60046-7332
Affiliated	2232	RICHFIELD DIALYSIS	Richfield PD Program	6601 LYNDALE AVE S	STE 150	RICHFIELD MN	55423-2490
Affiliated	2297	TOKAY HOME DIALYSIS CENTER	Tokay Home Dialysis-PD	777 S HAM LN	STE L	LODI CA	95242-3593
Affiliated	2302	SPIVEY PERITONEAL AND HOME DIALYSIS CENTER	Spivey Peritoneal Dialysis and Home Dialysis Center	1423 STOCKBRIDGE RD	STE B	JONESBORO GA	30236-3740
Affiliated	2326	WARRENSVILLE HEIGHTS PD DIALYSIS	Warrensville Heights PD Dialysis	4200 WARRENSVILLE CENTER RD	STE 210	WARRENSVILLE HEIGHTS OH	44122-7000
Affiliated	2340	EASTGATE HOME	Eastgate Home Training	4435 AICHOLTZ RD	STE 800B	CINCINNATI OH	45245-1692

Affiliated	2366	WESLEY CHAPEL DIALYSIS	Wesley Chapel Dialysis (PD ONLY)	2255 GREEN HEDGES WAY		WESLEY CHAPEL	FL	33544-8183
Affiliated	2400	FRESNO PD	Fresno At Home Center-PD Only	568 E HERNDON AVE	STE 301	FRESNO	CA	93720-2989
Affiliated	2456	GRAND HOME DIALYSIS PD/ HHD	Grand Home Dialysis (PD only)	14674 W MOUNTAIN VIEW BLVD	STE 204	SURPRISE	AZ	85374-2708
Affiliated	2458	WASHINGTON COUNTY DIALYSIS	Washington County Dialysis PD Only (fka Hagerstown)	1136 OPAL CT		HAGERSTOWN	MD	21740-5940
Affiliated	2477	SAN JOSE PD	San Jose At Home-PD Only (Freestanding)	4400 STEVENS CREEK BLVD	STE 50	SAN JOSE	CA	95129-1104
Affiliated	2483	FREMONT HOME TRAINING JV	DNVO-Fremont At Home PD/ HHD-CA	39355 CALIFORNIA AVE		FREMONT	CA	94538
Affiliated	2490	HOME DIALYSIS OPTIONS OF BALDWIN COUNTY	Home Dialysis Options of Baldwin County-PD Only	27880 N MAIN ST	STE A	DAPHNE	AL	36526-7080
Affiliated	3299	TRI COUNTIES HOME TRAINING	Tri Counties Home Dialysis	433 S BRIDGE ST		VISALIA	CA	93277-2801
Affiliated	3640	WHITE OAK HOME TRAINING DIALYSIS	White Oak Home Training	5520 CHEVIOT RD	STE B	CINCINNATI	OH	45247-7069
Affiliated	3683	BUTLER COUNTY HOME TRAINING DIALYSIS	Butler County Home Training	3497 S DIXIE HWY		FRANKLIN	OH	45005-5717
Affiliated	3727	HANFORD AT HOME DIALYSIS	Hanford Home Dialysis PD	900 N DOUTY ST		HANFORD	CA	93230-3918
Affiliated	3735	HIOAKS DIALYSIS PD	Hioaks Dialysis PD	681 HIOAKS RD	STE B	RICHMOND	VA	23225-4043
Affiliated	3891	MEMPHIS EAST DIALYSIS PD	Memphis East Dialysis PD	50 HUMPHREYS CTR	STE 28B	MEMPHIS	TN	38120-2369
Affiliated	3892	NASHVILLE HOME TRAINING DIALYSIS PD	Nashville Home Training Dialysis PD	1919 CHARLOTTE AVE	STE 200	NASHVILLE	TN	37203-2245
Affiliated	3989	DEARBORN HOME DIALYSIS	Dearborn Home Dialysis-PD	22030 PARK ST		DEARBORN	MI	48124-2854

Affiliated	4308	GALLERIA HOME TRAINING DIALYSIS	Galleria Home Training Dialysis PD (aka SW Tennessee)	9045 HIGHWAY 64	STE 102	LAKELAND	TN	38002-8394
Affiliated	4310	GREATER TAMPA AT HOME	Greater Tampa At Home PD	4204 N MACDILL AVE	STE 1B NORTH BLDG	TAMPA	FL	33607-6364
Affiliated	4315	LORAIN COUNTY HOME DIALYSIS	DNVO-Lorain County Home Dialysis HHD/ PD-OH	824 E BROAD ST		ELYRIA	OH	44035-6557
Affiliated	4375	GARFIELD HOME PROGRAM	Garfield Home Program (PD Only)	228 N GARFIELD AVE	STE 301	MONTEREY PARK	CA	91754-1709
Affiliated	4453	BINZ HOME TRAINING	Binz Home Training - PD only	1213 HERMANN DR	STE 180	HOUSTON	TX	77004-7018
Affiliated	5021	FRANKLIN AT HOME PD	Franklin At Home PD	301 CALLOWHILL ST		PHILADELPHIA	PA	19123-4117
Affiliated	5028	CALDWELL DIALYSIS CENTER PD	Caldwell Dialysis Center	821 S SMEED PKWY		CALDWELL	ID	83605-5130
Affiliated	5170	FORT WAYNE HOME DIALYSIS	DNVO-Fort Wayne Home Dialysis (PD-HHD)-IN	3124 E STATE BLVD	STE 5B	FORT WAYNE	IN	46805-4763
Affiliated	5556	VISALIA AT HOME	Visalia At Home PD	1120 N CHINOWTH ST		VISALIA	CA	93291-7896
Affiliated	5569	BLUEMOUND PD	Bluemound PD	601 N 99TH ST STE 300		WAUWATOSA	WI	53226-4362
Affiliated	5581	WOODLAWN HOME PROGRAM PD	Woodlawn Home Program PD Only	5841 S MARYLAND AVE	RM L-026	CHICAGO	IL	60637-1447
Affiliated	5599	BEVERLY DIALYSIS PD	Beverly PD	8109 S WESTERN AVE		CHICAGO	IL	60620-5939
Affiliated	5600	WOODLAWN PEDIATRIC HOME PROGRAM	Woodlawn Pediatrics Home Program PD Only	5841 S MARYLAND AVE L026		CHICAGO	IL	60615
Affiliated	5616	SPRINGHILL HOME TRAINING DIALYSIS	Springhill Home Training (PD Only)	3401 SPRINGHILL DR	STE 330	NORTH LITTLE ROCK	AR	72117-2945

Affiliated	5647	FIRST COLONIAL DAVITA PD	First Colonial DaVita PD	1157 FIRST COLONIAL RD	STE 200	VIRGINIA BEACH	VA	23454-2432
Affiliated	5898	AMHERST AT HOME	Amherst At Home	3200 COOPER FOSTER PRK RD W		LORAIN	OH	44053-3654
Affiliated	5900	CATHERDRAL CITY AT HOME	DNVO JV-Cathedral City At Home-CA	30-885 DATE PALM DR		CATHEDRAL CITY	CA	92234-2958
Affiliated	5904	ROBBINSDALE AT HOME	Robbinsdale At Home	3461 WEST BROADWAY AVE		ROBBINSDALE	MN	55422-2955
Affiliated	5905	NORTH PALM BEACH AT HOME	North Palm Beach At Home	2841 PGA BLVD		PALM BEACH GARDENS	FL	33410-2910
Affiliated	5907	SOUTHTOWNS AT HOME	Southtowns At Home (Hamburg)	4910 CAMP RD	STE 100	HAMBURG	NY	14075-2617
Affiliated	5909	FORT WAYNE HOME AT HOME	DNVO-Fort Wayne Home At Home	3124 E STATE BLVD	STE 5B	FORT WAYNE	IN	46805-4763
Affiliated	5910	FORT WAYNE WEST AT HOME	DNVO JV-Fort Wayne West At Home	4916 ILLINOIS RD	STE 118	FORT WAYNE	IN	46804-5116
Affiliated	5913	WINCHESTER AT HOME	Winchester At Home	2301 VALOR DR		WINCHESTER	VA	22601-6111
Affiliated	5914	MARSHFIELD AT HOME	Marshfield At Home	123 NORTHRIDGE ST		MARSHFIELD	WI	54449-8341
Affiliated	5915	MOSCOW AT HOME	Moscow At Home	212 RODEO DR	STE 110	MOSCOW	ID	83843-9791

Affiliated	5919	AVON AT HOME	Avon At Home	9210 ROCKVILLE RD	STE D	INDIANAPOLIS	IN	46234-2670
Affiliated	5923	NORTHSIDE AT HOME	Northside At Home	320 E NORTH AVE	4TH FLOOR SOUTH TOWER	PITTSBURGH	PA	15212-4756
Affiliated	5926	PANAMA CITY AT HOME	Panama City At Home	615 HIGHWAY 231		PANAMA CITY	FL	32405-4704
Affiliated	5927	MAGNOLIA OAKS AT HOME	Magnolia Oaks At Home (aka Hinesville, Satilla River)	2377 HIGHWAY 196 W	BLDG A MAGNOLIA OAKS	HINESVILLE	GA	31313-8036
Affiliated	5928	WESTBANK AT HOME	Westbank At Home	3631 BEHRMAN PL		NEW ORLEANS	LA	70114-0906
Affiliated	5931	ROCKSIDE AT HOME	Rockside At Home	4801 ACORN DR		INDEPENDENCE	OH	44131-2566
Affiliated	5932	WADSWORTH AT HOME	Wadsworth At Home	195 WADSWORTH RD STE 302	FOUNDERS HALL 3RD FLOOR	WADSWORTH	OH	44281-9504
Affiliated	5933	WOODLAWN AT HOME HHD	Woodlawn Home Program At Home	5841 S MARYLAND AVE	RM L-026	CHICAGO	IL	60637-1447
Affiliated	5934	WESLEY CHAPEL AT HOME	Wesley Chapel At Home	2255 GREEN HEDGES WAY		WESLEY CHAPEL	FL	33544-8183
Affiliated	5935	THOUSAND OAKS AT HOME	Thousand Oaks At Home	375 ROLLING OAKS DR	STE 100	THOUSAND OAKS	CA	91361-1024
Affiliated	5936	SIMI VALLEY AT HOME	Simi Valley At Home	2950 SYCAMORE DR	STE 100	SIMI VALLEY	CA	93065-1210
Affiliated	5937	MIDWEST FAIRBORN AT HOME	Midwest Fairborn At Home	1266 N BROAD ST		FAIRBORN	OH	45324
Affiliated	5938	NORTH ST LOUIS COUNTY AT HOME	North St. Louis County At Home	13119 NEW HALLS FERRY RD		FLORISSANT	MO	63033-3228
Affiliated	5939	BLUEMOUND AT HOME	Bluemound At Home	601 N 99TH ST	STE 110	WAUWATOSA	WI	53226
Affiliated	5940	MESA COUNTY AT HOME	Mesa County At Home (Grand Junction)	561 25 RD	STE D	GRAND JUNCTION	CO	81505-1303

Affiliated	5942	PLANO AT HOME	Plano At Home	481 SHILOH RD	STE 100	PLANO	TX	75074-7231
Affiliated	5943	WEST BLOOMFIELD AT HOME	West Bloomfield At Home	6010 W MAPLE RD		WEST BLOOMFIELD	MI	48322-4406
Affiliated	5945	BINZ HOME TRAINING AT HOME	Binz Home Training At Home	1213 HERMANN DR		HOUSTON	TX	77004-7070
Affiliated	5947	HANNIBAL AT HOME	Hannibal At Home	3140 PALMYRA RD		HANNIBAL	MO	63401-2204
Affiliated	5949	BEVERLY AT HOME	Beverly At Home	8109 SOUTH WESTERN AVE		CHICAGO	IL	60620-5939
Affiliated	5950	NORTH JACKSON AT HOME	North Jackson At Home (fka Stonegate)	217 STERLING FARM DR		JACKSON	TN	38305-5727
Affiliated	5951	PORTAGE AT HOME	Portage At Home	5823 US HIGHWAY 6		PORTAGE	IN	46368-4851
Affiliated	5952	ROGUE VALLEY AT HOME	Rogue Valley At Home	760 GOLF VIEW DR		MEDFORD	OR	97504-9685
Affiliated	5953	EVERETT AT HOME	Everett At Home	8130 EVERGREEN WAY		EVERETT	WA	98203-6419
Affiliated	5954	OLYMPIA AT HOME	Olympia At Home	335 COOPER POINT ROAD	SUITE 105	OLYMPIA	WA	98502-4436
Affiliated	5955	LORAIN COUNTY HOME AT HOME	DNVO-Lorain County Home At Home	824 EAST BROAD ST		ELYRIA	OH	44035-6559
Affiliated	5956	RENAISSANCE AT HOME	Renaissance At Home	1840 DARBY DR		FLORENCE	AL	35630-2623
Affiliated	5957	POOLER AT HOME	Pooler At Home	54 TRADERS WAY	LIVE OAK PLAZA	POOLER	GA	31322-4158
Affiliated	5958	GULF SHORES AT HOME	Gulf Shores At Home	3947 GULF SHORES PKWY	UNIT 150	GULF SHORES	AL	36542-2735
Affiliated	5959	FRANKLIN AT HOME	Franklin At Home	301 CALLOWHILL ST		PHILADELPHIA	PA	19123-4117
Affiliated	5961	RENO AT HOME	Reno At Home	1500 EAST 2ND STREET	STE 101, 106	RENO	NV	89502-1189

Affiliated	5963	JACKSONVILLE SOUTH AT HOME	Jacksonville South At Home	14965 OLD SAINT AUGUSTINE RD	UNIT 114	JACKSONVILLE FL	32258-9481
Affiliated	5964	LAKE ST LOUIS AT HOME	Lake St. Louis At Home	200 BREVCO PLZ	STE 202	LAKE ST LOUIS MO	63367-2950
Affiliated	5965	UNION CITY AT HOME (GA)	Union City At Home (GA)	6851 SHANNON PARKWAY	STE 200	UNION CITY GA	30291-2049
Affiliated	5966	WEBER VALLEY AT HOME	Weber Valley At Home	1920 W 250TH N		MARRIOTT-SLATERVILLE UT	84404-9233
Affiliated	5968	PARKER DIALYSIS CENTER	Parker At Home	10371 S PARK GLENN WAY	STE 180	PARKER CO	80138-3871
Affiliated	5971	KENNESTONE AT HOME	Kennestone At Home	200 COBB PKWY N	STE 318	MARIETTA GA	30062-3558
Affiliated	5973	NORTH COLORADO SPRINGS AT HOME	North Colorado Springs At Home	6071 E WOODMEN RD	STE 100	COLORADO SPRINGS CO	80923-2610
Affiliated	5974	PGH HOME MODALITY COD/HHD	Pittsburgh Home Modality Center of Excellence At Home	5171 LIBERTY AVE	STE A	PITTSBURGH PA	15224-2254
Affiliated	5977	FRESNO AT HOME CENTER	Fresno At Home Center-HHD Only	568 E HERNDON AVE	STE 301	FRESNO CA	93720-2989
Affiliated	5978	BLUFF CITY AT HOME	Bluff City At Home	2400 LUCY LEE PKWY	STE E	POPLAR BLUFF MO	63901-2427
Affiliated	5979	NORTH METRO AT HOME	North Metro At Home	12365 HURON ST	STE 500	WESTMINSTER CO	80234-3498
Affiliated	5980	FIVE STAR AT HOME	Five Star At Home (fka Las Vegas Multi-Care)	2400 TECH CENTER CT		LAS VEGAS NV	89128-0804
Affiliated	5981	KIDNEY HOME AT HOME	Kidney HOME (Home Operations & Medical Education) At Home	2245 ROLLING RUN DR	STE 3	WINDSOR MILL MD	21244-1858
Affiliated	5982	FARGO AT HOME	Fargo At Home	4474 23RD AVE S	STE M	FARGO ND	58104-8795

Affiliated	5983	GALLERIA HOME TRAINING AT HOME	Galleria Home Training At Home	9045 HIGHWAY 64	STE 102	LAKELAND	TN	38002-8394
Affiliated	5986	BELDEN COMMUNITY AT HOME	Belden Community At Home	4685 FULTON DR NW		CANTON	OH	44718-2379
Affiliated	5987	MAINPLACE AT HOME	Mainplace At Home	972 W TOWN AND COUNTRY RD		ORANGE	CA	92868-4714
Affiliated	5988	PENNSAUKEN AT HOME	Pennsauken At Home	7024 KAIGHNS AVE		PENNSAUKEN	NJ	08109-4417
Affiliated	5989	JEDBURG AT HOME	Jedburg At Home	2897 W 5TH NORTH ST		SUMMERVILLE	SC	29483-9674
Affiliated	5993	CAPE CORAL SOUTH AT HOME	Cape Coral South At Home	3046 DEL PRADO BLVD S	STE 4A	CAPE CORAL	FL	33904-7232
Affiliated	5994	GREATER TAMPA HOME AT HOME	Greater Tampa At Home	4204 N MACDILL AVE	STE 1B NORTH BLDG	TAMPA	FL	33607-6364
Affiliated	5995	ATHENS EAST AT HOME	Athens East At Home	2026 S MILLEDGE AVE	STE A2	ATHENS	GA	30605-6480
Affiliated	5996	UNIVERSITY UNIT RIVERSIDE AT HOME	University Unit Riverside At Home	1045 WESTGATE DR	STE 90	SAINT PAUL	MN	55114-1079
Affiliated	5997	WOODRIDGE AT HOME	Woodridge Home At Home	7425 JANES AVE	STE 103	WOODRIDGE	IL	60517-2356
Affiliated	5998	INDY SOUTH AT HOME	Indy South At Home	972 EMERSON PKWY	STE E	GREENWOOD	IN	46143-6202
Affiliated	5999	LOCKPORT HOME AT HOME	Lockport Home Dialysis At Home	16626 W 159TH ST	STE 703	LOCKPORT	IL	60441-8019
Affiliated	6000	CAMELBACK AT HOME HEMO	Camelback Dialysis At Home	7321 E OSBORN DR		SCOTTSDALE	AZ	85251-6418
Affiliated	6002	WEST BOUNTIFUL DIALYSIS AT HOME	West Bountiful Dialysis At Home	724 W 500 S	STE 300	WEST BOUNTIFUL	UT	84087-1471

Affiliated	6002	WEST BOUNTIFUL DIALYSIS AT HOME	West Bountiful Dialysis At Home	724 W 500 S STE 300	WEST BOUNTIFUL	UT	84087-1471
Affiliated	6004	CORNERSTONE DIALYSIS AT HOME	Cornerstone Dialysis At Home	23857 GREENFIELD RD	SOUTHFIELD	MI	48075-3122
Affiliated	6006	DIALYSIS CARE OF MOORE COUNTY AT HOME	Dialysis Care of Moore County At Home (aka Pinehurst)	16 REGIONAL DR	PINEHURST	NC	28374-8850
Affiliated	6007	HOME DIALYSIS AT HOME	Home Dialysis At Home (Minneapolis)	825 S 8TH ST STE 1224	MINNEAPOLIS	MN	55404-1223
Affiliated	6009	ST PAUL CAPITOL DIALYSIS AT HOME	St Paul Capital Dialysis At Home	555 PARK ST STE 210	SAINT PAUL	MN	55103-2193
Affiliated	6011	BALLENGER PT AT HOME	Ballenger Pt. At Home	2262 S BALLENGER HWY	FLINT	MI	48503-3447
Affiliated	6012	LAKWOOD AT HOME	Lakewood At Home	1750 PIERCE ST	LAKWOOD	CO	80214-1434
Affiliated	6013	MED-CENTER AT HOME	Med-Center at Home	7580 FANNIN STE 230 ST	HOUSTON	TX	77054-1939

Affiliated	6014	UTAH VALLEY DIALYSIS AT HOME	Utah Valley Dialysis At Home	1055 N 500 W	STE 221	PROVO	UT	84604-3305
Affiliated	6015	LOWRY AT HOME	Lowry At Home	7465 E 1ST AVE	STE A	DENVER	CO	80230-6877
Affiliated	6016	MANZANITA AT HOME	Manzanita At Home	4005 MANZANITA AVE	STE 17	CARMICHAEL	CA	95608-1779
Affiliated	6017	FIRST COLONIAL DAVITA AT HOME	First Colonial DaVita At Home	1157 FIRST COLONIAL RD	STE 200	VIRGINIA BEACH	VA	23454-2432
Affiliated	6019	LAKEWOOD WASHINGTON AT HOME	Lakewood Washington At Home	5919 LAKEWOOD TOWNE CENTER BLVD SW	STE A	LAKEWOOD	WA	98499-6513
Affiliated	6020	GRAPEVINE AT HOME	Grapevine At Home	1600 W NORTHWEST HWY	STE 100	GRAPEVINE	TX	76051-8131
Affiliated	6021	GRAND RAPIDS AT HOME (CHERRY STREET)	Grand Rapids At Home (Cherry Street)	801 CHERRY ST SE		GRAND RAPIDS	MI	49506-1440
Affiliated	6022	FEDERAL WAY AT HOME	Federal Way At Home	1015 S 348TH ST		FEDERAL WAY	WA	98003-7078
Affiliated	6023	CENTURY CITY AT HOME	Century City At Home	10630 SANTA MONICA BLVD		LOS ANGELES	CA	90025
Affiliated	6024	REDDING AT HOME	Redding At Home	1876 PARK MARINA DR		REDDING	CA	96001-0913
Affiliated	6025	OLYMPIA FIELDS AT HOME	Olympia Fields At Home	4557B LINCOLN HWY	STE B	MATTESON	IL	60443-2318
Affiliated	6026	MT VERNON AT HOME	Mount Vernon At Home	1800 JEFFERSON AVE		MOUNT VERNON	IL	62864-4300
Affiliated	6028	YAKIMA AT HOME	Yakima At Home	1221 N 16TH AVE		YAKIMA	WA	98902-1347
Affiliated	6029	MID- COLUMBIA AT HOME	Mid Columbia At Home	6825 BURDEN BLVD	STE A	PASCO	WA	99301-9584

Affiliated	6030	GEORGETOWN ON THE POTOMAC AT HOME	Georgetown on the Potomac At Home	3323 K STREET NW	SUITE 110	WASHINGTON	DC	20007
Affiliated	6031	SIOUX FALLS AT HOME	Sioux Falls At Home	800 E 21ST ST		SIOUX FALLS	SD	57105-1016
Affiliated	6032	HILLSBORO AT HOME	Hillsboro At Home	2500 NW 229TH AVE	STE 300 BLDG E	HILLSBORO	OR	97124-7516
Affiliated	6033	PIKES PEAK AT HOME	Pikes Peak At Home	2002 LELARAY ST	STE 130	COLORADO SPRINGS	CO	80909-2804
Affiliated	6034	WALNUT CREEK AT HOME	Walnut Creek At Home	400 N WIGET LN		WALNUT CREEK	CA	94598-2408
Affiliated	6035	SAN ANTONIO AT HOME	San Antonio At Home	5284 MEDICAL DR	STE 100	SAN ANTONIO	TX	78229-4849
Affiliated	6036	SANTA ROSA AT HOME	Santa Rosa At Home	5819 HIGHWAY 90		MILTON	FL	32583-1763
Affiliated	6037	DUNMORE AT HOME	Dunmore At Home	1212 ONEILL HWY		DUNMORE	PA	18512-1717
Affiliated	6038	PALMERTON AT HOME	Palmerton At Home	185 DELAWARE AVE	STE C	PALMERTON	PA	18071-1716
Affiliated	6039	LONGVIEW AT HOME	Longview At Home	425 N FREDONIA ST		LONGVIEW	TX	75601-6464
Affiliated	6040	JB ZACHARY AT HOME	JB Zachary At Home	333 CASSELL DR	STE 2300	BALTIMORE	MD	21224-6815
Affiliated	6041	MEMPHIS EAST AT HOME	Memphis East At Home	50 HUMPHREYS CTR	STE 28B	MEMPHIS	TN	38120-2369
Affiliated	6042	PLAINFIELD AT HOME	Plainfield At Home	1200 RANDOLPH RD	KENYAN HOUSE	PLAINFIELD	NJ	07060-3361
Affiliated	6045	CHARLOTTE AT HOME	Charlotte (NC) At Home	2321 W MOREHEAD ST	STE 102	CHARLOTTE	NC	28208-5145
Affiliated	6046	DALY CITY AT HOME	Daly City At Home	1498 SOUTHGATE AVE	STE 101	DALY CITY	CA	94015-4015
Affiliated	6047	SALEM AT HOME	Salem At Home (OR)	3550 LIBERTY RD S	STE 100	SALEM	OR	97302-5700
Affiliated	6048	OMAHA WEST AT HOME	Omaha West At Home	13014 W DODGE RD		OMAHA	NE	68154-2148
Affiliated	6049	TUCSON EAST AT HOME	Tucson East At Home	6420 E BROADWAY BLVD	STE C300	TUCSON	AZ	85710-3512

Affiliated	6050	WHITE OAK AT HOME	White Oak At Home	5520 CHEVIOT RD	STE B	CINCINNATI	OH	45247-7069
Affiliated	6051	BELPRE AT HOME	Belpre At Home	2906 WASHINGTON BLVD		BELPRE	OH	45714-1848
Affiliated	6052	BIRMINGHAM AT HOME	Birmingham At Home	2101 7TH AVE S		BIRMINGHAM	AL	35233-3105
Affiliated	6053	STAMFORD AT HOME	Stamford At Home	30 COMMERCE RD		STAMFORD	CT	06902-4506
Affiliated	6054	WHITEBRIDGE AT HOME	Whitebridge At Home	103 WHITE BRIDGE PIKE	STE 6	NASHVILLE	TN	37209-4539
Affiliated	6055	ZANESVILLE AT HOME	Zanesville At Home	3120 NEWARK RD		ZANESVILLE	OH	43701-9659
Affiliated	6056	TYSON' S CORNER AT HOME	Tyson' s Corner At Home	8391 OLD COURTHOUSE RD	STE 160	VIENNA	VA	22182-3819
Affiliated	6057	BRADFORD AT HOME	Bradford At Home	665 E MAIN ST		BRADFORD	PA	16701-1869
Affiliated	6059	NORTHLAND AT HOME	Northland At Home	2750 CLAY EDWARDS DR	STE 515	N KANSAS CITY	MO	64116-3258
Affiliated	6060	LAKE WORTH AT HOME	Lake Worth At Home	2459 S CONGRESS AVE	STE 100	PALM SPRINGS	FL	33406-7616
Affiliated	6061	MEADVILLE AT HOME	Meadville At Home	19050 PARK AVENUE PLZ		MEADVILLE	PA	16335-4012
Affiliated	6063	WILLINGBORO AT HOME	Willingboro At Home	230 VAN SCIVER PKWY		WILLINGBORO	NJ	08046-1131
Affiliated	6064	DERENNE AT HOME	DeRenne At Home	5303 MONTGOMERY ST		SAVANNAH	GA	31405-5138
Affiliated	6065	BRUNSWICK AT HOME	Brunswick At Home	53 SCRANTON CONNECTOR		BRUNSWICK	GA	31525-1862
Affiliated	6067	AIKEN AT HOME	Aiken At Home	775 MEDICAL PARK DR		AIKEN	SC	29801-6306
Affiliated	6068	BRIDGEPORT AT HOME	Bridgeport At Home	900 MADISON AVE		BRIDGEPORT	CT	06606-5534
Affiliated	6069	ST PETERSBURG AT HOME	St Petersburg At Home	2850 34TH ST S		ST PETERSBURG	FL	33711-3817

Affiliated	6070	DENISON AT HOME	Denison At Home	1220 REBA MACENTIRE LN		DENISON	TX	75020-9057
Affiliated	6072	ATLANTIC AT HOME	Atlantic At Home	6 INDUSTRIAL WAY W	STE B	EATONTOWN	NJ	07724-2258
Affiliated	6073	NEWTOWN AT HOME	Newtown At Home (fka St. Mary)	60 BLACKSMITH RD		NEWTOWN	PA	18940-1847
Affiliated	6075	FOX RIVER AT HOME	Fox River At Home	1910 RIVERSIDE DR		GREEN BAY	WI	54301-2319
Affiliated	6076	TOKAY AT HOME	Tokay At Home	777 S HAM LN	STE L	LODI	CA	95242-3593
Affiliated	6077	CAPITAL CITY AT HOME	Capital City At Home	307 N 46TH ST		LINCOLN	NE	68503-3714
Affiliated	6081	GREATER MIAMI AT HOME	Greater Miami At Home	160 NW 176TH ST	STE 100	MIAMI	FL	33169-5023
Affiliated	6083	EFFINGHAM AT HOME	Effingham At Home	904 MEDICAL PARK DR	STE 1	EFFINGHAM	IL	62401-2193
Affiliated	6084	SPRINGFIELD CENTRAL AT HOME	Springfield Central At Home	932 N RUTLEDGE ST		SPRINGFIELD	IL	62702-3721
Affiliated	6085	DECATUR EAST WOOD AT HOME	Decatur East Wood At Home	794 E WOOD ST		DECATUR	IL	62523-1155
Affiliated	6086	ILLINI AT HOME	Illini At Home	507 E UNIVERSITY AVE		CHAMPAIGN	IL	61820-3828
Affiliated	6087	JANESVILLE AT HOME	Janesville At Home	1305 WOODMAN RD		JANESVILLE	WI	53545-1068
Affiliated	6088	NEW HAVEN AT HOME	New Haven At Home	100 CHURCH ST S	STE C	NEW HAVEN	CT	06519-1703
Affiliated	6089	NASHUA AT HOME	Nashua At Home	38 TYLER ST	STE 100	NASHUA	NH	03060-2912
Affiliated	6090	EAST EVANSVILLE AT HOME	East Evansville At Home	1312 PROFESSIONAL BLVD		EVANSVILLE	IN	47714-8007
Affiliated	6095	BROOKRIVER AT HOME	Brookriver At Home	8101 BROOKRIVER DR		DALLAS	TX	75247-4003
Affiliated	6098	METRO EAST AT HOME	Metro East At Home	5105 W MAIN ST		BELLEVILLE	IL	62226-4728

Affiliated 6099 MARION AT
HOME

Marion At Home 324 S 4TH ST

MARION

IL 62959-1241

Page 114 of 123

Affiliated	6100	ROXBURY AT HOME	Roxbury At Home	622 ROXBURY RD		ROCKFORD	IL	61107-5089
Affiliated	6101	SYCAMORE AT HOME	Sycamore At Home	2200 GATEWAY DR		SYCAMORE	IL	60178-3113
Affiliated	6103	WESTVIEW AT HOME	Westview At Home	3749 COMMERCIAL DR	STE B	INDIANAPOLIS	IN	46222-1676
Affiliated	6105	OCALA AT HOME	Ocala At Home	2860 SE 1ST AVE		OCALA	FL	34471-0406
Affiliated	6106	COMPLETE CARE AT HOME	Complete Care At Home	7850 W SAMPLE RD		MARGATE	FL	33065-4710
Affiliated	6107	INTERAMERICAN AT HOME	InterAmerican At Home	7815 CORAL WAY	STE 115	MIAMI	FL	33155-6541
Affiliated	6109	PURCELLVILLE AT HOME	Purcellville At Home	280 N HATCHER AVE		PURCELLVILLE	VA	20132-3193
Affiliated	6110	TABLE ROCK AT HOME	Table Rock At Home	5610 GAGE ST	STE B	BOISE	ID	83706
Affiliated	6111	TWIN FALLS AT HOME	Twin Falls At Home	1840 CANYON CREST DR		TWIN FALLS	ID	83301-3007
Affiliated	6113	FOUR RIVERS AT HOME	Four Rivers At Home	515 EAST LN		ONTARIO	OR	97914-3953
Affiliated	6114	OLYMPIC VIEW AT HOME	Olympic View At Home	125 16TH AVE E	FL 5	SEATTLE	WA	98112-5211
Affiliated	6115	SPIVEY AT HOME	Spivey At Home	1423 STOCKBRIDGE RD	STE B	JONESBORO	GA	30236-3740
Affiliated	6116	EAST DES MOINES AT HOME	East Des Moines At Home	1301 PENNSYLVANIA AVE	STE 208	DES MOINES	IA	50316-2365
Affiliated	6118	KETTERING AT HOME	Kettering At Home	5721 BIGGER RD		KETTERING	OH	45440-2752
Affiliated	6119	CITRUS VALLEY AT HOME	Citrus Valley At Home	894 HARDT ST		SAN BERNARDINO	CA	92408-2854
Affiliated	6124	MERIDIAN PARK AT HOME	Meridian Park At Home	19255 SW 65TH AVE	STE 100	TUALATIN	OR	97062-9712
Affiliated	6125	MARYVILLE AT HOME	Maryville At Home	2136B VADALABENE DR		MARYVILLE	IL	62062-5632
Affiliated	6128	PDI-WORCESTER AT HOME	PDI-Worcester At Home	19 GLENNIE ST	STE A	WORCESTER	MA	01605-3918

Affiliated	6129	PDI-ROCKY HILL AT HOME	PDI-Rocky Hill At Home	30 WATERCHASE DR		ROCKY HILL	CT	06067-2110
Affiliated	6133	WICHITA AT HOME	Wichita At Home	909 N TOPEKA ST		WICHITA	KS	67214-3620
Affiliated	6134	ASHEVILLE KIDNEY AT HOME	Asheville Kidney At Home	1600 CENTERPARK DR		ASHEVILLE	NC	28805-6206
Affiliated	6136	STRONGSVILLE AT HOME	Strongsville At Home	17792 PEARL RD		STRONGSVILLE	OH	44136-6909
Affiliated	6137	BATON ROUGE AT HOME	DSI Divest- Baton Rouge At Home	3888 NORTH BLVD	STE 101	BATON ROUGE	LA	70806-3824
Affiliated	6138	WEST BROADWAY DIALYSIS AT HOME	West Broadway At Home	720 W BROADWAY	STE 200	LOUISVILLE	KY	40202-3245
Affiliated	6140	BRONX AT HOME	Bronx At Home	1615 EASTCHESTER RD		BRONX	NY	10461-2603
Affiliated	6142	CLEVE HILL AT HOME	Cleve Hill At Home	1461 KENSINGTON AVE		BUFFALO	NY	14215-1436
Affiliated	6144	WHITE PLAINS AT HOME	White Plains At Home	200 HAMILTON AVE	STE 13B	WHITE PLAINS	NY	10601-1859
Affiliated	6146	LAKE VILLA AT HOME	Lake Villa At Home	37809 N IL ROUTE 59		LAKE VILLA	IL	60046-7332
Affiliated	6148	TULSA AT HOME	Tulsa At Home	4436 S HARVARD AVE		TULSA	OK	74135-2605
Affiliated	6151	LITHONIA AT HOME	Lithonia At Home	2485 PARK CENTRAL BLVD		DECATUR	GA	30035-3902
Affiliated	6152	LANHAM AT HOME	Lanham At Home	8855 ANNAPOLIS RD	STE 200	LANHAM	MD	20706-2919
Affiliated	6153	HAMMOND AT HOME	Hammond At Home	222 DOUGLAS ST		HAMMOND	IN	46320-1960
Affiliated	6156	UNION CITY CENTER AT HOME (CA)	Union City Center At Home (CA)	32930 ALVARADO NILES RD	STE 300	UNION CITY	CA	94587-8101
Affiliated	6157	CHICO AT HOME	Chico At Home	530 COHASSET RD		CHICO	CA	95926-2212
Affiliated	6158	MONTCLAIR AT HOME	Montclair At Home	5050 PALO VERDE ST	STE 100	MONTCLAIR	CA	91763-2333

Affiliated	6161	PDI - LANCASTER AT HOME	PDI-Lancaster At Home	1412 E KING ST		LANCASTER	PA	17602-3240
Affiliated	6162	PDI JOHNSTOWN AT HOME	PDI-Johnstown At Home	344 BUDFIELD ST		JOHNSTOWN	PA	15904-3214
Affiliated	6163	CAMP HILL AT HOME	Camp Hill At Home	425 N 21ST ST	PLAZA 21 BLDG 1ST FL	CAMP HILL	PA	17011-2202
Affiliated	6164	PDI MONTGOMERY AT HOME	PDI- Montgomery At Home	1001 FOREST AVE		MONTGOMERY	AL	36106-1181
Affiliated	6165	FAIRFAX AT HOME	Fairfax At Home	8501 ARLINGTON BLVD	STE 100	FAIRFAX	VA	22031-4625
Affiliated	6170	WEST SACRAMENTO AT HOME	West Sacramento At Home	3450 INDUSTRIAL BLVD	STE 100	WEST SACRAMENTO	CA	95691-5003
Affiliated	6171	EAST MACON AT HOME	East Macon At Home	165 EMERY HWY	STE 101	MACON	GA	31217-3666
Affiliated	6178	GERMANTOWN AT HOME	Germantown At Home	20111 CENTURY BLVD	STE C	GERMANTOWN	MD	20874-9165
Affiliated	6180	SEDC- WILMINGTON AT HOME	SEDC- Wilmington (NC) At Home	2215 YAUPON DR		WILMINGTON	NC	28401-7334
Affiliated	6182	HERMISTON COMMUNITY AT HOME	Hermiston Community At Home	1155 W LINDA AVE		HERMISTON	OR	97838-9601
Affiliated	6183	SHREVEPORT HHD LA	Shreveport Home Dialysis At Home	1560 IRVING PL		SHREVEPORT	LA	71101-4604
Affiliated	6184	DOWNTOWN SAN ANTONIO AT HOME	Downtown San Antonio At Home	615 E QUINCY ST		SAN ANTONIO	TX	78212
Affiliated	6186	COLUMBIA MO AT HOME	RTC-Columbia (MO) At Home	1701 E BROADWAY	STE G102	COLUMBIA	MO	65201-8029
Affiliated	6188	REGENCY AT HOME	Regency At Home (fka Jacksonville)	9535 REGENCY SQUARE BLVD N		JACKSONVILLE	FL	32225-8128
Affiliated	6193	WEST GEORGIA AT HOME	West Georgia At Home (fka Columbus (GA))	1216 STARK AVE		COLUMBUS	GA	31906-2500
Affiliated	6194	BUFORD AT HOME	Buford At Home	1550 BUFORD HWY	STE 1E	BUFORD	GA	30518-3666

Affiliated	6195	KALAMAZOO WEST AT HOME	Kalamazoo West At Home	1040 N 10TH ST		KALAMAZOO	MI	49009-6149
Affiliated	6196	SOUTH VALLEY AT HOME	South Valley At Home	17815 VENTURA BLVD	STE 100	ENCINO	CA	91316-3600
Affiliated	6204	QUEENS VILLAGE AT HOME	Queens Village At Home	22202 HEMPSTEAD AVE	STE 170	QUEENS VILLAGE	NY	11429-2123
Affiliated	6207	LANSING AT HOME-MI	Lansing Home Hemodialysis At Home	1675 WATERTOWER PL	STE 700	EAST LANSING	MI	48823-6397
Affiliated	6208	SOUTH COUNTY AT HOME	South County At Home (Deaconess)	4145 UNION RD		SAINT LOUIS	MO	63129-1064
Affiliated	6211	TACOMA AT HOME	Tacoma At Home	3401 S 19TH ST		TACOMA	WA	98405-1909
Affiliated	6213	CEDAR PARK AT HOME	Cedar Park At Home (fka North Austin)	1720 E WHITESTONE BLVD		CEDAR PARK	TX	78613-7640
Affiliated	6214	SOUTH FORT WORTH DIALYSIS AT HOME	South Fort Worth At Home	6260 SOUTHWEST BLVD		BENBROOK	TX	76109-6906
Affiliated	6215	THE WOODLANDS AT HOME	DNVO-The Woodlands At Home	9301 PINECROFT DR		SHENANDOAH	TX	77380-3179
Affiliated	6218	ARROWHEAD LAKES AT HOME	Arrowhead Lakes At Home	20325 N 51ST AVE	STE 184 BLDG 11	GLENDALE	AZ	85308-4625
Affiliated	6220	COLUMBUS WEST HOME TRAINING	Columbus West Home Training At Home	1391 GEORGESVILLE RD		COLUMBUS	OH	43228-3611
Affiliated	6221	RICHMOND KIDNEY CENTER AT HOME	Richmond Kidney Center At Home (Staten Island)	1366 VICTORY BLVD		STATEN ISLAND	NY	10301-3907
Affiliated	6225	DIALYSIS CARE OF KANNAPOLIS AT HOME	Dialysis Care of Kannapolis At Home	1607 N MAIN ST		KANNAPOLIS	NC	28081-2317
Affiliated	6226	BUTLER-FARM AT HOME	Butler Farm At Home	501 BUTLER FARM RD	STE A	HAMPTON	VA	23666-1777
Affiliated	6228	NEW PORT RICHEY AT HOME	New Port Richey Kidney At Home	7421 RIDGE RD		PORT RICHEY	FL	34668-6933

Affiliated 6229 GRAND HOME AT Grand Home At 14674 W STE 204 SURPRISE AZ 85374-2708
HOME Home MOUNTAIN
VIEW BLVD

Affiliated 6230	WILLIAMSBURG AT HOME	Williamsburg At Home (fka Yorktown)	500 SENTARA CIR STE 103	WILLIAMSBURG	VA	23188-5727
Affiliated 6231	BALDWIN COUNTY AT HOME	Home Dialysis Options of Baldwin County At Home	27880 N MAIN ST STE A	DAPHNE	AL	36526-7080
Affiliated 6232	CLINTON TOWNSHIP AT HOME	Clinton Township at Home	15918 19 MILE RD STE 110	CLINTON TOWNSHIP	MI	48038-1101
Affiliated 6233	GROSSE POINTE AT HOME	Grosse Pointe At Home	18000 E WARREN AVE STE 100	DETROIT	MI	48224-1336
Affiliated 6234	GREENSBURG AT HOME	Greensburg At Home	1531 N COMMERCE EAST DR STE 6	GREENSBURG	IN	47240-3259
Affiliated 6236	GULF BREEZE AT HOME	Gulf Breeze At Home	1519 MAIN ST	DUNEDIN	FL	34698-4650
Affiliated 6237	JACKSONVILLE CENTRAL AT HOME	Jacksonville Central At Home	400 T P WHITE DR	JACKSONVILLE	AR	72076-3287
Affiliated 6238	SAN JOSE AT HOME	San Jose At Home (Freestanding)	4400 STEVENS CREEK BLVD STE 50	SAN JOSE	CA	95129-1104
Affiliated 6243	ORLANDO AT HOME	Orlando At Home (0178)	14050 TOWN LOOP BLVD STE 104B	ORLANDO	FL	32837-6190
Affiliated 6244	KENNEDY HOME DIALYSIS-AT HOME	Kennedy Home Dialysis-At Home	5509 N CUMBERLAND AVE STE 515	CHICAGO	IL	60656-4702
Affiliated 6245	YPSILANTI AT HOME	Ypsilanti At Home	2762 WASHTEAW RD	YPSILANTI	MI	48197-1506
Affiliated 6246	JACKSONVILLE AT HOME	SEDC (NC II) Jacksonville At Home	14 OFFICE PARK DR	JACKSONVILLE	NC	28546-7325
Affiliated 6247	LEBANON AT HOME	Lebanon At Home	918 COLUMBUS AVE STE 2 UNIT B	LEBANON	OH	45036-1402
Affiliated 6248	SLIDELL KIDNEY CARE AT HOME	Slidell Kidney Care At Home	1150 ROBERT BLVD STE 240	SLIDELL	LA	70458-2005
Affiliated 6249	WATERBURY AT HOME	Waterbury At Home	150 MATTATUCK HEIGHTS RD	WATERBURY	CT	06705-3893

Affiliated	6251	WHITE LANE AT HOME	White Lane At Home	7701 WHITE LN	STE D	BAKERSFIELD	CA	93309-0201
Affiliated	6253	HANFORD AT HOME	Hanford At Home	900 N DOUTY ST		HANFORD	CA	93230-3918
Affiliated	6254	ANAHEIM AT HOME	Anaheim At Home	1107 W LA PALMA AVE		ANAHEIM	CA	92801-2804
Affiliated	6255	MERCED AT HOME	Merced At Home	3150 NORTH G ST	STE B	MERCED	CA	95340-1346
Affiliated	6257	ST JOSEPH AT HOME	St. Joseph At Home	5514 CORPORATE DR	STE 100	SAINT JOSEPH	MO	64507-7752
Affiliated	6258	CENTRAL LITTLE ROCK AT HOME	Central Little Rock At Home	5800 W 10TH ST	STE 510	LITTLE ROCK	AR	72204-1760
Affiliated	6260	DURHAM WEST AT HOME	Durham West At Home	4307 WESTERN PARK PL	STE 101	DURHAM	NC	27705-1204
Affiliated	6262	TOLEDO AT HOME	Toledo At Home	1614 S BYRNE RD		TOLEDO	OH	43614-3464
Affiliated	6263	HIOAKS AT HOME	Hioaks At Home	681 HIOAKS RD	STE D	RICHMOND	VA	23225-4043
Affiliated	6264	ELIZABETH AT HOME	Elizabeth At Home	201 MCKEESPORT RD		ELIZABETH	PA	15037-1623
Affiliated	6265	ABINGTON AT HOME	Abington At Home	3940A COMMERCE AVE		WILLOW GROVE	PA	19090-1705
Affiliated	6267	NORTH ORANGEBURG AT HOME	North Orangeburg At Home	124 FIRE TOWER RD		ORANGEBURG	SC	29118-1401
Affiliated	6268	DEARBORN HOME DIALYSIS - AT HOME	Dearborn Home Dialysis-At Home	22030 PARK ST		DEARBORN	MI	48124-2854
Affiliated	6269	OCEAN SPRINGS AT HOME	Ocean Springs At Home	13150 PONCE DEL LEON		OCEAN SPRINGS	MS	39564-2460
Affiliated	6270	HAKC - HUNTINGTON AT HOME	HAKC- Huntington At Home	256 BROADWAY		HUNTINGTON STATION	NY	11746-1403
Affiliated	6271	42ND ST AT HOME	Philadelphia 42nd Street At Home	4126 WALNUT ST		PHILADELPHIA	PA	19104-3511
Affiliated	6275	CHARLOTTESVILLE NORTH AT HOME	Charlottesville North At Home	1800 TIMBERWOOD BLVD	STE C	CHARLOTTESVILLE	VA	22911-7544

Affiliated	6276	HEARTLAND AT HOME	Heartland At Home	925 NE 8TH ST		OKLAHOMA CITY	OK	73104-5800
Affiliated	6278	LAKELAND SOUTH AT HOME	Lakeland South At Home	5050 S FLORIDA AVE	STE 1	LAKELAND	FL	33813-2501
Affiliated	6282	RAINBOW CITY AT HOME	Rainbow City At Home	2800 RAINBOW DR		RAINBOW CITY	AL	35906-5811
Affiliated	6283	ATHENS AT HOME	Athens At Home	15953 ATHENS LIMESTONE DR	STE 15	ATHENS	AL	35613-2214
Affiliated	6284	SYLACAUGA AT HOME	Sylacauga At Home	331 JAMES PAYTON BLVD		SYLACAUGA	AL	35150
Affiliated	6287	PITTSBURGH AT HOME	Pittsburgh At Home	4312 PENN AVE		PITTSBURGH	PA	15224-1310
Affiliated	6289	RADNOR AT HOME	Radnor At Home	250 KING OF PRUSSIA RD		RADNOR	PA	19087-5220
Affiliated	6291	RADFORD AT HOME	Radford At Home	600 E MAIN ST	STE B	RADFORD	VA	24141-1826
Affiliated	6292	HARRISONBURG AT HOME	Harrisonburg At Home	871 CANTRELL AVE	STE 100	HARRISONBURG	VA	22801-4323
Affiliated	6293	KERRVILLE AT HOME	Kerrville At Home	515 GRANADA PL		KERRVILLE	TX	78028-5992
Affiliated	6294	WEST TALLAHASSEE AT HOME	West Tallahassee At Home	2645 W TENNESSEE ST	STE 8	TALLAHASSEE	FL	32304-2521
Affiliated	6295	ROME AT HOME	Rome At Home	15 JOHN MADDOX DR NW		ROME	GA	30165-1413
Affiliated	6297	ST LOUIS WEST AT HOME	St. Louis West At Home	450 N LINDBERGH BLVD	STE 100C	CREVE COEUR	MO	63141-7858
Affiliated	6298	COOKEVILLE AT HOME	Cookeville At Home	140 W 7TH ST		COOKEVILLE	TN	38501-1726
Affiliated	6300	DOTHAN AT HOME	Dothan At Home	216 GRACELAND DR		DOTHAN	AL	36305-7346
Affiliated	6302	HENRICO COUNTY AT HOME	Henrico County At Home	5270 CHAMBERLAYNE RD		RICHMOND	VA	23227-2950
Affiliated	6303	WEYMOUTH CLINIC AT HOME	Weymouth At Home	330 LIBBEY INDUSTRIAL PKWY	STE 900	WEYMOUTH	MA	02189-3122
Affiliated	6304	ERIE AT HOME	Erie At Home	350 E BAYFRONT PKWY	STE A	ERIE	PA	16507-2410

Affiliated 6305	WILSON AT HOME	Wilson At Home	1605 MEDICAL PARK DR W		WILSON	NC 27893-2799
Affiliated 6306	NORTH FULTON AT HOME	North Fulton At Home	1250 NORTHMEADOW PKWY	STE 120	ROSWELL	GA 30076-4914
Affiliated 6311	BRADENTON AT HOME	Bradenton At Home	3501 CORTEZ RD W	STE 104	BRADENTON	FL 34210-3104
Affiliated 6312	COLUMBIA UNIVERSITY AT HOME	Columbia University At Home	60 HAVEN AVENUE		NEW YORK	NY 10032-2604
Affiliated 6313	NEW BEDFORD AT HOME	New Bedford At Home	524 UNION ST		NEW BEDFORD	MA 02740-3546
Affiliated 6314	MUSKEGON AT HOME	Muskegon At Home	1277 MERCY DR		MUSKEGON	MI 49444-4605
Affiliated 6315	WELLINGTON CIRCLE AT HOME	Wellington Circle At Home	10 CABOT RD	STE 103B	MEDFORD	MA 02155-5173
Affiliated 6316	FREDERICK AT HOME	Frederick At Home	140 THOMAS JOHNSON DR	STE 100	FREDERICK	MD 21702-4475
Affiliated 6317	SELINSGROVE AT HOME	Selinsgrove At Home	1030 N SUSQUEHANNA TRL		SELINSGROVE	PA 17870-7767
Affiliated 6318	LAKE CHARLES SOUTHWEST AT HOME	Lake Charles Southwest At Home	300 18th ST		LAKE CHARLES	LA 70601-7342
Affiliated 6319	LENEXA AT HOME	Lenexa At Home	8630 HALSEY ST		LENEXA	KS 66215-2880
Affiliated 6321	NASHVILLE HOME TRAINING AT HOME	Nashville Home Training At Home	1919 CHARLOTTE AVE	STE 200	NASHVILLE	TN 37203-2245
Affiliated 6322	GOLDSBORO AT HOME	Goldsboro At Home	2609 HOSPITAL RD		GOLDSBORO	NC 27534-9424
Affiliated 6323	MIAMI CAMPUS AT HOME	Miami Campus At Home	1500 NW 12TH AVE	STE 106	MIAMI	FL 33136-1028
Affiliated 6324	DAYTONA BEACH AT HOME	Daytona Beach At Home	578 HEALTH BLVD		DAYTONA BEACH	FL 32114-1492
Affiliated 6325	GRASS VALLEY AT HOME	Grass Valley At Home	360 CROWN POINT CIR	STE 210	GRASS VALLEY	CA 95945-2543

Affiliated 6326 POMONA AT HOME Pomona At 2111 NORTH POMONA CA 91767
Home GAREY AVENUE

Page 116 of 123

Affiliated	6327	MID ATLANTA HOME AT HOME	MidAtlanta Home At Home	418 DECATUR ST SE SUITE B	ATLANTA	GA	30312-1801
Affiliated	6328	MARTINSVILLE AT HOME	Martinsville Dialysis	33 BRIDGE ST S	MARTINSVILLE	VA	24112-6214
Affiliated	6329	HUBBARD ROAD AT HOME	Hubbard Road At Home	1963 HUBBARD RD	MADISON	OH	44057
Affiliated	6350	PLAINFIELD RENAL CENTER AT HOME	Plainfield Renal At Home (P278)	8110 NETWORK DR	PLAINFIELD	IN	46168-9024
Affiliated	6351	NORTH ANDOVER RENAL CENTER AT HOME	North Andover Renal At Home (P178)	201 SUTTON ST	NORTH ANDOVER	MA	1845
Affiliated	6352	JACKSON NORTH DIALYSIS AT HOME	Jackson North At Home (P181)	571 BEASLEY RD STE B	JACKSON	MS	39206-3042
Affiliated	6353	SUMMIT RENAL AT HOME	Summit Renal At Home (P186)	73 MASSILLON RD	AKRON	OH	44312-1028
Affiliated	6354	MARLTON DIALYSIS AT HOME	Marlton At Home (P200)	769 E RTE 70	MARLTON	NJ	08053-2341
Affiliated	6355	CENTRAL FORT WAYNE DIALYSIS AT HOME	Central Fort Wayne At Home (P223)	1940 BLUFTON RD	FORT WAYNE	IN	46809-1307
Affiliated	6356	LAS CRUCES RENAL CENTER AT HOME	Las Cruces Renal At Home (P237)	3961 E LOHMAN AVE STE 29	LAS CRUCES	NM	88011-8272
Affiliated	6357	NORTHEAST PORTLAND RENAL CENTER AT HOME	Northeast Portland Renal At Home (P240)	703 NE HANCOCK ST	PORTLAND	OR	97212-3955
Affiliated	6358	KANSAS CITY RENAL CENTER AT HOME	Kansas City Renal At Home (P264)	4333 MADISON AVE	KANSAS CITY	MO	64111-3429

Affiliated	6359	COASTAL DIALYSIS AT HOME	South Texas Renal At Home (P257)	4300 S PADRE ISLAND DR		CORPUS CHRISTI	TX	78411-4433
Affiliated	6360	NORTH SPOKANE RENAL CENTER AT HOME	North Spokane Renal At Home (P262)	12610 E MARIBEAU PRKWY	STE 100	SPOKANE	WA	99216
Affiliated	5659	TEMPE DIALYSIS PD	Tempe Dialysis Center PD	2149 EAST WARNER RD	STE 109	TEMPE	AZ	85284-3496
Affiliated	5660	ARROWHEAD LAKES DIALYSIS PD	Arrowhead Lakes Dialysis PD	20325 N 51ST AVE	BLDG 11, STE 184	GLENDALE	AZ	85308-4625
Affiliated	5916	SHAKER SQUARE AT HOME	Shaker Square At Home	12800 SHAKER BLVD	STE 1	CLEVELAND	OH	44120-2004
Affiliated	6130	SIERRA ROSE AT HOME	Sierra Rose At Home	685 SIERRA ROSE DR		RENO	NV	89511-2060
Affiliated	6217	TEMPE AT HOME	Tempe At Home	2149 E WARNER RD	STE 109	TEMPE	AZ	85284-3496
Affiliated	6281	TUSCALOOSA AT HOME	Tuscaloosa At Home	805 OLD MILL ST		TUSCALOOSA	AL	35401-7132

TEMPORARY CLOSURES

(Included above are several centers that have temporarily suspended operations for a variety of reasons, but are scheduled to resume operations within the coming few months)

- 614 Lynwood
- 643 Vidalia
- 3518 Huntingdon
Valley Dialysis
- 626 Tuba City
- 903 Littleton

Exhibit SR-1

Purchase Data Submission Form

Contract #: «Contract» Dialysis Center: **DaVita Inc.**

1. Purchase Data For Measurement Period: *[Enter Measurement Period (for example, Q4 2013)]*

ESA 1: _____ *[Product NameX]*

ESA 2: _____ *[Product NameY]*

ESA 3: _____ *[Product NameZ]*

[Example 1 for illustration purposes only]

<u>Dialysis Center Committed Purchasers</u>		<u>Total Number of [DELETED] Purchased</u>
	<u>ESA</u>	
	<i>ESA 1</i>	<i>1,000 [DELETED]</i>
	<i>ESA 2</i>	<i>XX mcg</i>
	<i>ESA 3</i>	<i>2,000 [DELETED]</i>

[Example 2 for illustration purposes only]

<u>Dialysis Center Purchasers</u>		<u>Total Number of [DELETED] Purchased</u>
	<u>ESA</u>	
	<i>ESA 1</i>	<i>1,000 [DELETED]</i>
	<i>ESA 2</i>	<i>XX mcg</i>
	<i>ESA 3</i>	<i>2,000 [DELETED]</i>

2. Number of patients who received any and each ESA or combination from Dialysis Center Purchasers during the entire Measurement Period.

[Example 1 for illustration purposes only]

	<u>ESA</u>	<u>Total Number of Patients</u>
ESA 1		50
ESA 2		10
ESA 3		5

[Example 2 for illustration purposes only]

	<u>ESA</u>	<u>Total Number of Patients</u>
ESA 1		60
ESA 2		

[Example 3 for illustration purposes only]

	<u>ESA</u>	<u>Total Number of Patients</u>
ESA 1		100
ESA 3		

[Example 4 for illustration purposes only]

	<u>ESA</u>	<u>Total Number of Patients</u>
ESA 2		100
ESA 3		

Completed Purchase Data Submission Forms should be submitted electronically as an Excel file to Amgen by e-mail at [DELETED], or as otherwise specified in writing by Amgen.

Schedule 1

Data

<u>Category</u>	<u>Data Element</u>	<u>Facility</u>	<u>Patient</u>
Facility Reference	Facility Name	✓	
	Address	✓	
	City, State, Zip	✓	
	Phone	✓	
	Facility ID (unique within account)	✓	
	Regional ID (unique within account)	✓	
	State in which facility is located	✓	
Patient Demographics	De-identified Patient ID		✓
	Date of Service (Treatment Date)		✓
	Treatment Date/Date of Encounter (evaluated as treatment date)		✓
	[DELETED] (in [DELETED])		✓
	[DELETED] Date		✓
	Date of [DELETED] (month, day & year)		✓
	Date of [DELETED]		✓
	[DELETED] Date		✓
	[DELETED] Date		✓
	[DELETED]		By the end of Q4 2012
	[DELETED] Type ([DELETED])*		✓
	[DELETED] Date*		✓
	Primary Payor (Govnt - Medicare, Medicaid, VA or Commercial - Medicare Advantage, MCO, HMO, PPO)		By the end of Q1 2012
	Secondary Payor (Govnt - Medicare, Medicaid, VA or Commercial - Medicare Advantage, MCO, HMO, PPO)		By the end of Q1 2012
Medications	ESA Name		✓
	ESA Dose (EPOGEN / Aranesp)		✓
	EPOGEN Administration Frequency (On DVA offered Protocol)		By the end of Q1 2012
	Aranesp Administration Frequency*		By the end of Q1 2012
	ESA Route of Administration		By the end of Q1 2012
	ESA Start Date		By the end of Q1 2012
	ESA Stop Date (Missed dose due to held)*		By the end of Q1 2012
[DELETED] Name		✓	

	[DELETED]	✓
	[DELETED] Administration Frequency (Maintenance / Loading)*	By the end of Q1 2012
	[DELETED] Order (Not administered, stop)*	By the end of Q1 2012
	Vitamin D Name	✓
	Vitamin D Dose	✓
	Vitamin D Order (Stop date)*	By the end of Q1 2012
Lab Measurements	Hemoglobin	✓
	[DELETED]	✓
	[DELETED]	✓
	[DELETED] / [DELETED]	✓
	[DELETED] ([DELETED])	✓
	[DELETED] ([DELETED] or [DELETED])	✓
	[DELETED]	✓
	Corrected [DELETED]	✓
	Corrected [DELETED] Product	✓
	Albumin	✓
Other Measurements	[DELETED] ([DELETED])	✓
	[DELETED]	✓
	[DELETED]	✓
	Kt/v	✓
	URR (until CMS no longer requires)	✓
	Modality	✓
	PD treatments (# pts per month)	✓
	Home HD treatments (# pts per month)*	✓
	Home HD treatments (# txs per month)	By the end of Q1 2012

* For designated fields, Dialysis Center will provide Amgen business rules to calculate value of the field based on the submitted Data.

Timing on providing Data with specific target date in the data column means Data or business rules will be delivered to Amgen by the end of the specified Quarter. For example: by end of Q1 2012 means deadline for delivery is March 31, 2012.

Schedule 2

Compensation Data

Product Data Submission Requirements. Compensation Data shall be sent in either Excel or a tab-delimited text file to the following email address: [DELETED]. The file naming convention shall include the Dialysis Center name, EPOGEN, and data month and year (i.e. DaVita_Epogen_January_2011). Dialysis Center must supply all of the information set forth in the table below.

<u>ID</u>	<u>Data Field Name</u>	<u>Data Field Description</u>
1	Unique Account Identifier	DaVita' s numeric identifier for each account (PFac & OFac)
2	Account Name	Account requesting EPOGEN
3	Account Street Address	Account requesting EPOGEN
4	Account City	Account requesting EPOGEN
5	Account State	Account requesting EPOGEN
6	Account zip	Account requesting EPOGEN
7	Dispensing Pharmacy for EPOGEN	DaVita' s numeric identifier for location that has dispensed EPOGEN
8	EPOGEN NDC Number	
9	EPOGEN Description	Name of EPOGEN including strength (Label Name)
10	Quantity Shipped	
11	Unit Of Measure	Tabs, bottles, vials, etc.
12	EPOGEN shipped/dispensed date	

Schedule 3

Available EPOGEN SKU Schedule

EPOGEN® (Epoetin alfa):

<u>VII. NDC</u>	<u>Description</u>
55513-126-10	2,000 Unit, 1 mL (2,000 Units/mL) single-use vial 10 vials/pack, 10 packs/case
55513-267-10	3,000 Unit, 1 mL (3,000 Units/mL) single-use vial 10 vials/pack, 10 packs/case
55513-148-10	4,000 Unit, 1 mL (4,000 Units/mL) single-use vial 10 vials/pack, 10 packs/case
55513-144-10	10,000 Unit, 1 mL (10,000 Units/mL) single-use vial 10 vials/pack, 10 packs/case
55513-283-10	20,000 Unit, 2 mL (10,000 Units/mL) multi-use vial 10 vials/pack, 4 packs/case
55513-478-10	20,000 Unit, 1 mL (20,000 Units/mL) multi-use vial 10 vials/pack, 4 packs/case

DAVITA INC.
RATIO OF EARNINGS TO FIXED CHARGES

The ratio of earnings to fixed charges is computed by dividing earnings by fixed charges. Earnings for this purpose are defined as pretax income from continuing operations adjusted by adding back fixed charges expensed during the period less noncontrolling interests. Fixed charges include debt expense (interest expense and the amortization of deferred financing costs), the estimated interest component of rent expense on operating leases, and capitalized interest.

	Year ended December 31,				
	2011	2010	2009	2008	2007
(dollars in thousands)					
Earnings adjusted for fixed charges:					
Income from continuing operations before income taxes	\$892,674	\$743,990	\$757,579	\$656,720	\$673,967
Add:					
Debt expense	241,090	181,607	185,755	224,716	257,147
Interest portion of rent expense	96,205	86,879	80,912	72,404	64,457
Less: Noncontrolling interests	(96,049)	(79,406)	(57,803)	(47,331)	(46,702)
	<u>241,246</u>	<u>189,080</u>	<u>208,864</u>	<u>249,789</u>	<u>274,902</u>
	<u>\$1,133,920</u>	<u>\$933,070</u>	<u>\$966,443</u>	<u>\$906,509</u>	<u>\$948,869</u>
Fixed charges:					
Debt expense	\$241,090	\$181,607	\$185,755	\$224,716	\$257,147
Interest portion of rent expense	96,205	86,879	80,912	72,404	64,457
Capitalized interest	4,887	2,621	3,627	4,189	3,878
	<u>\$342,182</u>	<u>\$271,107</u>	<u>\$270,294</u>	<u>\$301,309</u>	<u>\$325,482</u>
Ratio of earnings to fixed charges	<u>3.31</u>	<u>3.44</u>	<u>3.58</u>	<u>3.01</u>	<u>2.92</u>

SUBSIDIARIES OF THE COMPANY

<u>Name</u>	<u>Structure</u>	<u>Jurisdiction of Incorporation</u>
Aberdeen Dialysis, LLC	Limited Liability Company	DE
Alamosa Dialysis, LLC	Limited Liability Company	DE
American Fork Dialysis, LLC	Limited Liability Company	DE
Amery Dialysis, LLC	Limited Liability Company	DE
Anderson Kidney Dialysis, LLC	Limited Liability Company	DE
Animas Dialysis, LLC	Limited Liability Company	DE
Arcadia Gardens Dialysis, LLC	Limited Liability Company	DE
Astro, Hobby, West Mt. Renal Care Limited Partnership	Limited Partnership	DE
Austin Dialysis Centers, L.P.	Limited Partnership	DE
Barton Dialysis, LLC	Limited Liability Company	DE
Beacon Dialysis, LLC	Limited Liability Company	DE
Bear Creek Dialysis, L.P.	Limited Partnership	DE
Beverly Dialysis, LLC	Limited Liability Company	DE
Beverly Hills Dialysis Partnership	Partnership	CA
Birch Dialysis, LLC	Limited Liability Company	OH
Bladon Dialysis, LLC	Limited Liability Company	DE
Blake Dialysis, LLC	Limited Liability Company	DE
Blanco Dialysis, LLC	Limited Liability Company	DE
Bluegrass Dialysis, LLC	Limited Liability Company	DE
Bottle Dialysis, LLC	Limited Liability Company	DE
Brantley Dialysis, LLC	Limited Liability Company	DE
Bridges Dialysis, LLC	Limited Liability Company	DE
Bright Dialysis Center, LLC	Limited Liability Company	DE
Brighton Dialysis Center, LLC	Limited Liability Company	DE
Brook Dialysis, LLC	Limited Liability Company	DE
Brownsville Kidney Center, Ltd	Limited Partnership	TX
Bruno Dialysis, LLC	Limited Liability Company	DE
Buford Dialysis, LLC	Limited Liability Company	DE
Bullards Dialysis, LLC	Limited Liability Company	DE
Burney Dialysis, LLC	Limited Liability Company	DE
Caballo Dialysis, LLC	Limited Liability Company	DE
Caddo Dialysis, LLC	Limited Liability Company	DE
Canyon Springs Dialysis, LLC	Limited Liability Company	DE
Capelville Dialysis, LLC	Limited Liability Company	DE
Capes Dialysis, LLC	Limited Liability Company	DE
Capital Dialysis Partnership	Partnership	CA
Carroll County Dialysis Facility Limited Partnership	Limited Partnership	MD
Cascades Dialysis, LLC	Limited Liability Company	DE
Cedar Dialysis, LLC	Limited Liability Company	DE

Centennial LV, LLC	Limited Liability Company	DE
Central Carolina Dialysis Centers, LLC	Limited Liability Company	DE
Central Georgia Dialysis, LLC	Limited Liability Company	DE
Central Iowa Dialysis Partners, LLC	Limited Liability Company	DE

<u>Name</u>	<u>Structure</u>	<u>Jurisdiction of Incorporation</u>
Central Kentucky Dialysis Centers, LLC	Limited Liability Company	DE
Cerito Dialysis Partners, LLC	Limited Liability Company	DE
Channel Dialysis, LLC	Limited Liability Company	DE
Chicago Heights Dialysis, LLC	Limited Liability Company	DE
Chipeta Dialysis, LLC	Limited Liability Company	DE
Churchill Dialysis, LLC	Limited Liability Company	DE
Cinco Rios Dialysis, LLC	Limited Liability Company	DE
Clinton Township Dialysis, LLC	Limited Liability Company	DE
Coast Dialysis, LLC	Limited Liability Company	DE
Columbus-RNA-DaVita, LLC	Limited Liability Company	DE
Commerce Township Dialysis Center, LLC	Limited Liability Company	DE
Continental Dialysis Center, Inc.	Corporation	VA
Continental Dialysis Center of Springfield-Fairfax, Inc.	Corporation	VA
Court Dialysis, LLC	Limited Liability Company	DE
Creek Dialysis, LLC	Limited Liability Company	DE
Crystals Dialysis, LLC	Limited Liability Company	DE
Dallas-Fort Worth Nephrology, L.P.	Limited Partnership	DE
Dallas-Fort Worth Nephrology II, LLC	Limited Liability Company	DE
Damon Dialysis, LLC	Limited Liability Company	DE
DaVita Care Pte, Ltd	Limited Partnership	Singapore
DaVita Dakota Dialysis Center, LLC	Limited Liability Company	DE
DaVita DPC Holding Co., LLC	Limited Liability Company	DE
DaVita El Paso East, L.P.	Limited Partnership	DE
DaVita of New York, Inc.	Corporation	NY
DaVita Renal Pte, Ltd	Private Company	Singapore
DaVita-Riverside, LLC	Limited Liability Company	DE
DaVita-Riverside II, LLC	Limited Liability Company	DE
DaVita Rx, LLC	Limited Liability Company	DE
DaVita Tidewater, LLC	Limited Liability Company	DE
DaVita Tidewater-Virginia Beach, LLC	Limited Liability Company	DE
DaVita VillageHealth Insurance of Alabama, Inc.	Corporation	AL
DaVita VillageHealth of Georgia, Inc.	Corporation	GA
DaVita VillageHealth of Ohio, Inc.	Corporation	OH
DaVita VillageHealth of Virginia, Inc.	Corporation	VA
Dialysis of Des Moines, LLC	Limited Liability Company	DE
Dialysis of North Atlanta, LLC	Limited Liability Company	DE
Dialysis of Northern Illinois, LLC	Limited Liability Company	DE
Dialysis Specialists of Dallas, Inc.	Corporation	TX
DNP Management Company, LLC	Limited Liability Company	DE
Dolores Dialysis, LLC	Limited Liability Company	DE
Dome dialysis, LLC	Limited Liability Company	DE
Doves Dialysis, LLC	Limited Liability Company	DE
Downriver Centers, Inc.	Corporation	MI
Downtown Houston Dialysis Center, L.P.	Limited Partnership	DE
Durango Dialysis Center, LLC	Limited Liability Company	DE
DV Care GmbH	Gesellschaft mit beschränkter Haftung(GmbH)	Germany

<u>Name</u>	<u>Structure</u>	<u>Jurisdiction of Incorporation</u>
DVA Healthcare of Maryland, Inc.	Corporation	MD
DVA Healthcare of Massachusetts, Inc.	Corporation	MA
DVA Healthcare of New London, LLC	Limited Liability Company	TN
DVA Healthcare of Norwich, LLC	Limited Liability Company	TN
DVA Healthcare of Pennsylvania, Inc.	Corporation	PA
DVA Healthcare of Tuscaloosa, LLC	Limited Liability Company	TN
DVA Healthcare Renal Care, Inc.	Corporation	NV
DVA Healthcare-Southwest Ohio, LLC	Limited Liability Company	TN
DVA Laboratory Services, Inc.	Corporation	FL
DVA of New York, Inc.	Corporation	NY
DVA Renal Healthcare, Inc.	Corporation	TN
DVA/Washington University Healthcare of Greater St. Louis, LLC	Limited Liability Company	DE
East End Dialysis Center, Inc.	Corporation	VA
East Ft. Lauderdale, LLC	Limited Liability Company	DE
East Houston Kidney Center, L.P.	Limited Partnership	DE
Elberton Dialysis Facility, Inc.	Corporation	GA
Elk Grove Dialysis Center, LLC	Limited Liability Company	DE
Empire State DC, Inc.	Corporation	NY
Enchanted Dialysis, LLC	Limited Liability Company	DE
Fairfield Dialysis, LLC	Limited Liability Company	DE
Falcon, LLC	Limited Liability Company	DE
Falls Dialysis, LLC	Limited Liability Company	DE
Fields Dialysis, LLC	Limited Liability Company	DE
Five Star Dialysis, LLC	Limited Liability Company	DE
Flamingo Park Kidney Center, Inc.	Corporation	FL
Flor Dialysis, LLC	Limited Liability Company	DE
Forester Dialysis, LLC	Limited Liability Company	DE
Fort Dialysis, LLC	Limited Liability Company	DE
Freehold Artificial Kidney Center, LLC	Limited Liability Company	NJ
Fullerton Dialysis Center, LLC	Limited Liability Company	DE
Gardenside Dialysis, LLC	Limited Liability Company	DE
Garner Dialysis, LLC	Limited Liability Company	DE
Give Life Dialysis, LLC	Limited Liability Company	DE
Golden Sun Bear, LLC	Limited Liability Company	DE
Grand Home Dialysis, LLC	Limited Liability Company	DE
Great Dialysis, LLC	Limited Liability Company	DE
Greater Las Vegas Dialysis LLC	Limited Liability Company	DE
Greater Los Angeles Dialysis Centers, LLC	Limited Liability Company	DE
Green County Dialysis, LLC	Limited Liability Company	DE
Green Desert Dialysis, LLC	Limited Liability Company	DE
Greenwood Dialysis, LLC	Limited Liability Company	DE
Griffin Dialysis, LLC	Limited Liability Company	DE
Grove Dialysis, LLC	Limited Liability Company	DE
Hagerstown Dialysis, LLC	Limited Liability Company	DE
Hanford Dialysis, LLC	Limited Liability Company	DE

Hart Dialysis, LLC
Hawaiian Gardens Dialysis, LLC

Limited Liability Company
Limited Liability Company

DE
DE

Page 3 of 8

<u>Name</u>	<u>Structure</u>	<u>Jurisdiction of Incorporation</u>
Hills Dialysis, LLC	Limited Liability Company	DE
Historic Dialysis, LLC	Limited Liability Company	DE
HomeChoice Partners, Inc	Corporation	DE
Honey Dialysis, LLC	Limited Liability Company	DE
Honeyman Dialysis, LLC	Limited Liability Company	DE
Houston Acute Dialysis, L.P.	Limited Partnership	DE
Houston Kidney Center/Total Renal Care Integrated Service Network Limited Partnership	Limited Partnership	DE
Huntington Artificial Kidney Center, Ltd.	Limited Liability Company	NY
Huntington Park Dialysis, LLC	Limited Liability Company	DE
Hyattsville Dialysis, LLC	Limited Liability Company	DE
Indian River Dialysis Center, LLC	Limited Liability Company	DE
Ionia Dialysis, LLC	Limited Liability Company	DE
ISD Bartlett, LLC	Limited Liability Company	DE
ISD Bends Dialysis, LLC	Limited Liability Company	DE
ISD Brandon, LLC	Limited Liability Company	DE
ISD Buffalo Grove, LLC	Limited Liability Company	DE
ISD Canton, LLC	Limited Liability Company	DE
ISD Corpus Christi, LLC	Limited Liability Company	DE
ISD I Holding Company, Inc.	Corporation	DE
ISD II Holding Company, Inc.	Corporation	DE
ISD Kansas City, LLC	Limited Liability Company	DE
ISD Kendallville, LLC	Limited Liability Company	DE
ISD Las Vegas, LLC	Limited Liability Company	DE
ISD Lees Summit, LLC	Limited Liability Company	DE
ISD Plainfield, LLC	Limited Liability Company	DE
ISD Renal, Inc.	Corporation	DE
ISD Schaumburg, LLC	Limited Liability Company	DE
ISD Spring Valley, LLC	Limited Liability Company	DE
ISD Summit Renal Care, LLC	Limited Liability Company	DE
ISD Trenton, LLC	Limited Liability Company	DE
Jedburg Dialysis, LLC	Limited Liability Company	DE
Joliet Dialysis, LLC	Limited Liability Company	DE
Kearn Dialysis, LLC	Limited Liability Company	DE
Kidney Centers of Michigan, LLC	Limited Liability Company	DE
Kidney Home Center, LLC	Limited Liability Company	DE
Kimball Dialysis, LLC	Limited Liability Company	DE
Knickerbocker Dialysis, Inc.	Corporation	NY
Landing Dialysis, LLC	Limited Liability Company	DE
Las Vegas Pediatric Dialysis, LLC	Limited Liability Company	DE
Lawrenceburg Dialysis, LLC	Limited Liability Company	DE
Leasburg Dialysis, LLC	Limited Liability Company	DE
Liberty RC, Inc.	Corporation	NY
Lighthouse Dialysis, LLC	Limited Liability Company	DE
Limon Dialysis, LLC	Limited Liability Company	DE
Lincoln Park Dialysis Services, Inc.	Corporation	IL

Little Rock Dialysis Centers, LLC
Livingston Dialysis, LLC

Limited Liability Company
Limited Liability Company

DE
DE

Page 4 of 8

<u>Name</u>	<u>Structure</u>	<u>Jurisdiction of Incorporation</u>
Llano Dialysis, LLC	Limited Liability Company	DE
Lockhart Dialysis, LLC	Limited Liability Company	DE
Lockport Dialysis, LLC	Limited Liability Company	DE
Lone Dialysis, LLC	Limited Liability Company	DE
Long Beach Dialysis Center, LLC	Limited Liability Company	DE
Lord Baltimore Dialysis, LLC	Limited Liability Company	DE
Lory Dialysis, LLC	Limited Liability Company	DE
Los Angeles Dialysis Center	Partnership	CA
Los Arcos Dialysis, LLC	Limited Liability Company	DE
Loup Dialysis, LLC	Limited Liability Company	DE
Lurleen Dialysis, LLC	Limited Liability Company	DE
Mammoth Dialysis, LLC	Limited Liability Company	DE
Manzano Dialysis, LLC	Limited Liability Company	DE
Maple Grove Dialysis, LLC	Limited Liability Company	DE
Maples Dialysis, LLC	Limited Liability Company	DE
Marlton Dialysis Center, LLC	Limited Liability Company	DE
Marysville Dialysis Center, LLC	Limited Liability Company	DE
Mason-Dixon Dialysis Facilities, Inc.	Corporation	MD
Memorial Dialysis Center, L.P.	Limited Partnership	DE
Mena Dialysis Center, LLC	Limited Liability Company	DE
Meridian Dialysis, LLC	Limited Liability Company	DE
Mesilla Dialysis, LLC	Limited Liability Company	DE
Middlesex Dialysis Center, LLC	Limited Liability Company	DE
Minam Dialysis, LLC	Limited Liability Company	DE
Miramar Dialysis Center, LLC	Limited Liability Company	DE
Moncrief Dialysis Center/Total Renal Care Limited Partnership	Limited Partnership	DE
Morro Dialysis, LLC	Limited Liability Company	DE
Mountain West Dialysis Services, LLC	Limited Liability Company	DE
Muskogee Dialysis, LLC	Limited Liability Company	DE
National Trail Dialysis, LLC	Limited Liability Company	DE
Natomas Dialysis, LLC	Limited Liability Company	DE
Nephrolife Care (India) Pte. Ltd.	Corporation	India
Nephrology Medical Associates of Georgia, LLC	Limited Liability Company	DE
Neptune Artificial Kidney Center, LLC	Limited Liability Company	NJ
New Bay Dialysis, LLC	Limited Liability Company	DE
New Springs Dialysis, LLC	Limited Liability Company	DE
North Austin Dialysis, LLC	Limited Liability Company	DE
North Colorado Springs Dialysis, LLC	Limited Liability Company	DE
Northwest Tucson Dialysis, LLC	Limited Liability Company	DE
Nuevo Dialysis, LLC	Limited Liability Company	DE
Oasis Dialysis, LLC	Limited Liability Company	DE
Ohio River Dialysis, LLC	Limited Liability Company	DE
Open Access Lifeline, LLC	Limited Liability Company	DE
Orange Dialysis, LLC	Limited Liability Company	CA
Owasso Dialysis, LLC	Limited Liability Company	DE

<u>Name</u>	<u>Structure</u>	<u>Jurisdiction of Incorporation</u>
Paladina Health, LLC	Limited Liability Company	DE
Palomar Dialysis, LLC	Limited Liability Company	DE
Patch Dialysis, LLC	Limited Liability Company	DE
Peaks Dialysis, LLC	Limited Liability Company	DE
Pfeiffer Dialysis, LLC	Limited Liability Company	DE
Physicians Choice Dialysis of Alabama, LLC	Limited Liability Company	DE
Physicians Dialysis Acquisitions, Inc.	Corporation	DE
Physicians Dialysis of Houston, LLP	Limited Liability Partnership	TX
Physicians Dialysis of Lancaster, LLC	Limited Liability Company	PA
Physicians Dialysis Ventures, Inc	Corporation	DE
Physicians Dialysis, Inc.	Corporation	DE
Pike Dialysis, LLC	Limited Liability Company	DE
Pittsburg Dialysis Partners, LLC	Limited Liability Company	DE
Plaine Dialysis, LLC	Limited Liability Company	DE
Platte Dialysis, LLC	Limited Liability Company	DE
Pointe Dialysis, LLC	Limited Liability Company	DE
Portola Dialysis, LLC	Limited Liability Company	DE
Rancho Dialysis, LLC	Limited Liability Company	DE
Rayburn Dialysis, LLC	Limited Liability Company	DE
Red Willow Dialysis, LLC	Limited Liability Company	DE
Refuge Dialysis, LLC	Limited Liability Company	DE
Renal Clinic Of Houston, LLC	Limited Liability Company	DE
Renal Life Link, Inc.	Corporation	DE
Renal Treatment Centers–California, Inc.	Corporation	DE
Renal Treatment Centers–Illinois, Inc.	Corporation	DE
Renal Treatment Centers, Inc.	Corporation	DE
Renal Treatment Centers–Mid-Atlantic, Inc.	Corporation	DE
Renal Treatment Centers–Northeast, Inc.	Corporation	DE
Renal Treatment Centers–Southeast, L.P.	Limited Partnership	DE
Renal Treatment Centers–West, Inc.	Corporation	DE
Rickwood Dialysis, LLC	Limited Liability Company	DE
Riddle Dialysis, LLC	Limited Liability Company	DE
Rio Dialysis, LLC	Limited Liability Company	DE
Ripley Dialysis, LLC	Limited Liability Company	DE
Rita Ranch Dialysis, LLC	Limited Liability Company	DE
River Valley Dialysis, LLC	Limited Liability Company	DE
RMS Lifeline, Inc.	Corporation	DE
RNA-DaVita Dialysis, LLC	Limited Liability Company	DE
Robinson Dialysis, LLC	Limited Liability Company	DE
Rochester Dialysis Center, LLC	Limited Liability Company	DE
Rocky Mountain Dialysis Services, LLC	Limited Liability Company	DE
Roose Dialysis, LLC	Limited Liability Company	DE
Ross Clark Circle Dialysis, LLC	Limited Liability Company	DE
Routt Dialysis, LLC	Limited Liability Company	DE
Royale Dialysis, LLC	Limited Liability Company	DE
Rusk Dialysis, LLC	Limited Liability Company	DE

<u>Name</u>	<u>Structure</u>	<u>Jurisdiction of Incorporation</u>
Saddleback Dialysis, LLC	Limited Liability Company	DE
SafeHarbor Dialysis, LLC	Limited Liability Company	DE
SAKDC-DaVita Dialysis Partners, L.P.	Limited Partnership	DE
Sandusky Dialysis, LLC	Limited Liability Company	DE
San Marcos Dialysis, LLC	Limited Liability Company	DE
Santa Fe Springs Dialysis, LLC	Limited Liability Company	DE
Seneca Dialysis, LLC	Limited Liability Company	DE
Shadow Dialysis, LLC	Limited Liability Company	DE
Shayano Dialysis, LLC	Limited Liability Company	DE
Sherman Dialysis, LLC	Limited Liability Company	DE
Shining Star Dialysis, Inc.	Corporation	NJ
Siena Dialysis Center, LLC	Limited liability Company	DE
Simeon Dialysis, LLC	Limited Liability Company	DE
Soledad Dialysis Center, LLC	Limited Liability Company	DE
Somerville Dialysis Center, LLC	Limited Liability Company	DE
South Central Florida Dialysis Partners, LLC	Limited Liability Company	DE
South Shore Dialysis Center. L.P.	Limited Partnership	DE
Southcrest Dialysis, LLC	Limited Liability Company	DE
Southeastern Indiana Dialysis, LLC	Limited Liability Company	DE
Southern Colorado Joint Ventures, LLC	Limited Liability Company	DE
Southern Hills Dialysis Center, LLC	Limited Liability Company	DE
Southwest Atlanta Dialysis Centers, LLC	Limited Liability Company	DE
Southwest Kidney-DaVita Dialysis Partners, LLC	Limited Liability Company	DE
St. Luke' s Dialysis, LLC	Limited Liability Company	DE
Star Dialysis, LLC	Limited Liability Company	DE
Steam Dialysis, LLC	Limited Liability Company	DE
Stevenson Dialysis, LLC	Limited Liability Company	DE
Stewart Dialysis, LLC	Limited Liability Company	DE
Storrie Dialysis, LLC	Limited Liability Company	DE
Strongsville Dialysis, LLC	Limited Liability Company	DE
Sugarite Dialysis, LLC	Limited Liability Company	DE
Sugarloaf Dialysis, LLC	Limited Liability Company	DE
Summer Dialysis, LLC	Limited Liability Company	DE
Summit Dialysis Center, L.P.	Limited Partnership	DE
Sun City Dialysis Center, LLC	Limited Liability Company	DE
Sun City West Dialysis Center LLC	Limited Liability Company	DE
Sunset Dialysis, LLC	Limited Liability Company	DE
Taylor Dialysis, LLC	Limited Liability Company	DE
Tel-Huron Dialysis, LLC	Limited Liability Company	DE
Tennessee Valley Dialysis Center, LLC	Limited Liability Company	DE
The Woodlands Dialysis Center, L.P.	Limited Partnership	DE
Tortugas Dialysis, LLC	Limited Liability Company	DE
Total Renal Care/Crystal River Dialysis, L.C.	Limited Liability Company	FL
Total Renal Care/Eaton Canyon Dialysis Center Partnership	Partnership	CA
Total Renal Care, Inc.	Corporation	CA

<u>Name</u>	<u>Structure</u>	<u>Jurisdiction of Incorporation</u>
Total Renal Care North Carolina, LLC	Limited Liability Company	DE
Total Renal Care Texas Limited Partnership	Limited Partnership	DE
Total Renal Laboratories, Inc.	Corporation	FL
Total Renal Research, Inc.	Corporation	DE
Transmountain Dialysis, L.P.	Limited Partnership	DE
TRC-Dyker Heights, L.P.	Limited Partnership	NY
TRC-Four Corners Dialysis Clinics, LLC	Limited Liability Company	NM
TRC-Georgetown Regional Dialysis LLC	Limited Liability Company	DC
TRC-Indiana LLC	Limited Liability Company	IN
TRC-Petersburg, LLC	Limited Liability Company	DE
TRC El Paso Limited Partnership	Limited Partnership	DE
TRC of New York, Inc.	Corporation	NY
TRC West, Inc.	Corporation	DE
Tree City Dialysis, LLC	Limited Liability Company	DE
Tugman Dialysis, LLC	Limited Liability Company	DE
Tulsa Dialysis, LLC	Limited Liability Company	DE
Tumalo Dialysis, LLC	Limited Liability Company	DE
Turlock Dialysis Center, LLC	Limited Liability Company	DE
Tustin Dialysis Center, LLC	Limited Liability Company	DE
University Dialysis Center, LLC	Limited Liability Company	DE
Upper Valley Dialysis, L.P	Limited Partnership	DE
USC-DaVita Dialysis Center, LLC	Limited Liability Company	CA
UT Southwestern DVA Healthcare, LLP	Limited Liability Partnership	TX
Valley Springs Dialysis, LLC	Limited Liability Company	DE
Verde Dialysis, LLC	Limited Liability Company	DE
Victory Dialysis, LLC	Limited Liability Company	DE
VillageHealth DM, LLC	Limited Liability Company	DE
Villanueva Dialysis, LLC	Limited Liability Company	DE
Walker Dialysis, LLC	Limited Liability Company	DE
Wauseon Dialysis, LLC	Limited Liability Company	DE
Wesley Chapel Dialysis, LLC	Limited Liability Company	DE
West Elk Grove Dialysis, LLC	Limited Liability Company	DE
West Sacramento Dialysis, LLC	Limited Liability Company	DE
Weston Dialysis Center, LLC	Limited Liability Company	DE
Whitney Dialysis, LLC	Limited Liability Company	DE
Wilder Dialysis, LLC	Limited Liability Company	DE
Willowbrook Dialysis Center, L.P.	Limited Partnership	DE
Winds Dialysis, LLC	Limited Liability Company	DE
Wood Dialysis, LLC	Limited Liability Company	DE
Wyandotte Central Dialysis, LLC	Limited Liability Company	DE
Wyler Dialysis, LLC	Limited Liability Company	DE
Ybor City Dialysis, LLC	Limited Liability Company	DE
Yucaipa Dialysis, LLC	Limited Liability Company	DE
Zephyrhills Dialysis Center, LLC	Limited Liability Company	DE

Consent of Independent Registered Public Accounting Firm

The Board of Directors and Shareholders

DaVita Inc.:

We consent to the incorporation by reference in the registration statements on Forms S-8 (No. 333-169467, No. 33-84610, No. 33-83018, No. 33-99862, No. 33-99864, No. 333-01620, No. 333-34693, No. 333-34695, No. 333-46887, No. 333-75361, No. 333-56149, No. 333-30734, No. 333-30736, No. 333-63158, No. 333-42653, No. 333-86550, No. 333-86556, No. 333-144097 and No. 333-158220) and Form S-3 (No. 333-169690 and No. 333-69227) of DaVita Inc. of our reports dated February 24, 2012, with respect to the consolidated balance sheets of DaVita Inc. and subsidiaries as of December 31, 2011 and 2010, and the related consolidated statements of income, equity and comprehensive income, and cash flows for each of the years in the three-year period ended December 31, 2011, and related financial statement schedule, and the effectiveness of internal control over financial reporting as of December 31, 2011, which reports appear in the December 31, 2011 annual report on Form 10-K of DaVita Inc.

/s/ KPMG LLP

Seattle, Washington

February 24, 2012

SECTION 302 CERTIFICATION

I, Kent J. Thiry, certify that:

1. I have reviewed this annual report on Form 10-K of DaVita Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

- (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
- (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
- (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
- (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

- (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ KENT J. THIRY

Kent J. Thiry
Chief Executive Officer

Date: February 24, 2012

SECTION 302 CERTIFICATION

I, Luis A. Borgen, certify that:

1. I have reviewed this annual report on Form 10-K of DaVita Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

- (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
- (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
- (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
- (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

- (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ LUIS A. BORGEN

Luis A. Borgen
Chief Financial Officer

Date: February 24, 2012

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Annual Report of DaVita Inc. (the “Company”) on Form 10-K for the year ending December 31, 2011 as filed with the Securities and Exchange Commission on the date hereof (the “Periodic Report”), I, Kent J. Thiry, Chief Executive Officer of the Company, certify, pursuant to 18.U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Periodic Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ KENT J. THIRY

Kent J. Thiry

Chief Executive Officer

February 24, 2012

**CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Annual Report of DaVita Inc. (the “Company”) on Form 10-K for the year ending December 31, 2011 as filed with the Securities and Exchange Commission on the date hereof (the “Periodic Report”), I, Luis A. Borgen, Chief Financial Officer of the Company, certify, pursuant to 18.U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Periodic Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ LUIS A. BORGEN

Luis A. Borgen
Chief Financial Officer

February 24, 2012

**Amortizable intangibles
(Tables)**

Amortizable Intangible Assets

**12 Months Ended
Dec. 31, 2011**

Amortizable intangible assets were comprised of the following:

	<u>December 31,</u>	
	<u>2011</u>	<u>2010</u>
Noncompetition and other agreements	\$335,012	\$309,405
Lease agreements	8,081	8,466
Deferred debt financing costs	66,011	61,405
	<u>409,104</u>	<u>379,276</u>
Less accumulated amortization	<u>(249,613)</u>	<u>(216,641)</u>
Total amortizable intangible assets	<u>\$159,491</u>	<u>\$162,635</u>

Amortizable Intangible Liabilities

Amortizable intangible liabilities were comprised of the following:

	<u>December 31,</u>	
	<u>2011</u>	<u>2010</u>
Alliance and product supply agreement commitment (See Note 22)	\$68,200	\$68,200
Less accumulated amortization	<u>(48,213)</u>	<u>(42,883)</u>
	<u>\$19,987</u>	<u>\$25,317</u>

Scheduled Amortization Charges from Intangible Assets and Liabilities

Scheduled amortization charges from intangible assets and liabilities as of December 31, 2011 were as follows:

	Noncompetition and other agreements	Deferred debt financing costs	Alliance and Product Supply Agreement liability
2012	24,453	10,552	(5,330)
2013	21,928	10,260	(5,330)
2014	19,724	9,747	(5,330)
2015	15,761	8,514	(3,997)
2016	6,669	5,017	—
Thereafter	17,520	9,346	—

**Organization and Summary
of Significant Accounting
Policies - Additional
Information (Detail)**

**12 Months
Ended
Dec. 31, 2011**

<u>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</u>	
<u>Number of consolidated entities that third parties held noncontrolling ownership interests</u>	196
Maximum	
<u>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</u>	
<u>Percentage of management fees included in net operating revenues</u>	1.00%
Noncompetition and other agreements	
<u>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</u>	
<u>Amortization period</u>	10
Alliance and Product Supply Agreement liability	
<u>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</u>	
<u>Amortization period</u>	10
UNITED STATES	
<u>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</u>	
<u>Number of dialysis centers that the company operated or provided administrative services</u>	1,809
<u>Number of states that dialysis centers located</u>	43
<u>Number of patients served</u>	142,000
Outside United States	
<u>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</u>	
<u>Number of dialysis centers that the company operated or provided administrative services</u>	11
Buildings	
<u>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</u>	
<u>Useful lives of the assets, minimum</u>	20
<u>Useful lives of the assets, maximum</u>	40
Equipment and Information Systems	
<u>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</u>	
<u>Useful lives of the assets, minimum</u>	3
<u>Useful lives of the assets, maximum</u>	8
Dialysis and related lab services Maximum	
<u>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</u>	
<u>Percentage of risk on revenue</u>	1.00%

Acquisitions (Tables)

12 Months Ended Dec. 31, 2011

[Acquisition of Dialysis and Other Businesses](#)

During 2011, 2010, and 2009, the Company acquired total dialysis and other businesses as follows:

	Year ended December 31,		
	2011	2010	2009
Cash paid, net of cash acquired	\$1,077,442	\$188,502	\$87,617
Deferred purchase price and other acquisition obligations	19,010	449	338
Aggregate purchase cost	<u>\$1,096,452</u>	<u>\$188,951</u>	<u>\$87,955</u>
Number of chronic dialysis centers acquired	<u>178</u>	<u>41</u>	<u>19</u>

[Results from Discontinued Operations](#)

The results from discontinued operations related to the dialysis and related lab services segment were as follows:

	Year ended December 31,		
	2011	2010	2009
Net operating revenues	\$16,648	\$9,341	\$8,152
Income before income taxes	1,896	468	645
Income tax expense	675	187	252
Income from discontinued operations	<u>\$1,221</u>	<u>\$281</u>	<u>\$393</u>

[Net Assets of Discontinued Operations Sold](#)

Net assets of discontinued operations related to the dialysis and related lab services segment as of September 30, 2011, were as follows:

Current assets	\$ 71,384
Property and equipment, net	5,183
Goodwill	7,999
Liabilities and noncontrolling interests	(836)
Net assets from discontinued operations	<u>\$83,730</u>

[Pro Forma Summary of Results of Operations](#)

	Year ended December 31,	
	2011	2010
	(unaudited)	
Pro forma net revenues	\$7,309,901	\$6,983,641
Pro forma net income attributable to DaVita Inc.	520,625	471,635
Pro forma income from continuing operations attributable to DaVita Inc.	524,379	471,354
Pro forma basic net income per share attributable to DaVita Inc.	5.50	4.65
Pro forma diluted net income per share attributable to DaVita Inc.	5.39	4.58

CDSI I Holding Company, Inc

[Aggregate Purchase Cost Allocations](#)

The following table summarizes the assets acquired and liabilities assumed in the transaction and recognized at the acquisition date at their estimated fair values, as well as the estimated fair value of the noncontrolling interests in DSI at that date:

Current assets	\$ 164,227
----------------	------------

Property and equipment	67,080
Amortizable intangible and other long-term assets	6,523
Goodwill	500,662
Long-term deferred income taxes	79,420
Current liabilities assumed	(54,046)
Other long-term liabilities	(11,213)
Noncontrolling interests	(23,100)
	<u>\$729,553</u>

Other dialysis acquisitions
[Aggregate Purchase Cost](#)
[Allocations](#)

The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values, as well as the estimated fair value of the noncontrolling interests assumed in these transactions:

	Year ended December 31,		
	2011	2010	2009
Tangible assets, principally leasehold improvements and equipment	\$32,649	\$21,257	\$11,140
Amortizable intangible assets	19,804	18,300	6,703
Goodwill	388,844	152,252	78,199
Noncontrolling interests assumed	(70,821)	(1,171)	(7,567)
Liabilities assumed	<u>(3,577)</u>	<u>(1,687)</u>	<u>(520)</u>
Aggregate purchase cost	<u>\$366,899</u>	<u>\$188,951</u>	<u>\$87,955</u>

**Reconciliation of the
Beginning and Ending
Liability for Unrecognized
Tax Benefits that Do Not
Meet the More-Likely-than-
not Threshold (Detail) (USD
\$)**

12 Months Ended

Dec. 31, 2011 Dec. 31, 2010

**In Thousands, unless
otherwise specified**

Income Tax Contingency [Line Items]

<u>Balance beginning</u>	\$ 8,138	\$ 30,693
<u>Additions for tax positions related to current year</u>	2,052	1,515
<u>Additions for tax positions related to prior years</u>	786	69
<u>Reductions for tax positions related to prior years</u>	(2,033)	(24,139)
<u>Balance ending</u>	\$ 8,943	\$ 8,138

Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share (Detail) (USD \$) In Thousands, except Share data, unless otherwise specified	3 Months Ended				12 Months Ended				
	Dec.	Sep.	Jun.	Mar.	Dec.	Sep.	Jun.	Mar.	
	31,	30,	30,	31,	31,	30,	30,	31,	Dec. 31,
	2011	2011	2011	2011	2010	2010	2010	2010	2009

Basic:

<u>Income from continuing operations attributable to DaVita Inc.</u>									\$ 481,755	\$ 405,402	\$ 422,291
<u>Decrease (increase) in noncontrolling interest redemption rights in excess of fair value</u>									335	(68)	(267)
<u>Income from continuing operations for basic earnings per share calculation</u>									482,090	405,334	422,024
<u>Discontinued operations attributable to DaVita Inc.</u>									(3,754)	281	393
<u>Net income attributable to DaVita Inc. for basic earnings per share calculation</u>									478,336	405,615	422,417
<u>Weighted average shares outstanding during the period</u>									94,655,000	101,497,000	103,595,000
<u>Vested stock units</u>									3,000	7,000	9,000
<u>Weighted average shares for basic earnings per share calculation</u>									94,658,027	101,504,373	103,603,885
<u>Basic income from continuing operations per share attributable to DaVita Inc.</u>	\$	\$	\$	\$	\$	\$	\$	\$	\$ 5.09	\$ 3.99	\$ 4.07
<u>Basic net income per share attributable to DaVita Inc.</u>	1.60	1.48	1.05	0.98	0.71	1.16	1.06	1.05	\$ 5.05	\$ 4.00	\$ 4.08

Diluted:

<u>Income from continuing operations attributable to DaVita Inc.</u>									481,755	405,402	422,291
<u>Decrease (increase) in noncontrolling interest redemption rights in excess of fair value</u>									335	(68)	(267)
<u>Income from continuing operations for diluted earnings per share calculation</u>									482,090	405,334	422,024
<u>Discontinued operations attributable to DaVita Inc.</u>									(3,754)	281	393

Net income attributable to DaVita Inc. for diluted earnings per share calculation									\$ 478,336	\$ 405,615	\$ 422,417
Weighted average shares outstanding during the period									94,655,000	101,497,000	103,595,000
Vested stock units									3,000	7,000	9,000
Assumed incremental shares from stock plans									1,874,000	1,555,000	564,000
Weighted average shares for diluted earnings per share calculation									96,532,110	103,059,171	104,167,685
Diluted income from continuing operations per share attributable to DaVita Inc.	\$	\$	\$	\$	\$	\$	\$	\$	\$ 4.99	\$ 3.93	\$ 4.05
Diluted net income per share attributable to DaVita Inc.	1.58	1.45	1.02	0.96	0.70	1.15	1.04	1.04	\$ 4.96	\$ 3.94	\$ 4.06
Anti-dilutive stock-settled awards excluded from calculation									2,388,000	[1]1,452,000	[1]9,912,000 [1]

[1] Shares associated with stock-settled stock appreciation rights and stock options that are excluded from the diluted denominator calculation because they are anti-dilutive under the treasury stock method.

Unamortized original facilities and accrued interest									
Redemption of total amount of debt including principal and interest	1,297,215								
Cash under agreement	38,953								
Date of Redemption	Nov. 19, 2010								
Premium paid on redemption	6,677								
Escrow accounts and other amounts	74,431	241,090	255,989	185,755					
Interest cash received				823,000					
Amount paid for cashing notes on 100 principal amount					1,019,06				
Aggregate debt outstanding at stated amount					142,356	200,000		119,173	
Redemption price of debt						101.656%			
Total redemption price received by the company					101.656%			103.625%	
Outstanding balance					4,127				
Date of redemption changes and write-off of other finance costs									
Date of redemption and redemption charges	74,382							70,255	
Term Loan A, Term Loan A-2 and Term Loan B amounts									
Date range									
Interest Rate Description									12 months 1 month

At December 31, 2011, the overall weighted average interest rate for the Term Loan A was determined based upon the LIBOR interest rates in effect for all of the individual tranches plus the interest rate margin. In January 2011, the Company entered into several interest rate swap agreements that had the economic effect of fixing all of the Term Loan A LIBOR variable component of the Company's interest rate as described below. At December 31, 2011, the Term Loan A-2 bears interest at LIBOR (floor of 1.00%) plus an interest rate margin of 3.50% subject to a ratings based step-down to 3.25%. At December 31, 2011, the Term Loan B bears interest at LIBOR (floor of 1.50%) plus a margin of 3.00% subject to a ratings based step-down to 2.75%. The Company is subject to these LIBOR-based floors until such time as the LIBOR-based component of the interest rate exceeds 1.00% on the Term Loan A-2 and 1.50% on the Term Loan B. At such time, the Company will then be subject to LIBOR-based interest rate volatility on the LIBOR variable component of its interest rate and the overall weighted average interest rate for the Term Loan A-2 and Term Loan B will then be determined based upon the LIBOR interest rates in effect for all individual tranches plus the interest rate margin.

Number of interest rate agreements									
Interest rate agreements								9	5
Notional amount								950,000	1,250,000
Fixed interest rate, before float	4.05%							1.50%	
Outstanding outstanding debt									483,000
Fixed Interest Rate, Three Lines	4.70%							1.64%	
Weighted average effective interest rate								4.11%	5.84%
Interest rate margin in effect	1.50%							2.50%	
Interest rate agreements								Sep. 30, 2014	Sep. 30, 2014
Outstanding balance								10,900	
Unamortized original facilities	350,000								
Weighted average effective interest rate	5.28%								
Overall weighted average effective interest rate	5.27%								
Interest expense	230,953	172,265	176,100						
Amortization of deferred financing costs	10,137	9,342	9,655						
Outstanding letters of credit									
Some items	\$ 0	\$ 0	\$ 0		\$ 0	\$ 0			32,297
	1,550,000	1,550,000			775,000	775,000			

**Segment Reporting -
Additional Information
(Detail) (USD \$)
In Thousands, unless
otherwise specified**

12 Months Ended

Dec. 31, 2011 Dec. 31, 2010 Dec. 31, 2009

Segment Reporting Information [Line Items]

Depreciation and amortization expense \$ 249,060 \$ 218,666 \$ 213,657

Dialysis and related lab services

Segment Reporting Information [Line Items]

Depreciation and amortization expense 259,685 227,029 221,317

Total amount of expenditures for property and equipment 425,228 271,559

Other-Ancillary services and strategic initiatives

Segment Reporting Information [Line Items]

Depreciation and amortization expense 6,943 6,701 7,079

Total amount of expenditures for property and equipment \$ 10,692 \$ 7,226

**DaVita Inc. stock-based
compensation and
shareholders' equity (Tables)**

**12 Months Ended
Dec. 31, 2011**

[Summary of the Status of Awards
Under Stock-Based Compensation
Plans and Agreements](#)

A combined summary of the status of awards under the Company's stock-based compensation plans, including base shares for stock-settled stock appreciation rights and shares subject to stock option and stock unit awards, is as follows:

	Year ended December 31, 2011				
	Stock appreciation rights and stock options			Stock units	
	Awards	Weighted average exercise price	Weighted average remaining contractual life	Awards	Weighted average remaining contractual life
Outstanding at beginning of year	11,013,487	\$51.94		501,564	
Granted	2,707,500	82.17		150,246	
Exercised	(3,032,329)	51.46		(78,106)	
Cancelled	(483,094)	59.59		(60,596)	
Outstanding at end of period	<u>10,205,564</u>	<u>\$59.74</u>	<u>2.6</u>	<u>513,108</u>	<u>1.5</u>
Awards exercisable at end of period	<u>4,348,803</u>	<u>\$50.62</u>	<u>1.7</u>	<u>3,446</u>	<u>0.6</u>
Weighted-average fair value of awards granted during 2011	<u>\$21.93</u>			<u>\$85.28</u>	
Weighted-average fair value of awards granted during 2010	<u>\$15.87</u>			<u>\$62.85</u>	
Weighted-average fair value of awards granted during 2009	<u>\$12.08</u>			<u>\$54.31</u>	

[Summary of Range of Exercise Prices](#)

<u>Range of exercise prices</u>	Awards outstanding	Weighted average	Awards exercisable	Weighted average
---------------------------------	--------------------	------------------	--------------------	------------------

		exercise		exercise	
		price		price	
\$ 0.00–\$ 0.01	513,108	\$—	3,446	\$—	
\$40.01–\$50.00	3,856,250	45.69	2,254,496	45.54	
\$50.01–\$60.00	1,868,878	52.43	1,453,292	52.47	
\$60.01–\$70.00	1,993,936	64.40	621,015	64.04	
\$70.01–\$80.00	397,500	74.20	20,000	72.52	
\$80.01–\$90.00	2,089,000	85.01	—	—	
Total	10,718,672	\$56.88	4,352,249	\$50.58	

Summary of the Weighted Average Valuation Inputs

A summary of the weighted average valuation inputs described above used for estimating the grant-date fair value of stock options and stock-settled stock appreciation rights granted in the periods indicated is as follows:

	Year ended December 31,					
	2011		2010		2009	
Expected term	4.2	years	3.5	years	3.5	years
Expected volatility	30	%	30	%	32	%
Expected dividend yield	0.0	%	0.0	%	0.0	%
Risk-free interest rate	1.6	%	1.7	%	1.8	%

Effects of Changes in DaVita Inc's Ownership Interest on Company's Equity

The effects of changes in DaVita Inc.'s ownership interest on the Company's equity are as follows:

	Year ended December 31, 2011	Year ended December 31, 2010	Year ended December 31, 2009
Net income attributable to DaVita Inc.	\$ 478,001	\$ 405,683	\$ 422,684
Decrease in paid-in capital for sales of noncontrolling interest in several joint ventures	(1,299)	(298)	(529)
Decrease in paid-in capital for the purchase of a noncontrolling interest in several joint ventures	(9,486)	(5,537)	(3,721)
Net transfer to noncontrolling interests	(10,785)	(5,835)	(4,250)
Change from net income attributable to DaVita Inc. and transfers to noncontrolling interests	<u>\$ 467,216</u>	<u>\$ 399,848</u>	<u>\$ 418,434</u>

Consolidating financial statements

**12 Months Ended
Dec. 31, 2011**

[Consolidating financial statements](#)

27. Consolidating financial statements

The following information is presented in accordance with Rule 3-10 of Regulation S-X. The operating and investing activities of the separate legal entities included in the Company's consolidated financial statements are fully interdependent and integrated. Revenues and operating expenses of the separate legal entities include intercompany charges for management and other services. The senior notes were issued by the Company on October 20, 2010 and are guaranteed by substantially all of its direct and indirect domestic wholly-owned subsidiaries. Each of the guarantor subsidiaries has guaranteed the notes on a joint and several basis. However, the guarantor subsidiaries can be released from their obligations in the event of a sale or other disposition of all or substantially all of the assets of such subsidiary, if such subsidiary guarantor is designated as an unrestricted subsidiary or otherwise ceases to be a restricted subsidiary, and if such subsidiary guarantor no longer guaranties any other indebtedness of the Company. Non-wholly-owned subsidiaries, certain wholly-owned subsidiaries, foreign subsidiaries, joint ventures, partnerships and third parties are not guarantors of these obligations.

Consolidating Statements of Income

	<u>DaVita Inc.</u>	<u>Guarantor Subsidiaries</u>	<u>Non- Guarantor Subsidiaries</u>	<u>Consolidating Adjustments</u>	<u>Consolidated Total</u>
For the year ended December 31, 2011					
Net operating revenues	\$457,460	\$5,527,588	\$1,541,618	\$(544,452)	\$6,982,214
Operating expenses	301,255	4,827,005	1,267,624	(544,452)	5,851,432
Operating income	156,205	700,583	273,994	—	1,130,782
Debt (expense)	(242,730)	(218,182)	(9,215)	229,037	(241,090)
Other income, net	229,658	1,583	778	(229,037)	2,982
Income tax expense	56,681	248,139	10,924	—	315,744
Equity earnings in subsidiaries	391,549	184,404	—	(575,953)	—
Income from continuing operations	478,001	420,249	254,633	(575,953)	576,930
Discontinued operations net of (loss) gain on disposal of discontinued operations	—	(4,191)	656	—	(3,535)
Net income	478,001	416,058	255,289	(575,953)	573,395
Less: Net income attributable to noncontrolling interests	—	—	—	(95,394)	(95,394)
Net income attributable to DaVita Inc.	<u>\$478,001</u>	<u>\$416,058</u>	<u>\$255,289</u>	<u>\$(671,347)</u>	<u>\$478,001</u>
For the year ended December 31, 2010					
Net operating revenues	\$431,780	\$5,195,449	\$1,288,259	\$(477,438)	\$6,438,050
Operating expenses	259,302	4,615,716	1,043,910	(477,438)	5,441,490
Operating income	172,478	579,733	244,349	—	996,560
Debt (expense)	(257,243)	(163,034)	(1,277)	165,565	(255,989)
Other income, net	165,934	1,837	1,213	(165,565)	3,419

Income tax expense	31,656	220,867	7,529	—	260,052
Equity earnings in subsidiaries	<u>356,170</u>	<u>157,278</u>	<u>—</u>	<u>(513,448)</u>	<u>—</u>
Income from continuing operations	405,683	354,947	236,756	(513,448)	483,938
Income from operations of discontinued operations net of tax	<u>—</u>	<u>172</u>	<u>109</u>	<u>—</u>	<u>281</u>
Net income	405,683	355,119	236,865	(513,448)	484,219
Less: Net income attributable to noncontrolling interests	<u>—</u>	<u>—</u>	<u>—</u>	<u>(78,536)</u>	<u>(78,536)</u>
Net income attributable to DaVita Inc.	<u>\$405,683</u>	<u>\$355,119</u>	<u>\$236,865</u>	<u>\$(591,984)</u>	<u>\$405,683</u>
For the year ended December 31, 2009					
Net operating revenues	\$401,058	\$5,005,839	\$1,147,394	\$(453,643)	\$6,100,648
Operating expenses	<u>246,578</u>	<u>4,375,032</u>	<u>993,053</u>	<u>(453,643)</u>	<u>5,161,020</u>
Operating income	154,480	630,807	154,341	—	939,628
Debt (expense)	(188,109)	(181,853)	(1,721)	185,928	(185,755)
Other income, net	186,189	2,718	727	(185,928)	3,706
Income tax expense	60,414	218,618	(819)	—	278,213
Equity earnings in subsidiaries	<u>330,538</u>	<u>94,964</u>	<u>—</u>	<u>(425,502)</u>	<u>—</u>
Income from continuing operations	422,684	328,018	154,166	(425,502)	479,366
Income from operations of discontinued operations net of tax	<u>—</u>	<u>180</u>	<u>213</u>	<u>—</u>	<u>393</u>
Net income	422,684	328,198	154,379	(425,502)	479,759
Less: Net income attributable to noncontrolling interests	<u>—</u>	<u>—</u>	<u>—</u>	<u>(57,075)</u>	<u>(57,075)</u>
Net income attributable to DaVita Inc.	<u>\$422,684</u>	<u>\$328,198</u>	<u>\$154,379</u>	<u>\$(482,577)</u>	<u>\$422,684</u>

Consolidating Balance Sheets

	<u>DaVita Inc.</u>	<u>Guarantor Subsidiaries</u>	<u>Non-Guarantor Subsidiaries</u>	<u>Consolidating Adjustments</u>	<u>Consolidated Total</u>
As of December 31, 2011					
Cash and cash equivalents	\$365,276	\$—	\$28,476	\$—	\$393,752
Accounts receivable, net	—	926,041	269,122	—	1,195,163
Other current assets	<u>14,665</u>	<u>598,721</u>	<u>79,307</u>	<u>—</u>	<u>692,693</u>
Total current assets	379,941	1,524,762	376,905	—	2,281,608
Property and equipment, net	78,038	971,867	382,746	—	1,432,651
Amortizable intangible assets, net	53,276	95,900	10,315	—	159,491
Investments in subsidiaries	6,696,039	1,089,920	—	(7,785,959)	—
Intercompany receivables	—	472,200	253,447	(725,647)	—

Other long-term assets and investments	11,388	56,134	3,924	—	71,446
Goodwill	—	3,903,542	1,043,434	—	4,946,976
Total assets	<u>\$7,218,682</u>	<u>\$8,114,325</u>	<u>\$2,070,771</u>	<u>\$(8,511,606)</u>	<u>\$8,892,172</u>
Current liabilities	\$148,994	\$889,172	\$114,950	\$—	\$1,153,116
Intercompany payables	271,890	—	453,757	(725,647)	—
Long-term debt and other long-term liabilities	4,351,346	585,675	55,694	—	4,992,715
Noncontrolling interests subject to put provisions	305,377	—	—	172,839	478,216
Total DaVita Inc. shareholders' equity	2,141,075	6,639,478	1,146,481	(7,785,959)	2,141,075
Noncontrolling interest not subject to put provisions	—	—	299,889	(172,839)	127,050
Total equity	<u>2,141,075</u>	<u>6,639,478</u>	<u>1,446,370</u>	<u>(7,958,798)</u>	<u>2,268,125</u>
Total liabilities and equity	<u>\$7,218,682</u>	<u>\$8,114,325</u>	<u>\$2,070,771</u>	<u>\$(8,511,606)</u>	<u>\$8,892,172</u>
As of December 31, 2010					
Cash and cash equivalents	\$856,803	\$—	\$3,314	\$—	\$860,117
Accounts receivable, net	—	895,955	153,021	—	1,048,976
Other current assets	11,231	653,670	48,860	—	713,761
Total current assets	868,034	1,549,625	205,195	—	2,622,854
Property and equipment, net	30,409	888,927	251,472	—	1,170,808
Amortizable intangible assets, net	58,967	98,795	4,873	—	162,635
Investments in subsidiaries	6,154,398	555,579	—	(6,709,977)	—
Intercompany receivables	—	516,286	208,030	(724,316)	—
Other long-term assets and investments	8,951	56,996	873	—	66,820
Goodwill	—	3,731,983	359,324	—	4,091,307
Total assets	<u>\$7,120,759</u>	<u>\$7,398,191</u>	<u>\$1,029,767</u>	<u>\$(7,434,293)</u>	<u>\$8,114,424</u>
Current liabilities	\$61,384	\$786,114	\$76,847	\$—	\$924,345
Intercompany payables	611,919	—	112,397	(724,316)	—
Long-term debt and other long-term liabilities	4,210,703	539,620	19,570	—	4,769,893
Noncontrolling interests subject to put provisions	258,331	—	—	124,721	383,052
Total DaVita Inc. shareholders' equity	1,978,422	6,072,457	637,520	(6,709,977)	1,978,422
Noncontrolling interest not subject to put provisions	—	—	183,433	(124,721)	58,712
Total equity	<u>1,978,422</u>	<u>6,072,457</u>	<u>820,953</u>	<u>(6,834,698)</u>	<u>2,037,134</u>

Total liabilities and equity	<u>\$7,120,759</u>	<u>\$7,398,191</u>	<u>\$1,029,767</u>	<u>\$(7,434,293)</u>	<u>\$8,114,424</u>
------------------------------	--------------------	--------------------	--------------------	----------------------	--------------------

Consolidating Statements of Cash Flows

	DaVita Inc.	Guarantor Subsidiaries	Non-Guarantor Subsidiaries	Consolidating Adjustments	Consolidated Total
For the year ended December 31, 2011					
Cash flows from operating activities:					
Net income.	\$478,001	\$416,058	\$255,289	\$(575,953)	\$573,395
Changes in operating assets and liabilities and non cash items included in net income	(268,798)	325,807	(26,311)	575,953	606,651
Net cash provided by operating activities	<u>209,203</u>	<u>741,865</u>	<u>228,978</u>	<u>—</u>	<u>1,180,046</u>
Cash flows from investing activities:					
Additions of property and equipment, net	(52,653)	(232,540)	(114,963)	—	(400,156)
Acquisitions	—	(1,048,136)	(29,306)	—	(1,077,442)
Proceeds from asset sales	—	75,183	—	—	75,183
Proceeds from investment sales and other items	(6,077)	9,264	—	—	3,187
Net cash used in by investing activities	<u>(58,730)</u>	<u>(1,196,229)</u>	<u>(144,269)</u>	<u>—</u>	<u>(1,399,228)</u>
Cash flows from financing activities:					
Long-term debt and related financing costs, net	113,762	(1,896)	15,794	—	127,660
Intercompany borrowing	(464,564)	460,262	4,302	—	—
Other items	(291,198)	(4,002)	(79,643)	—	(374,843)
Net cash (used in) provided by financing activities	<u>(642,000)</u>	<u>454,364</u>	<u>(59,547)</u>	<u>—</u>	<u>(247,183)</u>
Net (decrease) increase in cash and cash equivalents	(491,527)	—	25,162	—	(466,365)
Cash and cash equivalents at beginning of the year	<u>856,803</u>	<u>—</u>	<u>3,314</u>	<u>—</u>	<u>860,117</u>
Cash and cash equivalents at the end of the year	<u>\$365,276</u>	<u>\$—</u>	<u>\$28,476</u>	<u>\$—</u>	<u>\$393,752</u>
For the year ended December 31, 2010					
Cash flows from operating activities:					
Net income.	\$405,683	\$355,119	\$236,865	\$(513,448)	\$484,219

Changes in operating assets and liabilities and non cash items included in net income	(319,090)	136,348	24,758	513,448	355,464
Net cash provided by operating activities	86,593	491,467	261,623	—	839,683
Cash flows from investing activities:					
Additions of property and equipment, net	(24,118)	(199,147)	(50,337)	—	(273,602)
Acquisitions	—	(188,502)	—	—	(188,502)
Proceeds from asset sales	—	22,727	—	—	22,727
Proceeds from investment sales and other items	(470)	3,214	—	—	2,744
Net cash used in investing activities	(24,588)	(361,708)	(50,337)	—	(436,633)
Cash flows from financing activities:					
Long-term debt and related financing costs, net	563,350	1,987	(4,391)	—	560,946
Intercompany borrowing	255,351	(121,887)	(133,464)	—	—
Other items	(558,453)	(9,859)	(75,026)	—	(643,338)
Net cash provided by (used in) financing activities	260,248	(129,759)	(212,881)	—	(82,392)
Net increase (decrease) in cash and cash equivalents	322,253	—	(1,595)	—	320,658
Cash and cash equivalents at beginning of the year	534,550	—	4,909	—	539,459
Cash and cash equivalents at the end of the year	<u>\$856,803</u>	<u>\$—</u>	<u>\$3,314</u>	<u>\$—</u>	<u>\$860,117</u>
For the year ended December 31, 2009					
Cash flows from operating activities:					
Net income.	\$422,684	\$328,198	\$154,379	\$(425,502)	\$479,759
Changes in operating assets and liabilities and non cash items included in net income	(257,591)	(58,813)	77,853	425,502	186,951
Net cash provided by operating activities	165,093	269,385	232,232	—	666,710
Cash flows from investing activities:					
Additions of property and equipment, net	(1,748)	(207,738)	(65,119)	—	(274,605)
Acquisitions	—	(87,617)	—	—	(87,617)
Proceeds from asset sales	—	7,697	—	—	7,697
Proceeds from investment sales and other items	11,631	(3,166)	—	—	8,465
Net cash provided by (used in) investing activities	9,883	(290,824)	(65,119)	—	(346,060)

Cash flows from financing activities:					
Long-term debt	(60,619)	(1,962)	1,307	—	(61,274)
Intercompany borrowing	101,254	20,885	(122,139)	—	—
Other items	(78,637)	2,516	(54,677)	—	(130,798)
Net cash (used in) provided by financing activities	<u>(38,002)</u>	<u>21,439</u>	<u>(175,509)</u>	<u>—</u>	<u>(192,072)</u>
Net increase (decrease) in cash and cash equivalents	136,974	—	(8,396)	—	128,578
Cash and cash equivalents at beginning of the year	<u>397,576</u>	<u>—</u>	<u>13,305</u>	<u>—</u>	<u>410,881</u>
Cash and cash equivalents at the end of the year	<u>\$534,550</u>	<u>\$—</u>	<u>\$4,909</u>	<u>\$—</u>	<u>\$539,459</u>

Derivative Instruments
(Detail) (USD \$)
In Thousands, unless
otherwise specified

Dec. 31, 2011

Interest rate swap agreements | Other long-term liabilities

[Derivative \[Line Items\]](#)

[Interest rate swap agreements](#)

\$ 23,145

Interest rate cap | Other long-term assets

[Derivative \[Line Items\]](#)

[Interest rate cap agreements](#)

\$ 1,381

**Allocation of Income Tax
Expense (Detail) (USD \$)
In Thousands, unless
otherwise specified**

12 Months Ended

	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
<u>Income Taxes [Line Items]</u>			
<u>Continuing operations</u>	\$ 315,744	\$ 260,052	\$ 278,213
<u>Discontinued operations</u>	675	187	252
<u>Loss on discontinued operations</u>	(693)		
<u>Income Tax Expense (Benefit), Continuing Operations and Discontinued Operations, Total</u>	\$ 315,726	\$ 260,239	\$ 278,465

**Charges and Credits to
Other Comprehensive
Income (Detail) (USD \$)
In Thousands, unless
otherwise specified**

12 Months Ended

	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
<u>Before tax amount</u>			
<u>Unrealized losses on interest rate swap and cap agreements</u>	\$ (47,544)	\$ (217)	\$ (4,220)
<u>Less reclassification of net swap and cap agreements realized losses into net income</u>	15,911	9,093	17,253
<u>Net swap activity</u>	(31,633)	8,876	13,033
<u>Unrealized gains (losses) on investments</u>	(986)	1,007	1,614
<u>Less reclassification of net investment realized losses (gains) into net income</u>	(93)	22	(261)
<u>Net investment activity</u>	(1,079)	1,029	1,353
<u>Total</u>	(32,712)	9,905	14,386
<u>Tax (expense) benefit</u>			
<u>Unrealized losses on interest rate swap and cap agreements</u>	18,495	83	1,642
<u>Less reclassification of net swap and cap agreements realized losses into net income</u>	(6,190)	(3,536)	(6,711)
<u>Net swap activity</u>	12,305	(3,453)	(5,069)
<u>Unrealized gains (losses) on investments</u>	384	(392)	(628)
<u>Less reclassification of net investment realized losses (gains) into net income</u>	36	(9)	102
<u>Net investment activity</u>	420	(401)	(526)
<u>Total</u>	12,725	(3,854)	(5,595)
<u>Net-of-tax amount</u>			
<u>Unrealized losses on interest rate swap and cap agreements</u>	(29,049)	(134)	(2,578)
<u>Less reclassification of net swap and cap agreements realized losses into net income</u>	9,721	5,557	10,542
<u>Net swap activity</u>	(19,328)	5,423	7,964
<u>Unrealized gains (losses) on investments</u>	(602)	615	986
<u>Less reclassification of net investment realized gains into net income</u>	(57)	13	(159)
<u>Net investment activity</u>	(659)	628	827
<u>Total</u>	\$ (19,987)	\$ 6,051	\$ 8,791

Other Receivables (Detail)
(USD \$)

**In Thousands, unless
otherwise specified**

Dec. 31, 2011 Dec. 31, 2010

[Accounts, Notes, Loans and Financing Receivable \[Line Items\]](#)

[Other receivables](#)

\$ 269,832 \$ 304,366

Supplier rebates and other non-trade receivables

[Accounts, Notes, Loans and Financing Receivable \[Line Items\]](#)

[Other receivables](#)

195,426 238,156

Medicare bad debt claims

[Accounts, Notes, Loans and Financing Receivable \[Line Items\]](#)

[Other receivables](#)

57,232 46,250

Operating advances under management and administrative services agreements

[Accounts, Notes, Loans and Financing Receivable \[Line Items\]](#)

[Other receivables](#)

\$ 17,174 \$ 19,960

**Consolidating Balance
Sheets (Detail) (USD \$)
In Thousands, unless
otherwise specified**

**Dec. 31,
2011** **Dec. 31,
2010** **Dec. 31,
2009** **Dec. 31,
2008**

**Condensed Financial Statements, Captions [Line
Items]**

<u>Cash and cash equivalents</u>	\$ 393,752	\$ 860,117	\$ 539,459	\$ 410,881
<u>Accounts receivable, net</u>	1,195,163	1,048,976		
<u>Other current assets</u>	692,693	713,761		
<u>Total current assets</u>	2,281,608	2,622,854		
<u>Property and equipment, net</u>	1,432,651	1,170,808		
<u>Amortizable intangible assets, net</u>	159,491	162,635		
<u>Other long-term assets and investments</u>	71,446	66,820		
<u>Goodwill</u>	4,946,976	4,091,307	3,951,196	
<u>Total assets</u>	8,892,172	8,114,424		
<u>Current liabilities</u>	1,153,116	924,345		
<u>Long-term debt and other long-term liabilities</u>	4,992,715	4,769,893		
<u>Noncontrolling interests subject to put provisions</u>	478,216	383,052		
<u>Total DaVita Inc. shareholders' equity</u>	2,141,075	1,978,422		
<u>Noncontrolling interest not subject to put provisions</u>	127,050	58,712		
<u>Total equity</u>	2,268,125	2,037,134		
<u>Total liabilities and equity</u>	8,892,172	8,114,424		

DaVita Inc.

**Condensed Financial Statements, Captions [Line
Items]**

<u>Cash and cash equivalents</u>	365,276	856,803	534,550	397,576
<u>Other current assets</u>	14,665	11,231		
<u>Total current assets</u>	379,941	868,034		
<u>Property and equipment, net</u>	78,038	30,409		
<u>Amortizable intangible assets, net</u>	53,276	58,967		
<u>Investments in subsidiaries</u>	6,696,039	6,154,398		
<u>Other long-term assets and investments</u>	11,388	8,951		
<u>Total assets</u>	7,218,682	7,120,759		
<u>Current liabilities</u>	148,994	61,384		
<u>Intercompany payables</u>	271,890	611,919		
<u>Long-term debt and other long-term liabilities</u>	4,351,346	4,210,703		
<u>Noncontrolling interests subject to put provisions</u>	305,377	258,331		
<u>Total DaVita Inc. shareholders' equity</u>	2,141,075	1,978,422		
<u>Total equity</u>	2,141,075	1,978,422		
<u>Total liabilities and equity</u>	7,218,682	7,120,759		

Guarantor Subsidiaries

**Condensed Financial Statements, Captions [Line
Items]**

<u>Accounts receivable, net</u>	926,041	895,955		
---------------------------------	---------	---------	--	--

<u>Other current assets</u>	598,721	653,670
<u>Total current assets</u>	1,524,762	1,549,625
<u>Property and equipment, net</u>	971,867	888,927
<u>Amortizable intangible assets, net</u>	95,900	98,795
<u>Investments in subsidiaries</u>	1,089,920	555,579
<u>Intercompany receivables</u>	472,200	516,286
<u>Other long-term assets and investments</u>	56,134	56,996
<u>Goodwill</u>	3,903,542	3,731,983
<u>Total assets</u>	8,114,325	7,398,191
<u>Current liabilities</u>	889,172	786,114
<u>Long-term debt and other long-term liabilities</u>	585,675	539,620
<u>Total DaVita Inc. shareholders' equity</u>	6,639,478	6,072,457
<u>Total equity</u>	6,639,478	6,072,457
<u>Total liabilities and equity</u>	8,114,325	7,398,191

Non-Guarantor Subsidiaries

Condensed Financial Statements, Captions [Line Items]

<u>Cash and cash equivalents</u>	28,476	3,314	4,909	13,305
<u>Accounts receivable, net</u>	269,122	153,021		
<u>Other current assets</u>	79,307	48,860		
<u>Total current assets</u>	376,905	205,195		
<u>Property and equipment, net</u>	382,746	251,472		
<u>Amortizable intangible assets, net</u>	10,315	4,873		
<u>Intercompany receivables</u>	253,447	208,030		
<u>Other long-term assets and investments</u>	3,924	873		
<u>Goodwill</u>	1,043,434	359,324		
<u>Total assets</u>	2,070,771	1,029,767		
<u>Current liabilities</u>	114,950	76,847		
<u>Intercompany payables</u>	453,757	112,397		
<u>Long-term debt and other long-term liabilities</u>	55,694	19,570		
<u>Total DaVita Inc. shareholders' equity</u>	1,146,481	637,520		
<u>Noncontrolling interest not subject to put provisions</u>	299,889	183,433		
<u>Total equity</u>	1,446,370	820,953		
<u>Total liabilities and equity</u>	2,070,771	1,029,767		

Consolidating Adjustments

Condensed Financial Statements, Captions [Line Items]

<u>Investments in subsidiaries</u>	(7,785,959)	(6,709,977)
<u>Intercompany receivables</u>	(725,647)	(724,316)
<u>Total assets</u>	(8,511,606)	(7,434,293)
<u>Intercompany payables</u>	(725,647)	(724,316)
<u>Noncontrolling interests subject to put provisions</u>	172,839	124,721
<u>Total DaVita Inc. shareholders' equity</u>	(7,785,959)	(6,709,977)
<u>Noncontrolling interest not subject to put provisions</u>	(172,839)	(124,721)

<u>Total equity</u>	(7,958,798)	(6,834,698)
<u>Total liabilities and equity</u>	\$ (8,511,606)	\$ (7,434,293)

Long Term Debt (Detail)
(USD \$)
In Thousands, unless
otherwise specified

Dec. 31, 2011 Dec. 31, 2010

Debt Instrument [Line Items]

<u>Senior notes</u>	\$ 1,550,000	\$ 1,550,000
<u>Acquisition obligations and other notes payable</u>	37,447	9,049
<u>Capital lease obligations</u>	43,364	8,074
<u>Total principal debt outstanding</u>	4,512,811	4,317,123
<u>Discount on long-term debt</u>	(7,842)	(8,381)
<u>Long-term Debt, Total</u>	4,504,969	4,308,742
<u>Less current portion</u>	(87,345)	(74,892)
<u>Long-term debt</u>	4,417,624	4,233,850

Term Loan A

Debt Instrument [Line Items]

<u>Senior Secured Credit Facilities</u>	950,000	1,000,000
---	---------	-----------

Term Loan A-2

Debt Instrument [Line Items]

<u>Senior Secured Credit Facilities</u>	199,500	
---	---------	--

Term Loan B

Debt Instrument [Line Items]

<u>Senior Secured Credit Facilities</u>	\$ 1,732,500	\$ 1,750,000
---	--------------	--------------

**Summary of Range of
Exercise Prices (Detail)
(USD \$)**

**12 Months
Ended
Dec. 31, 2011**

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

<u>Awards outstanding</u>	10,718,672
<u>Weighted average exercise price</u>	\$ 56.88
<u>Awards exercisable</u>	4,352,249
<u>Weighted average exercise price</u>	\$ 50.58

Range 1

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

<u>Range of exercise prices, lower range</u>	\$ 0.00
<u>Range of exercise prices, upper range</u>	\$ 0.01
<u>Awards outstanding</u>	513,108
<u>Awards exercisable</u>	3,446

Range 2

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

<u>Range of exercise prices, lower range</u>	\$ 40.01
<u>Range of exercise prices, upper range</u>	\$ 50.00
<u>Awards outstanding</u>	3,856,250
<u>Weighted average exercise price</u>	\$ 45.69
<u>Awards exercisable</u>	2,254,496
<u>Weighted average exercise price</u>	\$ 45.54

Range 3

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

<u>Range of exercise prices, lower range</u>	\$ 50.01
<u>Range of exercise prices, upper range</u>	\$ 60.00
<u>Awards outstanding</u>	1,868,878
<u>Weighted average exercise price</u>	\$ 52.43
<u>Awards exercisable</u>	1,453,292
<u>Weighted average exercise price</u>	\$ 52.47

Range 4

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

<u>Range of exercise prices, lower range</u>	\$ 60.01
<u>Range of exercise prices, upper range</u>	\$ 70.00
<u>Awards outstanding</u>	1,993,936
<u>Weighted average exercise price</u>	\$ 64.40
<u>Awards exercisable</u>	621,015
<u>Weighted average exercise price</u>	\$ 64.04

Range 5

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price

Range [Line Items]

<u>Range of exercise prices, lower range</u>	\$ 70.01
<u>Range of exercise prices, upper range</u>	\$ 80.00
<u>Awards outstanding</u>	397,500
<u>Weighted average exercise price</u>	\$ 74.20
<u>Awards exercisable</u>	20,000
<u>Weighted average exercise price</u>	\$ 72.52

Range 6

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price

Range [Line Items]

<u>Range of exercise prices, lower range</u>	\$ 80.01
<u>Range of exercise prices, upper range</u>	\$ 90.00
<u>Awards outstanding</u>	2,089,000
<u>Weighted average exercise price</u>	\$ 85.01

**Leases - Additional
Information (Detail) (USD \$)
In Thousands, unless
otherwise specified**

12 Months Ended
Dec. 31, **Dec. 31,** **Dec. 31,**
2011 **2010** **2009**
Year

Leases Disclosure [Line Items]

<u>Facilities leased under non-cancellable operating leases term range, minimum</u>	5		
<u>Facilities leased under non-cancellable operating leases term range, maximum</u>	15		
<u>Facilities leased under non-cancellable operating leases renewal option range, minimum</u>	5		
<u>Facilities leased under non-cancellable operating leases renewal option range, maximum</u>	10		
<u>Rent expense under all operating leases</u>	\$ 296,051	\$ 266,849	\$ 248,154
<u>Net book value of property and equipment under capital leases</u>	\$ 41,514	\$ 7,579	

**Summary of the Weighted
Average Valuation Inputs
(Detail) (Stock Options And
Stock Appreciation Rights)**

12 Months Ended
Dec. 31, Dec. 31, Dec. 31,
2011 2010 2009
Year Year Year

Stock Options And Stock Appreciation Rights

**Share-based Compensation Arrangement by Share-based Payment
Award [Line Items]**

<u>Expected term</u>	4.2	3.5	3.5
<u>Expected volatility</u>	30.00%	30.00%	32.00%
<u>Expected dividend yield</u>	0.00%	0.00%	0.00%
<u>Risk-free interest rate</u>	1.60%	1.70%	1.80%

**Scheduled Maturities of
Long-term Debt (Detail)**

(USD \$)

Dec. 31, 2011

**In Thousands, unless
otherwise specified**

Debt Instrument [Line Items]

<u>2012</u>	\$ 87,345
<u>2013</u>	125,106
<u>2014</u>	176,910
<u>2015</u>	676,293
<u>2016</u>	1,858,567
<u>Thereafter</u>	\$ 1,588,590

Income Taxes - Additional Information (Detail) (USD \$) In Thousands, unless otherwise specified	12 Months Ended	
	Dec. 31, 2011	Dec. 31, 2010
<u>Income Taxes [Line Items]</u>		
<u>Total unrecognized tax benefits that would affect effective tax rate, if recognized</u>	\$ 8,943	
<u>Accrued interest and penalties related to unrecognized tax benefits, net of federal tax benefits</u>	3,420	3,177
<u>Decrease in valuation allowance related to changes in the estimated tax benefit of federal and state operating losses of separate-return entities</u>	4,644	
Federal		
<u>Income Taxes [Line Items]</u>		
<u>Net operating loss carryforwards</u>	288,604	
<u>Net operating loss carryforwards, expiration date</u>	Expire through 2031	
Federal Maximum		
<u>Income Taxes [Line Items]</u>		
<u>Net operating loss carryforwards, expiration year</u>	2031	
State		
<u>Income Taxes [Line Items]</u>		
<u>Net operating loss carryforwards</u>	\$ 390,774	
<u>Net operating loss carryforwards, expiration date</u>	Expire through 2031	
State Maximum		
<u>Income Taxes [Line Items]</u>		
<u>Net operating loss carryforwards, expiration year</u>	2031	

Acquisitions

12 Months Ended Dec. 31, 2011

[Acquisitions](#)

19. Acquisitions

During 2011, 2010, and 2009, the Company acquired total dialysis and other businesses as follows:

	Year ended December 31,		
	2011	2010	2009
Cash paid, net of cash acquired	\$1,077,442	\$188,502	\$87,617
Deferred purchase price and other acquisition obligations	19,010	449	338
Aggregate purchase cost	<u>\$1,096,452</u>	<u>\$188,951</u>	<u>\$87,955</u>
Number of chronic dialysis centers acquired	<u>178</u>	<u>41</u>	<u>19</u>

The assets and liabilities for all acquisitions were recorded at their estimated fair values at the dates of the acquisitions and are included in the Company's financial statements and operating results from the effective dates of the acquisitions.

Acquisition of DSI Renal Inc.

On September 2, 2011, the Company completed its acquisition of all of the outstanding common stock of CDSI I Holding Company, Inc., the parent company of dialysis provider DSI Renal Inc. (DSI), pursuant to an agreement and plan of merger for approximately \$723,012 in net cash, plus the assumption of certain liabilities totaling approximately \$6,541, subject to certain post-closing adjustments. DSI had 113 outpatient dialysis centers that provide services to approximately 8,000 patients in 23 states. The Company also incurred approximately \$21,700 in transaction and integration costs during 2011 associated with this acquisition that are included in general and administrative expenses in the consolidated statements of income.

The initial purchase price allocation for the DSI acquisition is recorded at estimated fair values based upon the best information available to management and will be finalized when certain information arranged to be obtained has been received. In particular, certain income tax amounts are pending issuance of the final tax returns.

The following table summarizes the assets acquired and liabilities assumed in the transaction and recognized at the acquisition date at their estimated fair values, as well as the estimated fair value of the noncontrolling interests in DSI at that date:

Current assets	\$ 164,227
Property and equipment	67,080
Amortizable intangible and other long-term assets	6,523
Goodwill	500,662
Long-term deferred income taxes	79,420
Current liabilities assumed	(54,046)
Other long-term liabilities	(11,213)
Noncontrolling interests	(23,100)
	<u>\$729,553</u>

Amortizable intangible assets acquired in this acquisition had weighted average estimated useful lives of nine years.

Of the goodwill recognized in this acquisition, approximately \$262,000 is expected to be deductible for tax purposes over the next 15 years.

The noncontrolling interests acquired as part of the acquisition are stated at fair value based upon a third-party appraisal that was informed by implied multiples used in conjunction with the acquisition of the DSI group, as well as the Company's overall experience and contractual multiples typical for such arrangements.

The operating results of DSI are included in the Company's consolidated financial statements effective September 1, 2011.

Other acquisitions

During 2011, the Company acquired other dialysis related and other ancillary businesses consisting of 57 dialysis centers in the U.S., eight dialysis centers outside of the U.S. and one vascular access center for a total of \$354,430 in net cash and deferred purchase price of \$12,469. During 2010 and 2009, the Company acquired other dialysis businesses consisting of 41 centers and 19 centers for a total of \$188,951 and \$87,955, respectively, in cash and deferred purchase price obligations. The assets and liabilities for all acquisitions were recorded at their estimated fair market values at the dates of the acquisitions and are included in the Company's financial statements and operating results from the effective dates of the acquisitions.

The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values, as well as the estimated fair value of the noncontrolling interests assumed in these transactions:

	<u>Year ended December 31,</u>		
	<u>2011</u>	<u>2010</u>	<u>2009</u>
Tangible assets, principally leasehold improvements and equipment	\$32,649	\$21,257	\$11,140
Amortizable intangible assets	19,804	18,300	6,703
Goodwill	388,844	152,252	78,199
Noncontrolling interests assumed	(70,821)	(1,171)	(7,567)
Liabilities assumed	<u>(3,577)</u>	<u>(1,687)</u>	<u>(520)</u>
Aggregate purchase cost	<u>\$366,899</u>	<u>\$188,951</u>	<u>\$87,955</u>

Amortizable intangible assets acquired during 2011, 2010 and 2009 had weighted-average estimated useful lives of nine, nine and seven years, respectively. In 2011, 2010 and 2009, \$352,674, \$152,252 and \$78,199 of goodwill was associated with the dialysis and related lab services business. In addition, in 2011 \$36,170 of goodwill was associated with the other ancillary services and strategic initiatives. The total amount of goodwill deductible for tax purposes associated with these acquisitions for 2011, 2010, and 2009 was approximately \$298,000, \$154,000 and \$72,000, respectively.

Discontinued operations

Pursuant to a consent order issued by the Federal Trade Commission on September 2, 2011, the Company agreed to divest a total of 30 outpatient dialysis centers and several home-based

dialysis programs in order to complete the acquisition of DSI. In conjunction with the consent order, on September 30, 2011, the Company completed the sale of 28 outpatient dialysis centers to Dialysis Newco, Inc. (Dialysis Newco), a portfolio company of Frazier Healthcare VI, L.P. and New Enterprise Associates 13, Limited Partnership pursuant to an asset purchase agreement dated August 26, 2011. Effective October 31, 2011, the Company also completed the sale of two additional outpatient dialysis centers to Dialysis Newco that were previously pending state regulatory approval. The Company anticipates receiving total net cash consideration of approximately \$82,000 for all of the outpatient dialysis centers that were divested. As part of this transaction, Dialysis Newco assumed specific liabilities related to the centers it acquired. All other liabilities were retained by the Company. The Company recorded a loss of approximately \$4,756, net of tax, during the year ended December 31, 2011 related to the divestiture of its historical DaVita centers.

The operating results of the historical DaVita divested centers are reflected as discontinued operations for all periods presented. In addition, the operating results of the DSI divested centers are reflected as discontinued operations in the consolidated financial statements beginning September 1, 2011.

The results from discontinued operations related to the dialysis and related lab services segment were as follows:

	<u>Year ended December 31,</u>		
	<u>2011</u>	<u>2010</u>	<u>2009</u>
Net operating revenues	\$16,648	\$9,341	\$8,152
Income before income taxes	1,896	468	645
Income tax expense	675	187	252
Income from discontinued operations	<u>\$1,221</u>	<u>\$281</u>	<u>\$393</u>

Net assets of discontinued operations related to the dialysis and related lab services segment as of September 30, 2011, were as follows:

Current assets	\$ 71,384
Property and equipment, net	5,183
Goodwill	7,999
Liabilities and noncontrolling interests	(836)
Net assets from discontinued operations	<u>\$83,730</u>

Pro forma financial information

The following summary, prepared on a pro forma basis, combines the results of operations as if all acquisitions and divestitures in 2011 and 2010 had been consummated as of the beginning of 2010, after including the impact of certain adjustments such as amortization of intangibles, interest expense on acquisition financing and income tax effects.

	<u>Year ended December 31,</u>	
	<u>2011</u>	<u>2010</u>
	(unaudited)	
Pro forma net revenues	\$7,309,901	\$6,983,641
Pro forma net income attributable to DaVita Inc.	520,625	471,635

Pro forma income from continuing operations attributable to		
DaVita Inc.	524,379	471,354
Pro forma basic net income per share attributable to DaVita Inc.	5.50	4.65
Pro forma diluted net income per share attributable to DaVita Inc.	5.39	4.58

Segment reporting (Tables)

[Summary of Segment Revenues, Segment Operating Income Loss and a Reconciliation of Segment Income to Consolidated Income Before Income Taxes](#)

12 Months Ended Dec. 31, 2011

The following is a summary of segment revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income before income taxes:

	Year ended December 31,		
	2011	2010	2009
Segment revenues:			
Dialysis and related lab services (1)			
External sources	\$6,473,829	\$6,054,252	\$5,766,795
Intersegment revenues	11,141	9,300	16,782
Total dialysis and related lab services	6,484,970	6,063,552	5,783,577
Other – Ancillary services and strategic initiatives			
External sources (2)	\$508,385	\$383,798	\$333,853
Intersegment revenues	5,796	—	—
Total ancillary services and strategic initiatives	514,181	383,798	333,853
Total segment revenues	6,999,151	6,447,350	6,117,430
Elimination of intersegment revenues	(16,937)	(9,300)	(16,782)
Consolidated revenues	\$6,982,214	\$6,438,050	\$6,100,648
Segment operating margin (loss): (3)			
Dialysis and related lab services	\$1,224,672	\$1,038,698	\$993,834
Other—Ancillary services and strategic initiatives	(53,948)	(5,586)	(12,226)
Total segment margin	1,170,724	1,033,112	981,608
Reconciliation of segment operating margin to consolidated income before income taxes:			
Stock-based compensation	(48,718)	(45,551)	(44,422)
Equity investment income	8,776	8,999	2,442
Consolidated operating income	1,130,782	996,560	939,628

Debt expense	(241,090)	(181,607)	(185,755)
Debt refinancing and redemption charges	—	(74,382)	—
Other income	2,982	3,419	3,706
Consolidated income from continuing operations before income taxes	<u>\$892,674</u>	<u>\$743,990</u>	<u>\$757,579</u>

- (1) Includes management fees for providing management and administrative services to dialysis centers in which the Company either owns a minority equity investment or are wholly-owned by third parties.
- (2) Revenues from external sources in 2010 and 2009 that were previously eliminated within the ancillary services and strategic initiatives segment have now been reported as a component of revenue from external sources to conform to current year presentations.
- (3) Certain costs previously reported in the Ancillary Services and Strategic Initiatives have been reclassified to the dialysis and related lab services to conform to the current year presentation.

Summary of Assets by Segment

Summary of assets by segment is as follows:

	December 31,	
	2011	2010
Segment assets		
Dialysis and related lab services	\$8,588,671	\$7,862,882
Other—Ancillary services and strategic initiatives	276,176	225,624
Equity investments	27,325	25,918
Consolidated assets	<u>\$8,892,172</u>	<u>\$8,114,424</u>

Other liabilities (Tables)

**12 Months Ended
Dec. 31, 2011**

Other Accrued Liabilities

Other accrued liabilities were comprised of the following:

	<u>December 31,</u>	
	<u>2011</u>	<u>2010</u>
Payor refunds and rejections	\$193,966	\$216,655
Insurance and self-insurance accruals	69,962	65,950
Accrued interest	17,469	22,905
Accrued non-income tax liabilities	15,174	9,995
Other	29,163	27,438
	<u>\$325,734</u>	<u>\$342,943</u>

**Reconciliation between our
Effective Tax Rate from
Continuing Operations and
the U.S. Federal Income Tax
Rate (Detail)**

12 Months Ended

	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
<u>Income Taxes [Line Items]</u>			
<u>Federal income tax rate</u>	35.00%	35.00%	35.00%
<u>State taxes, net of federal benefit</u>	4.10%	3.90%	3.70%
<u>Changes in deferred tax valuation allowances</u>	(0.30%)	(0.10%)	0.20%
<u>Other</u>	0.80%	0.20%	0.80%
<u>Impact of noncontrolling interests primarily attributable to non-tax paying entities</u>	(4.20%)	(4.00%)	(3.00%)
<u>Effective tax rate</u>	35.40%	35.00%	36.70%

**Pro Forma Summary of
Results of Operations
(Detail) (USD \$)
In Thousands, except Per
Share data, unless otherwise
specified**

12 Months Ended

Dec. 31, 2011 Dec. 31, 2010

Business Acquisition [Line Items]

<u>Pro forma net revenues</u>	\$ 7,309,901	\$ 6,983,641
<u>Pro forma net income attributable to DaVita Inc.</u>	520,625	471,635
<u>Pro forma income from continuing operations attributable to DaVita Inc.</u>	\$ 524,379	\$ 471,354
<u>Pro forma basic net income per share attributable to DaVita Inc.</u>	\$ 5.50	\$ 4.65
<u>Pro forma diluted net income per share attributable to DaVita Inc.</u>	\$ 5.39	\$ 4.58

Other receivables (Tables)

**12 Months Ended
Dec. 31, 2011**

Other Receivables

Other receivables were comprised of the following:

	December 31,	
	2011	2010
Supplier rebates and other non-trade receivables	\$195,426	\$238,156
Medicare bad debt claims	57,232	46,250
Operating advances under management and administrative services agreements	17,174	19,960
	<u>\$269,832</u>	<u>\$304,366</u>

**Selected quarterly financial
data (unaudited) (Tables)**

**12 Months Ended
Dec. 31, 2011**

[Selected Quarterly Financial
Data \(Unaudited\)](#)

	2011				2010			
	December 31	September 30	June 30	March 31	December 31	September 30	June 30	March 31
Net operating revenues	\$1,862,318	\$1,807,869	\$1,708,643	\$1,603,384	\$1,646,924	\$1,649,557	\$1,584,821	\$1,556,748
Operating income	330,112	318,712	246,624	235,334	255,258	256,745	242,512	242,045
Income from continuing operations before income taxes	269,149	258,662	187,283	177,580	132,215	218,014	195,469	198,292
Discontinued operations, net of tax.	(1,307)	(2,612)	253	131	93	(95)	(89)	372
Net income attributable to DaVita Inc.	\$148,123	\$135,361	\$100,015	\$94,502	\$69,020	\$119,387	\$107,853	\$109,423
Basic income from continuing operations per share attributable to DaVita Inc.	1.60	1.48	1.05	0.98	0.71	1.16	1.06	1.05
Basic net income per share attributable to DaVita Inc.	1.59	1.45	1.05	0.98	0.71	1.16	1.05	1.05
Diluted income from continuing operations per share attributable to DaVita Inc.	\$1.58	\$1.45	\$1.02	\$0.96	\$0.70	\$1.15	\$1.04	\$1.04
Diluted net income per share attributable to DaVita Inc.	\$1.56	\$1.42	\$1.03	\$0.96	\$0.70	\$1.15	\$1.04	\$1.04

Changes in Book Value of Goodwill (Detail) (USD \$) In Thousands, unless otherwise specified	3 Months Ended	12 Months Ended
	Jun. 30, 2011	Dec. 31, 2011 Dec. 31, 2010
<u>Goodwill [Line Items]</u>		
<u>Beginning balance</u>		\$ 4,091,307 \$ 3,951,196
<u>Acquisitions</u>		889,506 152,252
<u>Divestitures</u>		(9,837) (12,128)
<u>Impairment charge</u>	(24,000)	(24,000)
<u>Other adjustments</u>		(13)
<u>Ending balance</u>		\$ 4,946,976 \$ 4,091,307

**VALUATION AND
QUALIFYING ACCOUNTS**

**(Detail) (Allowance for
Doubtful Accounts, USD \$)**

**In Thousands, unless
otherwise specified**

12 Months Ended

Dec. 31, 2011 Dec. 31, 2010 Dec. 31, 2009

Allowance for Doubtful Accounts

Valuation and Qualifying Accounts Disclosure [Line Items]

<u>Balance at beginning of year</u>	\$ 235,629	\$ 229,317	\$ 211,222
<u>DSI Renal Inc. Acquisition</u>	16,193		
<u>Amounts charged to income</u>	198,750	171,250	161,786
<u>Amounts written off</u>	200,229	164,938	143,691
<u>Balance at end of year</u>	\$ 250,343	\$ 235,629	\$ 229,317

**Amortizable Intangible
Liabilities (Detail) (USD \$)
In Thousands, unless
otherwise specified**

Dec. 31, 2011 Dec. 31, 2010

Acquired Finite-Lived Intangible Assets [Line Items]

<u>Alliance and product supply agreement commitment (See Note 22)</u>	\$ 68,200	\$ 68,200
<u>Less accumulated amortization</u>	(48,213)	(42,883)
<u>Alliance and product supply agreement, net</u>	\$ 19,987	\$ 25,317

**Other comprehensive income
(Tables)**

Charges and Credits to Other
Comprehensive Income

**12 Months Ended
Dec. 31, 2011**

Charges and credits to other comprehensive income have been as follows:

	2009		
	Before tax amount	Tax (expense) benefit	Net-of- tax amount
Unrealized losses on interest rate swaps	\$(4,220)	\$ 1,642	\$(2,578)
Less reclassification of net swap realized losses into net income	17,253	(6,711)	10,542
Net swap activity	13,033	(5,069)	7,964
Unrealized gains on investments	1,614	(628)	986
Less reclassification of net investment realized gains into net income	(261)	102	(159)
Net investment activity	1,353	(526)	827
Total	\$14,386	\$ (5,595)	\$8,791

	2010		
	Before tax amount	Tax (expense) benefit	Net-of- tax amount
Unrealized losses on interest rate swaps	\$(217)	\$ 83	\$(134)
Less reclassification of net swap realized losses into net income	9,093	(3,536)	5,557
Net swap activity	8,876	(3,453)	5,423
Unrealized gains on investments	1,007	(392)	615
Less reclassification of net investment realized losses into net income	22	(9)	13
Net investment activity	1,029	(401)	628
Total	\$9,905	\$ (3,854)	\$6,051

	2011		
	Before tax amount	Tax (expense) benefit	Net-of- tax amount

Unrealized losses on interest rate swap and cap agreements	\$ (47,544)	\$ 18,495	\$ (29,049)
Less reclassification of net swap and cap agreements realized losses into net income	15,911	(6,190)	9,721
Net swap and cap agreements activity	(31,633)	12,305	(19,328)
Unrealized losses on investments	(986)	384	(602)
Less reclassification of net investment realized gains into net income	(93)	36	(57)
Net investment activity	(1,079)	420	(659)
Total	<u>\$ (32,712)</u>	<u>\$ 12,725</u>	<u>\$ (19,987)</u>

Changes in Accumulated Other Comprehensive Income (Loss)

Changes in accumulated other comprehensive income (loss) has been as follows:

	Interest rate swap and cap agreements	Investment securities	Accumulated other comprehensive income
Balance			
December 31, 2009	\$ (5,423)	\$ (125)	\$ (5,548)
Net activity	5,423	628	6,051
Balance			
December 31, 2010	\$—	\$ 503	\$ 503
Net activity	(19,328)	(659)	(19,987)
Balance			
December 31, 2011	<u>\$ (19,328)</u>	<u>\$ (156)</u>	<u>\$ (19,484)</u>

Accounts receivable

**12 Months Ended
Dec. 31, 2011**

[Accounts receivable](#)

3. Accounts receivable

Approximately 16% and 15% of the accounts receivable balances as of December 31, 2011 and 2010, respectively, were more than six months old, and there were no significant balances over one year old. Approximately 2% of the Company's accounts receivable as of December 31, 2011 and 2010, related to amounts due from patients. Accounts receivable are principally from Medicare and Medicaid programs and commercial insurance plans.

**Amortizable Intangibles -
Additional Information
(Detail) (USD \$)
In Thousands, unless
otherwise specified**

12 Months Ended

Dec. 31, 2011 Dec. 31, 2010 Dec. 31, 2009

Finite-Lived Intangible Assets [Line Items]

<u>Net amortization expense</u>	\$ 17,568	\$ 15,064	\$ 14,739
<u>Lease agreements which are amortized to rent expense</u>	\$ 361	\$ 480	\$ 565

Income taxes (Tables)

[Reconciliation of the Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet the More-Likely-than-not Threshold](#)

**12 Months Ended
Dec. 31, 2011**

A reconciliation of the beginning and ending liability for unrecognized tax benefits that do not meet the more-likely-than-not threshold were as follows:

	Year ended December 31,	
	2011	2010
Balance beginning	\$8,138	\$30,693
Additions for tax positions related to current year	2,052	1,515
Additions for tax positions related to prior years	786	69
Reductions for tax positions related to prior years	(2,033)	(24,139)
Balance ending	<u>\$8,943</u>	<u>\$8,138</u>

[Components of Income Tax Expense](#)

Income tax expense consisted of the following:

	Year ended December 31,		
	2011	2010	2009
Current:			
Federal	\$217,885	\$153,502	\$193,181
State	44,403	31,338	34,415
Deferred:			
Federal	46,779	67,901	44,376
State	6,659	7,498	6,493
	<u>\$315,726</u>	<u>\$260,239</u>	<u>\$278,465</u>

[Allocation of Income Tax Expense](#)

The allocation of income tax expense was as follows:

	Year ended December 31,		
	2011	2010	2009
Continuing operations	\$315,744	\$260,052	\$278,213
Discontinued operations	675	187	252
Loss on discontinued operations	(693)	—	—
	<u>\$315,726</u>	<u>\$260,239</u>	<u>\$278,465</u>

[Deferred Tax Assets and Liabilities Arising from Temporary Differences](#)

Deferred tax assets and liabilities arising from temporary differences were as follows:

	<u>December 31,</u>	
	<u>2011</u>	<u>2010</u>
Receivables	\$125,159	\$110,332
Alliance and product supply agreement	7,775	9,849
Accrued liabilities	163,770	127,073
Net operating loss carryforwards	118,745	11,272
Other	<u>64,120</u>	<u>49,096</u>
Deferred tax assets	479,569	307,622
Valuation allowance	<u>(15,642)</u>	<u>(10,998)</u>
Net deferred tax assets	<u>463,927</u>	<u>296,624</u>
Intangible assets	(439,203)	(377,456)
Property and equipment	(164,404)	(110,472)
Other	<u>(3,036)</u>	<u>(4,072)</u>
Deferred tax liabilities	<u>(606,643)</u>	<u>(492,000)</u>
Net deferred tax liabilities	<u><u>\$ (142,716)</u></u>	<u><u>\$ (195,376)</u></u>

[Reconciliation between our Effective Tax Rate from Continuing Operations and the U.S. Federal Income Tax Rate](#)

The reconciliation between the Company's effective tax rate from continuing operations and the U.S. federal income tax rate is as follows:

	<u>Year ended December 31,</u>		
	<u>2011</u>	<u>2010</u>	<u>2009</u>
Federal income tax rate	35.0%	35.0%	35.0%
State taxes, net of federal benefit	4.1	3.9	3.7
Changes in deferred tax valuation allowances	(0.3)	(0.1)	0.2
Other	0.8	0.2	0.8
Impact of noncontrolling interests primarily attributable to non-tax paying entities	<u>(4.2)</u>	<u>(4.0)</u>	<u>(3.0)</u>
Effective tax rate	<u><u>35.4%</u></u>	<u><u>35.0%</u></u>	<u><u>36.7%</u></u>

Fair values of financial instruments

**12 Months Ended
Dec. 31, 2011**

[Fair values of financial instruments](#)

23. Fair values of financial instruments

The Company measures the fair value of certain assets, liabilities and noncontrolling interests subject to put provisions (temporary equity) based upon certain valuation techniques that include observable or unobservable inputs and assumptions that market participants would use in pricing these assets, liabilities, temporary equity and commitments. The Company also has classified certain assets, liabilities and temporary equity that are measured at fair value into the appropriate fair value hierarchy levels as defined by FASB.

The following tables summarize the Company's assets, liabilities and temporary equity measured at fair value on a recurring basis as of December 31, 2011 and 2010:

	December 31, 2011			
	Total	Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Assets				
Available for sale securities	\$15,535	\$ 15,535	\$ —	\$—
Interest rate cap agreements	\$1,381	\$ —	\$ 1,381	\$—
Liabilities				
Interest rate swap agreements	\$23,145	\$ —	\$ 23,145	\$—
Temporary equity				
Noncontrolling interests subject to put provisions	\$478,216	\$ —	\$ —	\$478,216

	December 31, 2010			
	Total	Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Assets				
Available for sale securities	\$10,048	\$ 10,048	\$ —	\$—
Temporary equity				
Noncontrolling interests subject to put provisions	\$383,052	\$ —	\$ —	\$383,052

The available for sale securities represent investments in various open-ended registered investment companies, or mutual funds, and are recorded at fair value based upon quoted prices reported by each mutual fund. The available for sale securities also include the fair value of

NxStage common stock based upon quoted market prices as reported by NASDAQ. See Note 9 to the consolidated financial statements for further discussion.

The interest rate swap and cap agreements are recorded at fair value based upon valuation models utilizing the income approach and commonly accepted valuation techniques that use inputs from closing prices for similar assets and liabilities in active markets as well as other relevant observable market inputs at quoted intervals such as current interest rates, forward yield curves, implied volatility and credit default swap pricing. The Company does not believe the ultimate amount that could be realized upon settlement of these interest rate swap and cap agreements would be materially different than the fair values as currently reported. See Note 13 to the consolidated financial statements for further discussion.

See Note 22 to the consolidated financial statements for a discussion of the Company's methodology for estimating the fair value of noncontrolling interests subject to put obligations.

Other financial instruments consist primarily of cash, accounts receivable, accounts payable, other accrued liabilities and debt. The balances of the non-debt financial instruments are presented in the consolidated financial statements at December 31, 2011 and 2010 at their approximate fair values due to the short-term nature of their settlements. The carrying balance of the Company's Senior Secured Credit Facilities totaled \$2,874,158 as of December 31, 2011, and the fair value was \$2,860,465 based upon quoted market prices. The fair value of the Company's senior notes was approximately \$1,565,500 at December 31, 2011 based upon quoted market prices, as compared to the carrying amount of \$1,550,000.

**Noncontrolling interests
subject to put provisions and
other commitments**

12 Months Ended

Dec. 31, 2011

[Noncontrolling interests
subject to put provisions and
other commitments](#)

22. Noncontrolling interests subject to put provisions and other commitments

Noncontrolling interests subject to put provisions

The Company has potential obligations to purchase the noncontrolling interests held by third parties in several of its joint ventures and non-wholly-owned subsidiaries. These obligations are in the form of put provisions and are exercisable at the third-party owners' discretion within specified periods as outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase the third-party owners' noncontrolling interests at either the appraised fair market value or a predetermined multiple of earnings or cash flow attributable to the noncontrolling interests put to the Company, which is intended to approximate fair value. The methodology the Company uses to estimate the fair values of noncontrolling interests subject to put provisions assumes either the higher of a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators, as well as other factors. During the second quarter of 2010, the Company refined its methodology used to estimate the fair value of noncontrolling interests subject to put provisions by eliminating an annual inflation factor that was previously applied to the put provisions until they became exercisable. The Company believes that eliminating an annual inflation factor will result in a better representation of the estimated actual fair value of the noncontrolling interests subject to put provisions as of the reporting date. The estimated fair values of the noncontrolling interests subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interests obligations may be settled will vary significantly depending upon market conditions including potential purchasers' access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners' noncontrolling interests. The amount of noncontrolling interests subject to put provisions that contractually employ a predetermined multiple of earnings rather than fair value are immaterial.

Additionally, the Company has certain other potential commitments to provide operating capital to several dialysis centers that are wholly-owned by third parties or centers in which the Company owns a minority equity investment as well as to physician-owned vascular access clinics that the Company operates under management and administrative service agreements of approximately \$4,000.

Certain consolidated joint ventures are contractually scheduled to dissolve after terms ranging from ten to fifty years. Accordingly, the noncontrolling interests in these joint ventures are considered mandatorily redeemable instruments, for which the classification and measurement requirements have been indefinitely deferred. Future distributions upon dissolution of these entities would be valued below the related noncontrolling interest carrying balances in the consolidated balance sheet.

Other commitments

In November 2011, the Company entered into a seven year Sourcing and Supply Agreement with Amgen USA Inc. that expires on December 31, 2018. Under terms of the agreement, the Company will purchase EPO in amounts necessary to meet no less than 90% of its requirements

for erythropoiesis stimulations agents. The agreement replaces in its entirety the prior one-year supply agreement between the Company and Amgen that expired on December 31, 2011, and among other things, provides for discounted pricing and rebates for EPO. Some of the rebates are subject to various conditions including future pricing levels of EPO by Amgen and data submission by the Company. In the initial years of the agreement the total rebate opportunity is less than what was provided for in the agreement that expired at the end of 2011, however, the opportunity for the Company to earn discounts and rebates increases over the term of the agreement. The actual amount of EPO that the Company will purchase from Amgen will depend upon the amount of EPO administered during dialysis as prescribed by physicians and the overall number of patients that the Company serves.

In January 2010, the Company entered into an agreement with Fresenius which committed the Company to purchase a certain amount of dialysis equipment, parts and supplies from them through 2013. During 2011 and 2010, the Company purchased \$107,977 and \$103,183, respectively, of certain equipment, parts and supplies from Fresenius.

In July 2010, the Company announced that it will construct a new corporate headquarters in Denver, Colorado. In July 2010, the Company acquired the land and existing improvements for approximately \$12,000. Effective December 18, 2010, the Company entered into a construction agreement for the construction of the new building. The Company currently estimates the total construction costs and other project costs of the building will be approximately \$95,000. Construction began in early 2011, and is estimated to be completed in the second half of 2012. In 2011 and 2010, the Company paid construction costs and architecture and other design costs totaling approximately \$44,000 and \$5,000, respectively.

In conjunction with the acquisition of DVA Renal Healthcare, Inc., formerly known as Gambro Healthcare, Inc., which occurred in October 2005, the Company entered into an Alliance and Product Supply Agreement (the Product Supply Agreement) with Gambro AB and Gambro Renal Products, Inc (Gambro Renal Products). Because the Product Supply Agreement results in higher costs for most of the products covered by the Product Supply Agreement than would otherwise be available to the Company, the Product Supply Agreement represented an intangible liability initially valued at \$162,100 as of the acquisition date.

The Product Supply Agreement committed the Company to purchase a significant majority of its hemodialysis products, supplies and equipment at fixed prices through 2015. The agreement was amended in 2006 (the Amended Product Supply Agreement) to reduce the Company's purchase obligations for certain hemodialysis product supplies and equipment, and in 2007, the Company terminated its obligation to purchase certain dialysis machines under the Amended Product Supply Agreement. However, the Company continues to be subject to the Product Supply Agreement's requirements to purchase a majority of its hemodialysis non-equipment product supplies, such as dialyzers, from Gambro at fixed prices.

During 2011, 2010 and 2009, the Company purchased \$120,938, \$115,682 and \$87,983 of hemodialysis product supplies from Gambro Renal Products, representing 2% of the Company's total operating costs, for all years presented.

Other than operating leases disclosed in Note 14 to the consolidated financial statements, the letters of credit disclosed in Note 13 to the consolidated financial statements, and the arrangements as described above, the Company has no off balance sheet financing arrangements as of December 31, 2011.

					for certain hemodialysis product supplies and equipment, and in 2007, the Company terminated its obligation to purchase certain dialysis machines under the Amended Product Supply Agreement.
Long term purchase commitment, expiration year		2013	2015		
Purchase commitment, purchase during the period	107,977	103,183	120,938	115,682	87,983
Percentage of total operating costs during the period			2.00%	2.00%	2.00%
Long-term purchase commitment, time period					In January 2010, the Company entered into an agreement with Fresenius which committed the Company to purchase a certain amount of dialysis equipment, parts and supplies from them through 2013.
Product Supply Agreement, intangible liability initially valued as of the acquisition date	\$ 68,200	\$ 68,200			\$ 162,100

**Accounts Receivable -
Additional Information
(Detail)**

Dec. 31, 2011 Dec. 31, 2010

Accounts, Notes, Loans and Financing Receivable [Line Items]

Accounts receivable, percentage of balances more than six months old 16.00% 15.00%

Health Care Patient

Accounts, Notes, Loans and Financing Receivable [Line Items]

Accounts receivable, percentage of amounts due from patients 2.00% 2.00%

Long-term debt (Tables)

12 Months Ended Dec. 31, 2011

[Long Term Debt](#)

Long-term debt was comprised of the following:

	December 31,	
	2011	2010
Senior Secured Credit Facilities:		
Term Loan A	\$950,000	\$1,000,000
Term Loan A-2	199,500	—
Term Loan B	1,732,500	1,750,000
Senior notes	1,550,000	1,550,000
Acquisition obligations and other notes payable	37,447	9,049
Capital lease obligations	43,364	8,074
Total principal debt outstanding	4,512,811	4,317,123
Discount on long-term debt	(7,842)	(8,381)
	4,504,969	4,308,742
Less current portion	(87,345)	(74,892)
	<u>\$4,417,624</u>	<u>\$4,233,850</u>

[Scheduled Maturities of Long-term Debt](#)

Scheduled maturities of long-term debt at December 31, 2011 were as follows:

2012	87,345
2013	125,106
2014	176,910
2015	676,293
2016	1,858,567
Thereafter	1,588,590

[Derivative Instruments](#)

The following table summarizes the Company's derivative instruments as of December 31, 2011 and 2010:

	Interest rate swap and cap agreements (liabilities and assets)			
	December 31, 2011		December 31, 2010	
	Balance sheet location	Fair value	Balance sheet location	Fair value
Derivatives designated as hedging instruments				
Interest rate swap agreements	Other long-term liabilities	\$23,145	Other long-term liabilities	\$ —
Interest rate cap agreements	Other long-term assets	\$1,381	Other long-term assets	\$ —

[Effects of Interest Rate Swap Agreements](#)

The following table summarizes the effects of the Company's interest rate swap and cap agreements for the years ended December 31, 2011, 2010 and 2009:

Amount of gains (losses) recognized in OCI on interest rate swap and cap agreements	Location of (losses) gains reclassified from	Amount of gains (losses) reclassified from accumulated OCI into income
	from	

Derivatives designated as cash flow hedges	Years ended December 31,			accumulated OCI into income	Years ended December 31,		
	2011	2010	2009		2011	2010	2009
Interest rate swap agreements	\$(35,767)	\$(217)	\$(4,220)	Debt expense	\$(12,622)	\$(9,093)	\$(17,253)
Interest rate cap agreements	(11,777)	—	—	Debt expense	(3,289)	—	—
Tax benefit	18,495	83	1,642		6,190	3,536	6,711
Total	<u>\$(29,049)</u>	<u>\$(134)</u>	<u>\$(2,578)</u>		<u>\$(9,721)</u>	<u>\$(5,557)</u>	<u>\$(10,542)</u>

Segment reporting

**12 Months Ended
Dec. 31, 2011**

[Segment reporting](#)

24. Segment reporting

The Company operates principally as a dialysis and related lab services business but also operates other ancillary services and strategic initiatives. These ancillary services and strategic initiatives consist primarily of pharmacy services, infusion therapy services, disease management services, vascular access services, ESRD clinical research programs, physician services and the Company's international dialysis operations. For internal management reporting the dialysis and related lab services business and each of the ancillary services and strategic initiatives have been defined as separate operating segments by management since separate financial information is regularly produced and reviewed by the Company's chief operating decision maker in making decisions about allocating resources and assessing financial results. The Company's chief operating decision maker is its Chief Executive Officer. The U.S. dialysis and related lab services business qualifies as a separately reportable segment and all of the other ancillary services and strategic initiatives operating segments have been combined and disclosed in the other segments category.

The Company's operating segment financial information is prepared on an internal management reporting basis that the Chief Executive Officer uses to allocate resources and analyze the performance of the operating segments. For internal management reporting, segment operations include direct segment operating expenses with the exception of stock-based compensation expense and equity investment income. In addition, beginning in 2011, the ancillary services and strategic initiatives segment operations also include an allocation of corporate general and administrative expenses.

The following is a summary of segment revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income before income taxes:

	Year ended December 31,		
	2011	2010	2009
Segment revenues:			
Dialysis and related lab services (1)			
External sources	\$6,473,829	\$6,054,252	\$5,766,795
Intersegment revenues	11,141	9,300	16,782
Total dialysis and related lab services	<u>6,484,970</u>	<u>6,063,552</u>	<u>5,783,577</u>
Other – Ancillary services and strategic initiatives			
External sources (2)	\$508,385	\$383,798	\$333,853
Intersegment revenues	5,796	—	—
Total ancillary services and strategic initiatives	<u>514,181</u>	<u>383,798</u>	<u>333,853</u>
Total segment revenues	6,999,151	6,447,350	6,117,430
Elimination of intersegment revenues	(16,937)	(9,300)	(16,782)
Consolidated revenues	<u>\$6,982,214</u>	<u>\$6,438,050</u>	<u>\$6,100,648</u>

Segment operating margin (loss): (3)			
Dialysis and related lab services	\$1,224,672	\$1,038,698	\$993,834
Other—Ancillary services and strategic initiatives	(53,948)	(5,586)	(12,226)
Total segment margin	1,170,724	1,033,112	981,608
Reconciliation of segment operating margin to consolidated income before income taxes:			
Stock-based compensation	(48,718)	(45,551)	(44,422)
Equity investment income	8,776	8,999	2,442
Consolidated operating income	1,130,782	996,560	939,628
Debt expense	(241,090)	(181,607)	(185,755)
Debt refinancing and redemption charges	—	(74,382)	—
Other income	2,982	3,419	3,706
Consolidated income from continuing operations before income taxes	<u>\$892,674</u>	<u>\$743,990</u>	<u>\$757,579</u>

- (1) Includes management fees for providing management and administrative services to dialysis centers in which the Company either owns a minority equity investment or are wholly-owned by third parties.
- (2) Revenues from external sources in 2010 and 2009 that were previously eliminated within the ancillary services and strategic initiatives segment have now been reported as a component of revenue from external sources to conform to current year presentations.
- (3) Certain costs previously reported in the Ancillary Services and Strategic Initiatives have been reclassified to the dialysis and related lab services to conform to the current year presentation.

Depreciation and amortization expense for the dialysis and related lab services for 2011, 2010 and 2009 were \$259,685, \$227,029 and \$221,317, respectively, and were \$6,943, \$6,701 and \$7,079, respectively, for the ancillary services and strategic initiatives.

Summary of assets by segment is as follows:

	December 31,	
	2011	2010
Segment assets		
Dialysis and related lab services	\$8,588,671	\$7,862,882
Other—Ancillary services and strategic initiatives	276,176	225,624
Equity investments	27,325	25,918
Consolidated assets	<u>\$8,892,172</u>	<u>\$8,114,424</u>

In 2011 and 2010, the total amount of expenditures for property and equipment for the dialysis and related lab services were \$425,228 and \$271,559, respectively, and were \$10,692 and \$7,226, respectively, for the ancillary services and strategic initiatives.

**Supplemental cash flow
information**

[Supplemental cash flow
information](#)

**12 Months Ended
Dec. 31, 2011**

25. Supplemental cash flow information

The table below provides supplemental cash flow information:

	Year ended December 31,		
	2011	2010	2009
Cash paid:			
Income taxes	\$145,687	\$207,265	\$161,671
Interest	236,446	190,949	186,280
Non-cash investing and financing activities:			
Fixed assets under capital lease obligations	35,764	3,983	—
Assets exchanged for equity investments	—	—	2,618
Assets received for additional noncontrolling interests	—	—	51
Issuance of noncontrolling interests	—	1,139	—

Earnings per share

12 Months Ended Dec. 31, 2011

Earnings per share

2. Earnings per share

Basic net income per share is calculated by dividing net income attributable to DaVita Inc., net of the decrease (increase) in noncontrolling interest redemption rights in excess of fair value, by the weighted average number of common shares and vested stock units outstanding. Diluted net income per share includes the dilutive effect of outstanding stock-settled stock appreciation rights, stock options and unvested stock units (under the treasury stock method).

The reconciliations of the numerators and denominators used to calculate basic and diluted net income per share are as follows:

	Year ended December 31,		
	2011	2010	2009
	(shares in thousands)		
Basic:			
Income from continuing operations attributable to DaVita Inc.	\$481,755	\$405,402	\$422,291
Decrease (increase) in noncontrolling interest redemption rights in excess of fair value	335	(68)	(267)
Income from continuing operations for basic earnings per share calculation	\$482,090	\$405,334	\$422,024
Discontinued operations attributable to DaVita Inc.	(3,754)	281	393
Net income attributable to DaVita Inc. for basic earnings per share calculation	\$478,336	\$405,615	\$422,417
Weighted average shares outstanding during the period	94,655	101,497	103,595
Vested stock units	3	7	9
Weighted average shares for basic earnings per share calculation	94,658	101,504	103,604
Basic income from continuing operations per share attributable to DaVita Inc.	\$5.09	\$3.99	\$4.07
Basic net income per share attributable to DaVita Inc.	\$5.05	\$4.00	\$4.08
Diluted:			
Income from continuing operations attributable to DaVita Inc.	\$481,755	\$405,402	\$422,291
Decrease (increase) in noncontrolling interest redemption rights in excess of fair value	335	(68)	(267)
Income from continuing operations for diluted earnings per share calculation	\$482,090	\$405,334	\$422,024
Discontinued operations attributable to DaVita Inc.	(3,754)	281	393
Net income attributable to DaVita Inc. for diluted earnings per share calculation	\$478,336	\$405,615	\$422,417
Weighted average shares outstanding during the period	94,655	101,497	103,595
Vested stock units	3	7	9
Assumed incremental shares from stock plans	1,874	1,555	564

Weighted average shares for diluted earnings per share calculation	<u>96,532</u>	<u>103,059</u>	<u>104,168</u>
Diluted income from continuing operations per share attributable to DaVita Inc.	<u>\$4.99</u>	<u>\$3.93</u>	<u>\$4.05</u>
Diluted net income per share attributable to DaVita Inc.	<u><u>\$4.96</u></u>	<u><u>\$3.94</u></u>	<u><u>\$4.06</u></u>
Anti-dilutive stock-settled awards excluded from calculation (1)	<u>2,388</u>	<u>1,452</u>	<u>9,912</u>

(1) Shares associated with stock-settled stock appreciation rights and stock options that are excluded from the diluted denominator calculation because they are anti-dilutive under the treasury stock method.

Selected quarterly financial data (unaudited)

**12 Months Ended
Dec. 31, 2011**

[Selected quarterly financial data \(unaudited\)](#)

26. Selected quarterly financial data (unaudited)

	2011				2010			
	December 31	September 30	June 30	March 31	December 31	September 30	June 30	March 31
Net operating revenues	\$1,862,318	\$1,807,869	\$1,708,643	\$1,603,384	\$1,646,924	\$1,649,557	\$1,584,821	\$1,556,748
Operating income	330,112	318,712	246,624	235,334	255,258	256,745	242,512	242,045
Income from continuing operations before income taxes	269,149	258,662	187,283	177,580	132,215	218,014	195,469	198,292
Discontinued operations, net of tax.	(1,307)	(2,612)	253	131	93	(95)	(89)	372
Net income attributable to DaVita Inc.	\$148,123	\$135,361	\$100,015	\$94,502	\$69,020	\$119,387	\$107,853	\$109,423
Basic income from continuing operations per share attributable to DaVita Inc.	1.60	1.48	1.05	0.98	0.71	1.16	1.06	1.05
Basic net income per share attributable to DaVita Inc.	1.59	1.45	1.05	0.98	0.71	1.16	1.05	1.05
Diluted income from continuing operations per share attributable to DaVita Inc.	\$1.58	\$1.45	\$1.02	\$0.96	\$0.70	\$1.15	\$1.04	\$1.04
Diluted net income per share attributable to DaVita Inc.	\$1.56	\$1.42	\$1.03	\$0.96	\$0.70	\$1.15	\$1.04	\$1.04

Employee Benefit Plans - Additional Information (Detail) (USD \$) In Thousands, unless otherwise specified	12 Months Ended	
	Dec. 31, 2011	Dec. 31, 2010
Nonqualified Deferred Compensation Plan Rabbi Trust		
Defined Benefit Plan Disclosure [Line Items]		
Total fair value of assets held in trust	\$ 11,090	\$ 10,048
Nonqualified Deferred Compensation Plan DaVita Voluntary Deferral Plan		
Defined Benefit Plan Disclosure [Line Items]		
Voluntary compensation deferral plan description	The Company also maintains a voluntary compensation deferral plan, the DaVita Voluntary Deferral Plan. This plan is non-qualified and permits certain employees whose annualized base salary equals or exceeds a minimum annual threshold amount as set by the Company to elect to defer all or a portion of their annual bonus payment and up to 50% of their base salary into a deferral account maintained by the Company.	
Maximum percentage of employees' base salary to be maintained into deferral account	50.00%	
Non-qualified deferred compensation plan, contributions	2,416	1,125 2,062
Deferred compensation arrangement, timing of payments	Deferred amounts are generally paid out in cash at the participant's election either in the first or second year following retirement or in a specified future period at least three to four years after the deferral election was effective	
Non-qualified deferred compensation plan, distributions	955	701 601
Nonqualified Deferred Compensation Plan DaVita Voluntary Deferral Plan Rabbi Trust		
Defined Benefit Plan Disclosure [Line Items]		
Total fair value of assets held in trust	9,796	8,547

Nonqualified Deferred Compensation Plan Executive Retirement Plan			
<u>Defined Benefit Plan Disclosure [Line Items]</u>			
<u>Executive Retirement Plan, distributions</u>	194		198 241
Nonqualified Deferred Compensation Plan Executive Retirement Plan Rabbi Trust			
<u>Defined Benefit Plan Disclosure [Line Items]</u>			
<u>Total fair value of assets held in trust</u>	1,294		1,501
Control Protection Program			
<u>Defined Benefit Plan Disclosure [Line Items]</u>			
<u>Cash bonuses to employees in the event of a change of control</u>	\$ 277,000		

**Investments in debt and
equity securities (Tables)**

**12 Months Ended
Dec. 31, 2011**

Investments

The Company's investments consist of the following:

	December 31, 2011			December 31, 2010		
	Held to maturity	Available for sale	Total	Held to maturity	Available for sale	Total
Certificates of deposit, money market funds and U.S. treasury notes due within one year	\$11,754	\$—	\$11,754	\$21,803	\$—	\$21,803
Investments in mutual funds and NxStage common stock	—	15,535	15,535	—	10,048	10,048
	<u>\$11,754</u>	<u>\$15,535</u>	<u>\$27,289</u>	<u>\$21,803</u>	<u>\$10,048</u>	<u>\$31,851</u>
Short-term investments	\$11,754	\$5,645	\$17,399	\$21,803	\$1,200	\$23,003
Long-term investments	—	9,890	9,890	—	8,848	8,848
	<u>\$11,754</u>	<u>\$15,535</u>	<u>\$27,289</u>	<u>\$21,803</u>	<u>\$10,048</u>	<u>\$31,851</u>

**Consolidating financial
statements (Tables)**
[Consolidating Statements of
Income](#)

**12 Months Ended
Dec. 31, 2011**
Consolidating Statements of Income

	DaVita Inc.	Guarantor Subsidiaries	Non- Guarantor Subsidiaries	Consolidating Adjustments	Consolidated Total
For the year ended December 31, 2011					
Net operating revenues	\$457,460	\$5,527,588	\$1,541,618	\$(544,452)	\$6,982,214
Operating expenses	301,255	4,827,005	1,267,624	(544,452)	5,851,432
Operating income	156,205	700,583	273,994	—	1,130,782
Debt (expense)	(242,730)	(218,182)	(9,215)	229,037	(241,090)
Other income, net	229,658	1,583	778	(229,037)	2,982
Income tax expense	56,681	248,139	10,924	—	315,744
Equity earnings in subsidiaries	391,549	184,404	—	(575,953)	—
Income from continuing operations	478,001	420,249	254,633	(575,953)	576,930
Discontinued operations net of (loss) gain on disposal of discontinued operations	—	(4,191)	656	—	(3,535)
Net income	478,001	416,058	255,289	(575,953)	573,395
Less: Net income attributable to noncontrolling interests	—	—	—	(95,394)	(95,394)
Net income attributable to DaVita Inc.	<u>\$478,001</u>	<u>\$416,058</u>	<u>\$255,289</u>	<u>\$(671,347)</u>	<u>\$478,001</u>
For the year ended December 31, 2010					
Net operating revenues	\$431,780	\$5,195,449	\$1,288,259	\$(477,438)	\$6,438,050
Operating expenses	259,302	4,615,716	1,043,910	(477,438)	5,441,490
Operating income	172,478	579,733	244,349	—	996,560
Debt (expense)	(257,243)	(163,034)	(1,277)	165,565	(255,989)
Other income, net	165,934	1,837	1,213	(165,565)	3,419
Income tax expense	31,656	220,867	7,529	—	260,052
Equity earnings in subsidiaries	356,170	157,278	—	(513,448)	—
Income from continuing operations	405,683	354,947	236,756	(513,448)	483,938
Income from operations of discontinued operations net of tax	—	172	109	—	281
Net income	405,683	355,119	236,865	(513,448)	484,219
Less: Net income attributable to noncontrolling interests	—	—	—	(78,536)	(78,536)
Net income attributable to DaVita Inc.	<u>\$405,683</u>	<u>\$355,119</u>	<u>\$236,865</u>	<u>\$(591,984)</u>	<u>\$405,683</u>
For the year ended December 31, 2009					
Net operating revenues	\$401,058	\$5,005,839	\$1,147,394	\$(453,643)	\$6,100,648
Operating expenses	246,578	4,375,032	993,053	(453,643)	5,161,020
Operating income	154,480	630,807	154,341	—	939,628

Debt (expense)	(188,109)	(181,853)	(1,721)	185,928	(185,755)
Other income, net	186,189	2,718	727	(185,928)	3,706
Income tax expense	60,414	218,618	(819)	—	278,213
Equity earnings in subsidiaries	330,538	94,964	—	(425,502)	—
Income from continuing operations	422,684	328,018	154,166	(425,502)	479,366
Income from operations of discontinued operations net of tax	—	180	213	—	393
Net income	422,684	328,198	154,379	(425,502)	479,759
Less: Net income attributable to noncontrolling interests	—	—	—	(57,075)	(57,075)
Net income attributable to DaVita Inc.	<u>\$422,684</u>	<u>\$328,198</u>	<u>\$154,379</u>	<u>\$(482,577)</u>	<u>\$422,684</u>

Consolidating Balance Sheets

Consolidating Balance Sheets

	<u>DaVita Inc.</u>	<u>Guarantor Subsidiaries</u>	<u>Non-Guarantor Subsidiaries</u>	<u>Consolidating Adjustments</u>	<u>Consolidated Total</u>
As of December 31, 2011					
Cash and cash equivalents	\$365,276	\$—	\$28,476	\$—	\$393,752
Accounts receivable, net	—	926,041	269,122	—	1,195,163
Other current assets	14,665	598,721	79,307	—	692,693
Total current assets	379,941	1,524,762	376,905	—	2,281,608
Property and equipment, net	78,038	971,867	382,746	—	1,432,651
Amortizable intangible assets, net	53,276	95,900	10,315	—	159,491
Investments in subsidiaries	6,696,039	1,089,920	—	(7,785,959)	—
Intercompany receivables	—	472,200	253,447	(725,647)	—
Other long-term assets and investments	11,388	56,134	3,924	—	71,446
Goodwill	—	3,903,542	1,043,434	—	4,946,976
Total assets	<u>\$7,218,682</u>	<u>\$8,114,325</u>	<u>\$2,070,771</u>	<u>\$(8,511,606)</u>	<u>\$8,892,172</u>
Current liabilities	\$148,994	\$889,172	\$114,950	\$—	\$1,153,116
Intercompany payables	271,890	—	453,757	(725,647)	—
Long-term debt and other long-term liabilities	4,351,346	585,675	55,694	—	4,992,715
Noncontrolling interests subject to put provisions	305,377	—	—	172,839	478,216
Total DaVita Inc. shareholders' equity	2,141,075	6,639,478	1,146,481	(7,785,959)	2,141,075
Noncontrolling interest not subject to put provisions	—	—	299,889	(172,839)	127,050
Total equity	<u>2,141,075</u>	<u>6,639,478</u>	<u>1,446,370</u>	<u>(7,958,798)</u>	<u>2,268,125</u>

Total liabilities and equity	<u>\$7,218,682</u>	<u>\$8,114,325</u>	<u>\$2,070,771</u>	<u>\$(8,511,606)</u>	<u>\$8,892,172</u>
As of December 31, 2010					
Cash and cash equivalents	\$856,803	\$—	\$3,314	\$—	\$860,117
Accounts receivable, net	—	895,955	153,021	—	1,048,976
Other current assets	11,231	653,670	48,860	—	713,761
Total current assets	868,034	1,549,625	205,195	—	2,622,854
Property and equipment, net	30,409	888,927	251,472	—	1,170,808
Amortizable intangible assets, net	58,967	98,795	4,873	—	162,635
Investments in subsidiaries	6,154,398	555,579	—	(6,709,977)	—
Intercompany receivables	—	516,286	208,030	(724,316)	—
Other long-term assets and investments	8,951	56,996	873	—	66,820
Goodwill	—	3,731,983	359,324	—	4,091,307
Total assets	<u>\$7,120,759</u>	<u>\$7,398,191</u>	<u>\$1,029,767</u>	<u>\$(7,434,293)</u>	<u>\$8,114,424</u>
Current liabilities	\$61,384	\$786,114	\$76,847	\$—	\$924,345
Intercompany payables	611,919	—	112,397	(724,316)	—
Long-term debt and other long-term liabilities	4,210,703	539,620	19,570	—	4,769,893
Noncontrolling interests subject to put provisions	258,331	—	—	124,721	383,052
Total DaVita Inc. shareholders' equity	1,978,422	6,072,457	637,520	(6,709,977)	1,978,422
Noncontrolling interest not subject to put provisions	—	—	183,433	(124,721)	58,712
Total equity	<u>1,978,422</u>	<u>6,072,457</u>	<u>820,953</u>	<u>(6,834,698)</u>	<u>2,037,134</u>
Total liabilities and equity	<u>\$7,120,759</u>	<u>\$7,398,191</u>	<u>\$1,029,767</u>	<u>\$(7,434,293)</u>	<u>\$8,114,424</u>

[Consolidating Statements of Cash Flows](#)

Consolidating Statements of Cash Flows

	DaVita Inc.	Guarantor Subsidiaries	Non-Guarantor Subsidiaries	Consolidating Adjustments	Consolidated Total
For the year ended December 31, 2011					
Cash flows from operating activities:					
Net income.	\$478,001	\$416,058	\$255,289	\$(575,953)	\$573,395
Changes in operating assets and liabilities and non cash items included in net income	(268,798)	325,807	(26,311)	575,953	606,651
Net cash provided by operating activities	209,203	741,865	228,978	—	1,180,046
Cash flows from investing activities:					

Additions of property and equipment, net	(52,653)	(232,540)	(114,963)	—	(400,156)
Acquisitions	—	(1,048,136)	(29,306)	—	(1,077,442)
Proceeds from asset sales	—	75,183	—	—	75,183
Proceeds from investment sales and other items	(6,077)	9,264	—	—	3,187
Net cash used in by investing activities	(58,730)	(1,196,229)	(144,269)	—	(1,399,228)
Cash flows from financing activities:					
Long-term debt and related financing costs, net	113,762	(1,896)	15,794	—	127,660
Intercompany borrowing	(464,564)	460,262	4,302	—	—
Other items	(291,198)	(4,002)	(79,643)	—	(374,843)
Net cash (used in) provided by financing activities	(642,000)	454,364	(59,547)	—	(247,183)
Net (decrease) increase in cash and cash equivalents	(491,527)	—	25,162	—	(466,365)
Cash and cash equivalents at beginning of the year	856,803	—	3,314	—	860,117
Cash and cash equivalents at the end of the year	<u>\$365,276</u>	<u>\$—</u>	<u>\$28,476</u>	<u>\$—</u>	<u>\$393,752</u>
For the year ended December 31, 2010					
Cash flows from operating activities:					
Net income.	\$405,683	\$355,119	\$236,865	\$(513,448)	\$484,219
Changes in operating assets and liabilities and non cash items included in net income	(319,090)	136,348	24,758	513,448	355,464
Net cash provided by operating activities	86,593	491,467	261,623	—	839,683
Cash flows from investing activities:					
Additions of property and equipment, net	(24,118)	(199,147)	(50,337)	—	(273,602)
Acquisitions	—	(188,502)	—	—	(188,502)
Proceeds from asset sales	—	22,727	—	—	22,727
Proceeds from investment sales and other items	(470)	3,214	—	—	2,744
Net cash used in investing activities	(24,588)	(361,708)	(50,337)	—	(436,633)
Cash flows from financing activities:					
Long-term debt and related financing costs, net	563,350	1,987	(4,391)	—	560,946
Intercompany borrowing	255,351	(121,887)	(133,464)	—	—
Other items	(558,453)	(9,859)	(75,026)	—	(643,338)

Net cash provided by (used in) financing activities	260,248	(129,759)	(212,881)	—	(82,392)
Net increase (decrease) in cash and cash equivalents	322,253	—	(1,595)	—	320,658
Cash and cash equivalents at beginning of the year	534,550	—	4,909	—	539,459
Cash and cash equivalents at the end of the year	<u>\$856,803</u>	<u>\$—</u>	<u>\$3,314</u>	<u>\$—</u>	<u>\$860,117</u>
For the year ended December 31, 2009					
Cash flows from operating activities:					
Net income.	\$422,684	\$328,198	\$154,379	\$(425,502)	\$479,759
Changes in operating assets and liabilities and non cash items included in net income	(257,591)	(58,813)	77,853	425,502	186,951
Net cash provided by operating activities	165,093	269,385	232,232	—	666,710
Cash flows from investing activities:					
Additions of property and equipment, net	(1,748)	(207,738)	(65,119)	—	(274,605)
Acquisitions	—	(87,617)	—	—	(87,617)
Proceeds from asset sales	—	7,697	—	—	7,697
Proceeds from investment sales and other items	11,631	(3,166)	—	—	8,465
Net cash provided by (used in) investing activities	9,883	(290,824)	(65,119)	—	(346,060)
Cash flows from financing activities:					
Long-term debt	(60,619)	(1,962)	1,307	—	(61,274)
Intercompany borrowing	101,254	20,885	(122,139)	—	—
Other items	(78,637)	2,516	(54,677)	—	(130,798)
Net cash (used in) provided by financing activities	(38,002)	21,439	(175,509)	—	(192,072)
Net increase (decrease) in cash and cash equivalents	136,974	—	(8,396)	—	128,578
Cash and cash equivalents at beginning of the year	397,576	—	13,305	—	410,881
Cash and cash equivalents at the end of the year	<u>\$534,550</u>	<u>\$—</u>	<u>\$4,909</u>	<u>\$—</u>	<u>\$539,459</u>

**Components of Income Tax
Expense (Detail) (USD \$)
In Thousands, unless
otherwise specified**

12 Months Ended

	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
<u>Current:</u>			
<u>Federal</u>	\$ 217,885	\$ 153,502	\$ 193,181
<u>State</u>	44,403	31,338	34,415
<u>Deferred:</u>			
<u>Federal</u>	46,779	67,901	44,376
<u>State</u>	6,659	7,498	6,493
<u>Income Tax Expense (Benefit), Continuing Operations and Discontinued Operations, Total</u>	\$ 315,726	\$ 260,239	\$ 278,465

**CONSOLIDATED
STATEMENTS OF
INCOME (USD \$)**
In Thousands, except Share
data, unless otherwise
specified

12 Months Ended

	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
<u>Net operating revenues</u>	\$ 6,982,214	\$ 6,438,050	\$ 6,100,648
<u>Operating expenses and charges:</u>			
<u>Patient care costs</u>	4,680,772	4,467,107	4,242,147
<u>General and administrative</u>	691,243	579,000	531,531
<u>Depreciation and amortization</u>	266,628	233,730	228,396
<u>Provision for uncollectible accounts</u>	197,565	170,652	161,388
<u>Equity investment income</u>	(8,776)	(8,999)	(2,442)
<u>Goodwill impairment charge</u>	24,000		
<u>Total operating expenses and charges</u>	5,851,432	5,441,490	5,161,020
<u>Operating income</u>	1,130,782	996,560	939,628
<u>Debt expense</u>	(241,090)	(181,607)	(185,755)
<u>Debt refinancing and redemption charges</u>		(74,382)	
<u>Other income</u>	2,982	3,419	3,706
<u>Income from continuing operations before income taxes</u>	892,674	743,990	757,579
<u>Income tax expense</u>	315,744	260,052	278,213
<u>Income from continuing operations</u>	576,930	483,938	479,366
<u>Discontinued operations:</u>			
<u>Income from operations of discontinued operations, net of tax</u>	1,221	281	393
<u>Loss on disposal of discontinued operations, net of tax</u>	(4,756)		
<u>Net income</u>	573,395	484,219	479,759
<u>Less: Net income attributable to noncontrolling interests</u>	(95,394)	(78,536)	(57,075)
<u>Net income attributable to DaVita Inc.</u>	478,001	405,683	422,684
<u>Earnings per share:</u>			
<u>Basic income from continuing operations per share attributable to DaVita Inc.</u>	\$ 5.09	\$ 3.99	\$ 4.07
<u>Basic net income per share attributable to DaVita Inc.</u>	\$ 5.05	\$ 4.00	\$ 4.08
<u>Diluted income from continuing operations per share attributable to DaVita Inc.</u>	\$ 4.99	\$ 3.93	\$ 4.05
<u>Diluted net income per share attributable to DaVita Inc.</u>	\$ 4.96	\$ 3.94	\$ 4.06
<u>Weighted average shares for earnings per share:</u>			
<u>Basic</u>	94,658,027	101,504,373	103,603,885
<u>Diluted</u>	96,532,110	103,059,171	104,167,685
<u>Amounts attributable to DaVita Inc.:</u>			
<u>Income from continuing operations</u>	481,755	405,402	422,291
<u>Discontinued operations</u>	(3,754)	281	393
<u>Net income attributable to DaVita Inc.</u>	\$ 478,001	\$ 405,683	\$ 422,684

Leases (Tables)

**12 Months Ended
Dec. 31, 2011**

Future Minimum Lease Payments Under Non-cancelable Operating Leases and Capital Leases

Future minimum lease payments under non-cancelable operating leases and capital leases are as follows:

	<u>Operating leases</u>	<u>Capital leases</u>
2012	258,336	4,620
2013	232,569	4,656
2014	211,544	4,510
2015	193,874	4,260
2016	176,063	4,239
Thereafter	<u>635,608</u>	<u>42,335</u>
	<u>\$1,707,994</u>	64,620
Less portion representing interest		<u>(21,256)</u>
Total capital lease obligations, including current portion		<u>\$43,364</u>

**Net Assets of Discontinued
Operations Sold (Detail)
(USD \$)
In Thousands, unless
otherwise specified**

**Dec. 31,
2011**

**Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including
Discontinued Operations [Line Items]**

<u>Current assets</u>	\$ 71,384
<u>Property and equipment, net</u>	5,183
<u>Goodwill</u>	7,999
<u>Liabilities and noncontrolling interests</u>	(836)
<u>Net assets from discontinued operations</u>	\$ 83,730

CONSOLIDATED STATEMENTS OF EQUITY AND COMPREHENSIVE INCOME (USD \$) In Thousands, except Share data, unless otherwise specified	Total	Non- controlling interests subject to put provisions	Common Stock	Additional Paid-in Capital	Retained earnings	Treasury stock	Accumulated other comprehensive income (loss)	Total	Non- controlling interests not subject to put provisions	Comprehensive income
Beginning Balance at Dec. 31, 2008		\$ 291,397	\$ 135	\$ 584,358	\$ 1,889,450	\$ (691,857)	\$ (14,339)	\$ 1,767,747	\$ 59,152	
Beginning Balance (in shares) at Dec. 31, 2008			134,862,000			(31,109,000)				
Comprehensive income:										
Net income	479,759	38,381			422,684			422,684	18,694	479,759
Unrealized losses on interest rate swap and cap agreements, net of tax	(2,578)						(2,578)	(2,578)		(2,578)
Less reclassification of net swap and cap agreements realized losses into net income, net of tax	(10,542)						10,542	10,542		10,542
Unrealized (losses) gains on investments, net of tax	986						986	986		986
Less reclassification of net investment realized (gains) losses into net income, net of tax	159						(159)	(159)		(159)
Total comprehensive income										488,550
Stock purchase shares issued				2,135		2,387		4,522		
Stock purchase shares issued (in shares)						107,000				
Stock unit shares issued				(1,570)		1,570				
Stock unit shares issued (in shares)						69,000				
Stock options and SSARs exercised				15,598		48,055		63,653		
Stock options and SSARs exercised (in shares)						2,036,000				
Stock-based compensation expense				44,422				44,422		
Excess tax benefits from stock awards exercised				6,150				6,150		
Distributions to noncontrolling interests	(44,277)								(23,471)	
Contributions from noncontrolling interests	10,502								2,569	
Sales and assumptions of additional noncontrolling interests	13,483			(529)				(529)	4,039	
Purchases from noncontrolling interests	(2,594)			(3,721)				(3,721)	(544)	
Changes in fair value of noncontrolling interests	24,819			(24,819)				(24,819)		
Other adjustments	14			(339)				(339)	(1,346)	
Purchase of treasury stock						(153,495)		(153,495)		
Purchase of treasury stock (in shares)						(2,903,000)				
Ending Balance at Dec. 31, 2009	331,725	135	621,685	2,312,134	(793,340)	(5,548)		2,135,066	59,093	
Ending Balance (in shares) at Dec. 31, 2009			134,862,000			(31,800,000)				
Comprehensive income:										
Net income	484,219	52,589			405,683			405,683	25,947	484,219

<u>Unrealized losses on interest rate swap and cap agreements, net of tax</u>	(134)			(134)	(134)	(134)		(134)
<u>Less reclassification of net swap and cap agreements realized losses into net income, net of tax</u>	(5,557)			5,557	5,557	5,557		5,557
<u>Unrealized (losses) gains on investments, net of tax</u>	615			615	615	615		615
<u>Less reclassification of net investment realized (gains) losses into net income, net of tax</u>	(13)			13	13	13		13
<u>Total comprehensive income</u>								490,270
<u>Stock purchase shares issued</u>		2,129		2,151		4,280		
<u>Stock purchase shares issued (in shares)</u>				86,000				
<u>Stock unit shares issued</u>		(875)		875				
<u>Stock unit shares issued (in shares)</u>				32,000				
<u>Stock options and SSARs exercised</u>		455		48,231		48,686		
<u>Stock options and SSARs exercised (in shares)</u>				1,740,000				
<u>Stock-based compensation expense</u>		45,551				45,551		
<u>Excess tax benefits from stock awards exercised</u>		6,283				6,283		
<u>Distributions to noncontrolling interests</u>	(54,612)						(28,979)	
<u>Contributions from noncontrolling interests</u>	5,439						4,071	
<u>Sales and assumptions of additional noncontrolling interests</u>	4,059		(298)			(298)	2,308	
<u>Purchases from noncontrolling interests</u>	(4,949)		(5,537)			(5,537)	(3,728)	
<u>Impact on fair value due to change in methodology</u>	(24,571)		24,571			24,571		
<u>Changes in fair value of noncontrolling interests</u>	73,372		(73,372)			(73,372)		
<u>Other adjustments</u>			(46)			(46)		
<u>Purchase of treasury stock</u>				(618,496)		(618,496)		
<u>Purchase of treasury stock (in shares)</u>				(8,919,000)				
<u>Ending Balance at Dec. 31, 2010</u>	2,037,134	383,052	135	620,546	2,717,817	(1,360,579)	503	1,978,422
<u>Ending Balance (in shares) at Dec. 31, 2010</u>	96,001,535		134,862,000			(38,861,000)		58,712
<u>Comprehensive income:</u>								
<u>Net income</u>	573,395	59,135		478,001		478,001	36,259	573,395
<u>Unrealized losses on interest rate swap and cap agreements, net of tax</u>	(29,049)				(29,049)	(29,049)		(29,049)
<u>Less reclassification of net swap and cap agreements realized losses into net income, net of tax</u>	(9,721)			9,721	9,721	9,721		9,721
<u>Unrealized (losses) gains on investments, net of tax</u>	(602)			(602)	(602)	(602)		(602)
<u>Less reclassification of net investment realized (gains) losses into net income, net of tax</u>	57			(57)	(57)	(57)		(57)
<u>Total comprehensive income</u>								553,408

Stock purchase shares issued		4,268		6,554		10,822			
Stock purchase shares issued (in shares)				175,000					
Stock unit shares issued		(2,866)		2,866					
Stock unit shares issued (in shares)				78,000					
Stock options and SSARs exercised		(37,370)		42,813		5,443			
Stock options and SSARs exercised (in shares)				1,182,000					
Stock-based compensation expense		48,718				48,718			
Excess tax benefits from stock awards exercised		20,834				20,834			
Distributions to noncontrolling interests	(61,343)						(39,310)		
Contributions from noncontrolling interests	12,547						8,463		
Sales and assumptions of additional noncontrolling interests	49,343	(1,299)				(1,299)	55,566		
Purchases from noncontrolling interests	(2,103)	(9,486)				(9,486)	(2,100)		
Changes in fair value of noncontrolling interests	63,762	(63,762)				(63,762)			
Expired put provision	(26,177)	16,717				16,717	9,460		
Purchase of treasury stock				(323,348)		(323,348)			
Purchase of treasury stock (in shares)				(3,795,000)					
Ending Balance at Dec. 31, 2011	\$ 2,268,125	\$ 478,216	\$ 135	\$ 596,300	\$ 3,195,818	\$ (1,631,694)	\$ (19,484)	\$ 2,141,075	\$ 127,050
Ending Balance (in shares) at Dec. 31, 2011	93,641,363		134,862,000		(41,221,000)				

**Aggregate Purchase Cost
Allocations for Other
Dialysis Acquisitions (Detail)
(Other dialysis acquisitions,
USD \$)
In Thousands, unless
otherwise specified**

Dec. 31, 2011 Dec. 31, 2010 Dec. 31, 2009

Other dialysis acquisitions

Business Acquisition [Line Items]

<u>Tangible assets, principally leasehold improvements and equipment</u>	\$ 32,649	\$ 21,257	\$ 11,140
<u>Amortizable intangible assets</u>	19,804	18,300	6,703
<u>Goodwill</u>	388,844	152,252	78,199
<u>Noncontrolling interests assumed</u>	(70,821)	(1,171)	(7,567)
<u>Liabilities assumed</u>	(3,577)	(1,687)	(520)
<u>Aggregate purchase cost</u>	\$ 366,899	\$ 188,951	\$ 87,955

**Property and Equipment -
Additional Information
(Detail) (USD \$)
In Thousands, unless
otherwise specified**

12 Months Ended

Dec. 31, 2011 Dec. 31, 2010 Dec. 31, 2009

Property, Plant and Equipment [Line Items]

<u>Depreciation and amortization expense on property and equipment</u>	\$ 249,060	\$ 218,666	\$ 213,657
<u>Interest capitalized</u>	\$ 4,887	\$ 2,621	\$ 3,627

12 Months Ended

Concentrations - Additional Information (Detail) (USD \$) In Thousands, unless otherwise specified	12 Months Ended		Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2011	Dec. 31, 2010
	Dialysis and related lab services Sales Revenue, Services, Net Government-based Programs, Medicare and Medicaid	Dialysis and related lab services Sales Revenue, Services, Net Government-based Programs, Medicare and Medicaid	Dialysis and related lab services Sales Revenue, Services, Net Government-based Programs, Medicare and Medicaid	Dialysis and related lab services Sales Revenue, Services, Net Supplier Concentration Risk	Dialysis and related lab services Sales Revenue, Services, Net Supplier Concentration Risk		
Concentration Risk [Line Items]							
Concentration Risk, Percentage			66.00%	66.00%	65.00%	3.00%	18.00%
Accounts receivable, and other receivables, from Medicare and Medicaid-assigned plans			\$ 617,200	\$ 554,300			
Significant concentration of credit risk	No other single payor accounted for more than 5% of total accounts receivable.	No other single payor accounted for more than 5% of total accounts receivable.					

**Organization and summary
of significant accounting
policies (Policies)**

12 Months Ended

Dec. 31, 2011

Organization

Organization

DaVita Inc. principally operates kidney dialysis centers and provides related lab services primarily in outpatient dialysis centers and in contracted hospitals mainly across the United States. The Company also operates other ancillary services and strategic initiatives, which include the Company's international operations that relate primarily to its core business of providing kidney dialysis services. As of December 31, 2011, the Company operated or provided administrative services through a network of 1,809 outpatient dialysis centers located in the United States throughout 43 states and the District of Columbia, serving approximately 142,000 patients. In addition, as of December 31, 2011, the Company operated or provided administrative services to 11 outpatient dialysis centers located in three countries outside of the United States. The Company's U.S. dialysis and related lab services business qualifies as a separately reportable segment and all other ancillary services and strategic initiatives, including the Company's international operations, have been combined and disclosed in the other segments category.

Basis of presentation

Basis of presentation

These consolidated financial statements are prepared in accordance with United States generally accepted accounting principles. The financial statements include DaVita and its subsidiaries, partnerships and other entities in which it maintains a 100% or majority voting interest, another controlling financial interest, or of which it is the primary beneficiary (collectively, the Company). All significant intercompany transactions and balances have been eliminated. Non-marketable equity investments are recorded under the equity or cost method of accounting based upon whether the Company has significant influence over the investee. The Company has evaluated subsequent events through the date these consolidated financial statements were issued, and have included all necessary disclosures. For the Company's international subsidiaries, local currencies are their functional currencies. A translation adjustment results from the process of translating the Company's international subsidiaries' financial statements which are reflected at their functional currencies into the Company's reporting currency (USD). The translation adjustment as of and for the year ended December 31, 2011 was immaterial.

Use of estimates

Use of estimates

The preparation of financial statements in conformity with United States generally accepted accounting principles requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and temporary equity. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management's best judgments at the time made. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends, or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies. Interim changes in estimates related to annual operating costs are applied prospectively within annual periods.

Net operating revenues and accounts receivable

The most significant assumptions and estimates underlying these financial statements and accompanying notes involve revenue recognition and accounts receivable, impairments of long-lived assets and valuation adjustments, accounting for income taxes, quarterly and annual variable compensation accruals, purchase accounting valuation estimates, fair value estimates and stock-based compensation. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements.

Net operating revenues and accounts receivable

Revenues associated with Medicare and Medicaid programs are recognized based on: (a) the payment rates that are established by statute or regulation for the portion of the payment rates paid by the government payor (e.g., 80% for Medicare patients) and (b) for the portion not paid by the primary government payor, estimates of the amounts ultimately collectible from other government programs paying secondary coverage (e.g., Medicaid secondary coverage), the patient's commercial health plan secondary coverage, or the patient. Effective January 1, 2011, the Company's reimbursements from Medicare are now subject to certain variations under Medicare's new single bundled payment rate system, whereby reimbursements can be adjusted for certain patient characteristics and other factors. The Company's revenue recognition will depend upon its ability to effectively capture, document and bill for Medicare's base payment rate as well as these other variable factors. In addition, as a result of the potential range of variations that can occur in the Company's reimbursements from Medicare under the new single bundled payment rate system, the Company's revenue recognition is now subject to a greater degree of estimating risk.

Revenues associated with commercial health plans are estimated based on contractual terms for the patients under healthcare plans with which the Company has formal agreements, non-contracted health plan coverage terms if known, estimated secondary collections, historical collection experience, historical trends of refunds and payor payment adjustments (retractions), inefficiencies in the Company's billing and collection processes that can result in denied claims for payments, and regulatory compliance issues.

Operating revenues are recognized in the period services are provided. Revenues consist primarily of payments from Medicare, Medicaid and commercial health plans for dialysis and ancillary services provided to patients. A usual and customary fee schedule is maintained for the Company's dialysis treatments and other patient services; however, actual collectible revenue is normally recognized at a discount from the fee schedule.

Commercial revenue recognition also involves significant estimating risks. With many larger, commercial insurers the Company has several different contracts and payment arrangements, and these contracts often include only a subset of the Company's centers. It is often not possible to determine which contract, if any, should be applied prior to billing. In addition, for services provided by non-contracted centers, final collection may require specific negotiation of a payment amount, typically at a significant discount from the Company's usual and customary rates.

Effective January 1, 2011, services covered by Medicare are now subject to a greater degree of estimating risk under Medicare's new single bundled payment rate system, whereby reimbursements from Medicare can vary significantly depending upon certain patient characteristics and other variable factors. Prior to January 1, 2011, services covered by Medicare as well as Medicaid were less subject to estimating risks since both Medicare and Medicaid rates used a prospective payment method established in advance with definitive terms. Even with the

new bundled payment rate system, Medicare payments for bad debt claims are still subject to individual center profitability, as established by cost reports, and require evidence of collection efforts. As a result, billing and collection of Medicare bad debt claims can be delayed significantly, and final payment is subject to audit.

Medicaid payments, when Medicaid coverage is secondary, can also be difficult to estimate. For many states, Medicaid payment terms and methods differ from Medicare, and may prevent accurate estimation of individual payment amounts prior to billing.

Net revenue recognition and allowances for uncollectible billings require the use of estimates of the amounts that will ultimately be realized considering, among other items, retroactive adjustments that may be associated with regulatory reviews, audits, billing reviews and other matters. The Company's policy is to write-off any uncollectible accounts receivable balance only after all collection efforts have been exhausted or when write-off is mandated by federal or state policies or required by certain payor contracts. It is also the Company's policy to write-off any accounts receivable balance associated with any payors or patients upon the Company receiving notification of a bankruptcy filing.

The Company's range of revenue estimating risk for the dialysis and related lab services segment is generally expected to be within 1% of its revenue. Changes in revenue estimates for prior periods are separately disclosed, if material.

Management and administrative support services are provided to outpatient dialysis centers and physician practices and certain other clinics that the Company does not own or in which the Company owns a minority equity investment interest. The management fees are principally determined as a percentage of the managed operations' revenues or cash collections and in some cases an additional component based upon a percentage of operating income. Management fees are included in net operating revenues when earned, and represent less than 1% of total consolidated operating revenues.

Other income

Other income

Other income includes interest income on cash investments and other non-operating gains from investment transactions.

Cash and cash equivalents

Cash and cash equivalents

Cash equivalents are short-term highly liquid investments with maturities of three months or less at date of purchase.

Inventories

Inventories

Inventories are stated at the lower of cost (first-in, first-out) or market and consist principally of pharmaceuticals and dialysis-related supplies. Rebates related to inventory purchases are recorded when earned and are based on certain qualification requirements based upon a variety of factors including future pricing levels by the manufacturer and data submission.

Property and equipment

Property and equipment

Property and equipment is stated at cost less accumulated depreciation and amortization and is further reduced by any impairments. Maintenance and repairs are charged to expense as incurred. Depreciation and amortization expenses are computed using the straight-line method

over the useful lives of the assets estimated as follows: buildings, 20 to 40 years; leasehold improvements, the shorter of their economic useful life or the expected lease term; and equipment and information systems, principally 3 to 8 years. Disposition gains and losses are included in current operating expenses.

Investments

Investments

Based upon the Company's intentions and strategy involving investments in debt and equity securities, the Company classifies certain debt securities as held-to-maturity and measures them at amortized cost. Based upon the Company's other strategies involving investments, the Company classifies equity securities that have readily determinable fair values and certain other debt securities as available for sale and measures them at fair value. Unrealized gains or losses from available for sale investments are recorded in other comprehensive income until realized.

Amortizable intangibles

Amortizable intangibles

Amortizable intangible assets and liabilities include non-competition and similar agreements, lease agreements, hospital acute services contracts, deferred debt financing costs and the Alliance and Product Supply Agreement, each of which have finite useful lives. Non-competition and similar agreements are amortized over the terms of the agreements, typically ten years, using the straight-line method. Lease agreements and hospital acute service contracts are amortized on a straight-line basis over the term of the lease and the contract period, respectively. Deferred debt financing costs are amortized to debt expense over the term of the related debt using the effective interest method. The Alliance and Product Supply Agreement intangible liability is being amortized using the straight-line method over the term of the agreement, which is ten years.

Goodwill

Goodwill

Goodwill represents the difference between the fair value of acquired businesses and the fair value of the identifiable tangible and intangible net assets acquired. Goodwill is not amortized, but is assessed for valuation impairment as circumstances warrant and at least annually. An impairment charge would be recorded to the extent the carrying amount of goodwill exceeds its implied fair value. The Company operates several reporting units for goodwill impairment assessments. See Note 10 to the consolidated financial statements for further details.

Impairment of long-lived assets

Impairment of long-lived assets

Long-lived assets, including property and equipment, equity investments in non-consolidated businesses, and amortizable intangible assets with finite useful lives, are reviewed for possible impairment at least annually and whenever significant events or changes in circumstances indicate that an impairment may have occurred, including changes in the Company's business strategy and plans, changes in the quality or structure of its relationships with its partners and deteriorating operating performance of individual outpatient dialysis centers or other operations. An impairment is indicated when the sum of the expected future undiscounted net cash flows identifiable to an asset or asset group is less than its carrying amount. Impairment losses are measured based upon the difference between the actual or estimated fair values, which are based on market values, net realizable values or projections of discounted net cash flows, as appropriate, compared to the carrying amount of the asset. Impairment charges are included in operating expenses.

Income taxes

Income taxes

Federal and state income taxes are computed at current enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.

The Company uses a recognition threshold of more-likely-than not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements.

[Self insurance](#)

Self insurance

The Company maintains insurance reserves for professional and general liability and workers' compensation in excess of certain individual and or aggregate amounts not covered by third-party carriers. The Company estimates the self-insured retention portion of professional and general liability and workers' compensation risks using third-party actuarial calculations that are based upon historical claims experience and expectations for future claims.

[Noncontrolling interests](#)

Noncontrolling interests

Noncontrolling interests represent the third-party's minority equity ownership interests in consolidated entities which are majority-owned by the Company. As of December 31, 2011, third parties held noncontrolling ownership interests in 196 consolidated entities.

[Stock-based compensation](#)

Stock-based compensation

The Company's stock-based compensation awards are measured at their estimated fair value on the date of grant. Stock-based compensation expense recognized in a period represents the straight-line amortization during that period of the estimated grant date fair value of current and prior stock-based awards over their vesting terms, adjusted for expected forfeitures.

[Interest rate swap and cap agreements](#)

Interest rate swap and cap agreements

The Company has entered into several interest rate swap agreements as a means of hedging its exposure to and volatility from variable-based interest rate changes as part of its overall risk management strategy. These agreements are designated as cash flow hedges and are not held for trading or speculative purposes. The swap agreements have the economic effect of converting the LIBOR variable component of the Company's interest rate to fixed rates. In addition, in January 2011, the Company entered into several interest rate cap agreements that have the economic effect of capping the Company's maximum exposure to LIBOR variable interest rate changes on specific portions of the Company's other variable-based rate debt. See Note 13 to the consolidated financial statements for further details.

[Fair value estimates](#)

Fair value estimates

The Company currently measures the fair value of certain assets, liabilities and noncontrolling interests subject to put provisions (temporary equity) based upon certain valuation techniques that include observable or unobservable market inputs and assumptions that market participants would use in pricing these assets, liabilities and temporary equity. The Company also has classified its assets, liabilities and temporary equity into the appropriate fair value hierarchy levels as defined by the Financial Accounting Standards Board (FASB). See Note 23 to the consolidated financial statements for further details.

New accounting standards

New accounting standards

On January 1, 2012, the Company adopted FASB's Accounting Standard Update (ASU) No. 2011-08, *Intangibles – Goodwill and Other*. This standard amends the current two-step goodwill impairment test required under the existing accounting guidance. This amendment allows entities the option to first assess certain qualitative factors to ascertain whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount to determine if the two-step impairment test is necessary. If an entity concludes that certain events or circumstances prove that it is more likely than not that the fair value of a reporting unit is less than its carrying amount then an entity is required to proceed to step one of the two-step goodwill impairment test. This standard is effective during interim and annual periods beginning after December 15, 2011. The adoption of this standard did not have a material impact on the Company's consolidated financial statements.

On January 1, 2012, the Company adopted FASB's ASU No. 2011-07, *Health Care Entities- Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debts, and the Allowance for Doubtful Accounts*. This standard amends the current presentation and disclosure requirements for Health Care Entities that recognize significant amounts of patient service revenue at the time the services are rendered without assessing the patient's ability to pay. This standard requires health care entities to reclassify the provision for bad debts from an operating expense to a deduction from patient service revenues. In addition, this standard requires more disclosure on the policies for recognizing revenue, assessing bad debts, as well as quantitative and qualitative information regarding changes in the allowance for doubtful accounts. This standard is applied retrospectively to all prior periods presented and is effective during interim and annual periods beginning after December 15, 2011. The adoption of this standard will require the Company to change the presentation in its financial statements.

On January 1, 2012, the Company adopted FASB's ASU No. 2011-05, *Comprehensive Income – Presentation of Comprehensive Income*. This standard amends the current presentation requirements for comprehensive income by eliminating the presentation of the components of other comprehensive income within the statement of equity. This standard allows two options on how to present the various components of comprehensive income. These options are either to report the components of comprehensive income separately on the income statement or to present total other comprehensive income and the components of other comprehensive income in a separate statement. This standard does not change the items that must be reported in other comprehensive income or when an item must be reclassified into net income. This standard is applied retrospectively and is effective for fiscal years and interim periods within those years beginning after December 15, 2011. Early adoption is permitted. The adoption of this standard will require the Company to change the presentation in its financial statements.

On January 1, 2012, the Company adopted FASB's ASU No. 2011-04, *Fair Value Measurement*. This standard amends the current fair value measurement and disclosure

requirements to improve comparability between U.S. GAAP and International Financial Reporting Standards (IFRS). The intent of this standard is to update the disclosures that describe several of the requirements in U.S. GAAP for measuring fair value and to enhance disclosures about fair value measurements which will improve consistency between U.S. GAAP and IFRS. This standard does not change the application of the requirements on fair value measurements and disclosures. This standard is applied prospectively and is effective during interim and annual periods beginning after December 15, 2011. The adoption of this standard did not have a material impact on the Company's consolidated financial statements.

Investments (Detail) (USD \$)
In Thousands, unless
otherwise specified

Dec. 31,
2011 **Dec. 31,**
2010

Schedule of Trading Securities and Other Trading Assets [Line Items]

<u>Certificates of deposit, money market funds and U.S. treasury notes due within one year</u>	\$ 11,754	\$ 21,803
<u>Investments in mutual funds and NxStage common stock</u>	15,535	10,048
<u>Investments, Total</u>	27,289	31,851
<u>Short-term investments</u>	17,399	23,003
<u>Long-term investments</u>	9,890	8,848
<u>Investments</u>	27,289	31,851
Held to maturity		

Schedule of Trading Securities and Other Trading Assets [Line Items]

<u>Certificates of deposit, money market funds and U.S. treasury notes due within one year</u>	11,754	21,803
<u>Investments, Total</u>	11,754	21,803
<u>Short-term investments</u>	11,754	21,803
<u>Investments</u>	11,754	21,803
Available for sale		

Schedule of Trading Securities and Other Trading Assets [Line Items]

<u>Investments in mutual funds and NxStage common stock</u>	15,535	10,048
<u>Investments, Total</u>	15,535	10,048
<u>Short-term investments</u>	5,645	1,200
<u>Long-term investments</u>	9,890	8,848
<u>Investments</u>	\$ 15,535	\$ 10,048

Contingencies

**12 Months Ended
Dec. 31, 2011**

[Contingencies](#)

16. Contingencies

The majority of the Company's revenues are from government programs and may be subject to adjustment as a result of: (1) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (2) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (3) differing opinions regarding a patient's medical diagnosis or the medical necessity of services provided; and (4) retroactive applications or interpretations of governmental requirements. In addition, the Company's revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.

Inquiries by the Federal Government and Certain Related Civil Proceedings

2005 U.S. Attorney Investigation: In March 2005, the Company received a subpoena from the U.S. Attorney's Office for the Eastern District of Missouri in St. Louis. The subpoena required production of a wide range of documents relating to the Company's operations, including documents related to, among other things, pharmaceutical and other services provided to patients, relationships with pharmaceutical companies, and financial relationships with physicians and joint ventures. The subpoena covers the period from December 1, 1996 through March 2005. In October 2005, the Company received a follow-up request for additional documents related to specific medical director and joint venture arrangements. In February 2006, the Company received an additional subpoena for documents, including certain patient records relating to the administration and billing of EPO. In May 2007, the Company received a request for documents related to durable medical equipment and supply companies owned and operated by the Company. The Company cooperated with the inquiry and has produced the requested records. The subpoenas were issued in connection with a joint civil and criminal investigation. It is possible that criminal proceedings may be initiated against the Company in connection with this investigation. The Company has not received a communication from the St. Louis U.S. Attorney's Office on this matter in over two years.

Woodard Private Civil Suit: In February 2007, the Company received a request for information from the Office of Inspector General, U.S. Department of Health and Human Services, or OIG, for records relating to EPO claims submitted to Medicare. In August 2007, the Company received a subpoena from the OIG seeking similar documents. The requested documents relate to services provided from 2001 to 2004 by a number of the Company's centers. The request and subpoena were sent from the OIG's offices in Houston and Dallas, Texas. The Company cooperated with the inquiry and has produced all previously requested records to date. The Company was contacted by the U.S. Attorney's Office for the Eastern District of Texas, which stated that this was a civil investigation related to EPO claims. On July 6, 2009, the United States District Court for the Eastern District of Texas lifted the seal on the civil *qui tam* complaint related to these previous requests for information. The Company was subsequently served with a complaint by the relator, Ivey Woodard, purportedly on behalf of the federal government, under the *qui tam* provisions of the federal False Claims Act. The government did not intervene and is not actively pursuing this matter. The relator is pursuing the claims independently and the parties are engaged in active litigation. The complaint contains allegations relating to the Company's EPO practices for the period from 1992 through 2010 and seeks monetary damages and civil

penalties as well as costs and expenses. The court has ruled that claims earlier than 1996 are beyond the statute of limitations. The Company believes that there is some overlap between the subject of this complaint and the review of EPO utilization in the 2005 U.S. Attorney investigation described above. The Company is vigorously defending this matter and intends to continue to do so. The Company can make no assurances as to the time or resources that will be needed to devote to this litigation or its final outcome.

Vainer Private Civil Suit: In December 2008, the Company received a subpoena for documents from the OIG relating to the pharmaceutical products Zemplar, Hectorol, Venofer, Ferrlecit and EPO, as well as other related matters. The subpoena covers the period from January 2003 to December 2008. The Company was in contact with the U.S. Attorney's Office for the Northern District of Georgia and the U.S. Department of Justice in Washington, DC, since November 2008 relating to this matter, and was advised that this was a civil inquiry. On June 17, 2009, the Company learned that the allegations underlying this inquiry were made as part of a civil complaint filed by individuals and brought pursuant to the *qui tam* provisions of the federal False Claims Act. On April 1, 2011, the United States District Court for the Northern District of Georgia ordered the case to be unsealed. At that time, the Department of Justice and U.S. Attorney's Office filed a notice of declination stating that the United States would not be intervening and not pursuing the relators' allegation in litigation. On July 25, 2011, the relators, Daniel Barbir and Dr. Alon Vainer, filed their amended complaint in the United States District Court for the Northern District of Georgia, purportedly on behalf of the federal government. The allegations in the complaint relate to the Company's drug administration practices for Vitamin D and iron agents for a period from 2003 through 2010. The complaint seeks monetary damages and civil penalties as well as costs and expenses. The Company is vigorously defending this matter and intends to continue to do so. The Company can make no assurances as to the time or resources that will be needed to devote to this litigation or its final outcome.

2010 U.S. Attorney Physician Relationship Investigation: In May 2010, the Company received a subpoena from the OIG's office in Dallas, Texas. The subpoena covers the period from January 1, 2005 to May 2010, and seeks production of a wide range of documents relating to the Company's operations, including documents related to, among other things, financial relationships with physicians and joint ventures. The general subject matter of the inquiry appears to overlap with the 2005 U.S. Attorney Investigation described above. The Company met with representatives of the government to discuss the scope of the subpoena and the production of responsive documents. The Company has been advised that this is a civil investigation. The Company is cooperating with the inquiry and is producing the requested records. The Company can make no assurances as to the time or resources that will be needed to devote to this litigation or its final outcome.

2011 U.S. Attorney Physician Relationship Investigation: In August 2011, the Company announced it had learned that the U.S. Attorney's Office for the District of Colorado would be looking into certain activities of the Company in connection with information being provided to a grand jury. The Company announced further that it understood that this investigation was at a very preliminary stage, and while its precise scope was unclear, it appeared to overlap, at least in part, with the 2005 U.S. Attorney Investigation and 2010 U.S. Attorney Physician Relationship Investigation described above. Subsequent to the Company's announcement of this 2011 U.S. Attorney Physician Relationship Investigation, it received a subpoena for documents which substantially overlaps with the subpoena in the 2010 U.S. Attorney Physician Relationship Investigation described above and covers the period from January 2006 to September 2011. The

Company is cooperating with the government and is producing the requested records. Certain current and former members of the Board and executives received subpoenas in November 2011 and thereafter to testify before the grand jury, and other Company representatives may also receive subpoenas for testimony related to this matter. The Company can make no assurances as to the time or resources that will be needed to devote to this litigation or its final outcome.

2011 U.S. Attorney Medicaid Investigation: In October 2011, the Company announced that it would be receiving a request for documents, which could include an administrative subpoena from the Office of Inspector General for the U.S. Department of Health and Human Services. Subsequent to the Company's announcement of this 2011 U.S. Attorney Medicaid Investigation, the Company received a request for documents in connection with the inquiry by the United States Attorney's Office for the Eastern District of New York. The request relates to payments for infusion drugs covered by Medicaid composite payments for dialysis. The Company believes this inquiry is civil in nature. The Company does not know the time period or scope. The Company understands that certain other providers that operate dialysis clinics in New York may be receiving or have received a similar request for documents. The Company intends to cooperate with the government to provide responsive documents.

Except for the private civil complaints filed by the relators as described above, to the Company's knowledge, no proceedings have been initiated against the Company at this time in connection with any of the inquiries by the federal government. Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved, it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators. Responding to the subpoenas or inquiries and defending the Company in the relator proceedings will continue to require management's attention and significant legal expense. Any negative findings in the inquiries or relator proceedings could result in substantial financial penalties or awards against the Company, exclusion from future participation in the Medicare and Medicaid programs and, to the extent criminal proceedings may be initiated against the Company, possible criminal penalties. At this time, the Company cannot predict the ultimate outcome of these inquiries, or the potential outcome of the relators claims, or the potential range of damages, if any.

Other

The Company has received several notices of claims from commercial payors and other third parties related to historical billing practices and claims against DVA Renal Healthcare (formerly known as Gambro Healthcare), a subsidiary of the Company, related to historical Gambro Healthcare billing practices and other matters covered by its 2004 settlement agreement with the Department of Justice and certain agencies of the U.S. government. The Company has received no further indication that any of these claims are active, and some of them may be barred by applicable statutes of limitations. To the extent any of these claims might proceed, the Company intends to defend against them vigorously; however, the Company may not be successful and these claims may lead to litigation and any such litigation may be resolved unfavorably. At this time, the Company cannot predict the ultimate outcome of this matter or the potential range of damages, if any.

A wage and hour claim, which has been styled as a class action, is pending against the Company in the Superior Court of California. The Company was served with the complaint in this lawsuit in April 2008, and it has been amended since that time. The lawsuit, as amended,

alleges that the Company failed to provide meal periods, failed to pay compensation in lieu of providing rest or meal periods, failed to pay overtime, and failed to comply with certain other California Labor Code requirements. In September 2011, the court denied the plaintiffs' motion for class certification. Plaintiffs have appealed that decision. The Company intends to continue to vigorously defend against these claims. Any potential settlement of these claims is not anticipated to be material to the Company's consolidated financial statements.

In October 2007, the Company was contacted by the Attorney General's Office for the State of Nevada. The Attorney General's Office informed the Company that it was conducting a civil and criminal investigation of the Company's operations in Nevada and that the investigation related to the billing of pharmaceuticals, including EPO. In February 2008, the Attorney General's Office informed the Company that the civil and criminal investigation had been discontinued. The Attorney General's Office further advised the Company that Nevada Medicaid intended to conduct audits of end stage renal disease (ESRD) dialysis providers in Nevada and such audits would relate to the issues that were the subjects of the investigation. To the Company's knowledge, no court proceedings have been initiated against the Company at this time. Any negative audit findings could result in a substantial repayment by the Company. At this time, the Company cannot predict the ultimate outcome of this matter or the potential range of damages, if any.

In June 2004, DVA Renal Healthcare was served with a complaint filed in the Superior Court of California by one of its former employees who worked for its California acute services program. The complaint, which is styled as a class action, alleges, among other things, that DVA Renal Healthcare failed to provide overtime wages, defined rest periods and meal periods, or compensation in lieu of such provisions and failed to comply with certain other California Labor Code requirements. The parties have reached an agreement, subject to approval by the court, which fully resolves this matter for an amount that did not materially impact the Company's financial results.

In addition to the foregoing, the Company is subject to claims and suits, including from time to time, contractual disputes and professional and general liability claims, as well as audits and investigations by various government entities, in the ordinary course of business. The Company believes that the ultimate resolution of any such pending proceedings, whether the underlying claims are covered by insurance or not, will not have a material adverse effect on its financial condition, results of operations or cash flows.

Earnings per share (Tables)

12 Months Ended Dec. 31, 2011

[Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share](#)

The reconciliations of the numerators and denominators used to calculate basic and diluted net income per share are as follows:

	Year ended December 31,		
	2011	2010	2009
	(shares in thousands)		
Basic:			
Income from continuing operations attributable to DaVita Inc.	\$481,755	\$405,402	\$422,291
Decrease (increase) in noncontrolling interest redemption rights in excess of fair value	335	(68)	(267)
Income from continuing operations for basic earnings per share calculation	\$482,090	\$405,334	\$422,024
Discontinued operations attributable to DaVita Inc.	(3,754)	281	393
Net income attributable to DaVita Inc. for basic earnings per share calculation	<u>\$478,336</u>	<u>\$405,615</u>	<u>\$422,417</u>
Weighted average shares outstanding during the period	94,655	101,497	103,595
Vested stock units	3	7	9
Weighted average shares for basic earnings per share calculation	<u>94,658</u>	<u>101,504</u>	<u>103,604</u>
Basic income from continuing operations per share attributable to DaVita Inc.	<u>\$5.09</u>	<u>\$3.99</u>	<u>\$4.07</u>
Basic net income per share attributable to DaVita Inc.	<u>\$5.05</u>	<u>\$4.00</u>	<u>\$4.08</u>
Diluted:			
Income from continuing operations attributable to DaVita Inc.	\$481,755	\$405,402	\$422,291
Decrease (increase) in noncontrolling interest redemption rights in excess of fair value	335	(68)	(267)
Income from continuing operations for diluted earnings per share calculation	\$482,090	\$405,334	\$422,024
Discontinued operations attributable to DaVita Inc.	(3,754)	281	393
Net income attributable to DaVita Inc. for diluted earnings per share calculation	<u>\$478,336</u>	<u>\$405,615</u>	<u>\$422,417</u>
Weighted average shares outstanding during the period	94,655	101,497	103,595
Vested stock units	3	7	9
Assumed incremental shares from stock plans	1,874	1,555	564

Weighted average shares for diluted earnings per share calculation	<u>96,532</u>	<u>103,059</u>	<u>104,168</u>
Diluted income from continuing operations per share attributable to DaVita Inc.	<u>\$4.99</u>	<u>\$3.93</u>	<u>\$4.05</u>
Diluted net income per share attributable to DaVita Inc.	<u><u>\$4.96</u></u>	<u><u>\$3.94</u></u>	<u><u>\$4.06</u></u>
Anti-dilutive stock-settled awards excluded from calculation (1)	<u>2,388</u>	<u>1,452</u>	<u>9,912</u>

(1) Shares associated with stock-settled stock appreciation rights and stock options that are excluded from the diluted denominator calculation because they are anti-dilutive under the treasury stock method.

**Variable Interest Entities -
Additional Information
(Detail) (USD \$) Dec. 31, 2011
In Thousands, unless
otherwise specified**

Variable Interest Entity [Line Items]

<u>Asset</u>	\$ 7,000
<u>Liabilities</u>	\$ 5,000

Other comprehensive income

12 Months Ended
Dec. 31, 2011

[Other comprehensive income](#) 18. Other comprehensive income

Charges and credits to other comprehensive income have been as follows:

	2009		Net-of- tax amount
	Before tax amount	Tax (expense) benefit	
Unrealized losses on interest rate swaps	\$(4,220)	\$ 1,642	\$(2,578)
Less reclassification of net swap realized losses into net income	17,253	(6,711)	10,542
Net swap activity	13,033	(5,069)	7,964
Unrealized gains on investments	1,614	(628)	986
Less reclassification of net investment realized gains into net income	(261)	102	(159)
Net investment activity	1,353	(526)	827
Total	<u>\$14,386</u>	<u>\$ (5,595)</u>	<u>\$8,791</u>

	2010		Net-of- tax amount
	Before tax amount	Tax (expense) benefit	
Unrealized losses on interest rate swaps	\$(217)	\$ 83	\$(134)
Less reclassification of net swap realized losses into net income	9,093	(3,536)	5,557
Net swap activity	8,876	(3,453)	5,423
Unrealized gains on investments	1,007	(392)	615
Less reclassification of net investment realized losses into net income	22	(9)	13
Net investment activity	1,029	(401)	628
Total	<u>\$ 9,905</u>	<u>\$ (3,854)</u>	<u>\$6,051</u>

	2011		Net-of-tax amount
	Before tax amount	Tax (expense) benefit	
Unrealized losses on interest rate swap and cap agreements	\$(47,544)	\$ 18,495	\$(29,049)
Less reclassification of net swap and cap agreements realized losses into net income	15,911	(6,190)	9,721

Net swap and cap agreements activity	(31,633)	12,305	(19,328)
Unrealized losses on investments	(986)	384	(602)
Less reclassification of net investment realized gains into net income	(93)	36	(57)
Net investment activity	(1,079)	420	(659)
Total	<u>\$(32,712)</u>	<u>\$ 12,725</u>	<u>\$(19,987)</u>

Changes in accumulated other comprehensive income (loss) has been as follows:

	Interest rate swap and cap agreements	Investment securities	Accumulated other comprehensive income
Balance December 31, 2009	\$(5,423)	\$ (125)	\$ (5,548)
Net activity	5,423	628	6,051
Balance December 31, 2010	\$—	\$ 503	\$ 503
Net activity	(19,328)	(659)	(19,987)
Balance December 31, 2011	<u>\$(19,328)</u>	<u>\$ (156)</u>	<u>\$ (19,484)</u>

Goodwill - Additional Information (Detail) (USD \$) In Thousands, unless otherwise specified	3 Months Ended Jun. 30, 2011	12 Months Ended Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Goodwill [Line Items]				
Goodwill		\$ 4,946,976	\$ 4,091,307	\$ 3,951,196
Pre-tax goodwill impairment charge	24,000	24,000		
Other-Ancillary services and strategic initiatives				
Goodwill [Line Items]				
Goodwill		81,112	68,942	
Dialysis and related lab services				
Goodwill [Line Items]				
Goodwill		4,865,864	4,022,365	
HomeChoice Partners Other-Ancillary services and strategic initiatives				
Goodwill [Line Items]				
Goodwill		\$ 32,000		

Consolidating Statements of Income (Detail) (USD \$) In Thousands, unless otherwise specified	1	3 Months Ended								12 Months Ended		
	Months Ended Nov. 19, 2010	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Condensed Financial Statements, Captions [Line Items]												
Net operating revenues		\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$
		1,862,318	1,807,869	1,708,643	1,603,384	1,646,924	1,649,557	1,584,821	1,556,748	6,982,214	6,438,050	6,100,648
Operating expenses										5,851,432	5,441,490	5,161,020
Operating income		330,112	318,712	246,624	235,334	255,258	256,745	242,512	242,045	1,130,782	996,560	939,628
Debt (expense)	(74,431)									(241,090)	(255,989)	(185,755)
Other income, net										2,982	3,419	3,706
Income tax expense										315,744	260,052	278,213
Income from continuing operations										576,930	483,938	479,366
Discontinued operations net of (loss) gain on disposal of discontinued operations		(1,307)	(2,612)	253	131	93	(95)	(89)	372	(3,535)	281	393
Net income										573,395	484,219	479,759
Less: Net income attributable to noncontrolling interests										(95,394)	(78,536)	(57,075)
Net income attributable to DaVita Inc.		148,123	135,361	100,015	94,502	69,020	119,387	107,853	109,423	478,001	405,683	422,684
DaVita Inc.												
Condensed Financial Statements, Captions [Line Items]												
Net operating revenues										457,460	431,780	401,058
Operating expenses										301,255	259,302	246,578
Operating income										156,205	172,478	154,480
Debt (expense)										(242,730)	(257,243)	(188,109)
Other income, net										229,658	165,934	186,189
Income tax expense										56,681	31,656	60,414
Equity earnings in subsidiaries										391,549	356,170	330,538
Income from continuing operations										478,001	405,683	422,684
Net income										478,001	405,683	422,684
Net income attributable to DaVita Inc.										478,001	405,683	422,684
Guarantor Subsidiaries												
Condensed Financial Statements, Captions [Line Items]												
Net operating revenues										5,527,588	5,195,449	5,005,839
Operating expenses										4,827,005	4,615,716	4,375,032
Operating income										700,583	579,733	630,807
Debt (expense)										(218,182)	(163,034)	(181,853)
Other income, net										1,583	1,837	2,718
Income tax expense										248,139	220,867	218,618
Equity earnings in subsidiaries										184,404	157,278	94,964
Income from continuing operations										420,249	354,947	328,018
Discontinued operations net of (loss) gain on disposal of discontinued operations										(4,191)	172	180
Net income										416,058	355,119	328,198
Net income attributable to DaVita Inc.										416,058	355,119	328,198

Non-Guarantor Subsidiaries

Condensed Financial Statements, Captions [Line Items]

<u>Net operating revenues</u>	1,541,618	1,288,259	1,147,394
<u>Operating expenses</u>	1,267,624	1,043,910	993,053
<u>Operating income</u>	273,994	244,349	154,341
<u>Debt (expense)</u>	(9,215)	(1,277)	(1,721)
<u>Other income, net</u>	778	1,213	727
<u>Income tax expense</u>	10,924	7,529	(819)
<u>Income from continuing operations</u>	254,633	236,756	154,166
<u>Discontinued operations net of (loss) gain on disposal of discontinued operations</u>	656	109	213
<u>Net income</u>	255,289	236,865	154,379
<u>Net income attributable to DaVita Inc.</u>	255,289	236,865	154,379

Consolidating Adjustments

Condensed Financial Statements, Captions [Line Items]

<u>Net operating revenues</u>	(544,452)	(477,438)	(453,643)
<u>Operating expenses</u>	(544,452)	(477,438)	(453,643)
<u>Debt (expense)</u>	229,037	165,565	185,928
<u>Other income, net</u>	(229,037)	(165,565)	(185,928)
<u>Equity earnings in subsidiaries</u>	(575,953)	(513,448)	(425,502)
<u>Income from continuing operations</u>	(575,953)	(513,448)	(425,502)
<u>Net income</u>	(575,953)	(513,448)	(425,502)
<u>Less: Net income attributable to noncontrolling interests</u>	(95,394)	(78,536)	(57,075)
<u>Net income attributable to DaVita Inc.</u>	\$ (671,347)	\$ (591,984)	\$ (482,577)

**Organization and summary
of significant accounting
policies**

12 Months Ended

Dec. 31, 2011

[Organization and summary of
significant accounting policies](#)

1. Organization and summary of significant accounting policies

Organization

DaVita Inc. principally operates kidney dialysis centers and provides related lab services primarily in outpatient dialysis centers and in contracted hospitals mainly across the United States. The Company also operates other ancillary services and strategic initiatives, which include the Company's international operations that relate primarily to its core business of providing kidney dialysis services. As of December 31, 2011, the Company operated or provided administrative services through a network of 1,809 outpatient dialysis centers located in the United States throughout 43 states and the District of Columbia, serving approximately 142,000 patients. In addition, as of December 31, 2011, the Company operated or provided administrative services to 11 outpatient dialysis centers located in three countries outside of the United States. The Company's U.S. dialysis and related lab services business qualifies as a separately reportable segment and all other ancillary services and strategic initiatives, including the Company's international operations, have been combined and disclosed in the other segments category.

Basis of presentation

These consolidated financial statements are prepared in accordance with United States generally accepted accounting principles. The financial statements include DaVita and its subsidiaries, partnerships and other entities in which it maintains a 100% or majority voting interest, another controlling financial interest, or of which it is the primary beneficiary (collectively, the Company). All significant intercompany transactions and balances have been eliminated. Non-marketable equity investments are recorded under the equity or cost method of accounting based upon whether the Company has significant influence over the investee. The Company has evaluated subsequent events through the date these consolidated financial statements were issued, and have included all necessary disclosures. For the Company's international subsidiaries, local currencies are their functional currencies. A translation adjustment results from the process of translating the Company's international subsidiaries' financial statements which are reflected at their functional currencies into the Company's reporting currency (USD). The translation adjustment as of and for the year ended December 31, 2011 was immaterial.

Use of estimates

The preparation of financial statements in conformity with United States generally accepted accounting principles requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and temporary equity. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management's best judgments at the time made. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends, or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies. Interim changes in estimates related to annual operating costs are applied prospectively within annual periods.

The most significant assumptions and estimates underlying these financial statements and accompanying notes involve revenue recognition and accounts receivable, impairments of long-lived assets and valuation adjustments, accounting for income taxes, quarterly and annual variable compensation accruals, purchase accounting valuation estimates, fair value estimates and stock-based compensation. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements.

Net operating revenues and accounts receivable

Revenues associated with Medicare and Medicaid programs are recognized based on: (a) the payment rates that are established by statute or regulation for the portion of the payment rates paid by the government payor (e.g., 80% for Medicare patients) and (b) for the portion not paid by the primary government payor, estimates of the amounts ultimately collectible from other government programs paying secondary coverage (e.g., Medicaid secondary coverage), the patient's commercial health plan secondary coverage, or the patient. Effective January 1, 2011, the Company's reimbursements from Medicare are now subject to certain variations under Medicare's new single bundled payment rate system, whereby reimbursements can be adjusted for certain patient characteristics and other factors. The Company's revenue recognition will depend upon its ability to effectively capture, document and bill for Medicare's base payment rate as well as these other variable factors. In addition, as a result of the potential range of variations that can occur in the Company's reimbursements from Medicare under the new single bundled payment rate system, the Company's revenue recognition is now subject to a greater degree of estimating risk.

Revenues associated with commercial health plans are estimated based on contractual terms for the patients under healthcare plans with which the Company has formal agreements, non-contracted health plan coverage terms if known, estimated secondary collections, historical collection experience, historical trends of refunds and payor payment adjustments (retractions), inefficiencies in the Company's billing and collection processes that can result in denied claims for payments, and regulatory compliance issues.

Operating revenues are recognized in the period services are provided. Revenues consist primarily of payments from Medicare, Medicaid and commercial health plans for dialysis and ancillary services provided to patients. A usual and customary fee schedule is maintained for the Company's dialysis treatments and other patient services; however, actual collectible revenue is normally recognized at a discount from the fee schedule.

Commercial revenue recognition also involves significant estimating risks. With many larger, commercial insurers the Company has several different contracts and payment arrangements, and these contracts often include only a subset of the Company's centers. It is often not possible to determine which contract, if any, should be applied prior to billing. In addition, for services provided by non-contracted centers, final collection may require specific negotiation of a payment amount, typically at a significant discount from the Company's usual and customary rates.

Effective January 1, 2011, services covered by Medicare are now subject to a greater degree of estimating risk under Medicare's new single bundled payment rate system, whereby reimbursements from Medicare can vary significantly depending upon certain patient characteristics and other variable factors. Prior to January 1, 2011, services covered by Medicare as well as Medicaid were less subject to estimating risks since both Medicare and Medicaid rates

used a prospective payment method established in advance with definitive terms. Even with the new bundled payment rate system, Medicare payments for bad debt claims are still subject to individual center profitability, as established by cost reports, and require evidence of collection efforts. As a result, billing and collection of Medicare bad debt claims can be delayed significantly, and final payment is subject to audit.

Medicaid payments, when Medicaid coverage is secondary, can also be difficult to estimate. For many states, Medicaid payment terms and methods differ from Medicare, and may prevent accurate estimation of individual payment amounts prior to billing.

Net revenue recognition and allowances for uncollectible billings require the use of estimates of the amounts that will ultimately be realized considering, among other items, retroactive adjustments that may be associated with regulatory reviews, audits, billing reviews and other matters. The Company's policy is to write-off any uncollectible accounts receivable balance only after all collection efforts have been exhausted or when write-off is mandated by federal or state policies or required by certain payor contracts. It is also the Company's policy to write-off any accounts receivable balance associated with any payors or patients upon the Company receiving notification of a bankruptcy filing.

The Company's range of revenue estimating risk for the dialysis and related lab services segment is generally expected to be within 1% of its revenue. Changes in revenue estimates for prior periods are separately disclosed, if material.

Management and administrative support services are provided to outpatient dialysis centers and physician practices and certain other clinics that the Company does not own or in which the Company owns a minority equity investment interest. The management fees are principally determined as a percentage of the managed operations' revenues or cash collections and in some cases an additional component based upon a percentage of operating income. Management fees are included in net operating revenues when earned, and represent less than 1% of total consolidated operating revenues.

Other income

Other income includes interest income on cash investments and other non-operating gains from investment transactions.

Cash and cash equivalents

Cash equivalents are short-term highly liquid investments with maturities of three months or less at date of purchase.

Inventories

Inventories are stated at the lower of cost (first-in, first-out) or market and consist principally of pharmaceuticals and dialysis-related supplies. Rebates related to inventory purchases are recorded when earned and are based on certain qualification requirements based upon a variety of factors including future pricing levels by the manufacturer and data submission.

Property and equipment

Property and equipment is stated at cost less accumulated depreciation and amortization and is further reduced by any impairments. Maintenance and repairs are charged to expense as incurred. Depreciation and amortization expenses are computed using the straight-line method

over the useful lives of the assets estimated as follows: buildings, 20 to 40 years; leasehold improvements, the shorter of their economic useful life or the expected lease term; and equipment and information systems, principally 3 to 8 years. Disposition gains and losses are included in current operating expenses.

Investments

Based upon the Company's intentions and strategy involving investments in debt and equity securities, the Company classifies certain debt securities as held-to-maturity and measures them at amortized cost. Based upon the Company's other strategies involving investments, the Company classifies equity securities that have readily determinable fair values and certain other debt securities as available for sale and measures them at fair value. Unrealized gains or losses from available for sale investments are recorded in other comprehensive income until realized.

Amortizable intangibles

Amortizable intangible assets and liabilities include non-competition and similar agreements, lease agreements, hospital acute services contracts, deferred debt financing costs and the Alliance and Product Supply Agreement, each of which have finite useful lives. Non-competition and similar agreements are amortized over the terms of the agreements, typically ten years, using the straight-line method. Lease agreements and hospital acute service contracts are amortized on a straight-line basis over the term of the lease and the contract period, respectively. Deferred debt financing costs are amortized to debt expense over the term of the related debt using the effective interest method. The Alliance and Product Supply Agreement intangible liability is being amortized using the straight-line method over the term of the agreement, which is ten years.

Goodwill

Goodwill represents the difference between the fair value of acquired businesses and the fair value of the identifiable tangible and intangible net assets acquired. Goodwill is not amortized, but is assessed for valuation impairment as circumstances warrant and at least annually. An impairment charge would be recorded to the extent the carrying amount of goodwill exceeds its implied fair value. The Company operates several reporting units for goodwill impairment assessments. See Note 10 to the consolidated financial statements for further details.

Impairment of long-lived assets

Long-lived assets, including property and equipment, equity investments in non-consolidated businesses, and amortizable intangible assets with finite useful lives, are reviewed for possible impairment at least annually and whenever significant events or changes in circumstances indicate that an impairment may have occurred, including changes in the Company's business strategy and plans, changes in the quality or structure of its relationships with its partners and deteriorating operating performance of individual outpatient dialysis centers or other operations. An impairment is indicated when the sum of the expected future undiscounted net cash flows identifiable to an asset or asset group is less than its carrying amount. Impairment losses are measured based upon the difference between the actual or estimated fair values, which are based on market values, net realizable values or projections of discounted net cash flows, as appropriate, compared to the carrying amount of the asset. Impairment charges are included in operating expenses.

Income taxes

Federal and state income taxes are computed at current enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.

The Company uses a recognition threshold of more-likely-than not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements.

Self insurance

The Company maintains insurance reserves for professional and general liability and workers' compensation in excess of certain individual and or aggregate amounts not covered by third-party carriers. The Company estimates the self-insured retention portion of professional and general liability and workers' compensation risks using third-party actuarial calculations that are based upon historical claims experience and expectations for future claims.

Noncontrolling interests

Noncontrolling interests represent the third-party's minority equity ownership interests in consolidated entities which are majority-owned by the Company. As of December 31, 2011, third parties held noncontrolling ownership interests in 196 consolidated entities.

Stock-based compensation

The Company's stock-based compensation awards are measured at their estimated fair value on the date of grant. Stock-based compensation expense recognized in a period represents the straight-line amortization during that period of the estimated grant date fair value of current and prior stock-based awards over their vesting terms, adjusted for expected forfeitures.

Interest rate swap and cap agreements

The Company has entered into several interest rate swap agreements as a means of hedging its exposure to and volatility from variable-based interest rate changes as part of its overall risk management strategy. These agreements are designated as cash flow hedges and are not held for trading or speculative purposes. The swap agreements have the economic effect of converting the LIBOR variable component of the Company's interest rate to fixed rates. In addition, in January 2011, the Company entered into several interest rate cap agreements that have the economic effect of capping the Company's maximum exposure to LIBOR variable interest rate changes on specific portions of the Company's other variable-based rate debt. See Note 13 to the consolidated financial statements for further details.

Fair value estimates

The Company currently measures the fair value of certain assets, liabilities and noncontrolling interests subject to put provisions (temporary equity) based upon certain valuation techniques that include observable or unobservable market inputs and assumptions that market participants would use in pricing these assets, liabilities and temporary equity. The Company also has classified its assets, liabilities and temporary equity into the appropriate fair value hierarchy levels as defined by the Financial Accounting Standards Board (FASB). See Note 23 to the consolidated financial statements for further details.

New accounting standards

On January 1, 2012, the Company adopted FASB's Accounting Standard Update (ASU) No. 2011-08, *Intangibles – Goodwill and Other*. This standard amends the current two-step goodwill impairment test required under the existing accounting guidance. This amendment allows entities the option to first assess certain qualitative factors to ascertain whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount to determine if the two-step impairment test is necessary. If an entity concludes that certain events or circumstances prove that it is more likely than not that the fair value of a reporting unit is less than its carrying amount then an entity is required to proceed to step one of the two-step goodwill impairment test. This standard is effective during interim and annual periods beginning after December 15, 2011. The adoption of this standard did not have a material impact on the Company's consolidated financial statements.

On January 1, 2012, the Company adopted FASB's ASU No. 2011-07, *Health Care Entities-Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debts, and the Allowance for Doubtful Accounts*. This standard amends the current presentation and disclosure requirements for Health Care Entities that recognize significant amounts of patient service revenue at the time the services are rendered without assessing the patient's ability to pay. This standard requires health care entities to reclassify the provision for bad debts from an operating expense to a deduction from patient service revenues. In addition, this standard requires more disclosure on the policies for recognizing revenue, assessing bad debts, as well as quantitative and qualitative information regarding changes in the allowance for doubtful accounts. This standard is applied retrospectively to all prior periods presented and is effective during interim and annual periods beginning after December 15, 2011. The adoption of this standard will require the Company to change the presentation in its financial statements.

On January 1, 2012, the Company adopted FASB's ASU No. 2011-05, *Comprehensive Income – Presentation of Comprehensive Income*. This standard amends the current presentation requirements for comprehensive income by eliminating the presentation of the components of other comprehensive income within the statement of equity. This standard allows two options on how to present the various components of comprehensive income. These options are either to report the components of comprehensive income separately on the income statement or to present total other comprehensive income and the components of other comprehensive income in a separate statement. This standard does not change the items that must be reported in other comprehensive income or when an item must be reclassified into net income. This standard is applied retrospectively and is effective for fiscal years and interim periods within those years beginning after December 15, 2011. Early adoption is permitted. The adoption of this standard will require the Company to change the presentation in its financial statements.

On January 1, 2012, the Company adopted FASB's ASU No. 2011-04, *Fair Value Measurement*. This standard amends the current fair value measurement and disclosure

requirements to improve comparability between U.S. GAAP and International Financial Reporting Standards (IFRS). The intent of this standard is to update the disclosures that describe several of the requirements in U.S. GAAP for measuring fair value and to enhance disclosures about fair value measurements which will improve consistency between U.S. GAAP and IFRS. This standard does not change the application of the requirements on fair value measurements and disclosures. This standard is applied prospectively and is effective during interim and annual periods beginning after December 15, 2011. The adoption of this standard did not have a material impact on the Company's consolidated financial statements.

**CONSOLIDATED
BALANCE SHEETS (USD**

)

**In Thousands, unless
otherwise specified**

**Dec. 31, Dec. 31,
2011 2010**

ASSETS

<u>Cash and cash equivalents</u>	\$ 393,752	\$ 860,117
<u>Short-term investments</u>	17,399	23,003
<u>Accounts receivable, less allowance of \$250,343 and \$235,629</u>	1,195,163	1,048,976
<u>Inventories</u>	75,731	76,008
<u>Other receivables</u>	269,832	304,366
<u>Other current assets</u>	49,349	43,994
<u>Income tax receivable</u>		40,330
<u>Deferred income taxes</u>	280,382	226,060
<u>Total current assets</u>	2,281,608	2,622,854
<u>Property and equipment, net</u>	1,432,651	1,170,808
<u>Amortizable intangibles, net</u>	159,491	162,635
<u>Equity investments</u>	27,325	25,918
<u>Long-term investments</u>	9,890	8,848
<u>Other long-term assets</u>	34,231	32,054
<u>Goodwill</u>	4,946,976	4,091,307
<u>Total assets</u>	8,892,172	8,114,424

LIABILITIES AND EQUITY

<u>Accounts payable</u>	289,653	181,033
<u>Other liabilities</u>	325,734	342,943
<u>Accrued compensation and benefits</u>	412,972	325,477
<u>Current portion of long-term debt</u>	87,345	74,892
<u>Income taxes payable</u>	37,412	
<u>Total current liabilities</u>	1,153,116	924,345
<u>Long-term debt</u>	4,417,624	4,233,850
<u>Other long-term liabilities</u>	132,006	89,290
<u>Alliance and product supply agreement, net</u>	19,987	25,317
<u>Deferred income taxes</u>	423,098	421,436
<u>Total liabilities</u>	6,145,831	5,694,238
<u>Commitments and contingencies</u>		
<u>Noncontrolling interests subject to put provisions</u>	478,216	383,052

Equity:

<u>Preferred stock (\$0.001 par value, 5,000,000 shares authorized; none issued)</u>		
<u>Common stock (\$0.001 par value, 450,000,000 shares authorized; 134,862,283 shares issued; 93,641,363 and 96,001,535 shares outstanding)</u>	135	135
<u>Additional paid-in capital</u>	596,300	620,546
<u>Retained earnings</u>	3,195,818	2,717,817
<u>Treasury stock, at cost (41,220,920 and 38,860,748 shares)</u>	(1,631,694)	(1,360,579)
<u>Accumulated other comprehensive (loss) income</u>	(19,484)	503

<u>Total DaVita Inc. shareholders' equity</u>	2,141,075	1,978,422
<u>Noncontrolling interests not subject to put provisions</u>	127,050	58,712
<u>Total equity</u>	2,268,125	2,037,134
<u>Total liabilities and equity</u>	\$	\$
	8,892,172	8,114,424

Other liabilities

[Other liabilities](#)

12 Months Ended

Dec. 31, 2011

11. Other liabilities

Other accrued liabilities were comprised of the following:

	December 31,	
	2011	2010
Payor refunds and retractions	\$193,966	\$216,655
Insurance and self-insurance accruals	69,962	65,950
Accrued interest	17,469	22,905
Accrued non-income tax liabilities	15,174	9,995
Other	29,163	27,438
	<u>\$325,734</u>	<u>\$342,943</u>

Summary of Segment Revenues, Segment Operating Income Loss and a Reconciliation of Segment Income to Consolidated Income Before Income Taxes (Detail) (USD \$) In Thousands, unless otherwise specified	3 Months Ended								12 Months Ended		
	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Segment Reporting Information [Line Items]											
Net operating revenues	\$ 1,862,318	\$ 1,807,869	\$ 1,708,643	\$ 1,603,384	\$ 1,646,924	\$ 1,649,557	\$ 1,584,821	\$ 1,556,748	\$ 6,982,214	\$ 6,438,050	\$ 6,100,648
Stock-based compensation									(48,718)	(45,551)	(44,422)
Equity investment income									8,776	8,999	2,442
Operating income	330,112	318,712	246,624	235,334	255,258	256,745	242,512	242,045	1,130,782	996,560	939,628
Debt expense									(241,090)	(181,607)	(185,755)
Debt refinancing and redemption charges										(74,382)	
Other income									2,982	3,419	3,706
Income from continuing operations before income taxes	269,149	258,662	187,283	177,580	132,215	218,014	195,469	198,292	892,674	743,990	757,579
Dialysis and related lab services											
Segment Reporting Information [Line Items]											
External sources									6,473,829 ^[1]	6,054,252 ^[1]	5,766,795 ^[1]
Intersegment revenues									11,141 ^[1]	9,300 ^[1]	16,782 ^[1]
Net operating revenues									6,484,970 ^[1]	6,063,552 ^[1]	5,783,577 ^[1]
Operating income									1,224,672 ^[2]	1,038,698 ^[2]	993,834 ^[2]
Other-Ancillary services and strategic initiatives											
Segment Reporting Information [Line Items]											
External sources									508,385 ^[3]	383,798 ^[3]	333,853 ^[3]
Intersegment revenues									5,796		
Net operating revenues									514,181	383,798	333,853
Operating income									(53,948) ^[2]	(5,586) ^[2]	(12,226) ^[2]
Operating Segments before Elimination											
Segment Reporting Information [Line Items]											
Net operating revenues									6,999,151	6,447,350	6,117,430
Operating income									1,170,724 ^[2]	1,033,112 ^[2]	981,608 ^[2]
Intersegment Elimination											
Segment Reporting Information [Line Items]											
Net operating revenues									\$ (16,937)	\$ (9,300)	\$ (16,782)

[1] Includes management fees for providing management and administrative services to dialysis centers in which the Company either owns a minority equity investment or are wholly-owned by third parties.

[2] Certain costs previously reported in the Ancillary Services and Strategic Initiatives have been reclassified to the dialysis and related lab services to conform to the current year presentation.

[3] Revenues from external sources in 2010 and 2009 that were previously eliminated within the ancillary services and strategic initiatives segment have now been reported as a component of revenue from external sources to conform to current year presentations.

**Aggregate Purchase Cost
Allocations for Acquisition
of DSI Renal Inc (Detail)
(CDSI I Holding Company,
Inc, USD \$)
In Thousands, unless
otherwise specified**

Sep. 02, 2011

CDSI I Holding Company, Inc

Business Acquisition [Line Items]

<u>Current assets</u>	\$ 164,227
<u>Property and equipment</u>	67,080
<u>Amortizable intangible and other long-term assets</u>	6,523
<u>Goodwill</u>	500,662
<u>Long-term deferred income taxes</u>	79,420
<u>Current liabilities assumed</u>	(54,046)
<u>Other long-term liabilities</u>	(11,213)
<u>Noncontrolling interests</u>	(23,100)
<u>Aggregate purchase cost</u>	\$ 729,553

**Acquisition of Dialysis and
Other Businesses (Detail)**

(USD \$)

**In Thousands, unless
otherwise specified**

Dec. 31, 2011 Dec. 31, 2010 Dec. 31, 2009
Entity Entity Entity

Business Acquisition [Line Items]

<u>Cash paid, net of cash acquired</u>	\$ 1,077,442	\$ 188,502	\$ 87,617
<u>Deferred purchase price and other acquisition obligations</u>	19,010	449	338
<u>Aggregate purchase cost</u>	\$ 1,096,452	\$ 188,951	\$ 87,955
<u>Number of chronic dialysis centers acquired</u>	178	41	19

Document and Entity Information (USD \$)	12 Months Ended		
	Dec. 31, 2011	Jan. 31, 2012	Jun. 30, 2011
Document Type	10-K		
Amendment Flag	false		
Document Period End Date	Dec. 31, 2011		
Document Fiscal Year Focus	2011		
Document Fiscal Period Focus	FY		
Trading Symbol	DVA		
Entity Registrant Name	DAVITA INC		
Entity Central Index Key	0000927066		
Current Fiscal Year End Date	--12-31		
Entity Well-known Seasoned Issuer	Yes		
Entity Current Reporting Status	Yes		
Entity Voluntary Filers	No		
Entity Filer Category	Large Accelerated Filer		
Entity Common Stock, Shares Outstanding		93,700,000	93,500,000
Entity Public Float		\$ 7,700,000,000	\$ 8,100,000,000

Income taxes

12 Months Ended Dec. 31, 2011

[Income taxes](#)

12. Income taxes

A reconciliation of the beginning and ending liability for unrecognized tax benefits that do not meet the more-likely-than-not threshold were as follows:

	Year ended December 31,	
	2011	2010
Balance beginning	\$8,138	\$30,693
Additions for tax positions related to current year	2,052	1,515
Additions for tax positions related to prior years	786	69
Reductions for tax positions related to prior years	(2,033)	(24,139)
Balance ending	<u>\$8,943</u>	<u>\$8,138</u>

As of December 31, 2011, unrecognized tax benefits totaling \$8,943 would affect the Company's effective tax rate, if recognized.

The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense. At December 31, 2011 and 2010, the Company had approximately \$3,420 and \$3,177, respectively, accrued for interest and penalties related to unrecognized tax benefits, net of federal tax benefits.

The Company and its subsidiaries file U.S. federal income tax returns and various state returns. The Company is no longer subject to U.S. federal, state and local examinations by tax authorities for years before 2006.

Income tax expense consisted of the following:

	Year ended December 31,		
	2011	2010	2009
Current:			
Federal	\$217,885	\$153,502	\$193,181
State	44,403	31,338	34,415
Deferred:			
Federal	46,779	67,901	44,376
State	6,659	7,498	6,493
	<u>\$315,726</u>	<u>\$260,239</u>	<u>\$278,465</u>

The allocation of income tax expense was as follows:

	Year ended December 31,		
	2011	2010	2009
Continuing operations	\$315,744	\$260,052	\$278,213
Discontinued operations	675	187	252
Loss on discontinued operations	(693)	—	—
	<u>\$315,726</u>	<u>\$260,239</u>	<u>\$278,465</u>

Deferred tax assets and liabilities arising from temporary differences were as follows:

	December 31,	
	2011	2010
Receivables	\$125,159	\$110,332
Alliance and product supply agreement	7,775	9,849
Accrued liabilities	163,770	127,073
Net operating loss carryforwards	118,745	11,272
Other	64,120	49,096
Deferred tax assets	479,569	307,622
Valuation allowance	(15,642)	(10,998)
Net deferred tax assets	463,927	296,624
Intangible assets	(439,203)	(377,456)
Property and equipment	(164,404)	(110,472)
Other	(3,036)	(4,072)
Deferred tax liabilities	(606,643)	(492,000)
Net deferred tax liabilities	<u>\$ (142,716)</u>	<u>\$ (195,376)</u>

At December 31, 2011, the Company had federal net operating loss carryforwards of approximately \$288,604 that expire through 2031, and state net operating loss carryforwards of \$390,774 that expire through 2031. The increase in federal and state net operating loss carryforwards is a result of the acquisition of DSI Renal, Inc. The utilization of a portion of these losses may be limited in future years based on the profitability of certain entities. The valuation allowance increase of \$4,644 is primarily due to changes in the estimated tax benefit and utilization of federal and state operating losses.

The reconciliation between the Company's effective tax rate from continuing operations and the U.S. federal income tax rate is as follows:

	Year ended December 31,		
	2011	2010	2009
Federal income tax rate	35.0%	35.0%	35.0%
State taxes, net of federal benefit	4.1	3.9	3.7
Changes in deferred tax valuation allowances	(0.3)	(0.1)	0.2
Other	0.8	0.2	0.8
Impact of noncontrolling interests primarily attributable to non-tax paying entities	(4.2)	(4.0)	(3.0)
Effective tax rate	<u>35.4%</u>	<u>35.0%</u>	<u>36.7%</u>

**Effects of Interest Rate Swap
Agreements (Detail) (Cash
Flow Hedging, USD \$)
In Thousands, unless
otherwise specified**

12 Months Ended

	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
<u>Derivative [Line Items]</u>			
<u>Amount of gains (losses) recognized in OCI on interest rate swap and cap agreements</u>	\$ (29,049)	\$ (134)	\$ (2,578)
<u>Amount of gains (losses) reclassified from accumulated OCI into income</u>	(9,721)	(5,557)	(10,542)
Interest rate swap agreements			
<u>Derivative [Line Items]</u>			
<u>Amount of gains (losses) recognized in OCI on interest rate swap and cap agreements</u>	(35,767)	(217)	(4,220)
Interest rate swap agreements Debt expense			
<u>Derivative [Line Items]</u>			
<u>Amount of gains (losses) reclassified from accumulated OCI into income</u>	(12,622)	(9,093)	(17,253)
Interest rate cap			
<u>Derivative [Line Items]</u>			
<u>Amount of gains (losses) recognized in OCI on interest rate swap and cap agreements</u>	(11,777)		
Interest rate cap Debt expense			
<u>Derivative [Line Items]</u>			
<u>Amount of gains (losses) reclassified from accumulated OCI into income</u>	(3,289)		
Tax benefit (expense)			
<u>Derivative [Line Items]</u>			
<u>Amount of gains (losses) recognized in OCI on interest rate swap and cap agreements</u>	18,495	83	1,642
<u>Amount of gains (losses) reclassified from accumulated OCI into income</u>	\$ 6,190	\$ 3,536	\$ 6,711

**Changes in Accumulated
Other Comprehensive
Income (Loss) (Detail) (USD
\$)**

12 Months Ended

Dec. 31, 2011 Dec. 31, 2010 Dec. 31, 2009

**In Thousands, unless
otherwise specified**

Accumulated Other Comprehensive Income (Loss) [Line Items]

<u>Beginning Balance</u>	\$ 503	\$ (5,548)	
<u>Net activity</u>	(19,987)	6,051	8,791
<u>Ending Balance</u>	(19,484)	503	(5,548)

Interest rate swap and cap agreements

Accumulated Other Comprehensive Income (Loss) [Line Items]

<u>Beginning Balance</u>		(5,423)	
<u>Net activity</u>	(19,328)	5,423	
<u>Ending Balance</u>	(19,328)		

Investment securities

Accumulated Other Comprehensive Income (Loss) [Line Items]

<u>Beginning Balance</u>	503	(125)	
<u>Net activity</u>	(659)	628	
<u>Ending Balance</u>	\$ (156)	\$ 503	

**CONSOLIDATED
BALANCE SHEETS**
(Parenthetical) (USD \$)
**In Thousands, except Share
data, unless otherwise
specified**

Dec. 31, 2011 Dec. 31, 2010

<u>Accounts receivable, allowance</u>	\$ 250,343	\$ 235,629
<u>Preferred stock, par value</u>	\$ 0.001	\$ 0.001
<u>Preferred stock, shares authorized</u>	5,000,000	5,000,000
<u>Preferred stock, issued</u>	0	0
<u>Common stock, par value</u>	\$ 0.001	\$ 0.001
<u>Common stock, shares authorized</u>	450,000,000	450,000,000
<u>Common stock, shares issued</u>	134,862,283	134,862,283
<u>Common stock, shares outstanding</u>	93,641,363	96,001,535
<u>Treasury stock, shares</u>	41,220,920	38,860,748

Property and equipment

12 Months Ended
Dec. 31, 2011

[Property and equipment](#)

6. Property and equipment

Property and equipment were comprised of the following:

	December 31,	
	2011	2010
Land	\$23,004	\$23,182
Buildings	34,173	33,937
Leasehold improvements	1,266,499	1,106,935
Equipment and information systems	1,269,343	1,107,778
New center and capital asset projects in progress	144,124	38,721
	<u>2,737,143</u>	<u>2,310,553</u>
Less accumulated depreciation and amortization	<u>(1,304,492)</u>	<u>(1,139,745)</u>
	<u>\$1,432,651</u>	<u>\$1,170,808</u>

Depreciation and amortization expense on property and equipment was \$249,060, \$218,666 and \$213,657 for 2011, 2010 and 2009, respectively.

Interest on debt incurred during the development of new centers and other capital asset projects is capitalized as a component of the asset cost based on the respective in-process capital asset balances. Interest capitalized was \$4,887, \$2,621 and \$3,627 for 2011, 2010 and 2009, respectively.

Other current assets

**12 Months Ended
Dec. 31, 2011**

[Other current assets](#)

5. Other current assets

Other current assets consist principally of prepaid expenses and operating deposits.

**DaVita Inc. stock-based
compensation and
shareholders' equity**

12 Months Ended

Dec. 31, 2011

[DaVita Inc. stock-based
compensation and
shareholders' equity](#)

17. DaVita Inc. stock-based compensation and shareholders' equity

Stock-based compensation

Stock-based compensation recognized in a period represents the straight-line amortization during that period of the estimated grant-date fair value of stock-based awards over their vesting terms, adjusted for expected forfeitures. Shares issued upon exercise of stock awards are generally issued from shares held in treasury.

Stock-based compensation plans

On June 6, 2011, the Company's stockholders approved the DaVita Inc. 2011 Incentive Award Plan (the 2011 Plan), which constituted an amendment and restatement of the DaVita Inc. 2002 Equity Compensation Plan (the 2002 Plan, and jointly the Plan).

The 2011 Plan is the Company's omnibus equity compensation plan and provides for grants of stock-based awards to employees, directors and other individuals providing services to the Company, except that incentive stock options may only be awarded to employees. The 2011 Plan authorizes the Company to provide equity-based compensation in the form of stock options, stock appreciation rights, restricted stock units, restricted stock, and certain other performance-based awards, and is designed to enable the Company to grant equity and cash awards that qualify as performance-based compensation under Section 162(m) of the Internal Revenue Code. The 2011 Plan does not increase the number of shares authorized under the 2002 Plan, continues to mandate a maximum award term of five years, and continues to stipulate that stock appreciation rights and stock options be granted with prices not less than the fair market value on the date of grant. The 2011 Plan also continues to require that full share awards such as restricted stock units reduce shares available under the Plan at a rate of 3.0:1. The Company's nonqualified stock appreciation rights and stock units awarded under the Plan generally vest over 48 to 60 months from the date of grant. At December 31, 2011, there were 10,205,564 stock-settled stock appreciation rights, 10,000 cash-settled stock appreciation rights, 513,108 stock units outstanding under the Plan, and 8,405,431 shares available for future grants under the Plan.

On June 7, 2010, the Company's stockholders had previously approved an amendment and restatement of the 2002 Plan to increase the number of shares reserved to the Plan by 10,000,000 shares.

In connection with this 2010 amendment, the Board of Directors has committed to the Company's stockholders that over the three-year period commencing on April 1, 2010 it will not grant a number of shares subject to stock awards under the Plan, including stock options, stock appreciation rights, restricted stock units or other stock awards, at an average annual rate greater than 4.02% of the number of shares of the Company's common stock that management believes will be outstanding over such three-year period. This 4.02% rate is the average of the 2009 and 2010 three-year average median grant rate plus one standard deviation as published by RiskMetrics Group for the Russell 3000 companies in the GICS 3510 industry segment. Awards that are settled in cash, awards that are granted pursuant to stockholder approved exchange programs, awards sold under the Company's employee stock purchase plan and awards assumed or substituted in business combination transactions will be excluded from the Company's grant rate calculation. For purposes of calculating the number of shares granted, any "full-value"

awards (i.e., restricted stock, restricted stock unit, performance share or any other award that does not have an exercise price per share at least equal to the per share fair market value of the Company's common stock on the grant date) will count as equivalent to 3.0 shares. The Company will publicly report its compliance with this three-year average annual grant rate commitment, and the data necessary to independently confirm it, in a public filing shortly after March 31, 2013.

Predecessor plans. Various prior stock-based compensation plans were terminated upon original shareholder approval of the 2002 Plan in 2002 and the 1999 Non-Executive Officer and Non-Director Equity Compensation Plan expired in 2009, both except with respect to option awards then outstanding. Stock options granted under these terminated plans were generally issued with exercise prices equal to the market price of the stock on the date of grant, vested over four years from the date of grant, and bore maximum award terms of five to 10 years. There were no stock awards remaining outstanding under these terminated plans as of December 31, 2011.

A combined summary of the status of awards under the Company's stock-based compensation plans, including base shares for stock-settled stock appreciation rights and shares subject to stock option and stock unit awards, is as follows:

	Year ended December 31, 2011				
	Stock appreciation rights and stock options			Stock units	
	Awards	Weighted average exercise price	Weighted average remaining contractual life	Awards	Weighted average remaining contractual life
Outstanding at beginning of year	11,013,487	\$51.94		501,564	
Granted	2,707,500	82.17		150,246	
Exercised	(3,032,329)	51.46		(78,106)	
Cancelled	(483,094)	59.59		(60,596)	
Outstanding at end of period	<u>10,205,564</u>	<u>\$59.74</u>	<u>2.6</u>	<u>513,108</u>	<u>1.5</u>
Awards exercisable at end of period	<u>4,348,803</u>	<u>\$50.62</u>	<u>1.7</u>	<u>3,446</u>	<u>0.6</u>
Weighted-average fair value of awards granted during 2011	<u>\$21.93</u>			<u>\$85.28</u>	
Weighted-average fair value of awards granted during 2010	<u>\$15.87</u>			<u>\$62.85</u>	
Weighted-average fair value of awards granted during 2009	<u>\$12.08</u>			<u>\$54.31</u>	

<u>Range of exercise prices</u>	<u>Awards outstanding</u>	<u>Weighted average exercise price</u>	<u>Awards exercisable</u>	<u>Weighted average exercise price</u>
\$ 0.00–\$ 0.01	513,108	\$—	3,446	\$—
\$40.01–\$50.00	3,856,250	45.69	2,254,496	45.54
\$50.01–\$60.00	1,868,878	52.43	1,453,292	52.47
\$60.01–\$70.00	1,993,936	64.40	621,015	64.04
\$70.01–\$80.00	397,500	74.20	20,000	72.52
\$80.01–\$90.00	2,089,000	85.01	—	—
Total	10,718,672	\$56.88	4,352,249	\$50.58

The Company also granted 10,000 cash-settled stock appreciation rights in 2011 at a base price of \$79.57. These liability-classified awards remain outstanding but unvested at December 31, 2011, have no intrinsic value at that date, and have contributed \$0 to total stock-based compensation for 2011.

For the years ended December 31, 2011, 2010, and 2009, the aggregate intrinsic value of stock awards exercised was \$98,235, \$67,935 and \$46,896, respectively. At December 31, 2011, the aggregate intrinsic value of stock awards outstanding was \$222,347 and the aggregate intrinsic value of stock awards exercisable was \$109,791.

Estimated fair value of stock-based compensation awards

The Company has estimated the grant-date fair value of stock-settled stock appreciation rights awards and stock options using the Black-Scholes-Merton valuation model and stock unit awards at intrinsic value on the date of grant. The following assumptions were used in estimating these values and determining the total stock-based compensation attributable to the current period:

Expected term of the awards: The expected term of awards granted represents the period of time that they are expected to remain outstanding from the date of grant. The Company determines the expected term of its stock awards based on its historical experience with similar awards, considering the Company's historical exercise and post-vesting termination patterns, and the terms expected by peer companies in near industries.

Expected volatility: Expected volatility represents the volatility anticipated over the expected term of the award. The Company determines the expected volatility for its awards based on the volatility of the price of its common stock over the most recent retrospective period commensurate with the expected term of the award, considering the volatility expectations implied by the market price of its exchange-traded options and the volatilities expected by peer companies in near industries.

Expected dividend yield: The Company has not paid dividends on its common stock and does not currently expect to pay dividends during the term of stock awards granted.

Risk-free interest rate: The Company bases the expected risk-free interest rate on the implied yield currently available on stripped interest coupons of U.S. Treasury issues with a remaining term equivalent to the expected term of the award.

A summary of the weighted average valuation inputs described above used for estimating the grant-date fair value of stock options and stock-settled stock appreciation rights granted in the periods indicated is as follows:

	Year ended December 31,					
	2011		2010		2009	
Expected term	4.2	years	3.5	years	3.5	years
Expected volatility	30	%	30	%	32	%
Expected dividend yield	0.0	%	0.0	%	0.0	%
Risk-free interest rate	1.6	%	1.7	%	1.8	%

The Company estimates expected forfeitures based upon historical experience with separate groups of employees that have exhibited similar forfeiture behavior in the past. Stock-based compensation expense is recorded only for awards that are expected to vest.

Employee stock purchase plan

The Employee Stock Purchase Plan entitles qualifying employees to purchase up to \$25 of the Company's common stock during each calendar year. The amounts used to purchase stock are accumulated through payroll withholdings or through optional lump sum payments made in advance of the first day of the purchase right period. This compensatory plan allows employees to purchase stock for the lesser of 100% of the fair market value on the first day of the purchase right period or 85% of the fair market value on the last day of the purchase right period. Purchase right periods begin on January 1 and July 1, and end on December 31. Payroll withholdings and lump-sum payments related to the plan, included in accrued compensation and benefits and used to purchase the Company's common stock for 2011, 2010 and 2009 participation periods, were \$5,889, \$4,933, and \$4,280, respectively. Shares purchased pursuant to the plan's 2011, 2010 and 2009 participation periods were 91,353, 83,865, and 86,213, respectively. At December 31, 2011, there were 787,497 shares remaining available for future grants under this plan.

The fair value of employees' purchase rights was estimated as of the beginning dates of the purchase right periods using the Black-Scholes-Merton valuation model with the following weighted average assumptions for purchase right periods in 2011, 2010 and 2009, respectively: expected volatility of 22%, 22% and 34%; risk-free interest rate of 0.5%, 0.3% and 0.2%, and no dividends. Using these assumptions, the weighted average estimated fair value of these purchase rights was \$17.20, \$13.80 and \$13.90 for 2011, 2010 and 2009, respectively.

Stock-based compensation expense and proceeds

For the years ended December 31, 2011, 2010 and 2009, the Company recognized \$48,718, \$45,551 and \$44,422, respectively, in stock-based compensation expense for stock settled-stock appreciation rights, stock options, stock units and discounted employee stock plan purchases, which is primarily included in general and administrative expenses. The estimated tax benefits recorded for this stock-based compensation in 2011, 2010 and 2009 were \$18,424, \$17,273 and \$16,810, respectively. As of December 31, 2011, there was \$91,305 of total estimated unrecognized compensation cost related to nonvested stock-settled compensation arrangements under the Company's equity compensation and stock purchase plans. The Company expects to recognize this cost over a weighted average remaining period of 1.4 years.

During the years ended December 31, 2011, 2010 and 2009, the Company received \$5,443, \$48,686 and \$63,653 in cash proceeds from stock option exercises and \$38,199, \$26,706 and \$18,241 in total actual tax benefits upon the exercise of stock awards, respectively.

Stock repurchases

During 2011 and 2010, the Company repurchased a total of 3,794,686 and 8,918,760 shares of its common stock for \$323,348 and \$618,496, or an average price of \$85.21 and \$69.35 per share, respectively, pursuant to previously announced authorizations by the Board of Directors. On November 3, 2010, the Company's Board of Directors authorized an additional \$800,000 of share repurchases of its common stock. As a result of these transactions, the total outstanding authorization for share repurchases as of December 31, 2011 was approximately \$358,200. The Company has not repurchased any additional shares of its common stock from January 1, 2012 through February 24, 2012. This stock repurchase program has no expiration date.

Shareholder rights plan

The Company's Board of Directors approved a shareholder rights plan on November 14, 2002. This plan provided a mechanism whereby the Board of Directors could take certain actions to dilute the ownership stake of a person or group which acquired, or announced a tender offer for, 15% or more of DaVita Inc.'s outstanding common stock.

On March 10, 2011, the Company and The Bank of New York Mellon Trust Company, N.A., as rights agent, entered into an amendment to this plan. This amendment accelerated the expiration of the rights issued under the plan from the close of business on November 14, 2012 to the close of business on March 10, 2011. Accordingly, as of the close of business on March 10, 2011, the rights issued under this plan expired and are no longer outstanding.

Charter documents & Delaware law

The Company's charter documents include provisions that may deter hostile takeovers, delay or prevent changes of control or changes in management, or limit the ability of stockholders to approve transactions that they may otherwise determine to be in their best interests. These include provisions prohibiting stockholders from acting by written consent, requiring 90 days advance notice of stockholder proposals or nominations to the Board of Directors and granting the Board of Directors the authority to issue up to five million shares of preferred stock and to determine the rights and preferences of the preferred stock without the need for further stockholder approval.

The Company is also subject to Section 203 of the Delaware General Corporation Law that, subject to exceptions, would prohibit the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period of three years following the date on which that stockholder became an interested stockholder. These restrictions may discourage, delay or prevent a change in the control of the Company.

Changes in DaVita Inc.'s ownership interest in consolidated subsidiaries

The effects of changes in DaVita Inc.'s ownership interest on the Company's equity are as follows:

	Year ended December 31, 2011	Year ended December 31, 2010	Year ended December 31, 2009
Net income attributable to DaVita Inc.	\$ 478,001	\$ 405,683	\$ 422,684
Decrease in paid-in capital for sales of noncontrolling interest in several joint ventures	(1,299)	(298)	(529)

Decrease in paid-in capital for the purchase of a noncontrolling interest in several joint ventures	<u>(9,486)</u>	<u>(5,537)</u>	<u>(3,721)</u>
Net transfer to noncontrolling interests	<u>(10,785)</u>	<u>(5,835)</u>	<u>(4,250)</u>
Change from net income attributable to DaVita Inc. and transfers to noncontrolling interests	<u>\$467,216</u>	<u>\$399,848</u>	<u>\$418,434</u>

In addition in 2011, 2010 and 2009, the Company also acquired additional ownership interests in several existing majority-owned joint ventures for \$13,689, \$14,214 and \$6,859, respectively.

Long-term debt

12 Months Ended
Dec. 31, 2011

Long-term debt

13. Long-term debt

Long-term debt was comprised of the following:

	December 31,	
	2011	2010
Senior Secured Credit Facilities:		
Term Loan A	\$950,000	\$1,000,000
Term Loan A-2	199,500	—
Term Loan B	1,732,500	1,750,000
Senior notes	1,550,000	1,550,000
Acquisition obligations and other notes payable	37,447	9,049
Capital lease obligations	43,364	8,074
Total principal debt outstanding	4,512,811	4,317,123
Discount on long-term debt	(7,842)	(8,381)
	4,504,969	4,308,742
Less current portion	(87,345)	(74,892)
	<u>\$4,417,624</u>	<u>\$4,233,850</u>

Scheduled maturities of long-term debt at December 31, 2011 were as follows:

2012	87,345
2013	125,106
2014	176,910
2015	676,293
2016	1,858,567
Thereafter	1,588,590

Senior Secured Credit Facility

On August 26, 2011, the Company entered into an Increase Joinder Agreement under its existing Senior Secured Credit Agreement, as described below. Pursuant to the Increase Joinder Agreement, the Company increased the revolving credit facility by \$100,000, to a total of \$350,000, and entered into an additional \$200,000 Term Loan A-2. The new Term Loan A-2 required a principal payment of \$500 on December 31, 2011, and thereafter requires annual principal payments of \$2,000 with a balance of \$191,500 due in 2016, and bears interest at LIBOR (floor of 1.00%) plus an interest rate margin of 3.50% subject to a rating based step-down to 3.25%.

On October 20, 2010, the Company entered into a \$3,000,000 Senior Secured Credit Agreement (the Credit Agreement), consisting of a five year \$250,000 revolving line of credit, a five year \$1,000,000 Term Loan A and a six year \$1,750,000 Term Loan B. The Company also has the right to request an increase to the borrowing capacity to a total aggregate principal amount of not more than \$4,000,000 subject to bank participation. The revolving line of credit and the Term Loan A bore interest at LIBOR plus an interest rate margin of 2.75% until June 30, 2011, when the interest rate margin was reduced to 2.50%. The interest rate margin is still subject to adjustment depending upon the Company's leverage ratio and can range from 2.25% to 2.75%.

The Term Loan A requires annual principal payments of \$50,000 in 2011, \$50,000 in 2012, \$100,000 in 2013, and \$150,000 in 2014, with the balance of \$650,000 due in 2015. The Term Loan B bears interest at LIBOR (floor of 1.50%) plus 3.00% subject to a ratings based step-down to 2.75%. The Term Loan B requires annual principal payments of \$17,500 in each year from 2011 through 2015 with the balance of \$1,662,500 due in 2016. The borrowings under the Credit Agreement are guaranteed by substantially all of the Company's direct and indirect wholly-owned domestic subsidiaries and are secured by substantially all of the Company's and its guarantors' assets. The Credit Agreement contains customary affirmative and negative covenants such as various restrictions on investments, acquisitions, the payment of dividends, redemptions and acquisitions of capital stock, capital expenditures and other indebtedness, as well as limitations on the amount of tangible net assets in non-guarantor subsidiaries. However, many of these restrictions will not apply as long as the Company's leverage ratio is below 3.50:1.00. In addition, the Credit Agreement requires compliance with financial covenants including an interest coverage ratio and a leverage ratio that determines the interest rate margins as described above.

On October 20, 2010, the Company also issued \$775,000 aggregate principal amount of 6 ³/₈% senior notes due 2018 and \$775,000 aggregate principal amount of 6 ⁵/₈% senior notes due 2020 (collectively the New Senior Notes). The New Senior Notes will pay interest on May 1 and November 1 of each year, beginning May 1, 2011. The New Senior Notes are unsecured senior obligations and rank equally to other unsecured senior indebtedness. The New Senior Notes are guaranteed by substantially all of the Company's direct and indirect wholly owned domestic subsidiaries. The Company may redeem some or all of the 6 ³/₈% senior notes at any time on or after November 1, 2013 at certain redemption prices and may redeem some or all of the 6 ⁵/₈% senior notes at any time on or after November 1, 2014 at certain redemption prices.

The Company received total proceeds of \$4,300,000 from these transactions, \$2,750,000 from the borrowings on Term Loan A and Term Loan B and an additional \$1,550,000 from the issuance of the New Senior Notes. The Company used a portion of the proceeds to pay-off the outstanding principal balances of its existing Senior Secured Credit Facilities plus accrued interest totaling \$1,795,363 and to purchase pursuant to a cash tender offer \$557,644 of the outstanding principal balances of the Company's \$700,000 6 ⁵/₈% senior notes due 2013 and \$730,827 of the outstanding balances of the Company's \$850,000 7 ¹/₄% senior subordinated notes due 2015, (the Existing Notes), plus accrued interest totaling \$1,297,215. The total amount paid for the Existing Notes was \$1,019.06 per \$1,000 principal amount of the 6 ⁵/₈% senior notes and \$1,038.75 per \$1,000 principal amount of the 7 ¹/₄% senior subordinated notes. This resulted in the Company paying a cash tender premium of \$38,933 in order to extinguish this portion of the Existing Notes. On November 19, 2010, the Company redeemed the remaining outstanding balance of the existing 6 ⁵/₈% senior notes of \$142,356 at 101.656% per \$1,000 and the remaining outstanding balance of the existing 7 ¹/₄% senior subordinated notes of \$119,173 at 103.625% per \$1,000 plus accrued interest totaling \$264,742. In addition, the Company paid a call premium totaling \$6,677. The Company also paid an additional \$74,431 in fees, discounts and other expenses. As a result of the above transactions, the Company received approximately \$823,000 in excess cash which it has been using for general purposes and other opportunities, including share repurchases, acquisitions and other growth investments.

In connection with these transactions, the Company expensed debt refinancing and redemption charges totaling \$70,255, which includes the write off of certain existing deferred financing costs and other new financing costs, the cash tender and call premiums, as described above and other expenses.

On June 7, 2010, the Company redeemed \$200,000 aggregate principal amount of its outstanding 6 ⁵/₈% senior notes due 2013, at a price of 101.656% plus accrued interest. As a result of this transaction, the Company expensed debt redemption charges of \$4,127, which includes the call premium and the net write-off of other finance costs.

Term Loans

Term Loan A, Term Loan A-2 and Term Loan B total outstanding borrowings can consist of various individual tranches that can range in maturity from one month to twelve months (currently all tranches are one month in duration). Each tranche for the Term Loan A bears interest at a LIBOR rate determined by the duration of such tranche plus an interest rate margin, currently 2.50%. The LIBOR variable component of the interest rate for each tranche is reset as such tranche matures and a new tranche is established. At December 31, 2011, the overall weighted average interest rate for the Term Loan A was determined based upon the LIBOR interest rates in effect for all of the individual tranches plus the interest rate margin. In January 2011, the Company entered into several interest rate swap agreements that had the economic effect of fixing all of the Term Loan A LIBOR variable component of the Company's interest rate, as described below. At December 31, 2011, the Term Loan A-2 bears interest at LIBOR (floor of 1.00%) plus an interest rate margin of 3.50% subject to a ratings based step-down to 3.25%. At December 31, 2011, the Term Loan B bears interest at LIBOR (floor of 1.50%) plus a margin of 3.00% subject to a ratings based step-down to 2.75%. The Company is subject to these LIBOR-based floors until such time as the LIBOR-based component of the interest rate exceeds 1.00% on the Term Loan A-2 and 1.50% on the Term Loan B. At such time, the Company will then be subject to LIBOR-based interest rate volatility on the LIBOR variable component of its interest rate and the overall weighted average interest rate for the Term Loan A-2 and Term Loan B will then be determined based upon the LIBOR interest rates in effect for all individual tranches plus the interest rate margin. In January 2011, the Company entered into several interest rate cap agreements that have the economic effect of capping the LIBOR variable component of the Company's interest rate at a maximum of 4.00% on \$1,250,000 of outstanding principal debt on the Term Loan B, as described below. The remaining \$483,000 outstanding principal balance of the Term Loan B is subject to LIBOR-based interest rate volatility above a floor of 1.50%.

During 2011 and 2010, the Company made mandatory principal payments totaling \$50,000 and \$65,625, respectively, on the current and previous outstanding Term Loan A. During 2011, the Company made principal payments totaling \$500 on the Term Loan A-2 and made principal payments totaling \$17,500 on the Term Loan B. During 2010, the Company did not make, nor was the Company required to make, any principal payments on the previous outstanding Term Loan B.

Revolving Lines of Credit

The Company has an undrawn revolving line under the Senior Secured Credit Facilities totaling \$350,000, of which approximately \$52,297 was committed for outstanding letters of credit.

Senior and Senior Subordinated Notes

The Company's senior notes, as of December 31, 2011 and 2010, consisted of \$775,000 of 6 ³/₈ senior notes due 2018 and \$775,000 of 6 ⁵/₈ senior notes due 2020, as discussed above.

Interest rate swaps and caps

In January 2011, the Company entered into several interest rate swap agreements as a means of hedging its exposure to and volatility from variable-based interest rate changes as part of its overall risk management strategy. These agreements are not held for trading or speculative purposes and have the economic effect of converting the LIBOR variable component of the Company's interest rate to a fixed rate. These swap agreements are designated as cash flow hedges, and as a result, hedge-effective gains or losses resulting from changes in the fair values of these swaps are reported in other comprehensive income until such time as each specific swap tranche is realized, at which time the amounts are reclassified into net income. Net amounts paid or received for each specific swap tranche that have settled have been reflected as adjustments to debt expense. In addition, in January 2011, the Company entered into several interest rate cap agreements that have the economic effect of capping the Company's maximum exposure to LIBOR variable interest rate changes on specific portions of the Company's Term Loan B debt, as described below. These cap agreements are also designated as cash flow hedges and as a result changes in the fair values of these cap agreements are reported in other comprehensive income. The amortization of the original cap premium is recognized as a component of debt expense on a straight line basis over the term on the cap agreements. The swap and cap agreements do not contain credit-risk contingent features.

As of December 31, 2011, the Company maintained a total of nine interest rate swap agreements with amortizing notional amounts totaling \$950,000. These agreements had the economic effect of modifying the LIBOR variable component of the Company's interest rate on an equivalent amount of the Company's Term Loan A to fixed rates ranging from 1.59% to 1.64%, resulting in an overall weighted average effective interest rate of 4.11%, including the Term Loan A margin of 2.50%. The swap agreements expire by September 30, 2014 and require monthly interest payments. The Company estimates that approximately \$10,900 of existing unrealized pre-tax losses in other comprehensive income at December 31, 2011 will be reclassified into income over the next twelve months.

As of December 31, 2011, the Company maintained five interest rate cap agreements with notional amounts totaling \$1,250,000. These agreements have the economic effect of capping the LIBOR variable component of the Company's interest rate at a maximum of 4.00% on an equivalent amount of the Company's Term Loan B debt. The cap agreements expire on September 30, 2014.

During 2010, the Company had several interest rate swap agreements outstanding that had the economic effect of modifying the LIBOR variable component of the Company's interest rate on an equivalent amount of the Company's debt to fixed rates ranging from 4.05% to 4.70%, resulting in an overall weighted average effective interest rate of 5.84% on the hedged portion of the Company's Senior Secured Credit Facilities, including the margin of 1.50%. These agreements did not contain credit-risk contingent features and had expired as of September 30, 2010.

The following table summarizes the Company's derivative instruments as of December 31, 2011 and 2010:

	<u>Interest rate swap and cap agreements (liabilities and assets)</u>			
	<u>December 31, 2011</u>		<u>December 31, 2010</u>	
	<u>Balance sheet</u>		<u>Balance sheet</u>	
<u>Derivatives designated as hedging instruments</u>	<u>location</u>	<u>Fair value</u>	<u>location</u>	<u>Fair value</u>

Interest rate swap agreements	Other long-term liabilities	<u>\$23,145</u>	Other long-term liabilities	<u>\$ —</u>
Interest rate cap agreements	Other long-term assets	<u>\$1,381</u>	Other long-term assets	<u>\$ —</u>

The following table summarizes the effects of the Company's interest rate swap and cap agreements for the years ended December 31, 2011, 2010 and 2009:

Derivatives designated as cash flow hedges	Amount of gains (losses) recognized in OCI on interest rate swap and cap agreements			Location of (losses) gains reclassified from accumulated OCI into income	Amount of gains (losses) reclassified from accumulated OCI into income		
	Years ended December 31,				Years ended December 31,		
	2011	2010	2009		2011	2010	2009
Interest rate swap agreements	\$(35,767)	\$(217)	\$(4,220)	Debt expense	\$(12,622)	\$(9,093)	\$(17,253)
Interest rate cap agreements	(11,777)	—	—	Debt expense	(3,289)	—	—
Tax benefit	18,495	83	1,642		6,190	3,536	6,711
Total	<u>\$(29,049)</u>	<u>\$(134)</u>	<u>\$(2,578)</u>		<u>\$(9,721)</u>	<u>\$(5,557)</u>	<u>\$(10,542)</u>

The Company's overall weighted average effective interest rate in 2011 was 5.28% and as of December 31, 2011 was 5.27%.

Debt expense

Debt expense consisted of interest expense of \$230,953, \$172,265 and \$176,100, including the amortization and accretion of debt discounts and premiums and the amortization of deferred financing costs of \$10,137, \$9,342 and \$9,655 for 2011, 2010 and 2009, respectively. The interest expense amounts are net of capitalized interest.

DaVita Inc. Stock-Based Compensation and Shareholders' Equity - Additional Information (Detail) (USD \$)	12 Months Ended				12 Months Ended				12 Months Ended				12 Months Ended								
	Dec. 31, 2011 Year	Dec. 31, 2010	Dec. 31, 2009	Nov. 03, 2010	Dec. 31, 2011 Cash-settled stock appreciation	Dec. 31, 2011 Stock Unit	Dec. 31, 2010 Stock Unit	Dec. 31, 2011 Stockholder Rights Plan Minimum	Dec. 31, 2011 Stock Incentive Plan 2011	Dec. 31, 2011 Stock Incentive Plan 2011 Stock Settled Stock Appreciation Rights and Employee Stock Options	Dec. 31, 2011 Stock Incentive Plan 2011 Cash-settled stock appreciation	Dec. 31, 2011 Stock Incentive Plan 2011 Stock Unit	Dec. 31, 2011 Stock Incentive Plan 2011 Minimum	Dec. 31, 2011 Stock Incentive Plan 2011 Maximum	Dec. 31, 2011 Stock Incentive Plan 2011 Minimum	Dec. 31, 2011 Stock Incentive Plan 2011 Maximum	Dec. 31, 2011 Employee stock purchase plan	Dec. 31, 2010 Employee stock purchase plan	Dec. 31, 2009 Employee stock purchase plan	Dec. 31, 2011 Employee stock purchase plan Beginning of Period	Dec. 31, 2011 Employee stock purchase plan End of Period
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]																					
Terms of award (in years)																					
Award reduction rate																					
Vesting period																					
Outstanding balance																					
Outstanding balance																					
Payroll withholdings and lump-sum payments related to the plan, included in accrued compensation and benefits	\$ 412,972,000	\$ 325,477,000															\$ 5,889,000	\$ 4,933,000	\$ 4,280,000		
Stock issued for employee stock purchase plans																	91,353	83,865	86,213		
Shares available for future grants																	787,497				
Increase in number of shares of common stock available for issuance																					
The average median grant rate																					
Equivalent number of shares for any full-value awards																					
Stock appreciation rights granted during period																					
Base Price outstanding balance																					
Stock-based compensation expense	48,718,000	45,551,000	44,422,000		0																
Tax benefit for stock-based Compensation	18,424,000	17,273,000	16,810,000																		
Unrecognized compensation cost related to nonvested stock-based compensation arrangements under equity compensation and stock purchase plans	91,305,000																				
Unrecognized compensation cost related to nonvested stock-based compensation arrangements under equity compensation and stock purchase plans, weighted average remaining period (in years)	1.4																				
Aggregate intrinsic value of stock awards exercised	98,235,000	67,935,000	46,896,000																		
Aggregate intrinsic value of stock awards outstanding	222,347,000																				
Aggregate intrinsic value exercisable	109,791,000																				
Proceeds from stock option exercises	5,443,000	48,686,000	63,653,000																		
Tax benefits from stock award exercises	38,199,000	26,706,000	18,241,000																		
Common stock shares repurchased	3,794,686	8,918,760																			
Common stock shares repurchased Amount	323,348,000	618,496,000																			
Average repurchase price	\$ 85.21	\$ 69.35																			
Additional share repurchase amount authorized by the Board of Directors																					
Repurchase share authorized outstanding amount	358,200,000																				
Charter documents and Delaware law description	The Company's charter documents include provisions that may deter hostile takeovers, delay or prevent changes of control or changes in management, or limit the ability of stockholders to approve transactions that they may otherwise determine to be in their best interests. These include provisions prohibiting stockholders from acting by written consent, requiring 90 days advance notice of stockholder proposals or nominations to the Board of Directors and granting the Board of Directors the authority to issue up to five million																				

shares of preferred stock and to determine the rights and preferences of the preferred stock without the need for further stockholder approval. The Company is also subject to Section 203 of the Delaware General Corporation Law that, subject to exceptions, would prohibit the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period of three years following the date on which that stockholder became an interested stockholder. These restrictions may discourage, delay or prevent a change in the control of the Company.

[Preferred stock authorized to be issued](#) 5,000,000 5,000,000

[Acquisition of additional ownership interests in several existing majority-owned joint ventures](#) 13,689,000 14,214,000 6,859,000

[Employee entitlement for purchase of the Company's common stock during each calendar year](#) \$ 25,000

[Expected volatility Rate](#) 22.00% 22.00% 34.00%

[Risk free interest rate](#) 0.50% 0.30% 0.20%

[Weighted average fair value](#) \$ 17.20 \$ 13.80 \$ 13.90

[Stock purchase price as percentage of fair market value](#) 100.00% 85.00%

[Percentage of voting stock ownership bid which triggers the stockholder rights plan](#) 15.00%

Investments in debt and equity securities

**12 Months Ended
Dec. 31, 2011**

Investments in debt and equity securities 9. **Investments in debt and equity securities**

Based on the Company's intentions and strategy involving investments in debt and equity securities, the Company classifies certain debt securities as held-to-maturity and records them at amortized cost. Equity securities that have readily determinable fair values and other debt securities classified as available for sale are recorded at fair value.

The Company's investments consist of the following:

	December 31, 2011			December 31, 2010		
	Held to maturity	Available for sale	Total	Held to maturity	Available for sale	Total
Certificates of deposit, money market funds and U.S. treasury notes due within one year	\$11,754	\$—	\$11,754	\$21,803	\$—	\$21,803
Investments in mutual funds and NxStage common stock	—	15,535	15,535	—	10,048	10,048
	<u>\$11,754</u>	<u>\$15,535</u>	<u>\$27,289</u>	<u>\$21,803</u>	<u>\$10,048</u>	<u>\$31,851</u>
Short-term investments	\$11,754	\$5,645	\$17,399	\$21,803	\$1,200	\$23,003
Long-term investments	—	9,890	9,890	—	8,848	8,848
	<u>\$11,754</u>	<u>\$15,535</u>	<u>\$27,289</u>	<u>\$21,803</u>	<u>\$10,048</u>	<u>\$31,851</u>

The cost of the certificates of deposit and money market funds at December 31, 2011 and in addition, U.S. treasury notes at December 31, 2010, approximate fair value. As of December 31, 2011 and 2010, the available for sale investments included \$(255) and \$824, respectively, of gross pre-tax unrealized (loss) gains. During 2011 and 2010 the Company recorded gross pre-tax unrealized (loss) gains of \$(986) and \$1,007, respectively, in other comprehensive income associated with changes in the fair value of these investments. During 2011, the Company sold investments in mutual funds for net proceeds of \$1,149, and recognized a pre-tax gain of \$93, or \$57 after tax, that was previously recorded in other comprehensive income. During 2010, the Company sold investments in mutual funds for net proceeds of \$900, and recognized a pre-tax loss of \$22, or \$13 after tax, that was previously recorded in other comprehensive income.

In addition, the available for sale securities, as of December 31, 2011, include the fair value of NxStage Medical Inc. (NxStage) common stock totaling \$4,445, which is based upon quoted prices as reported by NASDAQ. Under the terms of the NxStage First National Service Provider Agreement effective July 22, 2010, the Company may, in lieu of a cash rebate, vest in warrants to purchase NxStage common stock based on achieving certain System One home patient growth targets by June 30, 2011, 2012 and 2013. The warrants are exercisable for up to a cumulative total of 5,500,000 shares of common stock over three years at an initial exercise price of \$14.22 per share. As of June 30, 2011, the Company earned warrants to purchase 250,000 shares of NxStage common stock and in October 2011, the Company exercised its right and purchased these shares for a total of \$3,555. In February 2012, the Company sold all 250,000 shares for approximately \$5,200.

The investments in mutual funds classified as available for sale are held within a trust to fund existing obligations associated with several of the Company's non-qualified deferred compensation plans.

As of December 31, 2011 and 2010, there were investments totaling \$7,224 and \$18,537, respectively, classified as held to maturity that were used to maintain certain capital requirements of the special needs plans of VillageHealth, which is a wholly-owned subsidiary of the Company. As of December 31, 2009, the Company discontinued the VillageHealth special needs plans and is in process of paying out all incurred claims. During the fourth quarter of 2011, the Company received a total of \$11,313 from various state regulatory agencies for the release of certain investments that were previously held to maintain certain capital requirements.

**Amortizable Intangible
Assets (Detail) (USD \$)
In Thousands, unless
otherwise specified**

Dec. 31, 2011 Dec. 31, 2010

Finite-Lived Intangible Assets [Line Items]

<u>Noncompetition and other agreements</u>	\$ 335,012	\$ 309,405
<u>Lease agreements</u>	8,081	8,466
<u>Deferred debt financing costs</u>	66,011	61,405
<u>Finite-Lived Intangible Assets, Gross, Total</u>	409,104	379,276
<u>Less accumulated amortization</u>	(249,613)	(216,641)
<u>Total amortizable intangible assets</u>	\$ 159,491	\$ 162,635

**Consolidating Statements of
Cash Flows (Detail) (USD \$)
In Thousands, unless
otherwise specified**

12 Months Ended

	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
<u>Cash flows from operating activities:</u>			
<u>Net income.</u>	\$ 573,395	\$ 484,219	\$ 479,759
<u>Changes in operating assets and liabilities and non cash items included in net income</u>	606,651	355,464	186,951
<u>Net cash provided by operating activities</u>	1,180,046	839,683	666,710
<u>Cash flows from investing activities:</u>			
<u>Additions of property and equipment, net</u>	(400,156)	(273,602)	(274,605)
<u>Acquisitions</u>	(1,077,442)	(188,502)	(87,617)
<u>Proceeds from asset sales</u>	75,183	22,727	7,697
<u>Proceeds from investment sales and other items</u>	3,187	2,744	8,465
<u>Net cash provided by (used in) investing activities</u>	(1,399,228)	(436,633)	(346,060)
<u>Cash flows from financing activities:</u>			
<u>Long-term debt</u>	127,660	560,946	(61,274)
<u>Other items</u>	(374,843)	(643,338)	(130,798)
<u>Net cash (used in) provided by financing activities</u>	(247,183)	(82,392)	(192,072)
<u>Net (decrease) increase in cash and cash equivalents</u>	(466,365)	320,658	128,578
<u>Cash and cash equivalents at beginning of the year</u>	860,117	539,459	410,881
<u>Cash and cash equivalents at end of year</u>	393,752	860,117	539,459
DaVita Inc.			
<u>Cash flows from operating activities:</u>			
<u>Net income.</u>	478,001	405,683	422,684
<u>Changes in operating assets and liabilities and non cash items included in net income</u>	(268,798)	(319,090)	(257,591)
<u>Net cash provided by operating activities</u>	209,203	86,593	165,093
<u>Cash flows from investing activities:</u>			
<u>Additions of property and equipment, net</u>	(52,653)	(24,118)	(1,748)
<u>Proceeds from investment sales and other items</u>	(6,077)	(470)	11,631
<u>Net cash provided by (used in) investing activities</u>	(58,730)	(24,588)	9,883
<u>Cash flows from financing activities:</u>			
<u>Long-term debt</u>	113,762	563,350	(60,619)
<u>Intercompany borrowing</u>	(464,564)	255,351	101,254
<u>Other items</u>	(291,198)	(558,453)	(78,637)
<u>Net cash (used in) provided by financing activities</u>	(642,000)	260,248	(38,002)
<u>Net (decrease) increase in cash and cash equivalents</u>	(491,527)	322,253	136,974
<u>Cash and cash equivalents at beginning of the year</u>	856,803	534,550	397,576
<u>Cash and cash equivalents at end of year</u>	365,276	856,803	534,550
Guarantor Subsidiaries			
<u>Cash flows from operating activities:</u>			
<u>Net income.</u>	416,058	355,119	328,198

<u>Changes in operating assets and liabilities and non cash items included in net income</u>	325,807	136,348	(58,813)
<u>Net cash provided by operating activities</u>	741,865	491,467	269,385
<u>Cash flows from investing activities:</u>			
<u>Additions of property and equipment, net</u>	(232,540)	(199,147)	(207,738)
<u>Acquisitions</u>	(1,048,136)	(188,502)	(87,617)
<u>Proceeds from asset sales</u>	75,183	22,727	7,697
<u>Proceeds from investment sales and other items</u>	9,264	3,214	(3,166)
<u>Net cash provided by (used in) investing activities</u>	(1,196,229)	(361,708)	(290,824)
<u>Cash flows from financing activities:</u>			
<u>Long-term debt</u>	(1,896)	1,987	(1,962)
<u>Intercompany borrowing</u>	460,262	(121,887)	20,885
<u>Other items</u>	(4,002)	(9,859)	2,516
<u>Net cash (used in) provided by financing activities</u>	454,364	(129,759)	21,439
Non-Guarantor Subsidiaries			
<u>Cash flows from operating activities:</u>			
<u>Net income.</u>	255,289	236,865	154,379
<u>Changes in operating assets and liabilities and non cash items included in net income</u>	(26,311)	24,758	77,853
<u>Net cash provided by operating activities</u>	228,978	261,623	232,232
<u>Cash flows from investing activities:</u>			
<u>Additions of property and equipment, net</u>	(114,963)	(50,337)	(65,119)
<u>Acquisitions</u>	(29,306)		
<u>Net cash provided by (used in) investing activities</u>	(144,269)	(50,337)	(65,119)
<u>Cash flows from financing activities:</u>			
<u>Long-term debt</u>	15,794	(4,391)	1,307
<u>Intercompany borrowing</u>	4,302	(133,464)	(122,139)
<u>Other items</u>	(79,643)	(75,026)	(54,677)
<u>Net cash (used in) provided by financing activities</u>	(59,547)	(212,881)	(175,509)
<u>Net (decrease) increase in cash and cash equivalents</u>	25,162	(1,595)	(8,396)
<u>Cash and cash equivalents at beginning of the year</u>	3,314	4,909	13,305
<u>Cash and cash equivalents at end of year</u>	28,476	3,314	4,909
Consolidating Adjustments			
<u>Cash flows from operating activities:</u>			
<u>Net income.</u>	(575,953)	(513,448)	(425,502)
<u>Changes in operating assets and liabilities and non cash items included in net income</u>	\$ 575,953	\$ 513,448	\$ 425,502

Amortizable intangibles

**12 Months Ended
Dec. 31, 2011**

Amortizable intangibles

7. Amortizable intangibles

Amortizable intangible assets were comprised of the following:

	December 31,	
	2011	2010
Noncompetition and other agreements	\$335,012	\$309,405
Lease agreements	8,081	8,466
Deferred debt financing costs	66,011	61,405
	409,104	379,276
Less accumulated amortization	(249,613)	(216,641)
Total amortizable intangible assets	<u>\$159,491</u>	<u>\$162,635</u>

Amortizable intangible liabilities were comprised of the following:

	December 31,	
	2011	2010
Alliance and product supply agreement commitment (See Note 22)	\$68,200	\$68,200
Less accumulated amortization	(48,213)	(42,883)
	<u>\$19,987</u>	<u>\$25,317</u>

Net amortization expense from noncompetition and other agreements and the amortizable intangible liabilities was \$17,568, \$15,064 and \$14,739 for 2011, 2010 and 2009, respectively. Lease agreements which are amortized to rent expense were \$361 in 2011, \$480 in 2010 and \$565 in 2009, respectively. Deferred debt issuance costs are amortized to debt expense as described in Note 13 to the consolidated financial statements.

Scheduled amortization charges from intangible assets and liabilities as of December 31, 2011 were as follows:

	Noncompetition and other agreements	Deferred debt financing costs	Alliance and Product Supply Agreement liability
2012	24,453	10,552	(5,330)
2013	21,928	10,260	(5,330)
2014	19,724	9,747	(5,330)
2015	15,761	8,514	(3,997)
2016	6,669	5,017	—
Thereafter	17,520	9,346	—

Equity investments

**12 Months Ended
Dec. 31, 2011**

[Equity investments](#)

8. Equity investments

Equity investments in non-consolidated businesses were \$27,325 and \$25,918 at December 31, 2011 and 2010, respectively. During 2011, 2010 and 2009, the Company recognized income of \$8,776, \$8,999 and \$2,442, respectively, relating to equity investments in non-consolidated businesses under the equity method of accounting.

Goodwill

**12 Months Ended
Dec. 31, 2011**

Goodwill

10. Goodwill

Changes in the book value of goodwill were as follows:

	Year ended December 31,	
	2011	2010
Balance at January 1	\$4,091,307	\$3,951,196
Acquisitions	889,506	152,252
Divestitures	(9,837)	(12,128)
Impairment charge	(24,000)	—
Other adjustments	—	(13)
Balance at December 31	<u>\$4,946,976</u>	<u>\$4,091,307</u>

As of December 31, 2011, there was \$4,865,864 and \$81,112 of goodwill associated with the dialysis and related lab services business and the ancillary services and strategic initiatives, respectively.

As of December 31, 2010, there was \$4,022,365 and \$68,942 of goodwill associated with the dialysis and related lab services business and the ancillary services and strategic initiatives, respectively.

In the second quarter of 2011, the Company determined that circumstances indicated it was more likely than not that the fair value of one of its ancillary businesses, HCP, which provides infusion therapy services, was less than its carrying amount. The primary factor informing the Company's conclusion was the recent decline in the operating performance of HCP caused mainly by rapid expansion. This led management to revise its view of HCP's organizational growth capability and scale back significantly its plans for HCP's future growth initiatives and to update HCP's forecasts and current operating budgets accordingly. These revisions reflected the current and expected future cash flows that the Company believed market participants would use in determining the fair value of the HCP business. As a result, in the second quarter of 2011, the Company estimated that the carrying amount of goodwill related to HCP exceeded its implied fair value by \$24,000, resulting in a pre-tax goodwill impairment charge of that amount. As of December 31, 2011, after giving effect to this impairment charge, the Company has approximately \$32,000 of HCP goodwill remaining. During the fourth quarter of 2011, the Company finalized its calculation of this impairment charge, which did not change the goodwill impairment charge previously recorded.

**Equity Investments -
Additional Information
(Detail) (USD \$)
In Thousands, unless
otherwise specified**

12 Months Ended

Dec. 31, 2011 Dec. 31, 2010 Dec. 31, 2009

Schedule of Equity Method Investments [Line Items]

<u>Equity investments in non-consolidated businesses</u>	\$ 27,325	\$ 25,918	
<u>Equity investment income</u>	\$ 8,776	\$ 8,999	\$ 2,442

**Summary of the Status of
Awards Under Stock-Based
Compensation Plans and
Agreements (Detail) (USD \$)**

12 Months Ended

Dec. 31, 2011
Year **Dec. 31, 2010** **Dec. 31, 2009**

Stock Options And Stock Appreciation Rights

Awards

<u>Outstanding at beginning of year</u>	11,013,487		
<u>Granted</u>	2,707,500		
<u>Exercised</u>	(3,032,329)		
<u>Cancelled</u>	(483,094)		
<u>Outstanding at end of period</u>	10,205,564	11,013,487	
<u>Awards exercisable at end of period</u>	4,348,803		
<u>Weighted-average fair value of awards granted</u>	\$ 21.93	\$ 15.87	\$ 12.08

Weighted average exercise price

<u>Outstanding at beginning of year</u>	\$ 51.94		
<u>Granted</u>	\$ 82.17		
<u>Exercised</u>	\$ 51.46		
<u>Cancelled</u>	\$ 59.59		
<u>Outstanding at end of period</u>	\$ 59.74	\$ 51.94	
<u>Awards exercisable at end of period</u>	\$ 50.62		

Weighted average remaining contractual life

<u>Outstanding at end of period</u>	2.6		
<u>Awards exercisable at end of period</u>	1.7		

Stock Unit

Awards

<u>Outstanding at beginning of year</u>	501,564		
<u>Granted</u>	150,246		
<u>Exercised</u>	(78,106)		
<u>Cancelled</u>	(60,596)		
<u>Outstanding at end of period</u>	513,108	501,564	
<u>Awards exercisable at end of period</u>	3,446		
<u>Weighted-average fair value of awards granted</u>	\$ 85.28	\$ 62.85	\$ 54.31

Weighted average remaining contractual life

<u>Outstanding at end of period</u>	1.5		
<u>Awards exercisable at end of period</u>	0.6		

Investments in Debt and Equity Securities - Additional Information (Detail) (USD \$) In Thousands, except Share data, unless otherwise specified	1	12 Months Ended		1 Months Ended			
	Months Ended	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2011 Common Stock	Feb. 24, 2012 Sale of Investments
<u>Schedule of Trading Securities and Other Trading Assets [Line Items]</u>							
<u>Available for sale investments gross pre-tax unrealized gain (loss)</u>		\$ (255)	\$ 824				
<u>Unrealized gain (loss) on investments, pre tax</u>		(986)	1,007	1,614			
<u>Proceeds from sale of investments available for sale</u>		1,149	900	16,693			5,200
<u>Pre tax reclassification of net investment realized losses (gains) into net income</u>		(93)	22	(261)			
<u>Reclassification of net investment realized losses (gains) into net income, net of tax</u>		(57)	13	(159)			
<u>Fair value of NxStage Medical Inc., warrants</u>						4,445	
<u>Maximum shares warrants to be earned</u>			5,500,000				
<u>Exercise price of the warrants</u>			\$ 14.22				
<u>Warrants to purchase common stock</u>			250,000				
<u>Payments to acquire available-for-sale securities, equity upon the exercise of warrant</u>	3,555						
<u>Held to maturity investment to maintain certain capital requirements of the special need plans</u>		7,224	18,537				
<u>Held-to-maturity securities, released from regulatory agencies</u>		\$ 11,313					

**Fair Value of Financial
Instruments - Additional
Information (Detail) (USD \$)
In Thousands, unless
otherwise specified**

**Dec. 31,
2011**

**Dec. 31,
2010**

**Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line
Items]**

<u>Debt instrument, carrying amount</u>	\$ 4,512,811	\$ 4,317,123
Senior Secured Credit Facility		

**Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line
Items]**

<u>Debt instrument, fair value</u>	2,860,465	
<u>Debt instrument, carrying amount</u>	2,874,158	
Senior Notes		

**Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line
Items]**

<u>Debt instrument, fair value</u>	1,565,500	
<u>Debt instrument, carrying amount</u>	\$ 1,550,000	

**Scheduled Amortization
Charges from Intangible
Assets and Liabilities
(Detail) (USD \$)
In Thousands, unless
otherwise specified**

**12 Months Ended

Dec. 31, 2011**

Noncompetition and other agreements

Expected Amortization Expense [Line Items]

<u>2012</u>	\$ 24,453
<u>2013</u>	21,928
<u>2014</u>	19,724
<u>2015</u>	15,761
<u>2016</u>	6,669
<u>Thereafter</u>	17,520

Deferred debt financing costs

Expected Amortization Expense [Line Items]

<u>2012</u>	10,552
<u>2013</u>	10,260
<u>2014</u>	9,747
<u>2015</u>	8,514
<u>2016</u>	5,017
<u>Thereafter</u>	9,346

Alliance and Product Supply Agreement liability

Expected Amortization Expense [Line Items]

<u>2012</u>	(5,330)
<u>2013</u>	(5,330)
<u>2014</u>	(5,330)
<u>2015</u>	(3,997)
<u>2016</u>	
<u>Thereafter</u>	

Acquisitions - Additional Information (Detail) (USD \$) In Thousands, unless otherwise specified	12 Months Ended		12 Months Ended		12 Months Ended		12 Months Ended		12 Months Ended		12 Months Ended						
	Sep. 02, 2011	Dec. 31, 2011	Oct. 31, 2011	Sep. 30, 2011	Dec. 31, 2010	Dec. 31, 2009	Sep. 02, 2011 CDSI I Holding Company, Inc Year Person Location	Dec. 31, 2011 CDSI I Holding Company, Inc	Dec. 31, 2011 Other dialysis Year Entity	Dec. 31, 2010 Other dialysis Year Entity	Dec. 31, 2009 Other dialysis Year Entity	Dec. 31, 2011 Other dialysis acquisitions and related lab services	Dec. 31, 2010 Other dialysis acquisitions and related lab services	Dec. 31, 2009 Other dialysis acquisitions and related lab services	Dec. 31, 2011 Other dialysis acquisitions Other-Ancillary services and strategic initiatives	Dec. 31, 2011 Other dialysis acquisitions UNITED STATES Entity	Dec. 31, 2011 Other dialysis acquisitions Foreign Country Entity
<u>Business Acquisition [Line Items]</u>																	
Cash paid to acquire business	\$				\$	\$	\$ 723,012		\$ 354,430								
	1,077,442				188,502	87,617											
Deferred purchase price obligations	19,010				449	338	6,541		12,469								
Number of dialysis centers							113		1	41	19					57	8
Approximate number of patients served							8,000										
Aggregate purchase cost	1,096,452				188,951	87,955			188,951	87,955							
Number of states							23										
Additional transaction and integration costs incurred in association with the acquisition									21,700								
Amortizable intangible assets acquired, weighted-average estimated useful lives							9		9	9	7						
Goodwill deductible for tax purposes associated with acquisitions							262,000		298,000	154,000	72,000						
Goodwill deductible period for tax purpose									15 years								
Goodwill							500,662		388,844	152,252	78,199	352,674	152,252	78,199	36,170		
Number of outpatient dialysis centers to be divested	30																
Number of outpatient dialysis centers divested			2	28													
Cash consideration received for outpatient dialysis centers divested		82,000															
Loss recorded on account of divestitures		\$(4,756)															

**SCHEDULE II-
VALUATION AND
QUALIFYING ACCOUNTS**

[SCHEDULE II-VALUATION AND
QUALIFYING ACCOUNTS](#)

12 Months Ended

Dec. 31, 2011

SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS

<u>Description</u>	<u>Balance at beginning of year</u>	<u>DSI Renal Inc. Acquisition</u>	<u>Amounts charged to income</u>	<u>Amounts written off</u>	<u>Balance at end of year</u>
	(in thousands)				
Allowance for uncollectible accounts:					
Year ended					
December 31,					
2009	\$211,222	\$ —	\$161,786	\$143,691	\$229,317
Year ended					
December 31,					
2010	\$229,317	\$ —	\$171,250	\$164,938	\$235,629
Year ended					
December 31,					
2011	\$235,629	\$ 16,193	\$198,750	\$200,229	\$250,343

**Supplemental cash flow
information (Tables)**

[Supplemental Cash Flow
Information](#)

**12 Months Ended
Dec. 31, 2011**

The table below provides supplemental cash flow information:

	<u>Year ended December 31,</u>		
	<u>2011</u>	<u>2010</u>	<u>2009</u>
Cash paid:			
Income taxes	\$145,687	\$207,265	\$161,671
Interest	236,446	190,949	186,280
Non-cash investing and financing activities:			
Fixed assets under capital lease obligations	35,764	3,983	—
Assets exchanged for equity investments	—	—	2,618
Assets received for additional noncontrolling interests	—	—	51
Issuance of noncontrolling interests	—	1,139	—

Employee benefit plans

**12 Months Ended
Dec. 31, 2011**

[Employee benefit plans](#)

15. Employee benefit plans

The Company has a savings plan for substantially all employees which has been established pursuant to the provisions of Section 401(k) of the Internal Revenue Code, or IRC. The plan allows for employees to contribute a percentage of their base annual salaries on a tax-deferred basis not to exceed IRC limitations. The Company does not provide any matching contributions.

The Company also maintains a voluntary compensation deferral plan, the DaVita Voluntary Deferral Plan. This plan is non-qualified and permits certain employees whose annualized base salary equals or exceeds a minimum annual threshold amount as set by the Company to elect to defer all or a portion of their annual bonus payment and up to 50% of their base salary into a deferral account maintained by the Company. Total contributions to this plan in 2011, 2010 and 2009 were \$2,416, \$1,125 and \$2,062, respectively. Deferred amounts are generally paid out in cash at the participant's election either in the first or second year following retirement or in a specified future period at least three to four years after the deferral election was effective. During 2011, 2010 and 2009 the Company distributed \$955, \$701 and \$601, respectively, to participants. Participants are credited with their proportional amount of annual earnings from the plan. The assets of this plan are held in a "rabbi trust" and as such are subject to the claims of the Company's general creditors in the event of its bankruptcy. As of December 31, 2011 and 2010, the total fair value of assets held in trust were \$9,796 and \$8,547, respectively.

As part of the acquisition of DVA Renal Healthcare on October 5, 2005, the Company acquired an Executive Retirement Plan for certain members of management. This plan is non-qualified and contributions to the plan were made at the discretion of DVA Renal Healthcare based upon a pre-determined percentage of a participant's base salary. Effective November 2005, all contributions to this plan were discontinued and the balance of the plan assets will be paid out upon termination of each individual participant. During 2011, 2010 and 2009, the Company distributed \$194, \$198 and \$241, respectively, to participants. As of December 31, 2011 and 2010, the total fair value of assets held in trust was \$1,294 and \$1,501, respectively.

The fair value of all of the assets held in plan trusts as of December 31, 2011, and 2010 totaled \$11,090 and \$10,048, respectively. These assets are available for sale and as such are recorded at fair market value with changes in the fair market values being recorded in other comprehensive income. Any fair market value changes to the corresponding liability balance will be recorded as compensation expense. See Note 9 to the consolidated financial statements.

Most of the Company's outstanding employee stock plan awards include a provision accelerating the vesting of the award in the event of a change of control. The Company also maintains a change of control protection program for its employees who do not have a significant number of stock awards, which has been in place since 2001, and which provides for cash bonuses to employees in the event of a change of control. Based on the market price of the Company's common stock and shares outstanding on December 31, 2011, these cash bonuses would total approximately \$277,000 if a control transaction occurred at that price and the Company's Board of Directors did not modify the program. This amount has not been accrued at December 31, 2011, and would only be accrued upon a change of control. These change of control provisions may affect the price an acquirer would be willing to pay for the Company.

Variable interest entities

**12 Months Ended
Dec. 31, 2011**

Variable interest entities

20. Variable interest entities

The Company is required to consolidate each entity determined to be a variable interest entity for which the Company is the primary beneficiary. Variable interest entities (VIEs) typically include those for which the entity's equity is not sufficient to finance its activities without additional subordinated financial support; those for which the equity holders as a group lack the power to direct the activities that most significantly influence the entity's economic performance, the obligation to absorb the entity's expected losses, or the right to receive the entity's expected returns; or those for which the voting rights of some investors are not proportional to their obligations to absorb the entity's losses.

The Company is deemed to be the primary beneficiary of all the variable interest entities it is associated with. These VIEs are principally operating subsidiaries owned by related party nominee owners for the Company's benefit in jurisdictions in which the Company does not qualify for direct ownership under applicable regulations or joint ventures that require subordinated support in addition to their equity capital to finance operations. These include both dialysis operations and physician practice management entities.

Under the terms of the applicable arrangement, the Company bears substantially all of the economic risks and rewards of ownership for these operating VIEs. In some cases, the Company has contractual arrangements with its respective related party nominee owners which indemnify them from the economic losses, and entitle the Company to the economic benefits, that may result from ownership of these VIEs. DaVita Inc. manages these VIEs and provides operating and capital funding as necessary to accomplish their operational and strategic objectives.

Accordingly, since the Company bears the majority of the risks and rewards attendant to their ownership, the Company consolidates these VIEs as their primary beneficiary. Total assets of these consolidated operating VIEs were approximately \$7,000 and their liabilities to unrelated third parties were approximately \$5,000 at December 31, 2011.

The Company also sponsors certain deferred compensation plans whose trusts qualify as VIEs and as their primary beneficiary the Company consolidates each of these plans. The assets of these plans are recorded in short-term or long-term investments with matching offsetting liabilities in accrued compensation and benefits and other long-term liabilities. See Note 9 for disclosures on the assets of these consolidated non-qualified deferred compensation plans.

**Results from Discontinued
Operations (Detail) (USD \$)
In Thousands, unless
otherwise specified**

**12 Months Ended
Dec. 31, Dec. 31, Dec. 31,
2011 2010 2009**

**Income Statement, Balance Sheet and Additional Disclosures by Disposal
Groups, Including Discontinued Operations [Line Items]**

<u>Net operating revenues</u>	\$ 16,648	\$ 9,341	\$ 8,152
<u>Income before income taxes</u>	1,896	468	645
<u>Income tax expense</u>	675	187	252
<u>Income from discontinued operations</u>	\$ 1,221	\$ 281	\$ 393

Fair values of financial instruments (Tables)

Assets, Liabilities and Temporary Equity Measured at Fair Value on a Recurring Basis

**12 Months Ended
Dec. 31, 2011**

The following tables summarize the Company's assets, liabilities and temporary equity measured at fair value on a recurring basis as of December 31, 2011 and 2010:

December 31, 2011				
	Total	Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Assets				
Available for sale securities	\$15,535	\$ 15,535	\$ —	\$—
Interest rate cap agreements	\$1,381	\$ —	\$ 1,381	\$—
Liabilities				
Interest rate swap agreements	\$23,145	\$ —	\$ 23,145	\$—
Temporary equity				
Noncontrolling interests subject to put provisions	\$478,216	\$ —	\$ —	\$478,216

December 31, 2010				
	Total	Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Assets				
Available for sale securities	\$10,048	\$ 10,048	\$ —	\$—
Temporary equity				
Noncontrolling interests subject to put provisions	\$383,052	\$ —	\$ —	\$383,052

**Summary of Assets by
Segment (Detail) (USD \$)
In Thousands, unless
otherwise specified**

Dec. 31, 2011 Dec. 31, 2010

Segment assets

Total assets \$ 8,892,172 \$ 8,114,424

Dialysis and related lab services

Segment assets

Total assets 8,588,671 7,862,882

Other-Ancillary services and strategic initiatives

Segment assets

Total assets 276,176 225,624

Equity investments

Segment assets

Total assets \$ 27,325 \$ 25,918

Goodwill (Tables)

**12 Months Ended
Dec. 31, 2011**

Changes in Book Value of Goodwill

Changes in the book value of goodwill were as follows:

	<u>Year ended December 31,</u>	
	<u>2011</u>	<u>2010</u>
Balance at		
January 1	\$4,091,307	\$3,951,196
Acquisitions	889,506	152,252
Divestitures	(9,837)	(12,128)
Impairment		
charge	(24,000)	—
Other		
adjustments	—	(13)
Balance at		
December 31	<u>\$4,946,976</u>	<u>\$4,091,307</u>

Selected Quarterly Financial
Data (Unaudited) (Detail)
(USD \$)

3 Months Ended

12 Months Ended

In Thousands, except Per
Share data, unless otherwise
specified

Dec. 31, Sep. 30, Jun. 30, Mar. 31, Dec. 31, Sep. 30, Jun. 30, Mar. 31, Dec. 31, Dec. 31, Dec. 31,
2011 2011 2011 2011 2010 2010 2010 2010 2011 2010 2009

**Quarterly Financial
Information [Line Items]**

	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
<u>Net operating revenues</u>	\$ 1,862,318	\$ 1,807,869	\$ 1,708,643	\$ 1,603,384	\$ 1,646,924	\$ 1,649,557	\$ 1,584,821	\$ 1,556,748	\$ 6,982,214	\$ 6,438,050	\$ 6,100,648
<u>Operating income</u>	330,112	318,712	246,624	235,334	255,258	256,745	242,512	242,045	1,130,782	996,560	939,628
<u>Income from continuing operations before income taxes</u>	269,149	258,662	187,283	177,580	132,215	218,014	195,469	198,292	892,674	743,990	757,579
<u>Discontinued operations, net of tax.</u>	(1,307)	(2,612)	253	131	93	(95)	(89)	372	(3,535)	281	393
<u>Net income attributable to DaVita Inc.</u>	\$ 148,123	\$ 135,361	\$ 100,015	\$ 94,502	\$ 69,020	\$ 119,387	\$ 107,853	\$ 109,423	\$ 478,001	\$ 405,683	\$ 422,684
<u>Basic income from continuing operations per share attributable to DaVita Inc.</u>	\$ 1.60	\$ 1.48	\$ 1.05	\$ 0.98	\$ 0.71	\$ 1.16	\$ 1.06	\$ 1.05	\$ 5.09	\$ 3.99	\$ 4.07
<u>Basic net income per share attributable to DaVita Inc.</u>	\$ 1.59	\$ 1.45	\$ 1.05	\$ 0.98	\$ 0.71	\$ 1.16	\$ 1.05	\$ 1.05	\$ 5.05	\$ 4.00	\$ 4.08
<u>Diluted income from continuing operations per share attributable to DaVita Inc.</u>	\$ 1.58	\$ 1.45	\$ 1.02	\$ 0.96	\$ 0.70	\$ 1.15	\$ 1.04	\$ 1.04	\$ 4.99	\$ 3.93	\$ 4.05
<u>Diluted net income per share attributable to DaVita Inc.</u>	\$ 1.56	\$ 1.42	\$ 1.03	\$ 0.96	\$ 0.70	\$ 1.15	\$ 1.04	\$ 1.04	\$ 4.96	\$ 3.94	\$ 4.06

**CONSOLIDATED
STATEMENTS OF CASH
FLOWS (USD \$)
In Thousands, unless
otherwise specified**

12 Months Ended

	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
<u>Cash flows from operating activities:</u>			
Net income	\$ 573,395	\$ 484,219	\$ 479,759
<u>Adjustments to reconcile net income to cash provided by operating activities:</u>			
Depreciation and amortization	267,315	234,378	228,986
Stock-based compensation expense	48,718	45,551	44,422
Tax benefits from stock award exercises	38,199	26,706	18,241
Excess tax benefits from stock award exercises	(20,834)	(6,283)	(6,950)
Deferred income taxes	53,438	75,399	50,869
Equity investment income, net	354	(3,298)	(204)
Loss on disposal of assets and other non-cash charges	20,329	9,585	20,945
Goodwill impairment charge	24,000		
Debt refinancing and redemption charges		74,382	
<u>Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:</u>			
Accounts receivable	(88,848)	55,379	(32,313)
Inventories	10,270	(3,892)	15,115
Other receivables and other current assets	53,697	(44,719)	(35,104)
Other long-term assets	2,039	901	7,288
Accounts payable	84,400	4,228	(104,879)
Accrued compensation and benefits	77,074	39,588	(9,138)
Other current liabilities	(51,979)	(111,444)	(43,543)
Income taxes	77,418	(45,737)	44,578
Other long-term liabilities	11,061	4,740	(11,362)
Net cash provided by operating activities	1,180,046	839,683	666,710
<u>Cash flows from investing activities:</u>			
Additions of property and equipment, net	(400,156)	(273,602)	(274,605)
Acquisitions	(1,077,442)	(188,502)	(87,617)
Proceeds from asset sales	75,183	22,727	7,697
Purchase of investments available-for-sale	(5,971)	(1,125)	(2,062)
Purchase of investments held-to-maturity	(37,628)	(56,615)	(22,664)
Proceeds from the sale of investments available-for-sale	1,149	900	16,693
Proceeds from maturities of investments held-to-maturity	47,695	59,932	16,380
Purchase of equity investments and other assets	(2,398)	(709)	(2,429)
Distributions received on equity investments	340	361	2,547
Net cash provided by (used in) investing activities	(1,399,228)	(436,633)	(346,060)
<u>Cash flows from financing activities:</u>			
Borrowings	36,395,105	24,809,258	18,767,592
Payments on long-term debt	(36,249,584)	(24,134,502)	(18,828,824)

<u>Interest rate cap premiums and other deferred financing costs</u>	(17,861)		
<u>Debt refinancing costs including tender and call premiums</u>		(113,810)	(42)
<u>Purchase of treasury stock</u>	(323,348)	(618,496)	(153,495)
<u>Distributions to noncontrolling interests</u>	(100,653)	(83,591)	(67,748)
<u>Stock award exercises and other share issuances, net</u>	11,316	53,760	67,908
<u>Excess tax benefits from stock award exercises</u>	20,834	6,283	6,950
<u>Contributions from noncontrolling interests</u>	21,010	9,510	13,071
<u>Proceeds from sales of additional noncontrolling interests</u>	9,687	3,410	9,375
<u>Purchases from noncontrolling interests</u>	(13,689)	(14,214)	(6,859)
<u>Net cash (used in) provided by financing activities</u>	(247,183)	(82,392)	(192,072)
<u>Net (decrease) increase in cash and cash equivalents</u>	(466,365)	320,658	128,578
<u>Cash and cash equivalents at beginning of the year</u>	860,117	539,459	410,881
<u>Cash and cash equivalents at end of year</u>	\$ 393,752	\$ 860,117	\$ 539,459

Effects of Changes in DaVita Inc's Ownership Interest on Company's Equity (Detail) (USD \$) In Thousands, unless otherwise specified	3 Months Ended								12 Months Ended		
	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
<u>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</u>											
<u>Net income attributable to DaVita Inc.</u>	\$ 148,123	\$ 135,361	\$ 100,015	\$ 94,502	\$ 69,020	\$ 119,387	\$ 107,853	\$ 109,423	\$ 478,001	\$ 405,683	\$ 422,684
<u>Net transfer to noncontrolling interests</u>									(10,785)	(5,835)	(4,250)
<u>Change from net income attributable to DaVita Inc. and transfers to noncontrolling interests</u>									467,216	399,848	418,434
Additional Paid-in Capital											
<u>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</u>											
<u>Decrease in paid-in capital for sales of noncontrolling interest in several joint ventures</u>									(1,299)	(298)	(529)
<u>Decrease in paid-in capital for the purchase of a noncontrolling interest in several joint ventures</u>									\$ (9,486)	\$ (5,537)	\$ (3,721)

Other receivables

**12 Months Ended
Dec. 31, 2011**

Other receivables

4. Other receivables

Other receivables were comprised of the following:

	December 31,	
	2011	2010
Supplier rebates and other non-trade receivables	\$195,426	\$238,156
Medicare bad debt claims	57,232	46,250
Operating advances under management and administrative services agreements	17,174	19,960
	<u>\$269,832</u>	<u>\$304,366</u>

Operating advances under management and administrative services agreements are generally unsecured.

**Property and Equipment
(Detail) (USD \$)
In Thousands, unless
otherwise specified**

Dec. 31, 2011 Dec. 31, 2010

Property, Plant and Equipment [Line Items]

<u>Land</u>	\$ 23,004	\$ 23,182
<u>Buildings</u>	34,173	33,937
<u>Leasehold improvements</u>	1,266,499	1,106,935
<u>Equipment and information systems</u>	1,269,343	1,107,778
<u>New center and capital asset projects in progress</u>	144,124	38,721
<u>Property, Plant and Equipment, Gross, Total</u>	2,737,143	2,310,553
<u>Less accumulated depreciation and amortization</u>	(1,304,492)	(1,139,745)
<u>Property and equipment, net</u>	\$ 1,432,651	\$ 1,170,808

**Future Minimum Lease
Payments Under Non-
cancelable Operating Leases
and Capital Leases (Detail)**

Dec. 31, 2011

(USD \$)

**In Thousands, unless
otherwise specified**

Operating leases

<u>2012</u>	\$ 258,336
<u>2013</u>	232,569
<u>2014</u>	211,544
<u>2015</u>	193,874
<u>2016</u>	176,063
<u>Thereafter</u>	635,608
<u>Operating Leases, Future Minimum Payments Due, Total</u>	1,707,994

Capital leases

<u>2012</u>	4,620
<u>2013</u>	4,656
<u>2014</u>	4,510
<u>2015</u>	4,260
<u>2016</u>	4,239
<u>Thereafter</u>	42,335
<u>Capital Leases, Future Minimum Payments Due, Total</u>	64,620
<u>Less portion representing interest</u>	(21,256)
<u>Total capital lease obligations, including current portion</u>	\$ 43,364

**Supplemental Cash Flow
Information (Detail) (USD \$)
In Thousands, unless
otherwise specified**

12 Months Ended

Dec. 31, 2011 Dec. 31, 2010 Dec. 31, 2009

Cash paid:

Income taxes

\$ 145,687 \$ 207,265 \$ 161,671

Interest

236,446 190,949 186,280

Non-cash investing and financing activities:

Fixed assets under capital lease obligations

35,764 3,983

Assets exchanged for equity investments

2,618

Assets received for additional noncontrolling interests

51

Issuance of noncontrolling interests

\$ 1,139

Other Accrued Liabilities
(Detail) (USD \$)
In Thousands, unless
otherwise specified

Dec. 31, 2011 Dec. 31, 2010

Other Liabilities [Line Items]

<u>Payor refunds and retractions</u>	\$ 193,966	\$ 216,655
<u>Insurance and self-insurance accruals</u>	69,962	65,950
<u>Accrued interest</u>	17,469	22,905
<u>Accrued non-income tax liabilities</u>	15,174	9,995
<u>Other</u>	29,163	27,438
<u>Other liabilities</u>	\$ 325,734	\$ 342,943

Concentrations

**12 Months Ended
Dec. 31, 2011**

Concentrations

21. Concentrations

Approximately 66% of the Company's total dialysis and related lab services revenues in 2011, 66% in 2010 and 65% in 2009 are from government-based programs, principally Medicare and Medicaid. Accounts receivable and other receivables, from Medicare, including Medicare-assigned plans, and Medicaid, including Medicaid-assigned plans, were approximately \$617,200 and \$554,300, respectively as of December 31, 2011 and 2010. No other single payor accounted for more than 5% of total accounts receivable.

EPO is a significant physician-prescribed pharmaceutical that is administered during dialysis and is provided by a sole supplier. The amount of EPO that is separately billable accounted for approximately 3% and 18% of the dialysis and related lab services net operating revenues in 2011 and 2010, respectively. As long as certain conditions are met by the Company, the agreement with Amgen limits their ability to unilaterally decide to increase the price it charges the Company for EPO.

**Deferred Tax Assets and
Liabilities Arising from
Temporary Differences
(Detail) (USD \$)
In Thousands, unless
otherwise specified**

Dec. 31, 2011 Dec. 31, 2010

Income Taxes [Line Items]

<u>Receivables</u>	\$ 125,159	\$ 110,332
<u>Alliance and product supply agreement</u>	7,775	9,849
<u>Accrued liabilities</u>	163,770	127,073
<u>Net operating loss carryforwards</u>	118,745	11,272
<u>Other</u>	64,120	49,096
<u>Deferred tax assets</u>	479,569	307,622
<u>Valuation allowance</u>	(15,642)	(10,998)
<u>Net deferred tax assets</u>	463,927	296,624
<u>Intangible assets</u>	(439,203)	(377,456)
<u>Property and equipment</u>	(164,404)	(110,472)
<u>Other</u>	(3,036)	(4,072)
<u>Deferred tax liabilities</u>	(606,643)	(492,000)
<u>Net deferred tax liabilities</u>	\$ (142,716)	\$ (195,376)

**Property and equipment
(Tables)**

[Property and Equipment](#)

**12 Months Ended
Dec. 31, 2011**

Property and equipment were comprised of the following:

	<u>December 31,</u>	
	<u>2011</u>	<u>2010</u>
Land	\$23,004	\$23,182
Buildings	34,173	33,937
Leasehold improvements	1,266,499	1,106,935
Equipment and information systems	1,269,343	1,107,778
New center and capital asset projects in progress	<u>144,124</u>	<u>38,721</u>
	2,737,143	2,310,553
Less accumulated depreciation and amortization	<u>(1,304,492)</u>	<u>(1,139,745)</u>
	<u>\$1,432,651</u>	<u>\$1,170,808</u>

Leases

**12 Months Ended
Dec. 31, 2011**

[Leases](#)

14. Leases

The majority of the Company's facilities are leased under non-cancelable operating leases, ranging in terms from five to 15 years, which contain renewal options of five to ten years at the fair rental value at the time of renewal. The Company leases are generally subject to periodic consumer price index increases or contain fixed escalation clauses. The Company also leases certain facilities and equipment under capital leases.

Future minimum lease payments under non-cancelable operating leases and capital leases are as follows:

	Operating leases	Capital leases
2012	258,336	4,620
2013	232,569	4,656
2014	211,544	4,510
2015	193,874	4,260
2016	176,063	4,239
Thereafter	635,608	42,335
	<u>\$1,707,994</u>	64,620
Less portion representing interest		<u>(21,256)</u>
Total capital lease obligations, including current portion		<u>\$43,364</u>

Rent expense under all operating leases for 2011, 2010, and 2009 was \$296,051, \$266,849 and \$248,154, respectively. Rent expense is recorded on a straight-line basis, over the term of the lease, for leases that contain fixed escalation clauses or include abatement provisions. Leasehold improvement incentives are deferred and amortized to rent expense over the term of the lease. The net book value of property and equipment under capital leases was \$41,514 and \$7,579 at December 31, 2011 and 2010, respectively. Capital lease obligations are included in long-term debt. See Note 13 to the consolidated financial statements.

**Assets, Liabilities and
Temporary Equity Measured
at Fair Value on a Recurring
Basis (Detail) (Fair Value,
Measurements, Recurring,
USD \$)
In Thousands, unless
otherwise specified**

Dec. 31, 2011 Dec. 31, 2010

Assets

<u>Available for sale securities</u>	\$ 15,535	\$ 10,048
<u>Interest rate cap agreements</u>	1,381	

Liabilities

<u>Interest rate swap agreements</u>	23,145	
--	--------	--

Temporary equity

<u>Noncontrolling interests subject to put provisions</u>	478,216	383,052
Quoted prices in active markets for identical assets (Level 1)		

Assets

<u>Available for sale securities</u>	15,535	10,048
Significant other observable inputs (Level 2)		

Assets

<u>Interest rate cap agreements</u>	1,381	
---	-------	--

Liabilities

<u>Interest rate swap agreements</u>	23,145	
Significant unobservable inputs (Level 3)		

Temporary equity

<u>Noncontrolling interests subject to put provisions</u>	\$ 478,216	\$ 383,052
---	------------	------------